FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Seah, DS
Gelber, S
Ruddy, KJ
Tamimi, RM
Schapira, L
Come, SE
Meyer, ME
Larsen, BG
Winer, EP
Partridge, A
AF Seah, Davinia Shien
Gelber, Shari
Ruddy, Kathryn Jean
Tamimi, Rulla M.
Schapira, Lidia
Come, Steven E.
Meyer, Meghan E.
Larsen, Bryce G.
Winer, Eric P.
Partridge, Ann
TI Quality of life and psychosocial distress in young women with advanced
breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e20508
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604780
ER
PT J
AU Sequist, LV
Soria, JC
Gadgeel, SM
Wakelee, HA
Camidge, DR
Varga, A
Fidias, P
Wozniak, AJ
Neal, JW
Doebele, RC
Garon, EB
Jaw-Tsai, SS
Stern, JC
Allen, AR
Goldman, JW
AF Sequist, Lecia V.
Soria, Jean-Charles
Gadgeel, Shirish M.
Wakelee, Heather A.
Camidge, D. Ross
Varga, Andrea
Fidias, Panos
Wozniak, Antoinette J.
Neal, Joel W.
Doebele, Robert Charles
Garon, Edward B.
Jaw-Tsai, Sarah S.
Stern, Jennifer C.
Allen, Andrew R.
Goldman, Jonathan Wade
TI First-in-human evaluation of CO-1686, an irreversible, selective, and
potent tyrosine kinase inhibitor of EGFR T790M.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Inst Gustave Roussy, Villejuif, France.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Stanford Canc Inst, Stanford, CA USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Univ Calif Los Angeles, Santa Monica, CA USA.
Clovis Oncol Inc, San Francisco, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 5
Z9 5
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2524
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601042
ER
PT J
AU Serrano-Garcia, C
Heinrich, MC
Zhu, MJ
Raut, CP
Eilers, G
Ravegnini, G
Demetri, GD
Bauer, S
Fletcher, JA
George, S
AF Serrano-Garcia, Cesar
Heinrich, Michael C.
Zhu, Meijun
Raut, Chandrajit P.
Eilers, Grant
Ravegnini, Gloria
Demetri, George D.
Bauer, Sebastian
Fletcher, Jonathan A.
George, Suzanne
TI In vitro and in vivo activity of regorafenib (REGO) in drug-resistant
gastrointestinal stromal tumors (GIST).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Duisburg Essen, Dept Med Oncol, West German Canc Ctr, Univ Hosp Essen, Essen, Germany.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10510
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600282
ER
PT J
AU Sethi, RV
Shih, HA
Kim, D
Yeap, BY
Mouw, K
Marcus, KC
Grabowski, E
Yock, TI
Tarbell, N
Mukai, S
MacDonald, SM
AF Sethi, Rosin V.
Shih, Helen Alice
Kim, David
Yeap, Beow Y.
Mouw, Kent
Marcus, Karen Chayt
Grabowski, Eric
Yock, Torunn I.
Tarbell, Nancy
Mukai, Shizuo
MacDonald, Shannon M.
TI Second non-ocular tumors among survivors of retinoblastom treated with
proton therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
Childrens Hosp, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Hematol & Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10018
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600172
ER
PT J
AU Seymour, JF
Davids, MS
Pagel, JM
Kahl, BS
Wierda, WG
Miller, TP
Gerecitano, JF
Kipps, TJ
Anderson, MA
Huang, DCS
Darden, DE
Gressick, LA
Nolan, CE
Yang, JN
Busman, TA
Graham, AM
Cerri, E
Enschede, SH
Humerickhouse, RA
Roberts, AW
AF Seymour, John Francis
Davids, Matthew Steven
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Miller, Thomas P.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Huang, David C. S.
Darden, David E.
Gressick, Lori A.
Nolan, Cathy E.
Yang, Jianning
Busman, Todd A.
Graham, Alison M.
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew Warwick
TI Updated results of a phase I first-in-human study of the BCL-2 inhibitor
ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic
lymphocytic leukemia (CLL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Arizona, Ctr Canc, Tucson, AZ USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Royal Melbourne Hosp, Melbourne, Vic, Australia.
Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
AbbVie Inc, N Chicago, IL USA.
Royal Melbourne Hosp, Melbourne, Vic, Australia.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7018
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602376
ER
PT J
AU Shah, A
Motiwala, S
Brose, MS
O'Dwyer, PJ
Flaherty, K
Keefe, SM
AF Shah, Amishi
Motiwala, Shweta
Brose, Marcia S.
O'Dwyer, Peter J.
Flaherty, Keith
Keefe, Stephen Michael
TI Increase in blood pressure with sorafenib exposure: Renal cell carcinoma
(RCC) versus other solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Penn, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e15564
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604137
ER
PT J
AU Shaheen, S
Upadhyay, S
Marak, CP
Kumar, G
Guddati, AK
AF Shaheen, Shagufta
Upadhyay, Shivanck
Marak, Creticus Petrov
Kumar, Gagan
Guddati, Achuta Kumar
TI Outcomes of invasive fungal infections in hematopoietic stem cell
transplant patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Columbia Univ, Harlem Hosp Ctr, New York, NY USA.
Montefiore Hosp, Albert Einstein Coll Med, New York, NY USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e18008
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604475
ER
PT J
AU Shaik, M
Korant, AK
Saha, SK
Johnston, G
Dhar, VK
Abadeer, B
Wiese, D
Arora, ML
Stewart, A
Saha, S
AF Shaik, Mohammed
Korant, Alpesh K.
Saha, Supriya Kumar
Johnston, Gregory
Dhar, Vikrom K.
Abadeer, Benjamin
Wiese, David
Arora, Madan L.
Stewart, Andrew
Saha, Sukamal
TI Impact of nodal metastasis on survival of stage IV colon cancer:
Analysis of National Cancer Data Base (NCDB)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Michigan State Univ, Hurley Med Ctr, Flint, MI USA.
Michigan State Univ, McLaren Reg Med Ctr, Flint, MI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
McLaren Macomb Med Ctr, Mt Clemens, MI USA.
Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
Amer Coll Surg, Commiss Canc, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3582
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601317
ER
PT J
AU Shapiro, G
Supko, JG
Cho, DC
Hilton, JF
Hadfield, M
Pruitt-Thompson, S
Bordoli-Trachsela, E
Zvereva, N
Wolanski, A
Sato-DiLorenzo, A
Gotthardt, S
Fox, EA
Verselis, SJ
Kumar, A
Holden, SA
Ram, S
Chafai-Fadela, K
Harding, K
Menon, KE
AF Shapiro, Geoffrey
Supko, Jeffrey G.
Cho, Daniel C.
Hilton, John Frederick
Hadfield, Matthew
Pruitt-Thompson, Salida
Bordoli-Trachsela, Eveline
Zvereva, Nela
Wolanski, Andrew
Sato-DiLorenzo, Aya
Gotthardt, Susan
Fox, Edward A.
Verselis, Sigitas Jonas
Kumar, Ashok
Holden, Sylvia A.
Ram, Siya
Chafai-Fadela, Karima
Harding, Kimberly
Menon, Krishna E.
TI A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic
study of thioureidobutyronitrile, a novel p53 targeted therapy, in
patients with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
KARD Sci, Beverly, MA USA.
Cellceutix, Beverly, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS2627
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605398
ER
PT J
AU Shapiro, G
Rosen, LS
Tolcher, AW
Goldman, JW
Gandhi, L
Papadopoulos, KP
Tolaney, SM
Beeram, M
Rasco, DW
Kulanthaivel, P
Li, Q
Hu, TL
Cronier, D
Chan, EM
Flaherty, K
Wen, PY
Patnaik, A
AF Shapiro, Geoffrey
Rosen, Lee S.
Tolcher, Anthony W.
Goldman, Jonathan Wade
Gandhi, Leena
Papadopoulos, Kyriakos P.
Tolaney, Sara M.
Beeram, Muralidhar
Rasco, Drew Warren
Kulanthaivel, Palaniappan
Li, Qian
Hu, Tianle
Cronier, Damien
Chan, Edward M.
Flaherty, Keith
Wen, Patrick Y.
Patnaik, Amita
TI A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for
patients with advanced cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA.
START Ctr Canc Care, San Antonio, TX USA.
START, San Antonio, TX USA.
Eli Lilly & Co, Indianapolis, IN 46285 USA.
PharmaNet I3, Indianapolis, IN USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 3
Z9 3
U1 6
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2500
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601018
ER
PT J
AU Shaw, AT
Mok, T
Spigel, DR
Nishio, M
Felip, E
Tan, DSW
Garcia-Campelo, MR
Gruen, HJM
Dakhil, SR
Schaefer, ES
Farrell, NJ
Blakesley, RE
Weir, A
Ristic, M
Selvaggi, G
Scagliotti, G
AF Shaw, Alice Tsang
Mok, Tony
Spigel, David R.
Nishio, Makoto
Felip, Enriqueta
Tan, Daniel Shao-Weng
Garcia-Campelo, M. Rosario
Gruen, Harry J. M.
Dakhil, Shaker R.
Schaefer, Eric Scott
Farrell, Nicholas John
Blakesley, Rick E.
Weir, Alexander
Ristic, Mirta
Selvaggi, Giovanni
Scagliotti, Giorgio
TI A phase II single-arm study of LDK378 in patients with ALK-activated
(ALK plus ) non-small cell lung cancer (NSCLC) previously treated with
chemotherapy and crizotinib (CRZ).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA.
Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan.
Vall dHebron Inst Oncol, Thorac Tumors Grp, Barcelona, Spain.
Natl Canc Ctr Singapore, Singapore, Singapore.
Complexo Hosp A Coruna, La Coruna, Spain.
Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
Canc Ctr Kansas, Wichita, KS USA.
Highlands Oncol Grp, Fayetteville, AZ USA.
Associates Oncol & Hematol, Rockville, MD USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Novartis Pharma AG, Basel, Switzerland.
Univ Turin, Orbassano, Italy.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS8119
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605508
ER
PT J
AU Shaw, AT
Mehra, R
Kim, DW
Felip, E
Chow, LQM
Camidge, DR
Tan, DSW
Vansteenkiste, JF
Sharma, S
De Pas, T
Wolf, J
Katayama, R
Lau, YYY
Goldwasser, M
Boral, A
Engelman, JA
AF Shaw, Alice Tsang
Mehra, Ranee
Kim, Dong-Wan
Felip, Enriqueta
Chow, Laura Quan Man
Camidge, D. Ross
Tan, Daniel Shao-Weng
Vansteenkiste, Johan F.
Sharma, Sunil
De Pas, Tommaso
Wolf, Juergen
Katayama, Ryohei
Lau, Yi-Yang Yvonne
Goldwasser, Meredith
Boral, Anthony
Engelman, Jeffrey A.
TI Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive
NSCLC.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
Vall dHebron Inst Oncol, Thorac Tumors Grp, Barcelona, Spain.
Univ Washington, Seattle Canc Care, Seattle, WA 98195 USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Natl Canc Ctr Singapore, Singapore, Singapore.
Univ Hosp KU Leuven, Louvain, Belgium.
Huntsman Canc Inst, Salt Lake City, UT USA.
European Inst Oncol, Milan, Italy.
Univ Hosp Cologne, Lung Canc Grp Cologne, Ctr Integrated Oncol, Cologne, Germany.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Novartis Inst BioMed Res Inc, Cambridge, MA USA.
NR 0
TC 27
Z9 28
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8010
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602492
ER
PT J
AU Shedlock, K
Porock, D
Brown, JK
Burton, H
Horvath, P
Berry, DL
AF Shedlock, Kathleen
Porock, Davina
Brown, Jean K.
Burton, Harold
Horvath, Peter
Berry, Donna Lynn
TI Effects of physical activity on symptoms in prostate cancer survivors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 SUNY, Univ Buffalo, Sch Nursing, Boston, MA USA.
Univ Nottingham, Sch Nursing, Buffalo, NY USA.
SUNY Buffalo, Sch Nursing, Buffalo, NY 14260 USA.
SUNY Buffalo, Dept Exercise & Nutr Sci, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e20540
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604810
ER
PT J
AU Sherman, SI
Cohen, EEW
Schoffski, P
Elisei, R
Schlumberger, M
Wirth, LJ
Mangeshkar, M
Aftab, DT
Clary, DO
Brose, MS
AF Sherman, Steven I.
Cohen, Ezra E. W.
Schoffski, Patrick
Elisei, Rossella
Schlumberger, Martin
Wirth, Lori J.
Mangeshkar, Milan
Aftab, Dana T.
Clary, Douglas O.
Brose, Marcia S.
TI Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC)
patients with RAS or RET mutations: Results from a phase III study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium.
Univ Pisa, Pisa, Italy.
Inst Gustave Roussy, Villejuit, France.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Exelixis Inc, San Francisco, CA USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 8
Z9 8
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6000
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602125
ER
PT J
AU Shi, Q
De Gramont, A
Buyse, ME
Grothey, A
Schmoll, HJ
Seymour, MT
Adams, RA
Saltz, L
Goldberg, RM
Punt, CJA
Douillard, JY
Hecht, JR
Hurwitz, H
Diaz-Rubio, E
Porschen, R
Tebbutt, NC
Fuchs, CS
Souglakos, J
Falcone, A
Sargent, DJ
AF Shi, Qian
De Gramont, Aimery
Buyse, Marc E.
Grothey, Axel
Schmoll, Hans-Joachim
Seymour, Matthew T.
Adams, Richard A.
Saltz, Leonard
Goldberg, Richard M.
Punt, Cornelis J. A.
Douillard, Jean-Yves
Hecht, J. Randolph
Hurwitz, Herbert
Diaz-Rubio, Eduardo
Porschen, Rainer
Tebbutt, Niall C.
Fuchs, Charles S.
Souglakos, John
Falcone, Alfredo
Sargent, Daniel J.
CA ARCAD Grp
TI Individual patient data (IPD) analysis of progression-free survival
(PFS) versus overall survival (OS) as an endpoint for metastatic
colorectal cancer (mCRC) in modern trials: Findings from the 16,700
patients (pts) ARCAD database.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mayo Clin, Rochester, MN USA.
Hosp St Antoine, Paris, France.
Int Inst Drug Dev, Louvain, Belgium.
Univ Halle Wittenberg, D-06108 Halle, Germany.
Canc Res UK Clin Ctr, Leeds, W Yorkshire, England.
Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
ICO Ctr Rene Gauducheau, St Herblain, France.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Hosp Clin San Carlos, Madrid, Spain.
Klinikum Bremen Ost, Bremen, Germany.
Austin Hlth, Heidelberg, Vic, Australia.
Univ Melbourne, Heidelberg, Vic, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Crete, Sch Med, Iraklion, Greece.
Santa Chiara Hosp, Pisa, Italy.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3533
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601269
ER
PT J
AU Shulman, LN
Berry, DA
Cirrincione, CT
Becker, H
Perez, EA
O'Regan, R
Martino, S
Shapiro, CL
Atkins, J
Schneider, C
Kimmick, GG
Burstein, HJ
Norton, L
Musa, HB
Hudis, C
Winer, EP
AF Shulman, Lawrence N.
Berry, Donald A.
Cirrincione, Constance T.
Becker, Heather
Perez, Edith A.
O'Regan, Ruth
Martino, Silvana
Shapiro, Charles L.
Atkins, James
Schneider, Charles
Kimmick, Gretchen Genevieve
Burstein, Harold J.
Norton, Larry
Musa, Hyman Bernard
Hudis, Clifford
Winer, Eric P.
CA Canc Leukemia Grp B
TI Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent
paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3
positive axillary nodes: CALGB 40101
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Duke Canc Inst Biostat, Durham, NC USA.
Univ Chicago, Chicago, IL 60637 USA.
Mayo Clin, Jacksonville, FL 32224 USA.
Grady Mem Hosp, Georgia Canc Ctr Excellence, Atlanta, GA USA.
Angeles Clin & Res Inst, Santa Monica, CA USA.
Ohio State Univ, Columbus, OH 43210 USA.
Southeastern Med Oncol Ctr, Goldsboro, NC USA.
Christiana Care Hlth Syst, Newark, DE USA.
Duke Canc Inst, Durham, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1007
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600229
ER
PT J
AU Siegel, DSD
Richardson, PGG
Vij, R
Hofmeister, CC
Baz, RC
Jagannath, S
Chen, C
Lonial, S
Jakubowiak, AJ
Bahlis, NJ
Song, KW
Belch, A
Raje, NS
Shustik, C
Lentzsch, S
Chen, M
Zaki, MH
Anderson, KC
AF Siegel, David Samuel DiCapua
Richardson, Paul Gerard Guy
Vij, Ravi
Hofmeister, Craig C.
Baz, Rachid C.
Jagannath, Sundar
Chen, Christine
Lonial, Sagar
Jakubowiak, Andrzej J.
Bahlis, Nizar J.
Song, Kevin W.
Belch, Andrew
Raje, Noopur S.
Shustik, Chaim
Lentzsch, Suzanne
Chen, Min
Zaki, Mohamed H.
Anderson, Kenneth Carl
TI Long-term safety and efficacy of pomalidomide (POM) with or without
low-dose dexamethasone (LoDEX) in relapsed and refractory multiple
myeloma (RRMM) patients enrolled in the MM-002 phase II trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Washington Univ, St Louis, MO USA.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Emory Univ, Sch Med, Atlanta, GA USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Univ Calgary, Calgary, AB, Canada.
Vancouver Gen Hosp, Vancouver, BC, Canada.
Univ Alberta, Edmonton, AB, Canada.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.
Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
Celgene Corp, Summit, NJ USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8588
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602683
ER
PT J
AU Smith, MR
Borre, M
Rathenborg, P
Werbrouck, P
Van Poppel, H
Heidenreich, A
Iversen, P
Baskin-Bey, E
Perabo, F
Phung, D
Tombal, B
AF Smith, Matthew Raymond
Borre, Michael
Rathenborg, Per
Werbrouck, Patrick
Van Poppel, Hendrik
Heidenreich, Axel
Iversen, Peter
Baskin-Bey, Edwina
Perabo, Frank
De Phung
Tombal, Bertrand
TI Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive
prostate cancer (HNPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Dept Hematol, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Dept Oncol, Boston, MA USA.
Arhus Univ Hosp, Dept Urol, Skejby, Denmark.
Herlev Hosp, Dept Urol, DK-2730 Herlev, Denmark.
AZ Groeninge Kortrijk, Dept Urol, Kortrijk, Belgium.
Univ Hosp Leuven, Dept Urol, Louvain, Belgium.
RWTH Univ, Dept Urol, Aachen, Germany.
Univ Copenhagen, Rigshosp, Dept Urologuy, DK-2100 Copenhagen, Denmark.
Astellas Pharma Global Dev Inc, Staines, England.
Astellas Pharma Global Dev Inc, Leiderdorp, Netherlands.
Clin Univ St Luc, Dept Urol, B-1200 Brussels, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5001
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601602
ER
PT J
AU Sonpavde, G
Pond, GR
Agarwal, N
Choueiri, TK
Qu, AQ
Fougeray, R
Salhi, Y
Vaughn, DJ
James, ND
Niegisch, G
Albers, P
Galsky, MD
Wong, YN
Stadler, WM
O'Donnell, PH
Vogelzang, NJ
Sridhar, SS
Ko, YJ
Sternberg, CN
Bellmunt, J
AF Sonpavde, Guru
Pond, Gregory Russell
Agarwal, Neeraj
Choueiri, Toni K.
Qu, Angela Q.
Fougeray, Ronan
Salhi, Yacine
Vaughn, David J.
James, Nicholas David
Niegisch, Guenter
Albers, Peter
Galsky, Matt D.
Wong, Yu-Ning
Stadler, Walter Michael
O'Donnell, Peter H.
Vogelzang, Nicholas J.
Sridhar, Srikala S.
Ko, Yoo-Joung
Sternberg, Cora N.
Bellmunt, Joaquim
TI Nomogram to estimate the activity of second-line therapy for advanced
urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
McMaster Univ, Hamilton, ON, Canada.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Rech Pierre Fabre, Boulogne, France.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Univ Birmingham, Birmingham, W Midlands, England.
Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Chicago, Chicago, IL 60637 USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
San Camillo Forlanini Hosp, Rome, Italy.
Univ Hosp del Mar, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4524
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601538
ER
PT J
AU Soriano, G
Landrum, MB
Weeks, JC
Arora, NK
Malin, J
Ganz, PA
van Ryn, M
Keating, NL
AF Soriano, Gabriela
Landrum, Mary Beth
Weeks, Jane C.
Arora, Neeraj K.
Malin, Jennifer
Ganz, Patricia A.
van Ryn, Michelle
Keating, Nancy Lynn
TI The role of families in decisions about cancer treatments
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, Brookline, MA USA.
Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Bethesda, MD 20892 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NSABP, Los Angeles, CA USA.
Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90095 USA.
Univ Minnesota, Minneapolis, MN USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6528
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602247
ER
PT J
AU Sosman, JA
Martin-Algarra, S
Wolchok, JD
Sharfman, WH
Bhatia, S
Hodi, FS
Hwu, WJ
Gajewski, T
Slingluff, CL
Kaufman, H
Gupta, M
McGirr, A
Horak, CE
Ahlers, CM
Wigginton, JM
Urba, WJ
AF Sosman, Jeffrey Alan
Martin-Algarra, Salvador
Wolchok, Jedd D.
Sharfman, William Howard
Bhatia, Shailender
Hodi, F. Stephen
Hwu, Wen-Jen
Gajewski, Thomas
Slingluff, Craig L.
Kaufman, Howard
Gupta, Manish
McGirr, Analia
Horak, Christine E.
Ahlers, Christoph Matthias
Wigginton, Jon M.
Urba, Walter John
TI An exploratory study of the biologic effects of nivolumab (Anti-PD-1;
BMS-936558; ONO-4538) treatment in patients (pts) with advanced
(unresectable or metastatic) melanoma (MEL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Univ Navarra, E-31080 Pamplona, Spain.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Washington, Seattle, WA 98195 USA.
Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
Rush Univ, Med Ctr, Chicago, IL 60612 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Earle A Chiles Res Inst, Portland, OR USA.
Providence Canc Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS3114
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605408
ER
PT J
AU Sosman, JA
Daud, A
Weber, JS
Kim, K
Kefford, R
Flaherty, K
Infante, JR
Hamid, O
Cebon, JS
Schuchter, LM
McWilliams, RR
Sznol, M
Sharfman, WH
Algazi, AP
Lewis, KD
Little, SM
Sun, P
Long, G
Patel, K
Gonzalez, R
AF Sosman, Jeffrey Alan
Daud, Adil
Weber, Jeffrey S.
Kim, Kevin
Kefford, Richard
Flaherty, Keith
Infante, Jeffrey R.
Hamid, Omid
Cebon, Jonathan S.
Schuchter, Lynn Mara
McWilliams, Robert R.
Sznol, Mario
Sharfman, William Howard
Algazi, Alain Patrick
Lewis, Karl D.
Little, Shonda M.
Sun, Peng
Long, Georgina
Patel, Kiran
Gonzalez, Rene
TI BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2
inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients
(pts) with BRAF mutation-positive metastatic melanoma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr, Tampa, FL USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Westmead Hosp, Westmead, NSW 2145, Australia.
Melanoma Inst Australia, Westmead, NSW, Australia.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Mayo Clin, Rochester, MN USA.
Yale Univ, New Haven, CT USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
GlaxoSmithKline, Collegeville, PA USA.
Univ Sydney, Sydney, NSW 2006, Australia.
UCHSC, Aurora, CO USA.
NR 0
TC 5
Z9 5
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9005
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602709
ER
PT J
AU Spigel, DR
Gettinger, SN
Horn, L
Herbst, RS
Gandhi, L
Gordon, MS
Cruz, C
Conkling, P
Cassier, PA
Antonia, SJ
Burris, HA
Fine, GD
Mokatrin, A
Kowanetz, M
Shen, XD
Chen, DS
Soria, JC
AF Spigel, David R.
Gettinger, Scott N.
Horn, Leora
Herbst, Roy S.
Gandhi, Leena
Gordon, Michael S.
Cruz, Cristina
Conkling, Paul
Cassier, Philippe Alexandre
Antonia, Scott J.
Burris, Howard A.
Fine, Gregg Daniel
Mokatrin, Ahmad
Kowanetz, Marcin
Shen, Xiaodong
Chen, Daniel S.
Soria, Jean-Charles
TI Clinical activity, safety, and biomarkers of MPDL3280A, an engineered
PD-L1 antibody in patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sarah Cannon Res Inst, Nashville, TN USA.
Yale Univ, Sch Med, New Haven, CT USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Yale Univ, New Haven, CT USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Virginia Oncol Associates US Oncol, Norfolk, VA USA.
Ctr Leon Berard, F-69373 Lyon, France.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Genentech Inc, San Francisco, CA 94080 USA.
Inst Gustave Roussy, Villejuif, France.
NR 0
TC 0
Z9 0
U1 0
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8008
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602490
ER
PT J
AU Spurgeon, SEF
Wagner-Johnston, ND
Furman, RR
Flinn, I
Coutre, SE
Brown, JR
Benson, DM
Byrd, JC
Leonard, J
Peterman, S
Johnson, DM
Gu, J
Dansey, RD
Godfrey, WR
Kahl, BS
AF Spurgeon, Stephen Edward Forbes
Wagner-Johnston, Nina D.
Furman, Richard R.
Flinn, Ian
Coutre, Steven E.
Brown, Jennifer R.
Benson, Don M.
Byrd, John C.
Leonard, John
Peterman, Sissy
Johnson, David Michael
Gu, Jessie
Dansey, Roger D.
Godfrey, Wayne R.
Kahl, Brad S.
TI Final results of a phase I study of idelalisib, a selective inhibitor of
phosphatidylinositol 3-kinase P110 delta (PI3K delta), in patients with
relapsed or refractory mantle cell lymphoma (MCL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Washington Univ, Sch Med, St Louis, MO USA.
Weill Cornell Med Coll, New York, NY USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Stanford Canc Inst, Stanford, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Gilead Sci Inc, Seattle, WA USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
NR 0
TC 1
Z9 1
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8519
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602615
ER
PT J
AU Stinchcombe, T
Sholl, LM
Wang, XFF
Gu, L
Socinski, MA
Rodig, SJ
Capelletti, M
Crawford, J
Edelman, MJ
Villalona-Calero, MA
Kratzke, RA
Vokes, EE
Miller, VA
Janne, PA
AF Stinchcombe, Tom
Sholl, Lynette M.
Wang, Xiaofei F.
Gu, Lin
Socinski, Mark A.
Rodig, Scott J.
Capelletti, Marzia
Crawford, Jeffrey
Edelman, Martin J.
Villalona-Calero, Miguel Angel
Kratzke, Robert Arthur
Vokes, Everett E.
Miller, Vincent A.
Janne, Pasi Antero
TI An analysis of the prevalence of HER2 and KRAS mutations, and ALK
rearrangements and clinical outcomes in Cancer and Leukemia Group B
[CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer
(NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ N Carolina, Chapel Hill, NC USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Canc & Leukemia Grp B Stat Ctr, Durham, NC USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Hematopathol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.
Univ Minnesota, Minneapolis, MN USA.
Univ Chicago Med & Biol Sci, Chicago, IL USA.
Fdn Med Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8039
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602520
ER
PT J
AU Strosberg, JR
Bobiak, S
Zornosa, CC
Choti, MA
Bergsland, EK
Benson, A
Bloomston, M
Kulke, M
Shah, MH
Yao, JC
AF Strosberg, Jonathan R.
Bobiak, Sarah
Zornosa, Carrie C.
Choti, Michael A.
Bergsland, Emily K.
Benson, Al Bowen
Bloomston, Mark
Kulke, Matthew
Shah, Manisha H.
Yao, James C.
TI Dosing patterns for octreotide LAR in neuroendocrine tumor (NET)
patients: NCCN NET outcomes database
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Natl Comprehens Canc Network, Ft Washington, PA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
Richard J Solove Res Inst, Columbus, OH USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RI Bloomston, Mark/E-2767-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4142
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601515
ER
PT J
AU Stuckey, A
Robison, K
Dizon, DS
Rogers, M
Ott, M
Miller, S
Politi, M
Clark, M
AF Stuckey, Ashley
Robison, Katina
Dizon, Don S.
Rogers, Michelle
Ott, Miles
Miller, Susan
Politi, Mary
Clark, Melissa
TI The role of oncologic health care providers in end of life discussions
for women with recurrent gynecologic or breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
Brown Univ, Publ Hlth Program, Providence, RI 02912 USA.
Washington Univ, Div Publ Hlth Sci, Sch Med St Louis, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e20543
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604812
ER
PT J
AU Stupp, R
Hegi, ME
Goriia, T
Erridge, S
Grujicic, D
Steinbach, JP
Wick, W
Tarnawski, R
Nam, DH
Weyerbrock, A
Hau, P
Taphoorn, MJB
Nabors, LB
Reardon, DA
Van den Bent, MJ
Perry, JR
Hong, YK
Hicking, C
Picard, M
Weller, M
AF Stupp, Roger
Hegi, Monika E.
Goriia, Thierry
Erridge, Sara
Grujicic, Danica
Steinbach, Joachim Peter
Wick, Wolfgang
Tarnawski, Rafal
Nam, Do-Hyun
Weyerbrock, Astrid
Hau, Peter
Taphoorn, Martin J. B.
Nabors, Louis B.
Reardon, David A.
Van den Bent, Martin J.
Perry, James R.
Hong, Yong Kil
Hicking, Christine
Picard, Martin
Weller, Michael
CA EORTC
Canadian Brain Tumor Consortium
CENTRIC Study Team
TI Cilengitide combined with standard treatment for patients with newly
diagnosed glioblastoma with O-6-methylguanine-DNA methyltransferase
(MGMT) promoter methylation: Final results of the multicenter,
randomized, open-label, controlled, phase III CENTRIC study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 CHU Vaudois, CH-1011 Lausanne, Switzerland.
EORTC Data Ctr, Brussels, Belgium.
Edinburgh Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
Clin Ctr Serbia, Inst Neurosurg, Belgrade, Serbia.
Klinikum JW Goethe Univ Frankfurt, Dr Senkenberg Inst Neuroonkol, Frankfurt, Germany.
Univ Klinikum Heidelberg, Heidelberg, Germany.
Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland.
Inst Oncol, Gliwice Branch, Radiotherapy & Chemotherapy Clin, Gliwice, Poland.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Univ Freiburg Klinikum, Freiburg, Germany.
Univ Klinikum Regensburg, Neurol & Wilhelm Sander Therapieeinheit NeuroOnko, Regensburg, Germany.
Med Ctr Haaglanden, The Hague, Netherlands.
Univ Alabama Birmingham, Birmingham, AL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Erasmus MC, Rotterdam, Netherlands.
Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea.
Merck KGaA, Darmstadt, Germany.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
RI Tarnawski, Rafal/N-7526-2016
NR 0
TC 0
Z9 0
U1 1
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA LBA2009
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605334
ER
PT J
AU Sullivan, RJ
Ibrahim, N
Lawrence, DP
Aldridge, J
Hodi, FS
Flaherty, K
Conley, C
DeNoble, S
Mier, JW
Cho, DC
Atkins, MB
McDermott, DF
AF Sullivan, Ryan J.
Ibrahim, Nageatte
Lawrence, Donald P.
Aldridge, Julie
Hodi, F. Stephen
Flaherty, Keith
Conley, Christine
DeNoble, Sarah
Mier, James Walter
Cho, Daniel C.
Atkins, Michael B.
McDermott, David F.
TI A phase I study of the combination of sorafenib (Sor) and bortezomib
(Bor) in patients (pts) with metastatic melanoma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Int Beast Canc Study Grp Stat Ctr, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9076
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602777
ER
PT J
AU Sznol, M
Kluger, HM
Hodi, FS
McDermott, DF
Carvajal, RD
Lawrence, DP
Topalian, SL
Atkins, MB
Powderly, JD
Sharfman, WH
Puzanov, I
Smith, DC
Wigginton, JM
Kollia, G
Gupta, AK
Sosman, JA
AF Sznol, Mario
Kluger, Harriet M.
Hodi, F. Stephen
McDermott, David F.
Carvajal, Richard D.
Lawrence, Donald P.
Topalian, Suzanne Louise
Atkins, Michael B.
Powderly, John D.
Sharfman, William Howard
Puzanov, Igor
Smith, David C.
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Sosman, Jeffrey Alan
TI Survival and long-term follow-up of safety and response in patients
(pts) with advanced melanoma (MEL) in a phase I trial of nivolumab
(anti-PD-1; BMS-936558; ONO-4538)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Canc Ctr, New Haven, CT USA.
Yale Univ, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
Carolina BioOncol Inst, Huntersville, NC USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA CRA9006
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603136
ER
PT J
AU Tanaka, S
Batchelor, T
Iafrate, AJ
Dias-Santagata, D
Borger, DR
Ellisen, LW
Yang, D
Louis, DN
Cahill, DP
Chi, AS
AF Tanaka, Shota
Batchelor, Tracy
Iafrate, Anthony John
Dias-Santagata, Dora
Borger, Darrell R.
Ellisen, Leif William
Yang, Daniel
Louis, David N.
Cahill, Daniel P.
Chi, Andrew S.
TI Association of PIK3CA-activating mutations with more disseminated
disease at presentation and earlier recurrence in glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2029
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600690
ER
PT J
AU Topalian, SL
Sznol, M
Brahmer, JR
McDermott, DF
Smith, DC
Gettinger, SN
Taube, JM
Drake, CG
Pardoll, DM
Powderly, JD
Carvajal, RD
Sosman, JA
Atkins, MB
Antonia, SJ
Spigel, DR
Lawrence, DP
Kollia, G
Gupta, AK
Wigginton, JM
Hodi, FS
AF Topalian, Suzanne Louise
Sznol, Mario
Brahmer, Julie R.
McDermott, David F.
Smith, David C.
Gettinger, Scott N.
Taube, Janis M.
Drake, Charles G.
Pardoll, Drew M.
Powderly, John D.
Carvajal, Richard D.
Sosman, Jeffrey Alan
Atkins, Michael B.
Antonia, Scott J.
Spigel, David R.
Lawrence, Donald P.
Kollia, Georgia
Gupta, Ashok Kumar
Wigginton, Jon M.
Hodi, F. Stephen
TI Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced
solid tumors: Survival and long-term safety in a phase I trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Yale Canc Ctr, New Haven, CT USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Yale Univ, New Haven, CT USA.
Johns Hopkins Sch Med, Baltimore, MD USA.
Carolina BioOncol Inst, Huntersville, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3002
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601135
ER
PT J
AU Touqir, Z
Shaheen, S
Upadhyay, S
Marak, CP
Kumar, G
Guddati, AK
AF Touqir, Zahra
Shaheen, Shagufta
Upadhyay, Shivanck
Marak, Creticus Petrov
Kumar, Gagan
Guddati, Achuta Kumar
TI Outcomes of severe sepsis in very elderly (age > 80 years) patients with
metastatic cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Columbia Univ, Ctr Hosp, New York, NY USA.
Montefiore Hosp, Albert Einstein Coll Med, New York, NY USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9558
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603041
ER
PT J
AU Tsao, CK
Gray, KP
Nakabayashi, M
Evan, C
Galsky, MD
Kantoff, PW
Oh, WK
Pomerantz, M
AF Tsao, Che-Kai
Gray, Kathryn P.
Nakabayashi, Mari
Evan, Caroline
Galsky, Matt D.
Kantoff, Philip W.
Oh, William K.
Pomerantz, Mark
TI Association of Gleason 9-10 prostate cancer with worse outcomes compared
to Gleason 8 disease.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mt Sinai Med Ctr, New York, NY 10029 USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA.
Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e16032
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604223
ER
PT J
AU Tseng, YD
Paciorek, AT
Martin, NE
D'Amico, AV
Cooperberg, MR
Nguyen, PL
AF Tseng, Yolanda Diana
Paciorek, Alan T.
Martin, Neil E.
D'Amico, Anthony Victor
Cooperberg, Matthew R.
Nguyen, Paul Linh
TI Impact of prostate cancer national guidelines on brachytherapy
monotherapy practice patterns
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5024
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601625
ER
PT J
AU Uno, H
Cronin, A
Schrag, D
Abel, GA
AF Uno, Hajime
Cronin, Angel
Schrag, Deborah
Abel, Gregory Alan
TI Derivation and validation of the SEER-Medicare MDS risk score (SMMRS).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Uno, Hajime; Cronin, Angel; Schrag, Deborah; Abel, Gregory Alan] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7128
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602485
ER
PT J
AU Urun, Y
Gray, KP
Signoretti, S
McDermott, DF
Atkins, MB
Lampron, ME
Freedman, M
Choueiri, TK
Pomerantz, MM
AF Urun, Yuksel
Gray, Kathryn P.
Signoretti, Sabina
McDermott, David F.
Atkins, Michael B.
Lampron, Megan E.
Freedman, Matthew
Choueiri, Toni K.
Pomerantz, Mark M.
TI Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity
in patients with metastatic renal cell carcinoma (mRCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4570
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601584
ER
PT J
AU Vakiavas, C
Abramson, VG
Lin, NU
Liu, MC
Rugo, HS
Nanda, R
Storniolo, AM
Traina, TA
Li, YF
Patil, S
Hayes, DF
Van Poznak, CH
Nangia, JR
Irvin, WJ
Krontiras, H
De Los Santos, JF
Haluska, P
Wolff, AC
Forero-Torres, A
AF Vakiavas, Christos
Abramson, Vandana Gupta
Lin, Nancy U.
Liu, Minetta C.
Rugo, Hope S.
Nanda, Rita
Storniolo, Anna Maria
Traina, Tiffany A.
Li, Yufeng
Patil, Sujata
Hayes, Daniel F.
Van Poznak, Catherine H.
Nangia, Julie R.
Irvin, William Johnson
Krontiras, Helen
De Los Santos, Jennifer F.
Haluska, Paul
Wolff, Antonio C.
Forero-Torres, Andres
CA TBCRC
TI TBCRC 019: An open label, randomized, phase II trial of nanoparticle
albumin-bound paclitaxel (nab-PAC) with or without the anti-death
receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with
metastatic triple negative breast cancer (TNBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Alabama Birmingham, Birmingham, AL USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Chicago, Chicago, IL 60637 USA.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Rush Univ, Med Ctr, Houston, TX USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Mayo Clin, Rochester, MN USA.
Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1052
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600292
ER
PT J
AU Van Allen, EM
Wagle, N
Carter, SL
Sucker, A
Farlow, DN
Hodis, F
Taylor-Weiner, A
Berking, C
Egberts, F
Hassel, JC
Gogas, H
Gutzmer, R
Goldinger, SM
Loquai, C
Ugurel, S
Zimmer, L
Gabriel, SB
Getz, G
Garraway, LA
Schadendorf, D
AF Van Allen, Eliezer Mendel
Wagle, Nikhil
Carter, Scott L.
Sucker, Antje
Farlow, Deborah Norman
Hodis, Fran
Taylor-Weiner, Amara
Berking, Carola
Egberts, Friederike
Hassel, Jessica Cecile
Gogas, Helen
Gutzmer, Ralf
Goldinger, Simone M.
Loquai, Carmen
Ugurel, Selma
Zimmer, Lisa
Gabriel, Stacey B.
Getz, Gad
Garraway, Levi A.
Schadendorf, Dirk
CA DeCOG
TI The genetic landscape of clinical resistance to RAF inhibition in
melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Broad Inst, Cambridge, MA USA.
Univ Hosp Essen, Essen, Germany.
Univ Munich, Dept Dermatol, Munich, Germany.
Univ Kiel, Kiel, Germany.
Univ Heidelberg Hosp, Univ Hautklin, Hauttumorzentrum, Heidelberg, Germany.
Hellen Cooperat Oncol Grp HeCOG, Athens, Greece.
Hannover Med Sch, D-30623 Hannover, Germany.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
Johannes Gutenberg Univ Mainz, Univ Med, D-55122 Mainz, Germany.
Univ Wurzburg, D-97070 Wurzburg, Germany.
Univ Hosp, Dept Dermatol, Essen, Germany.
Univ Klinikum Essen, Essen, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 11009
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600419
ER
PT J
AU Van Cutsem, E
Fram, RJ
Schlichting, M
Ryan, DP
AF Van Cutsem, Eric
Fram, Robert J.
Schlichting, Michael
Ryan, David P.
TI Efficacy and safety of gemcitabine in combination with TH-302 compared
with gemcitabine in combination with placebo in previously untreated
patients with metastatic or locally advanced unresectable pancreatic
adenocarcinoma: The MAESTRO trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Hosp Leuven, Louvain, Belgium.
EMD Serono Inc, Rockland, MA USA.
Merck KGaA, Darmstadt, Germany.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS4148
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605432
ER
PT J
AU Van Loon, K
Owzar, K
Jiang, C
Kindler, HL
Mulcahy, MF
Niedzwiecki, D
O'Reilly, EM
Fuchs, CS
Innocenti, F
Venook, AP
AF Van Loon, Katherine
Owzar, Kouros
Jiang, Chen
Kindler, Hedy Lee
Mulcahy, Mary Frances
Niedzwiecki, Donna
O'Reilly, Eileen Mary
Fuchs, Charles S.
Innocenti, Federico
Venook, Alan Paul
TI 25-hydroxyvitamin D levels and survival in patients with advanced
pancreatic cancer (APC): Findings from CALGB 80303
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
Duke Univ, Durham, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4022
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601397
ER
PT J
AU Vergote, I
Teneriello, M
Powell, MA
Miller, DS
Garcia, AA
Mikheeva, ON
Pinter, T
Bidzinski, M
Cebotaru, CL
Fan, J
Ren, M
Meneses, N
Funahashi, Y
Kadowaki, T
O'Brien, JP
Penson, RT
AF Vergote, Ignace
Teneriello, Michael
Powell, Matthew A.
Miller, David S.
Garcia, Agustin A.
Mikheeva, Olga N.
Pinter, Tamas
Bidzinski, Mariusz
Cebotaru, Cristina Ligia
Fan, Jean
Ren, Min
Meneses, Nicole
Funahashi, Yasuhiro
Kadowaki, Tadashi
O'Brien, James P.
Penson, Richard T.
TI A phase II trial of lenvatinib in patients with advanced or recurrent
endometrial cancer: Angiopoietin-2 as a predictive marker for clinical
outcomes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 UZ Leuven, Leuven, Belgium.
US Oncol, The Woodlands, TX USA.
Washington Univ, Sch Med, St Louis, MO USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ So Calif, Los Angeles, CA USA.
Leningrad Reg Oncol Ctr, State Healthcare Inst, St Petersburg, Russia.
Aladar Petz Teaching Cty Hosp, Gyor, Hungary.
Maria Sklodowska Curie Mem Inst Oncol, Warsaw, Poland.
Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania.
Eisai Inc, Woodcliff Lake, NJ USA.
Eisai Inc, Andover, MA USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
RI Miller, David/H-4604-2011
OI Miller, David/0000-0002-8215-5887
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5520
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602034
ER
PT J
AU Wagle, N
Van Allen, EM
Frederick, DT
Cooper, ZA
Farlow, DN
Treacy, D
Goetz, EM
Johannessen, CM
Carter, SL
Taylor-Weiner, A
Hodis, E
Lawrence, DP
Sullivan, RJ
Getz, G
Gabriel, SB
Flaherty, K
Wargo, JA
Garraway, LA
AF Wagle, Nikhil
Van Allen, Eliezer Mendel
Frederick, Dennie T.
Cooper, Zachary A.
Farlow, Deborah Norman
Treacy, Daniel
Goetz, Eva M.
Johannessen, Cory M.
Carter, Scott L.
Taylor-Weiner, Amaro
Hodis, Eran
Lawrence, Donald P.
Sullivan, Ryan J.
Getz, Gad
Gabriel, Stacey B.
Flaherty, Keith
Wargo, Jennifer Ann
Garraway, Levi A.
TI Whole exome and whole transcriptome sequencing in melanoma patients to
identify mechanisms of resistance to combined RAF/MEK inhibition
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Broad Inst, Cambridge, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9015
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602716
ER
PT J
AU Warren, JL
Mariotto, A
Melbert, D
Schrag, D
Doria-Rose, P
Penson, DF
Yabroff, KR
AF Warren, Joan L.
Mariotto, Angela
Melbert, Danielle
Schrag, Deborah
Doria-Rose, Paul
Penson, David F.
Yabroff, K. Robin
TI Sensitivity of Medicare claims to identify recurrence
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NCI, Bethesda, MD 20892 USA.
Informat Management Serv Inc, Beltsville, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6522
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602241
ER
PT J
AU Wattson, DA
Shih, HA
Niemierko, A
Merritt, RM
Lawrence, DP
Oh, KS
Sullivan, RJ
Flaherty, K
AF Wattson, Daniel A.
Shih, Helen Alice
Niemierko, Andrzej
Merritt, Ryan M.
Lawrence, Donald P.
Oh, Kevin S.
Sullivan, Ryan J.
Flaherty, Keith
TI Survival patterns following brain metastases for patients with melanoma
in the targeted therapy era
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9064
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602765
ER
PT J
AU Weidhaas, JB
Lee, JW
Slebos, R
Howard, J
Perez, J
Gilbert, J
Nallur, S
Paranjape, T
Garcia, JJ
Burtness, B
Forastiere, AA
Chung, CH
AF Weidhaas, Joanne B.
Lee, Ju-Whei
Slebos, Robbert
Howard, Jason
Perez, Jimena
Gilbert, Jill
Nallur, Sunitha
Paranjape, Trupti
Garcia, Joaquin J.
Burtness, Barbara
Forastiere, Arlene A.
Chung, Christine H.
TI Association of the 3 '-untranslated region KRAS-variant with cisplatin
resistance in patients with recurrent and/or metastatic head and neck
squamous cell carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Univ, Sch Med, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Yale Univ, New Haven, CT USA.
Mayo Clin, Rochester, MN USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Eviti Inc, Philadelphia, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6016
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602140
ER
PT J
AU Weiss, M
Gertz, MA
Little, RF
Rajkumar, V
Jacobus, SJ
Abonour, R
Anderson, KC
Barlogie, B
Callander, NS
Gorak, EJ
Matous, J
Mills, GM
Kane, RC
Katz, MS
Jensen, L
Omel, J
Orlowski, RZ
Richardson, PGG
Munshi, NC
AF Weiss, Matthias
Gertz, Morie A.
Little, Richard F.
Rajkumar, Vincent
Jacobus, Susanna J.
Abonour, Rafat
Anderson, Kenneth Carl
Barlogie, Bart
Callander, Natalie Scott
Gorak, Edward J.
Matous, Jeffrey
Mills, Glenn Morris
Kane, Robert C.
Katz, Michael S.
Jensen, LeeAnn
Omel, James
Orlowski, Robert Z.
Richardson, Paul Gerard Guy
Munshi, Nikhil C.
TI Strategies to overcome barriers to accrual (BtA) to NCI-sponsored
clinical trials: A project of the NCI-Myeloma Steering Committee Accrual
Working Group (NCI-MYSC AWG)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA.
Mayo Clin, Rochester, MN USA.
NCI, Rockville, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Myeloma Inst Res & Therapy, Little Rock, AR USA.
Univ Wisconsin, Madison, WI USA.
Geisinger Med Ctr, Danville, PA 17822 USA.
Rocky Mt Canc Centers, Denver, CO USA.
LSU Hlth Sci Ctr, Shreveport, LA USA.
US FDA, Silver Spring, MD USA.
Int Myeloma Fdn, North Hollywood, CA USA.
Patient Advocate, Rockville, MD USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
VA Boston Healthcare Syst, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8592
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602687
ER
PT J
AU Wen, PY
Yung, WKA
Mellinghoff, IK
Lamborn, K
Ramkissoon, S
Cloughesy, TF
Rinne, M
Omuro, AMP
DeAngelis, LM
Gilbert, MR
Chi, AS
Batchelor, T
Colman, H
Chang, SM
Massacesi, C
DiTomaso, E
Prados, M
Reardon, DA
Ligon, KL
AF Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Lamborn, Kathleen
Ramkissoon, Shakti
Cloughesy, Timothy Francis
Rinne, Mikael
Omuro, Antonio Marcilio Padula
DeAngelis, Lisa Marie
Gilbert, Mark R.
Chi, Andrew S.
Batchelor, Tracy
Colman, Howard
Chang, Susan Marina
Massacesi, Cristian
DiTomaso, Emmanuelle
Prados, Michael
Reardon, David A.
Ligon, Keith L.
TI Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor
BKM120 in recurrent glioblastoma (GBM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Novartis Pharma SAS, Rueil Malmaison, France.
Novartis Inst BioMed Res Inc, Cambridge, MA USA.
Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA.
RI Gilbert, Mark/J-7494-2016
OI Gilbert, Mark/0000-0003-2556-9722
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2015
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600676
ER
PT J
AU Wirth, LJ
Dakhil, SR
Kornek, G
Axelrod, R
Adkins, D
Pant, S
O'Brien, PE
Debruyne, PR
Oliner, KS
Dong, J
Bach, BA
AF Wirth, Lori J.
Dakhil, Shaker R.
Kornek, Gabriela
Axelrod, Rita
Adkins, Douglas
Pant, Shubham
O'Brien, Paul E.
Debruyne, Philip R.
Oliner, Kelly S.
Dong, Jun
Bach, Bruce A.
TI PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis)
chemotherapy with or without panitumumab (pmab) as first-line treatment
(tx) for recurrent or metastatic squamous cell carcinoma of the head and
neck (R/M SCCHN)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Canc Ctr Kansas, Wichita, KS USA.
Med Univ Wien, Vienna, Austria.
Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA.
Washington Univ Sch Med, St Louis, MO USA.
Univ Oklahoma Hlth Sci Ctr, Oklahoma City, OK USA.
Med Univ S Carolina, Charleston, SC 29425 USA.
AZ Groeninge Hosp, Kortrijk, Belgium.
Amgen Inc, Thousand Oaks, CA 91320 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6029
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602153
ER
PT J
AU Wood, ME
Qin, R
Le-Petross, HT
Hwang, ES
Ligibel, JA
Mayer, IA
Marshall, JR
Goodwin, PJ
AF Wood, Marie E.
Qin, Rui
Le-Petross, Hthong T.
Hwang, E. Shelley
Ligibel, Jennife A.
Mayer, Ingrid A.
Marshall, James Roger
Goodwin, Pamela Jean
TI Change in mammographic density with metformin use: A companion study to
NCIC study MA.32.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Vermont, Coll Med, Burlington, VT USA.
Mayo Clin, Rochester, MN USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Duke Univ, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS1608
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605381
ER
PT J
AU Wright, AA
Earle, C
Keating, NL
AF Wright, Alexi A.
Earle, Craig
Keating, Nancy Lynn
TI End-of-life care for Medicare beneficiaries with ovarian cancer:
Evaluation of intensity and rate of hospitalizations
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Clin Evaluat Sci, Toronto, ON, Canada.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9523
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603006
ER
PT J
AU Xu, CF
Johnson, T
Choueiri, TK
Deen, KC
Xue, ZY
Spraggs, CF
Bartlett-Pandite, AN
Carpenter, C
Motzer, RJ
AF Xu, Chun-Fang
Johnson, Toby
Choueiri, Toni K.
Deen, Keith C.
Xue, Zhengyu
Spraggs, Colin F.
Bartlett-Pandite, Arundathy N.
Carpenter, Christopher
Motzer, Robert John
TI Association of IL8 polymorphisms with overall survival in patients with
renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III
study)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 GlaxoSmithKline, Harlow, Essex, England.
GlaxoSmithKline, Uxbridge, Middx, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
GlaxoSmithKline, Collegeville, PA USA.
GlaxoSmithKline, Res Triangle Pk, NC USA.
GlaxoSmithKline Res & Dev Ltd, Collegeville, PA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4519
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601533
ER
PT J
AU Yardley, DA
Hortobagyi, GN
Lebrun, F
Beck, JT
Neven, P
Baselga, J
Petrakova, K
Dakhil, SR
Sabatini, S
Komorowski, A
Chouinard, EE
Young, RR
Gnant, M
Pritchard, KI
Zhang, J
Ziemiecki, R
Panneerselvam, A
Taran, T
Sahmoud, T
Noguchi, S
AF Yardley, Denise Aysel
Hortobagyi, Gabriel N.
Lebrun, Fabienne
Beck, J. Thaddeus
Neven, Patrick
Baselga, Jose
Petrakova, Katarina
Dakhil, Shaker R.
Sabatini, Silvia
Komorowski, Anna
Chouinard, Edmond Emilien
Young, Robyn R.
Gnant, Michael
Pritchard, Kathleen I.
Zhang, Jie
Ziemiecki, Ryan
Panneerselvam, Ashok
Taran, Tanya
Sahmoud, Tarek
Noguchi, Shinzaburo
TI Patient-reported physical, emotional, and social functioning in advanced
breast cancer: Insights from BOLERO-2.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Inst Jules Bordet, B-1000 Brussels, Belgium.
Highlands Oncol Grp, Fayetteville, AR USA.
Hosp Gasthuisberg, Louvain, Belgium.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Masaryk Mem Canc Inst, Brno, Czech Republic.
Canc Ctr Kansas, Wichita, KS USA.
Hosp Santa Maria, Terni, Italy.
Hematol Oncol Associates Rockland, Nyack, NY USA.
Cambridge Mem Hosp, Cambridge, ON, Canada.
Ctr Canc & Blood Disorders, Ft Worth, TX USA.
Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria.
Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada.
Univ Toronto, Toronto, ON, Canada.
Novartis Pharmaceut, Florham Pk, NJ USA.
RTI Hlth Solut, Res Triangle Pk, NC USA.
Novartis Pharmaceut, Florham Pk, NJ USA.
Novartis Pharmaceut, Global Oncol Dev, Florham Pk, NJ USA.
Osaka Univ, Osaka, Japan.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 553
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600058
ER
PT J
AU Yoo, SM
Werner, L
Nakabayashi, M
Sweeney, C
Hirsch, MS
Kantoff, PW
Pomerantz, MM
AF Yoo, Sun Mi
Werner, Lillian
Nakabayashi, Mari
Sweeney, Christopher
Hirsch, Michelle S.
Kantoff, Philip W.
Pomerantz, Mark M.
TI Clinicopathologic features and clinical outcomes associated with Gleason
upgrading from biopsy to radical prostatectomy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5056
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601654
ER
PT J
AU Youn, T
Jacene, HA
Dipiro, P
Tanaka, Y
Bellon, JR
Nakhlis, F
Hirshfield-Bartek, J
Yeh, E
Overmoyer, B
AF Youn, Trisha
Jacene, Heather A.
Dipiro, Pamela
Tanaka, Yoko
Bellon, Jennifer Ruth
Nakhlis, Faina
Hirshfield-Bartek, Judith
Yeh, Eren
Overmoyer, Beth
TI Metabolic characterization of inflammatory breast cancer (IBC) with
baseline FDG-PET/CT: Relationship with histopathology, hormone receptor
status, and pathologic response after neoadjuvant chemotherapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1105
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600463
ER
PT J
AU Yu, EY
Duan, FH
Muzi, M
Gorelick, J
Chin, B
Alumkal, JJ
Taplin, ME
Herman, B
Higano, CS
Doot, RK
Hartfeil, DM
Febbo, PG
Mankoff, DA
AF Yu, Evan Y.
Duan, Fenghai
Muzi, Mark
Gorelick, Jeremy
Chin, Bennett
Alumkal, Joshi J.
Taplin, Mary-Ellen
Herman, Ben
Higano, Celestia S.
Doot, Robert K.
Hartfeil, Donna M.
Febbo, Phillip G.
Mankoff, David A.
CA Dept Def Prostate Canc Clinical
Amer Coll Radiology Imaging
TI Correlation of F-18-fluoride PET response to dasatinib in
castration-resistant prostate cancer bone metastases with
progression-free survival: Preliminary results from ACRIN 6687
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
Brown Univ, Providence, RI 02912 USA.
Univ Washington, Seattle, WA 98195 USA.
Duke Univ, Durham, NC USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
Amer Coll Radiol Imaging Network, Philadelphia, PA USA.
Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
Univ Penn, Philadelphia, PA 19104 USA.
RI Duan, Fenghai/J-3709-2014
OI Duan, Fenghai/0000-0002-5084-0070
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5003
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601604
ER
PT J
AU Zafar, Y
Abernethy, AP
Tulsky, JA
Ubel, PA
Schrag, D
Rushing, C
Chino, F
Nicolla, J
Altomare, I
Samsa, G
Peppercorn, JM
AF Zafar, Yousuf
Abernethy, Amy Pickar
Tulsky, James A.
Ubel, Peter A.
Schrag, Deborah
Rushing, Christel
Chino, Fumiko
Nicolla, Jonathan
Altomare, Ivy
Samsa, Greg
Peppercorn, Jeffrey M.
TI Financial distress, communication, and cancer treatment decision making:
Does cost matter?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Duke Univ, Med Ctr, Durham, NC USA.
Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC USA.
Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Sch Med, Durham, NC USA.
Duke Univ, Med Ctr, Dept Biostat & Informat, Durham, NC USA.
Duke Canc Inst, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6506
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602226
ER
PT J
AU Zeghibe, CA
Luis, IMVD
Frank, ES
Sohl, J
Washington, KE
Silverman, SG
Fonte, JM
Mayer, EL
Overmoyer, B
Richardson, AL
Krop, IE
Winer, EP
Lin, NU
AF Zeghibe, Catherine A.
Luis, Ines Maria Vaz Duarte
Frank, Elizabeth S.
Sohl, Jessica
Washington, Kimberly E.
Silverman, Stuart G.
Fonte, Joseph M.
Mayer, Erica L.
Overmoyer, Beth
Richardson, Andrea L.
Krop, Ian E.
Winer, Eric P.
Lin, Nancy U.
TI Prospective clinical experience with research biopsies in breast cancer
patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Faulkner Hosp, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e17574
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604443
ER
PT J
AU Zeidan, A
Sun, ZX
Prebet, T
Greenberg, P
Juckett, M
Smith, MR
Paietta, E
Gabrilove, JL
Erba, HP
Gore, S
Tallman, MS
AF Zeidan, Amer
Sun, Zhuoxin
Prebet, Thomas
Greenberg, Peter
Juckett, Mark
Smith, Mitchell Reed
Paietta, Elisabeth
Gabrilove, Janice Lynn
Erba, Harry P.
Gore, Steven
Tallman, Martin S.
CA Eastern Cooperative Oncology Grp
TI Application of the French prognostic score (FPS) to assess overall
survival (OS) in a US-based cohort of patients (pts) treated with
azacitidine (Aza).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Aix Marseille Univ, Marseille, France.
Stanford Univ, Stanford, CA 94305 USA.
Univ Wisconsin, Madison, WI USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Montefiore Med Ctr, North Div, New York, NY USA.
Icahn Sch Med Mt Sinai, New York, NY USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7126
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602483
ER
PT J
AU Zhang, Y
Schnabel, CA
Schroeder, B
Jerevall, PL
Jankowitz, RC
Stal, O
Brufsky, A
Sgroi, D
Erlander, MG
AF Zhang, Yi
Schnabel, Catherine A.
Schroeder, Brock
Jerevall, Piiha-Lotta
Jankowitz, Rachel Catherine
Stal, Olle
Brufsky, Adam
Sgroi, Dennis
Erlander, Mark G.
TI Prediction of early and late distant recurrence in early-stage breast
cancer with Breast Cancer Index
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 BioTheranost Inc, San Diego, CA USA.
Massachusetts Gen Hosp, Charlestown, MA USA.
Univ Pittsburgh, Med Ctr, Magee Womens Canc Program, Pittsburgh, PA USA.
Linkoping Univ, Linkoping, Sweden.
Univ Pittsburgh, Sch Med, Div Hematol & Oncol, Pittsburgh, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 594
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600099
ER
PT J
AU Zuo, ZX
Keck, MK
Khattri, A
Patel, RD
Walter, K
Lingen, MW
White, KP
Hammerman, PS
Cohen, EEW
Stenson, K
Blair, EA
Shames, DS
Vokes, EE
Seiwert, TY
AF Zuo, Zhixiang
Keck, Michaela K.
Khattri, Arun
Patel, Rajesh D.
Walter, Kim
Lingen, Mark W.
White, Kevin P.
Hammerman, Peter S.
Cohen, Ezra E. W.
Stenson, Kerstin
Blair, Elizabeth A.
Shames, David S.
Vokes, Everett E.
Seiwert, Tanguy Y.
TI Multimodality determination of HPV status in head and neck cancers (HNC)
and development of an HPV signature
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Univ Chicago, Chicago, IL 60637 USA.
Genentech Inc, San Francisco, CA 94080 USA.
Univ Chicago Med & Biol Sci, Chicago, IL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Zuo, Zhixiang/M-4441-2016
OI Zuo, Zhixiang/0000-0002-2492-2689
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6008
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602133
ER
PT J
AU De Waal, EM
Liang, HY
Pierce, A
Hamilton, RT
Buffenstein, R
Chaudhuri, AR
AF De Waal, Eric M.
Liang, Hanyu
Pierce, Anson
Hamilton, Ryan T.
Buffenstein, Rochelle
Chaudhuri, Asish R.
TI Elevated protein carbonylation and oxidative stress do not affect
protein structure and function in the long-living naked-mole rat: A
proteomic approach
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Naked-mole rat; Peroxiredoxin 1; Triosephosphate isomerase; Protein
carbonylation; Oxidative stress
ID AGE-RELATED-CHANGES; 2-CYS PEROXIREDOXIN; TRIOSEPHOSPHATE ISOMERASE;
CRYSTAL-STRUCTURE; LONGEVITY; RODENT; ERYTHROCYTES; DISEASE
AB The 'oxidative stress theory of aging' predicts that aging is primarily regulated by progressive accumulation of oxidized macromolecules that cause deleterious effects to cellular homeostasis and induces a decline in physiological function. However, our reports on the detection of higher level of oxidized protein carbonyls in the soluble cellular fractions of long-living rodent naked-mole rats (NMRs, lifespan similar to 30 yrs) compared to short-lived mice (lifespan similar to 3.5 yrs) apparently contradicts a key tenet of the oxidative theory. As oxidation often inactivates enzyme function and induces higher-order soluble oligomers, we performed a comprehensive study to measure global protein carbonyl level in different tissues of age-matched NMRs and mice to determine if the traditional concept of oxidation mediated impairment of function and induction of higher-order structures of proteins are upheld in the NMRs. We made three intriguing observations with NMRs proteins: (1) protein carbonyl is significantly elevated across different tissues despite of its exceptional longevity, (2) enzyme function is restored despite of experiencing higher level of protein carbonylation, and (3) enzymes show lesser sensitivity to form higher-order non-reducible oligomers compared to short-living mouse proteins in response to oxidative stress. These observations were made based on the global analysis of protein carbonyl and identification of two heavily carbonylated proteins in the kidney, triosephosphate isomerase (TPI) and cytosolic peroxiredoxin (Prdx1). These un-expected intriguing observations thus strongly suggest that oxidative modification may not be the only criteria for impairment of protein and enzyme function; cellular environment is likely be the critical determining factor in this process and may be the underlying mechanism for exceptional longevity of NMR. (C) 2013 Elsevier Inc. All rights reserved.
C1 [De Waal, Eric M.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
[Liang, Hanyu] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA.
[Pierce, Anson] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
[Buffenstein, Rochelle; Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Hamilton, Ryan T.; Buffenstein, Rochelle] South Texas Vet Hlth Care Syst, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Chaudhuri, Asish R.] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
[Hamilton, Ryan T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chaudhuria@uthscsa.edu
FU National Institutes of Health/National Institute on Aging [K07 AG025063
04]; NIH/NIA [RO1AG-022891]
FX This work was supported by the National Institutes of Health/National
Institute on Aging pilot Grants K07 AG025063 04 (to A.C.) and from an
NIH/NIA RO1AG-022891 (to R.B.). The following funding sources had no
involvement in the interpretation, representation or publication of the
work other providing the funding necessary.
NR 20
TC 8
Z9 8
U1 1
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 17
PY 2013
VL 434
IS 4
BP 815
EP 819
DI 10.1016/j.bbrc.2013.04.019
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 161SI
UT WOS:000320213200020
PM 23618867
ER
PT J
AU Slopen, N
Goodman, E
Koenen, KC
Kubzansky, LD
AF Slopen, Natalie
Goodman, Elizabeth
Koenen, Karestan C.
Kubzansky, Laura D.
TI Socioeconomic and Other Social Stressors and Biomarkers of
Cardiometabolic Risk in Youth: A Systematic Review of Less Studied Risk
Factors
SO PLOS ONE
LA English
DT Review
ID CARDIOVASCULAR-DISEASE RISK; ADVERSE CHILDHOOD EXPERIENCES; BODY-MASS
INDEX; INSULIN-RESISTANCE; HEART-DISEASE; METABOLIC SYNDROME; ALLOSTATIC
LOAD; YOUNG-PEOPLE; WAIST CIRCUMFERENCE; PHYSICAL-ACTIVITY
AB Background: Socioeconomic disadvantage and other social stressors in childhood have been linked with cardiometabolic diseases in adulthood; however the mechanisms underlying these observed associations and the timing of their emergence are unclear. The aim of this review was to evaluate research that examined relationships between socioeconomic disadvantage and other social stressors in relation to less-studied cardiometabolic risk factors among youth, including carbohydrate metabolism-related factors, lipids, and central adiposity.
Methods: We searched PubMed and ISI Web of Science to identify relevant publications between 2001 and 2013. Studies were selected based on 4 criteria: (1) the study examined an association between at least one social or economic stressor and one relevant outcome prior to age 21; (2) the sample originated from a high-income country; (3) the sample was not selected based on a health condition; and (4) a central aim was to evaluate the effect of the social or economic stressor on at least one relevant outcome. Abstracts were screened and relevant publications were obtained and evaluated for inclusion criteria. We abstracted data from selected articles, summarized them by exposures and outcomes, and assigned an evidence grade.
Results: Our search identified 37 publications from 31 studies. Socioeconomic disadvantage was consistently associated with greater central adiposity. Research to date does not provide clear evidence of an association between childhood stressors and lipids or carbohydrate metabolism-related factors.
Conclusions: This review demonstrates a paucity of research on the relationship of socioeconomic disadvantage and other social stressors to lipid and carbohydrate metabolism-related factors in youth. Accordingly, it is not possible to form strong conclusions, particularly with regard to stressors other than socioeconomic disadvantage. Findings are used to inform priorities for future research. An improved understanding of these pathways is critical for identifying novel prevention targets and intervention opportunities to protect the long-term health of children and adolescents.
C1 [Slopen, Natalie] Harvard Univ, Ctr Developing Child, Cambridge, MA 02138 USA.
[Slopen, Natalie; Kubzansky, Laura D.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
[Goodman, Elizabeth] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA.
[Goodman, Elizabeth] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Koenen, Karestan C.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
RP Slopen, N (reprint author), Harvard Univ, Ctr Developing Child, Cambridge, MA 02138 USA.
EM nslopen@hsph.harvard.edu
RI Koenen, Karestan/K-5402-2014
OI Koenen, Karestan/0000-0003-3293-4281
FU NIH [DL46200]; Robert Wood Johnson Foundation
FX This research was supported in part by NIH grant DL46200, and funding
from the Robert Wood Johnson Foundation to support the research related
to the Early Childhood Innovation Project at the Center on the
Developing Child. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 85
TC 4
Z9 5
U1 7
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2013
VL 8
IS 5
AR e64418
DI 10.1371/journal.pone.0064418
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RJ
UT WOS:000319107900098
PM 23691213
ER
PT J
AU Rosen, LS
Lipton, L
Price, TJ
Belman, ND
Boccia, RV
Hurwitz, HI
Stephenson, JJ
Wirth, LJ
Mccoy, S
Hei, Y
Hsu, CP
Tebbutt, NC
AF Rosen, Lee S.
Lipton, Lara
Price, Timothy J.
Belman, Neil D.
Boccia, Ralph V.
Hurwitz, Herbert I.
Stephenson, Joe J., Jr.
Wirth, Lori J.
Mccoy, Sheryl
Hei, Yong-jiang
Hsu, Cheng-Pang
Tebbutt, Niall C.
TI The effect of different dosing regimens of motesanib on the gallbladder:
a randomized phase 1b study in patients with advanced solid tumors
SO BMC CANCER
LA English
DT Article
ID RENAL-CELL CARCINOMA; GASTROINTESTINAL STROMAL TUMORS; ORAL ANGIOGENESIS
INHIBITOR; IMATINIB MESYLATE; LUNG-CANCER; CONTROLLED-TRIALS;
CLINICAL-TRIALS; THYROID-CANCER; SAFETY; COMBINATION
AB Background: Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit. We assessed effects of motesanib on gallbladder size and function.
Methods: Patients with advanced metastatic solid tumors ineligible for or progressing on standard-of-care therapies with no history of cholecystitis or biliary disease were randomized 2:1:1 to receive motesanib 125 mg once daily (Arm A); 75 mg twice daily (BID), 14-days-on/7-days-off (Arm B); or 75 mg BID, 5-days-on/2-days-off (Arm C). Primary endpoints were mean change from baseline in gallbladder size (volume by ultrasound; independent review) and function (ejection fraction by CCK-HIDA; investigator assessment).
Results: Forty-nine patients received >= 1 dose of motesanib (Arms A/B/C, n = 25/12/12). Across all patients, gallbladder volume increased by a mean 22.2 cc (from 38.6 cc at baseline) and ejection fraction decreased by a mean 19.2% (from 61.3% at baseline) during treatment. Changes were similar across arms and appeared reversible after treatment discontinuation. Three patients had cholecystitis (grades 1, 2, 3, n = 1 each) that resolved after treatment discontinuation, one patient developed grade 3 acute cholecystitis requiring cholecystectomy, and two patients had other notable grade 1 gallbladder disorders (gallbladder wall thickening, gallbladder dysfunction) (all in Arm A). Two patients developed de novo gallstones during treatment. Twelve patients had right upper quadrant pain (Arms A/B/C, n = 8/1/3). The incidence of biliary "sludge" in Arms A/B/C was 39%/36%/27%.
Conclusions: Motesanib treatment was associated with increased gallbladder volume, decreased ejection fraction, biliary sludge, gallstone formation, and infrequent cholecystitis.
C1 [Rosen, Lee S.] Univ Calif Los Angeles, Dept Med, Santa Monica, CA USA.
[Lipton, Lara] Western Hosp, Footscray, Vic, Australia.
[Lipton, Lara] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
[Price, Timothy J.] Univ Adelaide, Queen Elizabeth Hosp, Sch Med, Woodville, SA 5011, Australia.
[Belman, Neil D.] Oncol Hematol Lehigh Valley, Bethlehem, PA USA.
[Boccia, Ralph V.] Ctr Canc & Blood Disorders, Bethesda, MD USA.
[Hurwitz, Herbert I.] Duke Univ, Med Ctr, Durham, NC USA.
[Stephenson, Joe J., Jr.] Canc Ctr Carolinas, Greenville, SC USA.
[Wirth, Lori J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wirth, Lori J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mccoy, Sheryl] Amgen Inc, Dept Biostat, San Francisco, CA USA.
[Hei, Yong-jiang] Amgen Inc, Dept Oncol, Thousand Oaks, CA 91320 USA.
[Hsu, Cheng-Pang] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA.
[Tebbutt, Niall C.] Austin Hosp, Ludwig Oncol Unit, Heidelberg, Vic 3084, Australia.
RP Rosen, LS (reprint author), Univ Calif Los Angeles, Dept Med, Santa Monica, CA USA.
EM LRosen@mednet.ucla.edu
RI Price, Timothy/G-1404-2012
OI Price, Timothy/0000-0002-3922-2693
FU Amgen Inc.; GSK
FX LSR, LL, NDB, and JJS have no competing interests to declare. TJP and
LJW have been consultants to Amgen Inc. RVB has received honoraria from
and holds stock in Amgen Inc. HIH has received research funding from
GSK. NCT has received research funding from Amgen Inc. and has provided
expert testimony on behalf of Amgen Inc. SM, Y-JH, and C-PH are
employees of and shareholders in Amgen Inc. The authors thank Rebeca
Melara (Amgen Inc.) for pharmacokinetic analysis; Benjamin Scott
(Complete Healthcare Communications, Inc., Chadds Ford, PA, USA), whose
work was funded by Amgen Inc., and Beate Quednau (Amgen Inc.) for
assistance in manuscript writing.
NR 41
TC 3
Z9 3
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 16
PY 2013
VL 13
AR 242
DI 10.1186/1471-2407-13-242
PG 11
WC Oncology
SC Oncology
GA 170XH
UT WOS:000320888000001
PM 23679351
ER
PT J
AU Bohr, S
Patel, SJ
Vasko, R
Shen, KY
Huang, GF
Yarmush, ML
Berthiaume, F
AF Bohr, Stefan
Patel, Suraj J.
Vasko, Radovan
Shen, Keyue
Huang, Guofeng
Yarmush, Martin L.
Berthiaume, Francois
TI Highly Upregulated Lhx2 in the Foxn1(-/-) Nude Mouse Phenotype Reflects
a Dysregulated and Expanded Epidermal Stem Cell Niche
SO PLOS ONE
LA English
DT Article
ID HAIR FOLLICLE DEVELOPMENT; SKIN EPITHELIAL-CELLS; IMMUNOHISTOCHEMICAL
EXPRESSION; PROMOTES DIFFERENTIATION; BETA-CATENIN; IN-VITRO;
KERATINOCYTES; CD34; SHH; CD200
AB Hair cycling is a prime example of stem cell dependent tissue regeneration and replenishment, and its regulatory mechanisms remain poorly understood. In the present study, we evaluated the effect of a blockage in terminal keratinocytic lineage differentiation in the Foxn1(-/-) nude phenotype on the epithelial progeny. Most notably we found a constitutive upregulation of LIM homeobox protein 2 (Lhx2), a marker gene of epithelial stem cellness indispensible for hair cycle progression. However, histological evidence along with an erratic, acyclic rise of otherwise suppressed CyclinD1 levels along with several key markers of keratinocyte lineage differentiation indicate a frustrated expansion of epithelial stem cell niches in skin. In addition, CD49f/CD34/CD200-based profiling demonstrated highly significant shifts in subpopulations of epithelial progeny. Intriguingly this appeared to include the expansion of Oct4+ stem cells in dermal fractions of skin isolates in the Foxn1 knock-out opposed to wild type. Overall our findings indicate that the Foxn1(-/-) phenotype has a strong impact on epithelial progeny and thus offers a promising model to study maintenance and regulation of stem cell niches within skin not feasible in other in vitro or in vivo models.
C1 [Bohr, Stefan; Patel, Suraj J.; Shen, Keyue; Huang, Guofeng; Yarmush, Martin L.] Harvard Univ, Shriners Hosp Children, Sch Med, Ctr Engn Med, Boston, MA 02115 USA.
[Bohr, Stefan; Patel, Suraj J.; Shen, Keyue; Huang, Guofeng; Yarmush, Martin L.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Vasko, Radovan] New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
[Yarmush, Martin L.; Berthiaume, Francois] Rutgers State Univ, Dept Biomed Engn, New Brunswick, NJ 08903 USA.
RP Bohr, S (reprint author), Harvard Univ, Shriners Hosp Children, Sch Med, Ctr Engn Med, Boston, MA 02115 USA.
EM bohrs@partners.org
FU Shriners Hospitals for Children; Deutsche Forschungs Gemeinschaft (DFG,
Germany) [GZ:BO3468/2-1]
FX This work was funded by the Shriners Hospitals for Children. S. Bohr is
a recipient of a Deutsche Forschungs Gemeinschaft (DFG, Germany)
postdoctoral fellowship award (GZ:BO3468/2-1). S. J. Patel was supported
by a Shriners Hospital for Children postdoctoral fellowship award. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 61
TC 2
Z9 2
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2013
VL 8
IS 5
AR e64223
DI 10.1371/journal.pone.0064223
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146HW
UT WOS:000319081900074
PM 23696871
ER
PT J
AU Prabhakar, S
Goto, J
Zuang, X
Sena-Esteves, M
Bronson, R
Brockmann, J
Gianni, D
Wojtkiewicz, GR
Chen, JW
Stemmer-Rachamimov, A
Kwiatkowski, DJ
Breakefield, XO
AF Prabhakar, Shilpa
Goto, June
Zuang, Xuan
Sena-Esteves, Miguel
Bronson, Roderick
Brockmann, Jillian
Gianni, Davide
Wojtkiewicz, Gregory R.
Chen, John W.
Stemmer-Rachamimov, Anat
Kwiatkowski, David J.
Breakefield, Xandra O.
TI Stochastic Model of Tsc1 Lesions in Mouse Brain
SO PLOS ONE
LA English
DT Article
ID TUBEROUS SCLEROSIS COMPLEX; MTOR PATHWAY; GIANT-CELLS; RAPAMYCIN;
ACTIVATION; MANAGEMENT; SURVIVAL; DEFICITS; MICE
AB Tuberous sclerosis complex (TSC) is an autosomal dominant disorder due to mutations in either TSC1 or TSC2 that affects many organs with hamartomas and tumors. TSC-associated brain lesions include subependymal nodules, subependymal giant cell astrocytomas and tubers. Neurologic manifestations in TSC comprise a high frequency of mental retardation and developmental disorders including autism, as well as epilepsy. Here, we describe a new mouse model of TSC brain lesions in which complete loss of Tsc1 is achieved in multiple brain cell types in a stochastic pattern. Injection of an adeno-associated virus vector encoding Cre recombinase into the cerebral ventricles of mice homozygous for a Tsc1 conditional allele on the day of birth led to reduced survival, and pathologic findings of enlarged neurons, cortical heterotopias, subependymal nodules, and hydrocephalus. The severity of clinical and pathologic findings as well as survival was shown to be dependent upon the dose and serotype of Cre virus injected. Although several other models of TSC brain disease exist, this model is unique in that the pathology reflects a variety of TSC-associated lesions involving different numbers and types of cells. This model provides a valuable and unique addition for therapeutic assessment.
C1 [Prabhakar, Shilpa; Zuang, Xuan; Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.
[Prabhakar, Shilpa; Zuang, Xuan; Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Radiol, Ctr Mol Imaging Res, Boston, MA 02114 USA.
[Prabhakar, Shilpa; Zuang, Xuan; Breakefield, Xandra O.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
[Goto, June; Kwiatkowski, David J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Translat Med Div,Dept Med, Boston, MA 02115 USA.
[Sena-Esteves, Miguel; Gianni, Davide] Univ Massachusetts, Sch Med, Dept Neurol, Gene Therapy Ctr, Worcester, MA USA.
[Bronson, Roderick] Harvard Univ, Sch Med, Rodent Histopathol Core Facil, Boston, MA USA.
[Brockmann, Jillian; Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Wojtkiewicz, Gregory R.; Chen, John W.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Wojtkiewicz, Gregory R.; Chen, John W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Breakefield, XO (reprint author), Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.
EM breakefield@hms.harvard.edu
FU NIH/NINDS [NS24279-23, R01NS070835, R01NS072167]; DOD Army Grant
[W81XWH-13-1-0076]
FX NIH/NINDS NS24279-23, R01NS070835, R01NS072167 and DOD Army Grant
W81XWH-13-1-0076 for the Award Mechanism: Exploration - Hypothesis
Development Award. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 39
TC 6
Z9 6
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2013
VL 8
IS 5
AR e64224
DI 10.1371/journal.pone.0064224
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146HW
UT WOS:000319081900075
PM 23696872
ER
PT J
AU Heo, K
Kim, JS
Kim, K
Kim, H
Choi, J
Yang, K
An, W
AF Heo, K.
Kim, J-S
Kim, K.
Kim, H.
Choi, J.
Yang, K.
An, W.
TI Cell-penetrating H4 tail peptides potentiate p53-mediated
transactivation via inhibition of G9a and HDAC1
SO ONCOGENE
LA English
DT Article
DE p53; histone; transcription; acetylation; methylation
ID TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REGULATION; CANCER-CELLS; COMPLEX;
PROTEIN; RECRUITMENT; TRANSDUCTION; ACTIVATION; REPRESSION; PHYSIOLOGY
AB Histone acetylation has a central role in establishing an active chromatin environment. The functional contribution of histone acetylation to chromatin transcription is accomplished by a dominant action of histone acetyltransferases over repressive histone-modifying activities at gene promoters; misregulation of these dynamic events can lead to various diseases. Here, we describe the synthesis and characterization of transducible peptides derived from histone H4 N-terminal tail as a molecular tool to establish and maintain the active state of p53 target genes. Cellular experiments demonstrate a distinct increase in p53 transactivation by acetylated H4 tail peptides, but only a modest change by unmodified H4 tail peptides. The molecular basis underlying the observed effects involves the selective interaction of the tail peptides with G9a histone methyltransferase and histone deacetylase 1 (HDAC1) and the disruption of their occupancy at p53 target promoters. Furthermore, treatment of xenograft models and cancer cell lines with the tail peptides sharply decline tumor cell growth and enhances apoptosis in response to DNA damage. These results indicate that H4 tail peptide mimics upregulate p53 transcription pathway and may be used as a novel strategy for anticancer therapy.
C1 [Heo, K.; Kim, K.; Kim, H.; Choi, J.; An, W.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.
[Heo, K.; Kim, J-S; Yang, K.] Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Pusan, South Korea.
[Kim, H.] Harvard Univ, Sch Med, Dept Pediat,Dana Farber Canc Inst,Childrens Hosp, Dept Pediat Oncol,Div Hematol Oncol, Boston, MA 02115 USA.
RP An, W (reprint author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1450 Biggy St NRT6507, Los Angeles, CA 90089 USA.
EM woojinan@usc.edu
OI Heo, Kyu/0000-0001-8833-4731
FU National Institutes of Health [R01GM84209]; American Cancer Society [RSG
DMC1005001]; DIRAMS from the Ministry of Education, Science and
Technology [50595-2012]
FX We thank Dr Michael Stallcup and Mr Dan Gerke for the gift of
pSG5-FLAG-G9a and G9a shRNA constructs. The technical assistance of Drs
Balachandra Hegde and Ralph Langen in circular dichroism analysis is
greatly acknowledged. We also thank Dr Jing Huang for p53K373me2
antibody. This work was supported by R01GM84209 to WA from the National
Institutes of Health, RSG DMC1005001 to WA from the American Cancer
Society and DIRAMS (50595-2012) to KH from the Ministry of Education,
Science and Technology.
NR 33
TC 7
Z9 8
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAY 16
PY 2013
VL 32
IS 20
BP 2510
EP 2520
DI 10.1038/onc.2012.273
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 148UY
UT WOS:000319274300002
PM 22751130
ER
PT J
AU Donelan, K
DesRoches, CM
Dittus, RS
Buerhaus, P
AF Donelan, Karen
DesRoches, Catherine M.
Dittus, Robert S.
Buerhaus, Peter
TI Perspectives of Physicians and Nurse Practitioners on Primary Care
Practice
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID DIRECTIONS
AB BACKGROUND
The U.S. health care system is at a critical juncture in health care workforce planning. The nation has a shortage of primary care physicians. Policy analysts have proposed expanding the supply and scope of practice of nurse practitioners to address increased demand for primary care providers. These proposals are controversial.
METHODS
From November 23, 2011, to April 9, 2012, we conducted a national postal-mail survey of 972 clinicians (505 physicians and 467 nurse practitioners) in primary care practice. Questionnaire domains included scope of work, practice characteristics, and attitudes about the effect of expanding the role of nurse practitioners in primary care. The response rate was 61.2%.
RESULTS
Physicians reported working longer hours, seeing more patients, and earning higher incomes than did nurse practitioners. A total of 80.9% of nurse practitioners reported working in a practice with a physician, as compared with 41.4% of physicians who reported working with a nurse practitioner. Nurse practitioners were more likely than physicians to believe that they should lead medical homes, be allowed hospital admitting privileges, and be paid equally for the same clinical services. When asked whether they agreed with the statement that physicians provide a higher-quality examination and consultation than do nurse practitioners during the same type of primary care visit, 66.1% of physicians agreed and 75.3% of nurse practitioners disagreed.
CONCLUSIONS
Current policy recommendations that are aimed at expanding the supply and scope of practice of primary care nurse practitioners are controversial. Physicians and nurse practitioners do not agree about their respective roles in the delivery of primary care. (Funded by the Gordon and Betty Moore Foundation and others.)
C1 [Donelan, Karen] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Donelan, Karen] Harvard Univ, Sch Med, Boston, MA USA.
[DesRoches, Catherine M.] Math Policy Res, Cambridge, MA USA.
[Dittus, Robert S.] Vanderbilt Univ, Dept Med, Inst Med & Publ Hlth, Nashville, TN USA.
[Dittus, Robert S.] VA Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA.
[Buerhaus, Peter] Vanderbilt Univ, Med Ctr, Ctr Interdisciplinary Hlth Workforce Studies, Nashville, TN USA.
RP Donelan, K (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,9th Fl, Boston, MA 02114 USA.
EM kdonelan@partners.org
FU Gordon and Betty Moore Foundation; Johnson & Johnson Campaign for
Nursing's Future; Robert Wood Johnson Foundation
FX Funded by the Gordon and Betty Moore Foundation and others.; Supported
by the Gordon and Betty Moore Foundation, the Johnson & Johnson Campaign
for Nursing's Future, and the Robert Wood Johnson Foundation.
NR 14
TC 50
Z9 50
U1 3
U2 30
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 16
PY 2013
VL 368
IS 20
BP 1898
EP 1906
DI 10.1056/NEJMsa1212938
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 143VK
UT WOS:000318896200009
PM 23675658
ER
PT J
AU Vyas, JM
Gonzalez, RG
Pierce, VM
AF Vyas, Jatin M.
Gonzalez, R. Gilberto
Pierce, Virginia M.
TI Case 15-2013: A 76-Year-Old Man with Fever, Worsening Renal Function,
and Altered Mental Status
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID WEST-NILE-VIRUS; INFECTIONS
C1 [Vyas, Jatin M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Pierce, Virginia M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Vyas, Jatin M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Pierce, Virginia M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Vyas, JM (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RI Vyas, Jatin/Q-1627-2016
OI Vyas, Jatin/0000-0002-9985-9565
NR 17
TC 3
Z9 3
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 16
PY 2013
VL 368
IS 20
BP 1919
EP 1927
DI 10.1056/NEJMcpc1302330
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 143VK
UT WOS:000318896200012
PM 23675661
ER
PT J
AU Drazen, JM
Solomon, CG
Greene, MF
AF Drazen, Jeffrey M.
Solomon, Caren G.
Greene, Michael F.
TI Informed Consent and SUPPORT
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID EXTREMELY PRETERM INFANTS; OXYGEN-SATURATION; TARGET
C1 [Greene, Michael F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
OI Drazen, Jeffrey/0000-0003-2715-9890
NR 5
TC 45
Z9 45
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 16
PY 2013
VL 368
IS 20
BP 1929
EP 1931
DI 10.1056/NEJMe1304996
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 143VK
UT WOS:000318896200013
PM 23593944
ER
PT J
AU Mantel, PY
Hoang, AN
Goldowitz, I
Potashnikova, D
Hamza, B
Vorobjev, I
Ghiran, I
Toner, M
Irimia, D
Ivanov, AR
Barteneva, N
Marti, M
AF Mantel, Pierre-Yves
Hoang, Anh N.
Goldowitz, Ilana
Potashnikova, Daria
Hamza, Bashar
Vorobjev, Ivan
Ghiran, Ionita
Toner, Mehmet
Irimia, Daniel
Ivanov, Alexander R.
Barteneva, Natasha
Marti, Matthias
TI Malaria-Infected Erythrocyte-Derived Microvesicles Mediate Cellular
Communication within the Parasite Population and with the Host Immune
System
SO CELL HOST & MICROBE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM GAMETOCYTES; IN-VITRO; MICROPARTICLES; CELLS;
VESICLES; GROWTH
AB Humans and mice infected with different Plasmodium strains are known to produce microvesicles derived from the infected red blood cells (RBCs), denoted RMVs. Studies in mice have shown that RMVs are elevated during infection and have proinflammatory activity. Here we present a detailed characterization of RMV composition and function in the human malaria parasite Plasmodium falciparum. Proteomics profiling revealed the enrichment of multiple host and parasite proteins, in particular of parasite antigens associated with host cell membranes and proteins involved in parasite invasion into RBCs. RMVs are quantitatively released during the asexual parasite cycle prior to parasite egress. RMVs demonstrate potent immunomodulatory properties on human primary macrophages and neutrophils. Additionally, RMVs are internalized by infected red blood cells and stimulate production of transmission stage parasites in a dose-dependent manner. Thus, RMVs mediate cellular communication within the parasite population and with the host innate immune system.
C1 [Mantel, Pierre-Yves; Goldowitz, Ilana; Marti, Matthias] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Hoang, Anh N.; Hamza, Bashar; Toner, Mehmet; Irimia, Daniel] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Charlestown, MA 02129 USA.
[Potashnikova, Daria; Vorobjev, Ivan; Barteneva, Natasha] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Barteneva, Natasha] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Potashnikova, Daria] Moscow MV Lomonosov State Univ, Dept Cell Biol & Histol, Moscow 119991, Russia.
[Vorobjev, Ivan] Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119991, Russia.
[Ghiran, Ionita] Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Ivanov, Alexander R.] Northeastern Univ, Barnett Inst Chem & Biol Anal, Boston, MA 02115 USA.
RP Marti, M (reprint author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.
EM mmarti@hsph.harvard.edu
OI Irimia, Daniel/0000-0001-7347-2082; Potashnikova,
Daria/0000-0002-0098-827X
FU Harvard Catalyst; Becton Dickinson Bioscience Immunology Award; Grand
Challenges Exploration grant from the Bill and Melinda Gates Foundation
[OPP1069401]; Novartis Foundation
FX We acknowledge Maria Ericsson for expert technical support with electron
microscopy, Dr. Xandra Breakefield for access to the NanoSight platform,
and Drs. Barbara Burleigh and Barry Bloom for critical reading of the
manuscript. Drs. Klaus Lingelbach (anti-Exp-1), Brian Cooke (anti-SBP1),
Diane Taylor (anti-KAHRP), Robin Anders (anti-RESA and anti-AMA1), and
Alan Cowman (anti-ATS 6H1, anti-EBA-175, and anti-EBA-181) are
gratefully acknowledged for providing specific antisera to P. falciparum
proteins. Anti-BIP has been provided by MR4 as MRA19. Thanks to Drs.
Sarah Volkman for parasite strains Sen.T135.09 and Sen.T151.09, Joe
Smith for parasite strains Pf2004 and Pf2006, and Manoj Duraisingh for
the CDPK5-DD transgenic parasite line. We also acknowledge Dr. Pardis
Sabeti for providing us with aliquots of serum samples derived from the
Millennium Village Project and Dr. Barry Karger for his instrumental
support. This work has been supported through a collaborative seed grant
from Harvard Catalyst to M. M., N.A.B., and A. R. I., a Becton Dickinson
Bioscience Immunology Award (M. M. and N.B.), Grand Challenges
Exploration grant OPP1069401 from the Bill and Melinda Gates Foundation
(D. I.), and a Novartis Foundation research fellowship to P.-Y.M.
NR 28
TC 94
Z9 94
U1 2
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD MAY 15
PY 2013
VL 13
IS 5
BP 521
EP 534
DI 10.1016/j.chom.2013.04.009
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AA1IW
UT WOS:000330850800006
PM 23684304
ER
PT J
AU Grant, SS
Hung, DT
AF Grant, Sarah Schmidt
Hung, Deborah T.
TI Persistent bacterial infections, antibiotic tolerance, and the oxidative
stress response
SO VIRULENCE
LA English
DT Review
DE persistent bacterial infections; antibiotic tolerance; persisters;
oxidative stress; small colony variants; biofilms
ID SMALL-COLONY VARIANTS; UROPATHOGENIC ESCHERICHIA-COLI;
MYCOBACTERIUM-TUBERCULOSIS PERSISTENCE; PNEUMONIAE BIOFILM RESISTANCE;
URINARY-TRACT INFECTION; STAPHYLOCOCCUS-AUREUS; CYSTIC-FIBROSIS;
PSEUDOMONAS-AERUGINOSA; STATIONARY-PHASE; INTRACELLULAR PERSISTENCE
AB Certain bacterial pathogens are able to evade the host immune system and persist within the human host. The consequences of persistent bacterial infections potentially include increased morbidity and mortality from the infection itself as well as an increased risk of dissemination of disease. Eradication of persistent infections is difficult, often requiring prolonged or repeated courses of antibiotics. During persistent infections, a population or subpopulation of bacteria exists that is refractory to traditional antibiotics, possibly in a non-replicating or metabolically altered state. This review highlights the clinical significance of persistent infections and discusses different in vitro models used to investigate the altered physiology of bacteria during persistent infections. We specifically focus on recent work establishing increased protection against oxidative stress as a key element of the altered physiologic state across different in vitro models and pathogens.
C1 [Grant, Sarah Schmidt; Hung, Deborah T.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Grant, Sarah Schmidt; Hung, Deborah T.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Grant, Sarah Schmidt; Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
RP Grant, SS (reprint author), Broad Inst MIT & Harvard, Cambridge, MA USA.
EM sgrant@broadinstitute.org; hung@molbio.mgh.harvard.edu
FU NIAID NIH HHS [K08 AI085033]
NR 120
TC 31
Z9 33
U1 4
U2 65
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2150-5594
J9 VIRULENCE
JI Virulence
PD MAY 15
PY 2013
VL 4
IS 4
BP 273
EP 283
DI 10.4161/viru.23987
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 198BQ
UT WOS:000322897100002
PM 23563389
ER
PT J
AU Le Grand, JN
Bon, K
Fraichard, A
Zhang, JH
Jouvenot, M
Risold, PY
Boyer-Guittaut, M
Delage-Mourroux, R
AF Le Grand, Jaclyn Nicole
Bon, Karine
Fraichard, Annick
Zhang, Jianhua
Jouvenot, Michele
Risold, Pierre-Yves
Boyer-Guittaut, Michael
Delage-Mourroux, Regis
TI Specific Distribution of the Autophagic Protein GABARAPL1/GEC1 in the
Developing and Adult Mouse Brain and Identification of Neuronal
Populations Expressing GABARAPL1/GEC1
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; GABA(A) RECEPTOR; MESSENGER-RNAS;
PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; IN-VIVO; GEC1; MICE; DEGRADATION;
INTERACTS
AB Macroautophagy is a highly conserved cellular degradation process, regulated by autophagy-related (atg) factors, in which a double membrane autophagosome engulfs cytoplasmic components to target them for degradation. In yeast, the Atg8 protein is indispensable for autophagosome formation. In mammals, this is complicated by the presence of six Atg8 homologues grouped into the GABARAP and MAP1LC3 subfamilies. Although these proteins share a high similarity, their transcript expression, regulation and protein interactions differ, suggesting they may display individual properties and specific functions. GABARAPL1/GEC1 is a member of the GABARAP subfamily and its mRNA is the most highly expressed Atg8 homologue in the central nervous system. Consequently, we performed an in depth study of GABARAPL1 distribution in the developing and adult murine brain. Our results show that GABARAPL1 brain expression is visible as early as embryonic day 11 and progressively increases to a maximum level in the adult. Immunohistochemical staining was detected in both fibers and immature neurons in embryos but was restrained to neurons in adult tissue. By E17, intense punctate-like structures were visible and these accumulated in cortical primary neurons treated with the autophagosome/lysosome fusion inhibitor Bafilomycin A1 (Baf A1), suggesting that they represent autophagosomes. Finally, GABARAPL1 expression was particularly intense in motoneurons in the embryo and in neurons involved in somatomotor and neuroendocrine functions in the adult, particularly in the substantia nigra pars compacta, a region affected in Parkinson's disease. Our study of cerebral GABARAPL1 protein expression provides insight into its role in the development and homeostasis of the mouse brain.
C1 [Le Grand, Jaclyn Nicole; Bon, Karine; Fraichard, Annick; Jouvenot, Michele; Risold, Pierre-Yves; Boyer-Guittaut, Michael; Delage-Mourroux, Regis] Univ Franche Comte, UFR Sci & Tech, Estrogenes Express Gen & Pathol Syst Nerveux Cent, Lab Biochim,SFR IBCT FED 4234, F-25030 Besancon, Doubs, France.
[Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35294 USA.
RP Delage-Mourroux, R (reprint author), Univ Franche Comte, UFR Sci & Tech, Estrogenes Express Gen & Pathol Syst Nerveux Cent, Lab Biochim,SFR IBCT FED 4234, F-25030 Besancon, Doubs, France.
EM regis.delage-mourroux@univ-fcomte.fr
FU Ministere de l'Enseignement Superieur et de la Recherche (MESR); VA
merit award; [NIHR01-NS064090]
FX JNLG is supported by a fellowship from the Ministere de l'Enseignement
Superieur et de la Recherche (MESR) and Dr. JZ was supported by
NIHR01-NS064090 and a VA merit award. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 43
TC 7
Z9 8
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2013
VL 8
IS 5
AR e63133
DI 10.1371/journal.pone.0063133
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145XK
UT WOS:000319052700021
PM 23690988
ER
PT J
AU Seay, K
Qi, XH
Zheng, JH
Zhang, C
Chen, K
Dutta, M
Deneroff, K
Ochsenbauer, C
Kappes, JC
Littman, DR
Goldstein, H
AF Seay, Kieran
Qi, Xiaohua
Zheng, Jian Hua
Zhang, Cong
Chen, Ken
Dutta, Monica
Deneroff, Kathryn
Ochsenbauer, Christina
Kappes, John C.
Littman, Dan R.
Goldstein, Harris
TI Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1
Expression: A New Model for Investigating HIV-1 Transmission and
Treatment Efficacy
SO PLOS ONE
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; LENTIVIRAL-VECTORS; MOUSE MODEL;
RAG2(-/-)GAMMA(-/-)(C) MICE; GENE-TRANSFER; INFECTION; REPLICATION;
ANTIBODY; VIVO; LYMPHOCYTES
AB Mice cannot be used to evaluate HIV-1 therapeutics and vaccines because they are not infectible by HIV-1 due to structural differences between several human and mouse proteins required for HIV-1 entry and replication including CD4, CCR5 and cyclin T1. We overcame this limitation by constructing mice with CD4 enhancer/promoter-regulated human CD4, CCR5 and cyclin T1 genes integrated as tightly linked transgenes (hCD4/R5/cT1 mice) promoting their efficient co-transmission and enabling the murine CD4-expressing cells to support HIV-1 entry and Tat-mediated LTR transcription. All of the hCD4/R5/ cT1 mice developed disseminated infection of tissues that included the spleen, small intestine, lymph nodes and lungs after intravenous injection with an HIV-1 infectious molecular clone (HIV-IMC) expressing Renilla reniformis luciferase (LucR). Furthermore, localized infection of cervical-vaginal mucosal leukocytes developed after intravaginal inoculation of hCD4/R5/ cT1 mice with the LucR-expressing HIV-IMC. hCD4/R5/cT1 mice reproducibly developed in vivo infection after inoculation with LucR-expressing HIV-IMC which could be bioluminescently quantified and visualized with a high sensitivity and specificity which enabled them to be used to evaluate the efficacy of HIV-1 therapeutics. Treatment with highly active anti-retroviral therapy or one dose of VRC01, a broadly neutralizing anti-HIV-1 antibody, almost completed inhibited acute systemic HIV-1 infection of the hCD4/R5/cT1 mice. hCD4/R5/cT1 mice could also be used to evaluate the capacity of therapies delivered by gene therapy to inhibit in vivo HIV infection. VRC01 secreted in vivo by primary B cells transduced with a VRC01-encoding lentivirus transplanted into hCD4/R5/cT1 mice markedly inhibited infection after intravenous challenge with LucR-expressing HIV-IMC. The reproducible infection of CD4/R5/cT1 mice with LucR-expressing HIV-IMC after intravenous or mucosal inoculation combined with the availability of LucR-expressing HIV-IMC expressing transmitted/ founder and clade A/E and C Envs will provide researchers with a highly accessible pre-clinical in vivo HIV-1-infection model to study HIV-1 acquisition, treatment, and prevention.
C1 [Seay, Kieran; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
[Qi, Xiaohua; Zheng, Jian Hua; Zhang, Cong; Dutta, Monica; Deneroff, Kathryn; Goldstein, Harris] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
[Chen, Ken] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA.
[Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA.
[Littman, Dan R.] NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY USA.
[Littman, Dan R.] NYU, Sch Med, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY USA.
RP Goldstein, H (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
EM harris.goldstein@einstein.yu.edu
FU National Institutes of Health (National Institute of Drug Abuse)
[R01-DA-033788]; National Institutes of Health (National Institute of
Allergy and Infectious Diseases) [R01-AI065309]; National Institutes of
Health (Einstein-Montefiore Center for AIDS Research) [AI51519]; Charles
Michael Chair in Autoimmune Diseases; NIH-funded AIDS training grant
[T32-AI007501]; VHA Merit Review Award; NIH Center for HIV-1/AIDS
Vaccine Immunology (CHAVI) [UO1-AI067854]; UAB Center for AIDS Research
[P30-AI-27767]; [U01-GM-094665]; [U54-GM-094662]; [P30-CA-013330]
FX The construct expressing VRC01 was a kind gift of Dr. John Mascola
(VRC/NIAID/NIH) which was used to generate VRC01 antibody in the
Einstein Macromolecular Therapeutics Facility (supported by
U01-GM-094665, U54-GM-094662 and P30-CA-013330) by Man K. Chan. The
following reagents were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl cells,
pT4B and pCCR-5.; This work was supported by the National Institutes of
Health (National Institute of Drug Abuse R01-DA-033788, National
Institute of Allergy and Infectious Diseases R01-AI065309 and the
Einstein-Montefiore Center for AIDS Research AI51519). HG was supported
by the Charles Michael Chair in Autoimmune Diseases, KS by an NIH-funded
AIDS training grant, T32-AI007501 and JCK by a VHA Merit Review Award.
Work by JCK and CO was supported by the NIH Center for HIV-1/AIDS
Vaccine Immunology (CHAVI), UO1-AI067854; and the UAB Center for AIDS
Research (P30-AI-27767). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 48
TC 14
Z9 14
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2013
VL 8
IS 5
AR e63537
DI 10.1371/journal.pone.0063537
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145XK
UT WOS:000319052700042
PM 23691059
ER
PT J
AU Rogers, IS
Massaro, JM
Truong, QA
Mahabadi, AA
Kriegel, MF
Fox, CS
Thanassoulis, G
Isselbacher, EM
Hoffmann, U
O'Donnell, CJ
AF Rogers, Ian S.
Massaro, Joseph M.
Truong, Quynh A.
Mahabadi, Amir A.
Kriegel, Matthias F.
Fox, Caroline S.
Thanassoulis, George
Isselbacher, Eric M.
Hoffmann, Udo
O'Donnell, Christopher J.
TI Distribution, Determinants, and Normal Reference Values of Thoracic and
Abdominal Aortic Diameters by Computed Tomography (from the Framingham
Heart Study)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID DIMENSIONS; DISEASE; CHILDREN; ADULTS; WOMEN; AREA; MEN; AGE
AB Current screening and detection of asymptomatic aortic aneurysms is based largely on uniform cut-point diameters. The aims of this study were to define normal aortic diameters in asymptomatic men and women in a community-based cohort and to determine the association between aortic diameters and traditional risk factors for cardiovascular disease. Measurements of the diameters of the ascending thoracic aorta (AA), descending thoracic aorta (DTA), infrarenal abdominal aorta (IRA), and lower abdominal aorta (LAA) were acquired from 3,431 Framingham Heart Study (FHS) participants. Mean diameters were stratified by gender, age, and body surface area. Univariate associations with risk factor levels were examined, and multivariate linear regression analysis was used to assess the significance of covariate-adjusted relations with aortic diameters. For men, the average diameters were 34.1 mm for the AA, 25.8 mm for the DTA, 19.3 mm for the IRA, and 18.7 mm for the LAA. For women, the average diameters were 31.9 mm for the AA, 23.1 mm for the DTA, 16.7 mm for the IRA, and 16.0 mm for the LAA. The mean aortic diameters were strongly correlated (p<0.0001) with age and body surface area in age-adjusted analyses, and these relations remained significant in multivariate regression analyses. Positive associations of diastolic blood pressure with AA and DTA diameters in both genders and pack-years of cigarette smoking with DTA diameter in women and IRA diameter in men and women were observed. In conclusion, average diameters of the thoracic and abdominal aorta by computed tomography are larger in men compared with women, vary significantly with age and body surface area, and are associated with modifiable cardiovascular disease risk factors, including diastolic blood pressure and cigarette smoking. Published by Elsevier Inc. (Am J Cardiol 2013;111:1510-1516)
C1 [Rogers, Ian S.; Truong, Quynh A.; Mahabadi, Amir A.; Kriegel, Matthias F.; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
[Rogers, Ian S.; Truong, Quynh A.; Isselbacher, Eric M.; O'Donnell, Christopher J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
[Rogers, Ian S.] Stanford Univ, Div Cardiovasc Med, Sch Med, Stanford, CA 94305 USA.
[Massaro, Joseph M.] Boston Univ, Dept Math, Boston, MA 02215 USA.
[Massaro, Joseph M.; Fox, Caroline S.; Thanassoulis, George; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Mahabadi, Amir A.] Univ Duisburg Essen, Dept Cardiol, West German Heart Ctr, Essen, Germany.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Thanassoulis, George] McGill Univ, Div Cardiol, Ctr Hlth, Montreal, PQ, Canada.
[Thanassoulis, George] McGill Univ, Div Clin Epidemiol, Ctr Hlth, Montreal, PQ, Canada.
RP O'Donnell, CJ (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
EM odonnellc@nhlbi.nih.gov
OI Massaro, Joseph/0000-0002-2682-4812
FU National Heart, Lung, and Blood Institute's FHS [N01-HC-25195]; National
Institutes of Health [1T32 HL076136, K23 HL098370, L30 HL093806];
American Heart Association [12CRP12060237]
FX From the Framingham Heart Study (FHS) of the National Heart, Lung, and
Blood Institute of the National Institutes of Health, Bethesda,
Maryland, and Boston University School of Medicine, Boston,
Massachusetts. This work was supported by the National Heart, Lung, and
Blood Institute's FHS (Contract N01-HC-25195). Drs. Rogers and Truong
received salary support from Grant 1T32 HL076136 from the National
Institutes of Health. Dr. Rogers also received salary support from Grant
12CRP12060237 from the American Heart Association. Dr. Truong also
received salary support from Grants K23 HL098370 and L30 HL093806 from
the National Institutes of Health.
NR 19
TC 32
Z9 33
U1 0
U2 6
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAY 15
PY 2013
VL 111
IS 10
BP 1510
EP 1516
DI 10.1016/j.amjcard.2013.01.306
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 150EB
UT WOS:000319371900023
PM 23497775
ER
PT J
AU Sun, HF
Qin, B
Liu, T
Wang, QX
Liu, J
Wang, J
Lin, XQ
Yang, YL
Taing, L
Rao, PK
Brown, M
Zhang, Y
Long, HW
Liu, XS
AF Sun, Hanfei
Qin, Bo
Liu, Tao
Wang, Qixuan
Liu, Jing
Wang, Juan
Lin, Xueqiu
Yang, Yulin
Taing, Len
Rao, Prakash K.
Brown, Myles
Zhang, Yong
Long, Henry W.
Liu, X. Shirley
TI CistromeFinder for ChIP-seq and DNase-seq data reuse
SO BIOINFORMATICS
LA English
DT Article
ID HUMAN GENOME
AB Chromatin immunoprecipitation and DNase I hypersensitivity assays with high-throughput sequencing have greatly accelerated the understanding of transcriptional and epigenetic regulation, although data reuse for the community of experimental biologists has been challenging. We created a data portal CistromeFinder that can help query, evaluate and visualize publicly available Chromatin immunoprecipitation and DNase I hypersensitivity assays with high-throughput sequencing data in human and mouse. The database currently contains 6378 samples over 4391 datasets, 313 factors and 102 cell lines or cell populations. Each dataset has gone through a consistent analysis and quality control pipeline; therefore, users could evaluate the overall quality of each dataset before examining binding sites near their genes of interest. CistromeFinder is integrated with UCSC genome browser for visualization, Primer3Plus for ChIP-qPCR primer design and CistromeMap for submitting newly available datasets. It also allows users to leave comments to facilitate data evaluation and update.
C1 [Sun, Hanfei; Qin, Bo; Wang, Qixuan; Liu, Jing; Wang, Juan; Lin, Xueqiu; Yang, Yulin; Zhang, Yong] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 20092, Peoples R China.
[Liu, Tao; Taing, Len; Rao, Prakash K.; Long, Henry W.; Liu, X. Shirley] Dana Faber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
[Liu, Tao; Liu, X. Shirley] Dana Faber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Liu, Tao; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA USA.
[Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02215 USA.
[Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
[Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02215 USA.
RP Liu, XS (reprint author), Dana Faber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
EM henry_long@dfci.harvard.edu; xsliu@jimmy.harvard.edu
RI Zhang, Yong/B-4838-2011; Liu, Tao/G-3585-2010;
OI Liu, Tao/0000-0003-0446-9001; Zhang, Yong/0000-0001-6316-2734; Liu,
Tao/0000-0002-8818-8313; Brown, Myles/0000-0002-8213-1658
FU National Basic Research (973) Program of China [2010CB944904]; National
Natural Science Foundation of China [31028011]; National Institutes of
Health [HG4069]
FX National Basic Research (973) Program of China [2010CB944904]; National
Natural Science Foundation of China [31028011]; and National Institutes
of Health [HG4069].
NR 12
TC 10
Z9 10
U1 2
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD MAY 15
PY 2013
VL 29
IS 10
BP 1352
EP 1354
DI 10.1093/bioinformatics/btt135
PG 3
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Computer Science, Interdisciplinary Applications; Mathematical &
Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Computer Science; Mathematical & Computational Biology; Mathematics
GA 150YR
UT WOS:000319428200018
PM 23508969
ER
PT J
AU Pucci, F
Pittet, MJ
AF Pucci, Ferdinando
Pittet, Mikael J.
TI Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions
with Immune Cells In Vivo
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PLACENTAL GROWTH-FACTOR; REGULATORY T-CELLS; DENDRITIC CELLS;
PLASMA-MEMBRANE; DIAGNOSTIC BIOMARKERS; PROTEOMIC ANALYSIS;
SUPPRESSOR-CELLS; PROGENITOR CELLS; MESSENGER-RNA; MYELOID CELLS
AB Cancer is not merely a cell-intrinsic genetic disease but also the result of complex cell-extrinsic interactions with host components, including immune cells. For example, effector T lymphocytes and natural killer cells are thought to participate in an immunosurveillance process, which eliminates neoplastic cells, whereas regulatory T lymphocytes and some myeloid cells, including macrophages, can create a milieu that prevents antitumor activity, supports tumor growth, and reduces survival of the host. Increasing evidence supports the notion that carcinoma cells communicate with immune cells directly, both within and away from the tumor stroma, and that this process fosters suppression of immunosurveillance and promotes tumor outgrowth. An important mode of communication between carcinoma cells and immune cells may involve tumor-derived microvesicles (tMV), also known as exosomes, ectosomes, or microparticles. These microvesicles carry lipids, proteins, mRNAs and microRNAs and travel short or long distances to deliver undegraded and undiluted material to other cells. Here, we consider the capacity of tMVs to control tumor-associated immune responses and highlight the known and unknown actions of tMVs in vivo. We also discuss why microvesicles may play a role in cancer diagnostics and prognostics and how they could be harnessed for anticancer therapy. (C) 2013 AACR.
C1 Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Pittet, MJ (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM mpittet@mgh.harvard.edu
FU U.S. NIH [R01-AI084880, P50-CA086355]; EMBO
FX This work was supported in part by U.S. NIH grants R01-AI084880 and
P50-CA086355 (to M.J. Pittet) and by the EMBO long-term fellowship
program (to F. Pucci).
NR 87
TC 20
Z9 20
U1 4
U2 28
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2013
VL 19
IS 10
BP 2598
EP 2604
DI 10.1158/1078-0432.CCR-12-0962
PG 7
WC Oncology
SC Oncology
GA 144AO
UT WOS:000318911600002
PM 23426276
ER
PT J
AU Coffee, EM
Faber, AC
Roper, J
Sinnamon, MJ
Goel, G
Keung, L
Wang, WV
Vecchione, L
de Vriendt, V
Weinstein, BJ
Bronson, RT
Tejpar, S
Xavier, RJ
Engelman, JA
Martin, ES
Hung, KE
AF Coffee, Erin M.
Faber, Anthony C.
Roper, Jatin
Sinnamon, Mark J.
Goel, Gautam
Keung, Lily
Wang, Wei Vivian
Vecchione, Loredana
de Vriendt, Veerle
Weinstein, Barbara J.
Bronson, Roderick T.
Tejpar, Sabine
Xavier, Ramnik J.
Engelman, Jeffrey A.
Martin, Eric S.
Hung, Kenneth E.
TI Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective
Treatment of BRAF(V600E) Colorectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID COLON-CANCER; MOUSE MODEL; B-RAF; MICROSATELLITE INSTABILITY; PATHWAY
ACTIVATION; ANTITUMOR-ACTIVITY; V600E MUTATION; MAPK PATHWAY;
INHIBITION; RESISTANCE
AB Purpose: BRAF(V600E) mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAF(V600E) CRC.
Experimental Design: We examined phosphoinositide 3-kinase (PI3K)/mTOR signaling in BRAF(V600E) CRC cell lines after BRAF inhibition and cell viability and apoptosis after combined BRAF and PI3K/mTOR inhibition. We assessed the efficacy of in vivo combination treatment using a novel genetically engineered mouse model (GEMM) for BRAF(V600E) CRC.
Results: Western blot analysis revealed sustained PI3K/mTOR signaling upon BRAF inhibition. Our BRAF(V600E) GEMM presented with sessile serrated adenomas/polyps, as seen in humans. Combination treatment in vivo resulted in induction of apoptosis and tumor regression.
Conclusions: We have established a novel GEMM to interrogate BRAF(V600E) CRC biology and identify more efficacious treatment strategies. Combination BRAF and PI3K/mTOR inhibitor treatment should be explored in clinical trials. (C) 2013 AACR.
C1 [Coffee, Erin M.; Roper, Jatin; Sinnamon, Mark J.; Keung, Lily; Wang, Wei Vivian; Hung, Kenneth E.] Tufts Med Ctr, Div Gastroenterol, Boston, MA 02111 USA.
[Weinstein, Barbara J.] Tufts Med Ctr, Dept Pathol, Boston, MA 02111 USA.
[Faber, Anthony C.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Goel, Gautam; Xavier, Ramnik J.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Bronson, Roderick T.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Martin, Eric S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Vecchione, Loredana; de Vriendt, Veerle; Tejpar, Sabine] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium.
RP Hung, KE (reprint author), Tufts Med Ctr, 750 Washington St,Box 233, Boston, MA 02111 USA.
EM kenneth.hung@tufts.edu
RI Waha, Andreas/J-2950-2014;
OI Roper, Jatin/0000-0002-8851-1352
FU Novartis; Sanofi-Aventis; National Institutes of Diabetes, Digestive and
Kidney Diseases (NIDDK) [K08-DK078033]; National Cancer Institute (NCI)
[U01-CA084301]
FX J.A. Engelman has commercial research grants from Novartis and
Sanofi-Aventis and is a consultant/advisory board member of Novartis,
Genentech, Sanofi-Aventis, and GSK. No potential conflicts of interest
were disclosed by the other authors.; This research was supported by
grants from the National Institutes of Diabetes, Digestive and Kidney
Diseases (NIDDK; K08-DK078033) and National Cancer Institute (NCI;
U01-CA084301).
NR 48
TC 42
Z9 43
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2013
VL 19
IS 10
BP 2688
EP 2698
DI 10.1158/1078-0432.CCR-12-2556
PG 11
WC Oncology
SC Oncology
GA 144AO
UT WOS:000318911600013
PM 23549875
ER
PT J
AU Zheng, BH
DeRan, M
Li, XY
Liao, XB
Fukata, M
Wu, X
AF Zheng, Baohui
DeRan, Michael
Li, Xinyan
Liao, Xuebin
Fukata, Masaki
Wu, Xu
TI 2-Bromopalmitate Analogues as Activity-Based Probes To Explore Palmitoyl
Acyltransferases
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID PROTEIN S-ACYLTRANSFERASES; FATTY-ACIDS; INHIBITORS; CANCER;
IDENTIFICATION; TRAFFICKING; STABILITY; DISCOVERY; ENZYMES; 5P15.33
AB Reversible S-palmitoylation is an important post-translational modification that regulates the trafficking, localization, and activity of proteins. Cysteine-rich Asp-His-His-Cys (DHHC) domain-containing enzymes are evolutionarily conserved protein palmitoyl acyltransferases (PATs). The human genome encodes 23 DHHC-PATs that regulate diverse cellular functions. Although chemical probes and proteomic methods to detect palmitoylated protein substrates have been reported, no probes for direct detection of the activity of PATs are available. Here we report the synthesis and characterization of 2-bromohexadec-15-ynoic acid and 2-bromooctadec-17-ynoic acid, which are analogues of 2-bromopalmitate (2-BP), as activity-based probes for PATs as well as other palmitoylating and 2-BP-binding enzymes. These probes will serve as new chemical tools for activity-based protein profiling to explore PATs, to dissect the functions of PATs in cell signaling and diseases, and to facilitate the identification of their inhibitors.
C1 [Zheng, Baohui; DeRan, Michael; Li, Xinyan; Wu, Xu] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Liao, Xuebin] Tsinghua Univ, Dept Pharmacol & Pharmaceut Sci, Beijing 100084, Peoples R China.
[Fukata, Masaki] Natl Inst Physiol Sci, Dept Cell Physiol, Div Membrane Physiol, Okazaki, Aichi 4448787, Japan.
RP Wu, X (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM xwu@cbrc2.mgh.harvard.edu
RI zheng, baohui/O-6828-2014
OI zheng, baohui/0000-0002-3272-843X
FU Massachusetts General Hospital (MGH) Institutional Fund; Stewart
Rahr-MRA Young Investigator Award
FX We thank Ross Tomaino at the Taplin Mass Spectrometry Facility of
Harvard Medical School for proteomics studies and Drs. Matthew Tremblay
and Jianming Zhang for critical comments on the manuscript. This work
was supported by the Massachusetts General Hospital (MGH) Institutional
Fund and the Stewart Rahr-MRA Young Investigator Award (X.W.).
NR 33
TC 26
Z9 26
U1 1
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAY 15
PY 2013
VL 135
IS 19
BP 7082
EP 7085
DI 10.1021/ja311416v
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 148NB
UT WOS:000319250200001
PM 23631516
ER
PT J
AU Deyo, RA
Smith, DHM
Johnson, ES
Tillotson, CJ
Donovan, M
Yang, XH
Petrik, A
Morasco, BJ
Dobscha, SK
AF Deyo, Richard A.
Smith, David H. M.
Johnson, Eric S.
Tillotson, Carrie J.
Donovan, Marilee
Yang, Xiuhai
Petrik, Amanda
Morasco, Benjamin J.
Dobscha, Steven K.
TI Prescription Opioids for Back Pain and Use of Medications for Erectile
Dysfunction
SO SPINE
LA English
DT Article
DE opioids; low back pain; erectile dysfunction; sexual dysfunction
ID CHRONIC NONCANCER PAIN; UNITED-STATES; ORAL OPIOIDS; ASSOCIATION;
HYPOGONADISM; TRENDS; MEN; EPIDEMIOLOGY; METAANALYSIS; PREVALENCE
AB Study Design. Cross-sectional analysis of electronic medical and pharmacy records.
Objective. To examine associations between use of medication for erectile dysfunction or testosterone replacement and use of opioid therapy, patient age, depression, and smoking status.
Summary of Background Data. Males with chronic pain may experience erectile dysfunction related to depression, smoking, age, or opioid-related hypogonadism. The prevalence of this problem in back pain populations and the relative importance of several risk factors are unknown.
Methods. We examined electronic pharmacy and medical records for males with back pain in a large group model health maintenance organization during 2004. Relevant prescriptions were considered for 6 months before and after the index visit. Results. There were 11,327 males with a diagnosis of back pain. Males who received medications for erectile dysfunction or testosterone replacement (n = 909) were significantly older than those who did not and had greater comorbidity, depression, smoking, and use of sedative-hypnotics. In logistic regressions, the long-term use of opioids was associated with greater use of medications for erectile dysfunction or testosterone replacement compared with no opioid use (odds ratio, 1.45; 95% confidence interval, 1.12-1.87, P < 0.01). Age, comorbidity, depression, and use of sedative-hypnotics were also independently associated with the use of medications for erectile dysfunction or testosterone replacement. Patients prescribed daily opioid doses of 120 mg of morphine-equivalents or more had greater use of medication for erectile dysfunction or testosterone replacement than patients without opioid use (odds ratio, 1.58; 95% confidence interval, 1.03-2.43), even with adjustment for the duration of opioid therapy.
Conclusion. Dose and duration of opioid use, as well as age, comorbidity, depression, and use of sedative-hypnotics, were associated with evidence of erectile dysfunction. These findings may be important in the process of decision making for the long-term use of opioids.
C1 [Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Family Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Publ Hlth, Portland, OR 97201 USA.
[Deyo, Richard A.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Prevent Med, Portland, OR 97201 USA.
[Deyo, Richard A.] Kaiser Ctr Hlth Res, Portland, OR USA.
[Smith, David H. M.; Johnson, Eric S.; Donovan, Marilee; Yang, Xiuhai; Petrik, Amanda] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Morasco, Benjamin J.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Morasco, Benjamin J.; Dobscha, Steven K.] Portland VA Med Ctr, Portland, OR USA.
RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, Mail Code FM, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.
EM deyor@ohsu.edu
FU NIH/NCRR
FX NIH/NCRR grant funds were received to support this work.
NR 38
TC 13
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD MAY 15
PY 2013
VL 38
IS 11
BP 909
EP 915
DI 10.1097/BRS.0b013e3182830482
PG 7
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 144CD
UT WOS:000318916300015
PM 23459134
ER
PT J
AU Harlow, BL
MacLehose, RF
Smolenski, DJ
Soares, CN
Otto, MW
Joffe, H
Cohen, LS
AF Harlow, Bernard L.
MacLehose, Richard F.
Smolenski, Derek J.
Soares, Claudio N.
Otto, Michael W.
Joffe, Hadine
Cohen, Lee S.
TI Disparate Rates of New-Onset Depression During the Menopausal Transition
in 2 Community-based Populations: Real, or Really Wrong?
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE bias; depression; prospective studies
ID DIRECTED ACYCLIC GRAPHS; BIAS; HEALTH; SENSITIVITY; PREVALENCE; HARVARD;
CYCLES; MOODS; WOMEN; TWIN
AB This study took place in eastern Massachusetts and included respondents from the Harvard Study of Moods and Cycles Cohort 1, enrolled between 1995 and 1997, and the Harvard Study of Moods and Cycles Cohort 2, enrolled between 2005 and 2009. In prospectively assessing rates of new-onset depression in 2 populations of late-reproductive-aged women with no Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) lifetime history of depression, we were surprised to find far lower rates of depression in the population with greater racial diversity and lower socioeconomic status, contrary to what had been reported in the scientific literature. To better understand why these disparate results occurred, we assessed confounding and outcome misclassification as potential explanations for the discrepancy. After determining that these were unlikely explanations for the findings, we explored 2 potential sources of selection bias: one induced by self-referral of healthy participants into the study and the other induced by the design of the study itself. We concluded that both types of selection bias were likely to have occurred in this study and could account for the observed difference in rates.
C1 [Harlow, Bernard L.; MacLehose, Richard F.; Smolenski, Derek J.] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN 55454 USA.
[MacLehose, Richard F.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55454 USA.
[Soares, Claudio N.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada.
[Soares, Claudio N.] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON, Canada.
[Otto, Michael W.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA.
[Joffe, Hadine; Cohen, Lee S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Womens Mental Hlth, Boston, MA USA.
RP Harlow, BL (reprint author), Univ Minnesota, Div Epidemiol & Community Hlth, 1300 South 2nd St,Suite 300, Minneapolis, MN 55454 USA.
EM harlow@umn.edu
FU National Institute of Mental Health, National Institutes of Health
[R01-MH-50013, R01-MH-69732]
FX This research was supported by grants R01-MH-50013 and R01-MH-69732 from
the National Institute of Mental Health, National Institutes of Health.
NR 19
TC 1
Z9 1
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2013
VL 177
IS 10
BP 1148
EP 1156
DI 10.1093/aje/kws365
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 142MJ
UT WOS:000318801200014
PM 23589585
ER
PT J
AU Huang, YH
Goel, S
Duda, DG
Fukumura, D
Jain, RK
AF Huang, Yuhui
Goel, Shom
Duda, Dan G.
Fukumura, Dai
Jain, Rakesh K.
TI Vascular Normalization as an Emerging Strategy to Enhance Cancer
Immunotherapy
SO CANCER RESEARCH
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; REGULATORY T-CELLS; TUMOR MICROENVIRONMENT;
ANTIANGIOGENIC THERAPY; INHIBITOR; BLOCKADE; SURVIVAL; HYPOXIA;
ANGIOGENESIS; PROGRESSION
AB The recent approval of Provenge has brought new hope for anticancer vaccine therapies. However, the immunosuppressive tumor microenvironment seems to impair the efficacy of vaccine therapies. The abnormal tumor vasculature creates a hypoxic microenvironment that polarizes inflammatory cells toward immune suppression. Moreover, tumors systemically alter immune cells' proliferation, differentiation, and function via secretion of growth factors and cytokines. For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a critical role in immunosuppression via these mechanisms. Hence, antiangiogenic treatment may be an effective modality to potentiate immunotherapy. Here, we discuss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable strategy to re-engineer the tumor-immune microenvironment and improve cancer immunotherapy by using lower "vascular normalizing" doses of antiangiogenic agents. Cancer Res; 73(10); 2943-8. (C) 2013 AACR.
C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Edwin L Steele Lab, Cox 734, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
OI Huang, Yuhui/0000-0003-1985-3575
FU Medimmune; Roche; NIH [P01-CA080124, R01-CA115767, R01-CA085140,
R01-CA126642, R21-CA139168, R01-CA159258, R01-CA096915]; Federal
Share/NCI Proton Beam Program; Department of Defense [W81XWH-10-1-0016];
Postdoctoral Research Fellowship [W81XWH-11-1-0619]; American Cancer
Society [RSG-11-073-01-TBG]; National Foundation for Cancer Research;
Australian-American Fulbright Commission; American Society of Clinical
Oncology
FX R.K. Jain has commercial research grants from Medimmune and Roche; has
ownership interest (including patents) in XTuit Pharmaceuticals,
Syn-DevRx, and Enlight Biosciences; and is a consultant/advisory board
member of Noxxon Pharmaceuticals, Zyngenia, SynDevRx, XTuit
Pharmaceuticals, Enlight, Hambrecht & Quist Healthcare Investors, and
Hambrecht & Quist Life Sciences Investors. No potential conflicts of
interest were disclosed by the other authors.; The study was supported
by NIH grants P01-CA080124 (R.K. Jain, D.G. Duda, D. Fukumura);
R01-CA115767, R01-CA085140, and R01-CA126642 (R. K. Jain); R21-CA139168
and R01-CA159258 (D.G. Duda); R01-CA096915 (D. Fukumura); Federal
Share/NCI Proton Beam Program Income Grants (R.K. Jain, D.G. Duda, D.
Fukumura); Department of Defense Innovator Award W81XWH-10-1-0016 (R.K.
Jain); Postdoctoral Research Fellowship W81XWH-11-1-0619 (Y. Huang);
American Cancer Society Grant RSG-11-073-01-TBG (D.G. Duda); National
Foundation for Cancer Research Grant (R.K. Jain); and
Australian-American Fulbright Commission and an American Society of
Clinical Oncology Young Investigator Award (S. Goel).
NR 35
TC 100
Z9 105
U1 6
U2 45
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2013
VL 73
IS 10
BP 2943
EP 2948
DI 10.1158/0008-5472.CAN-12-4354
PG 6
WC Oncology
SC Oncology
GA 143XY
UT WOS:000318903700003
PM 23440426
ER
PT J
AU Katayama, R
Aoyama, A
Yamori, T
Qi, J
Oh-hara, T
Song, Y
Engelman, JA
Fujita, N
AF Katayama, Ryohei
Aoyama, Aki
Yamori, Takao
Qi, Jie
Oh-hara, Tomoko
Song, Youngchul
Engelman, Jeffrey A.
Fujita, Naoya
TI Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET
Inhibition
SO CANCER RESEARCH
LA English
DT Article
ID RECEPTOR TYROSINE KINASE; CELL LUNG-CANCER; ANTICANCER DRUG SCREEN;
ANTITUMOR-ACTIVITY; GEFITINIB RESISTANCE; SELECTIVE INHIBITOR;
ACQUIRED-RESISTANCE; DOSE-ESCALATION; PLUS ERLOTINIB; IN-VITRO
AB The receptor tyrosine kinase c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF). The HGF/c-MET axis is often dysregulated in tumors. c-MET activation can be caused by MET gene amplification, activating mutations, and auto-or paracrine mechanisms. Thus, c-MET inhibitors are under development as anticancer drugs. Tivantinib (ARQ 197) was reported as a small-molecule c-MET inhibitor and early clinical studies suggest antitumor activity. To assess whether the antitumor activity of tivantinib was due to inhibition of c-MET, we compared the activity of tivantinib with other c-MET inhibitors in both c-MET-addicted and nonaddicted cancer cells. As expected, other c-MET inhibitors, crizotinib and PHA-665752, suppressed the growth of c-MET-addicted cancers, but not the growth of cancers that are not addicted to c-MET. In contrast, tivantinib inhibited cell viability with similar potency in both c-MET-addicted and nonaddicted cells. These results suggest that tivantinib exhibits its antitumor activity in a manner independent of c-MET status. Tivantinib treatment induced a G2-M cell-cycle arrest in EBC1 cells similarly to vincristine treatment, whereas PHA-665752 or crizotinib treatment markedly induced G(0)-G(1) cell-cycle arrest. To identify the additional molecular target of tivantinib, we conducted COMPARE analysis, an in silico screening of a database of drug sensitivities across 39 cancer cell lines (JFCR39), and identified microtubule as a target of tivantinib. Tivantinib-treated cells showed typical microtubule disruption similar to vincristine and inhibited microtubule assembly in vitro. These results suggest that tivantinib inhibits microtubule polymerization in addition to inhibiting c-MET. Cancer Res; 73(10); 3087-96. (C) 2013 AACR.
C1 [Katayama, Ryohei; Qi, Jie; Song, Youngchul; Engelman, Jeffrey A.; Fujita, Naoya] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Katayama, Ryohei; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Katayama, Ryohei; Aoyama, Aki; Oh-hara, Tomoko; Fujita, Naoya] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Expt Chemotherapy, Tokyo 170, Japan.
[Yamori, Takao] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Tokyo 170, Japan.
[Aoyama, Aki] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Tokyo, Japan.
[Yamori, Takao] PMDA, Tokyo, Japan.
RP Engelman, JA (reprint author), Bldg149,13th St, Charlestown, MA 02129 USA.
EM jengelman@partners.org; naoya.fujita@jfcr.or.jp
FU National Cancer Institute Lung SPORE [R01CA137008, R01CA140594]; JSPS
[24300344, 22112008]
FX The study was supported in part by R01CA137008, R01CA140594, National
Cancer Institute Lung SPORE (J.A. Engelman), and JSPS KAKENHI grant
number, 24300344 and 22112008 (N. Fujita).
NR 40
TC 81
Z9 83
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2013
VL 73
IS 10
BP 3087
EP 3096
DI 10.1158/0008-5472.CAN-12-3256
PG 10
WC Oncology
SC Oncology
GA 143XY
UT WOS:000318903700017
PM 23598276
ER
PT J
AU Womack, JA
Goulet, JL
Gibert, C
Brandt, CA
Skanderson, M
Gulanski, B
Rimland, D
Rodriguez-Barradas, MC
Tate, J
Yin, MT
Justice, AC
AF Womack, Julie A.
Goulet, Joseph L.
Gibert, Cynthia
Brandt, Cynthia A.
Skanderson, Melissa
Gulanski, Barbara
Rimland, David
Rodriguez-Barradas, Maria C.
Tate, Janet
Yin, Michael T.
Justice, Amy C.
CA Vet Aging Cohort Study Project
TI Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; frailty; fragility fractures; Veterans
ID BONE-MINERAL DENSITY; ALCOHOL INTAKE; OLDER-ADULTS; RISK-FACTORS;
ELDERLY-MEN; FALLS; WOMEN; INFLAMMATION; MORTALITY; INDEX
AB Background. The Veterans Aging Cohort Study (VACS) Index is associated with all-cause mortality in individuals infected with human immunodeficiency virus (HIV). It is also associated with markers of inflammation and may thus reflect physiologic frailty. This analysis explores the association between physiologic frailty, as assessed by the VACS Index, and fragility fracture.
Methods. HIV-infected men from VACS were included. We identified hip, vertebral, and upper arm fractures using ICD-9-CM codes. We used Cox regression models to assess fragility fracture risk factors including the VACS Index, its components (age, hepatitis C status, FIB-4 score, estimated glomerular filtration rate, hemoglobin, HIV RNA, CD4 count), and previously identified risk factors for fragility fractures.
Results. We included 40 115 HIV-infected male Veterans. They experienced 588 first fragility fractures over 6.0 +/- 3.9 years. The VACS Index score (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.11-1.19), white race (HR, 1.92; 95% CI, 1.63-2.28), body mass index (HR, 0.94; 95% CI, .92-.96), alcohol-related diagnoses (HR, 1.65; 95% CI, 1.26-2.17), cerebrovascular disease (HR, 1.95; 95% CI, 1.14-3.33), proton pump inhibitor use (HR, 1.87; 95% CI, 1.54-2.27), and protease inhibitor use (HR, 1.25; 95% CI, 1.04-1.50) were associated with fracture risk. Components of the VACS Index score most strongly associated with fracture risk were age (HR, 1.40; 95% CI, 1.27-1.54), log HIV RNA (HR, 0.91; 95% CI, .88-.94), and hemoglobin level (HR, 0.82; 95% CI, .78-.86).
Conclusions. Frailty, as measured by the VACS Index, is an important predictor of fragility fractures among HIV-infected male Veterans.
C1 [Womack, Julie A.] Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
[Goulet, Joseph L.; Brandt, Cynthia A.; Skanderson, Melissa; Gulanski, Barbara; Tate, Janet; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Goulet, Joseph L.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06536 USA.
[Gibert, Cynthia] George Washington Univ, Vet Affairs Med Ctr, Washington, DC USA.
[Gibert, Cynthia] George Washington Univ, Dept Med, Washington, DC USA.
[Brandt, Cynthia A.] Yale Univ, Yale Ctr Med Informat, New Haven, CT 06536 USA.
[Gulanski, Barbara; Justice, Amy C.] Yale Univ, Dept Internal Med, Sect Gen Internal Med, New Haven, CT 06536 USA.
[Rimland, David] Vet Affairs Med Ctr, Atlanta, GA 30033 USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Med Serv, Michael E De Bakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Yin, Michael T.] Columbia Univ, Dept Med, Med Ctr, Div Infect Dis, New York, NY USA.
RP Womack, JA (reprint author), Yale Univ, Sch Nursing, 100 Church St South, New Haven, CT 06536 USA.
EM julie.womack@yale.edu
OI Goulet, Joseph/0000-0002-0842-804X
FU Veterans Administration Office, Academic Affiliations, Information
Research and Development Medical Informatics Fellowship Program;
National Institute of Nursing Research of the National Institutes of
Health [1K01NR013437-01]; CTSA Grant from the National Center for
Research Resources, component of the National Institutes of Health [UL1
RR024139]; National Center for Advancing Translational Science,
component of the National Institutes of Health; National Institute on
Alcohol Abuse and Alcoholism [U10 AA 13566]; VHA Public Health Strategic
Health Core Group; NIH roadmap for Medical Research
FX This work was supported by the Veterans Administration Office, Academic
Affiliations, Information Research and Development Medical Informatics
Fellowship Program; the National Institute of Nursing Research of the
National Institutes of Health (grant number 1K01NR013437-01); CTSA Grant
Number UL1 RR024139 from the National Center for Research Resources and
the National Center for Advancing Translational Science, components of
the National Institutes of Health, and NIH roadmap for Medical Research;
the Veterans Aging Cohort Study funded by the National Institute on
Alcohol Abuse and Alcoholism (U10 AA 13566) and VHA Public Health
Strategic Health Core Group.
NR 40
TC 42
Z9 42
U1 3
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2013
VL 56
IS 10
BP 1498
EP 1504
DI 10.1093/cid/cit056
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 140EF
UT WOS:000318636500024
PM 23378285
ER
PT J
AU Schultheis, PJ
Fleming, SM
Clippinger, AK
Lewis, J
Tsunemi, T
Giasson, B
Dickson, DW
Mazzulli, JR
Bardgett, ME
Haik, KL
Ekhator, O
Chava, AK
Howard, J
Gannon, M
Hoffman, E
Chen, YH
Prasad, V
Linn, SC
Tamargo, RJ
Westbroek, W
Sidransky, E
Krainc, D
Shull, GE
AF Schultheis, Patrick J.
Fleming, Sheila M.
Clippinger, Amy K.
Lewis, Jada
Tsunemi, Taiji
Giasson, Benoit
Dickson, Dennis W.
Mazzulli, Joseph R.
Bardgett, Mark E.
Haik, Kristi L.
Ekhator, Osunde
Chava, Anil Kumar
Howard, John
Gannon, Matt
Hoffman, Elizabeth
Chen, Yinhuai
Prasad, Vikram
Linn, Stephen C.
Tamargo, Rafael J.
Westbroek, Wendy
Sidransky, Ellen
Krainc, Dimitri
Shull, Gary E.
TI Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited
-synuclein accumulation and age-dependent sensorimotor deficits
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID P-TYPE ATPASE; KUFOR-RAKEB-SYNDROME; PALLIDO-PYRAMIDAL DEGENERATION;
SUPRANUCLEAR UPGAZE PARESIS; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE;
ATP13A2 MUTATIONS; TRANSGENIC MICE; DOPAMINERGIC-NEURONS;
CEREBROSPINAL-FLUID
AB Mutations in ATP13A2 (PARK9), encoding a lysosomal P-type ATPase, are associated with both KuforRakeb syndrome (KRS) and neuronal ceroid lipofuscinosis (NCL). KRS has recently been classified as a rare genetic form of Parkinsons disease (PD), whereas NCL is a lysosomal storage disorder. Although the transport activity of ATP13A2 has not been defined, in vitro studies show that its loss compromises lysosomal function, which in turn is thought to cause neuronal degeneration. To understand the role of ATP13A2 dysfunction in disease, we disrupted its gene in mice. Atp13a2(/) and Atp13a2(/) mice were tested behaviorally to assess sensorimotor and cognitive function at multiple ages. In the brain, lipofuscin accumulation, -synuclein aggregation and dopaminergic pathology were measured. Behaviorally, Atp13a2(/) mice displayed late-onset sensorimotor deficits. Accelerated deposition of autofluorescent storage material (lipofuscin) was observed in the cerebellum and in neurons of the hippocampus and the cortex of Atp13a2(/) mice. Immunoblot analysis showed increased insoluble -synuclein in the hippocampus, but not in the cortex or cerebellum. There was no change in the number of dopaminergic neurons in the substantia nigra or in striatal dopamine levels in aged Atp13a2(/) mice. These results show that the loss of Atp13a2 causes sensorimotor impairments, -synuclein accumulation as occurs in PD and related synucleinopathies, and accumulation of lipofuscin deposits characteristic of NCL, thus providing the first direct demonstration that null mutations in Atp13a2 can cause pathological features of both diseases in the same organism.
C1 [Schultheis, Patrick J.; Clippinger, Amy K.; Haik, Kristi L.; Chava, Anil Kumar; Linn, Stephen C.] No Kentucky Univ, Dept Biol Sci, Highland Hts, KY 41099 USA.
[Bardgett, Mark E.; Gannon, Matt; Hoffman, Elizabeth] No Kentucky Univ, Dept Psychol Sci, Highland Hts, KY 41099 USA.
[Fleming, Sheila M.; Ekhator, Osunde] Univ Cincinnati, Dept Psychol & Neurol, Cincinnati, OH 45267 USA.
[Chen, Yinhuai; Prasad, Vikram; Shull, Gary E.] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.
[Lewis, Jada; Giasson, Benoit; Howard, John] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA.
[Lewis, Jada; Giasson, Benoit; Howard, John] Univ Florida, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32610 USA.
[Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.
[Tsunemi, Taiji; Mazzulli, Joseph R.; Krainc, Dimitri] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Sch Med, Boston, MA 02114 USA.
[Tsunemi, Taiji; Mazzulli, Joseph R.; Krainc, Dimitri] Mass Gen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.
[Tamargo, Rafael J.; Westbroek, Wendy; Sidransky, Ellen] NHGRI, Sect Mol Neurogenet, Med Genet Branch, NIH, Bethesda, MD 20892 USA.
RP Schultheis, PJ (reprint author), No Kentucky Univ, Dept Biol Sci, Highland Hts, KY 41099 USA.
EM schultheisp@nku.edu
FU National Institutes of Health [NS070268, GM103436, DK050594, HL061974,
NS077022, MH094955, NS076054]; UF CTRND; Department of Neuroscience; UC
Gardner Family Center for Parkinson's Disease and Movement Disorders;
Intramural Research program of the National Human Genome Research
Institute at the National Institutes of Health, Bethesda, MD, USA
FX This work was supported by the National Institutes of Health (NS070268
to P.J.S., GM103436 to P.J.S. and M. E. B., DK050594 and HL061974 to G.
E. S., NS077022 to S. M. F., MH094955 to M. E. B., NS076054 to D. K.);
the UF CTRND and Department of Neuroscience; the UC Gardner Family
Center for Parkinson's Disease and Movement Disorders and the Intramural
Research program of the National Human Genome Research Institute at the
National Institutes of Health, Bethesda, MD, USA.
NR 84
TC 36
Z9 38
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2013
VL 22
IS 10
BP 2067
EP 2082
DI 10.1093/hmg/ddt057
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 139CL
UT WOS:000318559000013
PM 23393156
ER
PT J
AU Crosslin, DR
McDavid, A
Weston, N
Zheng, XW
Hart, E
Andrade, M
Kullo, IJ
McCarty, CA
Doheny, KF
Pugh, E
Kho, A
Hayes, MG
Ritchie, MD
Saip, A
Crawford, DC
Crane, PK
Newton, K
Carrell, DS
Gallego, CJ
Nalls, MA
Li, R
Mirel, DB
Crenshaw, A
Couper, DJ
Tanaka, T
van Rooij, FJA
Chen, MH
Smith, AV
Zakai, NA
Yango, Q
Garcia, M
Liu, YM
Lumley, T
Folsom, AR
Reiner, AP
Felix, JF
Dehghan, A
Wilson, JG
Bis, JC
Fox, CS
Glazer, NL
Cupples, A
Coresh, J
Eiriksdottir, G
Gudnason, V
Bandinelli, S
Frayling, TM
Chakravarti, A
van Duijn, CM
Melzer, D
Levy, D
Boerwinkle, E
Singleton, AB
Hernandez, DG
Longo, DL
Witteman, JCM
Psaty, BM
Ferrucci, L
Harris, TB
O'Donnell, CJ
Ganesh, SK
Larson, EB
Carlson, CS
Jarvik, GP
AF Crosslin, David R.
McDavid, Andrew
Weston, Noah
Zheng, Xiuwen
Hart, Eugene
de Andrade, Mariza
Kullo, Iftikhar J.
McCarty, Catherine A.
Doheny, Kimberly F.
Pugh, Elizabeth
Kho, Abel
Hayes, M. Geoffrey
Ritchie, Marylyn D.
Saip, Alexander
Crawford, Dana C.
Crane, Paul K.
Newton, Katherine
Carrell, David S.
Gallego, Carlos J.
Nalls, Michael A.
Li, Rongling
Mirel, Daniel B.
Crenshaw, Andrew
Couper, David J.
Tanaka, Toshiko
van Rooij, Frank J. A.
Chen, Ming-Huei
Smith, Albert V.
Zakai, Neil A.
Yango, Qiong
Garcia, Melissa
Liu, Yongmei
Lumley, Thomas
Folsom, Aaron R.
Reiner, Alex P.
Felix, Janine F.
Dehghan, Abbas
Wilson, James G.
Bis, Joshua C.
Fox, Caroline S.
Glazer, Nicole L.
Cupples, Adrienne
Coresh, Josef
Eiriksdottir, Gudny
Gudnason, Vilmundur
Bandinelli, Stefania
Frayling, Timothy M.
Chakravarti, Aravinda
van Duijn, Cornelia M.
Melzer, David
Levy, Daniel
Boerwinkle, Eric
Singleton, Andrew B.
Hernandez, Dena G.
Longo, Dan L.
Witteman, Jacqueline C. M.
Psaty, Bruce M.
Ferrucci, Luigi
Harris, Tamara B.
O'Donnell, Christopher J.
Ganesh, Santhi K.
Larson, Eric B.
Carlson, Chris S.
Jarvik, Gail P.
CA CHARGE Hematology Working Grp
Elect Med Records Genomics eMERGE
TI Genetic variation associated with circulating monocyte count in the
eMERGE Network
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID BLOOD-CELL COUNT
AB With white blood cell count emerging as an important risk factor for chronic inflammatory diseases, genetic associations of differential leukocyte types, specifically monocyte count, are providing novel candidate genes and pathways to further investigate. Circulating monocytes play a critical role in vascular diseases such as in the formation of atherosclerotic plaque. We performed a joint and ancestry-stratified genome-wide association analyses to identify variants specifically associated with monocyte count in 11 014 subjects in the electronic Medical Records and Genomics Network. In the joint and European ancestry samples, we identified novel associations in the chromosome 16 interferon regulatory factor 8 (IRF8) gene (P-value 2.7810(16), 0.22). Other monocyte associations include novel missense variants in the chemokine-binding protein 2 (CCBP2) gene (P-value 1.8810(7), 0.30) and a region of replication found in ribophorin I (RPN1) (P-value 2.6310(16), 0.23) on chromosome 3. The CCBP2 and RPN1 region is located near GATA binding protein2 gene that has been previously shown to be associated with coronary heart disease. On chromosome 9, we found a novel association in the prostaglandin reductase 1 gene (P-value 2.2910(7), 0.16), which is downstream from lysophosphatidic acid receptor 1. This region has previously been shown to be associated with monocyte count. We also replicated monocyte associations of genome-wide significance (P-value 5.6810(17), 0.23) at the integrin, alpha 4 gene on chromosome 2. The novel IRF8 results and further replications provide supporting evidence of genetic regions associated with monocyte count.
C1 [Crosslin, David R.; Gallego, Carlos J.; Jarvik, Gail P.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Crosslin, David R.; Jarvik, Gail P.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Zheng, Xiuwen; Lumley, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Crane, Paul K.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA.
[Reiner, Alex P.; Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Bis, Joshua C.; Glazer, Nicole L.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Bis, Joshua C.; Glazer, Nicole L.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[McDavid, Andrew; Carlson, Chris S.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Weston, Noah; Hart, Eugene; Newton, Katherine; Carrell, David S.; Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA.
[de Andrade, Mariza] Div Biomed Stat & Informat, Rochester, MN USA.
[Kullo, Iftikhar J.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA.
[McCarty, Catherine A.] Essentia Inst Rural Hlth, Duluth, MN USA.
[McCarty, Catherine A.] Marshfield Clin Fdn Med Res & Educ, Ctr Human Genet, Marshfield, WI 54449 USA.
[Doheny, Kimberly F.; Pugh, Elizabeth] Johns Hopkins Univ, Ctr Inherited Dis Res, Baltimore, MD USA.
[Coresh, Josef] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
[Chakravarti, Aravinda] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Kho, Abel] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Kho, Abel] Northwestern Univ, Div Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Hayes, M. Geoffrey] Northwestern Univ, Div Endocrinol Metab & Mol Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Ritchie, Marylyn D.] Penn State Univ, Dept Biochem & Mol Biol, Ctr Syst Genom, University Pk, PA 16802 USA.
[Saip, Alexander] Vanderbilt Univ, Dept Biomed Informat, Nashville, TN USA.
[Crawford, Dana C.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
[Crawford, Dana C.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
[Nalls, Michael A.] NIA, Neurogenet Lab, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Garcia, Melissa; Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, NIH, Bethesda, MD 20892 USA.
[Li, Rongling] NHGRI, Off Populat Genom, Bethesda, MD 20892 USA.
[Mirel, Daniel B.; Crenshaw, Andrew; Singleton, Andrew B.; Hernandez, Dena G.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
[Couper, David J.] Univ N Carolina, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA.
[Tanaka, Toshiko; Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Clin Res Branch, NIH, Baltimore, MD 21224 USA.
[van Rooij, Frank J. A.; Felix, Janine F.; Dehghan, Abbas; van Duijn, Cornelia M.; Witteman, Jacqueline C. M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[van Rooij, Frank J. A.; Felix, Janine F.; Dehghan, Abbas; van Duijn, Cornelia M.; Witteman, Jacqueline C. M.] Netherlands Consortium Healthy Aging NGI NCHA, Netherlands Genom Initiat, Leiden, Netherlands.
[Chen, Ming-Huei; Yango, Qiong; Fox, Caroline S.; Cupples, Adrienne; Levy, Daniel; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Chen, Ming-Huei] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Smith, Albert V.; Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
[Smith, Albert V.; Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland.
[Zakai, Neil A.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
[Zakai, Neil A.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
[Yango, Qiong; Cupples, Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Liu, Yongmei] Wake Forest Univ, Div Publ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA.
[Folsom, Aaron R.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Wilson, James G.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA USA.
[Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
[Bandinelli, Stefania] Geriatr Unit ASF, Florence, Italy.
[Frayling, Timothy M.; Melzer, David] Univ Exeter, Peninsula Coll Med & Dent, Exeter, Devon, England.
[Melzer, David] PCMD, European Ctr Environm & Human Hlth, Truro, England.
[Levy, Daniel; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA.
[Hernandez, Dena G.] UCL, Dept Mol Neurosci, London, England.
[Hernandez, Dena G.] UCL, Inst Neurol, Reta Lila Labs, London, England.
[Longo, Dan L.] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Psaty, Bruce M.] Grp Hlth Res Inst, Dept Grp Hlth, Seattle, WA USA.
[O'Donnell, Christopher J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA USA.
[Ganesh, Santhi K.] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
RP Crosslin, DR (reprint author), Univ Washington, Dept Genome Sci, S213,Campus Mail Box 355065, Seattle, WA 98195 USA.
EM davidcr@u.washington.edu
RI Crane, Paul/C-8623-2014; Singleton, Andrew/C-3010-2009; Jarvik,
Gail/N-6476-2014; Gudnason, Vilmundur/K-6885-2015; Smith,
Albert/K-5150-2015;
OI Cupples, L. Adrienne/0000-0003-0273-7965; Felix,
Janine/0000-0002-9801-5774; Crane, Paul/0000-0003-4278-7465; McDavid,
Andrew/0000-0002-6581-1213; Zheng, Xiuwen/0000-0002-1390-0708; Jarvik,
Gail/0000-0002-6710-8708; Gudnason, Vilmundur/0000-0001-5696-0084;
Smith, Albert/0000-0003-1942-5845; Melzer, David/0000-0002-0170-3838;
Dehghan, Abbas/0000-0001-6403-016X
FU National Human Genome Research Institute (NHGRI), a component of the
National Institutes of Health (NIH), Bethesda, MD, USA [HG004610,
AG06781, HG04599, HG004608, HG004609, HG004438, HG004424, HG004603];
State of Washington Life Sciences Discovery Fund award; NIA/NIH
[AG000932-02]; NIH [N01-AG-12100, HHSN268200625226C, UL1RR025005,
HHSN268200782096C]; NIA Intramural Research Program; Hjartavernd (the
Icelandic Heart Association); Althingi (the Icelandic Parliament);
National Heart, Lung, and Blood Institute [N01-HC-55015, N01-HC-55016,
N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022,
R01HL087641, R01HL59367, R01HL086694, R01 HL-071862]; National Human
Genome Research Institute [U01HG004402]; Intramural Research Program of
the NIH, National Institute on Aging; MedStar Research Institute;
National Heart, Lung, and Blood Institute's Framingham Heart Study
[N01-HC-25195]; Affymetrix for genotyping services [N02-HL-6-4278];
Robert Dawson Evans Endowment of the Department of Medicine at Boston
University School of Medicine; Boston Medical Center; Intramural
Research Program of the NIH, National Institute on Aging, NIA
[N01AG62101, N01AG62103, N01AG62106]; NIA [1R01AG032098-01A1]; Italian
Ministry of Health [ICS 110.1RS97.71]; U.S. National Institute on Aging
[N01-AG-916413, N01-AG-821336, 263 MD 9164 13, 263 MD 821336];
Intramural Research Program, National Institute on Aging, National
Institutes of Health, USA; Netherlands Organization of Scientific
Research NWO [175.010.2005.011, 911.03.012]; Research Institute for
Diseases in the Elderly (RIDE); Netherlands Genomics Initiative
(NGI)/NWO [050 060 810]; Erasmus Medical Center; Erasmus University,
Rotterdam; Netherlands Organization for the Health Research and
Development (ZonMw); Netherlands Heart Foundation; Ministry of
Education, Culture, and Science; Ministry of Health, Welfare, and
Sports; European Commission (DG XII); Municipality of Rotterdam;
Netherlands Organization for Scientific Research (NWO, VICI)
[918-76-619]; Netherlands Organization for Scientific Research (NWO)
FX eMERGE: This study was supported by the following U01 grants from the
National Human Genome Research Institute (NHGRI), a component of the
National Institutes of Health (NIH), Bethesda, MD, USA: (i) HG004610,
AG06781 (Group Health Cooperative), (ii) HG04599 (Mayo Clinic), (iii)
HG004608 (Marshfield Clinic), (iv) HG004609 (Northwestern University),
(v) HG004438 (CIDR), (vi) HG004424 (BROAD) and (vii) HG004603
(Vanderbilt University). Additional support was provided by a State of
Washington Life Sciences Discovery Fund award to the Northwest Institute
of Genetic Medicine (GPJ). CHARGE: This research was made possible by
NIA/NIH contract AG000932-02 (2009) Characterization of Normal Genomic
Variability. This study utilized the high-performance computational
capabilities of the BiowulfLinux cluster at the National Institutes of
Health, Bethesda, MD (http://biowulf.nih.gov). The Age, Gene/Environment
Susceptibility Reykjavik Study was funded by NIH contract N01-AG-12100,
the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart
Association) and the Althingi (the Icelandic Parliament). The
Atherosclerosis Risk in Communities Study is carried out as a
collaborative study supported by National Heart, Lung, and Blood
Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018,
N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022 and grants
R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research
Institute contract U01HG004402; and National Institutes of Health
contract HHSN268200625226C. Infrastructure was partly supported by Grant
Number UL1RR025005, a component of the National Institutes of Health and
NIH Roadmap for Medical Research. The BLSA was supported in part by the
Intramural Research Program of the NIH, National Institute on Aging. A
portion of that support was through a R&D contract with MedStar Research
Institute. The National Heart, Lung, and Blood Institute's Framingham
Heart Study is a joint project of the National Institutes of Health and
Boston University School of Medicine and was supported by the National
Heart, Lung, and Blood Institute's Framingham Heart Study (contract No.
N01-HC-25195) and its contract with Affymetrix for genotyping services
(contract No. N02-HL-6-4278). Analyses reflect the efforts and resource
development from the Framingham Heart Study investigators participating
in the SNP Health Association Resource (SHARe) project. A portion of
this research was conducted using the Linux Cluster for Genetic Analysis
(LinGA-II) funded by the Robert Dawson Evans Endowment of the Department
of Medicine at Boston University School of Medicine and Boston Medical
Center. The Health ABC Study was supported in part by the Intramural
Research Program of the NIH, National Institute on Aging, NIA contracts
N01AG62101, N01AG62103 and N01AG62106. The genome-wide association study
was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University
Health Sciences, and genotyping services were provided by the Center for
Inherited Disease Research (CIDR). CIDR is fully funded through a
federal contract from the National Institutes of Health to The Johns
Hopkins University, contract number HHSN268200782096C. The InChianti
Study was supported as a 'targeted project' (ICS 110.1RS97.71) by the
Italian Ministry of Health, by the U.S. National Institute on Aging
(Contracts N01-AG-916413, N01-AG-821336, 263 MD 9164 13 and 263 MD
821336), and in part by the Intramural Research Program, National
Institute on Aging, National Institutes of Health, USA.; The GWAS
database of the Rotterdam Study was funded through the Netherlands
Organization of Scientific Research NWO (nr. 175.010.2005.011,
911.03.012) and the Research Institute for Diseases in the Elderly
(RIDE). This study was supported by the Netherlands Genomics Initiative
(NGI)/NWO project number 050 060 810 (Netherlands Consortium for Healthy
Ageing). The Rotterdam Study is supported by the Erasmus Medical Center
and Erasmus University, Rotterdam, the Netherlands organization for
scientific research (NWO), the Netherlands Organization for the Health
Research and Development (ZonMw), the Research Institute for Diseases in
the Elderly (RIDE), the Netherlands Heart Foundation, the Ministry of
Education, Culture, and Science, the Ministry of Health, Welfare, and
Sports, the European Commission (DG XII) and the Municipality of
Rotterdam. J.F.F. and A. D. were supported by the Netherlands
Organization for Scientific Research (NWO, VICI no. 918-76-619). The
participation of A. P. R. was supported by National Heart, Lung, and
Blood Institute grant R01 HL-071862.
NR 17
TC 27
Z9 28
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2013
VL 22
IS 10
BP 2119
EP 2127
DI 10.1093/hmg/ddt010
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 139CL
UT WOS:000318559000017
PM 23314186
ER
PT J
AU Sun, HY
Munoz, P
Torre-Cisneros, J
Aguado, JM
Lattes, R
Montejo, M
Garcia-Reyne, A
Bouza, E
Valerio, M
Lara, R
John, GT
Bruno, D
Singh, N
AF Sun, Hsin-Yun
Munoz, Patricia
Torre-Cisneros, Julian
Aguado, Jose M.
Lattes, Roberta
Montejo, Miguel
Garcia-Reyne, Ana
Bouza, Emilio
Valerio, Maricela
Lara, Rosario
John, George T.
Bruno, Didier
Singh, Nina
TI Mycobacterium Tuberculosis-Associated Immune Reconstitution Syndrome in
Solid-Organ Transplant Recipients
SO TRANSPLANTATION
LA English
DT Article
DE Immune reconstitution syndrome; Mycobacterium tuberculosis; Solid-organ
transplant recipients
ID CRYPTOCOCCUS-NEOFORMANS INFECTION; T-CELL RESPONSES; CLINICAL
CHARACTERISTICS; PULMONARY TUBERCULOSIS; INFLAMMATORY SYNDROME;
RISK-FACTORS; THERAPY; DISEASE
AB Background. Incidence, characteristics, and risk factors for tuberculosis (TB)-associated immune reconstitution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known.
Methods. Patients are composed of 64 consecutive SOT recipients with TB followed for 12 months. IRS was defined based on previously proposed criteria.
Results. IRS developed in 14% (9/64) of the patients, a median of 47 days after the use of anti-TB therapy. Liver versus other types of organ transplant recipients (adjusted odds ratio [OR], 6.11; 95% confidence interval [CI], 1.08-34.86), prior cytomegalovirus infection (adjusted OR, 5.65; 95% CI, 0.93-34.47), and rifampin use (adjusted OR, 4.56; 95% CI, 0.74-27) were associated with a higher risk of IRS. The presence of more than one factor (liver transplantation, cytomegalovirus infection, and rifampin use) when compared with none of these factors conferred a 19-fold increase in the risk of IRS (P=0.01). Mortality at 1 year after diagnosis was 33.3% in patients with IRS and 17.2% in those without IRS (P=0.31).
Conclusions. IRS was documented in 14% of the SOT recipients with TB. We determined clinically identifiable factors that may be useful in assessing the risk of tuberculosis-associated posttransplantation IRS.
C1 [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan.
[Munoz, Patricia; Bouza, Emilio; Valerio, Maricela] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Dept Med, Madrid, Spain.
[Torre-Cisneros, Julian; Lara, Rosario] Univ Cordoba, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba, Cordoba, Spain.
[Aguado, Jose M.; Garcia-Reyne, Ana] Hosp 12 Octubre, E-28041 Madrid, Spain.
[Lattes, Roberta] Inst Nefrol, Infect Dis Sect, Dept Transplantat, Buenos Aires, DF, Argentina.
[Montejo, Miguel] Hosp Univ Cruces, Bilbao, Spain.
[John, George T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
[Bruno, Didier] Hosp Univ Fdn Favaloro, Dept Internal Med, Buenos Aires, DF, Argentina.
[Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
RP Sun, HY (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
EM hy.jamie.sun@gmail.com
RI Montejo, Jose Miguel/E-1755-2012;
OI Bruno, Didier/0000-0002-9540-2269; Munoz Garcia, Patricia
Carmen/0000-0001-5706-5583; bouza, emilio/0000-0001-6967-9267; SUN,
HSIN-YUN/0000-0003-0074-7721
FU Ministerio de Economia y Competitividad, Instituto de Salud Carlos III;
European Development Regional Fund "A way to achieve Europe," Spanish
Network for the Research in Infectious Diseases [REIPI RD06/0008,
RD12/0015]; Instituto de Salud Carlos III (Rio Hortega) [CN09130]
FX The Spanish investigators are supported by Ministerio de Economia y
Competitividad, Instituto de Salud Carlos III-cofinanced by the European
Development Regional Fund "A way to achieve Europe," Spanish Network for
the Research in Infectious Diseases (REIPI RD06/0008 and RD12/0015).
A.G.-R. was supported by a grant from Instituto de Salud Carlos III (Rio
Hortega grant no. CN09130).
NR 33
TC 13
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 15
PY 2013
VL 95
IS 9
BP 1173
EP 1181
DI 10.1097/TP.0b013e31828719c8
PG 9
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 141ZF
UT WOS:000318764500018
PM 23435454
ER
PT J
AU Beverly, LJ
Howell, LA
Hernandez-Corbacho, M
Casson, L
Chipuk, JE
Siskind, LJ
AF Beverly, Levi J.
Howell, Lauren A.
Hernandez-Corbacho, Maria
Casson, Lavona
Chipuk, Jerry E.
Siskind, Leah J.
TI BAK activation is necessary and sufficient to drive ceramide
synthase-dependent ceramide accumulation following inhibition of
BCL2-like proteins
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE ABT-263; ABT-737; apoptosis; BCL2; ceramide; haematology; leukaemia;
sphingolipid
ID BCL-2 FAMILY INHIBITOR; CELL LUNG-CANCER; SPHINGOLIPID METABOLISM;
ANTIAPOPTOTIC BCL-2; INDUCED APOPTOSIS; DRUG-RESISTANCE; BH3 DOMAINS;
ABT-737; MCL-1; CHANNELS
AB Determining mechanistic details about how drugs kill cancer cells is critical for predicting which cancers will respond to given therapeutic regimens and for identifying effective combinations of drugs that more potently kill cancer cells while sparing normal cells. The BCL2 family of proteins and bioactive sphingolipids are intricately linked during apoptotic cell death. In fact, many chemotherapeutic drugs are known to cause accumulation of the pro-apoptotic sphingolipid ceramide; however, the mechanism by which this occurs is not completely understood. In the present study we demonstrate that direct inhibition of antiapoptotic BCL2 proteins with ABT-263 is sufficient to induce C-16-ceramide synthesis in multiple cell lines, including human leukaemia and myeloma cells. ABT-263 activates CerS (ceramide synthase) activity only in cells expressing BAK or in cells capable of activating BAK. Importantly, recombinant BAK is sufficient to increase in vitro CerS activity in microsomes purified from Bak-KO (knockout) cells and activated BAK more potently activates CerS than inactive BAK. Likewise, ABT-263 addition to wild-type, but not Bak-deficient, microsomes increases CerS in vitro activity. Furthermore, we present a feed-forward model by which BAK activation of CerS by chemotherapeutic drugs leads to elevated ceramide levels that result in synergistic channel formation by ceramide (or one of its metabolites) and BAX/BAK.
C1 [Beverly, Levi J.; Casson, Lavona] Univ Louisville, James Graham Brown Canc Ctr, Dept Med, Div Hematol & Oncol, Louisville, KY 40202 USA.
[Howell, Lauren A.; Siskind, Leah J.] South Carolina Coll Pharm, Med Sch South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Hernandez-Corbacho, Maria] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.
[Chipuk, Jerry E.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
[Siskind, Leah J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Beverly, LJ (reprint author), Univ Louisville, James Graham Brown Canc Ctr, Dept Med, Div Hematol & Oncol, Louisville, KY 40202 USA.
EM levi.beverly@louisville.edu; siskind@musc.edu
OI Chipuk, Jerry Edward/0000-0002-1337-842X
FU National Institute of Diabetes and Digestive and Kidney Diseases of the
NIH (National Institutes of Health) [R01DK093462]; Cancer Center Support
Grant [P30 CA138313]; NIH/NCRR (National Center for Research Resources)
COBRE (Centers of Biomedical Research Excellence) in Lipidomics and
Pathobiology [P20 RR17677]; NIH, Molecular Targets COBRE
[8P20GM103482-10]; Wendy Will Case Cancer Fund [GB220413]; Kosair
Pediatric Cancer Research Program award; James Graham Brown Cancer
Center, NIH [CA157740]; March of Dimes Foundation [5-FY11-74]
FX This work was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases of the NIH (National Institutes of Health)
[grant number R01DK093462 (to L.J.S.)], the Lipidomics Shared Resource
of the Hollings Cancer Center at the Medical University of South
Carolina supported by a Cancer Center Support Grant [grant number P30
CA138313], pilot project from the NIH/NCRR (National Center for Research
Resources) COBRE (Centers of Biomedical Research Excellence) in
Lipidomics and Pathobiology [grant number P20 RR17677 (to L.J.S)]; NIH,
Molecular Targets COBRE [grant number 8P20GM103482-10 (to L.J.B.)], the
Wendy Will Case Cancer Fund [grant number GB220413 (to L.J.B.)], a
Kosair Pediatric Cancer Research Program award (to L.J.B.) the James
Graham Brown Cancer Center, NIH R01 [grant number CA157740 (to J.E.C.)]
and the March of Dimes Foundation [grant number 5-FY11-74 (to J.E.C.)].
NR 49
TC 26
Z9 26
U1 0
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD MAY 15
PY 2013
VL 452
BP 111
EP 119
DI 10.1042/BJ20130147
PN 1
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 137RS
UT WOS:000318455700011
PM 23480852
ER
PT J
AU Manoach, DS
Lee, AKC
Hamalainen, MS
Dyckman, KA
Friedman, JS
Vangel, M
Goff, DC
Barton, JJS
AF Manoach, Dara S.
Lee, Adrian K. C.
Hamalainen, Matti S.
Dyckman, Kara A.
Friedman, Jesse S.
Vangel, Mark
Goff, Donald C.
Barton, Jason J. S.
TI Anomalous Use of Context During Task Preparation in Schizophrenia: A
Magnetoencephalography Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Anterior cingulate cortex; antisaccade; cognitive control; frontal eye
field; lateral prefrontal cortex; schizophrenia
ID FRONTAL EYE-FIELD; ANTERIOR CINGULATE CORTEX; DORSOLATERAL PREFRONTAL
CORTEX; VISUALLY GUIDED SACCADES; SIGNAL SPACE SEPARATION; FUNCTIONAL
CONNECTIVITY; VOLITIONAL SACCADES; COGNITIVE CONTROL; CORTICAL ACTIVITY;
BRAIN ACTIVATION
AB Background: Impaired ability to use contextual information to optimally prepare for tasks contributes to performance deficits in schizophrenia. We used magnetoencephalography and an antisaccade task to investigate the neural basis of this deficit.
Methods: In schizophrenia patients and healthy control participants, we examined the difference in preparatory activation to cues indicating an impending antisaccade or prosaccade. We analyzed activation for correct trials only and focused on the network for volitional ocular motor control-frontal eye field (FEF), dorsal anterior cingulate cortex (dACC), and the ventrolateral and dorsolateral prefrontal cortex (VLPFC, DLPFC).
Results: Compared with control subjects, patients made more antisaccade errors and showed reduced differential preparatory activation in the dACC and increased differential preparatory activation in the VLPFC. In patients only, antisaccade error rates correlated with preparatory activation in the FEF, DLPFC, and VLPFC.
Conclusions: In schizophrenia, reduced differential preparatory activation of the dACC may reflect reduced signaling of the need for control. Greater preparatory activation in the VLPFC and the correlations of error rate with FEF, DLPFC, and VLPFC activation may reflect that patients who are more error prone require stronger activation in these regions for correct performance. These findings provide the first evidence of abnormal task preparation, distinct from response generation, during volitional saccades in schizophrenia. We conclude that schizophrenia patients are impaired in using task cues to modulate cognitive control and that this contributes to deficits inhibiting prepotent but contextually inappropriate responses and to behavior that is stimulus bound and error prone rather than flexibly guided by context.
C1 [Manoach, Dara S.; Lee, Adrian K. C.; Dyckman, Kara A.; Friedman, Jesse S.; Goff, Donald C.] Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat, Sch Med, Boston, MA USA.
[Hamalainen, Matti S.; Vangel, Mark] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Sch Med, Boston, MA USA.
[Manoach, Dara S.; Lee, Adrian K. C.; Hamalainen, Matti S.; Vangel, Mark] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Lee, Adrian K. C.] Univ Washington, Inst Learning & Brain Sci, Seattle, WA 98195 USA.
[Barton, Jason J. S.] Univ British Columbia, Dept Neurol, Vancouver, BC V5Z 1M9, Canada.
[Barton, Jason J. S.] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
[Barton, Jason J. S.] Univ British Columbia, Dept Visual Sci, Vancouver, BC V5Z 1M9, Canada.
RP Manoach, DS (reprint author), Massachusetts Gen Hosp, Charlestown Navy Yard, 149 13th St Room 1-111, Charlestown, MA 02129 USA.
EM dara@nmr.mgh.harvard.edu
RI Barton, Jason/A-6362-2012; Hamalainen, Matti/C-8507-2013;
OI Lee, Adrian KC/0000-0002-7611-0500
FU National Institute for Mental Health [R01 MH67720, F32 MH082514];
National Alliance for Research on Schizophrenia and Depression; Mental
Illness and Neuroscience Discovery (MIND) Institute; Postdoctoral
Fellowship Award, MGH-ECOR Fund for Medical Discovery; Advanced
Multimodal Neuroimaging Training Program [1-R90 DA023427-02]; National
Center for Research Resources [P41RR14075]; CIHR [MOP-81270]; Sepracor,
Inc.; Pfizer; Janssen; Novartis; GlaxoSmithKline
FX Support: National Institute for Mental Health (R01 MH67720, F32
MH082514); National Alliance for Research on Schizophrenia and
Depression; Mental Illness and Neuroscience Discovery (MIND) Institute;
Postdoctoral Fellowship Award, MGH-ECOR Fund for Medical Discovery
(AKCL); Advanced Multimodal Neuroimaging Training Program (1-R90
DA023427-02 - AKCL); National Center for Research Resources P41RR14075;
Canada Research Chair and CIHR grant MOP-81270.; Dr. Manoach reports
having received research funding from Sepracor, Inc. and an honorarium
from Lilly, Inc. Dr. Goff reports having served as a consultant or
advisor to Xytis, Forest Labs, Pfizer, Indevus Pharmaceuticals, H.
Lundbeck, Schering-Plough, Eli Lilly, Takeda, Biovail, Solvay,
Hoffman-La Roche, Cypress, and Dianippon Sumitomo. He served on a Data
and Safety Monitoring Board for Otsuka and Wyeth. He received research
funding from Pfizer, Janssen, Novartis, and GlaxoSmithKline. Drs. Lee,
Dyckman, Hamalainen, Van gel, and Barton and Mr. Freidman reported: no
biomedical financial interests or potential conflicts of interest.
NR 70
TC 3
Z9 3
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2013
VL 73
IS 10
BP 967
EP 975
DI 10.1016/j.biopsych.2012.12.018
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 137SV
UT WOS:000318458600006
PM 23380717
ER
PT J
AU Calkins, ME
Ray, A
Gur, RC
Freedman, R
Green, MF
Greenwood, TA
Light, GA
Nuechterlein, KH
Olincy, A
Radant, AD
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Sugar, C
Swerdlow, NR
Tsuang, DW
Tsuang, MT
Turetsky, BI
Braff, DL
Lazzeroni, LC
Gur, RE
AF Calkins, Monica E.
Ray, Amrita
Gur, Ruben C.
Freedman, Robert
Green, Michael F.
Greenwood, Tiffany A.
Light, Gregory A.
Nuechterlein, Keith H.
Olincy, Ann
Radant, Allen D.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Sugar, Catherine
Swerdlow, Neal R.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Braff, David L.
Lazzeroni, Laura C.
Gur, Raquel E.
TI Sex Differences in Familiality Effects on Neurocognitive Performance in
Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Endophenotype; genetics; heritability; neurocognition; schizophrenia;
sex differences
ID 1ST-DEGREE RELATIVES; COGNITIVE DEFICITS; HERITABILITY; ENDOPHENOTYPES;
CONSORTIUM; GENETICS; IMPAIRMENTS; VALIDATION; SIBLINGS; FAMILIES
AB Background: Numerous studies have documented that patients with schizophrenia show neurocognitive impairments, which are also heritable in schizophrenia families. In view of these findings, the current investigation tested the hypothesis that neurocognitive performance of schizophrenia probands can predict the neurocognitive performance of their unaffected family members.
Methods: Participants (n = 1967; schizophrenia = 369; first-degree relatives = 1072; community comparison subjects = 526) in the Consortium on the Genetics of Schizophrenia were administered the Penn Computerized Neurocognitive Battery.
Results: Consistent with prior work, probands showed significant neurocognitive impairment, and neurocognitive ability was significantly heritable across domains. On average, unaffected relatives did not differ from community comparison subjects in their neurocognitive performance. However, in six of seven domains, proband scores predicted the performance of their unaffected siblings. Male, but not female, proband performance was predictive of their unaffected relatives' (siblings and mothers) performance, most consistently in face memory and spatial processing.
Conclusions: Using a novel approach in which individual probands are paired with their respective unaffected relatives within each family, we found that male proband performance predicted both sister and brother performance, an effect that was most powerfully observed for face memory and spatial processing. Results suggest that the familial transmission of sexually dimorphic neurocognitive domains, in which a particular sex tends to show a performance advantage over the other, may not itself be sex specific in schizophrenia families.
C1 [Calkins, Monica E.; Gur, Ruben C.; Turetsky, Bruce I.; Gur, Raquel E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Ray, Amrita; Tsuang, Debby W.; Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA.
[Ray, Amrita; Tsuang, Debby W.; Lazzeroni, Laura C.] Stanford Univ, Dept Behav Sci, Stanford, CA 94305 USA.
[Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA.
[Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA.
[Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
Vet Affairs San Diego Healthcare Syst, Vet Integrated Serv Network Mental Illness Res Ed, San Diego, CA USA.
[Radant, Allen D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Radant, Allen D.] US Dept Vet Affairs, Vet Integrated Serv Network Mental Illness Res Ed, Seattle, WA USA.
[Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Dept Psychiat, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA.
[Seidman, Larry J.; Stone, William S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div,Dept Psychiat,Sch Med, Boston, MA 02115 USA.
[Siever, Larry J.; Silverman, Jeremy M.] SUNY Upstate Med Univ, Med Genet Res Program, Syracuse, NY 13210 USA.
[Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Siever, Larry J.] James J Peters Vet Affairs, Bronx, NY USA.
[Siever, Larry J.] Vet Integrated Serv Network Mental Illness Res Ed, Bronx, NY USA.
[Green, Michael F.; Sugar, Catherine] US Dept Vet Affairs, Vet Integrated Serv Network Mental Illness Res Ed, Los Angeles, CA USA.
RP Calkins, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, Schizophrenia Res Ctr, 3600 Spruce St, Philadelphia, PA 19104 USA.
EM mcalkins@upenn.edu
RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016;
OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang,
Debby/0000-0002-4716-1894; Lazzeroni, Laura/0000-0002-1846-6920
FU National Institute of Mental Health [R01 MH086735, R01 MH65571, R01
MH42228, R01 MH65588, R01 MH65562, R01 MH65707, R01 MH65554, R01
MH65578, R01 MH65558, K08 MH79364]; Neuropsychiatry Postdoctoral
traineeship [MH19112]; Scottish Rite Schizophrenia Research Fellowship;
Abbott Laboratories; Amgen; Cypress; Lundbeck; Teva; Otsuka; Sunovion;
Janssen Scientific Affairs; Genentech; AstraZeneca; Pfizer
Pharmaceuticals; La Roche; Bristol-Myers
FX This study was supported by National Institute of Mental Health Grants
R01 MH086735, R01 MH65571, R01 MH42228, R01 MH65588, R01 MH65562, R01
MH65707, R01 MH65554, R01 MH65578, R01 MH65558, and K08 MH79364; a
Neuropsychiatry Postdoctoral traineeship (MH19112); and a Scottish Rite
Schizophrenia Research Fellowship.; Dr. Michael F. Green reports having
received consulting fees from Abbott Laboratories, Amgen, Cypress,
Lundbeck, and Teva. He has received speaking fees from Otsuka and
Sunovion. Dr. Gregory A. Light has received compensation for one-time
participation in a scientific advisory board meeting for Astellas Inc.
Dr. Keith H. Nuechterlein reports research grant funding from Janssen
Scientific Affairs and Genentech and consulting fees from Genentech and
Otsuka. Dr. Neal R. Swerdlow was a consultant to Neurocrine, Inc. Dr.
Bruce I. Turetsky reports unrelated research grant support from
AstraZeneca and Pfizer Pharmaceuticals and consulting fees from La Roche
and Bristol-Myers. Dr. Laura C Lazzeroni is named as an inventor on a
pharmacogenetic patent application that is being pursued by Stanford
University. All other authors report no biomedical financial interests
or potential conflicts of interest.
NR 33
TC 11
Z9 11
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2013
VL 73
IS 10
BP 976
EP 984
DI 10.1016/j.biopsych.2012.12.021
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 137SV
UT WOS:000318458600007
PM 23395246
ER
PT J
AU Lester-Coll, NH
Goldhaber, SZ
Sher, DJ
D'Amico, AV
AF Lester-Coll, Nataniel H.
Goldhaber, Samuel Z.
Sher, David J.
D'Amico, Anthony V.
TI Death from high-risk prostate cancer versus cardiovascular mortality
with hormonal therapy A Decision Analysis
SO CANCER
LA English
DT Article
DE prostate cancer; cardiovascular disease; hormonal therapy; radiation
therapy; decision analysis
ID ANDROGEN DEPRIVATION THERAPY; PHASE-III TRIAL; CONGESTIVE-HEART-FAILURE;
RADIATION-THERAPY; RANDOMIZED-TRIAL; MYOCARDIAL-INFARCTION;
RADIOTHERAPY; DISEASE; MEN; SUPPRESSION
AB BACKGROUND: Randomized trials have demonstrated improved survival when hormonal therapy (HT) is added to radiation therapy (RT) for high-risk prostate cancer. However, it is still unknown whether men who have a history of myocardial infarction (MI) or MI risk factors achieve a superior outcome from HT. METHODS: A Markov decision analysis model was used to compare quality-adjusted life expectancy (QALE) in men aged 50, 60, and 70 years who received RT and no HT, 6 months of HT (short-term), or 3 years of HT (long-term) for high-risk prostate cancer stratified by cardiac risk group. RESULTS: In men with a history of MI, there was a decrease of 0.1 to 0.2 quality-adjusted life years and 0.5 to 0.6 quality-adjusted life years across all ages with short-term HT and long-term HT, respectively, compared with no HT. In men without MI, receipt of short-term or long-term HT was associated with a QALE benefit versus no HT in all cohorts. Among men without MI, the optimal duration of HT was a function of age and the number of MI risk factors. Long-term HT improved QALE (range, 1.4-5.4 years) for men aged 50 or 60 years except those with MI; whereas, for men aged 70 years with 4 cardiac risk factors, short-term and long-term HT yielded identical QALE. CONCLUSIONS: Men who received RT for high-risk prostate cancer and had a history of MI experienced net harm when they received HT. Men without MI gained a QALE benefit from HT, even if they had up to 4 cardiac risk factors. The optimal duration of HT is a function of patient age and the number of cardiac risk factors. Cancer 2013. (c) 2013 American Cancer Society.
C1 [Lester-Coll, Nataniel H.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Goldhaber, Samuel Z.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Sher, David J.] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA.
[D'Amico, Anthony V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Lester-Coll, NH (reprint author), 15 York St,101 FMP, New Haven, CT 06510 USA.
EM nataniel.lester-coll@yale.edu
OI Lester-Coll, Nataniel/0000-0002-1012-1477
FU Daiichi Sankyo; Eisai; EKOS; Johnson Johnson; Sanofi Aventis; Baxter;
Boehringer Ingelheim; Bristol-Myers Squibb; Medscape; Merck; Portola
FX Samuel Z. Goldhaber has received research grants from Daiichi Sankyo,
Eisai, EKOS, Johnson & Johnson, and Sanofi Aventis and is a paid
consultant for Baxter, Boehringer Ingelheim, Bristol-Myers Squibb,
Daiichi Sankyo, Eisai, Medscape, Merck, Portola, and Sanofi Aventis.
NR 31
TC 9
Z9 9
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2013
VL 119
IS 10
BP 1808
EP 1815
DI 10.1002/cncr.27980
PG 8
WC Oncology
SC Oncology
GA 138JT
UT WOS:000318505500009
PM 23400678
ER
PT J
AU Iasonos, A
Keung, EZ
Zivanovic, O
Mancari, R
Peiretti, M
Nucci, M
George, S
Colombo, N
Carinelli, S
Hensley, ML
Raut, CP
AF Iasonos, Alexia
Keung, Emily Z.
Zivanovic, Oliver
Mancari, Rosanna
Peiretti, Michele
Nucci, Marisa
George, Suzanne
Colombo, Nicoletta
Carinelli, Silvestro
Hensley, Martee L.
Raut, Chandrajit P.
TI External validation of a prognostic nomogram for overall survival in
women with uterine leiomyosarcoma
SO CANCER
LA English
DT Article
DE nomogram; uterine leiomyosarcoma; International Federation of Gynecology
and Obstetrics and American Joint Committee on Cancer; cancer; staging;
validation
ID PROSTATE-CANCER; STAGE-I; SARCOMAS; RADIOTHERAPY; RECURRENCE; THERAPY;
SYSTEMS; 5-YEAR
AB BACKGROUND: There is no validated system to identify prognostically distinct cohorts of women with uterine leiomyosarcoma (ULMS). By using an independent, pooled, multi-institutional, international patient cohort, the authors validated a recently proposed ULMS nomogram. METHODS: The ULMS nomogram incorporated 7 clinical characteristics (age, tumor size, tumor grade, cervical involvement, locoregional metastases, distant metastases, and mitotic index (per 10 high-power fields) to predict overall survival (OS) after primary surgery. Independent cohorts from 2 sarcoma centers were included. Eligible women, at minimum, underwent a hysterectomy for primary, locally advanced, or metastatic ULMS and received part of their care at 1 of the centers between 1994 and 2010. RESULTS: In total, 187 women with ULMS were identified who met the above criteria described above (median age, 51 years; median tumor size, 9 cm; median mitotic index, 20 per 10 high-power fields). Tumors generally were high grade (88%), FIGO stage I or II (61%) without cervical involvement (93%) and without locoregional metastases (77%) or distant metastases (83%). The median OS and the 5-year OS rate were 4.5 years (95% confidence interval, 3.2-5.3 years) and 46%, respectively; and 65 women (35%) remained alive at last follow-up. The nomogram concordance index was 0.67(standard error, 0.02), which was as high as the concordance index from the initial cohort used for nomogram development. The concordance between actual OS and nomogram predictions suggests excellent calibration because predictions were within 1% of actual 5-year OS rates for patients with a predicted 5-year OS of less than 0.68. CONCLUSIONS: The ULMS nomogram was externally validated using independent cohorts. These findings support the international use of the ULMS nomogram prognostic of OS in ULMS. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Iasonos, Alexia] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10065 USA.
[Keung, Emily Z.; Raut, Chandrajit P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Surg,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zivanovic, Oliver] Univ Hosp Bonn, Dept Obstet & Gynecol, Bonn, Germany.
[Mancari, Rosanna; Peiretti, Michele] European Inst Oncol, Div Gynecol, Gynecol Med Oncol Unit, Milan, Italy.
[Nucci, Marisa] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pathol, Boston, MA 02115 USA.
[George, Suzanne] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Colombo, Nicoletta] Univ Milano Bicocca, Dept Surg Sci, Milan, Italy.
[Colombo, Nicoletta] European Inst Oncol, Milan, Italy.
[Carinelli, Silvestro] European Inst Oncol, Div Pathol & Lab Med, Milan, Italy.
[Hensley, Martee L.] Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, New York, NY 10021 USA.
[Hensley, Martee L.] Weill Cornell Med Coll, New York, NY USA.
RP Iasonos, A (reprint author), Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 407 East 63rd St, New York, NY 10065 USA.
EM iasonosa@mskcc.org
FU NCI NIH HHS [P30 CA008748]
NR 24
TC 15
Z9 17
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2013
VL 119
IS 10
BP 1816
EP 1822
DI 10.1002/cncr.27971
PG 7
WC Oncology
SC Oncology
GA 138JT
UT WOS:000318505500010
PM 23456762
ER
PT J
AU Sharma, A
Schwartz, SM
Mendez, E
AF Sharma, Arun
Schwartz, Stephen M.
Mendez, Eduardo
TI Hospital volume is associated with survival but not multimodality
therapy in Medicare patients with advanced head and neck cancer
SO CANCER
LA English
DT Article
DE head and neck neoplasms; survival; radiotherapy; chemoradiotherapy;
cisplatin
ID LOCALLY ADVANCED HEAD; SQUAMOUS-CELL CARCINOMA; STAGE LARYNGEAL-CANCER;
COMORBIDITY INDEX; CHEMOTHERAPY; RADIOTHERAPY; IMPACT; FACILITIES;
MORTALITY; RESECTION
AB BACKGROUND: Given the complexity of management of advanced head and neck squamous cell carcinoma (HNSCC), this study hypothesized that high hospital volume would be associated with receiving National Comprehensive Cancer Network (NCCN) guideline therapy and improved survival in patients with advanced HNSCC. METHODS: The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify patients with advanced HNSCC. Treatment modalities and survival were determined using Medicare data. Hospital volume was determined by the number of patients with HNSCC treated at each hospital. RESULTS: There were 1195 patients with advanced HNSCC who met inclusion criteria. In multivariable analyses, high hospital volume was not associated with receiving multimodality therapy per NCCN guidelines (odds ratio = 1.02, 95% confidence interval = 0.66-1.60), but showed a nearly significant inverse association with survival in a model adjusted for National Cancer Institutedesignated cancer center status, age, sex, race, socioeconomic status, marital status, comorbidity, year of diagnosis, tumor site, and tumor stage (hazard ratio = 0.85, 95% confidence interval = 0.69-1.04). CONCLUSIONS: Medicare patients with advanced HNSCC treated at high-volume hospitals were not more likely to receive NCCN guideline therapy, but had nearly statistically significant better survival, when compared with patients treated at low-volume hospitals. These results suggest that features of high-volume hospitals other than delivery of NCCN guideline therapy influence survival. Cancer 2013. (c) 2013 American Cancer Society.
C1 [Sharma, Arun; Mendez, Eduardo] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
[Schwartz, Stephen M.] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA.
[Schwartz, Stephen M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA.
[Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
RP Mendez, E (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave,North Mailstop D4-100, Seattle, WA 98109 USA.
EM edmendez@u.washington.edu
OI Schwartz, Stephen/0000-0001-7499-8502
FU National Institute on Deafness and Other Communication Disorders Grant
[2T32DC000018]; National Cancer Institute [N01-PC-35142]; National
Center for Research Resources Grant [5KL2RR025015]; Intuitive Surgical,
Inc.
FX This work was funded by National Institute on Deafness and Other
Communication Disorders Grant 2T32DC000018; National Cancer Institute
Contract N01-PC-35142; and National Center for Research Resources Grant
5KL2RR025015.; Dr. Mendez has received speaking fees/honoraria from
Intuitive Surgical, Inc. All other authors made no disclosures.
NR 29
TC 14
Z9 14
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2013
VL 119
IS 10
BP 1845
EP 1852
DI 10.1002/cncr.27976
PG 8
WC Oncology
SC Oncology
GA 138JT
UT WOS:000318505500014
PM 23456789
ER
PT J
AU Kolpa, HJ
Peal, DS
Lynch, SN
Giokas, AC
Ghatak, S
Misra, S
Norris, RA
MacRae, CA
Markwald, RR
Ellinor, P
Bischoff, J
Milan, DJ
AF Kolpa, Heather J.
Peal, David S.
Lynch, Stacey N.
Giokas, Andrea C.
Ghatak, Shibnath
Misra, Suniti
Norris, Russell A.
MacRae, Calum A.
Markwald, Roger R.
Ellinor, Patrick
Bischoff, Joyce
Milan, David J.
TI miR-21 represses Pdcd4 during cardiac valvulogenesis
SO DEVELOPMENT
LA English
DT Article
DE Cardiac valves; microRNA; Endothelium
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR GENE; VALVE
FORMATION; BREAST-CANCER; MICRORNA EXPRESSION; ZEBRAFISH; OSTEOPONTIN;
CELLS; GROWTH; MORPHOGENESIS
AB The discovery of small non-coding microRNAs has revealed novel mechanisms of post-translational regulation of gene expression, the implications of which are still incompletely understood. We focused on microRNA 21 (miR-21), which is expressed in cardiac valve endothelium during development, in order to better understand its mechanistic role in cardiac valve development. Using a combination of in vivo gene knockdown in zebrafish and in vitro assays in human cells, we show that miR-21 is necessary for proper development of the atrioventricular valve (AV). We identify pdcd4b as a relevant in vivo target of miR-21 and show that protection of pdcd4b from miR-21 binding results in failure of AV development. In vitro experiments using human pulmonic valve endothelial cells demonstrate that miR-21 overexpression augments endothelial cell migration. PDCD4 knockdown alone was sufficient to enhance endothelial cell migration. These results demonstrate that miR-21 plays a necessary role in cardiac valvulogenesis, in large part due to an obligatory downregulation of PDCD4.
C1 [Kolpa, Heather J.; Peal, David S.; Lynch, Stacey N.; Giokas, Andrea C.; MacRae, Calum A.; Ellinor, Patrick; Milan, David J.] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Ghatak, Shibnath; Misra, Suniti; Norris, Russell A.; Markwald, Roger R.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Bischoff, Joyce] Harvard Univ, Sch Med, Dept Surg, Vasc Biol Program,Childrens Hosp Boston, Boston, MA 02115 USA.
RP Milan, DJ (reprint author), Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Res Ctr, 55 Fruit St, Boston, MA 02114 USA.
EM dmilan@partners.org
OI Bischoff, Joyce/0000-0002-6367-1974
FU Fondation Leducq, Paris, France for the Transatlantic MITRAL Network of
Excellence [07CVD04]; American Heart Association [2261354,
11SDG5270006]; National Institutes of Health [HL33756]
FX This work was supported in part by the Fondation Leducq, Paris, France
for the Transatlantic MITRAL Network of Excellence to D. S. P, J.B.,
R.A.N, R. R. M. and D.J.M. [07CVD04]; by the American Heart Association
[2261354 to D.J.M. and 11SDG5270006 to R.A.N.]; and by the National
Institutes of Health [HL33756 to R. R. M.]. Deposited in PMC for release
after 12 months.
NR 53
TC 8
Z9 8
U1 0
U2 8
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
J9 DEVELOPMENT
JI Development
PD MAY 15
PY 2013
VL 140
IS 10
BP 2172
EP 2180
DI 10.1242/dev.084475
PG 9
WC Developmental Biology
SC Developmental Biology
GA 135FO
UT WOS:000318273900012
PM 23578931
ER
PT J
AU Parekh, VV
Wu, L
Boyd, KL
Williams, JA
Gaddy, JA
Olivares-Villagomez, D
Cover, TL
Zong, WX
Zhang, JH
Van Kaer, L
AF Parekh, Vrajesh V.
Wu, Lan
Boyd, Kelli L.
Williams, Janice A.
Gaddy, Jennifer A.
Olivares-Villagomez, Danyvid
Cover, Timothy L.
Zong, Wei-Xing
Zhang, Jianhua
Van Kaer, Luc
TI Impaired Autophagy, Defective T Cell Homeostasis, and a Wasting Syndrome
in Mice with a T Cell-Specific Deletion of Vps34
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NKT CELLS; MAMMALIAN-CELLS; KINASE VPS34; DEATH; EXPRESSION; ANTIGEN;
PROLIFERATION; INFLAMMATION; LYMPHOCYTES; METABOLISM
AB Autophagy plays a critical role in multiple aspects of the immune system, including the development and function of T lymphocytes. In mammalian cells, the class III PI3K vacuolar protein sorting (Vps) 34 is thought to play a critical role in autophagy. However, recent studies have cast doubt on the role of Vps34 in autophagy, at least in certain cell types. To study the effects of Vps34 on autophagy in T lymphocytes, we generated mice that selectively lack Vps34 in the T cell lineage. Vps34 ablation in T cells caused profound defects in autophagic flux, resulting in accumulation of cellular organelles and apoptosis. These animals exhibited normal intrathymic development of conventional T cells, but they were profoundly impaired in the intrathymic development of invariant NKT cells. In peripheral organs, T cell-specific ablation of Vps34 had a profound impact on T cell homeostasis and function. Furthermore, aged animals developed an inflammatory wasting syndrome characterized by weight loss, intestinal inflammation, and anemia. Consistent with this phenotype, Vps34 was required for the peripheral maintenance and function of CD4(+)Foxp3(+) regulatory T cells. Collectively, our study reveals a critical role for Vps34 in autophagy and for the peripheral homeostasis and function of T lymphocytes.
C1 [Parekh, Vrajesh V.; Wu, Lan; Boyd, Kelli L.; Olivares-Villagomez, Danyvid; Cover, Timothy L.; Van Kaer, Luc] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
[Williams, Janice A.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
[Gaddy, Jennifer A.; Cover, Timothy L.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA.
[Cover, Timothy L.] Vet Affairs Tennessee Valley Healthcare Sys, Nashville, TN 37232 USA.
[Zong, Wei-Xing] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.
[Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Zhang, Jianhua] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA.
RP Parekh, VV (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Med Ctr North, 21st Ave South Garland Ave,Room AA 5206, Nashville, TN 37232 USA.
EM vrajesh.v.parekh@vanderbilt.edu; luc.van.kaer@vanderbilt.edu
RI Van Kaer, Luc/H-1033-2015; Cover, Timothy/I-3814-2015;
OI Van Kaer, Luc/0000-0001-5275-2309; Cover, Timothy/0000-0001-8503-002X;
Zhang, Jianhua/0000-0002-2128-9574
FU National Institutes of Health [AI070305, HL089667, DK081536, CA129536,
GM97355, NS064090, P30DK058404]; Veterans Affairs merit award;
Vanderbilt Digestive Diseases Research Center; National Multiple
Sclerosis Society of America
FX This work was supported by National Institutes of Health Grants AI070305
(to L. V. K.), HL089667 (to L. V. K.), DK081536 (to L. W. and L. V. K.),
CA129536 (to W.-X.Z), GM97355 (to W.-X.Z.), and NS064090 (to J.Z.), a
Veterans Affairs merit award (to J.Z.), the Vanderbilt Digestive
Diseases Research Center (supported by National Institutes of Health
Grant P30DK058404), and a postdoctoral fellowship from the National
Multiple Sclerosis Society of America (to V.V.P.).
NR 53
TC 36
Z9 37
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2013
VL 190
IS 10
BP 5086
EP 5101
DI 10.4049/jimmunol.1202071
PG 16
WC Immunology
SC Immunology
GA 138YB
UT WOS:000318546700020
PM 23596309
ER
PT J
AU Xu, P
Wen, Z
Shi, X
Li, Y
Fan, L
Xiang, M
Li, A
Scott, MJ
Xiao, G
Li, S
Billiar, TR
Wilson, MA
Fan, J
AF Xu, Peng
Wen, Zongmei
Shi, Xueyin
Li, Yuehua
Fan, Liyan
Xiang, Meng
Li, Aijun
Scott, Melanie J.
Xiao, Guozhi
Li, Song
Billiar, Timothy R.
Wilson, Mark A.
Fan, Jie
TI Hemorrhagic Shock Augments Nlrp3 Inflammasome Activation in the Lung
through Impaired Pyrin Induction
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID FAMILIAL MEDITERRANEAN FEVER; RESPIRATORY-DISTRESS-SYNDROME; MULTIPLE
ORGAN FAILURE; SEVERE BLUNT TRAUMA; PULMONARY INFLAMMATION;
GENE-EXPRESSION; INTERLEUKIN-10; CYTOKINE; INJURY; MEDIATORS
AB Hemorrhagic shock (HS) promotes the development of systemic inflammatory response syndrome and organ injury by activating and priming the innate immune system for an exaggerated inflammatory response through, as of yet, unclear mechanisms. IL-1 beta also plays an important role in the development of post-HS systemic inflammatory response syndrome and active IL-1 beta production is tightly controlled by the inflammasome. Pyrin, a protein of 781 aa with pyrin domain at the N-terminal, negatively regulates inflammasome activation through interaction with nucleotide-binding oligomerization domain-like receptor protein (NLRP). Expression of pyrin can be induced by LPS and cytokines, and IL-10 is a known potent inducer of pyrin expression in macrophages. In the current study, we tested the hypothesis that HS downregulates IL-10 and therefore decreases pyrin expression to promote inflammasome activation and subsequent IL-1 beta processing and secretion in the lungs. Our results show that LPS, while activating Nlrp3 inflammasome in the lungs, also induced pyrin expression, which in turn suppressed inflammasome activation. More importantly, LPS-mediated upregulation of IL-10 enhanced pyrin expression, which serves, particularly in later phases, as a potent negative-feedback mechanism regulating inflammasome activation. However, HS-mediated suppression of IL-10 expression in alveolar macrophages attenuated the upregulation of pyrin in alveolar macrophages and lung endothelial cells and thereby significantly enhanced inflammasome activation and IL-1 beta secretion in the lungs. This study demonstrates a novel mechanism by which HS suppresses negative-feedback regulation of Nlrp3 inflammasome to enhance IL-1 beta secretion in response to subsequent LPS challenge and so primes for inflammation.
C1 [Xu, Peng; Wen, Zongmei; Li, Yuehua; Xiang, Meng; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15213 USA.
[Xu, Peng; Wen, Zongmei; Shi, Xueyin] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200003, Peoples R China.
[Fan, Liyan] Univ Pittsburgh, Sch Arts & Sci, Pittsburgh, PA 15213 USA.
[Xiang, Meng] Fudan Univ, Dept Physiol & Pathophysiol, Shanghai Med Coll, Shanghai 200032, Peoples R China.
[Li, Aijun] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai 200003, Peoples R China.
[Xiao, Guozhi] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
[Li, Song] Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Billiar, Timothy R.; Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
[Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA.
RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Bldg 1,2W109 151L U,Univ Dr C, Pittsburgh, PA 15240 USA.
EM shixueyin1128@yahoo.com.cn; jif7@pitt.edu
FU National Institutes of Health [R01-HL-079669]; National Institutes of
Health Center Grant [P50-GM-53789]; Veterans Affairs Merit Award; 12th
five-year key project grant of the People's Liberation Army [BWS12J027]
FX This work was supported by the National Institutes of Health Grant
R01-HL-079669 (to M. A. W. and J.F.), National Institutes of Health
Center Grant P50-GM-53789 (to T. R. B. and J.F.), a Veterans Affairs
Merit Award (to J.F.), and the 12th five-year key project grant of the
People's Liberation Army BWS12J027 (to X.S.).
NR 48
TC 17
Z9 19
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2013
VL 190
IS 10
BP 5247
EP 5255
DI 10.4049/jimmunol.1203182
PG 9
WC Immunology
SC Immunology
GA 138YB
UT WOS:000318546700036
PM 23585683
ER
PT J
AU Zanni, MV
Abbara, S
Lo, J
Wai, B
Hark, D
Marmarelis, E
Grinspoon, SK
AF Zanni, Markella V.
Abbara, Suhny
Lo, Janet
Wai, Bryan
Hark, David
Marmarelis, Eleni
Grinspoon, Steven K.
TI Increased coronary atherosclerotic plaque vulnerability by coronary
computed tomography angiography in HIV-infected men
SO AIDS
LA English
DT Article
DE atherosclerosis; cardiovascular disease; HIV; myocardial infarction;
plaque
ID ACTIVE ANTIRETROVIRAL THERAPY; ACUTE MYOCARDIAL-INFARCTION;
INTRAVASCULAR ULTRASOUND; RISK-FACTORS; DISEASE; DEATH; LESIONS;
INFLAMMATION; MORPHOLOGY; MORTALITY
AB Objective: Among HIV-infected patients, high rates of myocardial infarction (MI) and sudden cardiac death have been observed. Exploring potential underlying mechanisms, we used multidetector spiral coronary computed tomography angiography (coronary CTA) to compare atherosclerotic plaque morphology in HIV-infected patients and non-HIV-infected controls.
Methods: Coronary atherosclerotic plaques visualized by CTA in HIV-infected (101) and non-HIV-infected (41) men without clinically apparent heart disease matched on cardiovascular risk factors were analyzed for three vulnerability features: low attenuation, positive remodeling, and spotty calcification.
Results: Ninety-five percent of HIV-infected patients were receiving ART (median duration 7.9 years) and had well controlled disease (median CD4 cell count, 473 cells/mu l; median HIV RNA <50 copies/ml). Age and traditional cardiovascular risk factors were similar in HIV-infected patients and controls. Among the HIV-infected (versus control) group, there was a higher prevalence of patients with at least one: low attenuation plaque (22.8 versus 7.3%, P = 0.02), positively remodeled plaque (49.5 versus 31.7%, P = 0.05) and high-risk 3-feature plaque (7.9 versus 0%, P = 0.02). Moreover, patients in the HIV-infected (versus control) group demonstrated a higher number of low attenuation plaques (P = 0.01) and positively remodeled plaques (P = 0.03) per patient.
Conclusion: Our data demonstrate an increased prevalence of vulnerable plaque features among relatively young HIV-infected patients. Differences in coronary atherosclerotic plaque morphology - namely, increased vulnerable plaque among HIV-infected patients - are here for the first time reported and may contribute to increased rates of MI and sudden cardiac death in this population. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:1263-1272
C1 [Zanni, Markella V.; Lo, Janet; Hark, David; Marmarelis, Eleni; Grinspoon, Steven K.] Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA.
[Zanni, Markella V.; Abbara, Suhny; Lo, Janet; Wai, Bryan; Hark, David; Marmarelis, Eleni; Grinspoon, Steven K.] Harvard Univ, Sch Med, Boston, MA USA.
[Abbara, Suhny; Wai, Bryan] Massachusetts Gen Hosp, Cardiovasc Imaging Sect, Dept Radiol, Boston, MA 02114 USA.
RP Zanni, MV (reprint author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,LON207, Boston, MA 02114 USA.
EM mzanni@partners.org
FU Medical Research Investigator Training (MeRIT) award from Harvard
Catalyst \ The Harvard Clinical and Translational Science Center
(National Center for Research Resources and the National Center for
Advancing Translational Sciences) [8KL2TR000168-05]; Bristol Myers
Squibb; National Institutes of Health [K23 HL092792, K24 DK064545,
RO1HL095123, M01-RR-01066, 1 UL1 RR025758-01]; Harvard Clinical and
Translational Science Center; National Center for Research Resources;
NIH [P30DK040561]
FX This work was conducted with the support of a Medical Research
Investigator Training (MeRIT) award from Harvard Catalyst vertical bar
The Harvard Clinical and Translational Science Center (National Center
for Research Resources and the National Center for Advancing
Translational Sciences, National Institutes of Health Award
8KL2TR000168-05. The content is solely the responsibility of the authors
and does not necessarily represent the official views of Harvard
Catalyst, Harvard University and its affiliated academic healthcare
centers, or the National Institutes of Health. This work was also
conducted with research funding from Bristol Myers Squibb to S. K. G.
and with the support of National Institutes of Health Grants K23
HL092792 to J.L., K24 DK064545 and RO1HL095123 to S. K. G., and
M01-RR-01066 and 1 UL1 RR025758-01, Harvard Clinical and Translational
Science Center, from the National Center for Research Resources.
Finally, this work was supported in part by the NIH grant P30DK040561 to
the Nutrition Obesity Research Center at Harvard.
NR 37
TC 38
Z9 38
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2013
VL 27
IS 8
BP 1263
EP 1272
DI 10.1097/QAD.0b013e32835eca9b
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 133RG
UT WOS:000318156400009
PM 23324657
ER
PT J
AU Lang, JS
Scherzer, R
Weekley, CC
Tien, PC
Grunfeld, C
Shlipak, MG
AF Lang, Joshua
Scherzer, Rebecca
Weekley, Cristin C.
Tien, Phyllis C.
Grunfeld, Carl
Shlipak, Michael G.
TI Serum albumin and short-term risk for mortality and cardiovascular
disease among HIV-infected veterans
SO AIDS
LA English
DT Article
DE albumin; cardiovascular disease; end-stage renal disease; glomerular
filtration rate; kidney
ID INFLAMMATION; PROGRESSION; SURVIVAL; MARKERS; ASSOCIATION; PREDICTOR;
VIRUS; WOMEN
AB Objective: We examined the short-term and long-term associations of serum albumin with mortality and cardiovascular disease among HIV-infected veterans.
Design: Retrospective cohort analysis using a national database of US veterans with HIV infection.
Methods: This analysis evaluated all HIV-infected veterans in the Department of Veterans Affairs HIV Clinical Case Registry (CCR), a national database consisting of demographic, clinical, laboratory, pharmaceutical, and viral status data. There were 25 522 patients enrolled between 1986 and 2007. We evaluated the associations of baseline and time-updated serum albumin levels with all-cause mortality, atherosclerotic cardiovascular disease, and heart failure by multivariate proportional hazards models.
Results: Over 21 years, there were 10 869 deaths; the cumulative mortality was 73.2 per 1000 person-years. After multivariate adjustment for covariates measured at baseline, the lowest category of serum albumin (<2.5 g/dl) was associated with a higher mortality risk compared with the highest category (>4 g/dl; hazard ratio 3.00; 2.67-3.37). When analyzed as a time-dependent model, the association strengthened substantially (15.1; 14.0-16.4). Findings were similar for atherosclerotic cardiovascular disease and heart failure. We stratified the baseline mortality model by year of follow-up and found that albumin was more strongly associated with deaths that occurred within 1 year of baseline (9.29; 7.85-11.0) than in the second (1.66; 1.18-2.33) or third (1.22; 0.77-1.96) year after measurement.
Conclusion: Among ambulatory HIV-infected patients, lower serum albumin levels are strongly predictive of mortality risk, particularly within 1 year. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:1339-1343
C1 [Lang, Joshua] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA.
[Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Weekley, Cristin C.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA.
EM michael.shlipak@ucsf.edu
FU [1R03AG034871-01]
FX 1R03AG034871-01: 'Kidney Disease, Antiretroviral Therapy and
Cardiovascular Events in HIV-Infection' (principal investigator, M. G.
S.), which was administered by the Northern California Institute for
Research and Education, and with resources of the Veterans Affairs
Medical Center, San Francisco, CA, USA.
NR 16
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2013
VL 27
IS 8
BP 1339
EP 1343
DI 10.1097/QAD.0b013e32835f1dd6
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 133RG
UT WOS:000318156400017
PM 23343914
ER
PT J
AU Thomas, B
Matson, S
Chopra, V
Sun, LP
Sharma, S
Hersch, S
Rosas, HD
Scherzer, C
Ferrante, R
Matson, W
AF Thomas, Beena
Matson, Samantha
Chopra, Vanita
Sun, Liping
Sharma, Swati
Hersch, Steven
Rosas, H. Diana
Scherzer, Clemens
Ferrante, Robert
Matson, Wayne
TI A novel method for detecting 7-methyl guanine reveals aberrant
methylation levels in Huntington disease
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE 7-Methyl guanine (7-MG); Guanine (G); Huntington disease (HD);
Electrochemical detection (ECD)
ID TANDEM MASS-SPECTROMETRY; NF-KAPPA-B; LIQUID-CHROMATOGRAPHY;
ELECTROCHEMICAL DETECTION; DNA; ADDUCTS; BRAIN; CANCER; SENSITIVITY;
EPIGENETICS
AB Guanine methylation is a ubiquitous process affecting DNA and various RNA species. N-7 guanine methylation (7-MG), although relatively less studied, could have a significant role in normal transcriptional regulation as well as in the onset and development of pathological conditions. The lack of a sensitive method to accurately quantify trace amounts of altered bases such as 7-MG has been a major deterrent in delineating its biological function(s). Here we report the development of methods to detect trace amounts of 7-MG in biological samples using electrochemical detection combined with high-performance liquid chromatography (HPLC) separation of compounds. We further sought to assess global alterations in DNA methylation in Huntington disease (HD), where transcriptional dysregulation is a major factor in pathogenesis. The developed method was used to study guanine methylation in cytoplasmic and nuclear nucleic acids from human and transgenic mouse HD brain and controls. Significant differences were observed in the guanine methylation levels in mouse and human samples, consistent with the known transcriptional pathology of HD. The sensitivity of the method makes it capable of detecting subtle aberrations. Identification of changes in methylation pattern will provide insights into the molecular mechanism changes that translate into onset and/or development of symptoms in diseases such as HD. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Thomas, Beena; Sun, Liping; Sharma, Swati; Matson, Wayne] Bedford VA Med Ctr, Dept Syst Biochem, Bedford, MA 01730 USA.
[Matson, Samantha; Chopra, Vanita; Hersch, Steven] Massachusetts Gen Hosp, MassGeneral Inst Neurodegenerat Dis, Boston, MA 02115 USA.
[Chopra, Vanita; Hersch, Steven; Rosas, H. Diana] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Rosas, H. Diana] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Scherzer, Clemens] Harvard Univ, Sch Med, Biomarker Program, Harvard NeuroDiscovery Ctr, Cambridge, MA 02139 USA.
[Scherzer, Clemens] Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA.
[Ferrante, Robert] Vet Adm Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Ferrante, Robert] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA.
[Ferrante, Robert] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.
[Ferrante, Robert] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA.
RP Matson, W (reprint author), Bedford VA Med Ctr, Dept Syst Biochem, Bedford, MA 01730 USA.
EM wayne.matson@va.gov
FU National Institutes of Health (NIH)/National Institute of Neurological
Disorders and Stroke (NINDS) [PO1NS058793]
FX This research was supported by a National Institutes of Health
(NIH)/National Institute of Neurological Disorders and Stroke (NINDS)
grant (PO1NS058793). We also acknowledge the VA Medical Center (Bedford,
MA, USA).
NR 37
TC 17
Z9 17
U1 0
U2 39
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD MAY 15
PY 2013
VL 436
IS 2
BP 112
EP 120
DI 10.1016/j.ab.2013.01.035
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 128US
UT WOS:000317795800010
PM 23416183
ER
PT J
AU Hsiao, FJ
Cheng, CH
Chen, WT
Lin, YY
AF Hsiao, Fu-Jung
Cheng, Chia-Hsiung
Chen, Wei-Ta
Lin, Yung-Yang
TI Neural correlates of somatosensory paired-pulse suppression: A MEG study
using distributed source modeling and dynamic spectral power analysis
SO NEUROIMAGE
LA English
DT Article
DE Paired-pulse suppression; Somatosensory; Minimum norm estimates;
Spectral power; Magnetoencephalography
ID MEDIAN NERVE-STIMULATION; MAGNETIC-FIELDS; HUMAN BRAIN; OSCILLATORY
CHARACTERISTICS; ALPHA OSCILLATIONS; CORTICAL NETWORK; CORTEX;
SCHIZOPHRENIA; ACTIVATION; RESPONSES
AB Paired-pulse stimulation has been used previously to evaluate cortical excitability and sensory gating. To help elucidate the neural network involved in paired-pulse suppression of somatosensoly cortical processing, magnetoencephalographic (MEG) responses to paired-pulse electrical stimulation of the left median nerve of the wrists of 13 healthy males were recorded using an intra-pair interstimulus interval (ISI) of 500 ms and an inter-pair ISI of 8 s. Minimum norm estimates showed the presence of cortical activation in the bilateral primary somatosensmy cortex, the post-central sulcus and the supplementary motor areas. Compared with the responses to the first stimulation, the responses to the second stimulation were attenuated in these areas with gating ratios (the amplitude ratios of the second response to the first response) of 0.54-0.69. By spectral power dynamic analysis, beta frequency oscillations were found to be associated with an early-latency (30-36 ms) gating process in the contralateral primary somatosensory cortex and post-central sulcus, whereas theta and alpha oscillations were correlated with paired-pulse suppression of activations at 98-136 ms in the ipsilateral primary somatosensory cortex, the bilateral post-central sulcus and the supplementary motor areas. In summary, it can be concluded that differential oscillatory activities are involved in the pair-pulse suppression in various somatosensoty regions in response to repetitive external stimulations. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Hsiao, Fu-Jung; Cheng, Chia-Hsiung; Lin, Yung-Yang] Natl Yang Ming Univ, Inst Brain Sci, Sch Med, Taipei 112, Taiwan.
[Chen, Wei-Ta; Lin, Yung-Yang] Natl Yang Ming Univ, Dept Neurol, Sch Med, Taipei 112, Taiwan.
[Lin, Yung-Yang] Natl Yang Ming Univ, Inst Clin Med, Sch Med, Taipei 112, Taiwan.
[Lin, Yung-Yang] Natl Yang Ming Univ, Inst Physiol, Sch Med, Taipei 112, Taiwan.
[Hsiao, Fu-Jung] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan.
[Hsiao, Fu-Jung; Cheng, Chia-Hsiung; Lin, Yung-Yang] Taipei Vet Gen Hosp, Neurophysiol Lab, Taipei, Taiwan.
[Hsiao, Fu-Jung; Cheng, Chia-Hsiung; Lin, Yung-Yang] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan.
[Chen, Wei-Ta; Lin, Yung-Yang] Taipei Vet Gen Hosp, Dept Neurol, Taipei, Taiwan.
[Chen, Wei-Ta] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Lin, YY (reprint author), Natl Yang Ming Univ, Inst Brain Sci, 155,Sec 2,Linong St, Taipei 112, Taiwan.
EM yylin@vghtpe.gov.tw
OI Cheng, Chia-Hsiung/0000-0001-6654-9387
FU Taipei Veterans General Hospital [VGH-ER3-99-006, V99C1-156, V100C-146,
V101C-023, V102C-101]; National Science Council [NSC-98-2321-B-010-007,
NSC-99-2321-B-010-004-, NSC-99-2628-B-010-011-MY3, NSC
100-2218-E-010-002, 101-2314-B-010-068-MY3]; Taipei City Hospital
[99TPECH04]; Ministry of Education (Aim for the Top University Plan),
Taipei, Taiwan
FX The study was supported in part by research grants from Taipei Veterans
General Hospital (VGH-ER3-99-006; V99C1-156; V100C-146; V101C-023;
V102C-101) and from the National Science Council (NSC-98-2321-B-010-007;
NSC-99-2321-B-010-004-; NSC-99-2628-B-010-011-MY3; NSC
100-2218-E-010-002; 101-2314-B-010-068-MY3), Taipei City Hospital
(99TPECH04), and the grant from Ministry of Education (Aim for the Top
University Plan), Taipei, Taiwan.
NR 64
TC 7
Z9 7
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAY 15
PY 2013
VL 72
BP 133
EP 142
DI 10.1016/j.neuroimage.2013.01.041
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 120JO
UT WOS:000317166800013
PM 23370054
ER
PT J
AU Huang, SL
Du, F
Shih, YYI
Shen, Q
Gonzalez-Lima, F
Duong, TQ
AF Huang, Shiliang
Du, Fang
Shih, Yen-Yu I.
Shen, Qiang
Gonzalez-Lima, F.
Duong, Timothy Q.
TI Methylene blue potentiates stimulus-evoked fMRI responses and cerebral
oxygen consumption during normoxia and hypoxia
SO NEUROIMAGE
LA English
DT Article
DE fMRI; BOLD; CBF; Perfusion; Oxidative metabolism; Arterial spin
labeling; Cerebral metabolic rate of oxygen; Forepaw stimulation
ID RAT FOREPAW STIMULATION; FUNCTIONAL MRI; BLOOD-FLOW; QUANTITATIVE
PERFUSION; ANESTHETIZED RATS; DIFFUSION; BOLD; NEUROPROTECTION; MEMORY;
CBF
AB Methylene blue USP (MB) at low doses has metabolic-enhancing and antioxidant properties and exhibits experimental neurotherapeutic benefits, but little is known about its in vivo effects on cerebral blood flow (CBF), functional evoked responses, and the associated changes in cerebral metabolic rate of oxygen (CMRO2). This study used magnetic resonance imaging (MRI) to evaluate the in vivo effects of a single intravenous MB therapeutic dose (0.5 mg/kg) on basal CBF, blood oxygenation level-dependent (BOLD) and CBF responses to hypercapnic (5% CO2 in air) inhalation, as well as changes in BOLD, CBF, and CMRO2 during forepaw stimulation in the rat brain. MB did not have significant effects on arterial oxygen saturation, heart rate and fMRI responses to hypercapnia. However, MB significantly potentiated forepaw-evoked BOLD and CBF changes under normoxia. To further evaluate in vivo effects of MB under metabolic stress conditions, MRI measurements were also made under mild hypoxia (15% O-2). Hypoxia per se increased evoked functional MRI responses. MB under hypoxia further potentiated forepaw-evoked BOLD, CBF and oxygen consumption responses relative to normoxia. These findings provide insights into MB's effects on cerebral hemodynamics in vivo and could help to optimize treatments in neurological diseases with mitochondrial dysfunction and oxidative stress. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Huang, Shiliang; Du, Fang; Shih, Yen-Yu I.; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
[Gonzalez-Lima, F.] Univ Texas Austin, Dept Pharmacol & Toxicol, Austin, TX 78712 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Shen, Qiang/B-8784-2008;
OI Shen, Qiang/0000-0002-4287-3403; Shih, Yen-Yu Ian/0000-0001-6529-911X;
Gonzalez-Lima, Francisco/0000-0001-9856-0775
FU Translational Technology Resource grant via the Clinical Translational
Science Award (CTSA) [NIH 8UL1TR000149]; NIH/NEI [R01 EY014211,
EY018855]; NIH/NINDS [R01-NS45879]
FX This work was supported in part by a Translational Technology Resource
grant via the Clinical Translational Science Award (CTSA, parent grant
NIH 8UL1TR000149), the NIH/NEI (R01 EY014211 and EY018855), NIH/NINDS
(R01-NS45879). TQD holds the Stanley I Glickman, MD, Endowed Chair in
Ophthalmic Research. We thank Dr. Shaohau Yang and Dr. Ailing Lin for
the helpful discussion in various phases of the project
NR 46
TC 13
Z9 13
U1 1
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAY 15
PY 2013
VL 72
BP 237
EP 242
DI 10.1016/j.neuroimage.2013.01.027
PG 6
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 120JO
UT WOS:000317166800023
PM 23357077
ER
PT J
AU Ramos, RA
Zapata, J
Condat, CA
Deisboeck, TS
AF Ramos, R. A.
Zapata, Jair
Condat, C. A.
Deisboeck, Thomas S.
TI Modeling cancer immunotherapy: Assessing the effects of lymphocytes on
cancer cell growth and motility
SO PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS
LA English
DT Article
DE Tumor model; Cancer growth; Immunotherapy; Lymphocytes; Cell blockade
ID IMMUNE SYSTEM COMPETITION; MATHEMATICAL-MODEL; THERAPY; TUMORS;
INTERLEUKIN-2; CHEMOTHERAPY; TRIAL
AB A mesoscopic model is used to describe the effects of lymphocyte activity on a growing tumor. The model yields novel insights into the tumor immune system interaction. In particular, we found that the presence of a putative chemotactic messenger that helps guide the lymphocytes towards the tumor is not critical to elicit the anti-tumor effects of the immune system, while lymphocytes that block tumor cell migration contribute to limit cancer expansion and thus have a more significant therapeutic impact. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Ramos, R. A.; Zapata, Jair] Univ Puerto Rico, Dept Phys, Mayaguez, PR 00681 USA.
[Condat, C. A.] Univ Nacl Cordoba, IFEG CONICET, RA-5000 Cordoba, Argentina.
[Condat, C. A.] Univ Nacl Cordoba, FAMAF, RA-5000 Cordoba, Argentina.
[Deisboeck, Thomas S.] Massachusetts Gen Hosp, Complex Biosyst Modeling Lab, Harvard MIT HST Athinoula A Martinos Ctr Biomed I, Charlestown, MA 02129 USA.
RP Condat, CA (reprint author), Univ Nacl Cordoba, IFEG CONICET, RA-5000 Cordoba, Argentina.
EM condat@famaf.unc.edu.ar
FU SECyT-UNC; ANPCyT [PICT 2205/33675]; CONICET (Argentina) [PIP 6311/05]
FX This work was supported by SECyT-UNC, ANPCyT (PICT 2205/33675), and
CONICET (Argentina) through grant PIP 6311/05. CAC thanks the University
of Puerto Rico for its hospitality.
NR 43
TC 3
Z9 3
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4371
EI 1873-2119
J9 PHYSICA A
JI Physica A
PD MAY 15
PY 2013
VL 392
IS 10
BP 2415
EP 2425
DI 10.1016/j.physa.2013.01.047
PG 11
WC Physics, Multidisciplinary
SC Physics
GA 121OV
UT WOS:000317255000011
ER
PT J
AU Pignon, JC
Grisanzio, C
Geng, Y
Song, JX
Shivdasani, RA
Signoretti, S
AF Pignon, Jean-Christophe
Grisanzio, Chiara
Geng, Yan
Song, Jiaxi
Shivdasani, Ramesh A.
Signoretti, Sabina
TI p63-expressing cells are the stem cells of developing prostate, bladder,
and colorectal epithelia
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE large intestine; hindgut; genitourinary tract
ID MOUSE PROSTATE; SELF-RENEWAL; REGENERATIVE PROLIFERATION; UROTHELIAL
DEVELOPMENT; EXPRESSION PROFILES; P53 HOMOLOG; P63; CANCER; BASAL;
DIFFERENTIATION
AB The tumor protein p63 (p63), and more specifically the NH2-terminal truncated (Delta N) p63 isoform, is a marker of basal epithelial cells and is required for normal development of several epithelial tissues, including the bladder and prostate glands. Although p63-expressing cells are proposed to be the stem cells of the developing prostate epithelium and bladder urothelium, cell lineages in these endoderm-derived epithelia remain highly controversial, and rigorous lineage tracing studies are warranted. Here, we generated knock-in mice expressing Cre recombinase (Cre) under the control of the endogenous Delta Np63 promoter. Heterozygote Delta Np63(+/Cre) mice were phenotypically normal and fertile. Cre-mediated recombination in Delta Np63(+/Cre); ROSA26(EYFP) reporter mice faithfully recapitulated the pattern of Delta Np63 expression and were useful for genetic lineage tracing of Delta Np63-expressing cells of the caudal endoderm in vivo. We found that Delta Np63-positive cells of the urogenital sinus generated all epithelial lineages of the prostate and bladder, indicating that these cells represent the stem/progenitor cells of those epithelia during development. We also observed Delta Np63 expression in caudal gut endoderm and the contribution of Delta Np63-positive cells to the stem/progenitor compartment of adult colorectal epithelium. Because p63 is a master regulator of stratified epithelial development, this finding provides a unique developmental insight into the cell of origin of squamous cell metaplasia and squamous cell carcinoma of the colon.
C1 [Pignon, Jean-Christophe; Grisanzio, Chiara; Song, Jiaxi; Signoretti, Sabina] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Grisanzio, Chiara; Geng, Yan; Shivdasani, Ramesh A.; Signoretti, Sabina] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Signoretti, S (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
EM ssignoretti@partners.org
FU National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases [1R21DK72152, 1R01DK089975]; Harvard Stem
Cell Institute
FX We thank L. Ding and D. Tom (Enhanced Neuroimaging Core, Harvard
Neurodiscovery Center) for help with acquisition of the confocal images.
This work was supported by National Institutes of Health/National
Institute of Diabetes and Digestive and Kidney Diseases Grants
1R21DK72152 and 1R01DK089975 and the Harvard Stem Cell Institute (S.S.).
NR 42
TC 70
Z9 71
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 14
PY 2013
VL 110
IS 20
BP 8105
EP 8110
DI 10.1073/pnas.1221216110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156EH
UT WOS:000319803500035
PM 23620512
ER
PT J
AU Ramkissoon, LA
Horowitz, PM
Craig, JM
Ramkissoon, SH
Rich, BE
Schumacher, SE
McKenna, A
Lawrence, MS
Bergthold, G
Brastianos, PK
Tabak, B
Ducar, MD
Van Hummelen, P
MacConaill, LE
Pouissant-Young, T
Cho, YJ
Taha, H
Mahmoud, M
Bowers, DC
Margraf, L
Tabori, U
Hawkins, C
Packer, RJ
Hill, DA
Pomeroy, SL
Eberhart, CG
Dunn, IF
Goumnerova, L
Getz, G
Chan, JA
Santagata, S
Hahn, WC
Stiles, CD
Ligon, AH
Kieran, MW
Beroukhim, R
Ligon, KL
AF Ramkissoon, Lori A.
Horowitz, Peleg M.
Craig, Justin M.
Ramkissoon, Shakti H.
Rich, Benjamin E.
Schumacher, Steven E.
McKenna, Aaron
Lawrence, Michael S.
Bergthold, Guillaume
Brastianos, Priscilla K.
Tabak, Barbara
Ducar, Matthew D.
Van Hummelen, Paul
MacConaill, Laura E.
Pouissant-Young, Tina
Cho, Yoon-Jae
Taha, Hala
Mahmoud, Madeha
Bowers, Daniel C.
Margraf, Linda
Tabori, Uri
Hawkins, Cynthia
Packer, Roger J.
Hill, D. Ashley
Pomeroy, Scott L.
Eberhart, Charles G.
Dunn, Ian F.
Goumnerova, Liliana
Getz, Gad
Chan, Jennifer A.
Santagata, Sandro
Hahn, William C.
Stiles, Charles D.
Ligon, Azra H.
Kieran, Mark W.
Beroukhim, Rameen
Ligon, Keith L.
TI Genomic analysis of diffuse pediatric low-grade gliomas identifies
recurrent oncogenic truncating rearrangements in the transcription
factor MYBL1
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE cancer; aCGH; A-myb
ID MAPK PATHWAY ACTIVATION; CENTRAL-NERVOUS-SYSTEM; COPY-NUMBER ALTERATION;
DNA-SEQUENCING DATA; BRAF FUSION GENE; ASTROCYTOMAS; DUPLICATION;
MUTATIONS; CANCER; GLIOBLASTOMA
AB Pediatric low-grade gliomas (PLGGs) are among the most common solid tumors in children but, apart from BRAF kinase mutations or duplications in specific subclasses, few genetic driver events are known. Diffuse PLGGs comprise a set of uncommon subtypes that exhibit invasive growth and are therefore especially challenging clinically. We performed high-resolution copy-number analysis on 44 formalin-fixed, paraffin-embedded diffuse PLGGs to identify recurrent alterations. Diffuse PLGGs exhibited fewer such alterations than adult low-grade gliomas, but we identified several significantly recurrent events. The most significant event, 8q13.1 gain, was observed in 28% of diffuse astrocytoma grade IIs and resulted in partial duplication of the transcription factor MYBL1 with truncation of its C-terminal negative-regulatory domain. A similar recurrent deletion-truncation breakpoint was identified in two angiocentric gliomas in the related gene v-myb avian myeloblastosis viral oncogene homolog (MYB) on 6q23.3. Whole-genome sequencing of a MYBL1-rearranged diffuse astrocytoma grade II demonstrated MYBL1 tandem duplication and few other events. Truncated MYBL1 transcripts identified in this tumor induced anchorage-independent growth in 3T3 cells and tumor formation in nude mice. Truncated transcripts were also expressed in two additional tumors with MYBL1 partial duplication. Our results define clinically relevant molecular subclasses of diffuse PLGGs and highlight a potential role for the MYB family in the biology of low-grade gliomas.
C1 [Ramkissoon, Lori A.; Horowitz, Peleg M.; Craig, Justin M.; Ramkissoon, Shakti H.; Rich, Benjamin E.; Schumacher, Steven E.; Bergthold, Guillaume; Brastianos, Priscilla K.; Tabak, Barbara; Hahn, William C.; Beroukhim, Rameen; Ligon, Keith L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Stiles, Charles D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Kieran, Mark W.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Ducar, Matthew D.; Van Hummelen, Paul; MacConaill, Laura E.; Hahn, William C.; Beroukhim, Rameen] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
[Ligon, Azra H.; Ligon, Keith L.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Horowitz, Peleg M.; Dunn, Ian F.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Ramkissoon, Shakti H.; MacConaill, Laura E.; Packer, Roger J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Horowitz, Peleg M.; Schumacher, Steven E.; McKenna, Aaron; Lawrence, Michael S.; Bergthold, Guillaume; Tabak, Barbara; Pomeroy, Scott L.; Getz, Gad; Hahn, William C.; Beroukhim, Rameen] MIT, Broad Inst, Cambridge, MA 02142 USA.
[Horowitz, Peleg M.; Schumacher, Steven E.; McKenna, Aaron; Lawrence, Michael S.; Bergthold, Guillaume; Tabak, Barbara; Pomeroy, Scott L.; Getz, Gad; Hahn, William C.; Beroukhim, Rameen] Harvard Univ, Cambridge, MA 02142 USA.
[Horowitz, Peleg M.; Goumnerova, Liliana] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Ramkissoon, Shakti H.; Santagata, Sandro; Ligon, Keith L.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Pouissant-Young, Tina] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Pomeroy, Scott L.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Kieran, Mark W.] Boston Childrens Hosp, Dept Hematol Oncol, Boston, MA 02115 USA.
[Cho, Yoon-Jae] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA.
[Cho, Yoon-Jae] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.
[Taha, Hala; Mahmoud, Madeha] Childrens Canc Hosp, Dept Pediat Oncol & Pathol, Cairo 57357, Egypt.
[Bowers, Daniel C.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
[Margraf, Linda] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
[Tabori, Uri] Hosp Sick Children, Dept Hematol & Oncol, Toronto, ON M5G 1X8, Canada.
[Hawkins, Cynthia] Hosp Sick Children, Dept Pathol, Toronto, ON M5G 1X8, Canada.
[Packer, Roger J.] Childrens Natl Med Ctr, Ctr Neurosci & Behav Med, Washington, DC 20010 USA.
[Packer, Roger J.] Childrens Natl Med Ctr, Brain Tumor Inst, Washington, DC 20010 USA.
[Hill, D. Ashley] Childrens Natl Med Ctr, Dept Pathol, Washington, DC 20010 USA.
[Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA.
[Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
[Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA.
[Chan, Jennifer A.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB T2N 1N4, Canada.
[Santagata, Sandro; Ligon, Azra H.; Ligon, Keith L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Hahn, William C.; Beroukhim, Rameen] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Beroukhim, R (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM rameen_beroukhim@dfci.harvard.edu; keith_ligon@dfci.harvard.edu
RI Schumacher, Steven/E-9821-2013;
OI Schumacher, Steven/0000-0002-6819-5647; Tabori, Uri/0000-0002-5019-2683;
Brastianos, Priscilla/0000-0003-4470-8425; Kieran,
Mark/0000-0003-2184-7692; Horowitz, Peleg/0000-0002-5177-1783
FU Pediatric Low Grade Astrocytoma Foundation; Sontag Foundation; Goldhirsh
Foundation; Boston Children's Hospital Team Path to Cure; American Brain
Tumor Association; Eleanor and Miles Shore 50th Anniversary Fellowship
Program for Scholars in Medicine; Nuovo-Soldati Foundation; Philippe
Foundation, Inc.; National Institutes of Health [R01 CA109467, P30
HD018655, U54CA143789, K08CA122833, P01CA142536]
FX The authors thank Denise Garcia and Heather Homer for technical help
with FISH experiments; Yotam Drier and Cheng-Zhong Zhang for assistance
with analytical algorithms; and Anna Pisarek-Horowitz and Sophie
Horowitz for critical reading of the manuscript. This work was supported
by the Pediatric Low Grade Astrocytoma Foundation; The Sontag Foundation
(K. L. L., R. B.); Goldhirsh Foundation (K. L. L.); Boston Children's
Hospital Team Path to Cure (K. L. L.); American Brain Tumor Association
Basic Research Fellowship in Honor of Joel A. Gingras, Jr. (to L. A.
R.); the Eleanor and Miles Shore 50th Anniversary Fellowship Program for
Scholars in Medicine (to A. H. L.); Nuovo-Soldati Foundation and
Philippe Foundation, Inc. (to G. B.); and National Institutes of Health
Grants R01 CA109467 and P30 HD018655 (to S. L. P.), U54CA143789 and
K08CA122833 (to R. B.), and P01CA142536 (to K. L. L., W. C. H., S. S.,
C. D. S., L. E. M., and M.W.K.).
NR 35
TC 64
Z9 66
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 14
PY 2013
VL 110
IS 20
BP 8188
EP 8193
DI 10.1073/pnas.1300252110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156EH
UT WOS:000319803500049
PM 23633565
ER
PT J
AU Khandelwal, P
Blanco-Mezquita, T
Emami, P
Lee, HS
Reyes, NJ
Mathew, R
Huang, R
Saban, DR
AF Khandelwal, Payal
Blanco-Mezquita, Tomas
Emami, Parisa
Lee, Hyun Soo
Reyes, Nancy J.
Mathew, Rose
Huang, Randy
Saban, Daniel R.
TI Ocular Mucosal CD11b+and CD103+Mouse Dendritic Cells under Normal
Conditions and in Allergic Immune Responses
SO PLOS ONE
LA English
DT Article
ID CROSS-PRESENTATION; IN-VIVO; ANTIGEN; CONJUNCTIVITIS; SUBSETS
AB Steady state dendritic cells (DC) found in non-lymphoid tissue sites under normal physiologic conditions play a pivotal role in triggering T cell responses upon immune provocation. CD11b+ and CD103+ DC have received considerable attention in this regard. However, still unknown is whether such CD11b+ and CD103+ DC even exist in the ocular mucosa, and if so, what functions they have in shaping immune responses. We herein identified in the ocular mucosa of normal wild-type (WT) and Flt3-/- mice the presence of a CD11b+ DC (i.e., CD11c+ MHCII+ CD11b+ CD103-F4/80+ Sirp-a+). CD103+ DC (i.e. CD11c+ MHCII+ CD11b low CD103+ CD8a+ DEC205+ Langerin+) were also present in WT, but not in Flt3-/- mice. These CD103+ DC expressed high levels of Id2 and Flt3 mRNA; whereas CD11b+ DC expressed high Irf4, Csfr, and Cx3cr1 mRNA. Additionally, the functions of these DC differed in response to allergic immune provocation. This was assessed utilizing a previously validated model, which includes transferring specific populations of exogenous DC into the ocular mucosa of ovalbumin (OVA)/alum-primed mice. Interestingly, in such mice, topical OVA instillation following engraftment of exogenous CD11b+ DC led to dominant allergic T cell responses and clinical signs of ocular allergy relative to those engrafted with CD103+ DC. Thus, although CD11b+ and CD103+ DC are both present in the normal ocular mucosa, the CD11b+ DC subset plays a dominant role in a mouse model of ocular allergy.
C1 [Khandelwal, Payal; Emami, Parisa; Lee, Hyun Soo; Huang, Randy] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Schepens Eye Res Inst, Boston, MA 02114 USA.
[Blanco-Mezquita, Tomas; Reyes, Nancy J.; Mathew, Rose; Saban, Daniel R.] Duke Univ, Sch Med, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
[Saban, Daniel R.] Duke Univ, Sch Med, Dept Immunol, Durham, NC USA.
RP Saban, DR (reprint author), Duke Univ, Sch Med, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
EM daniel.saban@duke.edu
FU NIH [R01EY021798]
FX Funding for this work came exclusively from NIH grant R01EY021798
awarded to DRS, the PI. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 23
TC 15
Z9 15
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2013
VL 8
IS 5
AR e64193
DI 10.1371/journal.pone.0064193
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RE
UT WOS:000319107400104
PM 23691170
ER
PT J
AU Song, M
Wu, K
Ogino, S
Fuchs, CS
Giovannucci, EL
Chan, AT
AF Song, M.
Wu, K.
Ogino, S.
Fuchs, C. S.
Giovannucci, E. L.
Chan, A. T.
TI A prospective study of plasma inflammatory markers and risk of
colorectal cancer in men
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE C-reactive protein; interleukin-6; soluble tumour necrosis factor
receptor 2; colorectal cancer; body mass index
ID C-REACTIVE PROTEIN; PHYSICAL-ACTIVITY; COLON-CANCER; OBESITY; WOMEN;
DISEASE; ASSOCIATIONS; MECHANISMS; DIAGNOSIS; INSULIN
AB Background: Chronic inflammation may mediate risk of colorectal cancer (CRC); however, the association between circulating inflammatory markers and risk of CRC has been inconsistent.
Methods: We prospectively evaluated the association of plasma C-reactive protein (CRP), interleukin-6 (IL-6), and the soluble tumour necrosis factor receptor 2 (sTNFR-2) with incident CRC among 274 cases and 532 matched controls nested in the Health Professionals Follow-up Study.
Results: Multivariate relative risk (RR) of CRC comparing the extreme quartiles of plasma IL-6 was 1.54 (95% confidence interval (CI), 0.99-2.40; P-trend = 0.02). However, after excluding cases diagnosed within 2 years of blood draw, this association was not statistically significant (RR = 1.26, 95% CI, 0.78-2.05; P-trend = 0.21). In analyses restricted to cases diagnosed at least 2 years after blood draw, the association of IL-6 with CRC appeared to differ by body mass index such that the significantly positive association was only present among lean individuals (P-interaction = 0.03). We did not observe any significant association between CRP or sTNFR-2 and CRC.
Conclusion: Plasma inflammatory markers are not generally associated with risk of CRC among men. However, the possibility that plasma IL-6 is associated with increased risk of CRC among lean men requires further investigation.
C1 [Song, M.; Wu, K.; Giovannucci, E. L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Ogino, S.; Fuchs, C. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ogino, S.; Fuchs, C. S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Ogino, S.; Fuchs, C. S.; Giovannucci, E. L.; Chan, A. T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Div Network Med, Boston, MA 02115 USA.
[Ogino, S.; Giovannucci, E. L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Chan, A. T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Chan, A. T.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Chan, AT (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Div Network Med, Boston, MA 02115 USA.
EM achan@partners.org
RI Song, Mingyang/M-6701-2013
OI Song, Mingyang/0000-0002-1324-0316
FU US National Institute of Health [P01 CA55075, UM1 CA167552, P50
CA127003, R01 CA151993, R01 CA137178, K24 DK 098311]
FX We thank the participants and staff of the Health Professionals
Follow-up Study for their valuable contributions as well as the
following state cancer registries for their help: AL, AZ, AR, CA, CO,
CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY,
NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. We also thank
Xuehong Zhang, ScD, for assistance in programming; and Gary Bradwin and
Nader Rifai, PhD, for measurements of the inflammatory analytes. This
work was supported by US National Institute of Health Grants, P01
CA55075 (to WC Willett), UM1 CA167552 (to WC Willett), P50 CA127003 (to
CSF), R01 CA151993 (to SO), and R01 CA137178 and K24 DK 098311 (to ATC).
Dr Andrew T Chan is a Damon Runyon Cancer Foundation Clinical
Investigator.
NR 48
TC 31
Z9 32
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 14
PY 2013
VL 108
IS 9
BP 1891
EP 1898
DI 10.1038/bjc.2013.172
PG 8
WC Oncology
SC Oncology
GA 146WI
UT WOS:000319125300019
PM 23591192
ER
PT J
AU van der Meer, P
Postmus, D
Ponikowski, P
Cleland, JG
O'Connor, CM
Cotter, G
Metra, M
Davison, BA
Givertz, MM
Mansoor, GA
Teerlink, JR
Massie, BM
Hillege, HL
Voors, AA
AF van der Meer, Peter
Postmus, Douwe
Ponikowski, Piotr
Cleland, John G.
O'Connor, Christopher M.
Cotter, Gad
Metra, Marco
Davison, Beth A.
Givertz, Michael M.
Mansoor, George A.
Teerlink, John R.
Massie, Barry M.
Hillege, Hans L.
Voors, Adriaan A.
TI The Predictive Value of Short-Term Changes in Hemoglobin Concentration
in Patients Presenting With Acute Decompensated Heart Failure
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE acute heart failure; hemoglobin; outcome
ID RENAL DYSFUNCTION; ENDOGENOUS ERYTHROPOIETIN; ANEMIA; MORTALITY;
ROLOFYLLINE; PREVALENCE; SURVIVAL; ASSOCIATION; ANTAGONIST; REGISTRY
AB Objectives The study sought to investigate the clinical correlates and prognostic role of anemia and changes in hemoglobin in patients hospitalized for acute decompensated heart failure (AHF).
Background Anemia is related to a poor outcome in patients with heart failure. In addition, an increase in hemoglobin during hospitalization might be a sign of effective decongestion and therefore related to improved outcome.
Methods This is a post hoc analysis of the PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) study in 1,969 patients with AHF and mild to moderate impaired renal function. Hemoglobin levels were measured daily for the first 4 days and at day 7. The endpoint was 180-day all-cause mortality.
Results Anemia at baseline was observed in 50.3% of the patients. During follow-up, 359 patients (18.2%) died. Hemoglobin increased in 69.1% and was associated with a better renal function at baseline and more weight loss, but was associated with a deterioration of renal function (p = 0.01), whereas total dose diuretics was lower in patients with hemoconcentration (p < 0.01). Interaction analysis showed that greater weight loss and better baseline renal function were associated with a more rapid increase in hemoglobin concentration (p < 0.01 for both). The absolute change in hemoglobin (g/dl) independently predicted outcome (hazard ratio: 0.66; 95% confidence interval: 0.51 to 0.86; p = 0.002), whereas baseline hemoglobin levels did not.
Conclusions Patients with AHF and preserved renal function are decongested better, as shown by an increase in hemoglobin. A rapid increase in hemoglobin during the first week is independently associated with a favorable outcome, despite a slight decrease in renal function. (C) 2013 by the American College of Cardiology Foundation
C1 [van der Meer, Peter; Postmus, Douwe; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands.
[Ponikowski, Piotr] Kardiol Klin, Wroclaw, Poland.
[Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Mansoor, George A.] Merck Res Labs, Rahway, NJ USA.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
RP Voors, AA (reprint author), Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Ponikowski, Piotr/O-6454-2015;
OI Ponikowski, Piotr/0000-0002-3391-7064; Postmus,
Douwe/0000-0002-9458-7038; Metra, Marco/0000-0001-6691-8568; Davison,
Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016
FU Vifor Pharma; Amgen, Inc.; Merck; Abbott; Amgen; Biogen Idec; Corthera;
Cytokinetics; Johnson Johnson/Scios; Novartis; Relypsa; Solvay
FX Dr. Ponikowski has received honoraria from Merck; consulting fees from
Vifor Pharma and Amgen, Inc., honoraria from Vifor Pharma; and
travel/accommodation expenses covered by Vifor Pharma and Amgen, Inc.
Dr. Cleland was on the Steering Committee for the study; served on the
advisory board for MSD; and received payments for both. Dr. O'Connor is
a consultant to Merck and Amgen. Dr. Davison and Dr. Cotter are
employees of Momentum Research Inc, which was contracted to perform work
on the project by Merck. Drs. Metra and Massie have received honoraria
and reimbursements from NovaCardia, sponsors of the study, and from
Merck, which purchased the rights to rolofylline after completion of the
PROTECT pilot study. Dr. Givertz has received institutional research
support and served on a scientific Advisory Board for Merck. Dr. Mansoor
is an employee of Merck. Dr. Teerlink has received research funds and
consulting fees from Merck, the makers of rolofylline for the conduct of
this study and has also received research funds and consulting fees from
Abbott, Amgen, Biogen Idec, Corthera, Cytokinetics, Johnson &
Johnson/Scios, Novartis, Relypsa, and Solvay for research in related
areas. Dr. Voors has received speaker and consultancy fees from Merck.
All other authors have reported that they have no relationships relevant
to the contents of this paper to report.
NR 23
TC 56
Z9 57
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 14
PY 2013
VL 61
IS 19
BP 1973
EP 1981
DI 10.1016/j.jacc.2012.12.050
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 144AB
UT WOS:000318910300007
PM 23500313
ER
PT J
AU Piccini, JP
Stevens, SR
Lokhnygina, Y
Patel, MR
Halperin, JL
Singer, DE
Hankey, GJ
Hacke, W
Becker, RC
Nessel, CC
Mahaffey, KW
Fox, KAA
Califf, RM
Breithardt, G
AF Piccini, Jonathan P.
Stevens, Susanna R.
Lokhnygina, Yuliya
Patel, Manesh R.
Halperin, Jonathan L.
Singer, Daniel E.
Hankey, Graeme J.
Hacke, Werner
Becker, Richard C.
Nessel, Christopher C.
Mahaffey, Kenneth W.
Fox, Keith A. A.
Califf, Robert M.
Breithardt, Guenter
CA ROCKET AF Steering Comm Investigat
TI Outcomes After Cardioversion and Atrial Fibrillation Ablation in
Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE atrial fibrillation; cardioversion; catheter ablation; stroke;
rivaroxaban; warfarin
ID PREDICTING STROKE; ASSOCIATION; MANAGEMENT; RISK; THROMBOEMBOLISM;
ANTICOAGULATION
AB Objectives This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with warfarin or rivaroxaban.
Background There are limited data on outcomes following cardioversion or catheter ablation in AF patients treated with factor Xa inhibitors.
Methods We compared the incidence of electrical cardioversion (ECV), pharmacologic cardioversion (PCV), or AF ablation and subsequent outcomes in patients in a post hoc analysis of the ROCKET AF (Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation) trial.
Results Over a median follow-up of 2.1 years, 143 patients underwent ECV, 142 underwent PCV, and 79 underwent catheter ablation. The overall incidence of ECV, PCV, or AF ablation was 1.45 per 100 patient-years (n = 321; 1.44 [n = 161] in the warfarin arm, 1.46 [n = 160] in the rivaroxaban arm). The crude rates of stroke and death increased in the first 30 days after cardioversion or ablation. After adjustment for baseline differences, the long-term incidence of stroke or systemic embolism (hazard ratio [HR]: 1.38; 95% confidence interval [CI]: 0.61 to 3.11), cardiovascular death (HR: 1.57; 95% CI: 0.69 to 3.55), and death from all causes (HR: 1.75; 95% CI: 0.90 to 3.42) were not different before and after cardioversion or AF ablation. Hospitalization increased after cardioversion or AF ablation (HR: 2.01; 95% CI: 1.51 to 2.68), but there was no evidence of a differential effect by randomized treatment (p value for interaction = 0.58). The incidence of stroke or systemic embolism (1.88% vs. 1.86%) and death (1.88% vs. 3.73%) were similar in the rivaroxaban-treated and warfarin-treated groups.
Conclusions Despite an increase in hospitalization, there were no differences in long-term stroke rates or survival following cardioversion or AF ablation. Outcomes were similar in patients treated with rivaroxaban or warfarin. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation [ROCKET AF]; NCT00403767) (C) 2013 by the American College of Cardiology Foundation
C1 [Piccini, Jonathan P.; Stevens, Susanna R.; Lokhnygina, Yuliya; Patel, Manesh R.; Becker, Richard C.; Mahaffey, Kenneth W.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA.
[Halperin, Jonathan L.] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA.
[Singer, Daniel E.] Massachusetts Gen Hosp, Clin Epidemiol Unit, Div Gen Med, Boston, MA 02114 USA.
[Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
[Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Perth, WA, Australia.
[Hacke, Werner] Heidelberg Univ, Heidelberg, Germany.
[Nessel, Christopher C.] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
[Fox, Keith A. A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
[Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC 27710 USA.
[Breithardt, Guenter] Hosp Univ Munster, Dept Cardiovasc Med, Munster, Germany.
RP Piccini, JP (reprint author), Duke Univ, Med Ctr, Electrophysiol Sect, Duke Clin Res Inst, POB 17969, Durham, NC 27710 USA.
EM jonathan.piccini@duke.edu
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
FU Johnson & Johnson Pharmaceutical Research and Development; Bayer
HealthCare AG; Johnson Johnson; Bayer; Ortho McNeil Janssen; Bayer
HealthCare; Eliot B. and Edith C. Shoolman fund of Massachusetts General
Hospital; Boehringer-Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo;
Pfizer; Sanofi; Bristol Myers-Squibb; AstraZeneca; Eli Lilly;
GlaxoSmithKline; Merck; Momenta Pharmaceuticals; Novartis; Portola;
Pozen; Regado Biotechnologies; Sanofi-Aventis; Medicines Company;
Ortho/McNeill; Polymedix; Lilly
FX The ROCKET AF trial was sponsored by Johnson & Johnson Pharmaceutical
Research and Development and Bayer HealthCare AG. Dr. Piccini has
received research grants from Johnson & Johnson and is a
consultant/advisory board member for Medtronic, Forest Laboratories,
Sanofi Aventis, and Johnson & Johnson. Dr. Lokhnygina receives
consulting fees from Johnson & Johnson and Bayer. Dr. Patel has received
honoraria from Johnson & Johnson and Bayer; and consultancy fees from
Ortho McNeil Janssen, Bayer HealthCare, and is an advisory board member
with Genzyme. Dr. Singer is supported, in part, by the Eliot B. and
Edith C. Shoolman fund of Massachusetts General Hospital; and has
received consulting fees from Bayer HealthCare, Boehringer-Ingelheim,
Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Pfizer, and
Sanofi. Dr. Halperin has received honoraria from Johnson & Johnson and
Bayer; and advisory fees from Boehringer-Ingelheim, Bristol
Myers-Squibb, and Pfizer. Dr. Hankey has received honoraria from Johnson
& Johnson, Bayer, and Sanofi-Aventis and is a member of the trial
adjudication committee and advisory board for Boehringer-Ingelheim. Dr.
Hacke has received honoraria from Johnson & Johnson and Bayer and
advisory board fees from Boehringer-Ingelheim. Dr. Becker has received
research support from Bayer and Johnson & Johnson. Dr. Nessel is an
employee of Johnson & Johnson Mahaffey; received grant support from
AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta
Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies,
Sanofi-Aventis, Schering-Plough (now Merck), and The Medicines Company;
and has received consulting fees from AstraZeneca and Johnson & Johnson,
Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli
Lilly, Glaxo SmithKline, Merck, Novartis, Ortho/McNeill, Pfizer,
Polymedix, Sanofi-Aventis, and Schering-Plough (now Merck). Dr. Fox has
received research grants and honoraria from Bayer, Lilly,
Boehringer-Ingelheim, Sanofi-Aventis, and GlaxoSmith Kline. Dr. Califf
has received consulting fees and research funding from Johnson & Johnson
and all other industry interactions are listed at the Duke Clinical
Research Institute website. Dr. Breithardt has received honoraria from
Johnson & Johnson and Bayer; and advisory board fees from
Boehringer-Ingelheim, Bristol-Myers Squibb, Pfizer, and Sanofi-Aventis.
NR 17
TC 96
Z9 103
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 14
PY 2013
VL 61
IS 19
BP 1998
EP 2006
DI 10.1016/j.jacc.2013.02.025
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 144AB
UT WOS:000318910300011
PM 23500298
ER
PT J
AU Allison, TA
Sudore, RL
AF Allison, Theresa A.
Sudore, Rebecca L.
TI Disregard of Patients' Preferences Is a Medical Error
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID ADVANCE CARE
C1 [Allison, Theresa A.; Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Allison, Theresa A.; Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA.
[Allison, Theresa A.] Univ Calif San Francisco, Div Geriatr, Dept Family & Community Med, San Francisco, CA 94143 USA.
RP Allison, TA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,POB 181-G, San Francisco, CA 94941 USA.
EM Theresa.Allison@UCSF.edu
NR 9
TC 11
Z9 11
U1 1
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY 13
PY 2013
VL 173
IS 9
BP 787
EP 788
DI 10.1001/jamainternmed.2013.203
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159JN
UT WOS:000320041800018
PM 23545699
ER
PT J
AU Kerlikowske, K
Zhu, WW
Hubbard, RA
Geller, B
Dittus, K
Braithwaite, D
Wernli, KJ
Miglioretti, DL
O'Meara, ES
AF Kerlikowske, Karla
Zhu, Weiwei
Hubbard, Rebecca A.
Geller, Berta
Dittus, Kim
Braithwaite, Dejana
Wernli, Karen J.
Miglioretti, Diana L.
O'Meara, Ellen S.
CA Breast Canc Surveillance Consorti
TI Outcomes of Screening Mammography by Frequency, Breast Density, and
Postmenopausal Hormone Therapy
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID FALSE-POSITIVE RECALL; SERVICES TASK-FORCE; REPLACEMENT THERAPY; CANCER
RISK; TUMOR CHARACTERISTICS; WOMEN; ASSOCIATION; BENEFITS; COHORT;
REPRODUCIBILITY
AB Importance: Controversy exists about the frequency women should undergo screening mammography and whether screening interval should vary according to risk factors beyond age.
Objective: To compare the benefits and harms of screening mammography frequencies according to age, breast density, and postmenopausal hormone therapy (HT) use.
Design: Prospective cohort.
Setting: Data collected January 1994 to December 2008 from mammography facilities in community practice that participate in the Breast Cancer Surveillance Consortium (BCSC) mammography registries.
Participants: Data were collected prospectively on 11 474 women with breast cancer and 922 624 without breast cancer who underwent mammography at facilities that participate in the BCSC.
Main Outcomes and Measures: We used logistic regression to calculate the odds of advanced stage (IIb, III, or IV) and large tumors (> 20 mm in diameter) and 10-year cumulative probability of a false-positive mammography result by screening frequency, age, breast density, and HT use. The main predictor was screening mammography interval.
Results: Mammography biennially vs annually for women aged 50 to 74 years does not increase risk of tumors with advanced stage or large size regardless of women's breast density or HT use. Among women aged 40 to 49 years with extremely dense breasts, biennial mammography vs annual is associated with increased risk of advanced-stage cancer (odds ratio [OR], 1.89; 95% CI, 1.06-3.39) and large tumors (OR, 2.39; 95% CI, 1.37-4.18). Cumulative probability of a false-positive mammography result was high among women undergoing annual mammography with extremely dense breasts who were either aged 40 to 49 years (65.5%) or used estrogen plus progestogen (65.8%) and was lower among women aged 50 to 74 years who underwent biennial or triennial mammography with scattered fibroglandular densities (30.7% and 21.9%, respectively) or fatty breasts (17.4% and 12.1%, respectively).
Conclusions and Relevance: Women aged 50 to 74 years, even those with high breast density or HT use, who undergo biennial screening mammography have similar risk of advanced-stage disease and lower cumulative risk of false-positive results than those who undergo annual mammography. Whendeciding whether to undergo mammography, women aged 40 to 49 years who have extremely dense breasts should be informed that annual mammography may minimize their risk of advancedstage disease but the cumulative risk of false-positive results is high.
C1 [Kerlikowske, Karla; Braithwaite, Dejana] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kerlikowske, Karla] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA.
[Zhu, Weiwei; Hubbard, Rebecca A.; Wernli, Karen J.; Miglioretti, Diana L.; O'Meara, Ellen S.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[O'Meara, Ellen S.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Geller, Berta] Univ Vermont, Coll Med, Dept Family Med, Burlington, VT 05405 USA.
[Geller, Berta] Univ Vermont, Coll Med, Dept Radiol, Burlington, VT 05405 USA.
[Dittus, Kim] Univ Vermont, Coll Med, Dept Med Oncol, Burlington, VT 05405 USA.
[Miglioretti, Diana L.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA.
RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 4150 Clement St,Mailing Code 111A1, San Francisco, CA 94121 USA.
EM Karla.Kerlikowske@ucsf.edu
FU National Cancer Institute-funded Breast Cancer Surveillance Consortium
cooperative agreement [U01CA63740, U01CA86076, U01CA86082, U01CA63736,
U01CA70013, U01CA69976, U01CA63731, U01CA70040]; National Cancer
Institute [RC2CA148577, R03CA150007, P01 CA107584]
FX This work was supported by the National Cancer Institute-funded Breast
Cancer Surveillance Consortium cooperative agreement (grants U01CA63740,
U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731,
U01CA70040) and the National Cancer Institute-funded grants RC2CA148577,
R03CA150007, and P01 CA107584. The collection of cancer data used in
this study was supported in part by several state public health
departments and cancer registries throughout the United States For a
full description of these sources, please see
http://breastscreening.cancer.gov/work/acknowledgement.html.
NR 38
TC 58
Z9 59
U1 1
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY 13
PY 2013
VL 173
IS 9
BP 807
EP 816
DI 10.1001/jamainternmed.2013.307
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159JN
UT WOS:000320041800023
PM 23552817
ER
PT J
AU Chen, XH
Yang, GX
Song, JH
Xu, H
Li, D
Goldsmith, J
Zeng, HY
Parsons-Wingerter, PA
Reinecker, HC
Kelly, CP
AF Chen, Xinhua
Yang, Guoxun
Song, Joo-Hye
Xu, Hua
Li, Dan
Goldsmith, Jeffrey
Zeng, Huiyan
Parsons-Wingerter, Patricia A.
Reinecker, Hans-Christian
Kelly, Ciaran P.
TI Probiotic Yeast Inhibits VEGFR Signaling and Angiogenesis in Intestinal
Inflammation
SO PLOS ONE
LA English
DT Article
ID CLOSTRIDIUM-DIFFICILE DISEASE; ANTIBIOTIC-ASSOCIATED DIARRHEA;
ENDOTHELIAL GROWTH-FACTOR; SACCHAROMYCES-BOULARDII; BOWEL-DISEASE;
EXPERIMENTAL COLITIS; ULCERATIVE-COLITIS; TOXIN-A; GNOTOBIOTIC MICE;
CROHNS-DISEASE
AB Background and Aims: Saccharomyces boulardii (Sb) can protect against intestinal injury and tumor formation, but how this probiotic yeast controls protective mucosal host responses is unclear. Angiogenesis is an integral process of inflammatory responses in inflammatory bowel diseases (IBD) and required for mucosal remodeling during restitution. The aim of this study was to determine whether Sb alters VEGFR (vascular endothelial growth factor receptor) signaling, a central regulator of angiogenesis.
Methods: HUVEC were used to examine the effects of Sb on signaling and on capillary tube formation (using the ECMatrix (TM) system). The effects of Sb on VEGF-mediated angiogenesis were examined in vivo using an adenovirus expressing VEGF-A(164) in the ears of adult nude mice (NuNu). The effects of Sb on blood vessel volume branching and density in DSS-induced colitis was quantified using VESsel GENeration (VESGEN) software.
Results: 1) Sb treatment attenuated weight-loss (p<0.01) and histological damage (p<0.01) in DSS colitis. VESGEN analysis of angiogenesis showed significantly increased blood vessel density and volume in DSS-treated mice compared to control. Sb treatment significantly reduced the neo-vascularization associated with acute DSS colitis and accelerated mucosal recovery restoration of the lamina propria capillary network to a normal morphology. 2) Sb inhibited VEGF-induced angiogenesis in vivo in the mouse ear model. 3) Sb also significantly inhibited angiogenesis in vitro in the capillary tube assay in a dose-dependent manner (p<0.01). 4) In HUVEC, Sb reduced basal VEGFR-2 phosphorylation, VEGFR-2 phosphorylation in response to VEGF as well as activation of the downstream kinases PLC gamma and Erk1/2.
Conclusions: Our findings indicate that the probiotic yeast S boulardii can modulate angiogenesis to limit intestinal inflammation and promote mucosal tissue repair by regulating VEGFR signaling.
C1 [Chen, Xinhua; Yang, Guoxun; Xu, Hua; Li, Dan; Kelly, Ciaran P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA.
[Song, Joo-Hye; Reinecker, Hans-Christian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
[Goldsmith, Jeffrey] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol & Lab Med, Boston, MA 02215 USA.
[Zeng, Huiyan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Mol & Vasc Med, Boston, MA 02215 USA.
[Parsons-Wingerter, Patricia A.] John Glenn NASA Res Ctr, Cleveland, OH USA.
RP Chen, XH (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA.
EM xchen1@bidmc.harvard.edu
FU NIH [PO1 DK 33506, DK-068181, DK-043351, AI-093588]; Crohn's & Colitis
Foundation of America; Global Probiotic Council
FX This work was supported by NIH grants PO1 DK 33506 (CPK, HCR),
DK-068181, DK-043351 and AI-093588 (HCR), Crohn's & Colitis Foundation
of America (Research Fellowship and Career Development Award, XC) and
Global Probiotic Council (Young Investigator Award, XC). NASA and PPW
have filed a United States patent application for the VESGEN software.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 48
TC 7
Z9 7
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 13
PY 2013
VL 8
IS 5
AR e64227
DI 10.1371/journal.pone.0064227
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145RZ
UT WOS:000319036100060
PM 23675530
ER
PT J
AU Lai, PS
Hofmann, O
Baron, RM
Cernadas, M
Meng, QR
Bresler, HS
Brass, DM
Yang, IV
Schwartz, DA
Christiani, DC
Hide, W
AF Lai, Peggy S.
Hofmann, Oliver
Baron, Rebecca M.
Cernadas, Manuela
Meng, Quanxin Ryan
Bresler, Herbert S.
Brass, David M.
Yang, Ivana V.
Schwartz, David A.
Christiani, David C.
Hide, Winston
TI Integrating Murine Gene Expression Studies to Understand Obstructive
Lung Disease Due to Chronic Inhaled Endotoxin
SO PLOS ONE
LA English
DT Article
ID CIGARETTE-SMOKE; PULMONARY-DISEASE; BACTERIAL-ENDOTOXIN; FOLLOW-UP;
COPD; INHALATION; ASTHMA; LIPOPOLYSACCHARIDE; MICE; RISK
AB Rationale: Endotoxin is a near ubiquitous environmental exposure that that has been associated with both asthma and chronic obstructive pulmonary disease (COPD). These obstructive lung diseases have a complex pathophysiology, making them difficult to study comprehensively in the context of endotoxin. Genome-wide gene expression studies have been used to identify a molecular snapshot of the response to environmental exposures. Identification of differentially expressed genes shared across all published murine models of chronic inhaled endotoxin will provide insight into the biology underlying endotoxin-associated lung disease.
Methods: We identified three published murine models with gene expression profiling after repeated low-dose inhaled endotoxin. All array data from these experiments were re-analyzed, annotated consistently, and tested for shared genes found to be differentially expressed. Additional functional comparison was conducted by testing for significant enrichment of differentially expressed genes in known pathways. The importance of this gene signature in smoking-related lung disease was assessed using hierarchical clustering in an independent experiment where mice were exposed to endotoxin, smoke, and endotoxin plus smoke.
Results: A 101-gene signature was detected in three murine models, more than expected by chance. The three model systems exhibit additional similarity beyond shared genes when compared at the pathway level, with increasing enrichment of inflammatory pathways associated with longer duration of endotoxin exposure. Genes and pathways important in both asthma and COPD were shared across all endotoxin models. Mice exposed to endotoxin, smoke, and smoke plus endotoxin were accurately classified with the endotoxin gene signature.
Conclusions: Despite the differences in laboratory, duration of exposure, and strain of mouse used in three experimental models of chronic inhaled endotoxin, surprising similarities in gene expression were observed. The endotoxin component of tobacco smoke may play an important role in disease development.
C1 [Lai, Peggy S.; Christiani, David C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lai, Peggy S.; Hofmann, Oliver; Christiani, David C.; Hide, Winston] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Baron, Rebecca M.; Cernadas, Manuela] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Meng, Quanxin Ryan; Bresler, Herbert S.] Battelle Mem Inst, Columbus, OH USA.
[Brass, David M.] Duke Univ, Med Ctr, Dept Pediat Neonatol, Durham, NC USA.
[Yang, Ivana V.; Schwartz, David A.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA.
[Yang, Ivana V.; Schwartz, David A.] Univ Colorado, Dept Med, Aurora, CO USA.
RP Lai, PS (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM plai@partners.org
RI Hide, Winston Hide/C-7217-2009;
OI Hide, Winston Hide/0000-0002-8621-3271; Lai, Peggy/0000-0001-9501-8606;
Hofmann, Oliver/0000-0002-7738-1513
FU National Institute of Environmental Health Sciences [ES00002, P30
ES00002, P01 ES18181, F32 ES020082]; Battelle Memorial Institute
FX Support was provided by ES00002, P30 ES00002, and P01 ES18181 from the
National Institute of Environmental Health Sciences for generation of
primary microarray data for the Lai and Brass et al studies, Battelle
Memorial Institute's Corporate Science & Technology Program for
generation of microarray data for the Meng et al study, and F32 ES020082
from the National Institute of Environmental Health Sciences to PL as a
career development award. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Institute of Environmental Health Sciences or the National
Institutes of Health. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 52
TC 1
Z9 1
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 13
PY 2013
VL 8
IS 5
AR e62910
DI 10.1371/journal.pone.0062910
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145RZ
UT WOS:000319036100020
PM 23675439
ER
PT J
AU Beguelin, W
Popovic, R
Teater, M
Jiang, YW
Bunting, KL
Rosen, M
Shen, H
Yang, SN
Wang, L
Ezponda, T
Martinez-Garcia, E
Zhang, HK
Zheng, YP
Verma, SK
McCabe, MT
Ott, HM
Van Aller, GS
Kruger, RG
Liu, Y
McHugh, CF
Scott, DW
Chung, YR
Kelleher, N
Shaknovich, R
Creasy, CL
Gascoyne, RD
Wong, KK
Cerchietti, L
Levine, RL
Abdel-Wahab, O
Licht, JD
Elemento, O
Melnick, AM
AF Beguelin, Wendy
Popovic, Relja
Teater, Matt
Jiang, Yanwen
Bunting, Karen L.
Rosen, Monica
Shen, Hao
Yang, Shao Ning
Wang, Ling
Ezponda, Teresa
Martinez-Garcia, Eva
Zhang, Haikuo
Zheng, Yupeng
Verma, Sharad K.
McCabe, Michael T.
Ott, Heidi M.
Van Aller, Glenn S.
Kruger, Ryan G.
Liu, Yan
McHugh, Charles F.
Scott, David W.
Chung, Young Rock
Kelleher, Neil
Shaknovich, Rita
Creasy, Caretha L.
Gascoyne, Randy D.
Wong, Kwok-Kin
Cerchietti, Leandro
Levine, Ross L.
Abdel-Wahab, Omar
Licht, Jonathan D.
Elemento, Olivier
Melnick, Ari M.
TI EZH2 Is Required for Germinal Center Formation and Somatic EZH2
Mutations Promote Lymphoid Transformation
SO CANCER CELL
LA English
DT Article
ID B-CELL LYMPHOMA; HISTONE METHYLTRANSFERASE EZH2; EMBRYONIC STEM-CELLS;
NON-HODGKIN-LYMPHOMA; EXPRESSION PATTERNS; TRANSGENIC MICE; GROUP
PROTEINS; LYSINE 27; RNA-SEQ; POLYCOMB
AB The EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and targeted by somatic mutations in B cell lymphomas. Here, we find that EZH2 deletion or pharmacologic inhibition suppresses GC formation and functions. EZH2 represses proliferation checkpoint genes and helps establish bivalent chromatin domains at key regulatory loci to transiently suppress GC B cell differentiation. Somatic mutations reinforce these physiological effects through enhanced silencing of EZH2 targets. Conditional expression of mutant EZH2 in mice induces GC hyperplasia and accelerated lymphomagenesis in cooperation with BCL2. GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addicted to EZH2 but not the more differentiated activated B cell (ABC)-type DLBCLs, thus clarifying the therapeutic scope of EZH2 targeting.
C1 [Beguelin, Wendy; Teater, Matt; Jiang, Yanwen; Bunting, Karen L.; Rosen, Monica; Shen, Hao; Yang, Shao Ning; Wang, Ling; Shaknovich, Rita; Cerchietti, Leandro; Melnick, Ari M.] Weill Cornell Med Coll, Div Hematol Oncol, Dept Med, New York, NY 10021 USA.
[Teater, Matt; Jiang, Yanwen; Elemento, Olivier] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY 10021 USA.
[Cerchietti, Leandro; Melnick, Ari M.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY 10021 USA.
[Popovic, Relja; Ezponda, Teresa; Martinez-Garcia, Eva; Licht, Jonathan D.] Northwestern Univ, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
[Zhang, Haikuo; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Zheng, Yupeng; Kelleher, Neil] Northwestern Univ, Chem Life Proc Inst, Dept Chem, Evanston, IL 60208 USA.
[Zheng, Yupeng; Kelleher, Neil] Northwestern Univ, Chem Life Proc Inst, Dept Mol Biosci, Evanston, IL 60208 USA.
[Verma, Sharad K.; McCabe, Michael T.; Ott, Heidi M.; Van Aller, Glenn S.; Kruger, Ryan G.; Liu, Yan; McHugh, Charles F.; Creasy, Caretha L.] GlaxoSmithKline, Oncol R&D, Canc Res, Canc Epigenet Discovery Performance Unit, Collegeville, PA 19426 USA.
[Scott, David W.; Gascoyne, Randy D.] British Columbia Canc Res Ctr, British Columbia Canc Agcy, Ctr Lymphoid Canc, Dept Pathol, Vancouver, BC V5Z 1L3, Canada.
[Scott, David W.; Gascoyne, Randy D.] British Columbia Canc Res Ctr, British Columbia Canc Agcy, Ctr Lymphoid Canc, Dept Expt Therapeut, Vancouver, BC V5Z 1L3, Canada.
[Chung, Young Rock; Levine, Ross L.; Abdel-Wahab, Omar] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Chung, Young Rock; Levine, Ross L.; Abdel-Wahab, Omar] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA.
RP Licht, JD (reprint author), Northwestern Univ, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
EM j-licht@northwestern.edu; ole2001@med.cornell.edu;
amm2014@med.cornell.edu
RI Zheng, Yupeng/B-3782-2014;
OI Abdel-Wahab, Omar/0000-0002-3907-6171; Zheng,
Yupeng/0000-0002-3351-5161; Cerchietti, Leandro/0000-0003-0608-1350;
wong, kwok kin/0000-0001-6323-235X
FU Burroughs Wellcome Foundation; Chemotherapy Foundation; Samuel Waxman
Cancer Research Foundation; National Cancer Institute Physical Sciences
in Oncology Center program [U54 CA143869, CA143879]; Leukemia and
Lymphoma Society Specialized Center of Research Excellence; T & C
Schwartz Family Foundation; NIH K08 Clinical Investigator Award
[1K08CA160647-01]; CIHR; New Frontiers in Cancer Terry Fox Program
project [019001]; NCI [R01 CA104348]; NSF CAREER; Starr Cancer
Consortium
FX We thank Dr. Alexander Tarakhovsky (Rockefeller University) for sharing
the EZH2 conditional knockout mouse strain. A.M.M. is supported by the
Burroughs Wellcome Foundation and Chemotherapy Foundation. A.M.M.,
R.L.L., and J.D.L. are supported by the Samuel Waxman Cancer Research
Foundation and a collaborative transnetwork grant from the National
Cancer Institute Physical Sciences in Oncology Center program (U54
CA143869 and CA143879). J.D.L., A.M.M., and O.E. are supported by a
Leukemia and Lymphoma Society Specialized Center of Research Excellence,
and A.M.M. and J.D.L. are supported by the T & C Schwartz Family
Foundation. O.A.-W. is an American Society of Hematology Basic Research
Fellow and is supported by a grant from the NIH K08 Clinical
Investigator Award (1K08CA160647-01). L.C. is a Raymond and Beverly
Sackler Scholar and Scholar of the American Society of Hematology.
D.W.S. is supported by a CIHR postdoctoral fellowship award, and R.D.G.
is supported by a New Frontiers in Cancer Terry Fox Program project
grant (No. 019001). O.E. and A.M.M. are supported by NCI R01 CA104348.
O.E. is supported by the NSF CAREER grant and grants from the Starr
Cancer Consortium. This work was enabled by the Beverly and Raymond
Sackler Center for Physical and Biomedical Sciences as well as the Weill
Cornell Epigenomics Core Facility. S.K.V., M.T.M., H.M.O., G.S.V.A.,
R.G.K., Y.L., C.F.M., and C.L.C. are employees of GlaxoSmithKline.
NR 39
TC 193
Z9 196
U1 4
U2 35
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD MAY 13
PY 2013
VL 23
IS 5
BP 677
EP 692
DI 10.1016/j.ccr.2013.04.011
PG 16
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 146PQ
UT WOS:000319103400015
PM 23680150
ER
PT J
AU Cho, HS
Hashimoto, T
Wong, E
Hori, Y
Wood, LB
Zhao, LZ
Haigis, KM
Hyman, BT
Irimia, D
AF Cho, Hansang
Hashimoto, Tadafumi
Wong, Elisabeth
Hori, Yukiko
Wood, Levi B.
Zhao, Lingzhi
Haigis, Kevin M.
Hyman, Bradley T.
Irimia, Daniel
TI Microfluidic Chemotaxis Platform for Differentiating the Roles of
Soluble and Bound Amyloid-beta on Microglial Accumulation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; MOUSE MODEL; PLAQUES;
ACTIVATION; BRAIN; MAINTENANCE; EXPRESSION; CLEARANCE; CELLS
AB Progressive microglial accumulation at amyloid-beta (A beta) plaques is a well-established signature of the pathology of Alzheimer's disease, but how and why microglia accumulate in the vicinity of A beta plaques is unknown. To understand the distinct roles of A beta on microglial accumulation, we quantified microglial responses to week-long lasting gradients of soluble A beta and patterns of surface-bound A beta in microfluidic chemotaxis platforms. We found that human microglia chemotaxis in gradients of soluble A beta(42) was most effective at two distinct concentrations of 23 pg.mL(-1) and 23 ng.mL(-1) A beta(42) in monomers and oligomers. We uncovered that while the chemotaxis at higher A beta concentrations was exclusively due to A beta gradients, chemotaxis at lower concentrations was enhanced by A beta-induced microglial production of MCP-1. Microglial migration was inhibited by surface-bound A beta(42) in oligomers and fibrils above 45 pg.mm(-2). Better understanding of microglial migration can provide insights into the pathophysiology of senile plaques in AD.
C1 [Cho, Hansang; Wong, Elisabeth; Irimia, Daniel] Harvard Univ, Sch Med, Massachusetts Gen Hosp, BioMEMS Resource Ctr, Cambridge, MA 02138 USA.
[Hashimoto, Tadafumi; Hori, Yukiko; Zhao, Lingzhi; Hyman, Bradley T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Cambridge, MA 02138 USA.
[Wood, Levi B.; Haigis, Kevin M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Pathol Unit, Cambridge, MA 02138 USA.
[Zhao, Lingzhi] Weill Cornell Med Coll, Dept Neurol & Neurosci, Appel Alzheimers Dis Res Inst, New York, NY USA.
RP Irimia, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, BioMEMS Resource Ctr, Cambridge, MA 02138 USA.
EM dirimia@hms.harvard.edu
FU National Institutes of Health [AG005134, 27.3, GM092804, EB002503]
FX This work was supported in part by funding from the National Institutes
of Health, grants AG005134 - pilot project 27.3, GM092804 and EB002503.
We thank the BioMEMS RC for the use of fabrication facilities, Dr. Salil
Desai for advise on microscale patterning techniques, and Dr. Ken Arai
for discussion of A beta stability.
NR 30
TC 13
Z9 13
U1 4
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 10
PY 2013
VL 3
AR 1823
DI 10.1038/srep01823
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC0KF
UT WOS:000332182500001
PM 23665843
ER
PT J
AU Mwimanzi, P
Markle, TJ
Ogata, Y
Martin, E
Tokunaga, M
Mahiti, M
Kuang, XT
Walker, BD
Brockman, MA
Brumme, ZL
Ueno, T
AF Mwimanzi, Philip
Markle, Tristan J.
Ogata, Yoko
Martin, Eric
Tokunaga, Michiyo
Mahiti, Macdonald
Kuang, Xiaomei T.
Walker, Bruce D.
Brockman, Mark A.
Brumme, Zabrina L.
Ueno, Takamasa
TI Dynamic range of Nef functions in chronic HIV-1 infection
SO VIROLOGY
LA English
DT Article
DE HIV-1; Nef; Chronic infection; CD4; HLA class I; CD74; Infectivity;
Replication
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 DOWN-REGULATION; COMPLEX CLASS-II;
LONG-TERM-NONPROGRESSOR; INVARIANT CHAIN; VIRAL INFECTIVITY; ELITE
CONTROLLERS; T-LYMPHOCYTES; UP-REGULATION; GENETIC-CHARACTERIZATION
AB HIV-1 Nef is required for efficient viral replication and pathogenesis. However, the extent to which Nefs functions are maintained in natural sequences during chronic infection, and their clinical relevance, remains incompletely characterized. Relative to a control Nef from HIV-1 strain SF2, HLA class I and CD4 down-regulation activities of 46 plasma RNA Nef sequences derived from unique chronic infected individuals were generally high and displayed narrow dynamic ranges, whereas Nef-mediated virion infectivity, PBMC replication and CD74 up-regulation exhibited broader dynamic ranges. 80% of patient-derived Nets were active for at least three functions examined. Functional co-dependencies were identified, including positive correlations between CD4 down-regulation and virion infectivity, replication, and CD74 up-regulation, and between CD74 upregulation and PBMC replication. Net-mediated virion infectivity inversely correlated with patient CD +/- T-cell count. Strong functional co-dependencies and the polyfunctional nature of patient-derived Net sequences suggest a phenotypic requirement to maintain multiple Nef functions during chronic infection. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Mwimanzi, Philip; Ogata, Yoko; Tokunaga, Michiyo; Mahiti, Macdonald; Ueno, Takamasa] Kumamoto Univ, Ctr AIDS Res, Kumamoto 8600811, Japan.
[Mwimanzi, Philip; Markle, Tristan J.; Martin, Eric; Kuang, Xiaomei T.; Brockman, Mark A.; Brumme, Zabrina L.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada.
[Walker, Bruce D.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA.
[Walker, Bruce D.] Harvard Univ, Boston, MA 02115 USA.
[Brockman, Mark A.; Brumme, Zabrina L.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.
RP Ueno, T (reprint author), Kumamoto Univ, Ctr AIDS Res, 2-2-1 Honjo, Kumamoto 8600811, Japan.
EM zbrumme@sfu.ca; uenotaka@kumamoto-u.ac.jp
RI Kumamoto University, CAIDS/G-8446-2013; Ueno, Takamasa/F-5788-2013;
OI Ueno, Takamasa/0000-0003-4852-4236; Brockman, Mark/0000-0001-6432-1426
FU Ministry of Education, Science, Sports, and Culture (MEXT) of Japan;
Global COE Program (Global Education and Research Center Aiming at the
control of AIDS), MEXT, Japan; Ministry of Health, Labor, and Welfare of
Japan; Canadian Institutes for Health Research [MOP-93536]; Microsoft
Research; Japan AIDS Foundation; Global Health Research Initiative
(GHRI); CIHR; Canadian International Development Agency; International
Development Research Centre; Canadian Association of HIV Research;
Abbott Virology; Canadian Institutes of Health Research; Michael Smith
Foundation for Health Research
FX This research was supported by a grant-in-aid for scientific research
from the Ministry of Education, Science, Sports, and Culture (MEXT) of
Japan, by a Global COE Program (Global Education and Research Center
Aiming at the control of AIDS), MEXT, Japan, and by a grant-in-aid for
AIDS research from the Ministry of Health, Labor, and Welfare of Japan
(to TU). It was also supported in part by an operating grant from the
Canadian Institutes for Health Research (MOP-93536) and a Jim Gray seed
grant from Microsoft Research (to ZLB/MAB). PM is a postdoctoral fellow
who received support from the Japan AIDS Foundation and the Global
Health Research Initiative (GHRI), a collaborative research funding
partnership of the CIHR, the Canadian International Development Agency,
and the International Development Research Centre. EM was supported by a
Master's Scholarship from the Canadian Association of HIV Research and
Abbott Virology. MAB holds a Canada Research Chair, Tier 2, in Viral
Pathogenesis and Immunity. ZLB is the recipient of a New Investigator
Award from the Canadian Institutes of Health Research and a Scholar
Award from the Michael Smith Foundation for Health Research.
NR 57
TC 15
Z9 16
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAY 10
PY 2013
VL 439
IS 2
BP 74
EP 80
DI 10.1016/j.virol.2013.02.005
PG 7
WC Virology
SC Virology
GA 168EC
UT WOS:000320687500002
PM 23490051
ER
PT J
AU Russo, SB
Tidhar, R
Futerman, AH
Cowart, LA
AF Russo, Sarah Brice
Tidhar, Rotem
Futerman, Anthony H.
Cowart, L. Ashley
TI Myristate-derived d16:0 Sphingolipids Constitute a Cardiac Sphingolipid
Pool with Distinct Synthetic Routes and Functional Properties
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MAMMALIAN SERINE-PALMITOYLTRANSFERASE; TANDEM MASS-SPECTROMETRY;
CERAMIDE SYNTHASES; CELL-DEATH; ACYL-CHAIN; SPHINGOSINE 1-PHOSPHATE;
DIABETIC CARDIOMYOPATHY; HEART-FAILURE; LONG-CHAIN; RAT-BRAIN
AB The enzyme serine palmitoyltransferase (SPT) catalyzes the formation of the sphingoid base "backbone" from which all sphingolipids are derived. Previous studies have shown that inhibition of SPT ameliorates pathological cardiac outcomes in models of lipid overload, but the metabolites responsible for these phenotypes remain unidentified. Recent in vitro studies have shown that incorporation of the novel subunit SPTLC3 broadens the substrate specificity of SPT, allowing utilization of myristoyl-coenzyme A (CoA) in addition to its canonical substrate palmitoyl-CoA. However, the relevance of these findings in vivo has yet to be determined. The present study sought to determine whether myristate-derived d16 sphingolipids are represented among myocardial sphingolipids and, if so, whether their function and metabolic routes were distinct from those of palmitate-derived d18 sphingolipids. Data showed that d16: 0 sphingoid bases occurred in more than one-third of total dihydrosphingosine and dihydroceramides in myocardium, and a diet high in saturated fat promoted their de novo production. Intriguingly, d16-ceramides demonstrated highly limited N-acyl chain diversity, and in vitro enzyme activity assays showed that these bases were utilized preferentially to canonical bases by CerS1. Functional differences between myristate- and palmitate-derived sphingolipids were observed in that, unlike d18 sphingolipids and SPTLC2, d16 sphingolipids and SPTLC3 did not appear to contribute to myristate-induced autophagy, whereas only d16 sphingolipids promoted cell death and cleavage of poly(ADPribose) polymerase in cardiomyocytes. Thus, these results reveal a previously unappreciated component of cardiac sphingolipids with functional differences from canonical sphingolipids.
C1 [Russo, Sarah Brice; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA.
[Tidhar, Rotem; Futerman, Anthony H.] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
[Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
RP Cowart, LA (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Biochem & Mol Biol, 173 Ashley Ave,MSC509, Charleston, SC 29403 USA.
EM cowartl@musc.edu
OI Futerman, Anthony/0000-0003-0013-0115
FU National Institutes of Health (NIH), NIDDK [F30DK092125]; NIH [P30
CA138313, P20 RR017677]; NIH COBRE in Lipidomics and Pathobiology at
MUSC; Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health (NIH), NIDDK, Grant F30DK092125 (to S. B. R.); NIH Grant P30
CA138313 (Lipidomics Shared Resource, Hollings Cancer Center, Medical
University of South Carolina (MUSC)); NIH Grant P20 RR017677 (Lipidomics
Core in the South Carolina Lipidomics and Pathobiology Centers of
Biomedical Research Excellence (COBRE), Department of Biochemistry,
MUSC); and the NIH COBRE in Lipidomics and Pathobiology at MUSC (to L.
A. C.). This work was also supported by a Merit Award from the
Department of Veterans Affairs (to L. A. C.).
NR 63
TC 16
Z9 16
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 10
PY 2013
VL 288
IS 19
BP 13397
EP 13409
DI 10.1074/jbc.M112.428185
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 143EV
UT WOS:000318850300025
PM 23530041
ER
PT J
AU Qin, WP
Sun, L
Cao, J
Peng, YZ
Collier, L
Wu, Y
Creasey, G
Li, JH
Qin, YW
Jarvis, J
Bauman, WA
Zaidi, M
Cardozo, C
AF Qin, Weiping
Sun, Li
Cao, Jay
Peng, Yuanzhen
Collier, Lauren
Wu, Yong
Creasey, Graham
Li, Jianhua
Qin, Yiwen
Jarvis, Jonathan
Bauman, William A.
Zaidi, Mone
Cardozo, Christopher
TI The Central Nervous System (CNS)-independent Anti-bone-resorptive
Activity of Muscle Contraction and the Underlying Molecular and Cellular
Signatures
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SPINAL-CORD-INJURY; GENE-EXPRESSION; C-FOS; CELLS; DIFFERENTIATION;
IMMOBILIZATION; DISEASE; OSTEOCLASTOGENESIS; STIMULATION; NANDROLONE
AB Muscle and bone work as a functional unit. Cellular and molecular mechanisms underlying effects of muscle activity on bone mass are largely unknown. Spinal cord injury (SCI) causes muscle paralysis and extensive sublesional bone loss and disrupts neural connections between the central nervous system (CNS) and bone. Muscle contraction elicited by electrical stimulation (ES) of nerves partially protects against SCI-related bone loss. Thus, application of ES after SCI provides an opportunity to study the effects of muscle activity on bone and roles of the CNS in this interaction, as well as the underlying mechanisms. Using a rat model of SCI, the effects on bone of ES-induced muscle contraction were characterized. The SCI-mediated increase in serum C-terminal telopeptide of type I collagen (CTX) was completely reversed by ES. In ex vivo bone marrow cell cultures, SCI increased the number of osteoclasts and their expression of mRNA for several osteoclast differentiation markers, whereas ES significantly reduced these changes; SCI decreased osteoblast numbers, but increased expression in these cells of receptor activator of NF-kappa B ligand (RANKL) mRNA, whereas ES increased expression of osteoprotegerin (OPG) and the OPG/RANKL ratio. A microarray analysis revealed that ES partially reversed SCI-induced alterations in expression of genes involved in signaling through Wnt, FSH, parathyroid hormone (PTH), oxytocin, and calcineurin/nuclear factor of activated T-cells (NFAT) pathways. ES mitigated SCI-mediated increases in mRNA levels for the Wnt inhibitors DKK1, sFRP2, and sclerostin in ex vivo cultured osteoblasts. Our results demonstrate an anti-bone-resorptive activity of muscle contraction by ES that develops rapidly and is independent of the CNS. The pathways involved, particularly Wnt signaling, suggest future strategies to minimize bone loss after immobilization.
C1 [Qin, Weiping; Sun, Li; Peng, Yuanzhen; Li, Jianhua; Bauman, William A.; Zaidi, Mone; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.
[Sun, Li; Li, Jianhua; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
[Qin, Weiping; Peng, Yuanzhen; Collier, Lauren; Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA.
[Cao, Jay] Res Serv, USDA, Human Nutr Res Ctr, Grand Forks, ND 58201 USA.
[Creasey, Graham] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
[Creasey, Graham] Stanford Univ, Palo Alto, CA 94304 USA.
[Qin, Yiwen] Chapin Sch, New York, NY 10028 USA.
[Jarvis, Jonathan] Liverpool John Moores Univ, Sch Sport & Exercise Sci, Liverpool L3 3AF, Merseyside, England.
RP Qin, WP (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences SCI, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM weiping.qin@mssm.edu; Chris.cardozo@mssm.edu
FU United States Veterans Health Administration, Rehabilitation Research
and Development Service [B4162C, B4055X, B3347K]; United States
Department of Defense [SC090504]; National Institutes of Health
[AG23176, DK80459]; European Commission [QLG5-CT-2001-02191]
FX This work was supported by the United States Veterans Health
Administration, Rehabilitation Research and Development Service Grants
B4162C (to W. A. B.) and B4055X and B3347K (to C. C.), the United States
Department of Defense Grant SC090504 (to W. Q.), National Institutes of
Health Grants AG23176 and DK80459 (to M. Z.), and European Commission
Project RISE Grant QLG5-CT-2001-02191 (to J. J.).
NR 62
TC 21
Z9 21
U1 1
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 10
PY 2013
VL 288
IS 19
BP 13511
EP 13521
DI 10.1074/jbc.M113.454892
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 143EV
UT WOS:000318850300035
PM 23530032
ER
PT J
AU Raymond, VM
Mukherjee, B
Wang, F
Huang, SC
Stoffel, EM
Kastrinos, F
Syngal, S
Cooney, KA
Gruber, SB
AF Raymond, Victoria M.
Mukherjee, Bhramar
Wang, Fei
Huang, Shu-Chen
Stoffel, Elena M.
Kastrinos, Fay
Syngal, Sapna
Cooney, Kathleen A.
Gruber, Stephen B.
TI Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID NONPOLYPOSIS COLORECTAL-CANCER; DNA-MISMATCH-REPAIR; MSH2 MUTATION
CARRIERS; MICROSATELLITE INSTABILITY; EXTRACOLONIC CANCERS; GERMLINE
MUTATIONS; FAMILIES; GENES; BRCA1; MLH1
AB Purpose
Prostate cancer has been described as a component tumor of Lynch syndrome (LS), with tumors obtained from mutation carriers demonstrating the DNA mismatch repair deficiency phenotype. Previous studies quantifying prostate cancer risk in LS have provided conflicting results.
Methods
We examined cancer histories of probands and their first-through fourth-degree relatives for 198 independent mutation-positive LS families enrolled in two US familial cancer registries. Modified segregation analysis was used to calculate age-specific cumulative risk or penetrance estimates, with accompanying Wald-type CIs. Cumulative lifetime risks and hazard ratio (HR) estimates for prostate cancer were calculated and compared with those of the general population.
Results
Ninety-seven cases of prostate cancer were observed in 4,127 men. Median age at prostate cancer diagnosis was 65 years (range, 38 to 89 years), with 11.53% of affected individuals diagnosed before age 50 years. The cumulative risk of prostate cancer at ages 60 and 80 years was 6.30% (95% CI, 2.47 to 9.96) and 30.0% (95% CI, 16.54 to 41.30), as compared with the population risk of 2.59% and 17.84%, respectively. The overall prostate cancer HR among carriers was 1.99 (95% CI, 1.31 to 3.03).
Conclusion
The cumulative lifetime risk of prostate cancer in individuals with LS is two-fold higher than in the general population and is slightly higher in carriers diagnosed before age 60 years (HR, 2.48; 95% CI, 1.34 to 4.59). These estimates are clinically valuable to quantify risk for both patients and providers. J Clin Oncol 31:1713-1718. (C) 2013 by American Society of Clinical Oncology
C1 [Raymond, Victoria M.; Mukherjee, Bhramar; Wang, Fei; Huang, Shu-Chen; Stoffel, Elena M.; Cooney, Kathleen A.; Gruber, Stephen B.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Cooney, Kathleen A.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Stoffel, Elena M.; Kastrinos, Fay; Syngal, Sapna] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Stoffel, Elena M.; Kastrinos, Fay; Syngal, Sapna] Harvard Univ, Sch Med, Boston, MA USA.
[Kastrinos, Fay] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
[Gruber, Stephen B.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
RP Raymond, VM (reprint author), Univ Michigan, 300 North Ingalls, Ann Arbor, MI 48109 USA.
EM vraymond@umich.edu
FU NIH/NCI [K24 113433, P30 CA014089, P30 CA046592]; NCI [R01 CA136621, P50
CA69568]
FX Supported by Grants No. K24 113433 from NIH/NCI (S. S.), R01 CA136621
and P50 CA69568 from NCI (K. A. C.), and P30 CA014089 and P30 CA046592
from NIH/NCI (S.B.G.).
NR 33
TC 34
Z9 34
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2013
VL 31
IS 14
BP 1713
EP +
DI 10.1200/JCO.2012.44.1238
PG 8
WC Oncology
SC Oncology
GA 141ZW
UT WOS:000318766300008
PM 23530095
ER
PT J
AU Trunzer, K
Pavlick, AC
Schuchter, L
Gonzalez, R
McArthur, GA
Hutson, TE
Moschos, SJ
Flaherty, KT
Kim, KB
Weber, JS
Hersey, P
Long, GV
Lawrence, D
Ott, PA
Amaravadi, RK
Lewis, KD
Puzanov, I
Lo, RS
Koehler, A
Kockx, M
Spleiss, O
Schell-Steven, A
Gilbert, HN
Cockey, L
Bollag, G
Lee, RJ
Joe, AK
Sosman, JA
Ribas, A
AF Trunzer, Kerstin
Pavlick, Anna C.
Schuchter, Lynn
Gonzalez, Rene
McArthur, Grant A.
Hutson, Thomas E.
Moschos, Stergios J.
Flaherty, Keith T.
Kim, Kevin B.
Weber, Jeffrey S.
Hersey, Peter
Long, Georgina V.
Lawrence, Donald
Ott, Patrick A.
Amaravadi, Ravi K.
Lewis, Karl D.
Puzanov, Igor
Lo, Roger S.
Koehler, Astrid
Kockx, Mark
Spleiss, Olivia
Schell-Steven, Annette
Gilbert, Houston N.
Cockey, Louise
Bollag, Gideon
Lee, Richard J.
Joe, Andrew K.
Sosman, Jeffrey A.
Ribas, Antoni
TI Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in
Patients With Metastatic Melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID RAF INHIBITOR RESISTANCE; B-RAF; BRAF; MUTATIONS; CELLS; BRAF(V600E);
SURVIVAL; OVERCOME; PATHWAY; CANCER
AB Purpose
To assess pharmacodynamic effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of the mechanism of action of vemurafenib and ultimately to optimization of metastatic melanoma therapy.
Methods
In the phase II clinical study NP22657 (BRIM-2), patients received oral doses of vemurafenib (960 mg twice per day). Serial biopsies were collected to study changes in mitogen-activated protein kinase (MAPK) signaling, cell-cycle progression, and factors causing intrinsic or acquired resistance by immunohistochemistry, DNA sequencing, or somatic mutation profiling.
Results
Vemurafenib inhibited MAPK signaling and cell-cycle progression. An association between the decrease in extracellular signal-related kinase (ERK) phosphorylation and objective response was observed in paired biopsies (n = 22; P = .013). Low expression of phosphatase and tensin homolog showed a modest association with lower response. Baseline mutations in MEK1(P124) coexisting with BRAF(V600) were noted in seven of 92 samples; their presence did not preclude objective tumor responses. Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions and the appearance of secondary NRAS(Q61) mutations or MEK1(Q56P) or MEK1(E203K) mutations. These two activating MEK1 mutations had not previously been observed in vivo in biopsies of progressive melanoma tumors.
Conclusion
Vemurafenib inhibits tumor proliferation and oncogenic BRAF signaling through the MAPK pathway. Acquired resistance results primarily from MAPK reactivation driven by the appearance of secondary mutations in NRAS and MEK1 in subsets of patients. The data suggest that inhibition downstream of BRAF should help to overcome acquired resistance. (C) 2013 by American Society of Clinical Oncology
C1 [Trunzer, Kerstin; Spleiss, Olivia; Schell-Steven, Annette; Cockey, Louise] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland.
[Pavlick, Anna C.; Ott, Patrick A.] NYU, Med Ctr, New York, NY 10016 USA.
[Schuchter, Lynn; Amaravadi, Ravi K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Moschos, Stergios J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Gonzalez, Rene; Lewis, Karl D.] Univ Colorado, Denver, CO 80202 USA.
[McArthur, Grant A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Hersey, Peter] Univ Newcastle, Newcastle, NSW 2300, Australia.
[Long, Georgina V.] Univ Sydney, Westmead Inst Canc Res, Sydney, NSW 2006, Australia.
[Long, Georgina V.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia.
[Hutson, Thomas E.] Texas Oncol Baylor Sammons Canc Ctr, Dallas, TX USA.
[Kim, Kevin B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Flaherty, Keith T.; Lawrence, Donald] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Weber, Jeffrey S.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Puzanov, Igor; Sosman, Jeffrey A.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
[Lo, Roger S.; Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Gilbert, Houston N.] Genentech Inc, San Francisco, CA 94080 USA.
[Bollag, Gideon] Plexxikon, Berkeley, CA USA.
[Koehler, Astrid] Roche Diagnost, Penzberg, Germany.
[Kockx, Mark] HistoGeneX, Antwerp, Belgium.
[Lee, Richard J.; Joe, Andrew K.] F Hoffmann La Roche & Co Ltd, Nutley, NJ USA.
RP Sosman, JA (reprint author), Vanderbilt Ingram Canc Ctr, 777 Preston Res Bldg, Nashville, TN 37232 USA.
EM jeff.sosman@vanderbilt.edu
FU Genentech; Roche Genentech; F. Hoffmann-La Roche
FX Anna C. Pavlick, Genentech; Rene Gonzalez, Roche Genentech; Keith
Flaherty, Roche Genentech; Kevin B. Kim, Roche Genentech; Jeffrey S.
Weber, Roche Genentech; Georgina V. Long, Roche Genentech; Karl D.
Lewis, Roche Genentech; Houston N. Gilbert, Roche Genentech; Supported
by F. Hoffmann-La Roche.
NR 30
TC 140
Z9 142
U1 1
U2 33
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2013
VL 31
IS 14
BP 1767
EP 1774
DI 10.1200/JCO.2012.44.7888
PG 8
WC Oncology
SC Oncology
GA 141ZW
UT WOS:000318766300015
PM 23569304
ER
PT J
AU Steensma, DP
Sekeres, MA
AF Steensma, David P.
Sekeres, Mikkael A.
TI Decitabine in Older Adults With Acute Myeloid Leukemia: Why Was the
Dream Broken? Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
C1 [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Boston, MA USA.
[Sekeres, Mikkael A.] Cleveland Clin, Leukemia Program, Taussig Canc Inst, Cleveland, OH 44106 USA.
RP Steensma, DP (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
FU NCI NIH HHS [P30 CA016672]
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2013
VL 31
IS 14
BP 1796
EP 1797
DI 10.1200/JCO.2013.48.7140
PG 3
WC Oncology
SC Oncology
GA 141ZW
UT WOS:000318766300021
PM 23802242
ER
PT J
AU Chi, AS
Batchelor, TT
Yang, D
Dias-Santagata, D
Borger, DR
Ellisen, LW
Iafrate, AJ
Louis, DN
AF Chi, Andrew S.
Batchelor, Tracy T.
Yang, Daniel
Dias-Santagata, Dora
Borger, Darrell R.
Ellisen, Leif W.
Iafrate, A. John
Louis, David N.
TI BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely
Infiltrating Gliomas in Adults
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID IDH2 MUTATIONS; GENE; TEMOZOLOMIDE; GLIOBLASTOMA
C1 [Chi, Andrew S.; Batchelor, Tracy T.; Yang, Daniel] Harvard Univ, Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Canc Ctr,Med Sch, Boston, MA 02114 USA.
[Dias-Santagata, Dora; Borger, Darrell R.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Translat Res Lab,Med Sch, Boston, MA 02114 USA.
[Ellisen, Leif W.; Louis, David N.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Iafrate, A. John] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Translat Res Lab,Med Sch, Boston, MA 02114 USA.
[Iafrate, A. John; Louis, David N.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Pathol Serv,Med Sch, Boston, MA 02114 USA.
RP Chi, AS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Canc Ctr,Med Sch, Boston, MA 02114 USA.
NR 14
TC 19
Z9 19
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2013
VL 31
IS 14
BP E233
EP E236
DI 10.1200/JCO.2012.46.0220
PG 4
WC Oncology
SC Oncology
GA 141ZW
UT WOS:000318766300001
PM 23547069
ER
PT J
AU Rajabali, A
Caton, H
AF Rajabali, Alefiyah
Caton, Harmony
TI BOSTON MARATHON BOMBING A tale of two physicians: reflections on the
Boston Marathon bombing
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Editorial Material
C1 [Rajabali, Alefiyah; Caton, Harmony] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Rajabali, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
EM arajabali@partners.org
NR 0
TC 1
Z9 1
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD MAY 10
PY 2013
VL 346
AR f2993
DI 10.1136/bmj.f2993
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 144BV
UT WOS:000318915300006
PM 23667127
ER
PT J
AU Baxt, LA
Garza-Mayers, AC
Goldberg, MB
AF Baxt, Leigh A.
Garza-Mayers, Anna Cristina
Goldberg, Marcia B.
TI Subversion of Host Innate Immune Pathways
SO SCIENCE
LA English
DT Review
ID NF-KAPPA-B; PHOSPHOTHREONINE LYASE ACTIVITY; LEGIONELLA-PNEUMOPHILA;
EFFECTOR FAMILY; AUTOPHAGY; KINASE; GTPASE; INACTIVATION; CONTRIBUTES;
DYSFUNCTION
AB The pathogenesis of infection is a continuously evolving battle between the human host and the infecting microbe. The past decade has brought a burst of insights into the molecular mechanisms of innate immune responses to bacterial pathogens. In parallel, multiple specific mechanisms by which microorganisms subvert these host responses have been uncovered. This Review highlights recently characterized mechanisms by which bacterial pathogens avoid killing by innate host responses, including autophagy pathways and a proinflammatory cytokine transcriptional response, and by the manipulation of vesicular trafficking to avoid the toxicity of lysosomal enzymes.
C1 [Baxt, Leigh A.; Goldberg, Marcia B.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Cambridge, MA 02139 USA.
[Garza-Mayers, Anna Cristina; Goldberg, Marcia B.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
RP Goldberg, MB (reprint author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Cambridge, MA 02139 USA.
EM mgoldberg1@partners.org
FU NIAID NIH HHS [R01 AI081724]; NIGMS NIH HHS [T32 GM007753]
NR 50
TC 66
Z9 67
U1 2
U2 56
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 10
PY 2013
VL 340
IS 6133
BP 697
EP 701
DI 10.1126/science.1235771
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 139XR
UT WOS:000318619000027
PM 23661751
ER
PT J
AU Jardine, J
Julien, JP
Menis, S
Ota, T
Kalyuzhniy, O
McGuire, A
Sok, D
Huang, PS
MacPherson, S
Jones, M
Nieusma, T
Mathison, J
Baker, D
Ward, AB
Burton, DR
Stamatatos, L
Nemazee, D
Wilson, IA
Schief, WR
AF Jardine, Joseph
Julien, Jean-Philippe
Menis, Sergey
Ota, Takayuki
Kalyuzhniy, Oleksandr
McGuire, Andrew
Sok, Devin
Huang, Po-Ssu
MacPherson, Skye
Jones, Meaghan
Nieusma, Travis
Mathison, John
Baker, David
Ward, Andrew B.
Burton, Dennis R.
Stamatatos, Leonidas
Nemazee, David
Wilson, Ian A.
Schief, William R.
TI Rational HIV Immunogen Design to Target Specific Germline B Cell
Receptors
SO SCIENCE
LA English
DT Article
ID STRUCTURAL BASIS; ANTIBODIES; POTENT; BROAD; NEUTRALIZATION; VIRUSES;
ENV
AB Vaccine development to induce broadly neutralizing antibodies (bNAbs) against HIV-1 is a global health priority. Potent VRC01-class bNAbs against the CD4 binding site of HIV gp120 have been isolated from HIV-1-infected individuals; however, such bNAbs have not been induced by vaccination. Wild-type gp120 proteins lack detectable affinity for predicted germline precursors of VRC01-class bNAbs, making them poor immunogens to prime a VRC01-class response. We employed computation-guided, in vitro screening to engineer a germline-targeting gp120 outer domain immunogen that binds to multiple VRC01-class bNAbs and germline precursors, and elucidated germline binding crystallographically. When multimerized on nanoparticles, this immunogen (eOD-GT6) activates germline and mature VRC01-class B cells. Thus, eOD-GT6 nanoparticles have promise as a vaccine prime. In principle, germline-targeting strategies could be applied to other epitopes and pathogens.
C1 [Jardine, Joseph; Menis, Sergey; Ota, Takayuki; Kalyuzhniy, Oleksandr; Sok, Devin; MacPherson, Skye; Jones, Meaghan; Mathison, John; Burton, Dennis R.; Nemazee, David; Schief, William R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[Jardine, Joseph; Julien, Jean-Philippe; Menis, Sergey; Kalyuzhniy, Oleksandr; Sok, Devin; MacPherson, Skye; Jones, Meaghan; Nieusma, Travis; Ward, Andrew B.; Burton, Dennis R.; Wilson, Ian A.; Schief, William R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA.
[Jardine, Joseph; Julien, Jean-Philippe; Menis, Sergey; Kalyuzhniy, Oleksandr; Sok, Devin; MacPherson, Skye; Nieusma, Travis; Ward, Andrew B.; Burton, Dennis R.; Wilson, Ian A.; Schief, William R.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA.
[Jardine, Joseph; Menis, Sergey; Kalyuzhniy, Oleksandr; Huang, Po-Ssu; MacPherson, Skye; Jones, Meaghan; Baker, David; Schief, William R.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
[Julien, Jean-Philippe; Nieusma, Travis; Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
[McGuire, Andrew; Stamatatos, Leonidas] Seattle Biomed Res Inst, Seattle, WA 98109 USA.
[Burton, Dennis R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA 02129 USA.
[Stamatatos, Leonidas] Univ Washington, Dept Global Hlth, Seattle, WA 98109 USA.
[Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Schief, WR (reprint author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
EM schief@scripps.edu
RI Cheng, Yushao/E-6256-2011; Ward, Andrew/F-9203-2014; Baker,
David/K-8941-2012;
OI Ward, Andrew/0000-0001-7153-3769; Baker, David/0000-0001-7896-6217;
Spencer, Skye/0000-0001-9570-9634
FU IAVI Neutralizing Antibody Center, CHAVI-ID [UM1 AI100663]; NIH
[AI84817, AI081625, AI33292]; NIH National Research Service Award
[T32CA080416]; Canadian Institutes of Health Research; Creative and
Novel Ideas in HIV Research grant [P30 AI027767-24]; NIH
Interdisciplinary Training Program in Immunology [5T32AI007606-10];
Ragon Institute; DOE Office of Biological and Environmental Research;
NIH's National Center for Research Resources, Biomedical Technology
Program [P41RR001209]; National Institute of General Medical Sciences
(NIGMS); DOE, Basic Energy Sciences, Office of Science
[DE-AC02-06CH11357]; National Cancer Institute [Y1-CO-1020]; NIGMS
[Y1-GM-1104]
FX We thank J. Mascola and X. Wu for providing sequences of mature PGV19
and PGV20; R. Wyatt for providing the YU2 gp140 trimer; C. Sundling and
G. Karlsson Hedestam for the sequence of the Rhe1 VH gene; A. Bradley,
R. L. Stanfield, and D. C. Diwanji for technical assistance and
insightful discussions; and M. Azoitei, R. Jacak, and D. Kulp for
comments on the manuscript. The data presented in this manuscript are
tabulated in the main paper and the supplementary materials. Coordinates
and structure factors for GL-VRC01 Fab, eOD-GT6, and GL-VRC01+eODGT6
structures have been deposited with the PDB under accession codes 4JPI,
4JPJ, and 4JPK, respectively. The International AIDS Vaccine Initiative
(IAVI) has filed a patent relating to immunogens in this manuscript: PCT
Application PCT/US12/60062, titled "Engineered Outer Domain (EOD) of HIV
GP120 and Mutants Thereof," with inventors W. R. S., J. J., S. M., and
P.-S.H. Materials and information will be provided under a material
transfer agreement. This work was supported by IAVI Neutralizing
Antibody Center, CHAVI-ID (UM1 AI100663); NIH grants AI84817 (I. A. W.),
AI081625 (L. S.), and AI33292 (D. R. B.); NIH National Research Service
Award Training Grant fellowship T32CA080416 (J. J.); Canadian Institutes
of Health Research fellowship (J.-P.J.); Creative and Novel Ideas in HIV
Research grant P30 AI027767-24 (T.O.); NIH Interdisciplinary Training
Program in Immunology 5T32AI007606-10 (D. S.); and the Ragon Institute.
Portions of this research were carried out at the Stanford Synchrotron
Radiation Lightsource (SSRL), a directorate of the SLAC National
Accelerator Laboratory and an Office of Science User Facility operated
for the U.S. Department of Energy (DOE) Office of Science by Stanford
University. The SSRL Structural Molecular Biology Program is supported
by the DOE Office of Biological and Environmental Research; NIH's
National Center for Research Resources, Biomedical Technology Program
(P41RR001209); and the National Institute of General Medical Sciences
(NIGMS). Use of the Advanced Photon Source was supported by the DOE,
Basic Energy Sciences, Office of Science, under contract
DE-AC02-06CH11357. GM/CA CAT has been funded in whole or in part with
federal funds from the National Cancer Institute (grant Y1-CO-1020) and
NIGMS (grant Y1-GM-1104). This is manuscript 23050 from The Scripps
Research Institute.
NR 29
TC 203
Z9 207
U1 12
U2 85
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 10
PY 2013
VL 340
IS 6133
BP 711
EP 716
DI 10.1126/science.1234150
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 139XR
UT WOS:000318619000030
PM 23539181
ER
PT J
AU van Balkom, BWM
de Jong, OG
Smits, M
Brummelman, J
den Ouden, K
de Bree, PM
van Eijndhoven, MAJ
Pegtel, DM
Stoorvogel, W
Wurdinger, T
Verhaar, MC
AF van Balkom, Bas W. M.
de Jong, Olivier G.
Smits, Michiel
Brummelman, Jolanda
den Ouden, Krista
de Bree, Petra M.
van Eijndhoven, Monique A. J.
Pegtel, D. Michiel
Stoorvogel, Willem
Wuerdinger, Thomas
Verhaar, Marianne C.
TI Endothelial cells require miR-214 to secrete exosomes that suppress
senescence and induce angiogenesis in human and mouse endothelial cells
SO BLOOD
LA English
DT Article
ID PROMOTE TUMOR-GROWTH; PROGENITOR CELLS; DIAGNOSTIC BIOMARKERS; OXIDATIVE
STRESS; LUNG-CANCER; IN-VITRO; T-CELLS; MECHANISM; MICRORNA; EXPRESSION
AB Signaling between endothelial cells, endothelial progenitor cells, and stromal cells is crucial for the establishment and maintenance of vascular integrity and involves exosomes, among other signaling pathways. Exosomes are important mediators of intercellular communication in immune signaling, tumor survival, stress responses, and angiogenesis. The ability of exosomes to incorporate and transfer messenger RNAs (mRNAs) encoding for "acquired" proteins or micro RNAs (miRNAs) repressing "resident" mRNA translation suggests that they can influence the physiological behavior of recipient cells. We demonstrate that miR-214, an miRNA that controls endothelial cell function and angiogenesis, plays a dominant role in exosome-mediated signaling between endothelial cells. Endothelial cell-derived exosomes stimulated migration and angiogenesis in recipient cells, whereas exosomes from miR-214-depleted endothelial cells failed to stimulate these processes. Exosomes containing miR-214 repressed the expression of ataxia telangiectasia mutated in recipient cells, thereby preventing senescence and allowing blood vessel formation. Concordantly, specific reduction of miR-214 content in exosome-producing endothelial cells abolishes the angiogenesis stimulatory function of the resulting exosomes. Collectively, our data indicate that endothelial cells release miR-214-containing exosomes to stimulate angiogenesis through the silencing of ataxia telangiectasia mutated in neighboring target cells.
C1 [van Balkom, Bas W. M.; de Jong, Olivier G.; Brummelman, Jolanda; den Ouden, Krista; de Bree, Petra M.; Verhaar, Marianne C.] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, Utrecht, Netherlands.
[Smits, Michiel; Wuerdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Neurooncol Res Grp, Amsterdam, Netherlands.
[van Eijndhoven, Monique A. J.; Pegtel, D. Michiel] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
[Stoorvogel, Willem] Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, Utrecht, Netherlands.
[Wuerdinger, Thomas] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.
[Wuerdinger, Thomas] Harvard Univ, Sch Med, Boston, MA USA.
RP van Balkom, BWM (reprint author), Dept Hypertens & Nephrol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
EM b.w.m.vanbalkom@umcutrecht.nl
RI Pegtel, Dirk/M-8393-2015;
OI Pegtel, Dirk/0000-0002-7357-4406; Verhaar, Marianne/0000-0002-3276-6428
FU Netherlands Organization for Scientific Research (NGI/ZonMW)
[935190280]; UMC Utrecht Focus and Massa [DIGD-DGK-DHL]; Netherlands
Organization for Scientific Research (NWO-VIDI)
FX This work was supported by The Netherlands Organization for Scientific
Research (NGI/ZonMW Horizon project 935190280) (B. W. M. v. B.) and UMC
Utrecht Focus and Massa (grant DIGD-DGK-DHL) (M. C. V.). T. W. and M. C.
V. are both supported by The Netherlands Organization for Scientific
Research (NWO-VIDI).
NR 50
TC 92
Z9 96
U1 4
U2 37
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 9
PY 2013
VL 121
IS 19
BP 3997
EP 4006
DI 10.1182/blood-2013-02-478925
PG 10
WC Hematology
SC Hematology
GA 184EO
UT WOS:000321870900031
PM 23532734
ER
PT J
AU Loffredo, FS
Steinhauser, ML
Jay, SM
Gannon, J
Pancoast, JR
Yalamanchi, P
Sinha, M
Dall'Osso, C
Khong, D
Shadrach, JL
Miller, CM
Singer, BS
Stewart, A
Psychogios, N
Gerszten, RE
Hartigan, AJ
Kim, MJ
Serwold, T
Wagers, AJ
Lee, RT
AF Loffredo, Francesco S.
Steinhauser, Matthew L.
Jay, Steven M.
Gannon, Joseph
Pancoast, James R.
Yalamanchi, Pratyusha
Sinha, Manisha
Dall'Osso, Claudia
Khong, Danika
Shadrach, Jennifer L.
Miller, Christine M.
Singer, Britta S.
Stewart, Alex
Psychogios, Nikolaos
Gerszten, Robert E.
Hartigan, Adam J.
Kim, Mi-Jeong
Serwold, Thomas
Wagers, Amy J.
Lee, Richard T.
TI Growth Differentiation Factor 11 Is a Circulating Factor that Reverses
Age-Related Cardiac Hypertrophy
SO CELL
LA English
DT Article
ID DIASTOLIC HEART-FAILURE; HEMATOPOIETIC STEM-CELLS; SKELETAL-MUSCLE;
BLOOD-PRESSURE; MYOSTATIN; PROTEIN; MICE; REJUVENATION; EPIDEMIOLOGY;
CARDIOLOGY
AB The most common form of heart failure occurs with normal systolic function and often involves cardiac hypertrophy in the elderly. To clarify the biological mechanisms that drive cardiac hypertrophy in aging, we tested the influence of circulating factors using heterochronic parabiosis, a surgical technique in which joining of animals of different ages leads to a shared circulation. After 4 weeks of exposure to the circulation of young mice, cardiac hypertrophy in old mice dramatically regressed, accompanied by reduced cardiomyocyte size and molecular remodeling. Reversal of age-related hypertrophy was not attributable to hemodynamic or behavioral effects of parabiosis, implicating a blood-borne factor. Using modified aptamer-based proteomics, we identified the TGF-beta superfamily member GDF11 as a circulating factor in young mice that declines with age. Treatment of old mice to restore GDF11 to youthful levels recapitulated the effects of parabiosis and reversed age-related hypertrophy, revealing a therapeutic opportunity for cardiac aging.
C1 [Loffredo, Francesco S.; Jay, Steven M.; Sinha, Manisha; Dall'Osso, Claudia; Khong, Danika; Shadrach, Jennifer L.; Miller, Christine M.; Hartigan, Adam J.; Kim, Mi-Jeong; Serwold, Thomas; Wagers, Amy J.; Lee, Richard T.] Brigham & Womens Hosp, Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Loffredo, Francesco S.; Steinhauser, Matthew L.; Jay, Steven M.; Gannon, Joseph; Pancoast, James R.; Yalamanchi, Pratyusha; Lee, Richard T.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Sinha, Manisha; Dall'Osso, Claudia; Khong, Danika; Shadrach, Jennifer L.; Wagers, Amy J.] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
[Sinha, Manisha; Dall'Osso, Claudia; Khong, Danika; Shadrach, Jennifer L.; Wagers, Amy J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Miller, Christine M.; Hartigan, Adam J.; Kim, Mi-Jeong; Serwold, Thomas; Wagers, Amy J.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Singer, Britta S.; Stewart, Alex] SomaLogic Inc, Boulder, CO 80301 USA.
[Psychogios, Nikolaos; Gerszten, Robert E.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Charlestown, MA 02129 USA.
RP Wagers, AJ (reprint author), Brigham & Womens Hosp, Harvard Stem Cell Inst, 75 Francis St, Boston, MA 02115 USA.
EM amy_wagers@harvard.edu; rlee@partners.org
RI Loffredo, Francesco/F-6638-2014;
OI Loffredo, Francesco/0000-0001-5911-780X; Psychogios,
Nikolaos/0000-0002-2747-6012; Jay, Steven/0000-0002-3827-5988
FU NIH [P30DK036836, 1RO1 AG033053, 1DP2 OD004345, 5U01 HL100402, R01
AG032977 1R01 AG040019, KO8 DK090147]; American Heart Association; Glenn
Foundation; Watkins Cardiovascular Leadership Award
FX The authors gratefully acknowledge the HSCI and DRC (NIH Award Number
P30DK036836) Flow Cytometry Cores for excellent cytometry support. This
work was funded in part by grants from the American Heart Association to
F.S.L. (postdoctoral fellowship) and M.L.S. (AHA FTF), Glenn Foundation
and NIH (1RO1 AG033053, 1DP2 OD004345, and 5U01 HL100402) to A.J.W., NIH
(R01 AG032977 1R01 AG040019) to R.T.L., and NIH (KO8 DK090147) to M.L.S.
M.L.S. is supported by the Watkins Cardiovascular Leadership Award.
A.J.W. is an Early Career Scientist of the Howard Hughes Medical
Institute. Content is solely the responsibility of the authors and does
not necessarily represent the official views of the NIH or other funding
agencies. SOMAscan and SOMAmers are trademarks of Soma Logic, Inc.
NR 38
TC 224
Z9 235
U1 13
U2 151
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAY 9
PY 2013
VL 153
IS 4
BP 828
EP 839
DI 10.1016/j.cell.2013.04.015
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 143CN
UT WOS:000318844000012
PM 23663781
ER
PT J
AU Horman, SR
Janas, MM
Litterst, C
Wang, B
MacRae, IJ
Sever, MJ
Morrissey, DV
Graves, P
Luo, B
Umesalma, S
Qi, HH
Miraglia, LJ
Novina, CD
Orth, AP
AF Horman, Shane R.
Janas, Maja M.
Litterst, Claudia
Wang, Bingbing
MacRae, Ian J.
Sever, Mary J.
Morrissey, David V.
Graves, Paul
Luo, Biao
Umesalma, Shaikamjad
Qi, Hank H.
Miraglia, Loren J.
Novina, Carl D.
Orth, Anthony P.
TI Akt-Mediated Phosphorylation of Argonaute 2 Downregulates Cleavage and
Upregulates Translational Repression of MicroRNA Targets
SO MOLECULAR CELL
LA English
DT Article
ID MESSENGER-RNA DEGRADATION; P-BODIES; ENDONUCLEOLYTIC CLEAVAGE; DEPENDENT
LOCALIZATION; QUANTITATIVE-ANALYSIS; CELL-PROLIFERATION; GENE;
EXPRESSION; PROTEINS; DECAY
AB A high-throughput RNA interference (RNAi) screen targeting 542 genes of the human kinome was used to discover regulators of RNAi. Here we report that the proto-oncogene Akt-3/PKB gamma (Akt3) phosphorylates Argonaute 2 (Ago2) at S387, which down-regulates cleavage and upregulates translational repression of endogenous microRNA (miRNA)targeted messenger RNAs (mRNAs). We further demonstrate that Akt3 coimmunoprecipitates with Ago2 and phosphorylation of Ago2 at S387 facilitates its interaction with GW182 and localization to cytoplasmic processing bodies (P bodies), where miRNA-targeted nnRNAs are thought to be stored and degraded. Therefore, Akt3-mediated phosphorylation of Ago2 is a molecular switch between target mRNA cleavage and translational repression activities of Ago2.
C1 [Horman, Shane R.; Litterst, Claudia; Miraglia, Loren J.; Orth, Anthony P.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.
[Janas, Maja M.; Wang, Bingbing; Novina, Carl D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Janas, Maja M.; Wang, Bingbing; Novina, Carl D.] Harvard Univ, Sch Med, Dept Microbiol & lmmunobiol, Boston, MA 02215 USA.
[Janas, Maja M.; Wang, Bingbing; Luo, Biao; Novina, Carl D.] Broad Inst Harvard, Cambridge, MA 02142 USA.
[Janas, Maja M.; Wang, Bingbing; Luo, Biao; Novina, Carl D.] MIT, Cambridge, MA 02142 USA.
[MacRae, Ian J.; Sever, Mary J.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
[Morrissey, David V.] Novartis Inst Biomed Res, Cambridge, MA 02139 USA.
[Graves, Paul] New York Methodist Hosp, Dept Radiat Oncol, Brooklyn, NY 11215 USA.
[Umesalma, Shaikamjad; Qi, Hank H.] Univ Iowa, Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA.
RP Orth, AP (reprint author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.
EM aorth@gnf.org
FU W.M. Keck Foundation
FX We wish to thank Richard G. Brusch for assistance with confocal
microscopy, Angelica Romero for synthesis of viruses, Genevieve Welch
for running the human kinome siRNA screen, Anthony Marelli for
assistance with cloning Ago2 cDNAs, Myleen N. Medina for synthesis of
AKT shRNA plasmids, Daniel E. Mason for performing LC-MS, and Lauren C.
Fox for generation of Figure 6. This work was supported by a
Distinguished Young Scholars Award from the W.M. Keck Foundation to
C.D.N.
NR 47
TC 41
Z9 41
U1 2
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD MAY 9
PY 2013
VL 50
IS 3
BP 356
EP 367
DI 10.1016/j.molce1.2013.03.015
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 147RA
UT WOS:000319183500007
PM 23603119
ER
PT J
AU Sullivan, RJ
Flaherty, K
AF Sullivan, R. J.
Flaherty, K.
TI MAP kinase signaling and inhibition in melanoma
SO ONCOGENE
LA English
DT Review
DE melanoma; targeted therapy; BRAF
ID RANDOMIZED DISCONTINUATION TRIAL; UNTREATED METASTATIC MELANOMA; CHRONIC
MYELOID-LEUKEMIA; B-RAF INHIBITOR; NF-KAPPA-B; BRAF INHIBITION;
WILD-TYPE; MULTIKINASE INHIBITOR; AZD6244 ARRY-142886;
ACQUIRED-RESISTANCE
AB The mitogen-activated protein kinase (MAPK) pathway is critical to oncogenic signaling in the majority of patients with malignant melanoma. Driver mutations in both NRAS and BRAF have important implications for prognosis and treatment. The development of inhibitors to mediators of the MAPK pathway, including those to CRAF, BRAF, and MEK, has led to major advances in the treatment of patients with melanoma. In particular, the selective BRAF inhibitor vemurafenib has been shown to improve overall survival in patients with tumors harboring BRAF mutations. However, the duration of benefit is limited in many patients and highlights the need for understanding the limitations of therapy in order to devise more effective strategies. MEK inhibitors have proven to particularly active in BRAF mutant melanomas also. Emerging knowledge about mechanisms of resistance as well as a more complete understanding of the biology of MAPK pathway signaling provides insight into rational combination regimens and sequences of molecularly targeted therapies.
C1 [Sullivan, R. J.; Flaherty, K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Flaherty, K (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.
EM kflaherty@partners.org
NR 96
TC 55
Z9 58
U1 0
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAY 9
PY 2013
VL 32
IS 19
BP 2373
EP 2379
DI 10.1038/onc.2012.345
PG 7
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 140ZL
UT WOS:000318694900001
PM 22945644
ER
PT J
AU Gabuzda, D
Yankner, BA
AF Gabuzda, Dana
Yankner, Bruce A.
TI PHYSIOLOGY Inflammation links ageing to the brain
SO NATURE
LA English
DT Editorial Material
ID C-ELEGANS; NEURONS; LONGEVITY; PERSPECTIVE
C1 [Gabuzda, Dana] Dana Farber Canc Inst, Dept Neurol, Boston, MA 02115 USA.
[Gabuzda, Dana] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Yankner, Bruce A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Gabuzda, D (reprint author), Dana Farber Canc Inst, Dept Neurol, Boston, MA 02115 USA.
EM dana_gabuzda@dfci.harvard.edu; bruce_yankner@hms.harvard.edu
FU NIA NIH HHS [DP1 AG044161, P01 AG027916]; NIDA NIH HHS [DP1 DA028994];
NIH HHS [DP1 OD006849]; NIMH NIH HHS [R01 MH097659]
NR 15
TC 15
Z9 17
U1 0
U2 31
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 9
PY 2013
VL 497
IS 7448
BP 197
EP 198
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 139CD
UT WOS:000318558200027
PM 23636321
ER
PT J
AU Penson, RT
Goodman, A
Growdon, WB
Borger, DR
Lee, SI
Oliva, E
AF Penson, Richard T.
Goodman, Annekathryn
Growdon, Whitfield B.
Borger, Darrell R.
Lee, Susanna I.
Oliva, Esther
TI Case 14-2013: A 70-Year-Old Woman with Vaginal Bleeding
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; ENDOMETRIAL CANCER; UTERINE
SARCOMAS; UTERUS; CARCINOSARCOMA; TUMORS; PACLITAXEL; CARCINOMAS;
MUTATIONS
C1 [Penson, Richard T.; Borger, Darrell R.] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
[Goodman, Annekathryn; Growdon, Whitfield B.] Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA.
[Lee, Susanna I.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Penson, Richard T.; Borger, Darrell R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Goodman, Annekathryn; Growdon, Whitfield B.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
[Lee, Susanna I.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Oliva, Esther] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Penson, RT (reprint author), Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
FU Apotex; Genentech; AstraZeneca; Lifecore Biomedical; BioMarin
Pharmaceuticals; Clovis Oncology; Seattle Genetics; ImClone Systems;
Endocyte; Eisai Pharmaceuticals; Amgen; Leerink Swann Laboratory; Prous
Science Laboratory; Bio-Reference Laboratory
FX Dr. Penson reports receiving payment from Apotex for providing expert
testimony in a case of Aventis Pharma S. A. v. Apotex Inc.; payment for
serving on scientific advisory boards from Genentech, AstraZeneca,
Lifecore Biomedical, BioMarin Pharmaceuticals, Clovis Oncology, and
Seattle Genetics; and grant support through his institution from ImClone
Systems, Endocyte, AstraZeneca, Eisai Pharmaceuticals, and Amgen. Dr.
Borger reports receiving consulting fees from Leerink Swann, Prous
Science, and Bio-Reference Laboratories. Dr. Oliva reports providing
expert opinions in legal cases on behalf of patients or physicians. No
other potential conflict of interest relevant to this article was
reported.
NR 44
TC 1
Z9 1
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 9
PY 2013
VL 368
IS 19
BP 1827
EP 1835
DI 10.1056/NEJMcpc1209276
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 138WA
UT WOS:000318540000014
PM 23656649
ER
PT J
AU Kawai, T
Sachs, DH
Sykes, M
Cosimi, AB
AF Kawai, Tatsuo
Sachs, David H.
Sykes, Megan
Cosimi, A. Benedict
TI HLA-Mismatched Renal Transplantation without Maintenance
Immunosuppression
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID KIDNEY
C1 [Kawai, Tatsuo; Sachs, David H.; Cosimi, A. Benedict] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sykes, Megan] Columbia Univ, New York, NY USA.
RP Kawai, T (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM tkawai@partners.org
FU NHLBI NIH HHS [P01 HL018646]; NIAID NIH HHS [N01 AI015416, R01 AI037692,
R21 AI037692, U19 AI102405]
NR 5
TC 49
Z9 52
U1 0
U2 7
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 9
PY 2013
VL 368
IS 19
BP 1850
EP 1852
DI 10.1056/NEJMc1213779
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 138WA
UT WOS:000318540000030
PM 23656665
ER
PT J
AU Bogart, LM
Chetty, S
Giddy, J
Sypek, A
Sticklor, L
Walensky, RP
Losina, E
Katz, JN
Bassett, IV
AF Bogart, Laura M.
Chetty, Senica
Giddy, Janet
Sypek, Alexis
Sticklor, Laurel
Walensky, Rochelle P.
Losina, Elena
Katz, Jeffrey N.
Bassett, Ingrid V.
TI Barriers to care among people living with HIV in South Africa: Contrasts
between patient and healthcare provider perspectives
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE linkage to care; HIV; AIDS; qualitative methods; South Africa; stigma
ID ANTIRETROVIRAL THERAPY; INTERVENTION; ADHERENCE; DISEASE; ADULTS; CHINA
AB We collected qualitative data (semi-structured interviews with 11 healthcare providers and 10 patients; 8 focus groups with 41 patients) to identify barriers to linkage to care among people living with HIV in South Africa who were not yet taking antiretroviral treatment. Patients and providers identified HIV stigma as a sizable barrier. Patients felt that stigma-related issues were largely beyond their control, fearing discrimination if they disclosed to employers or were seen visiting clinics in their community. Providers believed that patients should take responsibility for overcoming internal stigma and disclosing serostatus. Patients had considerable concerns about inconvenient clinic hours, long queues, difficulty in appointment scheduling, and disrespect from staff. Providers seemed to minimize the effects of such barriers and not recognize the extent of patient dissatisfaction. Better communication and understanding between patients and providers are needed to facilitate greater patient satisfaction and retention in HIV care.
C1 [Bogart, Laura M.; Sticklor, Laurel] Boston Childrens Hosp, Dept Med, Div Gen Pediat, Boston, MA USA.
[Bogart, Laura M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Chetty, Senica; Giddy, Janet] McCord Hosp, Durban, South Africa.
[Sypek, Alexis; Walensky, Rochelle P.; Bassett, Ingrid V.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Walensky, Rochelle P.; Bassett, Ingrid V.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Walensky, Rochelle P.; Losina, Elena; Bassett, Ingrid V.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Walensky, Rochelle P.] Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA.
[Losina, Elena; Katz, Jeffrey N.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Katz, Jeffrey N.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Katz, Jeffrey N.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Katz, Jeffrey N.] Harvard Univ, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA.
RP Bogart, LM (reprint author), Boston Childrens Hosp, Dept Med, Div Gen Pediat, Boston, MA USA.
EM laura.bogart@childrens.harvard.edu
OI Walensky, Rochelle P./0000-0002-8795-379X
FU NCRR NIH HHS [UL1 RR025758, UL1 RR 025758]; NIAID NIH HHS [P30
AI060354]; NIAMS NIH HHS [K24 AR057827, K24AR057827]; NIMH NIH HHS [R01
MH090326, R01 MH073445]
NR 25
TC 30
Z9 30
U1 0
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD MAY 8
PY 2013
VL 25
IS 7
BP 843
EP 853
DI 10.1080/09540121.2012.729808
PG 11
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychology, Multidisciplinary; Respiratory System; Social Sciences,
Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 166RI
UT WOS:000320574400007
PM 23061894
ER
PT J
AU Bhargava, R
Janssen, W
Altmann, C
Andres-Hernando, A
Okamura, K
Vandivier, RW
Ahuja, N
Faubel, S
AF Bhargava, Rhea
Janssen, William
Altmann, Christopher
Andres-Hernando, Ana
Okamura, Kayo
Vandivier, R. William
Ahuja, Nilesh
Faubel, Sarah
TI Intratracheal IL-6 Protects against Lung Inflammation in Direct, but Not
Indirect, Causes of Acute Lung Injury in Mice
SO PLOS ONE
LA English
DT Article
ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY;
CRITICALLY-ILL PATIENTS; RESPIRATORY-DISTRESS-SYNDROME;
BILATERAL-NEPHRECTOMY; ALVEOLAR MACROPHAGES; MECHANICAL VENTILATION;
PERSISTENT ELEVATION; CARDIAC-SURGERY
AB Introduction: Serum and bronchoalveolar fluid IL-6 are increased in patients with acute respiratory distress syndrome (ARDS) and predict prolonged mechanical ventilation and poor outcomes, although the role of intra-alveolar IL-6 in indirect lung injury is unknown. We investigated the role of endogenous and exogenous intra-alveolar IL-6 in AKI-mediated lung injury (indirect lung injury), intraperitoneal (IP) endotoxin administration (indirect lung injury) and, for comparison, intratracheal (IT) endotoxin administration (direct lung injury) with the hypothesis that IL-6 would exert a pro-inflammatory effect in these causes of acute lung inflammation.
Methods: Bronchoalveolar cytokines (IL-6, CXCL1, TNF-alpha, IL-1 beta, and IL-10), BAL fluid neutrophils, lung inflammation (lung cytokines, MPO activity [ a biochemical marker of neutrophil infiltration]), and serum cytokines were determined in adult male C57Bl/ 6 mice with no intervention or 4 hours after ischemic AKI (22 minutes of renal pedicle clamping), IP endotoxin (10 mu g), or IT endotoxin (80 mu g) with and without intratracheal (IT) IL-6 (25 ng or 200 ng) treatment.
Results: Lung inflammation was similar after AKI, IP endotoxin, and IT endotoxin. BAL fluid IL-6 was markedly increased after IT endotoxin, and not increased after AKI or IP endotoxin. Unexpectedly, IT IL-6 exerted an anti-inflammatory effect in healthy mice characterized by reduced BAL fluid cytokines. IT IL-6 also exerted an anti-inflammatory effect in IT endotoxin characterized by reduced BAL fluid cytokines and lung inflammation; IT IL-6 had no effect on lung inflammation in AKI or IP endotoxin.
Conclusion: IL-6 exerts an anti-inflammatory effect in direct lung injury from IT endotoxin, yet has no role in the pathogenesis or treatment of indirect lung injury from AKI or IP endotoxin. Since intra-alveolar inflammation is important in the pathogenesis of direct, but not indirect, causes of lung inflammation, IT anti-inflammatory treatments may have a role in direct, but not indirect, causes of ARDS.
C1 [Bhargava, Rhea; Altmann, Christopher; Andres-Hernando, Ana; Okamura, Kayo; Ahuja, Nilesh] Univ Colorado Denver, Div Renal Dis & Hypertens, Dept Med, Aurora, CO USA.
[Janssen, William] Natl Jewish Hlth, Dept Med, Div Pulm Med, Denver, CO USA.
[Vandivier, R. William] Univ Colorado Denver, Div Pulm Med, Dept Med, Aurora, CO USA.
[Faubel, Sarah] Univ Colorado Denver, Div Renal Dis & Hypertens, Dept Med, Aurora, CO USA.
[Faubel, Sarah] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
RP Faubel, S (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, Dept Med, Aurora, CO USA.
EM Sarah.Faubel@ucdenver.edu
FU United States National Institutes of Health (NIH); NHLBI [R01 HL095363];
NIH [HL109517]; AHA Postdoctoral Fellowship
FX This work was supported by United States National Institutes of Health
(NIH) funding from NHLBI: R01 HL095363 to S.F., NIH HL109517, and AHA
Postdoctoral Fellowship to A.A.-H. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 48
TC 15
Z9 19
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2013
VL 8
IS 5
AR e61405
DI 10.1371/journal.pone.0061405
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145YI
UT WOS:000319055600011
PM 23667439
ER
PT J
AU Lewis, KB
Hughes, RJ
Epstein, MS
Josephson, NC
Kempton, CL
Kessler, CM
Key, NS
Howard, TE
Kruse-Jarres, R
Lusher, JM
Walsh, CE
Watts, RG
Ettinger, RA
Pratt, KP
AF Lewis, Kenneth B.
Hughes, Richard J.
Epstein, Melinda S.
Josephson, Neil C.
Kempton, Christine L.
Kessler, Craig M.
Key, Nigel S.
Howard, Tom E.
Kruse-Jarres, Rebecca
Lusher, Jeanne M.
Walsh, Christopher E.
Watts, Raymond G.
Ettinger, Ruth A.
Pratt, Kathleen P.
CA PATH Personalized Alternative
TI Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII
Characterized by Surface Plasmon Resonance
SO PLOS ONE
LA English
DT Article
ID FACTOR-VIII ANTIBODIES; HUMAN/PORCINE FACTOR-VIII;
VON-WILLEBRAND-FACTOR; FAB-ARM EXCHANGE; HEMOPHILIA-A; BETHESDA ASSAY;
IGG4 ANTIBODIES; B-CELL; MONOCLONAL-ANTIBODIES; INHIBITOR ANTIBODIES
AB Evidence of antibody isotype/ subtype switching may provide prognostic value regarding the state of immune responses to therapeutic proteins, e.g. anti-factor VIII (FVIII) antibodies that develop in many hemophilia A patients, clinically termed "inhibitors''. A sensitive, high-information-content surface plasmon resonance (SPR) assay has been developed to quantify IgG subtype distributions and the domain specificity of anti-drug antibodies. Plasma samples from 22 subjects with an alloor auto-immune reaction to FVIII were analyzed. Pre-analytical treatment protocols were developed to minimize nonspecific binding and specific matrix interference due to von Willebrand factor-FVIII interactions. The dynamic range for IgG quantification was 0.2-5 mu g/ml (similar to 1-33 nM), allowing characterization of inhibitor-positive samples. Subtype-specific monoclonal antibodies were used to quantify the IgG subtype distribution of FVIII-specific antibodies. Most samples obtained from multiply-infused inhibitor subjects contained IgG(4) antibodies. Several distinct phenotypes were assigned based on the IgG subtype distribution: IgG(1), IgG(4), IgG(1) & IgG(4), and IgG(1), IgG(2) & IgG(4). An IgG(1)-only response was found in mild/moderate HA subjects during early FVIII infusions, and analysis of serial samples followed antibody class switching as several subjects' immune responses developed. Competition studies utilizing a recombinant FVIII-C2 domain indicated 40-80% of FVIII-specific antibodies in most samples were directed against this domain.
C1 [Lewis, Kenneth B.; Josephson, Neil C.; Ettinger, Ruth A.; Pratt, Kathleen P.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA.
[Hughes, Richard J.; Epstein, Melinda S.; Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Josephson, Neil C.; Pratt, Kathleen P.] Univ Washington, Div Hematol, Seattle, WA 98195 USA.
[Kempton, Christine L.] Emory Univ, Atlanta, GA 30322 USA.
[Kessler, Craig M.] Georgetown Univ, Washington, DC USA.
[Key, Nigel S.] Univ N Carolina, Chapel Hill, NC USA.
[Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Howard, Tom E.] USC, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA.
[Kruse-Jarres, Rebecca] Tulane Univ, New Orleans, LA 70118 USA.
[Lusher, Jeanne M.] Wayne State Univ, Detroit, MI USA.
[Walsh, Christopher E.] Mt Sinai Sch Med, New York, NY USA.
[Watts, Raymond G.] Univ Alabama Birmingham, Birmingham, AL USA.
RP Pratt, KP (reprint author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
EM KathleenP@psbc.org
FU NHLBI [1RC2 HL101851]; Bayer HealthCare LLC
FX Major support for this work was from NHLBI 1RC2 HL101851: "Mechanisms of
Race-Based Differences in Factor VIII Immunogenicity in Hemophilia A"
(PIs TE Howard and KP Pratt). Minor support for this work was from: 1.
Unrestricted research support was received under a CSL Behring
Foundation Hemophilia grant: "Do Non-Synonymous Single Nucleotide
Polymorphisms in Factor VIII Lead to T-Cell Responses and Subsequent
Inhibitor Development in Black Hemophilia A Patients?" (PI: KP Pratt),
funder: CSL Behring Foundation for Research and Advancement of Patient
Health, http://www.cslbehringfoundation.com/.2. Unrestricted research
support was received from a Bayer Healthcare LLC grant: "Repository for
Human HLA-restricted T-Cell Clones" (PI: KP Pratt), funder: Bayer
HealthCare LLC, http://grants-contributions.bayerweb.com/en/home/index.
php, 800 Dwight Way, Berkeley, California 94710. These funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.; The authors have the following
interests. Dr's. Pratt and Lewis are inventors on a patent describing
the SPR methodology described in this study. Dr. Pratt received travel
support from GE Health Sciences to present preliminary SPR studies at
the 2011 DiPia meeting in Boston, Massachusetts. This study was partly
funded by Bayer HealthCare LLC. The authors thank Dr. Jason Schuman (GE
Health Sciences) for technical advice and Bill Church (Green Mountain
Antibodies, Burlington, Vermont) for donations of monoclonal antibodies.
Drs. Lewis and Pratt are inventors on the following patent:
International Patent Application No. PCT/US2012/61/553, 660, Title:
Antibody Response Phenotyping, Filed: October 31, 2012, Inventors:
Kathleen Pratt, PhD; Kenneth Lewis, PhD. There are no further patents,
products in development or marketed products to declare. This does not
alter the authors' adherence to all the PLOS ONE policies on sharing
data and materials, as detailed online in the guide for authors.
NR 43
TC 6
Z9 6
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2013
VL 8
IS 5
AR e61120
DI 10.1371/journal.pone.0061120
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145YI
UT WOS:000319055600009
PM 23667433
ER
PT J
AU Lobsien, D
Dreyer, AY
Stroh, A
Boltze, J
Hoffmann, KT
AF Lobsien, Donald
Dreyer, Antje Y.
Stroh, Albrecht
Boltze, Johannes
Hoffmann, Karl-Titus
TI Imaging of VSOP Labeled Stem Cells in Agarose Phantoms with
Susceptibility Weighted and T2*Weighted MR Imaging
SO PLOS ONE
LA English
DT Article
ID IRON-OXIDE PARTICLES; IN-VIVO; CLINICAL-APPLICATIONS; ISCHEMIC-STROKE;
BRAIN; TRACKING; NANOPARTICLES; RAT; GUIDELINES; MANAGEMENT
AB Objective: This study aimed to evaluate the detectability of stem cells labeled with very small iron oxide particles (VSOP) at 3T with susceptibility weighted (SWI) and T2* weighted imaging as a methodological basis for subsequent examinations in a large animal stroke model (sheep).
Materials and Methods: We examined ovine mesenchymal stem cells labeled with VSOP in agarose layer phantoms. The experiments were performed in 2 different groups, with quantities of 0-100,000 labeled cells per layer. 15 different SWI-and T2*-weighted sequences and 3 RF coils were used. All measurements were carried out on a clinical 3T MRI. Images of Group A were analyzed by four radiologists blinded for the number of cells, and rated for detectability according to a four-step scale. Images of Group B were subject to a ROI-based analysis of signal intensities. Signal deviations of more than the 0.95 confidence interval in cell containing layers as compared to the mean of the signal intensity of non cell bearing layers were considered significant.
Results: Group A: 500 or more labeled cells were judged as confidently visible when examined with a SWI-sequence with 0.15 mm slice thickness. Group B: 500 or more labeled cells showed a significant signal reduction in SWI sequences with a slice thickness of 0.25 mm. Slice thickness and cell number per layer had a significant influence on the amount of detected signal reduction.
Conclusion: 500 VSOP labeled stem cells could be detected with SWI imaging at 3 Tesla using an experimental design suitable for large animal models.
C1 [Lobsien, Donald; Hoffmann, Karl-Titus] Univ Hosp Leipzig, Dept Neuroradiol, Leipzig, Germany.
[Dreyer, Antje Y.; Boltze, Johannes] Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany.
[Dreyer, Antje Y.; Boltze, Johannes] Univ Leipzig, Translat Ctr Regenerat Med, D-04109 Leipzig, Germany.
[Stroh, Albrecht] Johannes Gutenberg Univ Mainz, Res Grp Mol Imaging & Optogenet, Inst Microscop Anat & Neurobiol, Focus Program Translat Neurosci, D-55122 Mainz, Germany.
[Boltze, Johannes] Massachusetts Gen Hosp, Charlestown, MA USA.
[Boltze, Johannes] Harvard Univ, Sch Med, Ctr Neurosci, Charlestown, MA USA.
RP Lobsien, D (reprint author), Univ Hosp Leipzig, Dept Neuroradiol, Leipzig, Germany.
EM donald.lobsien@medizin.uni-leipzig.de
NR 40
TC 3
Z9 3
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2013
VL 8
IS 5
AR e62644
DI 10.1371/journal.pone.0062644
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145YI
UT WOS:000319055600037
PM 23667503
ER
PT J
AU Nizar, K
Uhlirova, H
Tian, PF
Saisan, PA
Cheng, Q
Reznichenko, L
Weldy, KL
Steed, TC
Sridhar, VB
MacDonald, CL
Cui, JX
Gratiy, SL
Sakadzic, S
Boas, DA
Beka, TI
Einevoll, GT
Chen, J
Masliah, E
Dale, AM
Silva, GA
Devor, A
AF Nizar, Krystal
Uhlirova, Hana
Tian, Peifang
Saisan, Payam A.
Cheng, Qun
Reznichenko, Lidia
Weldy, Kimberly L.
Steed, Tyler C.
Sridhar, Vishnu B.
MacDonald, Christopher L.
Cui, Jianxia
Gratiy, Sergey L.
Sakadzic, Sava
Boas, David A.
Beka, Thomas I.
Einevoll, Gaute T.
Chen, Ju
Masliah, Eliezer
Dale, Anders M.
Silva, Gabriel A.
Devor, Anna
TI In vivo Stimulus-Induced Vasodilation Occurs without IP3 Receptor
Activation and May Precede Astrocytic Calcium Increase
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID TRANSGENIC MOUSE MODEL; CEREBRAL-BLOOD-FLOW; HEMODYNAMIC-RESPONSE;
NEURONAL-ACTIVITY; NEURAL ACTIVITY; HIPPOCAMPAL ASTROCYTES;
SOMATOSENSORY CORTEX; NETWORK ACTIVITY; RAT NEOCORTEX; BRAIN
AB Calcium-dependent release of vasoactive gliotransmitters is widely assumed to trigger vasodilation associated with rapid increases in neuronal activity. Inconsistent with this hypothesis, intact stimulus-induced vasodilation was observed in inositol 1,4,5-triphosphate (IP3) type-2 receptor (R2) knock-out (KO) mice, in which the primary mechanism of astrocytic calcium increase-the release of calcium from intracellular stores following activation of an IP3-dependent pathway-is lacking. Further, our results in wild-type (WT) mice indicate that in vivo onset of astrocytic calcium increase in response to sensory stimulus could be considerably delayed relative to the simultaneously measured onset of arteriolar dilation. Delayed calcium increases in WT mice were observed in both astrocytic cell bodies and perivascular endfeet. Thus, astrocytes may not play a role in the initiation of blood flow response, at least not via calcium-dependent mechanisms. Moreover, an increase in astrocytic intracellular calcium was not required for normal vasodilation in the IP3R2-KO animals.
C1 [Nizar, Krystal; Steed, Tyler C.] Univ Calif San Diego, Grad Program Neurosci, La Jolla, CA 92093 USA.
[Uhlirova, Hana; Gratiy, Sergey L.; Dale, Anders M.; Devor, Anna] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.
[Tian, Peifang; Saisan, Payam A.; Cheng, Qun; Reznichenko, Lidia; Weldy, Kimberly L.; Beka, Thomas I.; Masliah, Eliezer; Dale, Anders M.; Devor, Anna] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Sridhar, Vishnu B.; MacDonald, Christopher L.; Cui, Jianxia; Silva, Gabriel A.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
[Chen, Ju] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Silva, Gabriel A.] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
[Tian, Peifang] John Carroll Univ, Dept Phys, University Hts, OH 44118 USA.
[Sakadzic, Sava; Boas, David A.; Devor, Anna] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Beka, Thomas I.; Einevoll, Gaute T.] Norwegian Univ Life Sci, Dept Math Sci & Technol, CIGENE, N-1432 As, Norway.
RP Devor, A (reprint author), 9500 Gilman Dr,MC 0624, La Jolla, CA 92093 USA.
EM adevor@ucsd.edu
RI Uhlirova, Hana/E-2702-2012; Chen, Ju/E-5579-2011
FU National Institute of Neurological Disorders and Stroke [NS051188,
NS057198, NS057476, NS055104, NS054736]; National Institute of
Biomedical Imaging and Bioengineering [EB00790, EB009118]; American
Heart Association [11SDG7600037]; European Regional Development Fund
[Centre for Integrative Genetics] [CZ.1.05/1.1.00/02.0068]; John Carroll
University (JCU) Monville's fund grant; JCU Summer Research Fellowship
FX We gratefully acknowledge support from the National Institute of
Neurological Disorders and Stroke (Grants NS051188 and NS057198 to A.D.,
NS057476 and NS055104 to D.A.B., and NS054736 to G.A.S.), National
Institute of Biomedical Imaging and Bioengineering (Grant EB00790 to
A.M.D. and Grant EB009118 to A.D.), American Heart Association (Grant
11SDG7600037 to S.S.), European Regional Development Fund [Centre for
Integrative Genetics (CZ.1.05/1.1.00/02.0068) to H.U.], John Carroll
University (JCU) Monville's fund grant, and JCU Summer Research
Fellowship to P.T.
NR 72
TC 73
Z9 74
U1 1
U2 17
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 8
PY 2013
VL 33
IS 19
BP 8411
EP 8422
DI 10.1523/JNEUROSCI.3285-12.2013
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 142CZ
UT WOS:000318775200029
PM 23658179
ER
PT J
AU Hasegawa, K
Hiraide, A
Brown, DFM
AF Hasegawa, Kohei
Hiraide, Atsushi
Brown, David F. M.
TI Prehospital Airway Management for Out-of-Hospital Cardiac Arrest Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID ENDOTRACHEAL INTUBATION
C1 [Hasegawa, Kohei; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Hiraide, Atsushi] Kinki Univ, Fac Med, Dept Acute Med, Osaka, Japan.
RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
EM khasegawa1@partners.org
NR 4
TC 2
Z9 2
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 8
PY 2013
VL 309
IS 18
BP 1889
EP 1890
DI 10.1001/jama.2013.3107
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 138AZ
UT WOS:000318481900016
PM 23652515
ER
PT J
AU Ecker, J
AF Ecker, Jeffrey
TI Elective Cesarean Delivery on Maternal Request
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PLANNED VAGINAL BIRTH; TERM BREECH TRIAL;
PREGNANT-WOMEN; SECTION; OUTCOMES; MODE; STILLBIRTH; CLINICIAN;
MORBIDITY
AB Importance Some pregnant women prefer cesarean delivery and request it without maternal or fetal indication rather than proceeding with a plan for vaginal delivery.
Objective To review approaches for counseling women who ask for cesarean delivery without maternal or fetal indication (known as cesarean delivery on maternal request [CDMR]).
Evidence Review An Agency for Healthcare Research and Quality evidence report of studies published after 1990, a 2006 National Institutes of Health state-of-the-science conference report, and published literature were examined.
Findings The prevalence of CDMR in the United States is not precisely known but probably occurs in less than 3% of all deliveries. Most practicing obstetricians have received requests for CDMR from patients. Compared with a plan for vaginal delivery, CDMR may be associated with lower rates of hemorrhage, maternal incontinence, and rare but serious neonatal outcomes. However, CDMR is associated with a higher risk of neonatal respiratory morbidity. Adverse consequences of CDMR may be manifested only in future pregnancies. Repeated cesarean deliveries have higher rates of operative complications, placental abnormalities such as placenta previa and accreta, and consequent gravid hysterectomy.
Conclusions and Relevance There is no immediate expectation for CDMR to reduce the health risks of mothers or infants. Accordingly, counseling and decisions regarding CDMR should be made after considering a woman's full reproductive plans. JAMA. 2013;309(18):1930-1936 www.jama.com
C1 [Ecker, Jeffrey] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Ecker, Jeffrey] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
RP Ecker, J (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Founders 420A, Boston, MA 02114 USA.
EM jecker@partners.org
NR 35
TC 24
Z9 25
U1 2
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 8
PY 2013
VL 309
IS 18
BP 1930
EP 1936
DI 10.1001/jama.2013.3982
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 138AZ
UT WOS:000318481900028
PM 23652524
ER
PT J
AU Raitt, MH
AF Raitt, Merritt H.
TI Reducing Shocks and Improving Outcomes With Implantable Defibrillators
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID CARDIOVERTER-DEFIBRILLATORS; HEART-FAILURE; THERAPY; MORTALITY
C1 [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR USA.
[Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
RP Raitt, MH (reprint author), Portland VA Med Ctr, P-3 CARD,3710 SW US Vet Rd, Portland, OR 97239 USA.
EM merritt.raitt@va.gov
OI Raitt, Merritt/0000-0001-5638-7732
NR 13
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 8
PY 2013
VL 309
IS 18
BP 1937
EP 1938
DI 10.1001/jama.2013.5561
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 138AZ
UT WOS:000318481900029
PM 23652525
ER
PT J
AU Tchkonia, T
Thomou, T
Zhu, Y
Karagiannides, I
Pothoulakis, C
Jensen, MD
Kirkland, JL
AF Tchkonia, Tamara
Thomou, Thomas
Zhu, Yi
Karagiannides, Iordanes
Pothoulakis, Charalabos
Jensen, Michael D.
Kirkland, James L.
TI Mechanisms and Metabolic Implications of Regional Differences among Fat
Depots
SO CELL METABOLISM
LA English
DT Review
ID HUMAN ADIPOSE-TISSUE; INDUCED INSULIN-RESISTANCE; ACTIVATED
RECEPTOR-GAMMA; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; BODY-FAT;
CELLULAR SENESCENCE; HUMAN PREADIPOCYTES; ACID-METABOLISM; VISCERAL FAT
AB Fat distribution is closely linked to metabolic disease risk. Distribution varies with sex, genetic background, disease state, certain drugs and hormones, development, and aging. Preadipocyte replication and differentiation, developmental gene expression, susceptibility to apoptosis and cellular senescence, vascularity, inflammatory cell infiltration, and adipokine secretion vary among depots, as do fatty-acid handling and mechanisms of enlargement with positive-energy and loss with negative-energy balance. How interdepot differences in these molecular, cellular, and pathophysiological properties are related is incompletely understood. Whether fat redistribution causes metabolic disease or whether it is a marker of underlying processes that are primarily responsible is an open question.
C1 [Tchkonia, Tamara; Zhu, Yi; Kirkland, James L.] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA.
[Jensen, Michael D.] Mayo Clin, Endocrine Res Unit, Rochester, MN 55905 USA.
[Thomou, Thomas] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Karagiannides, Iordanes; Pothoulakis, Charalabos] Univ Calif Los Angeles, Inflammatory Bowel Dis Ctr, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA.
RP Jensen, MD (reprint author), Mayo Clin, Endocrine Res Unit, Rochester, MN 55905 USA.
EM jensen@mayo.edu; kirkland.james@mayo.edu
RI Kirkland, James/F-9159-2016
FU NIH [AG41122, AG13925, AG31736, DK50456, DK40484, DK45343, DK47343,
DK60729, DK86150]; Noaber Medical Foundation; Ellison Medical
Foundation; Broad Medical Foundation; Crohn's and Colitis Foundation of
America
FX The authors are grateful for the administrative support of L. Wadum and
J. Armstrong. This work was funded by NIH grants AG41122 (J. K.),
AG13925 (J. K.), AG31736 (J. K.), DK50456 (J. K. and M. D. J.), DK40484
(M. D. J.), DK45343 (M. D. J.), DK47343 (C. P.), DK60729 (C. P.), and
DK86150 (C. P.); the Noaber, Ellison, and Broad Medical Foundations; and
the Crohn's and Colitis Foundation of America.
NR 132
TC 110
Z9 114
U1 3
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD MAY 7
PY 2013
VL 17
IS 5
BP 644
EP 656
DI 10.1016/j.cmet.2013.03.008
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 242TU
UT WOS:000326266000007
PM 23583168
ER
PT J
AU Xie, H
Hou, S
Jiang, J
Sekutowicz, M
Kelly, J
Bacskai, BJ
AF Xie, Hong
Hou, Steven
Jiang, Jun
Sekutowicz, Maria
Kelly, Jonathan
Bacskai, Brian J.
TI Rapid cell death is preceded by amyloid plaque-mediated oxidative stress
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE in vivo imaging; reduction-oxidation sensitive GFP
ID GREEN FLUORESCENT PROTEIN; ANTIOXIDANT ENZYME-ACTIVITY; MILD COGNITIVE
IMPAIRMENT; ALZHEIMERS-DISEASE; IN-VIVO; TRANSGENIC MICE; MULTIPHOTON
MICROSCOPY; INCREASED PEROXIDATION; MITOCHONDRIAL-DNA; BETA-PLAQUES
AB Neuronal loss is the ultimate outcome in a variety of neurodegenerative diseases and central nerve system disorders. Understanding the sequelae of events that leads to cell death would provide insight into neuroprotective approaches. We imaged neurons in the living brain of a mouse model of Alzheimer's disease that overexpresses mutant human amyloid precursor protein and presenilin 1 and followed the death of individual neurons in real time. This mouse model exhibited limited neurodegeneration and atrophy, but we were able to identify a small fraction of vulnerable cells that would not have been detectable by using standard approaches. By exploiting a genetically encoded reporter of oxidative stress, we identified susceptible neurons by their increased redox potential. The oxidative stress was most dramatic in neurites near plaques, propagated to cell bodies, and preceded activation of caspases that led to cell death within 24 h. Thus, local oxidative stress surrounding plaques contributes to long-range toxicity and selective neuronal death in Alzheimer's disease.
C1 [Xie, Hong; Hou, Steven; Sekutowicz, Maria; Kelly, Jonathan; Bacskai, Brian J.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.
[Xie, Hong; Jiang, Jun] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China.
RP Bacskai, BJ (reprint author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.
EM bbacskai@partners.org
FU National Institutes of Health [AG024688, EB000768, NCSF31100776]
FX We thank James Remington (University of Oregon) for providing the roGFP
construct (proGFP-N1). This study was supported by National Institutes
of Health Grants AG024688 (to B.J.B.), EB000768 (to B.J.B.), and
NCSF31100776 (to H.X.).
NR 29
TC 37
Z9 37
U1 2
U2 30
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 7
PY 2013
VL 110
IS 19
BP 7904
EP 7909
DI 10.1073/pnas.1217938110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149NP
UT WOS:000319327700082
PM 23610434
ER
PT J
AU Desai, SP
Bhatia, SN
Toner, M
Irimia, D
AF Desai, Salil P.
Bhatia, Sangeeta N.
Toner, Mehmet
Irimia, Daniel
TI Mitochondrial Localization and the Persistent Migration of Epithelial
Cancer cells
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID AXONAL-TRANSPORT; BREAST-CANCER; METASTASIS; INVASION; TUMORS;
HETEROGENEITY; REORIENTATION; MICROTUBULES; TRAFFICKING; MACROPHAGES
AB During cancer cell invasion, faster moving cancer cells play a dominant role by invading further and metastasizing earlier. Despite the importance of these outlier cells, the source of heterogeneity in their migratory behavior remains poorly understood. Here, we show that anterior localization of mitochondria, in between the nucleus and the leading edge of migrating epithelial cancer cells, correlates with faster migration velocities and increased directional persistence. The asymmetry of mitochondrial localization along the axis of migration is absent during spontaneous cell migration on two-dimensional surfaces and only occurs in the presence of chemical attractant cues or in conditions of mechanical confinement. Moreover, perturbing the asymmetric distribution of mitochondria within migrating cells by interfering with mitochondria! fusion (opa-1) or fission (drp-1) proteins, significantly reduces the number of cells with anterior localization of mitochondria and significantly decreases the velocity and directional persistence of the fastest moving cells. We also observed similar changes after perturbing the linkage between mitochondria and microtubules by the knockdown of mitochondrial rhoGTPase-1 (miro-1). Taken together, the changes in migration velocity and directional persistence in cells with anterior-localized mitochondria could account for an order of magnitude differences in invasive abilities between cells from otherwise homogenous cell populations.
C1 [Desai, Salil P.; Bhatia, Sangeeta N.; Toner, Mehmet] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Desai, Salil P.; Toner, Mehmet; Irimia, Daniel] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Bhatia, Sangeeta N.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Irimia, D (reprint author), Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM dirimia@hms.harvard.edu
OI Irimia, Daniel/0000-0001-7347-2082
FU ECOR MGH-MIT Fellowship in Translational Medicine; National Institutes
of Health [CA135601, GM092840, EB002503]
FX This work was supported by the ECOR MGH-MIT Fellowship in Translational
Medicine and National Institutes of Health grants CA135601, GM092840,
and EB002503. S.N.B. is a Howard Hughes Investigator.
NR 36
TC 40
Z9 41
U1 5
U2 35
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD MAY 7
PY 2013
VL 104
IS 9
BP 2077
EP 2088
DI 10.1016/j.bpj.2013.03.025
PG 12
WC Biophysics
SC Biophysics
GA 141VJ
UT WOS:000318754300029
PM 23663851
ER
PT J
AU Mayr, M
Watkins, MT
AF Mayr, Manuel
Watkins, Michael T.
TI Endothelial Seeding for Abdominal Aortic Aneurysms Lessons Learned From
the Past and Present
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; aortic aneurysm, abdominal; endothelium; extracellular
matrix; growth factor; inflammation
ID FIBROBLAST-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; ARTERIAL PROSTHESES;
PROTEOMIC ANALYSIS; PROGENITOR-CELL; GRAFTS; PROGRESSION; SURFACES;
HEPARIN; MARKERS
C1 [Mayr, Manuel] Kings Coll London, British Heart Fdn Ctr, Div Cardiovasc, London WC2R 2LS, England.
[Watkins, Michael T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc & Endovasc Surg, Boston, MA USA.
RP Watkins, MT (reprint author), Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,Ste 440, Boston, MA 02114 USA.
EM mtwatkins@partners.org
OI Mayr, Manuel/0000-0002-0597-829X
FU British Heart Foundation [FS/13/2/29892, PG/10/61/28498]
NR 29
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 7
PY 2013
VL 127
IS 18
BP 1847
EP 1849
DI 10.1161/CIRCULATIONAHA.113.002573
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 140VU
UT WOS:000318685200007
PM 23572501
ER
PT J
AU Mega, JL
Braunwald, E
Murphy, SA
Plotnikov, AN
Burton, P
Kiss, RG
Parkhomenko, A
Tendera, M
Widimsky, P
Gibson, CM
AF Mega, Jessica L.
Braunwald, Eugene
Murphy, Sabina A.
Plotnikov, Alexei N.
Burton, Paul
Kiss, Robert Gabor
Parkhomenko, Alexander
Tendera, Michal
Widimsky, Petr
Gibson, C. Michael
TI Rivaroxaban in Patients Stabilized After a ST-Segment Elevation
Myocardial Infarction Results From the ATLAS ACS-2-TIMI-51 Trial
(Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard
Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In
Myocardial Infarction-51)
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
ID DOUBLE-BLIND; INTERVENTION; CLOPIDOGREL; DISEASE
AB Objectives The present analysis reports on the pre-specified subgroup of ST-elevation myocardial infarction (STEMI) patients, in whom anticoagulant therapy has been of particular interest.
Background In ATLAS ACS-2-TIMI-51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51), rivaroxaban reduced cardiovascular events across the spectrum of acute coronary syndrome (ACS).
Methods Seven thousand eight hundred seventeen patients in ATLAS ACS-2-TIMI 51 presented with a STEMI. After being stabilized (1 to 7 days), they underwent randomization to twice daily rivaroxaban 2.5 mg, rivaroxaban 5 mg, or placebo. Data are presented as 2-year Kaplan-Meier rates, and for intention-to-treat (ITT) and modified ITT (mITT) analyses.
Results Among STEMI patients, rivaroxaban reduced the primary efficacy endpoint of cardiovascular death, myocardial infarction, or stroke, compared with placebo (ITT: 8.4% vs. 10.6%, hazards ratio [HR]: 0.81, 95% confidence interval [CI]: 0.67 to 0.97, p = 0.019; mITT: 8.3% vs. 9.7%, HR: 0.85, 95% CI: 0.70 to 1.03, p = 0.09). This reduction emerged by 30 days (ITT and mITT: 1.7% vs. 2.3%, p = 0.042) and was evident in analyses that included events while patients received background dual antiplatelet therapies (ITT: 7.9% vs. 11.9%, p = 0.010; mITT: 7.7% vs. 10.1%, p = 0.061). In terms of the individual doses, rivaroxaban 2.5 mg reduced cardiovascular death (ITT: 2.5% vs. 4.2%, p = 0.006; mITT: 2.2% vs. 3.9%, p = 0.006), which was not seen with 5 mg of rivaroxaban. Rivaroxaban versus placebo increased non-coronary artery bypass grafting Thrombolysis In Myocardial Infarction major bleeding (2.2% vs. 0.6%, p < 0.001) and intracranial hemorrhage (0.6% vs. 0.1%, p = 0.015) without a significant increase in fatal bleeding (0.2% vs. 0.1%, p = 0.51).
Conclusions In patients with a recent STEMI, rivaroxaban reduced cardiovascular events. This benefit emerged early and persisted during continued treatment with background antiplatelet therapies. Rivaroxaban compared with placebo increased the rate of major bleeding, but there was no significant increase in fatal bleeding. (An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome; NCT00809965) 2013 by the American College of Cardiology Foundation
C1 [Mega, Jessica L.; Braunwald, Eugene; Murphy, Sabina A.; Gibson, C. Michael] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
[Plotnikov, Alexei N.; Burton, Paul] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
[Kiss, Robert Gabor] Mil Hosp, Dept Cardiol, Budapest, Hungary.
[Parkhomenko, Alexander] Natl Sci Ctr, Inst Cardiol, Kiev, Ukraine.
[Tendera, Michal] Med Univ Silesia, Katowice, Poland.
[Widimsky, Petr] Charles Univ Prague, Prague, Czech Republic.
[Gibson, C. Michael] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Cardiovasc,Dept Med, Boston, MA 02215 USA.
RP Mega, JL (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM jmega@partners.org
RI Widimsky, Petr/P-8088-2016
OI Widimsky, Petr/0000-0001-5686-7752
FU Johnson Johnson; Johnson & Johnson Pharmaceutical Research and
Development; Bayer Healthcare; Bristol-Myers Squibb/sanofi-aventis;
Daiichi Sankyo; Eli Lilly; Abbott; AstraZeneca; Amgen; GlaxoSmithKline;
Merck (SPRI); Pfizer; Roche (Diagnostics); sanofi-aventis
FX From the *TIMI Study Group, Cardiovascular Division, Department of
Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston,
Massachusetts; dagger Johnson & Johnson Pharmaceutical Research and
Development, Raritan, New Jersey; double dagger Department of
Cardiology, Military Hospital, Budapest, Hungary; National Scientific
Center Institute of Cardiology, Kiev, Ukraine; parallel to Medical
University of Silesia, Katowice, Poland; Charles University, Prague,
Czech Republic; and the #Cardiovascular Division, Department of
Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, Massachusetts. This study was supported by research grants from
Johnson & Johnson Pharmaceutical Research and Development and Bayer
Healthcare. Dr. Mega has received research grant support from Johnson &
Johnson, Bayer Healthcare, Bristol-Myers Squibb/sanofi-aventis, Daiichi
Sankyo, Eli Lilly; research supplies from Accumetrics and Nanosphere;
and honoraria for consulting from American Genomics, Boehringer
Ingelheim, Janssen, and Merck. Dr. Braunwald has received research grant
support from Abbott, AstraZeneca, Amgen, Bayer Healthcare, Bristol-Myers
Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Merck (SPRI),
Pfizer, Roche (Diagnostics), sanofi-aventis, Johnson & Johnson; and has
been a consultant for Merck (no compensation), Amorcyte, Daiichi Sankyo,
The Medicines Co., Ikaria, CardioRentis, sanofi-aventis, and CVRx (no
compensation). Ms. Murphy has received research grant support from Bayer
Healthcare, Johnson & Johnson; and honoraria for consulting from Amarin
Pharmaceuticals, and Eli Lilly and Company. Drs. Kiss, Parkhomenko,
Tendera, and Widimsky have received research grant support from Johnson
& Johnson and Bayer Healthcare. Drs. Burton and Plotnikov are employed
by and own stock in Johnson & Johnson. Dr. Gibson has received research
grant support from Johnson & Johnson, Bayer Healthcare, Bristol-Myers
Squibb; honoraria for consulting from Portola Pharmaceuticals,
sanofi-aventis, The Medicines Co., Daiichi Sankyo Company, Eli Lilly and
Company, Biogen IDEC, Bristol-Myers Squibb, Ischemix, Inc., Johnson &
Johnson, Bayer Healthcare, GlaxoSmithKline, Merck Schering Plough, Ortho
McNeil, Medicure, Inc., Archemix, Inc., Genentech, Inc., and Boeringer
Ingelheim; payment for lectures from Daiichi Sankyo Company, Eli Lilly
and Company, Medicines Co.; and payment for development of educational
presentations from Daiichi Sankyo Company and Eli Lilly and Company.
NR 8
TC 41
Z9 41
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 7
PY 2013
VL 61
IS 18
BP 1853
EP 1859
DI 10.1016/j.jacc.2013.01.066
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 139TL
UT WOS:000318607400004
PM 23500262
ER
PT J
AU Boutchko, R
Sitek, A
Gullberg, GT
AF Boutchko, R.
Sitek, A.
Gullberg, G. T.
TI Practical implementation of tetrahedral mesh reconstruction in emission
tomography
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID CARDIAC SPECT; POINT CLOUD; PHANTOM; MODEL
AB This paper presents a practical implementation of image reconstruction on tetrahedral meshes optimized for emission computed tomography with parallel beam geometry. Tetrahedral mesh built on a point cloud is a convenient image representation method, intrinsically three-dimensional and with a multi-level resolution property. Image intensities are defined at the mesh nodes and linearly interpolated inside each tetrahedron. For the given mesh geometry, the intensities can be computed directly from tomographic projections using iterative reconstruction algorithms with a system matrix calculated using an exact analytical formula. The mesh geometry is optimized for a specific patient using a two stage process. First, a noisy image is reconstructed on a finely-spaced uniform cloud. Then, the geometry of the representation is adaptively transformed through boundary-preserving node motion and elimination. Nodes are removed in constant intensity regions, merged along the boundaries, and moved in the direction of the mean local intensity gradient in order to provide higher node density in the boundary regions. Attenuation correction and detector geometric response are included in the system matrix. Once the mesh geometry is optimized, it is used to generate the final system matrix for ML-EM reconstruction of node intensities and for visualization of the reconstructed images. In dynamic PET or SPECT imaging, the system matrix generation procedure is performed using a quasi-static sinogram, generated by summing projection data from multiple time frames. This system matrix is then used to reconstruct the individual time frame projections. Performance of the new method is evaluated by reconstructing simulated projections of the NCAT phantom and the method is then applied to dynamic SPECT phantom and patient studies and to a dynamic microPET rat study. Tetrahedral mesh-based images are compared to the standard voxel-based reconstruction for both high and low signal-to-noise ratio projection datasets. The results demonstrate that the reconstructed images represented as tetrahedral meshes based on point clouds offer image quality comparable to that achievable using a standard voxel grid while allowing substantial reduction in the number of unknown intensities to be reconstructed and reducing the noise.
C1 [Boutchko, R.; Gullberg, G. T.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.
[Sitek, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Boutchko, R (reprint author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, 1 Cyclotron Rd,MS 55R0121, Berkeley, CA 94720 USA.
EM rbuchko@lbl.gov
OI Sitek, Arkadiusz/0000-0002-0677-4002
FU National Institutes of Health [R01-EB07219, R01-HL50663, R01-EB00121];
Office of Science, Office of Biological and Environmental Research of
the US Department of Energy [DE-AC02-05CH11231]
FX The work presented in this paper has been funded in part by National
Institutes of Health grants R01-EB07219, R01-HL50663 and R01-EB00121 and
by the Director, Office of Science, Office of Biological and
Environmental Research of the US Department of Energy under contract no.
DE-AC02-05CH11231. The authors would like to thank Dr Bryan Reutter
(formerly LBNL), Dr Youngho Seo (UCSF) and Mr Andrew Hernandez (formerly
UCSF) for their help in acquiring and preparing the experimental data
and Dr W Paul Segars, Department of Bioengineering, Duke University for
providing the digital NCAT phantom.
NR 18
TC 5
Z9 5
U1 0
U2 16
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 7
PY 2013
VL 58
IS 9
BP 3001
EP 3022
DI 10.1088/0031-9155/58/9/3001
PG 22
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 125ZD
UT WOS:000317579900017
PM 23588373
ER
PT J
AU Krishnan, K
Duncan, MJ
AF Krishnan, Karthik
Duncan, Margaret J.
TI Role of Sodium in the RprY-Dependent Stress Response in Porphyromonas
gingivalis
SO PLOS ONE
LA English
DT Article
ID BACTEROIDES-FRAGILIS; ESCHERICHIA-COLI; EPITHELIAL-CELLS; OXIDATIVE
STRESS; GENE-EXPRESSION; POLYHYDROXYALKANOATES; IDENTIFICATION;
PERIODONTITIS; PROTEIN; OPERON
AB Porphyromonas gingivalis is a Gram-negative oral anaerobe which is strongly associated with periodontal disease. Environmental changes in the gingival sulcus trigger the growth of P. gingivalis and a concurrent shift from periodontal health to disease. Bacteria adjust their physiology in response to environmental changes and gene regulation by two-component phospho-relay systems is one mechanism by which such adjustments are effected. In P. gingivalis RprY is an orphan response regulator and previously we showed that the RprY regulon included genes associated with oxidative stress and sodium metabolism. The goals of the present study were to identify environmental signals that induce rprY and clarify the role of the regulator in the stress response. In Escherichia coli an RprY-LacZ fusion protein was induced in sodium-depleted medium and a P. gingivalis rprY mutant was unable to grow in similar medium. By several approaches we established that sodium depletion induced up-regulation of genes involved in oxidative stress. In addition, we demonstrated that RprY interacted directly with the promoters of several molecular chaperones. Further, both genetic and transcription data suggest that the regulator acts as a repressor. We conclude that RprY is one of the regulators that controls stress responses in P. gingivalis, possibly by acting as a repressor since an rprY mutant showed a superstress reponse in sodium-depleted medium which we propose inhibited growth.
C1 [Krishnan, Karthik; Duncan, Margaret J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA.
[Krishnan, Karthik] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
RP Duncan, MJ (reprint author), Forsyth Inst, Dept Microbiol, Cambridge, MA USA.
EM mduncan@forsyth.org
FU National Institutes of Health [R01-DE015931]
FX This work was supported by National Institutes of Health grant
R01-DE015931 (MJD). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 45
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 6
PY 2013
VL 8
IS 5
AR e63180
DI 10.1371/journal.pone.0063180
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 177QL
UT WOS:000321390200045
PM 23671672
ER
PT J
AU Kiviranta, R
Yamana, K
Saito, H
Ho, DK
Laine, J
Tarkkonen, K
Nieminen-Pihala, V
Hesse, E
Correa, D
Maatta, J
Tessarollo, L
Rosen, ED
Horne, WC
Jenkins, NA
Copeland, NG
Warming, S
Baron, R
AF Kiviranta, Riku
Yamana, Kei
Saito, Hiroaki
Ho, Daniel K.
Laine, Julius
Tarkkonen, Kati
Nieminen-Pihala, Vappu
Hesse, Eric
Correa, Diego
Maatta, Jorma
Tessarollo, Lino
Rosen, Evan D.
Horne, William C.
Jenkins, Nancy A.
Copeland, Neal G.
Warming, Soren
Baron, Roland
TI Coordinated transcriptional regulation of bone homeostasis by Ebf1 and
Zfp521 in both mesenchymal and hematopoietic lineages
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID ZINC-FINGER PROTEIN; KAPPA-B LIGAND; OSTEOBLAST DIFFERENTIATION;
OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; CELL-FACTOR;
GENE-EXPRESSION; BETA-CATENIN; IN-VITRO; PROGENITORS
AB Bone homeostasis is maintained by the coupled actions of hematopoietic bone-resorbing osteoclasts (OCs) and mesenchymal bone-forming osteoblasts (OBs). Here we identify early B cell factor 1 (Ebf1) and the transcriptional coregulator Zfp521 as components of the machinery that regulates bone homeostasis through coordinated effects in both lineages. Deletion of Zfp521 in OBs led to impaired bone formation and increased OB-dependent osteoclastogenesis (OC-genesis), and deletion in hematopoietic cells revealed a strong cell-autonomous role for Zfp521 in OC progenitors. In adult mice, the effects of Zfp521 were largely caused by repression of Ebf1, and the bone phenotype of Zfp521(+/-) mice was rescued in Zfp521(+/-):Ebf1(+/-) mice. Zfp521 interacted with Ebf1 and repressed its transcriptional activity. Accordingly, deletion of Zfp521 led to increased Ebf1 activity in OBs and OCs. In vivo, Ebf1 overexpression in OBs resulted in suppressed bone formation, similar to the phenotype seen after OB-targeted deletion of Zfp521. Conversely, Ebf1 deletion led to cell-autonomous defects in both OB-dependent and cell-intrinsic OC-genesis, a phenotype opposite to that of the Zfp521 knockout. Thus, we have identified the interplay between Zfp521 and Ebf1 as a novel rheostat for bone homeostasis.
C1 [Kiviranta, Riku; Yamana, Kei; Saito, Hiroaki; Ho, Daniel K.; Hesse, Eric; Correa, Diego; Horne, William C.; Baron, Roland] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA.
[Kiviranta, Riku; Yamana, Kei; Saito, Hiroaki; Ho, Daniel K.; Hesse, Eric; Correa, Diego; Horne, William C.; Baron, Roland] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02115 USA.
[Rosen, Evan D.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Kiviranta, Riku; Yamana, Kei; Saito, Hiroaki; Ho, Daniel K.; Hesse, Eric; Correa, Diego; Horne, William C.; Baron, Roland] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Kiviranta, Riku; Laine, Julius; Tarkkonen, Kati; Nieminen-Pihala, Vappu] Univ Turku, Turku Univ Hosp, Dept Med Biochem & Genet, FI-20520 Turku, Finland.
[Kiviranta, Riku; Laine, Julius; Tarkkonen, Kati; Nieminen-Pihala, Vappu] Univ Turku, Turku Univ Hosp, Dept Med, FI-20520 Turku, Finland.
[Maatta, Jorma] Univ Turku, Turku Univ Hosp, Turku Ctr Dis Modeling, FI-20520 Turku, Finland.
[Tessarollo, Lino] NCI, Mouse Canc Genet Program, Ctr Canc Res, Ft Detrick, MD 21702 USA.
[Jenkins, Nancy A.; Copeland, Neal G.] Methodist Hosp, Res Inst, Houston, TX 77030 USA.
[Warming, Soren] Genentech Inc, San Francisco, CA 94080 USA.
RP Baron, R (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA.
EM roland_baron@hsdm.harvard.edu
OI Maatta, Jorma/0000-0001-8752-6862
FU National Institutes of Health-National Institute of Arthritis and
Musculoskeletal and Skin Diseases [AR048218, AR57769]; Academy of
Finland [10945, 120116]; Gideon and Sevgi Rodan Fellowship from the
International Bone and Mineral Society; Finnish Cultural Foundation;
Emil Aaltonen Foundation; Sigrid Juselius Foundation
FX This work was supported in part by National Institutes of
Health-National Institute of Arthritis and Musculoskeletal and Skin
Diseases grants to R. Baron (AR048218 and AR57769). Additional support
was provided by the Academy of Finland (Projects 10945 and 120116 to R.
Kiviranta), the Gideon and Sevgi Rodan Fellowship from the International
Bone and Mineral Society (to R. Kiviranta and E. Hesse), the Finnish
Cultural Foundation (to R. Kiviranta), the Emil Aaltonen Foundation (to
R. Kiviranta), and the Sigrid Juselius Foundation (R. Kiviranta).
NR 48
TC 16
Z9 16
U1 1
U2 6
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD MAY 6
PY 2013
VL 210
IS 5
BP 969
EP 985
DI 10.1084/jem.20121187
PG 17
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 139UG
UT WOS:000318609700008
PM 23569325
ER
PT J
AU Harrison, WJ
Retell, JD
Remington, RW
Mattingley, JB
AF Harrison, William J.
Retell, James D.
Remington, Roger W.
Mattingley, Jason B.
TI Visual Crowding at a Distance during Predictive Remapping
SO CURRENT BIOLOGY
LA English
DT Article
ID SACCADIC EYE-MOVEMENTS; OBJECT RECOGNITION; FRONTAL-CORTEX; ATTENTION;
REPRESENTATION; SIGNALS; VISION; MOTION; FIELD
AB When we move our eyes, images of objects are displaced on the retina, yet the visual world appears stable. Oculomotor activity just prior to an eye movement contributes to perceptual stability by providing information about the predicted location of a relevant object on the retina following a saccade [1, 2]. It remains unclear, however, whether an object's features are represented at the remapped location. Here, we exploited the phenomenon of visual crowding [3] to show that presaccadic remapping preserves the elementary features of objects at their predicted postsaccadic locations. Observers executed an eye movement and identified a letter probe flashed just before the saccade. Flanking stimuli were flashed around the location that would be occupied by the probe immediately following the saccade. Despite being positioned in the opposite visual field to the probe, these flankers disrupted observers' ability to identify the probe. Crucially, this "remapped crowding" interference was stronger when the flankers were visually similar to the probe than when the flanker and probe stimuli were distinct. Our findings suggest that visual processing at remapped locations is featurally dependent, providing a mechanism for achieving perceptual continuity of objects across saccades.
C1 [Harrison, William J.; Retell, James D.; Remington, Roger W.; Mattingley, Jason B.] Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.
[Mattingley, Jason B.] Univ Queensland, Queensland Brain Inst, St Lucia, Qld 4072, Australia.
RP Harrison, WJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02114 USA.
EM willjharri@gmail.com
RI Mattingley, Jason/J-1537-2014;
OI Mattingley, Jason/0000-0003-0929-9216; Harrison,
William/0000-0002-6408-0359
FU Australian Research Council [DP0666772, FL110100103]; ARC [DP120103721]
FX The authors thank Dustin Venini for his help with data collection. This
research was supported by an Australian Professorial Fellowship to
R.W.R. (DP0666772), an Australian Laureate Fellowship from the
Australian Research Council to J.B.M. (FL110100103), and an ARC
Discovery Grant to R.W.R. and J.B.M. (DP120103721). The study was
approved by The University of Queensland's School of Psychology Ethical
Review Committee.
NR 37
TC 18
Z9 19
U1 4
U2 25
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
J9 CURR BIOL
JI Curr. Biol.
PD MAY 6
PY 2013
VL 23
IS 9
BP 793
EP 798
DI 10.1016/j.cub.2013.03.050
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 141UB
UT WOS:000318750900031
PM 23562269
ER
PT J
AU Hai, HL
Shen, CA
Chai, JK
Li, HT
Yu, YM
Li, DW
AF Hai Heng-lin
Shen Chuan-an
Chai Jia-ke
Li Hua-tao
Yu Yong-ming
Li Da-wei
TI Quadrilobed superior gluteal artery perforator nap for sacrococcygeal
defects
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE quadrilobed superior gluteal artery perforator flap; sacrococcygeal
region; pressure sore; soft tissue defect
ID SACRAL PRESSURE SORES; FLAP; RECONSTRUCTION; COVERAGE; REPAIR
AB Background Perforator flaps are used extensively in repairing soft tissue defects. Superior gluteal artery perforator flaps are used for repairing sacral defects, but the tension required for direct closure of the donor area after harvesting of relatively large flaps carries a risk of postoperative dehiscence. This research was to investigate a modified superior gluteal artery perforator flap for repairing sacrococcygeal soft tissue defects.
Methods From June 2003 to April 2010, we used our newly designed superior gluteal artery perforator flap for repair of sacrococcygeal soft tissue defects in 10 patients (study group). The wound and donor areas were measured, and the flaps were designed accordingly. Wound healing was assessed over a follow-up period of 6-38 months. From January 1998 to February 2003, twelve patients with sacrococcygeal pressure sores were treated with traditional methods, VY advancement flaps or oblong flaps, as control group.
Results After debridement, the soft tissue defects ranged from 12 cm x 10 cm to 26 cm x 22 cm (mean 16.3 cm x 13.5 cm). Four patients were treated using right-sided flaps ranging from 15 cm x 11 cm to 25 cm x 20 cm (mean 18.2 cm x 14 cm). Four patients were treated using left-sided flaps, and two were treated using both right- and left-sided flaps. Suction drains were removed on postoperative Days 3-21 (mean 5.9) and sutures were removed on postoperative Days 12-14. Each flap included 1-2 perforators for each of the donor and recipient sites. Donor sites were closed directly. All flaps survived. In eight patients, the wounds healed after single-stage surgery. After further debridement, the wounds of the remaining two patients were considered healed on postoperative Days 26 and 33, respectively. The rate of first intention in the study group (80%, 8/10) significantly increased than that of control group ((25%, 3/12), chi(2)=4.583, P=0.032). Follow-up examinations found that the flaps had a soft texture without ulceration. In the two patients without paraplegia, the range of motion of the hip joints was not affected.
Conclusion The use of the quadrilobed superior gluteal artery perforator flap can overcome the disadvantages of traditional perforator flaps and represents an improved approach for repairing soft tissue defects in the sacrococcygeal region.
C1 [Hai Heng-lin; Shen Chuan-an; Chai Jia-ke; Li Da-wei] Peoples Liberat Army, Affiliated Hosp 1, Peoples Liberat Army Burn Ctr, Gen Hosp, Beijing 100048, Peoples R China.
[Hai Heng-lin; Li Hua-tao] Peoples Liberat Army, Hosp 98, Dept Burns & Plast Surg, Huzhou 313000, Zhejiang, Peoples R China.
[Yu Yong-ming] Massachusetts Gen Hosp, Burn Unit, Dept Surg, Boston, MA 02114 USA.
[Yu Yong-ming] Shriners Burns Hosp Boston, Boston, MA 02114 USA.
RP Shen, CA (reprint author), Peoples Liberat Army, Affiliated Hosp 1, Peoples Liberat Army Burn Ctr, Gen Hosp, Beijing 100048, Peoples R China.
EM shenchuanan@yahoo.com
FU National Natural Science Foundation of China [30971128]
FX This work was supported by a grant from the National Natural Science
Foundation of China (No. 30971128).
NR 23
TC 0
Z9 0
U1 3
U2 6
PU CHINESE MEDICAL ASSOC
PI BEIJING
PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAY 5
PY 2013
VL 126
IS 9
BP 1743
EP 1749
DI 10.3760/cma.j.issn.0366-6999.20130002
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 152JX
UT WOS:000319529100026
PM 23652061
ER
PT J
AU Cassol, E
Misra, V
Holman, A
Kamat, A
Morgello, S
Gabuzda, D
AF Cassol, Edana
Misra, Vikas
Holman, Alexander
Kamat, Anupa
Morgello, Susan
Gabuzda, Dana
TI Plasma metabolomics identifies lipid abnormalities linked to markers of
inflammation, microbial translocation, and hepatic function in HIV
patients receiving protease inhibitors
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; HCV; Antiretroviral therapy; Protease inhibitors; Dyslipidemia;
Metabolomics; Hepatic dysfunction; Inflammation
ID NONALCOHOLIC FATTY LIVER; HUMAN-IMMUNODEFICIENCY-VIRUS;
PLACEBO-CONTROLLED TRIAL; SIMPLE NONINVASIVE INDEX; HCV COINFECTED
PATIENTS; SERUM FIBROSIS MARKERS; C-VIRUS; INFECTED PATIENTS;
BILE-ACIDS; ANTIRETROVIRAL THERAPY
AB Background: Metabolic abnormalities are common in HIV-infected individuals on antiretroviral therapy (ART), but the biochemical details and underlying mechanisms of these disorders have not been defined.
Methods: Untargeted metabolomic profiling of plasma was performed for 32 HIV patients with low nadir CD4 counts (< 300 cells/ul) on protease inhibitor (PI)-based ART and 20 healthy controls using liquid or gas chromatography and mass spectrometry. Effects of Hepatitis C (HCV) co-infection and relationships between altered lipid metabolites and markers of inflammation, microbial translocation, and hepatic function were examined. Unsupervised hierarchical clustering, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), Random forest, pathway mapping, and metabolite set enrichment analysis (MSEA) were performed using dChip, Metaboanalyst, and MSEA software.
Results: A 35-metabolite signature mapping to lipid, amino acid, and nucleotide metabolism distinguished HIV patients with advanced disease on PI-based ART from controls regardless of HCV serostatus (p<0.05, false discovery rate (FDR)<0.1). Many altered lipids, including bile acids, sulfated steroids, polyunsaturated fatty acids, and eicosanoids, were ligands of nuclear receptors that regulate metabolism and inflammation. Distinct clusters of altered lipids correlated with markers of inflammation (interferon-a and interleukin-6), microbial translocation (lipopolysaccharide (LPS) and LPS-binding protein), and hepatic function (bilirubin) (p<0.05). Lipid alterations showed substantial overlap with those reported in non-alcoholic fatty liver disease (NALFD). Increased bile acids were associated with noninvasive markers of hepatic fibrosis (FIB-4, APRI, and YKL-40) and correlated with acylcarnitines, a marker of mitochondrial dysfunction.
Conclusions: Lipid alterations in HIV patients receiving PI-based ART are linked to markers of inflammation, microbial translocation, and hepatic function, suggesting that therapeutic strategies attenuating dysregulated innate immune activation and hepatic dysfunction may be beneficial for prevention and treatment of metabolic disorders in HIV patients.
C1 [Cassol, Edana; Misra, Vikas; Holman, Alexander; Kamat, Anupa; Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Cassol, Edana; Kamat, Anupa; Gabuzda, Dana] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
[Morgello, Susan] Mt Sinai Med Ctr, Dept Neurol Neurosci & Pathol, New York, NY 10029 USA.
[Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Gabuzda, D (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
EM dana_gabuzda@dfci.harvard.edu
FU National Institute on Drug Abuse (NIDA) grant [DP1 DA028994]; Canadian
Institutes of Health Research (CIHR); National Institute of Mental
Health (NIMH); National Institute of Neurological Disorders and Stroke
(NINDS) [U01MH083501, R24MH59724, U01MH083507, R24NS45491, U01MH083500,
R24NS38841, U01MH083506, R24MH59745, U01MH083545, N01MH32002,
N01MH22005]; Harvard Center for AIDS Research grant [P30 AI060354];
Dana-Farber Cancer Institute/Harvard Center for Cancer Research grant
[P30 CA065/6]
FX This work was supported by the National Institute on Drug Abuse (NIDA)
grant DP1 DA028994 to D.G. E.C. was supported by a fellowship from
Canadian Institutes of Health Research (CIHR). NNTC and CHARTER sites
were supported by National Institute of Mental Health (NIMH) and
National Institute of Neurological Disorders and Stroke (NINDS) (grants
U01MH083501, R24MH59724, U01MH083507, R24NS45491, U01MH083500,
R24NS38841, U01MH083506, R24MH59745, U01MH083545, N01MH32002, and
N01MH22005). Core facilities were supported by the Harvard Center for
AIDS Research grant (P30 AI060354) and Dana-Farber Cancer
Institute/Harvard Center for Cancer Research grant (P30 CA065/6).
NR 97
TC 31
Z9 33
U1 3
U2 41
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 4
PY 2013
VL 13
AR 203
DI 10.1186/1471-2334-13-203
PG 17
WC Infectious Diseases
SC Infectious Diseases
GA 147CG
UT WOS:000319142300001
PM 23641933
ER
PT J
AU Corey, KE
Misdraji, J
Zheng, H
Malecki, KM
Kneeman, J
Gelrud, L
Chung, RT
AF Corey, Kathleen E.
Misdraji, Joseph
Zheng, Hui
Malecki, Kyle M.
Kneeman, Jacob
Gelrud, Louis
Chung, Raymond T.
TI The Absence of Obstructive Sleep Apnea May Protect against Non-Alcoholic
Fatty Liver in Patients Undergoing Bariatric Surgery
SO PLOS ONE
LA English
DT Article
ID CHRONIC INTERMITTENT HYPOXIA; DISEASE; OBESE; STEATOHEPATITIS; RISK
AB Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide and its progressive form, steatohepatitis, will be the leading indication for liver transplant by 2020. While risk factors for steatohepatitis have been identified, little work has been performed to identify factors protective against NAFLD development.
Aim: This study sought to identify factors predictive of normal liver histology in a bariatric cohort.
Methods: Patients undergoing weight loss surgery with liver biopsies at the time of surgery were included. Patients with other causes of chronic liver disease were excluded.
Results: One hundred fifty-nine patients were included. Forty-nine patients had normal liver histology and 110 patients had NAFLD. Several previously identified factors associated with normal liver histology were found. Black race was the strongest predictor of the absence of NAFLD with an odds ratio (OR) of 6.8, 95% confidence interval (CI) 2.4-18.9. Low HOMA-IR was also associated with normal histology (OR 1.4, 95% CI 1.03-1.9). In contrast, low HDL was associated with a decreased chance of normal histology (OR 0.38, 95% CI 0.05-0.83). Interestingly, a novel protective factor, the absence of obstructive sleep apnea (OSA) was strongly associated with normal histology (OR 5.6, 95% CI 2.0-16.1). In multivariate regression controlling for BMI, black race, absence of OSA, low HOMA-IR and low ALT independently predicted normal liver histology with an area under the ROC curve of 0.85.
Conclusions: Our study confirmed several factors associated with normal liver histology, including black race and identified a novel factor, absence of OSA. Further evaluation of these factors will allow for improved understanding of the pathogenesis of NAFLD.
C1 [Corey, Kathleen E.; Malecki, Kyle M.; Kneeman, Jacob; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Misdraji, Joseph] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Zheng, Hui] Massachusetts Gen Hosp, MGH Biostat Ctr, Boston, MA 02114 USA.
[Corey, Kathleen E.; Zheng, Hui; Gelrud, Louis; Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA USA.
[Gelrud, Louis] Bon Secours Richmond Hlth Syst, Dept Internal Med, Richmond, VA USA.
RP Corey, KE (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
EM kcorey@partners.org; rtchung@partners.org
FU American Association for the Study of Liver Disease Clinical and
Translational Research Award; NIH [2T32DK0007191-37, DK078772]
FX KEC receives support from the American Association for the Study of
Liver Disease Clinical and Translational Research Award. JK receives
support from the NIH 2T32DK0007191-37. RTC receives support from NIH
DK078772. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 13
TC 6
Z9 6
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 3
PY 2013
VL 8
IS 5
AR e62504
DI 10.1371/journal.pone.0062504
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175AS
UT WOS:000321202100011
PM 23658732
ER
PT J
AU Yomogida, K
Wu, SL
Baravati, B
Avendano, C
Caldwell, T
Maniaci, B
Zhu, Y
Chu, CQ
AF Yomogida, Kentaro
Wu, Shili
Baravati, Bobby
Avendano, Camilo
Caldwell, Tom
Maniaci, Brian
Zhu, Yong
Chu, Cong-Qiu
TI Cell penetrating recombinant Foxp3 protein enhances Treg function and
ameliorates arthritis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Foxp3; T regulatory cells; Arthritis
ID REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; AUTOIMMUNITY;
ACTIVATION; GENERATION; EXPRESSION; TOLERANCE; ALLERGY; CD25
AB Foxp3 is the master transcription factor for T regulatory (Treg) cell differentiation and function. This study aimed to test the therapeutic potential of cell penetrating recombinant Foxp3 protein in arthritis. Recombinant Foxp3 protein was fused to a cell penetrating polyarginine (Foxp3-11R) tag to facilitate intracellular transduction. In vitro Foxp3-11R treated CD4(+) T cells showed a 50% increase in suppressive function compared with control protein treated cells. Severity of arthritis in Foxp3-11R treated mice was significantly reduced compared with those treated with a control protein. CD4(+) T cells of lymph nodes and spleen from Foxp3-11R treated mice showed increased levels of Foxp3 expression compared with those of a control protein treated. These results demonstrated that Foxp3-11R can enhance T cell suppressive function and ameliorate experimental arthritis and suggest that cell penetrating recombinant Foxp3 is a potentially useful agent in therapy of arthritis. Published by Elsevier Inc.
C1 [Yomogida, Kentaro; Chu, Cong-Qiu] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Yomogida, Kentaro; Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR 97239 USA.
[Wu, Shili; Baravati, Bobby; Avendano, Camilo; Caldwell, Tom; Maniaci, Brian; Zhu, Yong] VivoScript Inc, Costa Mesa, CA 92626 USA.
RP Chu, CQ (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,OP09, Portland, OR 97239 USA.
EM chuc@ohsu.edu
FU NIH [AR055254]; Portland VA Medical Center
FX This work was supported by a grant from NIH to CQC (AR055254) and
Portland VA Medical Center to CQC.
NR 24
TC 3
Z9 3
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 3
PY 2013
VL 434
IS 2
BP 263
EP 267
DI 10.1016/j.bbrc.2013.02.114
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 146NW
UT WOS:000319098800014
PM 23541572
ER
PT J
AU Bajunirwe, F
Bangsberg, DR
Sethi, AK
AF Bajunirwe, Francis
Bangsberg, David R.
Sethi, Ajay K.
TI Alcohol use and HIV serostatus of partner predict high-risk sexual
behavior among patients receiving antiretroviral therapy in South
Western Uganda
SO BMC PUBLIC HEALTH
LA English
DT Article
DE High-risk sexual behavior; Antiretroviral treatment; Rural and urban;
Uganda
ID QUALITY-OF-LIFE; FISHING COMMUNITIES; HOMOSEXUAL-MEN; LAKE VICTORIA;
RURAL UGANDA; TRANSMISSION; IMPACT; COHORT; ADULTS; KENYA
AB Background: Antiretroviral treatment restores the physical and immunological function for patients with HIV/AIDS and the return of sexual desire. The frequency and correlates of sexual activity among patients receiving ART have not been widely studied. There is concern that widespread availability of ART may result in sexual disinhibition including practice of high-risk sexual behavior. We determined the correlates of sexual activity and high-risk sexual behavior in an ART-treated population in rural and urban Uganda.
Methods: We conducted a cross-sectional study among 329 ART-treated adult patients at two hospitals, one located in rural and another in urban western Uganda. We collected data on sexual activity, frequency of condom use, pregnancy, viral load (VL) and CD4. Patients were considered sexually active if they had had sexual intercourse in the last 6 months. Any unprotected sex was considered high-risk sex. A two-stage logistic regression was performed to determine factors associated with sexual activity and high-risk sex among those sexually active.
Results: Overall, 222 (67%) patients were women, 138 (41.2%) had been on ART for at least one year, and 168 (51.4%) were sexually active of whom 127 (75.6%) used condoms at the last intercourse. Younger age (<=30 years) (Odds ratio; OR=2.3, 95% CI 1.2, 4.2), higher monthly income (OR=4.1, 95% CI 2.4, 7.4), and being married (OR=22.7, 95% CI 8.2, 62.9) were associated with being sexually active. Undetectable VL, CD4 count and treatment duration were not significantly associated with sexual activity. Among the sexually active, alcohol consumption (OR=3.3, 95% CI 1.2, 9.1) and unknown serostatus of partner (OR=5.8, 95% CI 1.5, 21.4) were significant predictors of high-risk sexual behavior. The frequency of unprotected sex at the last intercourse was 25.9% and 22.1% among the men and women respectively and was not significantly different (p value for chi square test =0.59).
Conclusion: Younger persons receiving ART are more likely to be sexually active. ART clients are more likely to engage in unprotected sex when sero-status of partner is unknown or report use of alcohol. Counseling on alcohol use and disclosure of sero-status may be useful in reducing high risk sexual behavior.
C1 [Bajunirwe, Francis] Mbarara Univ Sci & Technol, Dept Community Hlth, Mbarara, Uganda.
[Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA.
[Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Sethi, Ajay K.] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
RP Bajunirwe, F (reprint author), Mbarara Univ Sci & Technol, Dept Community Hlth, POB 1410, Mbarara, Uganda.
EM fbaj@yahoo.com
FU AIDS International Training and Research Program (AITRP) at Case Western
Reserve University through the Fogarty International Center (FIC) at the
National Institutes of Health [TW00011]; Harvard Global Scholars program
FX This study was funded by the AIDS International Training and Research
Program (AITRP) at Case Western Reserve University through the Fogarty
International Center (FIC) at the National Institutes of Health
(TW00011). FB receives support from the Harvard Global Scholars program.
NR 38
TC 10
Z9 10
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD MAY 3
PY 2013
VL 13
AR 430
DI 10.1186/1471-2458-13-430
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 140FQ
UT WOS:000318640200001
PM 23641795
ER
PT J
AU Joseph, K
Kulik, L
Coughlin, B
Kunchithapautham, K
Bandyopadhyay, M
Thiel, S
Thielens, NM
Holers, VM
Rohrer, B
AF Joseph, Kusumam
Kulik, Liudmila
Coughlin, Beth
Kunchithapautham, Kannan
Bandyopadhyay, Mausumi
Thiel, Steffen
Thielens, Nicole M.
Holers, V. Michael
Rohrer, Baerbel
TI Oxidative Stress Sensitizes Retinal Pigmented Epithelial (RPE) Cells to
Complement-mediated Injury in a Natural Antibody-, Lectin Pathway-, and
Phospholipid Epitope-dependent Manner
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INDUCED CHOROIDAL NEOVASCULARIZATION; LIPID-PEROXIDATION PRODUCTS;
MACULAR DEGENERATION AMD; MEMBRANE-ATTACK-COMPLEX; MANNOSE-BINDING
LECTIN; FACTOR-H; ISCHEMIA/REPERFUSION INJURY; SERINE-PROTEASE;
ALTERNATIVE PATHWAY; REPERFUSION INJURY
AB Uncontrolled activation of the alternative complement pathway (AP) is thought to be associated with age-related macular degeneration. Previously, we have shown that in retinal pigmented epithelial (RPE) monolayers, oxidative stress reduced complement inhibition on the cell surface, resulting in sublytic complement activation and loss of transepithelial resistance (TER), but the potential ligand and pathway involved are unknown. ARPE-19 cells were grown as monolayers on transwell plates, and sublytic complement activation was induced with H2O2 and normal human serum. TER deteriorated rapidly in H2O2-exposed monolayers upon adding normal human serum. Although the effect required AP activation, AP was not sufficient, because elimination of MASP, but not C1q, prevented TER reduction. Reconstitution experiments to unravel essential components of the lectin pathway (LP) showed that both ficolin and mannan-binding lectin can activate the LP through natural IgM antibodies (IgM-C2) that recognize phospholipid cell surface modifications on oxidatively stressed RPE cells. The same epitopes were found on human primary embryonic RPE monolayers. Likewise, mouse laser-induced choroidal neovascularization, an injury that involves LP activation, could be increased in antibody-deficient rag1(-/-) mice using the phospholipid-specific IgM-C2. In summary, using a combination of depletion and reconstitution strategies, we have shown that the LP is required to initiate the complement cascade following natural antibody recognition of neoepitopes, which is then further amplified by the AP. LP activation is triggered by IgM bound to phospholipids. Taken together, we have defined novel mechanisms of complement activation in oxidatively stressed RPE, linking molecular events involved in age-related macular degeneration, including the presence of natural antibodies and neoepitopes.
C1 [Joseph, Kusumam; Coughlin, Beth; Kunchithapautham, Kannan; Bandyopadhyay, Mausumi; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Kulik, Liudmila; Holers, V. Michael] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO 80045 USA.
[Thiel, Steffen] Aarhus Univ, Dept Biomed, DK-8000 Aarhus, Denmark.
[Thielens, Nicole M.] Univ Grenoble 1, CNRS, Inst Biol Struct, UMR 5075 CEA, F-38027 Grenoble 1, France.
[Rohrer, Baerbel] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI 511, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health Grant [R01EY019320, C06 RR015455];
Department of Veterans Affairs Grant [I01 RX000444]; Foundation Fighting
Blindness; Research to Prevent Blindness, Inc. (New York)
FX This work was supported, in whole or in part, by National Institutes of
Health Grant R01EY019320. This work was also supported by Department of
Veterans Affairs Grant I01 RX000444, Foundation Fighting Blindness, and
an unrestricted grant to the Medical University of South Carolina from
Research to Prevent Blindness, Inc. (New York). Animal studies were
conducted in a facility constructed with support from National
Institutes of Health Grant C06 RR015455.
NR 69
TC 19
Z9 20
U1 5
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2013
VL 288
IS 18
BP 12753
EP 12765
DI 10.1074/jbc.M112.421891
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 139AZ
UT WOS:000318555100032
PM 23493397
ER
PT J
AU Gameiro, PA
Laviolette, LA
Kelleher, JK
Iliopoulos, O
Stephanopoulos, G
AF Gameiro, Paulo A.
Laviolette, Laura A.
Kelleher, Joanne K.
Iliopoulos, Othon
Stephanopoulos, Gregory
TI Cofactor Balance by Nicotinamide Nucleotide Transhydrogenase (NNT)
Coordinates Reductive Carboxylation and Glucose Catabolism in the
Tricarboxylic Acid (TCA) Cycle
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ADENINE DINUCLEOTIDE PHOSPHATE; MALATE-ASPARTATE SHUTTLE; ISOCITRATE
DEHYDROGENASE; CELL-GROWTH; GLUTAMINE-METABOLISM; INSULIN-SECRETION;
MALIC ENZYME; TUMOR-CELLS; REDOX STATE; RAT LIVER
AB Cancer and proliferating cells exhibit an increased demand for glutamine-derived carbons to support anabolic processes. In addition, reductive carboxylation of alpha-ketoglutarate by isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) was recently shown to be a major source of citrate synthesis from glutamine. The role of NAD(P)H/NAD(P)(+) cofactors in coordinating glucose and glutamine utilization in the tricarboxylic acid (TCA) cycle is not well understood, with the source(s) of NADPH for the reductive carboxylation reaction remaining unexplored. Nicotinamide nucleotide transhydrogenase (NNT) is a mitochondrial enzyme that transfers reducing equivalents from NADH to NADPH. Here, we show that knockdown of NNT inhibits the contribution of glutamine to the TCA cycle and activates glucose catabolism in SkMel5 melanoma cells. The increase in glucose oxidation partially occurred through pyruvate carboxylase and rendered NNT knockdown cells more sensitive to glucose deprivation. Importantly, knocking down NNT inhibits reductive carboxylation in SkMel5 and 786-O renal carcinoma cells. Overexpression of NNT is sufficient to stimulate glutamine oxidation and reductive carboxylation, whereas it inhibits glucose catabolism in the TCA cycle. These observations are supported by an impairment of the NAD(P) H/NAD(P)+ ratios. Our findings underscore the role of NNT in regulating central carbon metabolism via redox balance, calling for other mechanisms that coordinate substrate preference to maintain a functional TCA cycle.
C1 [Gameiro, Paulo A.; Kelleher, Joanne K.; Stephanopoulos, Gregory] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Gameiro, Paulo A.; Laviolette, Laura A.; Iliopoulos, Othon] Massachusetts Gen Hosp Canc Ctr, Ctr Canc Res, Charlestown, MA 02129 USA.
[Gameiro, Paulo A.; Laviolette, Laura A.; Iliopoulos, Othon] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA.
[Laviolette, Laura A.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02139 USA.
[Gameiro, Paulo A.] Univ Coimbra, Dept Life Sci, P-3004517 Coimbra, Portugal.
RP Stephanopoulos, G (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
EM gregstep@mit.edu
FU Massachusetts General Hospital (MGH) ProtonBeam Federal Share Project;
National Institutes of Health [R01 DK075850, R01 CA122591];
Astra-Zeneca; Foundation for Science and Technology (FCT), Portugal
FX We thank Ana M. Metelo for insights on the xenograft experiments, Eric
L. Bell for help with the NNT cDNA plasmid, Taylor Murphy for help on
extracellular flux analyses, Thomas Wasylenko for feedback on cofactor
measurements, and Christian M. Metallo for scientific discussions. This
work was also supported by the Massachusetts General Hospital (MGH)
ProtonBeam Federal Share Project.; This work was supported, in whole or
in part, by National Institutes of Health Grants R01 DK075850 (to G.S.)
and R01 CA122591 (to O.I.). This work was also supported by an Award
from Astra-Zeneca (to O.I.) and the Foundation for Science and
Technology (FCT), Portugal (to P.A.G.).
NR 46
TC 30
Z9 30
U1 5
U2 28
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2013
VL 288
IS 18
BP 12967
EP 12977
DI 10.1074/jbc.M112.396796
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 139AZ
UT WOS:000318555100050
PM 23504317
ER
PT J
AU Donnelly, BF
Needham, PG
Snyder, AC
Roy, A
Khadem, S
Brodsky, JL
Subramanya, AR
AF Donnelly, Bridget F.
Needham, Patrick G.
Snyder, Avin C.
Roy, Ankita
Khadem, Shaheen
Brodsky, Jeffrey L.
Subramanya, Arohan R.
TI Hsp70 and Hsp90 Multichaperone Complexes Sequentially Regulate
Thiazide-sensitive Cotransporter Endoplasmic Reticulum-associated
Degradation and Biogenesis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; NA-CL COTRANSPORTER; HEAT-SHOCK
PROTEINS; CHAPERONE MACHINERY; QUALITY-CONTROL; MOLECULAR CHAPERONES;
GITELMANS-SYNDROME; MUTATIONS; CHIP; CFTR
AB The thiazide-sensitive NaCl cotransporter (NCC) is the primary mediator of salt reabsorption in the distal convoluted tubule and is a key determinant of the blood pressure set point. Given its complex topology, NCC is inefficiently processed and prone to endoplasmic reticulum (ER)-associated degradation (ERAD), although the mechanisms governing this process remain obscure. Here, we identify factors that impact the ER quality control of NCC. Analyses of NCC immunoprecipitates revealed that the cotransporter formed complexes with the core chaperones Hsp90, Hsp70, and Hsp40. Disruption of Hsp90 function accelerated NCC degradation, suggesting that Hsp90 promotes NCC folding. In addition, two cochaperones, the C terminus of Hsp70-interacting protein (CHIP) and the Hsp70/Hsp90 organizer protein, were associated with NCC. Although CHIP, an E3 ubiquitin ligase, promoted NCC ubiquitination and ERAD, the Hsp70/Hsp90 organizer protein stabilized NCC turnover, indicating that these two proteins differentially remodel the core chaperone systems to favor cotransporter degradation and biogenesis, respectively. Adjusting the folding environment in mammalian cells via reduced temperature enhanced NCC biosynthetic trafficking, increased Hsp90-NCC interaction, and diminished binding to Hsp70. In contrast, cotransporters harboring disease-causing mutations that impair NCC biogenesis failed to escape ERAD as efficiently as the wild type protein when cells were incubated at a lower temperature. Instead, these mutants interacted more strongly with Hsp70, Hsp40, and CHIP, consistent with a role for the Hsp70/Hsp40 system in selecting misfolded NCC for ERAD. Collectively, these observations indicate that Hsp70 and Hsp90 comprise two functionally distinct ER quality control checkpoints that sequentially monitor NCC biogenesis.
C1 [Needham, Patrick G.; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15261 USA.
[Donnelly, Bridget F.; Snyder, Avin C.; Roy, Ankita; Khadem, Shaheen; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA.
[Khadem, Shaheen; Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
RP Subramanya, AR (reprint author), 3550 Terrace St,S832 Scaife Hall, Pittsburgh, PA 15261 USA.
EM ars129@pitt.edu
FU National Institutes of Health [DK79307, GM75061]; U.S. Dept. of Veterans
Affairs; James A. Shaver Fund of the American Heart Association
[10BGIA3890010]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants DK79307 (to the Pittsburgh Center for Kidney Research,
Model Organisms Core) and GM75061 (to J. L. B.). This work was also
supported by a Mid-Level Career Development Award from the U.S. Dept. of
Veterans Affairs (to A. R. S.) and Grant 10BGIA3890010 from the James A.
Shaver Fund of the American Heart Association (to A. R. S.).
NR 52
TC 14
Z9 14
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2013
VL 288
IS 18
BP 13124
EP 13135
DI 10.1074/jbc.M113.455394
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 139AZ
UT WOS:000318555100062
PM 23482560
ER
PT J
AU Ramos, AD
Diaz, A
Nellore, A
Delgado, RN
Park, KY
Gonzales-Roybal, G
Oldham, MC
Song, JS
Lim, DA
AF Ramos, Alexander D.
Diaz, Aaron
Nellore, Abhinav
Delgado, Ryan N.
Park, Ki-Youb
Gonzales-Roybal, Gabriel
Oldham, Michael C.
Song, Jun S.
Lim, Daniel A.
TI Integration of Genome-wide Approaches Identifies lncRNAs of Adult Neural
Stem Cells and Their Progeny In Vivo
SO CELL STEM CELL
LA English
DT Article
ID LONG NONCODING RNAS; RETINAL DEVELOPMENT; GENE-EXPRESSION; MOUSE-BRAIN;
CHROMATIN; DIFFERENTIATION; REVEALS; NEUROGENESIS; LINCRNAS; LINEAGE
AB Long noncoding RNAs (lncRNAs) have been described in cell lines and various whole tissues, but lncRNA analysis of development in vivo is limited. Here, we comprehensively analyze lncRNA expression for the adult mouse subventricular zone neural stem cell lineage. We utilize complementary genome-wide techniques including RNA-seq, RNA CaptureSeq, and ChIP-seq to associate specific lncRNAs with neural cell types, developmental processes, and human disease states. By integrating data from chromatin state maps, custom microarrays, and FACS purification of the subventricular zone lineage, we stringently identify lncRNAs with potential roles in adult neurogenesis. shRNA-mediated knockdown of two such lncRNAs, Six3os and Dlx1as, indicate roles for lncRNAs in the glial-neuronal lineage specification of multipotent adult stem cells. Our data and workflow thus provide a uniquely coherent in vivo lncRNA analysis and form the foundation of a user-friendly online resource for the study of lncRNAs in development and disease.
C1 [Ramos, Alexander D.; Delgado, Ryan N.; Park, Ki-Youb; Gonzales-Roybal, Gabriel; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Ramos, Alexander D.; Delgado, Ryan N.; Park, Ki-Youb; Gonzales-Roybal, Gabriel; Oldham, Michael C.; Song, Jun S.; Lim, Daniel A.] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
[Ramos, Alexander D.; Delgado, Ryan N.] Univ Calif San Francisco, Med Scientist Training Program, Biomed Sci Grad Program, San Francisco, CA 94143 USA.
[Diaz, Aaron; Nellore, Abhinav; Song, Jun S.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Oldham, Michael C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Song, Jun S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
[Lim, Daniel A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM limd@neurosurg.ucsf.edu
OI Lim, Daniel/0000-0001-7221-3425
FU NIH [DP2-OD006505-01, R01CA163336]; VA [1I01 BX000252-01]; Sontag
Foundation; Sandler Foundation; NIH GMS [K12-GM081266]; California
Institute for Regenerative Medicine (CIRM); UCSF Program for
Breakthrough Biomedical Research; MSTP [2T32GM007618-34]
FX This project was supported by NIH DP2-OD006505-01, VA 1I01 BX000252-01,
and the Sontag Foundation to D.A.L., NIH R01CA163336 and the Sontag
Foundation to J.S.S., the UCSF Program for Breakthrough Biomedical
Research, which is funded in part by the Sandler Foundation, to M.C.O.,
NIH GMS K12-GM081266 to G.G.-R., a training grant from the California
Institute for Regenerative Medicine (CIRM) to A.D.R., MSTP training
grant 2T32GM007618-34 to A.D.R. and R.N.D, and facilities and resources
provided by the San Francisco Veterans Affairs Medical Center.
NR 55
TC 85
Z9 92
U1 2
U2 37
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 2
PY 2013
VL 12
IS 5
BP 616
EP 628
DI 10.1016/j.stem.2013.03.003
PG 13
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VE
UT WOS:000329569600016
PM 23583100
ER
PT J
AU Kanakry, JA
Li, HL
Gellert, LL
Lemas, MV
Hsieh, WS
Hong, FX
Tan, KL
Gascoyne, RD
Gordon, LI
Fisher, RI
Bartlett, NL
Stiff, P
Cheson, BD
Advani, R
Miller, TP
Kahl, BS
Horning, SJ
Ambinder, RF
AF Kanakry, Jennifer A.
Li, Hailun
Gellert, Lan L.
Lemas, M. Victor
Hsieh, Wen-son
Hong, Fangxin
Tan, King L.
Gascoyne, Randy D.
Gordon, Leo I.
Fisher, Richard I.
Bartlett, Nancy L.
Stiff, Patrick
Cheson, Bruce D.
Advani, Ranjana
Miller, Thomas P.
Kahl, Brad S.
Horning, Sandra J.
Ambinder, Richard F.
TI Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin
lymphoma: correlative analysis from a large North American cooperative
group trial
SO BLOOD
LA English
DT Article
ID TUMOR-ASSOCIATED MACROPHAGES; EBV-DNA; NASOPHARYNGEAL CARCINOMA;
PERIPHERAL-BLOOD; DISEASE; CELL; QUANTITATION; PROGNOSTICATION;
INTERGROUP; IMPACT
AB Epstein-Barr virus (EBV) is associated with Hodgkin lymphoma (HL) and can be detected by in situ hybridization (ISH) of viral nucleic acid (EBER) in tumor cells. We sought to determine whether plasma EBV-DNA could serve as a surrogate for EBER-ISH and to explore its prognostic utility in HL. Specimens from the Cancer Cooperative Intergroup Trial E2496 were used to compare pretreatment plasma EBV-DNA quantification with EBV tumor status by EBER-ISH. A cutoff of >60 viral copies/100 mu L plasma yielded 96% concordance with EBER-ISH. Pretreatment and month 6 plasma specimens were designated EBV(-) or EBV(1) by this cutoff. Patients with pretreatment EBV(1) plasma (n = 54) had inferior failure-free survival (FFS) compared with those with pretreatment EBV(-) plasma (n = 274), log-rank P = .009. By contrast, no difference in FFS was observed when patients were stratified by EBER-ISH. Pretreatment plasma EBV positivity was an independent predictor of treatment failure on multivariate analyses. At month 6, plasma EBV(1) patients (n = 7) had inferior FFS compared with plasma EBV(-) patients (n = 125), log-rank P = .007. These results confirm that plasma EBV-DNA is highly concordant with EBER-ISH in HL and suggest that it may have prognostic utility both at baseline and after therapy. This trial was registered at www.clinicaltrials.gov as #NCT00003389.
C1 [Kanakry, Jennifer A.; Lemas, M. Victor; Ambinder, Richard F.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA.
[Li, Hailun; Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gellert, Lan L.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.
[Hsieh, Wen-son] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore.
[Tan, King L.; Gascoyne, Randy D.] Univ British Columbia, Ctr Lymphoid Canc, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada.
[Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Fisher, Richard I.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA.
[Bartlett, Nancy L.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA.
[Stiff, Patrick] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Cheson, Bruce D.] Georgetown Univ, Ctr Hosp, Washington, DC USA.
[Advani, Ranjana] Stanford Univ, Stanford, CA 94305 USA.
[Miller, Thomas P.] Univ Arizona, Arizona Canc Ctr, Div Hematol & Med Oncol, Tucson, AZ USA.
[Kahl, Brad S.] Univ Wisconsin, Madison, WI USA.
[Horning, Sandra J.] Genentech Inc, San Francisco, CA 94080 USA.
RP Ambinder, RF (reprint author), Johns Hopkins Univ, Dept Hematol Malignancies, 1650 Orleans St,CRB1,Room 389, Baltimore, MD 21287 USA.
EM ambinder@jhu.edu
OI Gordon, Leo/0000-0003-1666-7064
FU National Cancer Institute, National Institutes of Health; Department of
Health and Human Services [CA96888, CA95423, CA21115, CA23318, CA66636,
CA16116, CA17145, CA21076]
FX This work was supported by National Cancer Institute, National
Institutes of Health, and the Department of Health and Human Services
(grants CA96888, CA95423, CA21115, CA23318, CA66636, CA16116, CA17145,
and CA21076). Its contents are solely the responsibility of the authors
and do not necessarily represent the official views of the National
Cancer Institute.
NR 26
TC 38
Z9 39
U1 1
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 2
PY 2013
VL 121
IS 18
BP 3547
EP 3553
DI 10.1182/blood-2012-09-454694
PG 7
WC Hematology
SC Hematology
GA 184EG
UT WOS:000321870000005
PM 23386127
ER
PT J
AU Mullally, A
Bruedigam, C
Poveromo, L
Heidel, FH
Purdon, A
Vu, T
Austin, R
Heckl, D
Breyfogle, LJ
Kuhn, CP
Kalaitzidis, D
Armstrong, SA
Williams, DA
Hill, GR
Ebert, BL
Lane, SW
AF Mullally, Ann
Bruedigam, Claudia
Poveromo, Luke
Heidel, Florian H.
Purdon, Amy
Vu, Therese
Austin, Rebecca
Heckl, Dirk
Breyfogle, Lawrence J.
Kuhn, Catherine Paine
Kalaitzidis, Demetrios
Armstrong, Scott A.
Williams, David A.
Hill, Geoff R.
Ebert, Benjamin L.
Lane, Steven W.
TI Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem
cells by interferon-alpha in a murine model of polycythemia vera
SO BLOOD
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; V617F MUTATION OCCURS; TYROSINE KINASE JAK2;
LONG-TERM TREATMENT; HEMATOPOIETIC STEM; ESSENTIAL THROMBOCYTHEMIA;
BONE-MARROW; PEGYLATED INTERFERON-ALPHA-2A; ACTIVATING MUTATION;
SELF-RENEWAL
AB Interferon-alpha (IFN alpha) is an effective treatment of patients with myeloproliferative neoplasms (MPNs). In addition to inducing hematological responses in most MPN patients, IFN alpha reduces the JAK2V617F allelic burden and can render the JAK2V617F mutant clone undetectable in some patients. The precise mechanism underlying these responses is incompletely understood and whether the molecular responses that are seen occur due to the effects of IFN alpha on JAK2V617F mutant stem cells is debated. Using a murine model of Jak2V617F MPN, we investigated the effects of IFN alpha on Jak2V617F MPN-propagating stem cells in vivo. We report that IFN alpha treatment induces hematological responses in the model and causes depletion of Jak2V617F MPN-propagating cells over time, impairing disease transplantation. We demonstrate that IFN alpha treatment induces cell cycle activation of Jak2V617F mutant long-term hematopoietic stem cells and promotes a predetermined erythroid-lineage differentiation program. These findings provide insights into the differential effects of IFN alpha on Jak2V617F mutant and normal hematopoiesis and suggest that IFN alpha achieves molecular remissions in MPN patients through its effects on MPN stem cells. Furthermore, these results support combinatorial therapeutic approaches in MPN by concurrently depleting dormant JAK2V617F MPN propagating stem cells with IFN alpha and targeting the proliferating downstream progeny with JAK2 inhibitors or cytotoxic chemotherapy.
C1 [Mullally, Ann; Poveromo, Luke; Heckl, Dirk; Breyfogle, Lawrence J.; Ebert, Benjamin L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA.
[Bruedigam, Claudia; Purdon, Amy; Vu, Therese; Austin, Rebecca; Kuhn, Catherine Paine; Hill, Geoff R.; Lane, Steven W.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Heidel, Florian H.] Otto Von Guericke Univ, Klin Hamatol & Onkol, Magdeburg, Germany.
[Kalaitzidis, Demetrios; Armstrong, Scott A.; Williams, David A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA.
[Kalaitzidis, Demetrios; Armstrong, Scott A.; Williams, David A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Lane, Steven W.] Univ Queensland, Brisbane, Qld, Australia.
RP Lane, SW (reprint author), Queensland Inst Med Res, 300 Herston Rd, Brisbane, Qld 4006, Australia.
EM amullally@partners.org; steven.lane@qimr.edu.au
RI Lane, Steven/C-3215-2012; Hill, Geoffrey/O-2630-2016
OI Lane, Steven/0000-0002-8050-6209; Hill, Geoffrey/0000-0003-2994-0429
FU MPN Foundation; National Institutes of Health, National Cancer Institute
[P01 CA108631, P01 CA066996]; National Institutes of Health, National
Heart, Lung, and Blood Institute [K08 HL109734]; German Cancer Aid
(Deutsche Krebshilfe) [DKH D/08/00661]; German Cancer Foundation,
Mildred-Scheel Fellowship; National Institute of Diabetes and Digestive
and Kidney Diseases [K01DK092300]; Jeanne D. Housman Fund for Research
on Myeloproliferative Disorders; Leukaemia Foundation of Australia;
National Health and Medical Research Council [1026594]; J.J. Richards/In
Vitro Technologies Rhys Pengelly Fellowship in Leukaemia Research
FX This work was supported by the MPN Foundation (B. L. E.) and the
National Institutes of Health, National Cancer Institute (P01 CA108631
and P01 CA066996 to B. L. E.) and the National Institutes of Health,
National Heart, Lung, and Blood Institute (K08 HL109734 to A. M.). G. R.
H. is a NHMRC Australia Fellow and Queensland Health Senior Clinical
Research Fellow. F. H. H. was supported by a Mildred-Scheel grant of the
German Cancer Aid (DKH D/08/00661, Deutsche Krebshilfe). D. H. was
supported by the German Cancer Foundation, Mildred-Scheel Fellowship.
D.K. was supported by National Institute of Diabetes and Digestive and
Kidney Diseases grant K01DK092300. A. M. has received support from the
Jeanne D. Housman Fund for Research on Myeloproliferative Disorders and
is an ASH Scholar recipient. S. W. L. has received funding from the
Leukaemia Foundation of Australia, National Health and Medical Research
Council project grant 1026594, J.J. Richards/In Vitro Technologies Rhys
Pengelly Fellowship in Leukaemia Research and private philanthropic
donations.
NR 56
TC 35
Z9 36
U1 0
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 2
PY 2013
VL 121
IS 18
BP 3692
EP 3702
DI 10.1182/blood-2012-05-432989
PG 11
WC Hematology
SC Hematology
GA 184EG
UT WOS:000321870000022
PM 23487027
ER
PT J
AU Van Daele, CM
De Meyer, T
De Buyzere, ML
Gillebert, TC
Denil, SLIJ
Bekaert, S
Chirinos, JA
Segers, P
De Backer, GG
De Bacquer, D
Rietzschel, ER
AF Van Daele, Caroline M.
De Meyer, Tim
De Buyzere, Marc L.
Gillebert, Thierry C.
Denil, Simon L. I. J.
Bekaert, Sofie
Chirinos, Julio A.
Segers, Patrick
De Backer, Guy G.
De Bacquer, Dirk
Rietzschel, Ernst R.
CA Asklepios Investigators
TI Addition of a Novel, Protective Family History Category Allows Better
Profiling of Cardiovascular Risk and Atherosclerotic Burden in the
General Population. The Asklepios Study
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; MIDDLE-AGED ADULTS; LOW-DENSITY-LIPOPROTEIN;
INTIMA-MEDIA THICKNESS; MYOCARDIAL-INFARCTION; PARENTAL-HISTORY; STROKE;
HEALTH; STATEMENT; MEDICINE
AB Objectives: Whereas the importance of family history (FH) is widely recognized in cardiovascular risk assessment, its full potential could be underutilized, when applied with its current simple guidelines-based definition (cFH): presence of premature cardiovascular disease (CVD) in a first-degree relative. We tested the added value of a new, extended family history definition (eFH), also taking into account later onset of disease, second-degree relatives and number of affected relatives, on profiling cardiovascular risk and atherosclerotic burden in the general population.
Design: longitudinal population study.
Setting: random, representative population sample from Erpe-Mere and Nieuwerkerken (Belgium, primary care).
Subjects: 2524 male/female volunteers, aged 35-55 years, free from overt CVD.
Main outcome measures: Subjects were extensively phenotyped including presence of atherosclerosis (ultrasound) and a newly developed FH questionnaire (4 generations).
Results: Compared to cFH, eFH was superior in predicting an adverse risk profile (glycemic state, elevated blood pressure, lipid abnormalities, presence of metabolic syndrome components) and presence of atherosclerosis (all age & sex-adjusted p<0.05). Unlike cFH, eFH remained a significant predictor of subclinical atherosclerosis after adjusting for confounders. Most relations with eFH were not graded but showed clear informational breakpoints, with absence of CVD (including late onset) in any first-degree relative being a negative predictor of atherosclerosis, and a particularly interesting phenotype for further study.
Conclusions: A novel, extended FH definition is superior to the conventional definition in profiling cardiovascular risk and atherosclerotic burden in the general population. There remain clear opportunities to refine and increase the performance and informational content of this simple, readily-available inexpensive tool.
C1 [Van Daele, Caroline M.; De Buyzere, Marc L.; Gillebert, Thierry C.; Rietzschel, Ernst R.] Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium.
[De Meyer, Tim; Denil, Simon L. I. J.] Univ Ghent, Fac Biosci Engn, Dept Math Modelling Stat & Bioinformat, B-9000 Ghent, Belgium.
[Bekaert, Sofie] Ghent Univ Hosp, Clin Res Ctr Ghent, Bimetra, Ghent, Belgium.
[Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA.
[Segers, Patrick] Univ Ghent, Inst Biomed Technol IbiTech, B-9000 Ghent, Belgium.
[De Backer, Guy G.; De Bacquer, Dirk; Rietzschel, Ernst R.] Univ Ghent, Fac Med & Hlth Sci, Dept Publ Hlth, B-9000 Ghent, Belgium.
RP Van Daele, CM (reprint author), Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium.
EM Caroline.Vandaele@UGent.be
OI Gillebert, Thierry/0000-0002-3832-919X
FU Fund for Scientific Research - Flanders (FWO) [G042703, G083810N]
FX The Asklepios Study is supported by the Fund for Scientific Research -
Flanders (FWO research grants G042703 and G083810N). The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 52
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 2
PY 2013
VL 8
IS 5
AR e63185
DI 10.1371/journal.pone.0063185
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175AF
UT WOS:000321200500058
PM 23658806
ER
PT J
AU Tirumani, SH
Jagannathan, JP
Regan, KO
Kim, KW
Shinagare, AB
Krajewski, KM
Ramaiya, NH
AF Tirumani, Sree Harsha
Jagannathan, Jyothi P.
Regan, Kevin O.
Kim, Kyung Won
Shinagare, Atul B.
Krajewski, Katherine M.
Ramaiya, Nikhil H.
TI Molecular targeted therapies in non-GIST soft tissue sarcomas: what the
radiologist needs to know
SO CANCER IMAGING
LA English
DT Review
DE Soft tissue sarcomas; molecular targeted therapies; CT; MRI; PET/CT;
drug toxicities
ID RENAL-CELL CARCINOMA; TUMOR RESPONSE ASSESSMENT; GASTROINTESTINAL
STROMAL TUMOR; POSITRON-EMISSION-TOMOGRAPHY; PHASE-II TRIAL;
SINGLE-INSTITUTION; IMATINIB MESYLATE; PART SARCOMA; DERMATOFIBROSARCOMA
PROTUBERANS; VILLONODULAR SYNOVITIS
AB Non-gastrointestinal stromal soft tissue sarcomas are uncommon neoplasms that have a dismal prognosis due to a high incidence of metastases and a poor response to conventional chemotherapy. The identification of characteristic genetic alterations in several of these tumors has opened the window for molecular targeted therapies in patients who have failed conventional chemotherapy. Imaging plays a critical role in assessing the response to these novel therapeutic agents. Just like the response of gastrointestinal stromal tumors to imatinib, the response of non-gastrointestinal stromal soft tissue sarcomas to molecular targeted drugs is better evaluated on imaging by alternate tumor response criteria such as the Choi criteria. In addition, these drugs are associated with distinct class-specific drug toxicities that can come to attention for the first time on imaging. The purpose of this article is to provide a primer for the radiologist on the various molecular targeted therapies in advanced/metastatic non-gastrointestinal stromal soft tissue sarcomas with emphasis on the role of imaging in assessing treatment response and complications.
C1 [Tirumani, Sree Harsha; Jagannathan, Jyothi P.; Kim, Kyung Won; Krajewski, Katherine M.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA.
[Tirumani, Sree Harsha; Jagannathan, Jyothi P.; Kim, Kyung Won; Shinagare, Atul B.; Krajewski, Katherine M.; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA.
[Regan, Kevin O.] Cork Univ Hosp, Dept Radiol, Cork, Ireland.
RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA.
EM stirumani@partners.org
NR 65
TC 7
Z9 7
U1 0
U2 7
PU E-MED
PI LONDON
PA PO BOX 29761, LONDON, NW3 7ZS, ENGLAND
SN 1470-7330
J9 CANCER IMAGING
JI Cancer Imaging
PD MAY 2
PY 2013
VL 13
IS 2
BP 197
EP 211
DI 10.1102/1470-7330.2013.0022
PG 15
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 173EA
UT WOS:000321059700001
PM 23649384
ER
PT J
AU Getz, G
Gabriel, SB
Cibulskis, K
Lander, E
Sivachenko, A
Sougnez, C
Lawrence, M
Kandoth, C
Dooling, D
Fulton, R
Fulton, L
Kalicki-Veizer, J
McLellan, MD
O'Laughlin, M
Schmidt, H
Wilson, RK
Ye, K
Ding, L
Mardis, ER
Ally, A
Balasundaram, M
Birol, I
Butterfield, YSN
Carlsen, R
Carter, C
Chu, A
Chuah, E
Chun, HJE
Dhalla, N
Guin, R
Hirst, C
Holt, RA
Jones, SJM
Lee, D
Li, HI
Marra, MA
Mayo, M
Moore, RA
Mungall, AJ
Plettner, P
Schein, JE
Sipahimalani, P
Tam, A
Varhol, RJ
Robertson, AG
Pashtan, I
Saksena, G
Onofrio, RC
Schumacher, SE
Tabak, B
Carter, SL
Hernandez, B
Gentry, J
Salvesen, HB
Ardlie, K
Getz, G
Winckler, W
Beroukhim, R
Gabriel, SB
Meyerson, M
Hadjipanayis, A
Lee, S
Mahadeshwar, HS
Park, P
Protopopov, A
Ren, XJ
Seth, S
Song, XZ
Tang, JB
Xi, RB
Yang, LX
Zeng, D
Kucherlapati, R
Chin, L
Zhang, JH
Auman, JT
Balu, S
Bodenheimer, T
Buda, E
Hayes, DN
Hoyle, AP
Jefferys, SR
Jones, CD
Meng, SW
Mieczkowski, PA
Mose, LE
Parker, JS
Perou, CM
Roach, J
Shi, Y
Simons, JV
Soloway, MG
Tan, DH
Topal, MD
Waring, S
Wu, JY
Hoadley, KA
Baylin, SB
Bootwalla, MS
Lai, PH
Triche, TJ
Van Den Berg, D
Weisenberger, DJ
Laird, PW
Shen, H
Chin, L
Zhang, JH
Getz, G
Cho, J
DiCara, D
Frazer, S
Heiman, D
Jing, R
Lin, P
Mallard, W
Stojanov, P
Voet, D
Zhang, HL
Zou, LH
Noble, M
Lawrence, M
Reynolds, SM
Shmulevich, I
Aksoy, BA
Antipin, Y
Ciriello, G
Dresdner, G
Gao, JJ
Gross, B
Jacobsen, A
Ladanyi, M
Reva, B
Sander, C
Sinha, R
Sumer, SO
Taylor, BS
Cerami, E
Weinhold, N
Schultz, N
Shen, RL
Benz, S
Goldstein, T
Haussler, D
Ng, S
Szeto, C
Stuart, J
Benz, CC
Yau, C
Zhang, W
Annala, M
Broom, BM
Casasent, TD
Ju, ZL
Liang, H
Liu, GY
Lu, YL
Unruh, AK
Wakefield, C
Weinstein, JN
Zhang, NX
Liu, YX
Broaddus, R
Akbani, R
Mills, GB
Adams, C
Barr, T
Black, AD
Bowen, J
Deardurff, J
Frick, J
Gastier-Foster, JM
Grossman, T
Harper, HA
Hart-Kothari, M
Helsel, C
Hobensack, A
Kuck, H
Kneile, K
Leraas, K
Lichtenberg, TM
McAllister, C
Pyatt, RE
Ramirez, NC
Tabler, TR
Vanhoose, N
White, P
Wise, L
Zmuda, E
Barnabas, N
Berry-Green, C
Blanc, V
Boice, L
Button, M
Farkas, A
Green, A
MacKenzie, J
Nicholson, D
Kalloger, SE
Gilks, CB
Karlan, BY
Lester, J
Orsulic, S
Borowsky, M
Cadungog, M
Czerwinski, C
Huelsenbeck-Dill, L
Iacocca, M
Petrelli, N
Petrelli, N
Witkin, G
Nemirovich-Danchenko, E
Potapova, O
Rotin, D
Berchuck, A
Birrer, M
DiSaia, P
Monovich, L
Curley, E
Gardner, J
Mallery, D
Penny, R
Dowdy, SC
Winterhoff, B
Dao, L
Gostout, B
Meuter, A
Teoman, A
Dao, F
Olvera, N
Bogomolniy, F
Garg, K
Soslow, RA
Levine, DA
Abramov, M
Bartlett, JMS
Kodeeswaran, S
Parfitt, J
Moiseenko, F
Clarke, BA
Goodman, MT
Carney, ME
Matsuno, RK
Fisher, J
Huang, M
Rathmell, WK
Thorne, L
Van Le, L
Dhir, R
Edwards, R
Elishaev, E
Zorn, K
Broaddus, R
Goodfellow, PJ
Mutch, D
Schultz, N
Liu, YX
Akbani, R
Cherniack, AD
Cerami, E
Weinhold, N
Shen, H
Hoadley, KA
Kahn, AB
Bell, DW
Pollock, PM
Wang, C
Wheeler, DA
Shinbrot, E
Karlan, BY
Berchuck, A
Dowdy, SC
Winterhoff, B
Goodman, MT
Robertson, AG
Beroukhim, R
Pashtan, I
Salvesen, HB
Laird, PW
Noble, M
Stuart, J
Ding, L
Kandoth, C
Gilks, CB
Soslow, RA
Goodfellow, PJ
Mutch, D
Broaddus, R
Zhang, W
Mills, GB
Kucherlapati, R
Mardis, ER
Levine, DA
Ayala, B
Chu, AL
Jensen, MA
Kothiyal, P
Pihl, TD
Pontius, J
Pot, DA
Snyder, EE
Srinivasan, D
Kahn, AB
Shaw, KRM
Sheth, M
Davidsen, T
Eley, G
Ferguson, ML
Demchok, JA
Yang, LM
Guyer, MS
Ozenberger, BA
Sofia, HJ
Kandoth, C
Schultz, N
Cherniack, AD
Akbani, R
Liu, YX
Shen, H
Robertson, AG
Pashtan, I
Shen, R
Benz, CC
Yau, C
Laird, PW
Ding, L
Zhang, W
Mills, GB
Kucherlapati, R
Mardis, ER
Levine, DA
AF Getz, Gad
Gabriel, Stacey B.
Cibulskis, Kristian
Lander, Eric
Sivachenko, Andrey
Sougnez, Carrie
Lawrence, Mike
Kandoth, Cyriac
Dooling, David
Fulton, Robert
Fulton, Lucinda
Kalicki-Veizer, Joelle
McLellan, Michael D.
O'Laughlin, Michelle
Schmidt, Heather
Wilson, Richard K.
Ye, Kai
Ding, Li
Mardis, Elaine R.
Ally, Adrian
Balasundaram, Miruna
Birol, Inanc
Butterfield, Yaron S. N.
Carlsen, Rebecca
Carter, Candace
Chu, Andy
Chuah, Eric
Chun, Hye-Jung E.
Dhalla, Noreen
Guin, Ranabir
Hirst, Carrie
Holt, Robert A.
Jones, Steven J. M.
Lee, Darlene
Li, Haiyan I.
Marra, Marco A.
Mayo, Michael
Moore, Richard A.
Mungall, Andrew J.
Plettner, Patrick
Schein, Jacqueline E.
Sipahimalani, Payal
Tam, Angela
Varhol, Richard J.
Robertson, A. Gordon
Pashtan, Itai
Saksena, Gordon
Onofrio, Robert C.
Schumacher, Steven E.
Tabak, Barbara
Carter, Scott L.
Hernandez, Bryan
Gentry, Jeff
Salvesen, Helga B.
Ardlie, Kristin
Getz, Gad
Winckler, Wendy
Beroukhim, Rameen
Gabriel, Stacey B.
Meyerson, Matthew
Hadjipanayis, Angela
Lee, Semin
Mahadeshwar, Harshad S.
Park, Peter
Protopopov, Alexei
Ren, Xiaojia
Seth, Sahil
Song, Xingzhi
Tang, Jiabin
Xi, Ruibin
Yang, Lixing
Zeng, Dong
Kucherlapati, Raju
Chin, Lynda
Zhang, Jianhua
Auman, J. Todd
Balu, Saianand
Bodenheimer, Tom
Buda, Elizabeth
Hayes, D. Neil
Hoyle, Alan P.
Jefferys, Stuart R.
Jones, Corbin D.
Meng, Shaowu
Mieczkowski, Piotr A.
Mose, Lisle E.
Parker, Joel S.
Perou, Charles M.
Roach, Jeff
Shi, Yan
Simons, Janae V.
Soloway, Mathew G.
Tan, Donghui
Topal, Michael D.
Waring, Scot
Wu, Junyuan
Hoadley, Katherine A.
Baylin, Stephen B.
Bootwalla, Moiz S.
Lai, Phillip H.
Triche, Timothy J., Jr.
Van Den Berg, DavidJ.
Weisenberger, Daniel J.
Laird, Peter W.
Shen, Hui
Chin, Lynda
Zhang, Jianhua
Getz, Gad
Cho, Juok
DiCara, Daniel
Frazer, Scott
Heiman, David
Jing, Rui
Lin, Pei
Mallard, Will
Stojanov, Petar
Voet, Doug
Zhang, Hailei
Zou, Lihua
Noble, Michael
Lawrence, Mike
Reynolds, Sheila M.
Shmulevich, Ilya
Aksoy, B. Arman
Antipin, Yevgeniy
Ciriello, Giovanni
Dresdner, Gideon
Gao, Jianjiong
Gross, Benjamin
Jacobsen, Anders
Ladanyi, Marc
Reva, Boris
Sander, Chris
Sinha, Rileen
Sumer, S. Onur
Taylor, Barry S.
Cerami, Ethan
Weinhold, Nils
Schultz, Nikolaus
Shen, Ronglai
Benz, Stephen
Goldstein, Ted
Haussler, David
Sam Ng
Szeto, Christopher
Stuart, Joshua
Benz, Christopher C.
Yau, Christina
Zhang, Wei
Annala, Matti
Broom, Bradley M.
Casasent, Tod D.
Ju, Zhenlin
Liang, Han
Liu, Guoyan
Lu, Yiling
Unruh, Anna K.
Wakefield, Chris
Weinstein, John N.
Zhang, Nianxiang
Liu, Yuexin
Broaddus, Russell
Akbani, Rehan
Mills, Gordon B.
Adams, Christopher
Barr, Thomas
Black, Aaron D.
Bowen, Jay
Deardurff, John
Frick, Jessica
Gastier-Foster, Julie M.
Grossman, Thomas
Harper, Hollie A.
Hart-Kothari, Melissa
Helsel, Carmen
Hobensack, Aaron
Kuck, Harkness
Kneile, Kelley
Leraas, KristenM.
Lichtenberg, Tara M.
McAllister, Cynthia
Pyatt, Robert E.
Ramirez, Nilsa C.
Tabler, Teresa R.
Vanhoose, Nathan
White, Peter
Wise, Lisa
Zmuda, Erik
Barnabas, Nandita
Berry-Green, Charlenia
Blanc, Victoria
Boice, Lori
Button, Michael
Farkas, Adam
Green, Alex
MacKenzie, Jean
Nicholson, Dana
Kalloger, Steve E.
Gilks, C. Blake
Karlan, Beth Y.
Lester, Jenny
Orsulic, Sandra
Borowsky, Mark
Cadungog, Mark
Czerwinski, Christine
Huelsenbeck-Dill, Lori
Iacocca, Mary
Petrelli, Nicholas
Petrelli, Nicholas
Witkin, Gary
Nemirovich-Danchenko, Elena
Potapova, Olga
Rotin, Daniil
Berchuck, Andrew
Birrer, Michael
DiSaia, Phillip
Monovich, Laura
Curley, Erin
Gardner, Johanna
Mallery, David
Penny, Robert
Dowdy, Sean C.
Winterhoff, Boris
Dao, Linda
Gostout, Bobbie
Meuter, Alexandra
Teoman, Attila
Dao, Fanny
Olvera, Narciso
Bogomolniy, Faina
Garg, Karuna
Soslow, Robert A.
Levine, Douglas A.
Abramov, Mikhail
Bartlett, John M. S.
Kodeeswaran, Sugy
Parfitt, Jeremy
Moiseenko, Fedor
Clarke, Blaise A.
Goodman, Marc T.
Carney, Michael E.
Matsuno, Rayna K.
Fisher, Jennifer
Huang, Mei
Rathmell, W. Kimryn
Thorne, Leigh
Van Le, Linda
Dhir, Rajiv
Edwards, Robert
Elishaev, Esther
Zorn, Kristin
Broaddus, Russell
Goodfellow, Paul J.
Mutch, David
Schultz, Nikolaus
Liu, Yuexin
Akbani, Rehan
Cherniack, Andrew D.
Cerami, Ethan
Weinhold, Nils
Shen, Hui
Hoadley, Katherine A.
Kahn, Ari B.
Bell, Daphne W.
Pollock, Pamela M.
Wang, Chen
Wheeler, David A.
Shinbrot, Eve
Karlan, Beth Y.
Berchuck, Andrew
Dowdy, Sean C.
Winterhoff, Boris
Goodman, Marc T.
Robertson, A. Gordon
Beroukhim, Rameen
Pashtan, Itai
Salvesen, Helga B.
Laird, Peter W.
Noble, Michael
Stuart, Joshua
Ding, Li
Kandoth, Cyriac
Gilks, C. Blake
Soslow, Robert A.
Goodfellow, Paul J.
Mutch, David
Broaddus, Russell
Zhang, Wei
Mills, Gordon B.
Kucherlapati, Raju
Mardis, Elaine R.
Levine, Douglas A.
Ayala, Brenda
Chu, Anna L.
Jensen, Mark A.
Kothiyal, Prachi
Pihl, Todd D.
Pontius, Joan
Pot, David A.
Snyder, Eric E.
Srinivasan, Deepak
Kahn, Ari B.
Shaw, Kenna R. Mills
Sheth, Margi
Davidsen, Tanja
Eley, Greg
Ferguson, Martin L.
Demchok, John A.
Yang, Liming
Guyer, Mark S.
Ozenberger, Bradley A.
Sofia, Heidi J.
Kandoth, Cyriac
Schultz, Nikolaus
Cherniack, Andrew D.
Akbani, Rehan
Liu, Yuexin
Shen, Hui
Robertson, A. Gordon
Pashtan, Itai
Shen, Ronglai
Benz, Christopher C.
Yau, Christina
Laird, Peter W.
Ding, Li
Zhang, Wei
Mills, Gordon B.
Kucherlapati, Raju
Mardis, Elaine R.
Levine, Douglas A.
CA Canc Genome Atlas Res Network
TI Integrated genomic characterization of endometrial carcinoma
SO NATURE
LA English
DT Article
ID GYNECOLOGIC-ONCOLOGY-GROUP; MICROSATELLITE INSTABILITY; MATRIX
FACTORIZATION; SOMATIC MUTATIONS; HIGH-FREQUENCY; LUNG-CANCER; TUMORS;
COLON; DOXORUBICIN; PROTEIN
AB We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine seroustumours and similar to 25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in the SWI/SNF chromatin remodelling complex gene ARID5B. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.
C1 [Getz, Gad; Gabriel, Stacey B.; Cibulskis, Kristian; Lander, Eric; Sivachenko, Andrey; Sougnez, Carrie; Lawrence, Mike; Pashtan, Itai; Saksena, Gordon; Onofrio, Robert C.; Schumacher, Steven E.; Tabak, Barbara; Carter, Scott L.; Hernandez, Bryan; Gentry, Jeff; Salvesen, Helga B.; Ardlie, Kristin; Winckler, Wendy; Beroukhim, Rameen; Meyerson, Matthew; Chin, Lynda; Cho, Juok; DiCara, Daniel; Frazer, Scott; Heiman, David; Jing, Rui; Lin, Pei; Mallard, Will; Stojanov, Petar; Voet, Doug; Zhang, Hailei; Zou, Lihua; Noble, Michael; Cherniack, Andrew D.] MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02139 USA.
[Kandoth, Cyriac; Dooling, David; Fulton, Robert; Fulton, Lucinda; Kalicki-Veizer, Joelle; McLellan, Michael D.; O'Laughlin, Michelle; Schmidt, Heather; Wilson, Richard K.; Ye, Kai; Ding, Li; Mardis, Elaine R.] Washington Univ, Genome Inst, St Louis, MO 63108 USA.
[Mardis, Elaine R.; Ally, Adrian; Balasundaram, Miruna; Birol, Inanc; Butterfield, Yaron S. N.; Carlsen, Rebecca; Carter, Candace; Chu, Andy; Chuah, Eric; Chun, Hye-Jung E.; Dhalla, Noreen; Guin, Ranabir; Hirst, Carrie; Holt, Robert A.; Jones, Steven J. M.; Lee, Darlene; Li, Haiyan I.; Marra, Marco A.; Mayo, Michael; Moore, Richard A.; Mungall, Andrew J.; Plettner, Patrick; Schein, Jacqueline E.; Sipahimalani, Payal; Tam, Angela; Varhol, Richard J.; Robertson, A. Gordon] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada.
Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02215 USA.
Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway.
Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway.
[Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Hadjipanayis, Angela; Ren, Xiaojia; Kucherlapati, Raju] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Lee, Semin; Park, Peter; Xi, Ruibin; Yang, Lixing] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
[Mahadeshwar, Harshad S.; Protopopov, Alexei; Seth, Sahil; Song, Xingzhi; Tang, Jiabin; Zeng, Dong; Zhang, Jianhua] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Inst Appl Canc Sci, Houston, TX 77054 USA.
[Park, Peter] Boston Childrens Hosp, Informat Program, Boston, MA 02115 USA.
[Auman, J. Todd] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
[Auman, J. Todd] Univ N Carolina, Inst Pharmacogenet & Individualized Therapy, Chapel Hill, NC 27599 USA.
[Balu, Saianand; Bodenheimer, Tom; Buda, Elizabeth; Hayes, D. Neil; Hoyle, Alan P.; Jefferys, Stuart R.; Meng, Shaowu; Mose, Lisle E.; Parker, Joel S.; Perou, Charles M.; Shi, Yan; Simons, Janae V.; Soloway, Mathew G.; Tan, Donghui; Topal, Michael D.; Waring, Scot; Wu, Junyuan; Rathmell, W. Kimryn] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Hayes, D. Neil] Univ N Carolina, Div Med Oncol, Dept Internal Med, Chapel Hill, NC 27599 USA.
[Jones, Corbin D.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.
[Mieczkowski, Piotr A.; Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Perou, Charles M.; Topal, Michael D.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
[Roach, Jeff] Univ N Carolina, Res Comp Ctr, Chapel Hill, NC 27599 USA.
[Baylin, Stephen B.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Canc Biol Div, Baltimore, MD 21231 USA.
[Bootwalla, Moiz S.; Lai, Phillip H.; Triche, Timothy J., Jr.; Van Den Berg, DavidJ.; Weisenberger, Daniel J.; Laird, Peter W.; Shen, Hui] Univ So Calif, Epigenome Ctr, Los Angeles, CA 90089 USA.
[Reynolds, Sheila M.; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA 98109 USA.
[Aksoy, B. Arman; Antipin, Yevgeniy; Ciriello, Giovanni; Dresdner, Gideon; Gao, Jianjiong; Gross, Benjamin; Jacobsen, Anders; Reva, Boris; Sander, Chris; Sinha, Rileen; Sumer, S. Onur; Cerami, Ethan; Weinhold, Nils; Schultz, Nikolaus] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA.
[Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Taylor, Barry S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.
[Shen, Ronglai] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
[Benz, Stephen; Goldstein, Ted; Haussler, David; Sam Ng; Szeto, Christopher; Stuart, Joshua] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.
[Benz, Stephen; Goldstein, Ted; Sam Ng; Szeto, Christopher; Stuart, Joshua] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.
[Benz, Christopher C.; Yau, Christina] Buck Inst Age Res, Novato, CA 94945 USA.
[Zhang, Wei; Annala, Matti; Liu, Guoyan; Liu, Yuexin] Univ Texas MD Anderson Canc Ctr, Canc Genom Core Lab, Houston, TX 77054 USA.
[Liu, Guoyan; Liu, Yuexin; Broaddus, Russell] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
Tampere Univ Technol, FI-33720 Tampere, Finland.
[Bootwalla, Moiz S.; Van Den Berg, DavidJ.; Weisenberger, Daniel J.; Broom, Bradley M.; Ju, Zhenlin; Liang, Han; Unruh, Anna K.; Wakefield, Chris; Akbani, Rehan] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
[Lu, Yiling; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
[Adams, Christopher; Barr, Thomas; Black, Aaron D.; Bowen, Jay; Deardurff, John; Frick, Jessica; Gastier-Foster, Julie M.; Grossman, Thomas; Harper, Hollie A.; Hart-Kothari, Melissa; Helsel, Carmen; Hobensack, Aaron; Kuck, Harkness; Kneile, Kelley; Leraas, KristenM.; Lichtenberg, Tara M.; McAllister, Cynthia; Pyatt, Robert E.; Ramirez, Nilsa C.; Tabler, Teresa R.; Vanhoose, Nathan; White, Peter; Wise, Lisa; Zmuda, Erik] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA.
[Gastier-Foster, Julie M.; Ramirez, Nilsa C.; Goodfellow, Paul J.] Ohio State Univ, Columbus, OH 43210 USA.
[Barnabas, Nandita; Berry-Green, Charlenia; Blanc, Victoria; Button, Michael; Farkas, Adam; Green, Alex; MacKenzie, Jean; Nicholson, Dana] Asterand, Detroit, MI 48202 USA.
[Boice, Lori; Fisher, Jennifer; Huang, Mei; Thorne, Leigh; Van Le, Linda] Univ N Carolina, Chapel Hill, NC 27599 USA.
[Kalloger, Steve E.; Gilks, C. Blake] British Columbia Canc Agcy, OvCaRe British Columbia, Vancouver, BC V5Z 4E6, Canada.
[Kalloger, Steve E.; Gilks, C. Blake] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
[Karlan, Beth Y.; Lester, Jenny; Orsulic, Sandra] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA.
[Borowsky, Mark; Cadungog, Mark; Czerwinski, Christine; Huelsenbeck-Dill, Lori; Iacocca, Mary; Petrelli, Nicholas; Witkin, Gary] Helen F Graham Canc Ctr Christiana Care, Newark, DC 19713 USA.
[Nemirovich-Danchenko, Elena; Potapova, Olga; Rotin, Daniil] Cureline Inc, San Francisco, CA 94080 USA.
[Berchuck, Andrew] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA.
[Birrer, Michael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[DiSaia, Phillip] Univ Calif Irvine, Med Ctr, Orange, CA 92868 USA.
[Monovich, Laura] Nationwide Childrens Hosp, Res Inst, GOG Tissue Bank, Columbus, OH 43205 USA.
[Curley, Erin; Gardner, Johanna; Mallery, David; Penny, Robert] Int Genom Consortium, Phoenix, AZ 85004 USA.
[Dowdy, Sean C.; Winterhoff, Boris; Gostout, Bobbie; Meuter, Alexandra; Teoman, Attila] Mayo Clin, Div Gynecol Oncol, Dept OB Gyn, Rochester, MN 55905 USA.
[Dao, Linda] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA.
[Dao, Fanny; Olvera, Narciso; Bogomolniy, Faina; Levine, Douglas A.] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA.
[Garg, Karuna; Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
[Abramov, Mikhail] NN Blokhin Russian Canc Res Ctr RAMS, Moscow 115478, Russia.
[Bartlett, John M. S.; Kodeeswaran, Sugy] Ontario Inst Canc Res, Ontario Tumour Bank, Toronto, ON M5G 0A3, Canada.
[Parfitt, Jeremy] London Hlth Sci Ctr, Ontario Tumour Bank, London, ON N6A 5A5, Canada.
[Moiseenko, Fedor] St Petersburg Acad Univ, St Petersburg 199034, Russia.
[Clarke, Blaise A.; Demchok, John A.; Yang, Liming] Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2C4, Canada.
[Goodman, Marc T.; Carney, Michael E.; Matsuno, Rayna K.; Eley, Greg] Univ Hawaii, Honolulu, HI 96813 USA.
[Goodman, Marc T.] Cedars Sinai Med Ctr, Los Angeles, CA 90024 USA.
[Dhir, Rajiv; Edwards, Robert; Elishaev, Esther; Zorn, Kristin] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
[Goodfellow, Paul J.; Mutch, David] Washington Univ, Sch Med, St Louis, MO 63110 USA.
[Kahn, Ari B.; Ayala, Brenda; Chu, Anna L.; Jensen, Mark A.; Kothiyal, Prachi; Pihl, Todd D.; Pontius, Joan; Pot, David A.; Snyder, Eric E.; Srinivasan, Deepak] SRA Int, Fairfax, VA 22033 USA.
[Bell, Daphne W.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
[Pollock, Pamela M.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
[Wang, Chen] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN 55905 USA.
[Wheeler, David A.; Shinbrot, Eve] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Shaw, Kenna R. Mills; Sheth, Margi; Davidsen, Tanja] NCI, Canc Genome Atlas Program Off, NIH, Bethesda, MD 20892 USA.
Scimentis LLC, Atlanta, GA 30666 USA.
[Ferguson, Martin L.] MLF Consulting, Arlington, MD 02474 USA.
[Guyer, Mark S.; Ozenberger, Bradley A.; Sofia, Heidi J.] NHGRI, NIH, Bethesda, MD 20892 USA.
RP Getz, G (reprint author), MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02139 USA.
RI Lee, Semin/S-2629-2016; Marra, Marco/B-5987-2008; Birol,
Inanc/G-5440-2011; salvesen, Helga/C-1187-2017; Jones,
Steven/C-3621-2009; Jacobsen, Anders/K-1081-2013; Schumacher,
Steven/E-9821-2013; Reva, Boris/B-6436-2014; Tang, Macy/B-9798-2014;
White, Peter/E-4301-2011; Moiseenko, Fedor/E-1775-2014; Holt,
Robert/C-3303-2009; Ye, Kai/B-3640-2012; Laird, Peter/G-8683-2012;
Schein, Jacquie/G-3674-2015; Gao, Jianjiong/B-5673-2016; Wang,
Chen/B-3244-2011
OI Seth, Sahil/0000-0003-4579-3959; Pot, David/0000-0002-1480-9826; Sinha,
Rileen/0000-0001-5497-5055; Casasent, Anna/0000-0002-7857-179X; Perou,
Charles/0000-0001-9827-2247; Lee, Semin/0000-0002-9015-6046; Birol,
Inanc/0000-0003-0950-7839; salvesen, Helga/0000-0002-4438-8831; Liang,
Han/0000-0001-7633-286X; Schultz, Nikolaus/0000-0002-0131-4904; Benz,
Stephen/0000-0002-4067-0602; Kandoth, Cyriac/0000-0002-1345-3573;
Triche, Tim/0000-0001-5665-946X; Soslow, Robert/0000-0002-7269-5898;
Jacobsen, Anders/0000-0001-6847-4980; Schumacher,
Steven/0000-0002-6819-5647; Reva, Boris/0000-0002-8805-389X; White,
Peter/0000-0002-5218-5903; Moiseenko, Fedor/0000-0003-2544-9042; Gao,
Jianjiong/0000-0002-5739-1781; Wang, Chen/0000-0003-2638-3081
FU US National Institutes of Health [5U24CA143799-04, 5U24CA143835-04,
5U24CA143840-04, 5U24CA143843-04, 5U24CA143845-04, 5U24CA143848-04,
5U24CA143858-04, 5U24CA143866-04, 5U24CA143867-04, 5U24CA143882-04,
5U24CA143883-04, 5U24CA144025-04, U54HG003067-11, U54HG003079-10,
U54HG003273-10]
FX We wish to thank all patients and families who contributed to this
study. We thank M. Sheth and L. Lund for administrative coordination of
TCGA activities, G. Monemvasitis for editing the manuscript, and C.
Gunter for critical reading of the manuscript. This work was supported
by the following grants from the US National Institutes of Health:
5U24CA143799-04, 5U24CA143835-04, 5U24CA143840-04, 5U24CA143843-04,
5U24CA143845-04, 5U24CA143848-04, 5U24CA143858-04, 5U24CA143866-04,
5U24CA143867-04, 5U24CA143882-04, 5U24CA143883-04, 5U24CA144025-04,
U54HG003067-11, U54HG003079-10 and U54HG003273-10.
NR 40
TC 642
Z9 646
U1 15
U2 160
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAY 2
PY 2013
VL 497
IS 7447
BP 67
EP 73
DI 10.1038/nature12113
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 134OK
UT WOS:000318221500035
ER
PT J
AU Ko, M
An, J
Bandukwala, HS
Chavez, L
Aijo, T
Pastor, WA
Segal, MF
Li, HM
Koh, KP
Lahdesmaki, H
Hogan, PG
Aravind, L
Rao, A
AF Ko, Myunggon
An, Jungeun
Bandukwala, Hozefa S.
Chavez, Lukas
Aijo, Tarmo
Pastor, William A.
Segal, Matthew F.
Li, Huiming
Koh, Kian Peng
Lahdesmaki, Harri
Hogan, Patrick G.
Aravind, L.
Rao, Anjana
TI Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC
domain protein IDAX
SO NATURE
LA English
DT Article
ID WNT SIGNALING PATHWAY; EMBRYONIC STEM-CELLS; CPG ISLANDS;
5-HYDROXYMETHYLCYTOSINE CONTENT; DNA METHYLATION; BINDING PROTEIN;
MAMMALIAN DNA; DIFFERENTIATION; COMPLEX; 5-CARBOXYLCYTOSINE
AB TET (ten-eleven-translocation) proteins are Fe(II)- and alpha-ketogluta-rate-dependent dioxygenases(1-3) that modify the methylation status of DNA by successively oxidizing 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxycytosine(1,3-5), potential intermediates in the active erasure of DNA-methylation marks(5,6). Here we show that IDAX (also known as CXXC4), a reported inhibitor of Wnt signalling(7) that has been implicated in malignant renal cell carcinoma(8) and colonic villous adenoma(9), regulates TET2 protein expression. IDAX was originally encoded within an ancestral TET2 gene that underwent a chromosomal gene inversion during evolution, thus separating the TET2 CXXC domain from the catalytic domain. The IDAX CXXC domain binds DNA sequences containing unmethylated CpG dinucleotides, localizes to promoters and CpG islands in genomic DNA and interacts directly with the catalytic domain of TET2. Unexpectedly, IDAX expression results in caspase activation and TET2 protein downregulation, in a manner that depends on DNA binding through the IDAX CXXC domain, suggesting that IDAX recruits TET2 to DNA before degradation. IDAX depletion prevents TET2 downregulation in differentiating mouse embryonic stem cells, and short hairpin RNA against IDAX increases TET2 protein expression in the human monocytic cell line U937. Notably, we find that the expression and activity of TET3 is also regulated through its CXXC domain. Taken together, these results establish the separate and linked CXXC domains of TET2 and TET3, respectively, as previously unknown regulators of caspase activation and TET enzymatic activity.
C1 [Ko, Myunggon; An, Jungeun; Bandukwala, Hozefa S.; Chavez, Lukas; Aijo, Tarmo; Pastor, William A.; Segal, Matthew F.; Hogan, Patrick G.; Rao, Anjana] La Jolla Inst Allergy & Immunol, Div Signaling & Gene Express, La Jolla, CA 92037 USA.
[Aijo, Tarmo; Lahdesmaki, Harri] Aalto Univ, Sch Sci, Dept Informat & Comp Sci, FI-00076 Aalto, Finland.
[Li, Huiming; Koh, Kian Peng; Rao, Anjana] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Li, Huiming; Koh, Kian Peng; Rao, Anjana] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Aravind, L.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
[Rao, Anjana] Sanford Consortium Regenerat Med, La Jolla, CA 92037 USA.
RP Rao, A (reprint author), La Jolla Inst Allergy & Immunol, Div Signaling & Gene Express, La Jolla, CA 92037 USA.
EM arao@liai.org
OI Chavez, Lukas/0000-0002-8718-8848
FU National Institutes of Health (NIH) [HD065812, CA151535]; California
Institute of Regenerative Medicine and Translational Research
[RM-01729]; Leukemia and Lymphoma Society [TRP 6187-12]; NIH [AI40127];
Leukemia and Lymphoma Society; Lady Tata Memorial Trust;
GlaxoSmithKline-Immune Disease Institute Alliance; National Science
Foundation
FX We thank G. Seumois, M. Ku and J. Day for help with library preparation,
B. Ren for use of his Illumina Hi-Seq 2000, J. A. Zepeda-Martinez for
the recombinant Flag-TET2CD, and members of the Rao
laboratory for discussions. This work was supported by National
Institutes of Health (NIH) R01 grants HD065812 and CA151535, grant
RM-01729 from the California Institute of Regenerative Medicine and
Translational Research, grant TRP 6187-12 from the Leukemia and Lymphoma
Society (to A. R.) and NIH R01 grant AI40127 (to P. G. H. and A. R). We
also gratefully acknowledge a Special Fellow Award from the Leukemia and
Lymphoma Society (to M. K.), postdoctoral fellowships from the Lady Tata
Memorial Trust and from the GlaxoSmithKline-Immune Disease Institute
Alliance (to H. S. B.) and a predoctoral graduate research fellowship
from the National Science Foundation (to W.A.P.).
NR 40
TC 86
Z9 90
U1 4
U2 55
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAY 2
PY 2013
VL 497
IS 7447
BP 122
EP +
DI 10.1038/nature12052
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 134OK
UT WOS:000318221500046
PM 23563267
ER
PT J
AU Miraoui, H
Dwyer, AA
Sykiotis, GP
Plummer, L
Chung, W
Feng, BH
Beenken, A
Clarke, J
Pers, TH
Dworzynski, P
Keefe, K
Niedziela, M
Raivio, T
Crowley, WF
Seminara, SB
Quinton, R
Hughes, VA
Kumanov, P
Young, J
Yialamas, MA
Hall, JE
Van Vliet, G
Chanoine, JP
Rubenstein, J
Mohammadi, M
Tsai, PS
Sidis, Y
Lage, K
Pitteloud, N
AF Miraoui, Hichem
Dwyer, Andrew A.
Sykiotis, Gerasimos P.
Plummer, Lacey
Chung, Wilson
Feng, Bihua
Beenken, Andrew
Clarke, Jeff
Pers, Tune H.
Dworzynski, Piotr
Keefe, Kimberley
Niedziela, Marek
Raivio, Taneli
Crowley, William F., Jr.
Seminara, Stephanie B.
Quinton, Richard
Hughes, Virginia A.
Kumanov, Philip
Young, Jacques
Yialamas, Maria A.
Hall, Janet E.
Van Vliet, Guy
Chanoine, Jean-Pierre
Rubenstein, John
Mohammadi, Moosa
Tsai, Pei-San
Sidis, Yisrael
Lage, Kasper
Pitteloud, Nelly
TI Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 Are Identified in
Individuals with Congenital Hypogonadotropic Hypogonadism
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; AUDITORY SENSORY EPITHELIUM;
KALLMANN-SYNDROME; MOUSE EMBRYOS; CELL-PROLIFERATION; DIGENIC MUTATIONS;
EXPRESSION; GROWTH; SEF; GENE
AB Congenital hypogonadotropic hypogonadism (CHH) and its anosmia-associated form (Kallmann syndrome [KS]) are genetically heterogeneous. Among the >15 genes implicated in these conditions, mutations in FGF8 and FGFR1 account for similar to 12% of cases; notably, KAL1 and HS6ST1 are also involved in FGFR1 signaling and can be mutated in CHH. We therefore hypothesized that mutations in genes encoding a broader range of modulators of the FGFR1 pathway might contribute to the genetics of CHH as causal or modifier mutations. Thus, we aimed to (1) investigate whether CHH individuals harbor mutations in members of the so-called "FGF8 synexpression" group and (2) validate the ability of a bioinformatics algorithm on the basis of protein-protein interactome data (interactome-based affiliation scoring [IBAS]) to identify high-quality candidate genes. On the basis of sequence homology, expression, and structural and functional data, seven genes were selected and sequenced in 386 unrelated CHH individuals and 155 controls. Except for FGF18 and SPRY2, all other genes were found to be mutated in CHH individuals: FGF17 (n = 3 individuals), IL17RD (n = 8), DUSP6 (n = 5), SPRY4 (n = 14), and FLRT3 (n = 3). Independently, IBAS predicted FGF17 and IL17RD as the two top candidates in the entire proteome on the basis of a statistical test of their protein-protein interaction patterns to proteins known to be altered in CHH. Most of the FGF17 and IL17RD mutations altered protein function in vitro. IL17RD mutations were found only in KS individuals and were strongly linked to hearing loss (6/8 individuals). Mutations in genes encoding components of the FGF pathway are associated with complex modes of CHH inheritance and act primarily as contributors to an oligogenic genetic architecture underlying CHH.
C1 [Miraoui, Hichem; Dwyer, Andrew A.; Hughes, Virginia A.; Sidis, Yisrael; Pitteloud, Nelly] Univ Lausanne, Serv Endocrinol Diabetol & Metab, CHU Vaudois, Fac Biol & Med, CH-1005 Lausanne, Switzerland.
[Miraoui, Hichem; Dwyer, Andrew A.; Sykiotis, Gerasimos P.; Plummer, Lacey; Feng, Bihua; Keefe, Kimberley; Crowley, William F., Jr.; Seminara, Stephanie B.; Hughes, Virginia A.; Hall, Janet E.; Sidis, Yisrael; Pitteloud, Nelly] Harvard Univ, Sch Med, Ctr Excellence Reprod Endocrinol, Reprod Endocrine Unit,Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sykiotis, Gerasimos P.] Univ Patras, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Patras 26500, Greece.
[Chung, Wilson; Tsai, Pei-San] Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA.
[Chung, Wilson; Tsai, Pei-San] Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA.
[Beenken, Andrew; Mohammadi, Moosa] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.
[Clarke, Jeff] Univ Calif San Francisco, Dept Psychiat, Ctr Neurobiol & Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94158 USA.
[Pers, Tune H.; Dworzynski, Piotr; Lage, Kasper] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark.
[Pers, Tune H.; Lage, Kasper] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Pers, Tune H.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02114 USA.
[Pers, Tune H.] Boston Childrens Hosp, Ctr Basic & Translat Obes Res, Boston, MA 02114 USA.
[Niedziela, Marek] Poznan Univ Med Sci, Dept Pediat Endocrinol & Rheumatol, PL-60572 Poznan, Poland.
[Raivio, Taneli] Helsinki Univ Cent Hosp, Univ Helsinki Childrens Hosp, Inst Biomed Physiol, Helsinki 00029, Finland.
[Quinton, Richard] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
[Kumanov, Philip] Med Univ Sofia, Clin Ctr Endocrinol, Sofia 1431, Bulgaria.
[Young, Jacques] Hop Bicetre, Serv Endocrinol & Malad Reprod, F-94275 Le Kremlin Bicetre, France.
[Yialamas, Maria A.] Brigham & Womens Hosp, Dept Med, Div Endocrine, Boston, MA 02114 USA.
[Van Vliet, Guy] Univ Montreal, Ctr Hosp St Justine, Fac Med, Serv Endocrinol, Montreal, PQ H3T 1C5, Canada.
[Van Vliet, Guy] Univ Montreal, Ctr Hosp St Justine, Fac Med, Res Ctr, Montreal, PQ H3T 1C5, Canada.
[Chanoine, Jean-Pierre] Univ British Columbia, British Columbia Childrens Hosp, Endocrinol & Diabet Unit, Vancouver, BC V6H 3V4, Canada.
[Lage, Kasper] Massachusetts Gen Hosp, Pediat Surg Res Labs, Dept Mol Biol, Boston, MA 02114 USA.
[Lage, Kasper] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Dept Med, Boston, MA 02114 USA.
[Lage, Kasper] Univ Copenhagen, Novo Nordisk Fdn Ctr Prot Res, DK-2200 Copenhagen, Denmark.
RP Pitteloud, N (reprint author), Univ Lausanne, Serv Endocrinol Diabetol & Metab, CHU Vaudois, Fac Biol & Med, Rue Bugnon 7, CH-1005 Lausanne, Switzerland.
EM nelly.pitteloud@chuv.ch
RI Dwyer, Andrew/D-8099-2012; PITTELOUD, Nelly/K-2709-2014;
OI Dwyer, Andrew/0000-0002-7023-6794; Chung, Wilson/0000-0003-0550-7567;
Tsai, Pei-San/0000-0002-8650-647X; Mohammadi, Moosa/0000-0003-2434-9437;
Hall, Janet/0000-0003-4644-3061; Sykiotis, Gerasimos/0000-0002-9565-4941
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development/National Institutes of Health [R01HD056264, R01HD15788,
U54HD028138, 2R01DE013686-11]; NINDS [R01 NS34661]; Swiss National
Science Foundation; COST Action [BM1105]
FX We thank the individuals and their families for their invaluable and
enthusiastic participation. This work was supported by the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development/National Institutes of Health R01HD056264 (N.P.), R01HD15788
(W.C.), through Cooperative Agreement U54HD028138 as part of the
Specialized Cooperative Centers Program in Reproduction and Infertility
Research, 2R01DE013686-11 (MM), NINDS R01 NS34661 (J.R.), the Swiss
National Science Foundation (N.P.), and COST Action BM1105.
NR 78
TC 54
Z9 73
U1 5
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAY 2
PY 2013
VL 92
IS 5
BP 725
EP 743
DI 10.1016/j.ajhg.2013.04.008
PG 19
WC Genetics & Heredity
SC Genetics & Heredity
GA 139KY
UT WOS:000318582800008
PM 23643382
ER
PT J
AU Hatoum, IJ
Greenawalt, DM
Cotsapas, C
Daly, MJ
Reitman, ML
Kaplan, LM
AF Hatoum, Ida J.
Greenawalt, Danielle M.
Cotsapas, Chris
Daly, Mark J.
Reitman, Marc L.
Kaplan, Lee M.
TI Weight Loss after Gastric Bypass Is Associated with a Variant at 15q26.1
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; ENERGY-EXPENDITURE; BARIATRIC
SURGERY; RISK-FACTORS; AQUAPORIN-11; OBESITY; BILE; INDIVIDUALS;
OVERWEIGHT
AB The amount of weight loss attained after Roux-en-Y gastric bypass (RYGB) surgery follows a wide and normal distribution, and recent evidence indicates that this weight loss is due to physiological, rather than mechanical, mechanisms. To identify potential genetic factors associated with weight loss after RYGB, we performed a genome-wide association study (GWAS) of 693 individuals undergoing RYGB and then replicated this analysis in an independent population of 327 individuals undergoing RYGB. We found that a 15q26.1 locus near ST8SIA2 and SLCO3A1 was significantly associated with weight loss after RYGB. Expression of ST8SIA2 in omental fat of these individuals at baseline was significantly associated with weight loss after RYGB. Gene expression analysis in RYGB and weight-matched, sham-operated (WMS) mice revealed that expression of St8sia2 and Slco3a1 was significantly altered in metabolically active tissues in RYGB-treated compared to WMS mice. These findings provide strong evidence for specific genetic influences on weight loss after RYGB and underscore the biological nature of the response to RYGB.
C1 [Hatoum, Ida J.; Kaplan, Lee M.] Massachusetts Gen Hosp, Obes Metab & Nutr Inst, Boston, MA 02114 USA.
[Hatoum, Ida J.; Kaplan, Lee M.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Hatoum, Ida J.; Cotsapas, Chris; Daly, Mark J.; Kaplan, Lee M.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Greenawalt, Danielle M.] Merck Res Labs, Dept Genet, Boston, MA 02115 USA.
[Cotsapas, Chris; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Cotsapas, Chris; Daly, Mark J.] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02141 USA.
[Reitman, Marc L.] Merck Res Labs, Clin Pharmacol, Rahway, NJ 07065 USA.
RP Kaplan, LM (reprint author), Massachusetts Gen Hosp, Obes Metab & Nutr Inst, Boston, MA 02114 USA.
EM lmkaplan@partners.org
RI Reitman, Marc/B-4448-2013
OI Cotsapas, Chris/0000-0002-7772-5910; Reitman, Marc/0000-0002-0426-9475
FU National Institutes of Health [DK093257, DK088661, DK090956]; Merck
Research Laboratories; Ethicon Endo-Surgery
FX The authors thank Shubhra Kashyap and Melissa Paziuk for their expert
technical assistance, Harveen Dhillon Natarajan and Nadia Ahmad for
their help with the animal studies, and Rahul Deo for his invaluable
statistical expertise. This work was supported by National Institutes of
Health grants DK093257 (I.J.H.), DK088661 (L.M.K.), and DK090956
(L.M.K.) and by research grants from Merck Research Laboratories
(L.M.K.) and Ethicon Endo-Surgery (L.M.K.). D.M.G. reports employment by
Merck Research Laboratories. M.L.R. reports former employment by Merck
Research Laboratories.
NR 35
TC 20
Z9 20
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAY 2
PY 2013
VL 92
IS 5
BP 827
EP 834
DI 10.1016/j.ajhg.2013.04.009
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 139KY
UT WOS:000318582800018
PM 23643386
ER
PT J
AU Lieberman, J
Sarnow, P
AF Lieberman, Judy
Sarnow, Peter
TI Micromanaging Hepatitis C Virus
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID MICRORNA; LIVER; PRIMATES; MIR-122; GENOME
C1 [Lieberman, Judy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Lieberman, Judy] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Sarnow, Peter] Stanford Univ, Dept Microbiol & Immunol, Palo Alto, CA 94304 USA.
RP Lieberman, J (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
RI Lieberman, Judy/A-2717-2015
NR 15
TC 9
Z9 9
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 2
PY 2013
VL 368
IS 18
BP 1741
EP 1743
DI 10.1056/NEJMe1301348
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 134MN
UT WOS:000318214400011
PM 23534545
ER
PT J
AU Kahle, KT
Duhaime, AC
AF Kahle, Kristopher T.
Duhaime, Ann-Christine
TI Intracranial-Pressure Monitoring in Traumatic Brain Injury
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Kahle, Kristopher T.; Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Duhaime, AC (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM aduhaime@partners.org
NR 3
TC 2
Z9 3
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 2
PY 2013
VL 368
IS 18
BP 1750
EP 1750
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 134MN
UT WOS:000318214400021
PM 23635062
ER
PT J
AU Nohria, A
AF Nohria, Anju
TI beta-Adrenergic Blockade for Anthracycline- and Trastuzumab-Induced
Cardiotoxicity Is Prevention Better Than Cure?
SO CIRCULATION-HEART FAILURE
LA English
DT Editorial Material
DE Editorials; anthracyclines; trastuzumab
ID BREAST-CANCER; ADJUVANT TRASTUZUMAB; HEART-FAILURE; INDUCED
CARDIOMYOPATHY; RETROSPECTIVE ANALYSIS; VENTRICULAR MYOCYTES;
DOXORUBICIN; CARVEDILOL; THERAPY; CHEMOTHERAPY
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiooncol Program,Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Nohria, A (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiooncol Program,Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM anohria@partners.org
NR 34
TC 7
Z9 7
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD MAY
PY 2013
VL 6
IS 3
BP 358
EP 361
DI 10.1161/CIRCHEARTFAILURE.113.000267
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AA8ZM
UT WOS:000331383500007
PM 23694770
ER
PT J
AU Chatterjee, NA
Murphy, RM
Malhotra, R
Dhakal, BP
Baggish, AL
Pappagianopoulos, PP
Hough, SS
Semigran, MJ
Lewis, GD
AF Chatterjee, Neal A.
Murphy, Ryan M.
Malhotra, Rajeev
Dhakal, Bishnu P.
Baggish, Aaron L.
Pappagianopoulos, Paul P.
Hough, Stacyann S.
Semigran, Marc J.
Lewis, Gregory D.
TI Prolonged Mean VO2 Response Time in Systolic Heart Failure An Indicator
of Impaired Right Ventricular-Pulmonary Vascular Function
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE exercise physiology; exercise testing; heart failure
ID OXYGEN-UPTAKE KINETICS; LOW-LEVEL EXERCISE; LOW-INTENSITY EXERCISE; O-2
UPTAKE KINETICS; SUBMAXIMAL EXERCISE; SKELETAL-MUSCLE; GAS-EXCHANGE;
AMBULATORY PATIENTS; HEAVY EXERCISE; PEAK EXERCISE
AB Background-In patients with left ventricular systolic dysfunction (LVSD), the rate at which oxygen uptake (Vo(2)) increases on initiation of exercise is inadequate to match metabolic demands. To gain mechanistic insights into delayed Vo(2) kinetics in LVSD, we simultaneously assessed hemodynamic measurements, ventilatory parameters, and peripheral oxygen usage during exercise.
Methods and Results-Forty-two patients with symptomatic LVSD (age, 59 +/- 2 years [mean +/- SEM]; LV ejection fraction, 30 +/- 1%) and 17 controls (LV ejection fraction, 68 +/- 1%) underwent maximum upright cycle ergometry cardiopulmonary exercise testing. Hemodynamic monitoring and first-pass radionuclide ventriculography were performed at rest and during exercise. Vo(2) kinetics were quantified by mean response time (MRT), which was significantly longer in patients with LVSD compared with controls (64 +/- 3 versus 45 +/- 5 s; P=0.004). In LVSD patients, MRT was associated with higher biventricular filling pressures and reduced cardiac output during early exercise. LVSD patients with MRT >= 60 s, compared with LVSD subjects with MRT < 60 s, demonstrated greater impairment in right ventricular-pulmonary vascular function during exercise as evidenced by lower right ventricular ejection fraction (35 +/- 2 versus 45 +/- 2%; P=0.03), steeper increment in transpulmonary gradient relative to cardiac output (3.7 versus 2.2 mm Hg/L; P<0.001), and increased ventilatory dead-space fraction (17 +/- 1 versus 12 +/- 2%; P=0.03). In contrast, MRT was not associated with LV ejection fraction (rest, exercise), Pao(2), hemoglobin, or resting pulmonary function test results.
Conclusions-Delayed oxygen uptake on initiation of exercise (ie, MRT >= 60 s) in LVSD is closely related to impaired right ventricular-pulmonary vascular function and may represent an important surrogate for inability to augment RV performance during physical activity in patients with heart failure.
C1 [Chatterjee, Neal A.; Murphy, Ryan M.; Malhotra, Rajeev; Dhakal, Bishnu P.; Baggish, Aaron L.; Semigran, Marc J.; Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA.
[Baggish, Aaron L.; Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Performance Program,Dept Med, Boston, MA USA.
[Pappagianopoulos, Paul P.; Hough, Stacyann S.; Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA USA.
RP Lewis, GD (reprint author), Massachusetts Gen Hosp, Heart Failure & Cardiac Transplantat Unit, Bigelow 800,Fruit St, Boston, MA 02114 USA.
EM glewis@partners.org
OI Malhotra, Rajeev/0000-0003-0120-4630
FU American Heart Association [11FTF7290032]; National Heart Lung and Blood
Institute Heart Failure Network training grant; Heart Failure Research
Innovation Fund; Massachusetts General Hospital Cardiac Performance
Program
FX We gratefully acknowledge support from the American Heart Association
(11FTF7290032 Dr Malhotra), the National Heart Lung and Blood Institute
Heart Failure Network training grant (Dr Lewis), the Heart Failure
Research Innovation Fund (Dr Lewis, R. M. Murphy, Dr Chatterjee, and Dr
Dhakal), and The Massachusetts General Hospital Cardiac Performance
Program (Drs Baggish and Lewis).
NR 47
TC 9
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD MAY
PY 2013
VL 6
IS 3
BP 499
EP +
DI 10.1161/CIRCHEARTFAILURE.112.000157
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AA8ZM
UT WOS:000331383500025
PM 23572493
ER
PT J
AU Colt, HG
Murgu, SD
Korst, RJ
Slatore, CG
Unger, M
Quadrelli, S
AF Colt, Henri G.
Murgu, Septimiu D.
Korst, Robert J.
Slatore, Christopher G.
Unger, Michael
Quadrelli, Silvia
TI Follow-up and Surveillance of the Patient With Lung Cancer After
Curative-Intent Therapy Diagnosis and Management of Lung Cancer, 3rd ed:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines
SO CHEST
LA English
DT Article
ID QUALITY-OF-LIFE; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; SOMATOSTATIN
RECEPTOR SCINTIGRAPHY; BRONCHIAL CARCINOID-TUMORS; SQUAMOUS-CELL
CARCINOMA; BRONCHOSCOPIC TREATMENT; NEUROENDOCRINE TUMORS; COMPLETE
RESECTION; PROGNOSTIC-FACTORS; RADIATION-THERAPY
AB Background: These guidelines are an update of the evidence-based recommendations for follow-up and surveillance of patients after curative-intent therapy for lung cancer. Particular updates pertain to whether imaging studies, health-related quality-of-life (HRQOL) measures, tumor markers, and bronchoscopy improve outcomes after curative-intent therapy.
Methods: Meta-analysis of Observational Studies in Epidemiology guidelines were followed for this systematic review, including published studies on posttreatment outcomes in patients who received curative-intent therapy since the previous American College of Chest Physicians subject review. Four population, intervention, comparison, and outcome questions were formulated to guide the review. The MEDLINE and CINAHL databases were searched from June 1, 2005, to July 8, 2011, to ensure overlap with the search strategies used previously.
Results: A total of 3,412 citations from MEDLINE and 431 from CINAHL were identified. Only 303 were relevant. Seventy-six of the 303 articles were deemed eligible on the basis of predefined inclusion criteria after full-text review, but only 34 provided data pertaining directly to the subject of the questions formulated to guide this review. In patients undergoing curative-intent surgical resection of non-small cell lung cancer, chest CT imaging performed at designated time intervals after resection is suggested for detecting recurrence. It is recommended that treating physicians who are able to incorporate the patient's clinical findings into decision-making processes be included in follow-up and surveillance strategies. The use of validated HRQOL instruments at baseline and during follow-up is recommended. Biomarker testing during surveillance outside clinical trials is not suggested. Surveillance bronchoscopy is suggested for patients with early central airway squamous cell carcinoma treated by curative-intent photodynamic therapy and for patients with intraluminal bronchial carcinoid tumor who have undergone curative-intent bronchoscopic treatment with Nd:YAG laser or electrocautery.
Conclusions: There is a paucity of well-designed prospective studies specifically targeting follow-up and surveillance modalities aimed at improving survival or QOL after curative-intent therapy. Additional research is warranted to clarify which curative-intent treatment modalities affect HRQOL the most and to identify patients who are at the most risk for recurrence or impaired QOL after treatment. Further evidence is needed to determine how the frequency and duration of surveillance programs that include imaging studies, QOL measurements, tumor markers, or bronchoscopy affect patient morbidity, survival, HRQOL, and health-care costs.
C1 [Colt, Henri G.] Univ Calif Irvine, Div Pulm & Crit Care Med, Irvine, CA USA.
[Murgu, Septimiu D.] Univ Chicago, Div Pulm & Crit Care Med, Chicago, IL 60637 USA.
[Korst, Robert J.] Valley Hosp, Valley Hlth Syst, Daniel & Gloria Blumenthal Canc Ctr, Paramus, NJ USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR 97201 USA.
[Unger, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Quadrelli, Silvia] Buenos Aires British Hosp, Buenos Aires, DF, Argentina.
RP Colt, HG (reprint author), 422 Glenneyre, Laguna Beach, CA 92651 USA.
EM hcolt@uci.edu
OI Slatore, Christopher/0000-0003-0958-8122
FU Lung Cancer Research Foundation; Boehringer Ingelheim Pharmaceuticals,
Inc.
FX The overall process for the development of these guidelines, including
matters pertaining to funding and conflicts of interest, are described
in the methodology article. 1 The development of this guideline was
supported primarily by the American College of Chest Physicians. The
lung cancer guidelines conference was supported in part by a grant from
the Lung Cancer Research Foundation. The publication and dissemination
of the guidelines was supported in part by a 2009 independent
educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. COI
grids reflecting the conflicts of interest that were current as of the
date of the conference and voting are posted in the online supplementary
materials.
NR 94
TC 23
Z9 23
U1 1
U2 10
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2013
VL 143
IS 5
SU S
BP E437
EP E454
DI 10.1378/chest.12-2365
PG 18
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AB1HL
UT WOS:000331542000020
PM 23649451
ER
PT J
AU Socinski, MA
Evans, T
Gettinger, S
Hensing, TA
Sequist, LV
Ireland, B
Stinchcombe, TE
AF Socinski, Mark A.
Evans, Tracey
Gettinger, Scott
Hensing, Thomas A.
Sequist, Lecia VanDam
Ireland, Belinda
Stinchcombe, Thomas E.
TI Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and
Management of Lung Cancer, 3rd ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines
SO CHEST
LA English
DT Article
ID PHASE-III TRIAL; PLATINUM-BASED CHEMOTHERAPY; FACTOR-RECEPTOR MUTATIONS;
QUALITY-OF-LIFE; COMPARING PACLITAXEL POLIGLUMEX; RANDOMIZED
CONTROLLED-TRIAL; CISPLATIN PLUS GEMCITABINE;
COOPERATIVE-ONCOLOGY-GROUP; POOR PERFORMANCE STATUS; PS 2 PATIENTS
AB Background: Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable, clinical entity in patients given the diagnosis at a time when their performance status (PS) remains good.
Methods: A systematic literature review was performed to update the previous edition of the American College of Chest Physicians Lung Cancer Guidelines.
Results: The use of pemetrexed should be restricted to patients with nonsquamous histology. Similarly, bevacizumab in combination with chemotherapy (and as continuation maintenance) should be restricted to patients with nonsquamous histology and an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1; however, the data now suggest it is safe to use in those patients with treated and controlled brain metastases. Data at this time are insufficient regarding the safety of bevacizumab in patients receiving therapeutic anticoagulation who have an ECOG PS of 2. The role of cetuximab added to chemotherapy remains uncertain and its routine use cannot be recommended. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as first-line therapy are the recommended treatment of those patients identified as having an EGFR mutation. The use of maintenance therapy with either pemetrexed or erlotinib should be considered after four cycles of first-line therapy in those patients without evidence of disease progression. The use of second-and third-line therapy in stage IV NSCLC is recommended in those patients retaining a good PS; however, the benefit of therapy beyond the third-line setting has not been demonstrated. In the elderly and in patients with a poor PS, the use of two-drug, platinum-based regimens is preferred. Palliative care should be initiated early in the course of therapy for stage IV NSCLC.
Conclusions: Significant advances continue to be made, and the treatment of stage IV NSCLC has become nuanced and specific for particular histologic subtypes and clinical patient characteristics and according to the presence of specific genetic mutations.
C1 [Socinski, Mark A.] Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA USA.
[Evans, Tracey] Perelman Ctr Adv Med, Philadelphia, PA USA.
[Gettinger, Scott] Yale Canc Ctr, New Haven, CT USA.
[Hensing, Thomas A.] NorthShore Univ HealthSyst, Evanston Hosp, Evanston, IL USA.
[Sequist, Lecia VanDam] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ireland, Belinda] TheEvidenceDoc LLC, St Louis, MO USA.
[Stinchcombe, Thomas E.] Univ N Carolina, Chapel Hill, NC USA.
RP Socinski, MA (reprint author), Div Hematol Oncol, Lung Canc Sect, UPMC Canc Pavilion,5150 Ctr Ave,Fifth Floor, Pittsburgh, PA 15232 USA.
EM socinskima@upmc.edu
FU Lung Cancer Research Foundation; Boehringer Ingelheim Pharmaceuticals,
Inc.
FX The overall process for the development of these guidelines, including
matters pertaining to funding and conflicts of interest, are described
in the methodology article. 1 The development of this guideline was
supported primarily by the American College of Chest Physicians. The
lung cancer guidelines conference was supported in part by a grant from
the Lung Cancer Research Foundation. The publication and dissemination
of the guidelines was supported in part by a 2009 independent
educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. COI
Grids reflecting the conflicts of interest that were current as of the
date of the conference and voting are posted in the online supplementary
materials.
NR 133
TC 37
Z9 39
U1 3
U2 10
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2013
VL 143
IS 5
SU S
BP E341
EP E368
DI 10.1378/chest.12-2361
PG 28
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AB1HL
UT WOS:000331542000016
PM 23649446
ER
PT J
AU Frank, JW
Hong, CS
Subramanian, SV
Wang, EA
AF Frank, Joseph W.
Hong, Clemens S.
Subramanian, S. V.
Wang, Emily A.
TI Neighborhood Incarceration Rate and Asthma Prevalence in New York City:
A Multilevel Approach
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID CHILDHOOD ASTHMA; HEALTH DISPARITIES; RACIAL DISPARITIES; RISK-FACTORS;
PRISONERS; CARE; MORBIDITY; FAMILIES; VIOLENCE; RELEASE
AB Objectives. We examined the association between neighborhood incarceration rate and asthma prevalence and morbidity among New York City adults.
Methods. We used multilevel modeling techniques and data from the New York City Community Health Survey (2004) to analyze the association between neighborhood incarceration rate and asthma prevalence, adjusting for individual-level sociodemographic, behavioral, and environmental characteristics. We examined interactions between neighborhood incarceration rate, respondent incarceration history, and race/ethnicity.
Results. The mean neighborhood rate of incarceration was 5.4% (range = 2.1%-12.8%). Neighborhood incarceration rate was associated with individual-level asthma prevalence (odds ratio [OR] = 1.06; 95% confidence interval [CI] = 1.03, 1.10) in unadjusted models but not after adjustment for sociodemographic characteristics (OR = 1.01; 95% CI = 0.98, 1.04). This association did not differ according to respondent race/ethnicity.
Conclusions. Among New York City adults, the association between neighborhood incarceration rate and asthma prevalence is explained by the sociodemographic composition of neighborhoods and disparities in asthma prevalence at the individual level. Public health practitioners should further engage with criminal justice professionals and correctional health care providers to target asthma outreach efforts toward both correctional facilities and neighborhoods with high rates of incarceration.
C1 [Frank, Joseph W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gen Med & Primary Care, Boston, MA 02115 USA.
[Hong, Clemens S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA.
[Subramanian, S. V.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Cambridge, MA 02138 USA.
[Wang, Emily A.] Yale Univ, Sch Med, Gen Internal Med Sect, New Haven, CT USA.
RP Frank, JW (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St,3rd Floor, Boston, MA 02120 USA.
EM josephwfrank@gmail.com
FU National Research Service Award [T32HP10251, T32HP12706]; Division of
General Medicine and Primary Care at Brigham and Women's Hospital;
General Medicine Division at Massachusetts General Hospital; National
Heart, Lung and Blood Institute [K23 HL103720]
FX J. W. Frank is supported by an institutional National Research Service
Award (T32HP10251) and by the Division of General Medicine and Primary
Care at Brigham and Women's Hospital. C. S. Hong was supported by an
institutional National Research Service Award (T32HP12706) and by the
General Medicine Division at Massachusetts General Hospital. E. A. Wang
is supported by the National Heart, Lung and Blood Institute (K23
HL103720).
NR 38
TC 4
Z9 4
U1 2
U2 7
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD MAY
PY 2013
VL 103
IS 5
BP E38
EP E44
DI 10.2105/AJPH.2013.301255
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA2UJ
UT WOS:000330949300014
PM 23488496
ER
PT J
AU Abukawa, H
Oriel, BS
Leaf, J
Vacanti, JP
Kaban, LB
Troulis, MJ
Hartnick, CJ
AF Abukawa, Harutsugi
Oriel, Brad S.
Leaf, Jeremy
Vacanti, Joseph P.
Kaban, Leonard B.
Troulis, Maria J.
Hartnick, Christopher J.
TI Growth Factor Directed Chondrogenic Differentiation of Porcine Bone
Marrow-Derived Progenitor Cells
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE Bone marrow; cartilage; chondrocytes; chondrogenic differentiation;
mandibular condyle; stem cells; tissue engineering
ID MESENCHYMAL STEM-CELLS; CARTILAGE; CULTURE; PROTEIN; MATRIX
AB Background: Despite advances in surgical technique, reconstruction of a mandibular condyle still causes significant donor-site morbidity. The purpose of this study was to compare the effect of 3 different growth factors and define optimal cell culture conditions for bone marrow-derived progenitor cells to differentiate into chondrocytes for mandibular condyle reconstruction.
Methods: Porcine bone marrow-derived progenitor cells (pBMPCs) were cultured as a pellet for 2, 3, and 4 weeks under the following conditions: group 1, TGF-beta 3 + standard medium; group 2, TGF-beta 3 + BMP-2 + standard medium; group 3, TGF-beta 3 + IGF-1 + standard medium; and group 4, TGF-beta 3 + BMP-2 + IGF-1 + standard medium. Chondrogenic differentiation was evaluated using 3 lineage differentiation markers.
Results: The mean type II collagen positive area increased over weeks 2, 3, and 4 in group 4 compared to all the other groups (ANOVA; P = 0.005). At week 4, there was significantly greater type II collagen production in group 4 compared to all the other groups (ANOVA; P = 0.003). The medium in group 4 produces the greatest amount of cartilage when compared to groups 1, 2, and 3, and that 4 weeks produces the greatest amount of type II collagen.
Conclusions: The results of this study indicate that the most efficacious medium for chondrogenic differentiation of pBMPCs was group 4 medium and the most type II collagen was produced at 4 weeks.
C1 [Abukawa, Harutsugi; Leaf, Jeremy; Kaban, Leonard B.; Troulis, Maria J.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Abukawa, Harutsugi; Leaf, Jeremy; Kaban, Leonard B.; Troulis, Maria J.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Abukawa, Harutsugi] Tokyo Med Univ, Dept Oral & Maxillofacial Surg, Tokyo 1600023, Japan.
[Oriel, Brad S.; Hartnick, Christopher J.] Massachusetts Eye & Ear Infirm, Dept Pediat Otolaryngol, Boston, MA 02114 USA.
[Oriel, Brad S.; Vacanti, Joseph P.; Hartnick, Christopher J.] Harvard Univ, Sch Med, Boston, MA USA.
[Oriel, Brad S.] Tufts Med Ctr, Dept Gen Surg, Boston, MA USA.
[Vacanti, Joseph P.] Massachusetts Gen Hosp, Dept Surg, Tissue Engn & Organ Fabricat Lab, Boston, MA 02114 USA.
RP Abukawa, H (reprint author), Tokyo Med Univ, Dept Oral & Maxillofacial Surg, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.
EM habukawa@tokyo-med.ac.jp
FU Center for Integration of Medicine and Innovative Technology (Boston,
MA); Massachusetts General Hospital's Department of Oral and
Maxillofacial Surgery Education and Research Fund
FX Funded in part by the Center for Integration of Medicine and Innovative
Technology (Boston, MA), and the Massachusetts General Hospital's
Department of Oral and Maxillofacial Surgery Education and Research
Fund.
NR 22
TC 3
Z9 3
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1049-2275
EI 1536-3732
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD MAY
PY 2013
VL 24
IS 3
BP 1026
EP 1030
DI 10.1097/SCS.0b013e31827ff323
PG 5
WC Surgery
SC Surgery
GA 294WI
UT WOS:000330078200118
PM 23714939
ER
PT J
AU Wen, LS
Baca, JT
O'Malley, P
Bhatia, K
Peak, D
Takayesu, JK
AF Wen, Leana S.
Baca, Justin T.
O'Malley, Patricia
Bhatia, Kriti
Peak, David
Takayesu, J. Kimo
TI Implementation of small-group reflection rounds at an emergency medicine
residency program
SO CANADIAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE burnout; humanism; reflection; residency training
AB Few residency curricular interventions have focused on improving well-being and promoting humanism. We describe the implementation of a novel curriculum based on small-group reflection rounds-the Emergency Medicine Reflection Rounds (EMRR)-at a 4-year US emergency medicine (EM) residency. During the inaugural year (2010-2011), nine residents volunteered to take part in 1-hour monthly sessions with faculty facilitators. Residents were provided with a confidential environment to discuss difficult ethical and interpersonal encounters from their clinical experiences. Ongoing feedback from participants was solicited, culminating with a four-question survey in which all respondents remarked that the EMRR contributed to improving their own well-being and agreed that it provided an important forum for residents to discuss difficult issues in a safe environment. In this article, we describe our innovation as an example of a wellness initiative that has promoted reflective practice and fostered cooperative learning around the communication, professional, and ethical challenges inherent in EM practice. Our EMRR model may be useful to other EM residences looking to supplement their wellness curriculum.
C1 [Wen, Leana S.; Baca, Justin T.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Div Emergency Med, Harvard Affiliated Emergency Med Residency, Boston, MA 02116 USA.
[O'Malley, Patricia; Peak, David; Takayesu, J. Kimo] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02116 USA.
[Bhatia, Kriti] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
RP Wen, LS (reprint author), Massachusetts Gen Hosp, Brigham & Womens Hosp, Harvard Affiliated Emergency Med Residency, 178 Marlborough St,5, Boston, MA 02116 USA.
EM Wen.Leana@gmail.com
NR 10
TC 1
Z9 1
U1 1
U2 2
PU DECKER PUBL INC
PI HAMILTON
PA 69 JOHN ST S, STE 310, HAMILTON, ONTARIO L8N 2B9, CANADA
SN 1481-8035
J9 CAN J EMERG MED
JI Can. J. Emerg. Med.
PD MAY
PY 2013
VL 15
IS 3
BP 175
EP 177
DI 10.2310/8000.2013.130935
PG 3
WC Emergency Medicine
SC Emergency Medicine
GA AA5MT
UT WOS:000331144300009
PM 23663465
ER
PT J
AU Buchanan, GL
Chieffo, A
Meliga, E
Mehran, R
Park, SJ
Onuma, Y
Capranzano, P
Valgimigli, M
Jegere, S
Makkar, R
Palacios, IF
Kim, YH
Buszman, P
Charavarty, T
Sheiban, I
Naber, C
Margey, R
Agnihotri, A
Marra, S
Davide, D
Leon, M
Fajadet, J
Lefevre, T
Morice, MC
Erglis, A
Tamburino, C
Alfieri, O
Serruys, PW
Colombo, A
AF Buchanan, G. L.
Chieffo, A.
Meliga, E.
Mehran, R.
Park, S. J.
Onuma, Y.
Capranzano, P.
Valgimigli, M.
Jegere, S.
Makkar, R.
Palacios, I. F.
Kim, Y. H.
Buszman, P.
Charavarty, T.
Sheiban, I.
Naber, C.
Margey, R.
Agnihotri, A.
Marra, S.
Davide, D.
Leon, M.
Fajadet, J.
Lefevre, T.
Morice, M. C.
Erglis, A.
Tamburino, C.
Alfieri, O.
Serruys, P. W.
Colombo, A.
TI THE ROLE OF FEMALE SEX IN THE CONTEMPORARY TREATMENT OF THE LEFT MAIN
CORONARY ARTERY INSIGHTS FROM THE W-DELTA (WOMEN-DRUG ELUTING STENT FOR
LEFT MAIN CORONARY ARTERY DISEASE) REGISTRY
SO HEART
LA English
DT Meeting Abstract
CT Annual Conference of the British-Cardiovascular-Society (BCS)
CY JUN 03-05, 2013
CL London, ENGLAND
SP British Cardiovascular Soc
C1 [Buchanan, G. L.; Chieffo, A.; Alfieri, O.; Colombo, A.] Ist Sci San Raffaele, Milan, Italy.
[Meliga, E.] AO Ordine Mauriziano Umberto I, Turin, Italy.
[Mehran, R.] Mt Sinai Med Ctr, New York, NY USA.
[Park, S. J.; Kim, Y. H.] Asan Med Ctr, Seoul, South Korea.
[Onuma, Y.; Serruys, P. W.] Erasmus MC, Rotterdam, Netherlands.
[Capranzano, P.; Davide, D.; Tamburino, C.] Ferrarotto Hosp, Catania, Italy.
[Valgimigli, M.] St Anna Hosp, Catanzaro, Italy.
[Jegere, S.; Erglis, A.] Univ Latvia, Riga, Latvia.
[Makkar, R.; Charavarty, T.; Margey, R.] Cedars Sinai Med Ctr, Los Angeles, CA USA.
[Palacios, I. F.; Agnihotri, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Palacios, I. F.; Agnihotri, A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Buszman, P.] Amer Heart Poland Inc, Katowice, Poland.
[Sheiban, I.] Giovanni Battista Hosp, Turin, Italy.
[Naber, C.] Contilia Heart & Vasc Ctr, Essen, Germany.
[Marra, S.] S Giovanni Battista Hosp, Turin, Italy.
[Leon, M.] Columbia Univ, Med Ctr, New York, NY 10027 USA.
[Fajadet, J.] Clin Pasteur, Toulouse, France.
[Lefevre, T.; Morice, M. C.] Inst Hosp Jacques Cartier, Massy, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD MAY
PY 2013
VL 99
SU 2
DI 10.1136/heartjnl-2013-304019.58
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AA6NJ
UT WOS:000331214700070
ER
PT J
AU Fadi, GH
Meaghan, B
Xing, DQ
Akash, K
Chen, YF
Alexander, S
Suzanne, O
AF Fadi, Hage G.
Meaghan, Bowling
Xing Dongqi
Akash, Kapadia
Chen Yu-Fai
Alexander, Szalai
Suzanne, Oparil
TI Estrogen Ameliorates Vascular Inflammation in Young but not Aged Mice
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Meeting Abstract
DE vascular injury; vascular inflammation; estrogen; aging
C1 [Fadi, Hage G.; Meaghan, Bowling; Xing Dongqi; Akash, Kapadia; Chen Yu-Fai; Alexander, Szalai; Suzanne, Oparil] Univ Alabama Birmingham, Birmingham, AL USA.
[Fadi, Hage G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAY
PY 2013
VL 15
SU 1
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AA0EX
UT WOS:000330769400102
ER
PT J
AU Fadi, GH
Maricica, P
Xing, DQ
Rob, H
Guo, YY
Chen, YF
AF Fadi, Hage G.
Maricica, Pacurari
Xing Dongqi
Rob, Hilgers
Guo YuanYuan
Chen Yiu-Fai
TI Endothelial Cell Transfusion in Nephrectomized Rats Ameliorates
Endothelial Dysfunction by Increasing eNOS Activity
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Meeting Abstract
DE Endothelial Cells; Endothelial Dysfunction; Chronic Kidney Disease;
Nitric Oxide Synthase
C1 [Fadi, Hage G.; Maricica, Pacurari; Xing Dongqi; Rob, Hilgers; Guo YuanYuan; Chen Yiu-Fai] Univ Alabama Birmingham, Birmingham, AL USA.
[Fadi, Hage G.; Guo YuanYuan] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAY
PY 2013
VL 15
SU 1
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AA0EX
UT WOS:000330769400094
ER
PT J
AU Oscar, R
Rene, AO
Joan, HF
Shuko, L
Robert, JC
AF Oscar, Rivera
Rene, Oliveros A.
Joan, Finch H.
Shuko, Lee
Robert, Chilton J.
TI Central Aortic Pulse Pressure, a Better Predictor of Vascular Aging
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Meeting Abstract
DE Central Pulse Pressure; Aging
C1 [Oscar, Rivera; Rene, Oliveros A.; Shuko, Lee; Robert, Chilton J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Rene, Oliveros A.; Joan, Finch H.; Shuko, Lee; Robert, Chilton J.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAY
PY 2013
VL 15
SU 1
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AA0EX
UT WOS:000330769400047
ER
PT J
AU Lawson, EA
Holsen, LM
Santin, M
DeSanti, R
Meenaghan, E
Eddy, KT
Herzog, DB
Goldstein, JM
Klibanski, A
AF Lawson, Elizabeth A.
Holsen, Laura M.
Santin, McKale
DeSanti, Rebecca
Meenaghan, Erinne
Eddy, Kamryn T.
Herzog, David B.
Goldstein, Jill M.
Klibanski, Anne
TI Postprandial Oxytocin Secretion Is Associated With Severity of Anxiety
and Depressive Symptoms in Anorexia Nervosa
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID DEFICIENT MICE; STRESS; HYPOACTIVATION; RESPONSES; BEHAVIOR; MODELS;
WOMEN; RATS; FAT
AB Objective: Anorexia nervosa, a psychiatric disorder characterized by self-induced starvation, is associated with endocrine dysfunction and comorbid anxiety and depression. Animal data suggest that oxytocin may have anxiolytic and antidepressant effects. We have reported increased postprandial oxytocin levels in women with active anorexia nervosa and decreased levels in weight-recovered women with anorexia nervosa compared to healthy controls. A meal may represent a significant source of stress in patients with disordered eating. We therefore investigated the association between postprandial oxytocin secretion and symptoms of anxiety and depression in anorexia nervosa.
Method: We performed a cross-sectional study of 35 women (13 women with active anorexia nervosa, 9 with weight-recovered anorexia nervosa, and 13 healthy controls). Anorexia nervosa was diagnosed according to DSM-IV-TR criteria. Serum oxytocin and cortisol and plasma leptin levels were measured fasting and 30, 60, and 120 minutes after a standardized mixed meal. The area under the curve (AUC) and, for oxytocin, postprandial nadir and peak levels were determined. Anxiety and depressive symptoms were assessed using the Spielberger State-Trait Anxiety Inventory (STAI) and Beck Depression Inventory II (BDI-II). The study was conducted from January 2009 to March 2011.
Results: In women with anorexia nervosa, oxytocin AUC and postprandial nadir and peak levels were positively associated with STAI trait and STAI premeal and postmeal state scores. Oxytocin AUC and nadir levels were positively associated with BDI-II scores. After controlling for cortisol AUC, all of the relationships remained significant. After controlling for leptin AUC, most of the relationships remained significant. Oxytocin secretion explained up to 51% of the variance in STAI trait and 24% of the variance in BDI-II scores.
Conclusions: Abnormal postprandial oxytocin secretion in women with anorexia nervosa is associated with increased symptoms of anxiety and depression. This link may represent an adaptive response of oxytocin secretion to food-related symptoms of anxiety and depression. (C) Copyright 2013 Physicians Postgraduate Press, Inc.
C1 [Lawson, Elizabeth A.; Santin, McKale; DeSanti, Rebecca; Meenaghan, Erinne; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Eddy, Kamryn T.; Herzog, David B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Holsen, Laura M.; Goldstein, Jill M.] Harvard Univ, Sch Med, Boston, MA USA.
[Holsen, Laura M.; Goldstein, Jill M.] Brigham & Womens Hosp, Dept Med, Div Womens Hlth, Boston, MA 02115 USA.
[Holsen, Laura M.; Goldstein, Jill M.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
RP Lawson, EA (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, 55 Fruit St,Bulfinch 457-D, Boston, MA 02114 USA.
EM ealawson@partners.org
FU Harvard Catalyst \ The Harvard Clinical and Translational Science Center
(National Institutes of Health [NIH] Award [UL1 RR025758]; NIH Office of
Research in Women's Health [K12 HD051959]; NIH [K23 MH092560]
FX Harvard Catalyst vertical bar The Harvard Clinical and Translational
Science Center (National Institutes of Health [NIH] Award #UL1
RR025758); Harvard K12 HD051959 Building Interdisciplinary Research
Careers in Women's Health Program supported by NIH Office of Research in
Women's Health; and NIH K23 MH092560.
NR 27
TC 15
Z9 16
U1 1
U2 6
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAY
PY 2013
VL 74
IS 5
BP E451
EP E457
DI 10.4088/JCP.12m08154
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AA5AI
UT WOS:000331107500007
PM 23759466
ER
PT J
AU Giannino, K
Berry, L
McCarthy, MW
Campbell, M
AF Giannino, Kerri
Berry, Laura
McCarthy, Maureen W.
Campbell, Melissa
TI THE POUCH HALF FULL: PROMOTING POSITIVITY THROUGH CREATIVE RESOURCES
SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING
LA English
DT Meeting Abstract
C1 [Giannino, Kerri; Berry, Laura; McCarthy, Maureen W.; Campbell, Melissa] Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM KmGiannino@partners.org; lberry1@partners.org; mmccarthy29@partners.org
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1071-5754
EI 1528-3976
J9 J WOUND OSTOMY CONT
JI J. Wound Ostomy Cont. Nurs.
PD MAY-JUN
PY 2013
VL 40
SU 3
MA 1608
BP S64
EP S65
PG 2
WC Nursing
SC Nursing
GA 300KD
UT WOS:000330461900179
ER
PT J
AU Giannino, K
McCarthy, MW
Berry, L
Campbell, M
AF Giannino, Kerri
McCarthy, Maureen W.
Berry, Laura
Campbell, Melissa
TI "LET'S TRY A BABY NIPPLE": CREATIVE MANAGEMENT OF A COMPLEX ABDOMINAL
WOUND
SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING
LA English
DT Meeting Abstract
C1 [Giannino, Kerri; McCarthy, Maureen W.; Berry, Laura; Campbell, Melissa] Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM KmGiannino@partners.org; mmccarthy29@partners.org; lberry1@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1071-5754
EI 1528-3976
J9 J WOUND OSTOMY CONT
JI J. Wound Ostomy Cont. Nurs.
PD MAY-JUN
PY 2013
VL 40
SU 3
MA 1449
BP S24
EP S24
PG 1
WC Nursing
SC Nursing
GA 300KD
UT WOS:000330461900065
ER
PT J
AU Hyder, JA
Kor, DJ
Cima, R
Subramanian, A
AF Hyder, J. A.
Kor, D. J.
Cima, R.
Subramanian, A.
TI SAMPLING STRATEGY FOR VITAL SIGNS AFFECTS PERFORMANCE OF INTRAOPERATIVE
RISK MODELS: THE EXAMPLE OF THE SURGICAL APGAR SCORE
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
CT Annual Meeting of the International-Anesthesia-Research-Society
CY MAY 04-07, 2013
CL San Diego, CA
SP Int Anesthesia Res Soc
C1 [Hyder, J. A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Cima, R.] Mayo Clin, Dept Surg, Rochester, MN USA.
[Kor, D. J.; Subramanian, A.] Mayo Clin, Dept Anesthesioloy, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
SU 1
MA S271
BP 216
EP 216
PG 1
WC Anesthesiology
SC Anesthesiology
GA 300CJ
UT WOS:000330441700186
ER
PT J
AU Campana, LM
George, E
Freeman, J
Ladd, D
MacNabb, C
Lee, JC
Voscopoulos, C
AF Campana, L. M.
George, E.
Freeman, J.
Ladd, D.
MacNabb, C.
Lee, J. C.
Voscopoulos, C.
TI THE USE OF NONINVASIVE RESPIRATORY VOLUME MONITORING TO ASSESS
OBSTRUCTIVE SLEEP APNEA IN THE POST-ANESTHESIA CARE UNIT
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
CT Annual Meeting of the International-Anesthesia-Research-Society
CY MAY 04-07, 2013
CL San Diego, CA
SP Int Anesthesia Res Soc
C1 [Campana, L. M.; Freeman, J.; MacNabb, C.; Lee, J. C.] Resp Mot Inc, Waltham, MA USA.
[George, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Ladd, D.] W Virginia Univ, Morgantown, WV 26506 USA.
[Voscopoulos, C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
SU 1
MA S286
BP 230
EP 230
PG 1
WC Anesthesiology
SC Anesthesiology
GA 300CJ
UT WOS:000330441700201
ER
PT J
AU Voscopoulos, C
Freeman, J
Ladd, D
Brayanov, JB
MacNabb, C
George, E
AF Voscopoulos, C.
Freeman, J.
Ladd, D.
Brayanov, J. B.
MacNabb, C.
George, E.
TI USE OF A NON-INVASIVE RESPIRATORY VOLUME MONITOR TO IDENTIFY OPIOID
INDUCED RESPIRATORY DEPRESSION IN THE POST-ANESTHESIA CARE UNIT
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
CT Annual Meeting of the International-Anesthesia-Research-Society
CY MAY 04-07, 2013
CL San Diego, CA
SP Int Anesthesia Res Soc
C1 [Voscopoulos, C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Freeman, J.; Brayanov, J. B.; MacNabb, C.] Resp Mot Inc, Waltham, MA USA.
[Ladd, D.] W Virginia Univ, Morgantown, WV 26506 USA.
[George, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
SU 1
MA S287
BP 231
EP 232
PG 2
WC Anesthesiology
SC Anesthesiology
GA 300CJ
UT WOS:000330441700202
ER
PT J
AU Wanderer, JP
Anderson-Dam, J
Levine, W
Bittner, EA
AF Wanderer, J. P.
Anderson-Dam, J.
Levine, W.
Bittner, E. A.
TI DEVELOPMENT AND VALIDATION OF AN INTRA-OPERATIVE PREDICTIVE MODEL FOR
UNPLANNED POST-OPERATIVE INTENSIVE CARE
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
CT Annual Meeting of the International-Anesthesia-Research-Society
CY MAY 04-07, 2013
CL San Diego, CA
SP Int Anesthesia Res Soc
C1 [Wanderer, J. P.] Vanderbilt Univ, Dept Anesthesiol, Nashville, TN 37235 USA.
[Anderson-Dam, J.; Levine, W.; Bittner, E. A.] Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
SU 1
MA S364
BP 287
EP 287
PG 1
WC Anesthesiology
SC Anesthesiology
GA 300CJ
UT WOS:000330441700244
ER
PT J
AU Preiss, D
AF Preiss, D.
TI THE NOISE BECOMES THE SIGNAL: VARIATIONS IN TIDAL VOLUME AND EXHALED CO2
CAN BE USED TO CALCULATE PULMONARY BLOOD FLOW
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
CT Annual Meeting of the International-Anesthesia-Research-Society
CY MAY 04-07, 2013
CL San Diego, CA
SP Int Anesthesia Res Soc
ID CARDIAC-OUTPUT
C1 [Preiss, D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
SU 1
MA S379
BP 304
EP 304
PG 1
WC Anesthesiology
SC Anesthesiology
GA 300CJ
UT WOS:000330441700259
ER
PT J
AU Chen, HH
Mekkaoui, C
Cho, H
Ngoy, S
Marinelli, B
Waterman, P
Nahrendorf, M
Liao, R
Josephson, L
Sosnovik, DE
AF Chen, Howard H.
Mekkaoui, Choukri
Cho, Hoonsung
Ngoy, Soeun
Marinelli, Brett
Waterman, Peter
Nahrendorf, Matthias
Liao, Ronglih
Josephson, Lee
Sosnovik, David E.
TI Fluorescence Tomography of Rapamycin-Induced Autophagy and
Cardioprotection In Vivo
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE apoptosis; autophagy; molecular imaging; myocardium; rapamycin
ID ISCHEMIC-MYOCARDIUM; ISCHEMIA/REPERFUSION INJURY; INFARCTED MYOCARDIUM;
REPERFUSION INJURY; CARDIAC MYOCYTES; CELL-DEATH; APOPTOSIS; HEART;
MICE; CARDIOMYOCYTES
AB Background-Autophagy is a biological process during which cells digest organelles in their cytoplasm and recycle the constituents. The impact of autophagy in the heart, however, remains unclear in part because of the inability to noninvasively image this process in living animals.
Methods and Results-Here, we report the use of fluorescence molecular tomography and a cathepsin-activatable fluorochrome to image autophagy in the heart in vivo after ischemia/reperfusion and rapamycin (RAP) therapy. We show that cathepsin-B activity in the lysosome is upregulated by RAP and that this allows the expanded lysosomal compartment in autophagy to be imaged in vivo with fluorescence molecular tomography. We further demonstrate that the delivery of diagnostic nanoparticles to the lysosome by endocytosis is enhanced during autophagy. The upregulation of autophagy by RAP was associated with a 23% reduction (P<0.05) of apoptosis in the area at risk and a 45% reduction in final infarct size (19.6 +/- 5.6% of area at risk with RAP versus 35.9 +/- 9.1% of area at risk without RAP; P<0.05).
Conclusions-The ability to perform noninvasive tomographic imaging of autophagy in the heart has the potential to provide valuable insights into the pathophysiology of autophagy, particularly its role in cardiomyocyte salvage. Although additional data are needed, our study supports the investigation of RAP therapy in patients with acute coronary syndromes.
C1 [Chen, Howard H.; Mekkaoui, Choukri; Josephson, Lee; Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Boston, MA USA.
[Chen, Howard H.; Marinelli, Brett; Waterman, Peter; Nahrendorf, Matthias; Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA USA.
[Chen, Howard H.; Mekkaoui, Choukri; Cho, Hoonsung; Josephson, Lee; Sosnovik, David E.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Cho, Hoonsung; Josephson, Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Translat Nucl Med & Mol Imaging, Boston, MA USA.
[Marinelli, Brett; Waterman, Peter; Nahrendorf, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
[Ngoy, Soeun; Liao, Ronglih] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Ngoy, Soeun; Liao, Ronglih] Harvard Univ, Sch Med, Boston, MA USA.
RP Sosnovik, DE (reprint author), Massachusetts Gen Hosp, 149 13th St, Charlestown, MA 02129 USA.
EM sosnovik@nmr.mgh.harvard.edu
FU National Institutes of Health [R01 HL093038, R01 EB011996, P41RR14075]
FX This work was funded in part by the following grants from the National
Institutes of Health: R01 HL093038 (Dr Sosnovik), R01 EB011996 (Dr
Josephson), and P41RR14075 (Martinos Center).
NR 31
TC 14
Z9 14
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD MAY
PY 2013
VL 6
IS 3
BP 441
EP +
DI 10.1161/CIRCIMAGING.112.000074
PG 10
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 298YI
UT WOS:000330360300019
PM 23537953
ER
PT J
AU Kato, K
Yonetsu, T
Jia, HB
Abtahian, F
Vergallo, R
Hu, SN
Tian, JW
Kim, SJ
Lee, H
McNulty, I
Lee, S
Uemura, S
Jang, Y
Park, SJ
Mizuno, K
Yu, B
Jang, IK
AF Kato, Koji
Yonetsu, Taishi
Jia, Haibo
Abtahian, Farhad
Vergallo, Rocco
Hu, Sining
Tian, Jinwei
Kim, Soo-Joong
Lee, Hang
McNulty, Iris
Lee, Stephen
Uemura, Shiro
Jang, Yangsoo
Park, Seung-Jung
Mizuno, Kyoichi
Yu, Bo
Jang, Ik-Kyung
TI Nonculprit Coronary Plaque Characteristics of Chronic Kidney Disease
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE cholesterol crystal; chronic kidney disease; optical coherence
tomography; plaque
ID OPTICAL COHERENCE TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION;
GLOMERULAR-FILTRATION-RATE; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC
PLAQUES; CARDIOVASCULAR-DISEASE; ARTERY-DISEASE; RISK-FACTOR;
MORPHOLOGY; DEATH
AB Background-Chronic kidney disease (CKD) promotes the development of atherosclerosis and increases the risk of cardiovascular disease. The aim of the present study was to compare the coronary plaque characteristics of patients with and without CKD using optical coherence tomography.
Methods and Results-We identified 463 nonculprit plaques from 287 patients from the Massachusetts General Hospital (MGH) optical coherence tomography registry. CKD was defined as estimated glomerular filtration rate <60 mL/min per 1.73 m(2). A total of 402 plaques (250 patients) were in the non-CKD group and 61 plaques (37 patients) were in the CKD group. Compared with non-CKD plaques, plaques with CKD had a larger lipid index (mean lipid arcxlipid length, 1248.4 +/- 782.8 mm degrees [non-CKD] versus 1716.1 +/- 1116.2 mm degrees [CKD]; P=0.003). Fibrous cap thickness was not significantly different between the groups. Calcification (34.8% [non-CKD] versus 50.8% [CKD]; P=0.041), cholesterol crystals (11.2% [non-CKD] versus 23.0% [CKD]; P=0.048), and plaque disruption (5.5% [non-CKD] versus 13.1% [CKD]; P=0.049) were more frequently observed in the CKD group. In the multivariate linear regression model, a lower estimated glomerular filtration rate and diabetes mellitus were independent risk factors for a larger lipid index.
Conclusions-Compared with non-CKD patients, the patients with CKD had a larger lipid index with a higher prevalence of calcium, cholesterol crystals, and plaque disruption. The multivariate linear regression model demonstrated that a lower estimated glomerular filtration rate was an independent risk factor for a larger lipid index.
C1 [Kato, Koji; Yonetsu, Taishi; Jia, Haibo; Abtahian, Farhad; Vergallo, Rocco; Hu, Sining; Tian, Jinwei; Kim, Soo-Joong; McNulty, Iris; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Jia, Haibo; Hu, Sining; Tian, Jinwei; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin 150086, Peoples R China.
[Kim, Soo-Joong] Kyung Hee Univ, Dept Cardiol, Coll Med, Seoul, South Korea.
[Lee, Hang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Biostat, Boston, MA USA.
[Lee, Stephen] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.
[Uemura, Shiro] Nara Med Univ, Dept Med 1, Nara, Japan.
[Jang, Yangsoo] Yonsei Univ, Severance Cardiovasc Hosp, Seoul 120749, South Korea.
[Park, Seung-Jung] Asan Med Ctr, Seoul, South Korea.
[Mizuno, Kyoichi] Nippon Med Sch, Dept Cardiovasc Med, Tokyo 113, Japan.
RP Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin 246 Xuefu Rd, Harbin 150086, Peoples R China.
EM yubodr@163.com
FU St. Jude Medical, the Cardiology Division of Massachusetts General
Hospital; Dr John Nam fellowship grant
FX This study was supported by research grants from St. Jude Medical, the
Cardiology Division of Massachusetts General Hospital, and the Dr John
Nam fellowship grant.
NR 42
TC 22
Z9 22
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD MAY
PY 2013
VL 6
IS 3
BP 448
EP +
DI 10.1161/CIRCIMAGING.112.000165
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 298YI
UT WOS:000330360300020
PM 23536265
ER
PT J
AU Parker, BA
Zaleski, AL
Capizzi, JA
Lorson, L
Ballard, KD
Troyanos, CS
Baggish, AL
D'Hemecourt, PA
Thompson, PD
AF Parker, Beth A.
Zaleski, Amanda L.
Capizzi, Jeffrey A.
Lorson, Lindsay
Ballard, Kevin D.
Troyanos, Christopher S.
Baggish, Aaron L.
D'Hemecourt, Pierre A.
Thompson, Paul D.
TI Chronic Exercise Does Not Mitigate The Effects Of Age And Cardiovascular
Risk On Coronary Atherosclerosis
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Parker, Beth A.; Zaleski, Amanda L.; Capizzi, Jeffrey A.; Lorson, Lindsay; Ballard, Kevin D.; Thompson, Paul D.] Hartford Hosp, Hartford, CT 06115 USA.
[Troyanos, Christopher S.; D'Hemecourt, Pierre A.] Childrens Hosp, Boston, MA 02115 USA.
[Baggish, Aaron L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 112
BP 10
EP 10
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469700032
ER
PT J
AU La Fountaine, MF
Bauman, WA
AF La Fountaine, Michael F.
Bauman, William A.
TI Use of Phase-rectified Signal Averaging to Examine Autonomic Dysfunction
After Concussive Head Trauma
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [La Fountaine, Michael F.] Seton Hall Univ, S Orange, NJ 07079 USA.
[Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 217
BP 40
EP 40
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469700119
ER
PT J
AU Contursi, ME
Baggish, AL
Lewis, GD
AF Contursi, Miranda E.
Baggish, Aaron L.
Lewis, Gregory D.
TI Exercise Induced Hemoptysis: A Hemodynamic Intervention Case Report
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Contursi, Miranda E.; Baggish, Aaron L.; Lewis, Gregory D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 1034
BP 224
EP 224
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469701380
ER
PT J
AU Zilinski, JL
Contursi, ME
Lowry, PA
O'Callaghan, CH
Fifer, MA
Lewis, GD
Baggish, AL
AF Zilinski, Jodi L.
Contursi, Miranda E.
Lowry, Patricia A.
O'Callaghan, Caitlin H.
Fifer, Michael A.
Lewis, Gregory D.
Baggish, Aaron L.
TI Syncope and Abnormal Electrocardiogram in an Adolescent Basketball
Player
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Zilinski, Jodi L.; Contursi, Miranda E.; Lowry, Patricia A.; O'Callaghan, Caitlin H.; Fifer, Michael A.; Lewis, Gregory D.; Baggish, Aaron L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 1772
BP 408
EP 409
PG 2
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469703180
ER
PT J
AU Scarborough, DM
Driscoll, S
Salzler, M
Berkson, EM
AF Scarborough, Donna M.
Driscoll, Sean
Salzler, Mathew
Berkson, Eric M.
TI Comparison Of The Biomechanics Of Running In Barefoot And Minimalist
Shoe Conditions
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Scarborough, Donna M.; Driscoll, Sean; Berkson, Eric M.] Massachusetts Gen Hosp, Foxboro, MA USA.
[Salzler, Mathew] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 5
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 1877
BP 425
EP 425
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469703221
ER
PT J
AU Ingram, KH
Thalacker-Mercer, A
Garvey, WT
AF Ingram, Katherine H.
Thalacker-Mercer, Anna
Garvey, W. Timothy
TI Amino Acids and Insulin Sensitivity in Non-Obese, Obese, and Type 2
Diabetic Patients
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Ingram, Katherine H.] Kennesaw State Univ, Kennesaw, GA USA.
[Thalacker-Mercer, Anna] Cornell Univ, Ithaca, NY USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 1886
BP 427
EP 428
PG 2
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469703229
ER
PT J
AU Ackerman, KE
Nazem, TG
Patel, KT
Ouellette, M
Huguenel, B
Shimodaira, K
Pierce, L
Guereca, G
Hubbard, J
Holmes, TM
Anderson, EJ
Misra, M
AF Ackerman, Kathryn Elizabeth
Nazem, Taraneh G.
Patel, Kamal T.
Ouellette, Miranda
Huguenel, Brynn
Shimodaira, Kenji
Pierce, Lisa
Guereca, Gabriela
Hubbard, Jane
Holmes, Tara M.
Anderson, Ellen J.
Misra, Madhusmita
TI Macro- and Micronutrient Intake Is Associated With Bone Density In Young
Athletes And Non-athletes
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [Ackerman, Kathryn Elizabeth] Boston Childrens Hosp, Boston, MA USA.
[Nazem, Taraneh G.; Patel, Kamal T.; Ouellette, Miranda; Huguenel, Brynn; Shimodaira, Kenji; Pierce, Lisa; Guereca, Gabriela; Hubbard, Jane; Holmes, Tara M.; Anderson, Ellen J.; Misra, Madhusmita] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 2246
BP 521
EP 521
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469704146
ER
PT J
AU McConnell, TR
Trevino, KM
AF McConnell, Timothy R.
Trevino, Kelly M.
TI A Longitudinal Evaluation Of Religiosity, Spirituality, And Religious
Coping Following A First Time Cardiac Event
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [McConnell, Timothy R.] Bloomsburg Univ Penn, Bloomsburg, PA 17815 USA.
[Trevino, Kelly M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 2367
BP 556
EP 556
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469704259
ER
PT J
AU DiPasquale, DM
Strangman, GE
Muza, SR
AF DiPasquale, Dana M.
Strangman, Gary E.
Muza, Stephen R.
TI Altitude Vs. Hypoxia: Comparing The Effects Of Exercise In Hypobaric And
Normobaric Hypoxia On Resting Heart Rate
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [DiPasquale, Dana M.; Strangman, Gary E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Muza, Stephen R.] US Army Res Inst Environm Med, Natick, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 2706
BP 632
EP 632
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469705068
ER
PT J
AU DiPiro, ND
Bowden, MG
Embry, AE
Perry, LA
Morgan, PJ
Gregory, CM
AF DiPiro, Nicole D.
Bowden, Mark G.
Embry, Aaron E.
Perry, Lindsay A.
Morgan, Patrick J.
Gregory, Chris M.
TI A Short-term, High-intensity Multimodal Exercise Program Improves
Strength and Function After Incomplete SCI
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-College-of-Sports-Medicine
CY MAY 28-JUN 01, 2013
CL Indianapolis, IN
SP Amer Coll Sports Med
C1 [DiPiro, Nicole D.; Embry, Aaron E.; Perry, Lindsay A.; Morgan, Patrick J.] MUSC, Charleston, SC USA.
[Bowden, Mark G.; Gregory, Chris M.] MUSC, Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2013
VL 45
IS 5
SU 1
MA 2767
BP 652
EP 652
PG 1
WC Sport Sciences
SC Sport Sciences
GA 300ND
UT WOS:000330469705129
ER
PT J
AU Killoran, A
Biglan, KM
Jankovic, J
Eberly, S
Kayson, E
Oakes, D
Young, AB
Shoulson, I
AF Killoran, Annie
Biglan, Kevin M.
Jankovic, Joseph
Eberly, Shirley
Kayson, Elise
Oakes, David
Young, Anne B.
Shoulson, Ira
TI Characterization of the Huntington intermediate CAG repeat expansion
phenotype in PHAROS
SO NEUROLOGY
LA English
DT Article
ID FRAGILE-X PREMUTATION; AGE-OF-ONSET; TRINUCLEOTIDE REPEAT; DISEASE
CHROMOSOMES; GENE; CARRIERS; ALLELES; LENGTH; HD
AB Objectives: We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study.
Methods: The Prospective Huntington At Risk Observational Study (PHAROS) enrolled adults at risk for Huntington disease (HD). They were assessed approximately every 9 months with the Unified Huntington's Disease Rating Scale (UHDRS) by investigators unaware of participants' gene status. UHDRS scores were compared according to the Huntingtin gene CAG repeat number: expanded >36, intermediate 27-35, and nonexpanded controls <26.
Results: Fifty (5.1%) of the 983 participants had an intermediate allele (IA). They were similar to controls on UHDRS motor, cognitive, and functional measures, but significantly worse behaviorally on apathy and suicidal ideation. On 5 of the 9 other behavioral items and on total behavior, the IA group's scores were worse than those of controls and expanded participants, who themselves scored significantly worse than controls on 6 behavioral measures. Retention rates at 4 years were 48% for the IA group compared to 58% and 60% for the expanded and control groups.
Conclusions: In a cohort at risk for HD, the IA was associated with significant behavioral abnormalities but normal motor and cognition. This behavioral phenotype may represent a prodromal stage of HD, with the potential for subsequent clinical manifestations, or be part of a distinct phenotype conferred by pathology independent of the CAG expansion length.
C1 [Killoran, Annie; Biglan, Kevin M.] Univ Rochester, Rochester, NY 14627 USA.
[Killoran, Annie] W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.
[Jankovic, Joseph] Baylor Coll Med, Houston, TX 77030 USA.
[Eberly, Shirley; Kayson, Elise; Oakes, David] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Young, Anne B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Shoulson, Ira] Georgetown Univ, Washington, DC USA.
RP Killoran, A (reprint author), Univ Rochester, Rochester, NY 14627 USA.
EM ankilloran@hsc.wvu.edu
FU NIH/NHGRI/National Institute of Neurological Disorders and Stroke
[R01HG02449]
FX Supported by NIH/NHGRI/National Institute of Neurological Disorders and
Stroke R01HG02449.
NR 27
TC 27
Z9 27
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY
PY 2013
VL 80
IS 22
BP 2022
EP 2027
DI 10.1212/WNL.0b013e318294b304
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 300LX
UT WOS:000330466500013
PM 23624566
ER
PT J
AU Cooper, ZA
Frederick, DT
Ahmed, Z
Wargo, JA
AF Cooper, Zachary A.
Frederick, Dennie T.
Ahmed, Zain
Wargo, Jennifer A.
TI Combining checkpoint inhibitors and BRAF-targeted agents against
metastatic melanoma
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE BRAF; checkpoint blockade; immunotherapy; melanoma; PDL1
ID INFILTRATION; ANTIBODY; CANCER; SAFETY
AB The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.
C1 [Cooper, Zachary A.; Frederick, Dennie T.; Ahmed, Zain; Wargo, Jennifer A.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
RP Wargo, JA (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
EM jwargo@partners.org
OI Cooper, Zachary/0000-0003-1059-0940
NR 10
TC 19
Z9 19
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD MAY
PY 2013
VL 2
IS 5
AR e24320
DI 10.4161/onci.24320
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA 301HQ
UT WOS:000330523800029
ER
PT J
AU Cortez-Retamozo, V
Engblom, C
Pittet, MJ
AF Cortez-Retamozo, Virna
Engblom, Camilla
Pittet, Mikael J.
TI Remote control of macrophage production by cancer
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE hematopoietic stem cell; monocyte; macrophage; cancer; NSCLC; lung
adenocarcinoma; Angiotensin II
ID TUMOR; MONOCYTES
AB The communication between tumor and host cells involves signals that act across extended distances in the body. recent evidence indicates that the hormone angiotensin II is overproduced by lung adenocarcinoma to remotely expand bone marrow-derived hematopoietic stem cells. this process amplifies the supply of tumor-associated macrophages, which promote disease progression.
C1 [Pittet, Mikael J.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Pittet, MJ (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
EM mpittet@mgh.harvard.edu
FU NIAID NIH HHS [R01 AI084880]
NR 10
TC 5
Z9 6
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD MAY
PY 2013
VL 2
IS 5
AR e24183
DI 10.4161/onci.24183
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA 301HQ
UT WOS:000330523800025
PM 23762799
ER
PT J
AU Black, EM
Antoci, V
Lee, JT
Weaver, MJ
Johnson, AH
Susarla, SM
Kwon, JY
AF Black, Eric M.
Antoci, Valentin
Lee, Jared T.
Weaver, Michael J.
Johnson, A. Holly
Susarla, Seenu M.
Kwon, John Y.
TI Role of Preoperative Computed Tomography Scans in Operative Planning for
Malleolar Ankle Fractures
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Article
DE trauma; CT scan; advanced imaging; malleolar ankle fracture; operative
planning
ID PILON FRACTURES; ANATOMY
AB Background: There remains no consensus regarding the role of computed tomography (CT) scans in preoperative planning for malleolar ankle fractures. The aim of this study was to determine the role of preoperative CT scans on operative planning in these fractures.
Methods: A retrospective analysis was performed on 100 consecutive patients treated at our institution for malleolar ankle fractures (AO type 44) with both preoperative radiographs and CT scans. Six study participants reviewed available radiographs and formulated an operative (or nonoperative) plan including positioning, operative approach, and fixation. Participants then analyzed CT scans of the same fractures, deciding whether (and how) they would alter operative strategy. Characteristics of fractures and radiographs were correlated with changes in operative strategy.
Results: Operative strategy was notably changed in 24% of cases after CT review, with strong intraclass correlation (0.733). Common changes included alterations in medial malleolar (21%) or posterior malleolar (15%) fixation and fixation of an occult anterolateral plafond fracture (9%). Notable predictors of changes in operative strategy included trimalleolar over unimalleolar fractures (29% vs 10% rate of change), preoperative dislocation over no dislocation (31% vs 20%), the presence of only radiographs with overlying plaster versus fractures with at least 1 set of radiographs without plaster (25% vs 14%), and suprasyndesmotic versus trans- and infra-syndesmotic fractures (40% vs 20% and 4%, respectively).
Conclusions: CT scans may be useful adjuncts in preoperative planning for malleolar ankle fractures, most notably in fracture dislocations, cases in which all available radiographs are obscured by plaster, trimalleolar fractures, and suprasyndesmotic fractures.
C1 [Black, Eric M.; Antoci, Valentin; Johnson, A. Holly; Susarla, Seenu M.; Kwon, John Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lee, Jared T.] Steadman Clin, Vail, CO USA.
[Weaver, Michael J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Kwon, JY (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM Jkwon@Partners.Org
OI Susarla, Srinivas/0000-0003-0155-8260
NR 12
TC 9
Z9 9
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1071-1007
EI 1944-7876
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD MAY
PY 2013
VL 34
IS 5
BP 697
EP 704
DI 10.1177/1071100713475355
PG 8
WC Orthopedics
SC Orthopedics
GA 298FE
UT WOS:000330308700010
PM 23637238
ER
PT J
AU Riegel, B
Hanlon, AL
Zhang, XM
Fleck, D
Sayers, SL
Goldberg, LR
Weintraub, WS
AF Riegel, Barbara
Hanlon, Alexandra L.
Zhang, Xuemei
Fleck, Desiree
Sayers, Steven L.
Goldberg, Lee R.
Weintraub, William S.
TI What is the best measure of daytime sleepiness in adults with heart
failure?
SO JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS
LA English
DT Article
DE Heart failure; screening; sleep disorders; outcomes
ID APNEA PATIENTS; SCALE; QUALITY; POPULATION; CONSEQUENCES; DEPRIVATION;
SENSITIVITY; PERFORMANCE; PREVALENCE; VIGILANCE
AB Purpose: To identify the best screening measure of daytime sleepiness in adults with heart failure (HF).
Data sources: A total of 280 adults with HF completed the Epworth Sleepiness Scale, the Stanford Sleepiness Scale, and a single Likert item measuring daytime sleepiness. The sensitivity and specificity of these self-report measures were assessed in relation to a measure of daytime dysfunction from poor sleep quality.
Conclusions: Only 16% of the sample reported significant daytime dysfunction because of poor sleep quality. Those reporting daytime dysfunction were likely to be younger (p < .001), to be unmarried (p = .002), to have New York Heart Association (NYHA) functional class IV HF (p = .015), and to report low income (p = .006) and fewer hours of sleep (p = .015). The measure of daytime sleepiness that was most sensitive to daytime dysfunction was a single Likert item measured on a 10-point (1-10) scale. Patients with a score >= 4 were 2.4 times more likely to have daytime dysfunction than those with a score <4.
Implications for practice: Complaints of daytime dysfunction because of poor sleep are not common in adults with HF. Routine use of a single question about daytime sleepiness can help nurse practitioners to identify those HF patients with significant sleep issues that may require further screening.
C1 [Riegel, Barbara; Hanlon, Alexandra L.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Zhang, Xuemei] Childrens Hosp Philadelphia Westat BDMC, Philadelphia, PA USA.
[Fleck, Desiree] Univ Penn, Sch Nursing, Childrens Hosp Penn, Philadelphia, PA 19104 USA.
[Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Weintraub, William S.] Christiana Care Ctr Outcomes Res Christiana Care, Newark, DE USA.
RP Riegel, B (reprint author), Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA.
EM briegel@nursing.upenn.edu
OI Goldberg, Lee/0000-0002-7906-9638
FU National Heart, Lung & Blood Institute [RO1 HL084394-01A1]; Philadelphia
Veterans Affairs Medical Center, VISN 4 Mental Illness Research,
Education, and Clinical Center (MIREC)
FX This work was funded by a grant from the National Heart, Lung & Blood
Institute (RO1 HL084394-01A1) and by the Philadelphia Veterans Affairs
Medical Center, VISN 4 Mental Illness Research, Education, and Clinical
Center (MIREC).
NR 47
TC 5
Z9 5
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2327-6886
EI 2327-6924
J9 J AM ASSOC NURSE PRA
JI J. Am. Assoc. Nurs. Pract.
PD MAY
PY 2013
VL 25
IS 5
BP 272
EP 279
DI 10.1111/j.1745-7599.2012.00784.x
PG 8
WC Health Care Sciences & Services; Nursing
SC Health Care Sciences & Services; Nursing
GA 296GM
UT WOS:000330173200006
PM 24170569
ER
PT J
AU Quinn, AM
Farraye, FA
Naini, BV
Cerda, S
Coukos, J
Li, Y
Khor, T
Odze, RD
AF Quinn, Andrew M.
Farraye, Francis A.
Naini, Bita V.
Cerda, Sandra
Coukos, Jennifer
Li, Yuan
Khor, Tze
Odze, Robert D.
TI Polypectomy is Adequate Treatment for Adenoma-like Dysplastic Lesions
(DALMs) in Crohn's Disease
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE adenoma-like DALM; Crohn's disease; dysplasia; adenocarcinoma; polyp
ID INFLAMMATORY-BOWEL-DISEASE; CHRONIC ULCERATIVE-COLITIS; CANCER-RISK;
COLORECTAL-CANCER; POLYPOID DYSPLASIA; SPORADIC ADENOMAS; ENDOSCOPIC
RESECTION; FOLLOW-UP; CARCINOMA; SURVEILLANCE
AB Background:The purpose of this study was to reevaluate the clinical and pathologic features and outcomes in patients with Crohn's disease with an adenoma-like dysplasia-associated lesion or mass (DALMs) to determine if polypectomy is adequate treatment.Methods:The clinical, endoscopic and pathologic features, and outcomes of 50 patients with Crohn's disease, each with 1 adenoma-like DALM were evaluated. The median length of follow-up was 39 months (range: 0.5-156 months).Results:Of the 50 patients with Crohn's disease (male to female ratio, 30:20; median age: 53 years; median duration of disease: 83 months), 11 had ileal disease, 26 had colonic disease, and 13 had both ileal and colonic disease. Approximately 43% of polyps occurred within areas of previous or concurrent colitis, whereas 57% occurred in areas not previously involved by colitis. Most polyps had tubular architecture and contained low-grade dysplasia. Of the patients who had polypectomy followed by surveillance, 45% developed new adenoma-like DALMs, but none developed flat dysplasia and only 1 had adenocarcinoma at the time of resection, which was within 3 months of polypectomy. There were no differences in the clinical or pathologic features or outcomes in patients who had adenoma-like DALMs within versus outside areas of previous or concurrent colitis, except that the former showed a higher risk of developing new polyps within areas of colitis and near the site of the original polyp compared with the latter.Conclusions:Patients with Crohn's disease who develop an adenoma-like DALM, regardless of its location in relationship to previous or concurrent colitis, may be treated safely with polypectomy and continued surveillance.
C1 [Quinn, Andrew M.; Odze, Robert D.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Farraye, Francis A.; Cerda, Sandra; Coukos, Jennifer] Boston Med Ctr, Boston, MA USA.
[Naini, Bita V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Li, Yuan; Khor, Tze] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Odze, RD (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM rodze@partners.org
OI Farraye, Francis/0000-0001-6371-2441; Cerda, Sandra/0000-0002-7779-6110
NR 33
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD MAY
PY 2013
VL 19
IS 6
BP 1186
EP 1193
DI 10.1097/MIB.0b013e318280e749
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 284WT
UT WOS:000329353200014
PM 23567776
ER
PT J
AU Klimesova, K
Kverka, M
Zakostelska, Z
Hudcovic, T
Hrncir, T
Stepankova, R
Rossmann, P
Ridl, J
Kostovcik, M
Mrazek, J
Kopecny, J
Kobayashi, KS
Tlaskalova-Hogenova, H
AF Klimesova, Klara
Kverka, Miloslav
Zakostelska, Zuzana
Hudcovic, Tomas
Hrncir, Tomas
Stepankova, Renata
Rossmann, Pavel
Ridl, Jakub
Kostovcik, Martin
Mrazek, Jakub
Kopecny, Jan
Kobayashi, Koichi S.
Tlaskalova-Hogenova, Helena
TI Altered Gut Microbiota Promotes Colitis-Associated Cancer in IL-1
Receptor-Associated Kinase M-Deficient Mice
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE cancer in IBD; mucosal immunity; colorectal cancer; microbiota;
germ-free
ID INFLAMMATORY-BOWEL-DISEASE; REGULATORY T-CELLS; COLORECTAL-CANCER;
IRAK-M; GERM-FREE; ANTIBIOTIC-TREATMENT; NEGATIVE REGULATOR; SYSTEMIC
IMMUNITY; TUMOR-GROWTH; TGF-BETA
AB Background:Microbial sensing by Toll-like receptors (TLR) and its negative regulation have an important role in the pathogenesis of inflammation-related cancer. In this study, we investigated the role of negative regulation of Toll-like receptors signaling and gut microbiota in the development of colitis-associated cancer in mouse model.Methods:Colitis-associated cancer was induced by azoxymethane and dextran sodium sulfate in wild-type and in interleukin-1 receptor-associated kinase M (IRAK-M)-deficient mice with or without antibiotic (ATB) treatment. Local cytokine production was analyzed by multiplex cytokine assay or enzyme-linked immunosorbent assay, and regulatory T cells were analyzed by flow cytometry. Changes in microbiota composition during tumorigenesis were analyzed by pyrosequencing, and -glucuronidase activity was measured in intestinal content by fluorescence assay.Results:ATB treatment of wild-type mice reduced the incidence and severity of tumors. Compared with nontreated mice, ATB-treated mice had significantly lower numbers of regulatory T cells in colon, altered gut microbiota composition, and decreased -glucuronidase activity. However, the -glucuronidase activity was not as low as in germ-free mice. IRAK-M-deficient mice not only developed invasive tumors, but ATB-induced decrease in -glucuronidase activity did not rescue them from severe carcinogenesis phenotype. Furthermore, IRAK-M-deficient mice had significantly increased levels of proinflammatory cytokines in the tumor tissue.Conclusions:We conclude that gut microbiota promotes tumorigenesis by increasing the exposure of gut epithelium to carcinogens and that IRAK-M-negative regulation is essential for colon cancer resistance even in conditions of altered microbiota. Therefore, gut microbiota and its metabolic activity could be potential targets for colitis-associated cancer therapy.
C1 [Klimesova, Klara; Kverka, Miloslav; Zakostelska, Zuzana; Hudcovic, Tomas; Hrncir, Tomas; Stepankova, Renata; Rossmann, Pavel; Tlaskalova-Hogenova, Helena] Acad Sci Czech Republic, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, CR-14220 Prague, Czech Republic.
[Klimesova, Klara; Kverka, Miloslav; Zakostelska, Zuzana; Hudcovic, Tomas; Hrncir, Tomas; Stepankova, Renata; Rossmann, Pavel; Tlaskalova-Hogenova, Helena] Acad Sci Czech Republic, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, Novy Hradek, Czech Republic.
[Ridl, Jakub] Acad Sci Czech Republic, Inst Mol Genet, Lab Genom & Bioinformat, Vvi, CR-14220 Prague, Czech Republic.
[Kostovcik, Martin] Acad Sci Czech Republic, Inst Microbiol, Dept Biogenesis & Biotechnol Nat Cpds, Vvi, CR-14220 Prague, Czech Republic.
[Mrazek, Jakub; Kopecny, Jan] Acad Sci Czech Republic, Lab Anaerob Microbiol, Inst Anim Physiol & Genet, Vvi, CR-14220 Prague, Czech Republic.
[Kobayashi, Koichi S.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Kobayashi, Koichi S.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
RP Klimesova, K (reprint author), Acad Sci Czech Republic, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, Videnska 1083, CR-14220 Prague, Czech Republic.
EM klimesov@biomed.cas.cz
RI Kopecny, Jan/C-3899-2011; Kverka, Miloslav/H-2507-2014; Mrazek,
Jakub/G-7198-2014; Hrncir, Tomas/H-6733-2014; Kostovcik,
Martin/H-2663-2014; Klimesova, Klara/J-6851-2014; Tlaskalova-Hogenova,
Helena/J-8008-2014; stepankova, renata/J-9735-2014; Hudcovic,
Tomas/H-7917-2014; Zakostelska, Zuzana/D-6518-2012
OI Kopecny, Jan/0000-0002-2428-2511; Kverka, Miloslav/0000-0002-1335-5252;
Mrazek, Jakub/0000-0003-1907-3333; Klimesova, Klara/0000-0003-1821-398X;
stepankova, renata/0000-0001-7504-6300; Hudcovic,
Tomas/0000-0002-4761-5040;
FU Czech Science Foundation [P304/11/1252, P303/08/0367, P303/12/0535];
Academy of Sciences of the Czech Republic [M200201207]; NIH
[R01DK074738, R03TW006833]; Institutional Research Concept [RVO:
61388971]
FX Supported by grants from the Czech Science Foundation (P304/11/1252,
P303/08/0367, and P303/12/0535), the Academy of Sciences of the Czech
Republic (No. M200201207), NIH (R01DK074738 and R03TW006833), and
Institutional Research Concept (RVO: 61388971).
NR 44
TC 27
Z9 27
U1 3
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD MAY
PY 2013
VL 19
IS 6
BP 1266
EP 1277
DI 10.1097/MIB.0b013e318281330a
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 284WT
UT WOS:000329353200025
PM 23567778
ER
PT J
AU Linder, JA
Rigotti, NA
Brawarsky, P
Kontos, EZ
Park, ER
Klinger, EV
Marinacci, L
Li, WJ
Haas, JS
AF Linder, Jeffrey A.
Rigotti, Nancy A.
Brawarsky, Phyllis
Kontos, Emily Z.
Park, Elyse R.
Klinger, Elissa V.
Marinacci, Lucas
Li, Wenjun
Haas, Jennifer S.
TI Use of Practice-Based Research Network Data to Measure Neighborhood
Smoking Prevalence
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID ELECTRONIC MEDICAL-RECORDS; SMALL-AREA ESTIMATION; PRIMARY-CARE;
PRIORITIZING COMMUNITIES; TOBACCO DEPENDENCE; MASSACHUSETTS
AB Introduction
Practice-Based Research Networks (PBRNs) and health systems may provide timely, reliable data to guide the development and distribution of public health resources to promote healthy behaviors, such as quitting smoking. The objective of this study was to determine if PBRN data could be used to make neighborhood-level estimates of smoking prevalence.
Methods
We estimated the smoking prevalence in 32 greater Boston neighborhoods (population = 877,943 adults) by using the electronic health record data of adults who in 2009 visited one of 26 Partners Primary Care PBRN practices (n = 77,529). We compared PBRN-derived estimates to population-based estimates derived from 1999-2009 Behavioral Risk Factor Surveillance System (BRFSS) data (n = 20,475).
Results
The PBRN estimates of neighborhood smoking status ranged from 5% to 22% and averaged 11%. The 2009 neighborhood-level smoking prevalence estimates derived from the BRFSS ranged from 5% to 26% and averaged 13%. The difference in smoking prevalence between the PBRN and the BRFSS averaged -2 percentage points (standard deviation, 3 percentage points).
Conclusion
Health behavior data collected during routine clinical care by PBRNs and health systems could supplement or be an alternative to using traditional sources of public health data.
C1 [Linder, Jeffrey A.; Brawarsky, Phyllis; Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA.
[Linder, Jeffrey A.; Rigotti, Nancy A.; Park, Elyse R.; Haas, Jennifer S.] Harvard Univ, Sch Med, Boston, MA USA.
[Rigotti, Nancy A.; Park, Elyse R.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
[Rigotti, Nancy A.; Park, Elyse R.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Kontos, Emily Z.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Li, Wenjun] Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Boston, MA 02125 USA.
RP Haas, JS (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA.
EM jhaas@partners.org
RI Li, Wenjun/F-5634-2015
OI Li, Wenjun/0000-0001-5335-7386
FU Lung Cancer Disparities Center at the Harvard School of Public Health
(National Cancer Institute) [P50 CA148596]; Harvard Catalyst, the
Harvard Clinical and Translational Science Center (NIH) [1 UL1 RR
025758-01]
FX This work was conducted with support from The Lung Cancer Disparities
Center at the Harvard School of Public Health (National Cancer Institute
Award no. P50 CA148596) and the Harvard Catalyst, the Harvard Clinical
and Translational Science Center (NIH Grant no. 1 UL1 RR 025758-01 and
financial contributions from participating institutions). The content is
solely the responsibility of the authors and does not necessarily
represent the official views of Harvard University and its affiliated
academic health care centers or the National Institutes of Health.
NR 23
TC 1
Z9 1
U1 0
U2 1
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAY
PY 2013
VL 10
AR UNSP 120132
DI 10.5888/pcd10.120132
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 285JX
UT WOS:000329391200018
ER
PT J
AU Wyte-Lake, T
Tran, K
Bowman, CC
Needleman, J
Dobalian, A
AF Wyte-Lake, Tamar
Tran, Kim
Bowman, Candice C.
Needleman, Jack
Dobalian, Aram
TI A Systematic Review of Strategies to Address the Clinical Nursing
Faculty Shortage
SO JOURNAL OF NURSING EDUCATION
LA English
DT Review
ID EDUCATION; PARTNERSHIP; WORKFORCE
AB This systematic review provides a comprehensive assessment of models used to expand the ranks of clinical nursing faculty. Nursing faculty shortages constrict the pipeline for educating nurses and make addressing the projected nursing shortage more difficult. Schools of nursing have denied admission to qualified applicants, citing insufficient numbers of nursing faculty as one major reason. Using key search terms in PubMed (R) and CINAHL (R), we identified 14 peer-reviewed articles published between 1980 and 2010 about models for expanding clinical faculty. Partnership models (n = 11) and expanded use of faculty resources (n = 9) were the most common strategies. Few (n = 8) studies assessed program efficacy. A need was identified for studies to assess the effect of alternative models on educational capacity and student performance and to examine the sub-components of academic-practice partnerships and other innovative approaches to understand the essential factors necessary to implement successful programs.
C1 [Wyte-Lake, Tamar; Tran, Kim; Bowman, Candice C.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Study Healthcare Provider, Sepulveda, CA 91343 USA.
[Needleman, Jack] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
[Dobalian, Aram] Vet Emergency Management Evaluat Ctr, North Hills, CA USA.
RP Wyte-Lake, T (reprint author), VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Study Healthcare Provider, 16111 Plummer St 152, Sepulveda, CA 91343 USA.
EM Tamar.wyte@va.gov
RI Needleman, Jack/I-5461-2013
OI Needleman, Jack/0000-0002-2875-0589
FU Robert Wood Johnson Foundation [64104]; Department of Veterans Affairs,
Veterans Health Administration, Office of Academic Affiliations [XVA
65-010]; Veterans Health Administration Health Service Research
Postdoctoral Fellowship program
FX This article is based on work supported by the Robert Wood Johnson
Foundation (Project 64104) and the Department of Veterans Affairs,
Veterans Health Administration, Office of Academic Affiliations (Project
XVA 65-010). Dr. Tran receives support from the Veterans Health
Administration Health Service Research Postdoctoral Fellowship program.
The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Robert Wood Johnson
Foundation, the Department of Veterans Affairs, or the United States
government.
NR 26
TC 9
Z9 9
U1 0
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0148-4834
EI 1938-2421
J9 J NURS EDUC
JI J. Nurs. Educ.
PD MAY
PY 2013
VL 52
IS 5
BP 245
EP U15
DI 10.3928/01484834-20130213-02
PG 12
WC Nursing
SC Nursing
GA 273RJ
UT WOS:000328553700002
PM 23402282
ER
PT J
AU Chan, BT
Hohmann, E
Barshak, MB
Pukkila-Worley, R
AF Chan, Brian T.
Hohmann, Elizabeth
Barshak, Miriam Baron
Pukkila-Worley, Read
TI Treatment of Listeriosis in First Trimester of Pregnancy
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
C1 [Chan, Brian T.; Hohmann, Elizabeth; Barshak, Miriam Baron; Pukkila-Worley, Read] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chan, Brian T.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Pukkila-Worley, R (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRJ 504, Boston, MA 02114 USA.
EM rpukkilaworley@partners.org
FU NIAID NIH HHS [T32 AI007433, K08 AI081747]
NR 10
TC 2
Z9 5
U1 0
U2 5
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2013
VL 19
IS 5
BP 839
EP 841
DI 10.3201/eid1905.121397
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 268LX
UT WOS:000328173400038
PM 23697599
ER
PT J
AU Birgfeld, CB
Saltzman, BS
Luquetti, DV
Latham, K
Starr, JR
Heike, CL
AF Birgfeld, Craig B.
Saltzman, Babette S.
Luquetti, Daniela V.
Latham, Kerry
Starr, Jackie R.
Heike, Carrie L.
TI Comparison of Two-Dimensional and Three-Dimensional Images for
Phenotypic Assessment of Craniofacial Microsomia
SO CLEFT PALATE-CRANIOFACIAL JOURNAL
LA English
DT Article
DE hemifacial microsomia; photography; 3D photography
ID HEMIFACIAL MICROSOMIA; HIGH AGREEMENT; LOW KAPPA; PHOTOGRAPHY;
ACQUISITION; PARADOXES; SYSTEM
AB Background and Purpose: Three-dimensional surface imaging is used in many craniofacial centers. However, few data exist to indicate whether such systems justify their cost. Craniofacial microsomia is associated with wide phenotypic variability and can affect most facial features. The purpose of this study is to compare three-dimensional versus two-dimensional images for classification of facial features in individuals with craniofacial microsomia.
Methods: We obtained a series of two-dimensional and three-dimensional images of 50 participants, aged 0-20 years, diagnosed with craniofacial microsomia, microtia, or Goldenhar syndrome. Three clinicians classified the craniofacial features on each image, and ratings were compared by calculating kappa statistics. We also evaluated image quality using a 5-point Likert scale.
Results: Reliability estimates were high for most features using both two-dimensional and three-dimensional image data. Our three-dimensional protocol did not allow for scoring of facial animation, occlusal cant, or tongue anomalies. Image quality scores for the mandible and soft tissue assessment were higher for three-dimensional images. Raters preferred two-dimensional photographs for assessment of the ear, ear canal, and eyes.
Conclusions: Both three-dimensional and two-dimensional images provide useful data for objective characterization of the craniofacial features affected in craniofacial microsomia. A series of two-dimensional images has relative advantages for assessment of some specific features, such as the ear, though three-dimensional images may have advantages for quantitative analysis and qualitative assessment of deformities of the jaw and soft tissue. These results should apply to any assessment of these features with or without a craniofacial microsomia diagnosis.
C1 [Birgfeld, Craig B.] Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USA.
[Birgfeld, Craig B.; Heike, Carrie L.] Seattle Childrens Hosp, Seattle, WA 98105 USA.
[Saltzman, Babette S.] Seattle Childrens Hosp, Craniofacial Ctr, Seattle, WA 98105 USA.
[Luquetti, Daniela V.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Latham, Kerry] Mil Med Ctr, Walter Reed Hosp, Bethesda, MD USA.
[Starr, Jackie R.] Forsyth Inst, Cambridge, MA USA.
[Heike, Carrie L.] Univ Washington, Dept Pediat, Div Craniofacial Med, Seattle, WA 98195 USA.
RP Birgfeld, CB (reprint author), Seattle Childrens Hosp, M-S 7847,4800 Sand Point Way, Seattle, WA 98105 USA.
OI Starr, Jacqueline/0000-0002-3039-2311
NR 26
TC 3
Z9 3
U1 1
U2 3
PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS
PI LAWRENCE
PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA
SN 1545-1569
EI 1055-6656
J9 CLEFT PALATE-CRAN J
JI Cleft Palate-Craniofac. J.
PD MAY
PY 2013
VL 50
IS 3
BP 305
EP 314
DI 10.1597/11-173
PG 10
WC Dentistry, Oral Surgery & Medicine; Surgery
SC Dentistry, Oral Surgery & Medicine; Surgery
GA 259OA
UT WOS:000327535000008
PM 22849636
ER
PT J
AU Bolkan, CR
Bonner, LM
Campbell, DG
Lanto, A
Zivin, K
Chaney, E
Rubenstein, LV
AF Bolkan, Cory R.
Bonner, Laura M.
Campbell, Duncan G.
Lanto, Andy
Zivin, Kara
Chaney, Edmund
Rubenstein, Lisa V.
TI Family Involvement, Medication Adherence, and Depression Outcomes Among
Patients in Veterans Affairs Primary Care
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; SERIOUS MENTAL-ILLNESS; SOCIAL SUPPORT;
QUALITY IMPROVEMENT; HEALTH; SCHIZOPHRENIA; METAANALYSIS; INDIVIDUALS;
HEART; TRIAL
AB Objective: Family involvement and social support are associated with recovery from mental disorders. This project explored how family involvement in health care and social support among depressed veterans in primary care related to medication adherence and depression outcomes. Methods: During a longitudinal telephone survey, 761 Veterans Affairs (VA) primary care patients (mean age=60 years) with probable major depression were asked about depression symptoms, self-reported health, medication adherence, social support, family involvement with care, and satisfaction with clinicians' efforts to involve the patients' families in their care. Follow-up interviews at seven and 18 months assessed depression severity and medication adherence. Results: Most participants lived with others (71%) and reported moderately high social support. Most participants (62%) reported being very likely to discuss treatment of a major medical condition with family, but 64% reported that VA providers had not involved the participants' family in their care within the prior six months. In multivariate regression analyses, lower depression severity and better medication adherence over time were significantly linked to higher satisfaction with limited efforts by clinicians to involve families in care. Neither social support nor the extent of family involvement by itself was associated with outcomes. Conclusions: The results suggested a link between patient satisfaction with family involvement by clinicians and clinical outcomes among depressed veterans. In addition, clinician responsiveness to patient wishes may be more important than the amount of family involvement per se. Further research is needed to clarify when and how clinicians should involve a patient's family in depression treatment in primary care.
C1 [Bolkan, Cory R.] Washington State Univ, Dept Human Dev, Vancouver, WA 98686 USA.
[Bonner, Laura M.] Vet Affairs VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Bonner, Laura M.] Hlth Serv Res & Dev Northwest Ctr Excellence, Seattle, WA USA.
[Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA.
[Lanto, Andy; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA USA.
[Zivin, Kara] US Dept Vet Affairs, Natl Serious Mental Illness Treatment Res & Evalu, Ann Arbor, MI USA.
[Zivin, Kara] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Chaney, Edmund] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Bolkan, CR (reprint author), Washington State Univ, Dept Human Dev, 14204 Salmon Creek Ave, Vancouver, WA 98686 USA.
EM bolkan@vancouver.wsu.edu
FU Veterans Affairs (VA) Health Services Research and Development Service;
VA Mental Health Quality Enhancement Research Initiative [MHI 99-375,
MNT 01-027, MHQ 10-06]
FX Funding was provided by the Veterans Affairs (VA) Health Services
Research and Development Service and the VA Mental Health Quality
Enhancement Research Initiative (MHI 99-375, MNT 01-027, and MHQ 10-06).
The authors acknowledge the contributions of the many study
participants, without whom this work would not have been possible. The
views expressed herein are those of the authors and do not necessarily
represent the views of the VA and other affiliated institutions.
NR 34
TC 11
Z9 12
U1 2
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD MAY
PY 2013
VL 64
IS 5
BP 472
EP 478
DI 10.1176/appi.ps.201200160
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255WI
UT WOS:000327270400019
PM 23370463
ER
PT J
AU Olumi, AF
Kaufman, DS
Zietman, A
Harisinghani, MG
Wu, CL
AF Olumi, Aria F.
Kaufman, Donald S.
Zietman, Anthony
Harisinghani, Mukesh G.
Wu, Chin-Lee
TI Case 25-2013: A 71-Year-Old Man with Hematuria and a Mass in the Bladder
SO GLOBAL PUBLIC HEALTH
LA English
DT Article
ID PROSTATIC DUCT ADENOCARCINOMA; RADICAL PROSTATECTOMY; ENDOMETRIOID
FEATURES; CARCINOMA; UTRICLE
AB A 71-year-old man with gross hematuria and a mass in the bladder was seen in the cancer center. Six weeks earlier, painless hematuria had developed, with passage of clots. CT and cystoscopy showed a lobulated mass at the bladder neck. A diagnostic test was performed. Presentation of CaseDr. Donald S. Kaufman: A 71-year-old man was seen in the outpatient cancer center of this hospital because of gross hematuria and a mass in the bladder. The patient had been well until 6 weeks earlier, when painless hematuria had developed, with passage of clots, while he was traveling in a wilderness area. After 2 days, he saw a nurse practitioner at a local facility. Attempts at passing a catheter into his bladder were unsuccessful, and he was referred to a hospital in a larger city. Computed tomography (CT) performed without the administration of contrast material reportedly ...
C1 [Olumi, Aria F.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Kaufman, Donald S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Zietman, Anthony] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Harisinghani, Mukesh G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Olumi, Aria F.] Harvard Univ, Sch Med, Dept Urol, Boston, MA USA.
[Kaufman, Donald S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Zietman, Anthony] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Harisinghani, Mukesh G.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Wu, Chin-Lee] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Olumi, AF (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1744-1692
EI 1744-1706
J9 GLOB PUBLIC HEALTH
JI Glob. Public Health
PD MAY 1
PY 2013
VL 8
IS 5
BP 660
EP 667
DI 10.1056/NEJMcpc1209278
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 243XE
UT WOS:000326350900009
ER
PT J
AU Garcia-Godoy, F
Trusbkowsky, RD
AF Garcia-Godoy, Franklin
Trusbkowsky, Richard D.
TI A diagnostic device to record dentin hypersensitivity
SO AMERICAN JOURNAL OF DENTISTRY
LA English
DT Editorial Material
ID DENTIFRICE; FLUORIDE; ETIOLOGY; 8-WEEK
C1 [Garcia-Godoy, Franklin] Univ Tennessee, Coll Dent, Biosci Res Ctr, Memphis, TN 38168 USA.
[Garcia-Godoy, Franklin] Forsyth Inst, Cambridge, MA USA.
[Trusbkowsky, Richard D.] NYU, Coll Dent, Adv Programs Int Dentists Esthet Dent, New York, NY USA.
RP Garcia-Godoy, F (reprint author), Univ Tennessee, Hlth Sci Ctr, Coll Dent, 875 Union Ave, Memphis, TN 38168 USA.
EM fgarciagodoy@gmail.com
NR 24
TC 0
Z9 0
U1 0
U2 0
PU MOSHER & LINDER, INC
PI WESTON
PA 318 INDIAN TRACE SUITE 500, WESTON, FL 33326 USA
SN 0894-8275
J9 AM J DENT
JI Am. J. Dent.
PD MAY
PY 2013
VL 26
SI B
BP 3B
EP 4B
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 233UZ
UT WOS:000325596300002
PM 24156202
ER
PT J
AU Custodio, JCD
Martins, CW
Lugon, MDV
Fregni, F
Nakamura-Palacios, EM
AF de Souza Custodio, Juliana Cardoso
Martins, Cleciane Waldetario
Valladao Lugon, Marcelo Di Marcello
Fregni, Felipe
Nakamura-Palacios, Ester Miyuki
TI Epidural Direct Current Stimulation Over the Left Medial Prefrontal
Cortex Facilitates Spatial Working Memory Performance in Rats
SO BRAIN STIMULATION
LA English
DT Article
DE Epidural direct current stimulation; Medial prefrontal cortex; Delayed
task; Spatial working memory; Radial maze
ID DEEP BRAIN-STIMULATION; RADIAL-ARM MAZE; CORTICAL SPREADING DEPRESSION;
ELECTRICAL-STIMULATION; MOTOR CORTEX; POLARIZING CURRENTS; SYNAPTIC
PLASTICITY; DOPAMINE MODULATION; CLINICAL-TRIAL; DOUBLE-BLIND
AB Background: Extensive evidence supports the notion that modulation of PFC excitability using low-intensity electrical stimulation is a promising modality for treating neuropsychiatric diseases and improving cognitive function.
Objective: This study examined the effects of epidural direct current stimulation (eDCS), a method providing smaller shunting of current and more focal stimulation, on spatial working memory.
Methods: Male Wistar rats that were well trained in an 8-arm radial maze and in which 5-mm round electrodes were implanted over the left medial prefrontal cortex (mPFC) received anodal eDCS (400 mu A during 11 min) (n = 9) or sham procedure (n = 9) five minutes before delayed tests in the radial maze.
Results: Animals that received eDCS over the left mPFC had significantly fewer errors in the post-delay performance on the 1-h (P < 0.01), 4-h (P < 0.001), and 10-h (P < 0.001) delayed tests compared with sham-treated animals. General locomotor activity was unaffected because time spent in each visited arm did not change significantly by eDCS. There was no evidence of neuronal lesions in the mPFC underneath the eDCS.
Conclusions: Our results suggest that epidural direct current stimulation over the mPFC facilitates spatial working memory in rats, an effect that persisted over the long term. (c) 2013 Elsevier Inc. All rights reserved.
C1 [de Souza Custodio, Juliana Cardoso; Martins, Cleciane Waldetario; Valladao Lugon, Marcelo Di Marcello; Nakamura-Palacios, Ester Miyuki] Univ Fed Espirito Santo, Program Postgrad Physiol Sci, Lab Cognit Sci, BR-29047105 Vitoria, ES, Brazil.
[Fregni, Felipe] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Lab Neuromodulat, Boston, MA USA.
[Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Spauding Rehabil Hosp, Boston, MA USA.
[Fregni, Felipe] Harvard Univ, Sch Med, Dept Neurol, Berenson Allen Ctr Noninvas Brain Stimulat,Beth I, Boston, MA 02115 USA.
RP Nakamura-Palacios, EM (reprint author), Univ Fed Espirito Santo, Programa Posgrad Ciencias Fisiol, Ctr Ciencias Saude, Av Marechal Campos 1468, BR-29047105 Vitoria, ES, Brazil.
EM emnpalacios@gmail.com
FU NIH [1R21DK81773-1A1]
FX FF is partially supported by a NIH grant (1R21DK81773-1A1) investigating
the mechanisms of DC stimulation.
NR 74
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAY
PY 2013
VL 6
IS 3
BP 261
EP 269
DI 10.1016/j.brs.2012.07.004
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 234VF
UT WOS:000325671700006
ER
PT J
AU Nahas, Z
Short, B
Burns, C
Archer, M
Schmidt, M
Prudic, J
Nobler, MS
Devanand, DP
Fitzsimons, L
Lisanby, SH
Payne, N
Perera, T
George, MS
Sackeim, HA
AF Nahas, Ziad
Short, Baron
Burns, Carol
Archer, Melanie
Schmidt, Matthew
Prudic, Joan
Nobler, Mitchell S.
Devanand, D. P.
Fitzsimons, Linda
Lisanby, Sarah H.
Payne, Nancy
Perera, Tarique
George, Mark S.
Sackeim, Harold A.
TI A Feasibility Study of a New Method for Electrically Producing Seizures
in Man: Focal Electrically Administered Seizure Therapy [FEAST]
SO BRAIN STIMULATION
LA English
DT Article
DE ECT; FEAST; Depression; Seizure
ID TRANSCRANIAL MAGNETIC STIMULATION; ELECTROCONVULSIVE-THERAPY; ELECTRODE
PLACEMENT; PERIPHERAL-NERVE; MOTOR CORTEX; STIMULUS-INTENSITY; COIL
STIMULATION; ECT; EFFICACY; MECHANISMS
AB Background: Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe major depression, but with significant risk of adverse cognitive effects. Unidirectional electrical stimulation with a novel electrode placement and geometry (Focal Electrically Administered Seizure Therapy (FEAST)) has been proposed as a means to initiate seizures in prefrontal cortex prior to secondary generalization. As such, it may have fewer cognitive side effects than traditional ECT. We report on its first human clinical application.
Method: Seventeen unmedicated depressed adults (5 men; 3 bipolar disorder; age 53 +/- 16 years) were recruited after being referred for ECT. Open-label FEAST was administered with a modified spECTrum 5000Q device and a traditional ECT dosing regimen until patients clinically responded. Clinical and cognitive assessments were obtained at baseline, and end of course. Time to orientation recovery, a predictor of long-term amnestic effects, was assessed at each treatment. Nonresponders to FEAST were transitioned to conventional ECT.
Results: One patient withdrew from the study after a single titration session. After the course of FEAST (median 10 sessions), there was a 46.1 +/- 35.5% improvement in Hamilton Rating Scale for Depression (HRSD24) scores compared to baseline (33.1 +/- 6.8, 16.8 +/- 10.9; P < 0.0001). Eight of 16 patients met response criteria (50% decrease in HRSD24) and 5/16 met remission criteria (HRSD24 < 10). Patients achieved full re-orientation (4 of 5 items) in 5.5 +/- 6.4 min (median = 3.6), timed from when their eyes first opened after treatment.
Conclusion: In this feasibility study, FEAST produced clinically meaningful antidepressant improvement, with relatively short time to reorientation. Our preliminary work first in primates and now depressed adults demonstrates that FEAST is feasible, safe, well-tolerated and, if efficacy can be optimized, has potential to replace traditional Ea. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Nahas, Ziad] Amer Univ Beirut, Dept Psychiat, Beirut, Lebanon.
[Nahas, Ziad; Short, Baron; Burns, Carol; Archer, Melanie; Schmidt, Matthew; George, Mark S.] Med Univ S Carolina, Charleston, SC USA.
[Prudic, Joan; Devanand, D. P.; Fitzsimons, Linda; Perera, Tarique; Sackeim, Harold A.] Columbia Univ, Dept Psychiat, New York, NY 10027 USA.
[Nobler, Mitchell S.] New York Med Coll, Dept Psychiat & Behav Sci, Valhalla, NY 10595 USA.
[Lisanby, Sarah H.] Duke Univ Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA.
[Payne, Nancy] NYU, New York, NY 10003 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Nahas, Z (reprint author), Amer Univ Beirut, Beirut, Lebanon.
EM zn17@aub.edu.lb
NR 46
TC 23
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAY
PY 2013
VL 6
IS 3
BP 403
EP 408
DI 10.1016/j.brs.2013.03.004
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 234VF
UT WOS:000325671700026
PM 23518262
ER
PT J
AU Neuss, MN
Polovich, M
McNiff, K
Esper, P
Gilmore, TR
LeFebvre, KB
Schulmeister, L
Jacobson, JO
AF Neuss, Michael N.
Polovich, Martha
McNiff, Kristen
Esper, Peg
Gilmore, Terry R.
LeFebvre, Kristine B.
Schulmeister, Lisa
Jacobson, Joseph O.
TI 2013 Updated American Society of Clinical Oncology/Oncology Nursing
Society Chemotherapy Administration Safety Standards Including Standards
for the Safe Administration and Management of Oral Chemotherapy
SO ONCOLOGY NURSING FORUM
LA English
DT Article
ID CANCER; ADHERENCE; LEUKEMIA; ERRORS
AB In 2009; the American Society-of Oncology (ASCO) and the Oncology Nursing Society (ONS) published standards for the safe use of parenteral, chemotherapy in the outpatient setting, including issues of practitioner orders, preparation, and administration of medication. In 2011, these were updated to include inpatient facilities. In December 2011; a multistakeholder workgroup met to address the issues associated with orally administered antineoplastics, under the leadership of ASCO and ONS. The workgroup participants developed,recommended Standards, which were presented for public comment Public comments informed final edits; and the final standards were reviewed and approved by the ASCO and ONS Boards of Directors. Significant newly identified recommendations include those associated with drug prescription and the necessity of ascertaining that prescriptions are filled. In addition; the importance of patient and family education regarding administration schedules, exception procedures, disposal of unused Oral medication, and aspects of continuity of care across settings were identified. This article presents the newly developed standards.
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Duke Oncol Network, Durham, NC USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[McNiff, Kristen] Amer Soc Clin Oncol, Alexandria, VA USA.
Oncol Nursing Soc, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RP McNiff, K (reprint author), Amer Soc Clin Oncol, 2318 Mill Rd,Ste 800, Alexandria, VA USA.
EM Kristen.mcniff@asco.org
NR 18
TC 25
Z9 25
U1 1
U2 5
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAY
PY 2013
VL 40
IS 3
BP 225
EP 233
DI 10.1188/13.ONF.40-03AP2
PG 9
WC Oncology; Nursing
SC Oncology; Nursing
GA 220EL
UT WOS:000324564800006
PM 23619103
ER
PT J
AU Wang, M
Maragani, S
Huang, LY
Jeon, S
Canteenwala, T
Hamblin, MR
Chiang, LY
AF Wang, Min
Maragani, Satyanarayana
Huang, Liyi
Jeon, Seaho
Canteenwala, Taizoon
Hamblin, Michael R.
Chiang, Long Y.
TI Synthesis of decacationic [60]fullerene decaiodides giving photoinduced
production of superoxide radicals and effective PDT-mediation on
antimicrobial photoinactivation
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Decacationic C-60 monoadducts; Photoinduced radicals;
Transesterification; Di(N,N
',N,N,N,N-hexapropyl-hexa(aminoethyl)amido)malonate arm;
Photosensitizer; Antimicrobial photodynamic therapy
ID GRAM-POSITIVE BACTERIA; PHOTODYNAMIC THERAPY; FULLERENE DERIVATIVES;
NEGATIVE BACTERIA; SURFACE-PROTEINS; INACTIVATION; C-60; OXYGEN;
INFECTIONS; WATER
AB We report a novel class of highly water-soluble decacationic methano[60]fullerene decaiodides C-60[>M(C3N6+C3)(2)]-(I-)(10) [1-(I-)(10)] capable of co-producing singlet oxygen (Type-II) and highly reactive hydroxyl radicals, formed from superoxide radicals in Type-I photosensitizing reactions, upon illumination at both UVA and white light wavelengths. The O-2(-)center dot-production efficiency of 1-(I-)(10) was confirmed by using an O-2(-)center dot-reactive bis(2,4-dinitrobenzenesulfonyl)tetrafluorofluorescein probe and correlated to the photoinduced electron-transfer event going from iodide anions to C-3(60)*[>M(C3N6+C3)(2)] leading to C-60(-)center dot[>M(C3N6+C3)(2)]. Incorporation of a defined number (ten) of quaternary ammonium cationic charges per C60 in 1 was aimed to enhance its ability to target pathogenic Gram-positive and Gram-negative bacterial cells. We used the well-characterized malonato[60]fullerene diester monoadduct C-60[>M(t-Bu)(2)] as the starting fullerene derivative to provide a better synthetic route to C-60[>M(C3N6+C3)(2)] via transesterification reaction under trifluoroacetic acid catalyzed conditions. These compounds may be used as effective photosensitizers and nano-PDT drugs for photoinactivation of pathogens. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [Wang, Min; Maragani, Satyanarayana; Jeon, Seaho; Canteenwala, Taizoon; Chiang, Long Y.] Univ Massachusetts, Inst Nanosci & Engn Technol, Dept Chem, Lowell, MA 01854 USA.
[Huang, Liyi; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Liyi; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Chiang, Long Y.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada.
RP Chiang, LY (reprint author), Univ Massachusetts, Inst Nanosci & Engn Technol, Dept Chem, Lowell, MA 01854 USA.
EM hamblin@helix.mgh.harvard.edu; long_chiang@uml.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU National Institute of Health (NIH) [R01 CA137108]
FX We thank the financial support of National Institute of Health (NIH)
under the grant number R01 CA137108. We thank Jin Xu of UML for the
collection of ESI-MS spectroscopic data.
NR 40
TC 12
Z9 12
U1 5
U2 45
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAY
PY 2013
VL 63
BP 170
EP 184
DI 10.1016/j.ejmech.2013.01.052
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 197MN
UT WOS:000322855400018
PM 23474903
ER
PT J
AU Karlin, BE
Agarwal, M
AF Karlin, Bradley E.
Agarwal, Madhulika
TI Achieving the Promise of Evidence-Based Psychotherapies for
Posttraumatic Stress Disorder and Other Mental Health Conditions for
Veterans
SO PSYCHOLOGICAL SCIENCE IN THE PUBLIC INTEREST
LA English
DT Editorial Material
ID COGNITIVE-BEHAVIORAL THERAPY; PROCESSING THERAPY; DISSEMINATION;
OUTCOMES
C1 [Karlin, Bradley E.; Agarwal, Madhulika] US Dept Vet Affairs, Cent Off, Washington, DC 20420 USA.
RP Karlin, BE (reprint author), US Dept Vet Affairs, Cent Off, 810 Vermont Ave, Washington, DC 20420 USA.
EM bradley.karlin2@va.gov
NR 16
TC 9
Z9 9
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1529-1006
J9 PSYCHOL SCI PUBL INT
JI Psychol. Sci. Public Interest
PD MAY
PY 2013
VL 14
IS 2
BP 62
EP 64
DI 10.1177/1529100613484706
PG 3
WC Psychology, Multidisciplinary
SC Psychology
GA 217ZQ
UT WOS:000324402500001
PM 26173291
ER
PT J
AU Meeker, JD
Cooper, EM
Stapleton, HM
Hauser, R
AF Meeker, John D.
Cooper, Ellen M.
Stapleton, Heather M.
Hauser, Russ
TI Urinary Metabolites of Organophosphate Flame Retardants: Temporal
Variability and Correlations with House Dust Concentrations
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE biomarker; epidemiology; exposure; human; TDCPP; triphenyl phosphate
ID SAN-ANTONIO STATEMENT; TRIS(1,3-DICHLORO-2-PROPYL) PHOSPHATE;
HORMONE-LEVELS; MEN; SERUM; RAT; DISPOSITION; WOMEN
AB BACKGROUND: A reduction in the use of polybrominated diphenyl ethers (PBDEs) because of human health concerns may result in an increased use of and human exposure to organophosphate flame retardants (OPFRs). Human exposure and health studies of OPFRs are lacking.
OBJECTIVES: We sought to define the degree of temporal variability in urinary OPFR metabolites in order to inform epidemiologic study design, and to explore a potential primary source of exposure by examining the relationship between OPFRs in house dust and their metabolites in urine.
METHODS: Nine repeated urine samples were collected from 7 men over the course of 3 months and analyzed for bis(1,3-dichloro-2-propyl) phosphate (BDCPP) and diphenyl phosphate (DPP), metabolites of the OPFRs tris(1,3-dichloro-2-propyl) phosphate (TDCPP) and triphenyl phosphate (TPP), respectively. Intraclass correlation coefficients (ICCs) were calculated to characterize temporal reliability. Paired house dust and urine samples were collected from 45 men.
RESULTS: BDCPP was detected in 91% of urine samples, and DPP in 96%. Urinary BDCPP showed moderate-to-strong temporal reliability (ICC range, 0.55-0.72). ICCs for DPP were lower, but moderately reliable (range, 0.35-0.51). There was a weak [Spearman r (r(S)) = 0.31] but significant (p = 0.03) correlation between urinary BDCPP and TDCPP concentrations in house dust that strengthened when nondetects (r(S) = 0.47) were excluded. There was no correlation between uncorrected DPP and TPP measured in house dust (r(S) < 0.1).
CONCLUSIONS: Household dust may be an important source of exposure to TDCPP but not TPP. Urinary concentrations of BDCPP and DPP were moderately to highly reliable within individuals over 3 months.
C1 [Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
[Cooper, Ellen M.; Stapleton, Heather M.] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA.
[Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA.
RP Meeker, JD (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, M6017 SPH II,1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM meekerj@umich.edu
OI Meeker, John/0000-0001-8357-5085
FU National Institute of Environmental Health Sciences, National Institutes
of Health [R01 ES009718, R01 ES016099]
FX This work was supported by grants R01 ES009718 and R01 ES016099 from the
National Institute of Environmental Health Sciences, National Institutes
of Health.
NR 26
TC 58
Z9 59
U1 11
U2 134
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD MAY
PY 2013
VL 121
IS 5
BP 580
EP 585
DI 10.1289/ehp.1205907
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA 208UX
UT WOS:000323707300021
PM 23461877
ER
PT J
AU Ali, O
Doherty, E
Dranoff, G
Mooney, D
AF Ali, Omar
Doherty, Ed
Dranoff, Glenn
Mooney, David
TI Infection-mimicking materials to regulate dendritic cell subsets and T
cell in situ for cancer vaccination
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Ali, Omar; Doherty, Ed; Dranoff, Glenn; Mooney, David] Harvard Univ, Sch Med, Wyss Inst Biol Inspired Engn, Boston, MA USA.
[Ali, Omar; Mooney, David] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Dranoff, Glenn] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4324
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987105139
ER
PT J
AU Bencherif, S
Draganov, D
Lewin, S
Li, A
Sands, R
Verbeke, C
Dranoff, G
Mooney, D
AF Bencherif, Sidi
Draganov, Dobrin
Lewin, Sarah
Li, Aileen
Sands, Roger
Verbeke, Catia
Dranoff, Glenn
Mooney, David
TI Immunologically active cryogels for breast cancer therapy
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Bencherif, Sidi; Li, Aileen; Sands, Roger; Verbeke, Catia; Mooney, David] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Bencherif, Sidi; Lewin, Sarah; Mooney, David] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
[Draganov, Dobrin; Dranoff, Glenn] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Draganov, Dobrin; Dranoff, Glenn] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4329
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987105144
ER
PT J
AU Bodhankar, S
Offner, H
AF Bodhankar, Sheetal
Offner, Halina
TI PD-1 interaction with PD-L1 but not PD-L2 on B cells mediates protective
effects of estrogen against EAE
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Bodhankar, Sheetal; Offner, Halina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bodhankar, Sheetal; Offner, Halina] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5176
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987107037
ER
PT J
AU Bodhankar, S
Chen, YX
Murphy, S
Offner, H
AF Bodhankar, Sheetal
Chen, Yingxin
Murphy, Stephanie
Offner, Halina
TI Opposing roles of PD-1 and PD-L in modulating CNS inflammation and
infarct volume following experimental stroke in mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Bodhankar, Sheetal; Chen, Yingxin; Murphy, Stephanie; Offner, Halina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bodhankar, Sheetal; Offner, Halina] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1012
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100014
ER
PT J
AU Boucau, J
Madouasse, J
Carlin, C
Zhu, T
Xu, Y
Shimada, M
Le Gall, S
AF Boucau, Julie
Madouasse, Julien
Carlin, Christopher
Zhu, Tom
Xu, Yang
Shimada, Mariko
Le Gall, Sylvie
TI Effect of cellular activation on the antigen processing machinery of
primary CD4 T cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Boucau, Julie; Madouasse, Julien; Carlin, Christopher; Zhu, Tom; Xu, Yang; Shimada, Mariko; Le Gall, Sylvie] Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5029
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106141
ER
PT J
AU Brandon, D
Williams, S
Zhang, X
AF Brandon, Danielle
Williams, Sarah
Zhang, Xian
TI Fli-1 transcription factor is involved in cytokine production in spleen
cells upon Toll-like receptor stimulation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Brandon, Danielle; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah; Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1218
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100217
ER
PT J
AU Bryce, S
Luster, A
Graham, G
Nibbs, R
AF Bryce, Steven
Luster, Andrew
Graham, Gerry
Nibbs, Rob
TI The 'atypical' chemokine receptor CCRL1 aids dendritic cell migration
from inflamed skin
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Bryce, Steven; Graham, Gerry; Nibbs, Rob] Univ Glasgow, Glasgow, Lanark, Scotland.
[Luster, Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P6352
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108188
ER
PT J
AU Chang, JJ
Woods, M
Lindsay, R
Doyle, E
Griesbeck, M
Chan, E
Robbins, G
Bosch, R
Altfeld, M
AF Chang, J. Judy
Woods, Matt
Lindsay, Robert
Doyle, Erin
Griesbeck, Morgane
Chan, Ellen
Robbins, Gregory
Bosch, Ronald
Altfeld, Marcus
TI Higher expression of several interferon-stimulated genes in
HIV-1-infected females after adjusting for the level of viral
replication
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Chang, J. Judy; Woods, Matt; Lindsay, Robert; Doyle, Erin; Griesbeck, Morgane; Altfeld, Marcus] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
[Chan, Ellen; Bosch, Ronald] Ctr Biostat AIDS Res, Boston, MA USA.
[Robbins, Gregory] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P3039
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987102216
ER
PT J
AU Choudhuri, K
Beilin, C
Bouma, G
Llodra, J
Malinova, D
Stokes, D
Springer, T
Shimaoka, M
Dustin, M
Thrasher, A
Burns, S
AF Choudhuri, Kaushik
Beilin, Chiara
Bouma, Gerben
Llodra, Jaime
Malinova, Dessislava
Stokes, David
Springer, Timothy
Shimaoka, Motomu
Dustin, Michael
Thrasher, Adrain
Burns, Siobhan
TI Dendritic cell-expressed common gamma-chain recruits IL-15 for
trans-presentation at the immunological synapse
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Choudhuri, Kaushik; Llodra, Jaime; Stokes, David; Dustin, Michael] NYU Sch Med, Skirball Inst Biomol Med, New York, NY USA.
[Beilin, Chiara; Bouma, Gerben; Malinova, Dessislava; Thrasher, Adrain; Burns, Siobhan] UCL, Inst Child Hlth, London, England.
[Springer, Timothy; Shimaoka, Motomu] Childrens Hosp, Immune Dis Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P6286
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108123
ER
PT J
AU Choudhuri, K
Llodra, J
Tsai, J
Roth, E
Gordo, S
Wucherpfennig, K
Kam, L
Stokes, D
Dustin, M
AF Choudhuri, Kaushik
Llodra, Jaime
Tsai, Jones
Roth, Eric
Gordo, Susana
Wucherpfennig, Kai
Kam, Lance
Stokes, David
Dustin, Michael
TI Polarized release and retroviral subversion of TCR-enriched
microvesicles at the T cell immunological synapse
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Choudhuri, Kaushik; Llodra, Jaime; Stokes, David; Dustin, Michael] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY USA.
[Tsai, Jones; Kam, Lance] Columbia Univ, Dept Biomed Engn, New York, NY USA.
[Gordo, Susana; Wucherpfennig, Kai] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Roth, Eric] Northwestern Univ, NUANCE Ctr, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P6155
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987107246
ER
PT J
AU Ding, YN
Hsu, HC
Li, J
Yang, P
Zajac, A
Mountz, J
AF Ding, Yanna
Hsu, Hui-Chen
Li, Jun
Yang, PingAr
Zajac, Allan
Mountz, John
TI IL-21 promotes autoreactive germinal center development in BXD2 mice
partially by regulating T-FR
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Ding, Yanna; Hsu, Hui-Chen; Li, Jun; Yang, PingAr; Zajac, Allan; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4116
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104185
ER
PT J
AU Dugan, J
Griffiths, E
Snow, P
Rosenzweig, H
Carr, D
Rosenbaum, J
Davey, M
AF Dugan, Jae
Griffiths, Eric
Snow, Paige
Rosenzweig, Holly
Carr, Daniel
Rosenbaum, Jim
Davey, Michael
TI Nucleotide-binding and oligomerization domain 2 (NOD2) knock-in mice
carrying a mutation associated with Blau syndrome show reduced amounts
of NOD2 protein and decreased muramyl dipeptide (MDP)-induced
inflammatory responses
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Dugan, Jae; Griffiths, Eric; Snow, Paige; Carr, Daniel; Davey, Michael] Portland VA Med Ctr, Portland, OR USA.
[Dugan, Jae; Rosenzweig, Holly; Carr, Daniel; Rosenbaum, Jim; Davey, Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Rosenzweig, Holly; Davey, Michael] Oregon Hlth & Sci Univ, MMI, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1254
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987101003
ER
PT J
AU Fletcher, A
Elman, J
Knoblich, K
Armant, M
Parekkadan, B
Boyd, R
Turley, S
AF Fletcher, Anne
Elman, Jessica
Knoblich, Konstantin
Armant, Myriam
Parekkadan, Biju
Boyd, Richard
Turley, Shannon
TI Identification of a new cell therapy candidate reveals immunological
specialization and robust therapeutic efficacy against high-mortality
sepsis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Fletcher, Anne; Knoblich, Konstantin; Turley, Shannon] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fletcher, Anne; Elman, Jessica; Armant, Myriam; Parekkadan, Biju; Turley, Shannon] Harvard Univ, Sch Med, Boston, MA USA.
[Fletcher, Anne; Boyd, Richard] Monash Univ, Immunol & Stem Cell Labs, Clayton, Vic, Australia.
[Elman, Jessica; Parekkadan, Biju] Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA.
[Elman, Jessica; Parekkadan, Biju] Shriners Hosp Children, Boston, MA USA.
[Knoblich, Konstantin] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
[Armant, Myriam] Boston Childrens Hosp, Ctr Human Cell Therapy, Boston, MA USA.
RI Knoblich, Konstantin/B-5980-2009
OI Knoblich, Konstantin/0000-0002-5646-837X
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4212
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987105029
ER
PT J
AU Gagnon, E
Wucherpfennig, K
AF Gagnon, Etienne
Wucherpfennig, Kai
TI Local changes in lipid environment of T cell receptor microclusters
regulate membrane binding by the CD3epsilon cytoplasmic domain (P1103)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Gagnon, Etienne; Wucherpfennig, Kai] Univ Montreal, IRIC, Montreal, PQ, Canada.
[Gagnon, Etienne] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100104
ER
PT J
AU Hansbro, P
Beckett, E
Stevens, R
Jarnicki, A
Kim, R
Hanish, I
Hansbro, N
Deane, A
Keely, S
Horvat, J
Yang, M
Oliver, B
van Rooijen, N
Inman, M
Adachi, R
Soberman, R
Hamadi, S
Wark, P
Foster, P
AF Hansbro, Philip
Beckett, Emma
Stevens, Richard
Jarnicki, Andrew
Kim, Richard
Hanish, Irwan
Hansbro, Nicole
Deane, Andrew
Keely, Simon
Horvat, Jay
Yang, Ming
Oliver, Brian
van Rooijen, Nico
Inman, Mark
Adachi, Roberto
Soberman, Roy
Hamadi, Sahar
Wark, Peter
Foster, Paul
TI A short-term model of COPD identifies a role for mast cell tryptase
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Hansbro, Philip; Beckett, Emma; Jarnicki, Andrew; Kim, Richard; Hanish, Irwan; Hansbro, Nicole; Deane, Andrew; Keely, Simon; Horvat, Jay; Yang, Ming; Wark, Peter; Foster, Paul] Univ Newcastle, Prior Res Ctr Asthma & Resp Dis, Callaghan, NSW 2308, Australia.
[Hansbro, Philip; Jarnicki, Andrew; Kim, Richard; Hanish, Irwan; Hansbro, Nicole; Deane, Andrew; Keely, Simon; Horvat, Jay; Yang, Ming; Wark, Peter; Foster, Paul] Hunter Med Res Inst, VIVA, New Lambton Hts, NSW, Australia.
[Stevens, Richard; Soberman, Roy; Hamadi, Sahar] Harvard Univ, Sch Med, Boston, MA USA.
[Stevens, Richard] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Oliver, Brian] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
[Oliver, Brian] Woolcock Inst Med Res, Sydney, NSW, Australia.
[van Rooijen, Nico] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
[Inman, Mark] St Josephs Healthcare, Firestone Inst Resp Hlth, Med, Hamilton, ON, Canada.
[Adachi, Roberto] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Soberman, Roy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wark, Peter] John Hunter Hosp, New Lambton Hts, NSW, Australia.
RI Oliver, Brian/E-7939-2010
OI Oliver, Brian/0000-0002-7122-9262
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P3242
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987103168
ER
PT J
AU Hu, Z
Xia, JX
Wargo, J
Yang, YG
AF Hu, Zheng
Xia, Jinxing
Wargo, Jennifer
Yang, Yong-Guang
TI Generation of human T cells expressing only the engineered tumor antigen
specific TCR in humanized mice for preclinical research and anticancer
therapy
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Hu, Zheng; Xia, Jinxing; Yang, Yong-Guang] Columbia Univ Coll Phys & Surg, Columbia Ctr Translat Immunol, New York, NY 10032 USA.
[Wargo, Jennifer] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RI Xia, Jinxing/E-5658-2015
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4364
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987105178
ER
PT J
AU Jost, S
Chang, J
Rands, K
Tomezsko, P
Doyle, E
Daillere, R
Dudek, T
Vrbanac, V
Allen, T
Tager, A
Altfeld, M
AF Jost, Stephanie
Chang, Judy
Rands, Keith
Tomezsko, Phillip
Doyle, Erin
Daillere, Romain
Dudek, Timothy
Vrbanac, Vladimir
Allen, Todd
Tager, Andrew
Altfeld, Marcus
TI Impact of NK cells on control of HIV infection in humanized BLT mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Jost, Stephanie; Chang, Judy; Rands, Keith; Tomezsko, Phillip; Doyle, Erin; Daillere, Romain; Dudek, Timothy; Allen, Todd; Tager, Andrew; Altfeld, Marcus] MIT & Harvard, Ragon Inst MGH, Boston, MA USA.
[Vrbanac, Vladimir; Tager, Andrew] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA 11827
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108044
ER
PT J
AU Kang, YJ
Chang, HC
AF Kang, Yoon-Joong
Chang, Hsiu-Ching
TI Transgenic mice expressing functional CD8 alpha beta without an active
CD8aa implies the contribution of CD8 alpha alpha in the biological
function of CD8 alpha alpha plus TCR alpha beta plus iIELs
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Kang, Yoon-Joong] Jungwon Univ, Dept Biomed Sci, Chungcheongbuk Do, South Korea.
[Kang, Yoon-Joong; Chang, Hsiu-Ching] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Kang, Yoon-Joong; Chang, Hsiu-Ching] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Chang, Hsiu-Ching] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1466
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987101188
ER
PT J
AU Karam, E
Williams, S
Zhang, J
AF Karam, Eva
Williams, Sarah
Zhang, John
TI Fli-1 transcription factor regulates inflammatory mediators in
endothelial cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Karam, Eva; Zhang, John] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah; Zhang, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA 11516
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108077
ER
PT J
AU Lee, KM
Kim, J
Yeh, H
Stott, R
Shi, S
Deng, SP
Markmann, J
AF Lee, Kang Mi
Kim, James
Yeh, Heidi
Stott, Ryan
Shi, Shuai
Deng, Shaoping
Markmann, James
TI Transplant tolerance depends on regulatory T cells induced by
TGF-beta-producing regulatory B cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Lee, Kang Mi; Kim, James; Yeh, Heidi; Stott, Ryan; Shi, Shuai; Deng, Shaoping; Markmann, James] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Deng, Shaoping] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China.
[Deng, Shaoping] Sichuan Acad Med Sci, Chengdu, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P2168
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987102117
ER
PT J
AU Li, H
Hsu, HC
Wu, Q
Yang, PA
Cua, D
Mountz, J
AF Li, Hao
Hsu, Hui-Chen
Wu, Qi
Yang, PingAr
Cua, Daniel
Mountz, John
TI IL-23 controls autoimmunity by maintaining the integrity of marginal
zone barrier that clears apoptotic bodies
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Li, Hao; Hsu, Hui-Chen; Wu, Qi; Yang, PingAr; Mountz, John] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Cua, Daniel] Merck Res Labs, Palo Alto, CA USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4178
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104246
ER
PT J
AU Li, H
Wu, Q
Yang, PA
Li, J
Fu, YX
Mountz, J
Hsu, HC
AF Li, Hao
Wu, Qi
Yang, PingAr
Li, Jun
Fu, YangXin
Mountz, John
Hsu, Hui-Chen
TI Increased type I interferon disrupts marginal zone barrier integrity via
dissociation of lymphotoxin-expressing B cells and marginal zone
macrophages in systemic autoimmunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Li, Hao; Wu, Qi; Yang, PingAr; Li, Jun; Mountz, John; Hsu, Hui-Chen] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Fu, YangXin] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4160
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104228
ER
PT J
AU Li, J
Hsu, HC
Yang, PA
Wu, Q
Spalding, D
Mountz, J
AF Li, Jun
Hsu, Hui-Chen
Yang, PingAr
Wu, Qi
Spalding, David
Mountz, John
TI Fucosylation is a hallmark of inflammatory macrophages and a novel
therapeutic target in rheumatoid arthritis (P5137)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Spalding, David; Mountz, John] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Hsu, Hui-Chen; Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA 13710
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106248
ER
PT J
AU Liao, GX
van Driel, B
Magelky, E
O'Keeffe, M
Herzog, R
Mizoguchi, E
Bhan, A
Terhorst, C
AF Liao, Gongxian
van Driel, Boaz
Magelky, Erica
O'Keeffe, Michael
Herzog, Roland
Mizoguchi, Emiko
Bhan, Atul
Terhorst, Cox
TI Glucocorticoid-induced TNF receptor family related protein ligand
regulates the egress of monocytes from the spleen
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Liao, Gongxian; van Driel, Boaz; Magelky, Erica; O'Keeffe, Michael; Terhorst, Cox] Harvard Univ, Sch Med, Div Immunol, BIDMC, Boston, MA USA.
[Herzog, Roland] Univ Florida, Gainesville, FL USA.
[Mizoguchi, Emiko; Bhan, Atul] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P3288
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987103213
ER
PT J
AU Lv, HJ
Smith, R
Shankar, J
Lipes, M
AF Lv, HuiJuan
Smith, Ross
Shankar, Jyotsna
Lipes, Myra
TI Shared and distinct immunogenetic pathways in myocarditis and type 1
diabetes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Lv, HuiJuan; Smith, Ross; Shankar, Jyotsna; Lipes, Myra] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Lv, HuiJuan; Smith, Ross; Shankar, Jyotsna; Lipes, Myra] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4108
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104177
ER
PT J
AU Martin-Gayo, E
Hickman, T
Pimenova, D
Pereyra, F
Rosenberg, E
Lichterfeld, M
Yu, X
AF Martin-Gayo, Enrique
Hickman, Taylor
Pimenova, Dina
Pereyra, Florencia
Rosenberg, Eric
Lichterfeld, Mathias
Yu, Xu
TI Cell-intrinsic HIV-1 immune responses in conventional dendritic cells
from HIV-1 elite controllers
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Martin-Gayo, Enrique; Hickman, Taylor; Pimenova, Dina; Pereyra, Florencia; Yu, Xu] Ragon Inst MGH MIT & Harvard, AIDS Res, Boston, MA USA.
[Rosenberg, Eric; Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P6171
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108009
ER
PT J
AU Matsui, A
Rittling, S
AF Matsui, Aritsune
Rittling, Susan
TI Osteopontin supports neutrophil survival and function in polymicrobial
infection.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Matsui, Aritsune; Rittling, Susan] Forsyth Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1281
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987101030
ER
PT J
AU Mikucki, M
Skitzki, J
Fisher, D
Curry, K
Frelinger, J
Luster, A
Evans, S
AF Mikucki, Maryann
Skitzki, Joseph
Fisher, Daniel
Curry, Kathryn
Frelinger, John
Luster, Andrew
Evans, Sharon
TI Non-redundant requirement for CXCR3 chemokine receptor in T cell
trafficking across tumor vascular gateways
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Mikucki, Maryann; Skitzki, Joseph; Fisher, Daniel; Curry, Kathryn; Evans, Sharon] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Frelinger, John] Univ Rochester, Med Ctr, Microbiol & Immunol & Canc Ctr, Rochester, NY 14642 USA.
[Luster, Andrew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P2137
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987102086
ER
PT J
AU Mora, JR
AF Mora, J. Rodrigo
TI Bone marrow precursors require beta 7 integrins to give rise to
intestinal mononuclear phagocytes with tolerogenic potential
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Mora, J. Rodrigo] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mora, J. Rodrigo] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P3290
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987103215
ER
PT J
AU Murshid, A
Gong, JL
Calderwood, S
AF Murshid, Ayesha
Gong, Jianlin
Calderwood, Stuart
TI Scavenger receptor SRECI can bind to Toll like receptor 4 and activate
LPS-mediated signaling
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Murshid, Ayesha; Calderwood, Stuart] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
[Gong, Jianlin] Boston Univ, Med Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1362
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987101111
ER
PT J
AU Nowling, T
Richard, E
Zhang, J
Siskind, L
AF Nowling, Tamara
Richard, Erin
Zhang, John
Siskind, Leah
TI Reducing Fli1 levels in the MRL/lpr lupus prone mouse model impacts T
cell activation and cytokine production
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Nowling, Tamara; Zhang, John; Siskind, Leah] Ralph H Johnson VAMC, Charleston, SC USA.
[Nowling, Tamara; Richard, Erin; Zhang, John; Siskind, Leah] Med Univ S Carolina, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4115
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104184
ER
PT J
AU Offner, H
Chen, YX
Murphy, S
Bodhankar, S
AF Offner, Halina
Chen, Yingxin
Murphy, Stephanie
Bodhankar, Sheetal
TI IL-10-producing B cells limit CNS inflammation and infarct volume after
experimental stroke in mice (P1090)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Offner, Halina; Chen, Yingxin; Murphy, Stephanie; Bodhankar, Sheetal] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Offner, Halina; Bodhankar, Sheetal] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100090
ER
PT J
AU Penaloza-MacMaster, P
Barouch, D
AF Penaloza-MacMaster, Pablo
Barouch, Dan
TI Severely exhausted CD8 T cells are refractory to rescue by PD-1
blockade, but re-invigorate following concomitant CD4 T cell depletion
in vivo
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Penaloza-MacMaster, Pablo; Barouch, Dan] Harvard Univ, BIDMC, Boston, MA 02115 USA.
[Barouch, Dan] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P6097
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987107189
ER
PT J
AU Penaranda, C
Hung, D
AF Penaranda, Cristina
Hung, Deborah
TI Identification of factors required for intracellular survival of
Pseudomonas aeruginosa
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Penaranda, Cristina; Hung, Deborah] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P3146
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987103072
ER
PT J
AU Pepper, M
Hondowicz, B
Garza, E
Moon, J
AF Pepper, Marion
Hondowicz, Brian
Garza, Esteban
Moon, James
TI Th2 differentiation during atopic asthma
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Pepper, Marion; Hondowicz, Brian; Garza, Esteban] Univ Washington, Seattle, WA 98195 USA.
[Moon, James] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1167
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100167
ER
PT J
AU Porichis, F
Hart, M
Barblu, L
Zupkosky, J
Kavanagh, D
Kaufmann, D
AF Porichis, Filippos
Hart, Meghan
Barblu, Lucie
Zupkosky, Jennifer
Kavanagh, Daniel
Kaufmann, Daniel
TI Impact of IFN gamma on HIV-specific CD4 T cell and antigen presenting
cell function
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Porichis, Filippos; Hart, Meghan; Barblu, Lucie; Zupkosky, Jennifer; Kavanagh, Daniel; Kaufmann, Daniel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ragon Inst MGH MIT & Harvard, Charlestown, MA USA.
[Barblu, Lucie; Kaufmann, Daniel] Univ Montreal, Ctr Rech, Ctr Hosp Univ Montreal, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P6163
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108002
ER
PT J
AU Prasad, A
Ramirez-Ortiz, Z
Means, T
AF Prasad, Amit
Ramirez-Ortiz, Zaida
Means, Terry
TI Mechanisms of AIM2 inflammasome regulation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Prasad, Amit; Ramirez-Ortiz, Zaida; Means, Terry] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4093
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104162
ER
PT J
AU Qiao, F
Zhang, LX
Yang, XF
Hua, YP
Narang, A
Holers, M
Kulik, L
Song, HB
Tomlinson, S
AF Qiao, Fei
Zhang, Lixia
Yang, Xiaofeng
Hua, Yunpeng
Narang, Aarti
Holers, Michael
Kulik, Liudmila
Song, Hongbin
Tomlinson, Stephen
TI Role of pathogenic natural antibodies and complement in a murine model
of spinal cord injury
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Qiao, Fei; Zhang, Lixia; Yang, Xiaofeng; Hua, Yunpeng; Narang, Aarti; Tomlinson, Stephen] Med Univ S Carolina, Charleston, SC 29425 USA.
[Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Holers, Michael; Kulik, Liudmila] Univ Colorado, Dept Med & Immunol, Denver, CO 80202 USA.
[Song, Hongbin] Acad Mil Med Sci, Inst Dis Control & Prevent, Beijing, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4051
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104120
ER
PT J
AU Richard, ML
Nowling, T
Zhang, X
AF Richard, Mara Lennard
Nowling, Tamara
Zhang, Xian
TI Fli-1 drives transcription from the MCP-1 gene promoter, which may
provide a novel mechanism for cytokine and chemokine activation.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Richard, Mara Lennard; Nowling, Tamara; Zhang, Xian] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
[Nowling, Tamara; Zhang, Xian] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA 11514
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987108073
ER
PT J
AU Salinthone, S
Wilkinson, A
Carr, D
AF Salinthone, Sonemany
Wilkinson, Amelia
Carr, Daniel
TI Dimethyl fumarate stimulates cyclic AMP production and suppresses
production of pro-inflammatory mediators in immune cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Salinthone, Sonemany; Wilkinson, Amelia; Carr, Daniel] Portland VA Med Ctr, Portland, OR USA.
[Salinthone, Sonemany; Carr, Daniel] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5143
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987107004
ER
PT J
AU Sato, S
Williams, S
Zhang, X
AF Sato, Shuzo
Williams, Sarah
Zhang, Xian
TI Fli-1 transcription factor affects inflammatory cell infiltration into
the kidneys independent of autoantibodies
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Sato, Shuzo; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4150
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987104218
ER
PT J
AU Sztokman, N
Zhang, X
AF Sztokman, Nicole
Zhang, Xian
TI Transcription factor Fli-1 is involved in regulation of inflammatory
mediator production and ECM remodeling in primary dermal fibroblasts
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Sztokman, Nicole; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Zhang, Xian] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5088
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106200
ER
PT J
AU Van Dyke, T
Herrera, B
Hasturk, H
Kantarci, A
AF Van Dyke, Thomas
Herrera, Bruno
Hasturk, Hatice
Kantarci, Alpdogan
TI RvE1 and phagocytosis of Porphyromonas gingivalis by PMN in type 2
diabetes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Van Dyke, Thomas; Herrera, Bruno; Hasturk, Hatice; Kantarci, Alpdogan] Forsyth Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P4227
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987105044
ER
PT J
AU Winstead, C
Way, SS
Moon, J
Weaver, C
AF Winstead, Colleen
Way, Sing Sing
Moon, James
Weaver, Casey
TI Using reporter mouse models to track CD4 T cell differentiation and fate
based on IL-2 expression
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Winstead, Colleen; Weaver, Casey] Univ Alabama Birmingham, Birmingham, AL USA.
[Way, Sing Sing] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Moon, James] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P1199
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987100198
ER
PT J
AU Yates, C
Rodrigues, M
Wells, A
AF Yates, Cecelia
Rodrigues, Melanie
Wells, Alan
TI Co-transplantation of mesenchymal stem cell and fibroblast reduces
inflammation and corrects defective dermal remodeling
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Yates, Cecelia] Univ Pittsburgh SON, Pittsburgh, PA USA.
[Yates, Cecelia; Rodrigues, Melanie; Wells, Alan] Univ Pittsburgh SOM, Pittsburgh, PA USA.
[Yates, Cecelia; Wells, Alan] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA.
[Yates, Cecelia; Wells, Alan] VA Pittsburgh Healthcare Syst, Pathol, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5062
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106174
ER
PT J
AU Yuki, K
Sen, M
Springer, T
AF Yuki, Koichi
Sen, Mehmet
Springer, Timothy
TI Common activation mechanism of beta 2 integrins
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 100th Annual Meeting of the American-Association-of-Immunologists
CY MAY 03-07, 2013
CL Honolulu, HI
SP Amer Assoc Immunologists
C1 [Yuki, Koichi] Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA.
[Yuki, Koichi; Sen, Mehmet; Springer, Timothy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
MA P5073
PG 1
WC Immunology
SC Immunology
GA 199ID
UT WOS:000322987106185
ER
PT J
AU Choy, G
Kropil, P
Scherer, A
El-Sherief, AH
Chung, J
Rojas, CA
Abbara, S
AF Choy, Garry
Kroepil, Patric
Scherer, Axel
El-Sherief, Ahmed H.
Chung, Jonathan
Rojas, Carlos A.
Abbara, Suhny
TI Pertinent reportable incidental cardiac findings on chest CT without
electrocardiography gating: review of 268 consecutive cases
SO ACTA RADIOLOGICA
LA English
DT Review
DE Computed tomography; incidental cardiac findings; chest CT without ECG
gating; coronary artery disease
ID AORTIC-STENOSIS; COMPUTED-TOMOGRAPHY; PULMONARY-EMBOLISM; MULTIDETECTOR
CT; MYOCARDIAL-INFARCTION; PATHOLOGICAL FINDINGS; ATRIAL-MYXOMA;
NONGATED CT; GATED CT; CALCIFICATION
AB Background: Pertinent reportable cardiac findings on non-electrocardiography (ECG)-gated chest CT examinations have become easier to detect given recent advancements in multidetector CT technology. However, those findings are easily overlooked on routine chest CT without ECG gating given residual inherent cardiac motion artifact and non-cardiac indications.
Purpose: To describe and quantify the types of pertinent reportable cardiac findings that can be detected on chest CT examinations without ECG gating and evaluate how often they were reported.
Material and Methods: Two radiologists retrospectively reviewed (blinded to the original interpretation) 268 consecutive routine adult chest CT examinations without ECG gating for the presence of pertinent reportable cardiac findings. Retrospective interpretations were then compared with the original radiological reports.
Results: One hundred and sixty-three patients (61%) had pertinent reportable cardiac findings. The findings encountered included: coronary artery disease (n = 131; 80.0%), coronary artery bypass grafts (n = 10; 6.1%), left ventricular aneurysm (n = 1; 0.6%), valve calcification (n 131; 80.0%), valve repair/replacement (n = 5; 3.1%), pericardial effusion (n = 33; 20.2%), left atrial appendage thrombus (n = 1; 0.6%), cardiac mass (n = 1; 0.6%), and cardiac chamber enlargement (n = 29; 17.8%). On the original radiological reports 22.3% of the pertinent reportable cardiac findings, detected by the two radiologists retrospectively, were not reported.
Conclusion: Detection of pertinent reportable cardiac findings on routine chest CT examinations without ECG gating is possible. The high volume of chest CT examinations without ECG gating represents an opportunity for radiologists to comment on the presence or absence of cardiac disease which may influence future clinical decisions.
C1 [Choy, Garry; El-Sherief, Ahmed H.; Chung, Jonathan; Rojas, Carlos A.; Abbara, Suhny] Massachusetts Gen Hosp, Dept Radiol, Cardiac Imaging Sect, Boston, MA 02114 USA.
[Kroepil, Patric; Scherer, Axel] Univ Dusseldorf, Fac Med, Dept Diagnost & Intervent Radiol, D-40225 Dusseldorf, Germany.
RP Kropil, P (reprint author), Univ Dusseldorf, Fac Med, Dept Diagnost & Intervent Radiol, D-40225 Dusseldorf, Germany.
EM patric.kroepil@med.uni-duesseldorf.de
NR 28
TC 4
Z9 4
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0284-1851
J9 ACTA RADIOL
JI Acta Radiol.
PD MAY
PY 2013
VL 54
IS 4
BP 396
EP 400
DI 10.1177/0284185113475918
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 190ER
UT WOS:000322322500007
PM 23436832
ER
PT J
AU Rosen, PL
Palmer, JN
O'Malley, BW
Cohen, NA
AF Rosen, Philip L.
Palmer, James N.
O'Malley, Bert W., Jr.
Cohen, Noam A.
TI Surfactants in the management of rhinopathologies
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID ENDOSCOPIC SINUS SURGERY; CITRIC ACID/ZWITTERIONIC SURFACTANT; BACTERIAL
BIOFILMS; CHRONIC RHINOSINUSITIS; STAPHYLOCOCCUS-AUREUS; TOPICAL
TOBRAMYCIN; IRRIGATION BOTTLE; ANIMAL-MODEL; SHEEP MODEL; IN-VITRO
AB Background: Surfactants are a class of amphiphilic surface active compounds that show several unique physical properties at liquid-liquid or liquid-solid surface interfaces including the ability to increase the solubility of substances, lower the surface tension of a liquid, and decrease friction between two mediums. Because of these unique physical properties several in vitro, ex vivo, and human trials have examined the role of surfactants as stand-alone or adjunct therapy in recalcitrant chronic rhinosinusitis (CRS).
Methods: A review of the literature was performed.
Results: The data from three different surfactants have been examined in this review: citric acid zwitterionic surfactant (CAZS; Medtronic ENT, Jacksonville FL), Johnson's Baby Shampoo (Johnson & Johnson, New Brunswick NJ), and SinuSurf (NeilMed Pharmaceuticals, Santa Rosa, CA). Dilute surfactant therapy shows in vitro antimicrobial effects with modest inhibition of bacterial biofilm formation. In patients with CRS, surfactants may improve symptoms, most likely through its mucolytic effects. In addition, surfactants have several distinct potential benefits including their ability to improve an irrigant's penetration of the nonoperated sinus and their synergistic effects with antibiotics. However, surfactants potential for nasal irritation and possible transient ciliotoxicity may limit their use.
Conclusion: Recent data suggest a possible therapeutic role of surfactants in treating rhinopathologies associated with mucostasis. Further investigation, including a standardization of surfactant formulations, is warranted to further elucidate the potential benefits and drawbacks of this therapy.
C1 [Rosen, Philip L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Palmer, James N.; O'Malley, Bert W., Jr.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Dept Otolaryngol, Surg Serv, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM noam.cohen@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932
NR 25
TC 6
Z9 8
U1 2
U2 7
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAY-JUN
PY 2013
VL 27
IS 3
BP 177
EP 180
DI 10.2500/ajra.2013.27.3873
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 193HF
UT WOS:000322549000007
PM 23710951
ER
PT J
AU Walensky, LD
AF Walensky, Loren D.
TI Playing FullBAK
SO CELL CYCLE
LA English
DT Editorial Material
ID BH3 DOMAIN; APOPTOSIS; BAX; OLIGOMERIZATION
C1 [Walensky, Loren D.] Harvard Univ, Sch Med, Dept Pediat Oncol, Boston, MA 02114 USA.
[Walensky, Loren D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dana Farber Canc Inst,Linde Program Canc Chem Bio, Boston, MA USA.
RP Walensky, LD (reprint author), Harvard Univ, Sch Med, Dept Pediat Oncol, Boston, MA 02114 USA.
EM Loren_Walensky@dfci.harvard.edu
FU NIGMS NIH HHS [R01 GM090299]
NR 8
TC 1
Z9 1
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD MAY 1
PY 2013
VL 12
IS 9
BP 1333
EP 1334
DI 10.4161/cc.24607
PG 2
WC Cell Biology
SC Cell Biology
GA 196FJ
UT WOS:000322758600004
PM 23588072
ER
PT J
AU Rowe, GC
Patten, IS
Zsengeller, ZK
El-Khoury, R
Okutsu, M
Bampoh, S
Koulisis, N
Farrell, C
Hirshman, MF
Yan, Z
Goodyear, LJ
Rustin, P
Arany, Z
AF Rowe, Glenn C.
Patten, Ian S.
Zsengeller, Zsuzsanna K.
El-Khoury, Riyad
Okutsu, Mitsuharu
Bampoh, Sophia
Koulisis, Nicole
Farrell, Caitlin
Hirshman, Michael F.
Yan, Zhen
Goodyear, Laurie J.
Rustin, Pierre
Arany, Zolt
TI Disconnecting Mitochondrial Content from Respiratory Chain Capacity in
PGC-1-Deficient Skeletal Muscle
SO CELL REPORTS
LA English
DT Article
ID TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; FIBER-TYPE DETERMINATION; PGC-1
COACTIVATORS; ENERGY-METABOLISM; ADAPTIVE THERMOGENESIS; ATP SYNTHASE;
ANGIOGENESIS; BIOGENESIS; DISEASE; MICE
AB The transcriptional coactivators PGC-1 alpha and PGC-1 beta are widely thought to be required for mitochondrial biogenesis and fiber typing in skeletal muscle. Here, we show that mice lacking both PGC-1s in myocytes do indeed have profoundly deficient mitochondrial respiration but, surprisingly, have preserved mitochondrial content, isolated muscle contraction capacity, fiber-type composition, in-cage ambulation, and voluntary running capacity. Most of these findings are recapitulated in cell culture and, thus, are cell autonomous. Functional electron microscopy reveals normal cristae density with decreased cytochrome oxidase activity. These data lead to the following surprising conclusions: (1) PGC-1s are in fact dispensable for baseline muscle function, mitochondrial content, and fiber typing, (2) endurance fatigue at low workloads is not limited by muscle mitochondrial capacity, and (3) mitochondrial content and cristae density can be dissociated from respiratory capacity.
C1 [Rowe, Glenn C.; Patten, Ian S.; Bampoh, Sophia; Koulisis, Nicole; Farrell, Caitlin; Arany, Zolt] Beth Israel Deaconess Med Ctr, Cardiovasc Inst, Boston, MA 02215 USA.
[Rowe, Glenn C.; Patten, Ian S.; Bampoh, Sophia; Koulisis, Nicole; Farrell, Caitlin; Arany, Zolt] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA.
[Zsengeller, Zsuzsanna K.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Zsengeller, Zsuzsanna K.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[El-Khoury, Riyad; Rustin, Pierre] Hop Robert Debre, INSERM, UMR 676, F-75019 Paris, France.
[El-Khoury, Riyad; Rustin, Pierre] Univ Paris 07, Fac Med Denis Diderot, F-75005 Paris, France.
[Okutsu, Mitsuharu; Yan, Zhen] Univ Virginia, Sch Med, Robert M Berne Cardiovasc Res Ctr, Ctr Skeletal Muscle Res, Charlottesville, VA 22908 USA.
[Hirshman, Michael F.; Goodyear, Laurie J.] Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Arany, Z (reprint author), Beth Israel Deaconess Med Ctr, Cardiovasc Inst, Boston, MA 02215 USA.
EM zarany@bidmc.harvard.edu
FU National Institutes of Health [NIAMS AR062128, AR42238, NHLBI HL094499]
FX This work was supported by grants from the National Institutes of Health
(NIAMS AR062128 to G.C.R. and AR42238 L.J.G., and NHLBI HL094499 to
Z.A.). G.C.R. and Z.A. designed the research; G.C.R., I.S.P., N.K.,
Z.K.Z., R.E., M.O., C.F., S.B., and M.F.H. performed research; G.C.R.,
Z.Y., L.J.G., P.R., and Z.A. analyzed data; and G.C.R. and Z.A. wrote
the paper.
NR 44
TC 41
Z9 41
U1 0
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAY
PY 2013
VL 3
IS 5
BP 1449
EP 1456
DI 10.1016/j.celrep.2013.04.023
PG 8
WC Cell Biology
SC Cell Biology
GA 184NY
UT WOS:000321899300016
PM 23707060
ER
PT J
AU Rheinbay, E
Suva, ML
Gillespie, SM
Wakimoto, H
Patel, AP
Shahid, M
Oksuz, O
Rabkin, SD
Martuza, RL
Rivera, MN
Louis, DN
Kasif, S
Chi, AS
Bernstein, BE
AF Rheinbay, Esther
Suva, Mario L.
Gillespie, Shawn M.
Wakimoto, Hiroaki
Patel, Anoop P.
Shahid, Mohammad
Oksuz, Ozgur
Rabkin, Samuel D.
Martuza, Robert L.
Rivera, Miguel N.
Louis, David N.
Kasif, Simon
Chi, Andrew S.
Bernstein, Bradley E.
TI An Aberrant Transcription Factor Network Essential for Wnt Signaling and
Stem Cell Maintenance in Glioblastoma
SO CELL REPORTS
LA English
DT Article
ID TUMOR-INITIATING CELLS; INTEGRATIVE GENOMICS VIEWER; CHROMATIN STATE;
SELF-RENEWAL; DNA METHYLATION; CANCER; GLIOMA; EXPRESSION; BRAIN;
DIFFERENTIATION
AB Glioblastoma (GBM) is thought to be driven by a sub-population of cancer stem cells (CSCs) that self-renew and recapitulate tumor heterogeneity yet remain poorly understood. Here, we present a comparative analysis of chromatin state in GBM CSCs that reveals widespread activation of genes normally held in check by Polycomb repressors. These activated targets include a large set of developmental transcription factors (TFs) whose coordinated activation is unique to the CSCs. We demonstrate that a critical factor in the set, ASCL1, activates Wnt signaling by repressing the negative regulator DKK1. We show that ASCL1 is essential for the maintenance and in vivo tumorigenicity of GBM CSCs. Genome-wide binding profiles for ASCL1 and the Wnt effector LEF-1 provide mechanistic insight and suggest widespread interactions between the TF module and the signaling pathway. Our findings demonstrate regulatory connections among ASCL1, Wnt signaling, and collaborating TFs that are essential for the maintenance and tumorigenicity of GBM CSCs.
C1 [Rheinbay, Esther; Suva, Mario L.; Gillespie, Shawn M.; Chi, Andrew S.; Bernstein, Bradley E.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Rheinbay, Esther; Suva, Mario L.; Gillespie, Shawn M.; Oksuz, Ozgur; Rivera, Miguel N.; Louis, David N.; Chi, Andrew S.; Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Rheinbay, Esther; Suva, Mario L.; Gillespie, Shawn M.; Oksuz, Ozgur; Rivera, Miguel N.; Louis, David N.; Chi, Andrew S.; Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
[Wakimoto, Hiroaki; Patel, Anoop P.; Rabkin, Samuel D.; Martuza, Robert L.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Chi, Andrew S.] Massachusetts Gen Hosp, Div Neurooncol, Boston, MA 02114 USA.
[Chi, Andrew S.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.
[Chi, Andrew S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Chi, Andrew S.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Rheinbay, Esther; Suva, Mario L.; Gillespie, Shawn M.; Rivera, Miguel N.; Chi, Andrew S.; Bernstein, Bradley E.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Rheinbay, Esther; Kasif, Simon] Boston Univ, Bioinformat Program, Boston, MA 02215 USA.
[Kasif, Simon] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Shahid, Mohammad] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Chi, AS (reprint author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
EM chi.andrew@mgh.harvard.edu; bernstein.bradley@mgh.harvard.edu
OI rabkin, samuel/0000-0003-2344-2795; Shahid, Mohammad/0000-0003-2615-9848
FU Joan Ambriz American Brain Tumor Association basic research fellowship;
Ben and Catherine Ivy Foundation; Oncosuisse grant
[BIL-KFS-02590-02-2010]; Medic Foundation grant; Burroughs Wellcome
Fund; Howard Hughes Medical Institute; NIH [RO1 CA160762]; Starr Cancer
Consortium; Harvard Stem Cell Institute; Affymetrix
FX We thank Tarjei Mikkelsen, Timothy Durham, and Noam Shoresh for
computational assistance and Chuck Epstein, Robbyn Issner, and the Broad
Institute Genome Sequencing Platform for help with data production. We
thank David Dombkowski for help with FACS analysis and Lauren Solomon
and Leslie Gaffney for assistance with graphics. A.S.C. is supported by
a Joan Ambriz American Brain Tumor Association basic research fellowship
and early career research award from the Ben and Catherine Ivy
Foundation. M.L.S. is supported by Oncosuisse grant
BIL-KFS-02590-02-2010 and a Medic Foundation grant. M.N.R. is supported
by awards from the Burroughs Wellcome Fund and the Howard Hughes Medical
Institute. S.D.R. supported in part by NIH (RO1 CA160762). This research
was supported by funds from the Starr Cancer Consortium (B.E.B.), the
Harvard Stem Cell Institute, the Burroughs Wellcome Fund (B.E.B.), and
the Howard Hughes Medical Institute (B.E.B.). M.N.R. and M.S. receive
research funding from Affymetrix.
NR 56
TC 66
Z9 67
U1 1
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAY
PY 2013
VL 3
IS 5
BP 1567
EP 1579
DI 10.1016/j.celrep.2013.04.021
PG 13
WC Cell Biology
SC Cell Biology
GA 184NY
UT WOS:000321899300027
PM 23707066
ER
PT J
AU Shiotani, B
Nguyen, HD
Hakansson, P
Marechal, A
Tse, A
Tahara, H
Zou, L
AF Shiotani, Bunsyo
Hai Dang Nguyen
Hakansson, Pelle
Marechal, Alexandre
Tse, Alice
Tahara, Hidetoshi
Zou, Lee
TI Two Distinct Modes of ATR Activation Orchestrated by Rad17 and Nbs1
SO CELL REPORTS
LA English
DT Article
ID REPLICATION PROTEIN-A; DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; S-PHASE
CHECKPOINT; MRE11 COMPLEX; RPA2 PHOSPHORYLATION; CHK1 ACTIVATION; END
RESECTION; MRN COMPLEX; TOPBP1
AB The ATM- and Rad3-related (ATR) kinase is a master regulator of the DNA damage response, yet how ATR is activated toward different substrates is still poorly understood. Here, we show that ATR phosphorylates Chk1 and RPA32 through distinct mechanisms at replication-associated DNA double-stranded breaks (DSBs). In contrast to the rapid phosphorylation of Chk1, RPA32 is progressively phosphorylated by ATR at Ser33 during DSB resection prior to the phosphorylation of Ser4/Ser8 by DNA-PKcs. Surprisingly, despite its reliance on ATR and TopBP1, substantial RPA32 Ser33 phosphorylation occurs in a Rad17-independent but Nbs1-dependent manner in vivo and in vitro. Importantly, the role of Nbs1 in RPA32 phosphorylation can be separated from ATM activation and DSB resection, and it is dependent upon the interaction of Nbs1 with RPA. An Nbs1 mutant that is unable to bind RPA fails to support proper recovery of collapsed replication forks, suggesting that the Nbs1-mediated mode of ATR activation is important for the repair of replication-associated DSBs.
C1 [Shiotani, Bunsyo; Hai Dang Nguyen; Hakansson, Pelle; Marechal, Alexandre; Tse, Alice; Zou, Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02129 USA.
[Zou, Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Zou, Lee] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Shiotani, Bunsyo; Tahara, Hidetoshi] Hiroshima Univ, Dept Cellular & Mol Biol, Hiroshima 7348553, Japan.
RP Shiotani, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02129 USA.
EM bshiotan@hiroshima-u.ac.jp; zou.lee@mgh.harvard.edu
OI Hakansson, Pelle/0000-0003-0421-2433
FU Swedish Research Council; FRSQ fellowship; Japanese Ministry of
Education, Culture, Sports, Science and Technology [KAKENHI 24800044,
KAKENHI 23300363]; NIH [GM076388]; ACS [RSG-08-297]; Federal Share of
MGH Proton Program
FX We thank Dr. K. Cimprich for communicating previously unpublished
results (Duursma et al., 2013); Drs. S. Elledge, A. Nussenzweig, T.
Paull, X. Wu, B. Chen, R. Baer, P. Concannon, and K. Komatsu for
reagents; and members of the Zou lab for helpful discussions. P.H. was
supported by a postdoctoral fellowship from the Swedish Research
Council. A.M. is supported by an FRSQ fellowship. L.Z. is a Jim and Ann
Orr Massachusetts General Hospital Research Scholar. This work was
supported by grants from the Japanese Ministry of Education, Culture,
Sports, Science and Technology to B.S. (KAKENHI 24800044) and H.T.
(KAKENHI 23300363), and grants from the NIH (GM076388), the ACS
(RSG-08-297), and the Federal Share of MGH Proton Program to L.Z.
NR 70
TC 48
Z9 48
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAY
PY 2013
VL 3
IS 5
BP 1651
EP 1662
DI 10.1016/j.celrep.2013.04.018
PG 12
WC Cell Biology
SC Cell Biology
GA 184NY
UT WOS:000321899300034
PM 23684611
ER
PT J
AU Wu, HT
Xiao, YB
Zhang, SH
Ji, SY
Wei, LY
Fan, FQ
Geng, J
Tian, J
Sun, XF
Qin, FN
Jin, CN
Lin, JJ
Yin, ZY
Zhang, T
Luo, LZ
Li, Y
Song, SY
Lin, SC
Deng, XM
Camargo, F
Avruch, J
Chen, LF
Zhou, DW
AF Wu, Hongtan
Xiao, Yubo
Zhang, Shihao
Ji, Suyuan
Wei, Luyao
Fan, Fuqin
Geng, Jing
Tian, Jing
Sun, Xiufeng
Qin, Funiu
Jin, Changnan
Lin, Jianjun
Yin, Zhen-Yu
Zhang, Ting
Luo, Lianzhong
Li, Yang
Song, Siyang
Lin, Sheng-Cai
Deng, Xianming
Camargo, Fernando
Avruch, Joseph
Chen, Lanfen
Zhou, Dawang
TI The Ets Transcription Factor GABP Is a Component of the Hippo Pathway
Essential for Growth and Antioxidant Defense
SO CELL REPORTS
LA English
DT Article
ID YES-ASSOCIATED PROTEIN; BINDING-PROTEIN; SIGNALING PATHWAY; DNA-BINDING;
CELL-PROLIFERATION; OXIDATIVE-STRESS; E4TF1 SUBUNITS; T-LYMPHOCYTES;
TISSUE-GROWTH; SELF-RENEWAL
AB The transcriptional coactivator Yes-associated protein (YAP) plays an important role in organ-size control and tumorigenesis. However, how Yap gene expression is regulated remains unknown. This study shows that the Ets family member GABP binds to the Yap promoter and activates YAP transcription. The depletion of GABP downregulates YAP, resulting in a G1/S cell-cycle block and increased cell death, both of which are substantially rescued by reconstituting YAP. GABP can be inactivated by oxidative mechanisms, and acetaminophen-induced glutathione depletion inhibits GABP transcriptional activity and depletes YAP. In contrast, activating YAP by deleting Mst1/Mst2 strongly protects against acetaminophen-induced liver injury. Similar to its effects on YAP, Hippo signaling inhibits GABP transcriptional activity through several mechanisms. In human liver cancers, enhanced YAP expression is correlated with increased nuclear expression of GABP. Therefore, we conclude that GABP is an activator of Yap gene expression and a potential therapeutic target for cancers driven by YAP.
C1 [Wu, Hongtan; Xiao, Yubo; Zhang, Shihao; Ji, Suyuan; Wei, Luyao; Fan, Fuqin; Geng, Jing; Tian, Jing; Sun, Xiufeng; Qin, Funiu; Li, Yang; Song, Siyang; Lin, Sheng-Cai; Deng, Xianming; Chen, Lanfen; Zhou, Dawang] Xiamen Univ, Sch Life Sci, State Key Lab Stress Cell Biol, Xiamen 361102, Jiangsu, Peoples R China.
[Jin, Changnan; Lin, Jianjun; Zhang, Ting] Xiamen Hosp Tradit Chinese Med, Dept Hepatol, Xiamen 361001, Fujian, Peoples R China.
[Yin, Zhen-Yu] Xiamen Univ, Dept Hepatobiliary Surg, Zhongshan Hosp, Xiamen 361004, Fujian, Peoples R China.
[Luo, Lianzhong] Xiamen Med Coll, Dept Pharm, Xiamen 361008, Fujian, Peoples R China.
[Avruch, Joseph] Massachusetts Gen Hosp, Dept Mol Biol, Diabet Unit, Med Serv, Boston, MA 02114 USA.
[Avruch, Joseph] Harvard Univ, Boston Childrens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Camargo, Fernando] Harvard Univ, Boston Childrens Hosp, Sch Med, Stem Cell Program, Boston, MA 02115 USA.
[Camargo, Fernando] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
RP Chen, LF (reprint author), Xiamen Univ, Sch Life Sci, State Key Lab Stress Cell Biol, Xiamen 361102, Jiangsu, Peoples R China.
EM chenlanfen@xmu.edu.cn; dwzhou@xmu.edu.cn
RI Chen, Lanfen/B-7975-2016;
OI Chen, Lanfen/0000-0002-9413-1284; Zhou, Dawang/0000-0002-9053-5249
FU China's 1000 Young Talents Program; 111 Project of the Ministration of
Education of China [B06016]; Fundamental Research Funds for the Central
Universities of China [2010111079]; National Natural Science Foundation
of China [81101503/H1602, 31270918/C080101, 81222030/H1602]; Natural
Science Foundation of Fujian [2011J05096]; Program of Introducing
Talents of Discipline to Universities [B12001]; ROI awards [CA136567,
DK17776]; DOD award [W81XWH-09-NFRP-NIA]; Stand Up to Cancer
FX D.Z. was supported by grants from the China's 1000 Young Talents
Program, the 111 Project of the Ministration of Education of China
(B06016), the Fundamental Research Funds for the Central Universities of
China (2010111079), the National Natural Science Foundation of China
(81101503/H1602, 31270918/C080101, and 81222030/H1602), the Natural
Science Foundation of Fujian (2011J05096), and the Program of
Introducing Talents of Discipline to Universities (B12001). J.A. was
supported in part by ROI awards CA136567 and DK17776, and institutional
funds. F.C. was supported in part by DOD award W81XWH-09-NFRP-NIA and
Stand Up to Cancer.
NR 49
TC 36
Z9 38
U1 3
U2 41
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAY
PY 2013
VL 3
IS 5
BP 1663
EP 1677
DI 10.1016/j.celrep.2013.04.020
PG 15
WC Cell Biology
SC Cell Biology
GA 184NY
UT WOS:000321899300035
PM 23684612
ER
PT J
AU Roffman, JL
Lamberti, JS
Achtyes, E
Macklin, EA
Galendez, GC
Raeke, LH
Silverstein, NJ
Smoller, JW
Hill, M
Goff, DC
AF Roffman, Joshua L.
Lamberti, J. Steven
Achtyes, Eric
Macklin, Eric A.
Galendez, Gail C.
Raeke, Lisa H.
Silverstein, Noah J.
Smoller, Jordan W.
Hill, Michele
Goff, Donald C.
TI Randomized Multicenter Investigation of Folate Plus Vitamin B-12
Supplementation in Schizophrenia
SO JAMA PSYCHIATRY
LA English
DT Article
ID CATECHOL-O-METHYLTRANSFERASE; FOLIC-ACID FORTIFICATION; HOMOCYSTEINE
LEVELS; NEGATIVE SYMPTOMS; RISK-FACTOR; MYOCARDIAL-INFARCTION; PLASMA
HOMOCYSTEINE; VASCULAR-DISEASE; CONTROLLED-TRIAL;
METHYLENETETRAHYDROFOLATE REDUCTASE
AB Importance: More effective treatments are needed for negative symptoms of schizophrenia, which are typically chronic, disabling, and costly. Negative symptoms have previously been associated with reduced blood folate levels, especially among patients with low-functioning variants in genes that regulate folate metabolism, suggesting the potential utility of folate supplementation.
Objectives: To determine whether folic acid plus vitamin B-12 supplementation reduces negative symptoms of schizophrenia and whether functional variants in folate-related genes influence treatment response.
Design: Parallel-group, randomized, double-blind, placebo-controlled clinical trial of 16 weeks of treatment with 2 mg of folic acid and 400 mu g of vitamin B-12.
Setting: Three community mental health centers affiliated with academic medical centers in the United States.
Participants: Outpatients with chronic schizophrenia who were psychiatrically stable but displayed persistent symptoms despite antipsychotic treatment. Eligible patients were 18 to 68 years old, were treated with an antipsychotic agent for 6 months or more at a stable dose for 6 weeks or more, and scored 60 or more on the Positive and Negative Syndrome Scale.
Intervention: One hundred forty subjects were randomized to receive daily oral folic acid plus vitamin B-12 or placebo.
Main Outcome Measures: Change in negative symptoms (Scale for the Assessment of Negative Symptoms [SANS]), as well as positive and total symptoms (Positive and Negative Syndrome Scale).
Results: Folate plus vitamin B-12 improved negative symptoms significantly compared with placebo (group difference, -0.33 change in SANS score per week; 95% CI, -0.62 to -0.05) when genotype was taken into account but not when genotype was excluded. An interaction of the 484C>T variant of FOLH1 (rs202676) with treatment was observed (P=.02), where only patients homozygous for the 484T allele demonstrated significantly greater benefit with active treatment (-0.59 change in SANS score per week; 95% CI, -0.99 to -0.18). In parallel, we observed an inverse relationship between red blood cell folate concentration at baseline and 484C allele load (P=.03), which persisted until 8 weeks of treatment. Change in positive and total symptoms did not differ between treatment groups.
Conclusions: Folate plus vitamin B-12 supplementation can improve negative symptoms of schizophrenia, but treatment response is influenced by genetic variation in folate absorption. These findings support a personalized medicine approach for the treatment of negative symptoms.
C1 [Roffman, Joshua L.; Galendez, Gail C.; Raeke, Lisa H.; Silverstein, Noah J.; Smoller, Jordan W.; Hill, Michele; Goff, Donald C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Roffman, Joshua L.; Macklin, Eric A.; Galendez, Gail C.; Raeke, Lisa H.; Silverstein, Noah J.; Smoller, Jordan W.; Hill, Michele; Goff, Donald C.] Harvard Univ, Sch Med, Boston, MA USA.
[Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Lamberti, J. Steven] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA.
[Achtyes, Eric] Michigan State Univ, Coll Human Med, Cherry St Hlth Serv, Grand Rapids, MI USA.
[Achtyes, Eric] Michigan State Univ, Coll Human Med, Dept Psychiat, Grand Rapids, MI USA.
RP Roffman, JL (reprint author), Massachusetts Gen Hosp, 149 13th St,Room 2606, Charlestown, MA 02129 USA.
EM jroffman@partners.org
OI Macklin, Eric/0000-0003-1618-3502; Achtyes, Eric/0000-0001-8939-1535
FU National Institute of Mental Health [R01MH070831]; Howard Hughes Medical
Institute Early Career Physician-Scientist Award; Harvard Catalyst, The
Harvard Clinical and Translational Science Center (National Center for
Research Resources); Harvard Catalyst, The Harvard Clinical and
Translational Science Center (National Center for Advancing
Translational Sciences, National Institutes of Health) [UL1 RR 025758];
Harvard University
FX This work was supported by National Institute of Mental Health grant
R01MH070831 (Dr Goff) and the Howard Hughes Medical Institute Early
Career Physician-Scientist Award (Dr Roffman). This work was conducted
with support from Harvard Catalyst, The Harvard Clinical and
Translational Science Center (National Center for Research Resources and
the National Center for Advancing Translational Sciences, National
Institutes of Health award UL1 RR 025758, and financial contributions
from Harvard University and its affiliated academic health care
centers).
NR 47
TC 26
Z9 28
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-622X
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAY
PY 2013
VL 70
IS 5
BP 481
EP 489
DI 10.1001/jamapsychiatry.2013.900
PG 9
WC Psychiatry
SC Psychiatry
GA 188PF
UT WOS:000322204200004
PM 23467813
ER
PT J
AU Kim, JK
Choi, JW
Yun, SH
AF Kim, Jun Ki
Choi, Jin Woo
Yun, Seok Hyun
TI 350-mu m side-view optical probe for imaging the murine brain in vivo
from the cortex to the hypothalamus
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE miniature endoscope; side-view probe; deep brain imaging; neuronal
imaging
ID MICROSCOPY; NEOCORTEX; TISSUE
AB Miniature endoscopic probes offer a solution for deep brain imaging by overcoming the limited depth of intravital microscopy. We describe a small-diameter (350 mu m) graded-index optical probe with a side-view design for in vivo cellular imaging of the mammalian brain. The side-view probe provides a unique view of the vertical network of neurons and penetrating blood vessels. At a given insertion site, the translational and rotational scanning of the probe provides access to a large tissue area (> 1 mm(2)) across the cortex, hippocampus, thalamus, and hypothalamus. (C) 2013 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Kim, Jun Ki; Choi, Jin Woo; Yun, Seok Hyun] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Kim, Jun Ki; Choi, Jin Woo; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Kim, Jun Ki; Yun, Seok Hyun] Korea Adv Inst Sci & Technol, WCU Grad Sch Nanosci & Technol, Taejon 305701, South Korea.
[Choi, Jin Woo] Wonkwang Univ, Sch Dent, Dept Dent Pharmacol, Iksan 570749, Chonbuk, South Korea.
[Choi, Jin Woo] Wonkwang Univ, Inst Biomat Implant, Iksan 570749, Chonbuk, South Korea.
[Yun, Seok Hyun] Harvard MIT Hlth Sci & Technol, Cambridge, MA 02140 USA.
RP Yun, SH (reprint author), Harvard Univ, Sch Med, 40 Blossom St, Boston, MA 02114 USA.
EM syun@hms.harvard.edu
FU Department of Defense [FA9550-10-1-0537]; National Research Foundation
of Korea [R31-2008-000-10071-0]
FX This work was supported by grants from the Department of Defense (Grant
No. FA9550-10-1-0537) and from the National Research Foundation of Korea
(Grant No. R31-2008-000-10071-0).
NR 14
TC 2
Z9 2
U1 0
U2 2
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD MAY
PY 2013
VL 18
IS 5
AR 050502
DI 10.1117/1.JBO.18.5.050502
PG 3
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 190KW
UT WOS:000322339900002
PM 23629547
ER
PT J
AU Gillis, JL
Selth, LA
Centenera, MM
Townley, SL
Sun, SH
Plymate, SR
Tilley, WD
Butler, LM
AF Gillis, Joanna L.
Selth, Luke A.
Centenera, Margaret M.
Townley, Scott L.
Sun, Shihua
Plymate, Stephen R.
Tilley, Wayne D.
Butler, Lisa M.
TI Constitutively-active androgen receptor variants function independently
of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
SO ONCOTARGET
LA English
DT Article
DE Androgen receptor; variant; HSP90; HSP90 inhibitor; prostate cancer
ID HEAT-SHOCK-PROTEIN; REFRACTORY PROSTATE-CANCER; SPLICE VARIANTS;
NUCLEAR-LOCALIZATION; BINDING DOMAIN; PROGRESSION; MUTATIONS; GROWTH;
THERAPY; COMPLEX
AB The development of lethal, castration resistant prostate cancer is associated with adaptive changes to the androgen receptor (AR), including the emergence of mutant receptors and truncated, constitutively active AR variants. AR relies on the molecular chaperone HSP90 for its function in both normal and malignant prostate cells, but the requirement for HSP90 in environments with aberrant AR expression is largely unknown. Here, we investigated the efficacy of three HSP90 inhibitors, 17-AAG, HSP990 and AUY922, against clinically-relevant AR missense mutants and truncated variants. HSP90 inhibition effectively suppressed the signaling of wild-type AR and all AR missense mutants tested. By contrast, two truncated AR variants, AR-V7 and ARv567es, exhibited marked resistance to HSP90 inhibitors. Supporting this observation, nuclear localization of the truncated AR variants was not affected by HSP90 inhibition and AR variant: HSP90 complexes could not be detected in prostate cancer cells. Interestingly, HSP90 inhibition resulted in accumulation of AR-V7 and ARv567es in both cell lines and human tumor explants. Despite the apparent independence of AR variants from HSP90 and their treatment-associated induction, the growth of cell lines with endogenous or enforced expression of AR-V7 or ARv567es remained highly sensitive to AUY922. This study demonstrates that functional AR variant signaling does not confer resistance to HSP90 inhibition, yields insight into the interaction between AR and HSP90 and provides further impetus for the clinical application of HSP90 inhibitors in advanced prostate cancer.
C1 [Gillis, Joanna L.; Selth, Luke A.; Centenera, Margaret M.; Townley, Scott L.; Tilley, Wayne D.; Butler, Lisa M.] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia.
[Gillis, Joanna L.; Selth, Luke A.; Centenera, Margaret M.; Townley, Scott L.; Tilley, Wayne D.; Butler, Lisa M.] Univ Adelaide, Adelaide Prostate Canc Res Ctr, Adelaide, SA, Australia.
[Gillis, Joanna L.; Selth, Luke A.; Centenera, Margaret M.; Townley, Scott L.; Tilley, Wayne D.; Butler, Lisa M.] Hanson Inst, Adelaide, SA, Australia.
[Sun, Shihua; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Plymate, Stephen R.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA.
[Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA USA.
RP Butler, LM (reprint author), Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia.
EM lisa.butler@adelaide.edu.au
FU Prostate Cancer Foundation; Prostate Cancer Foundation of
Australia/Cancer Australia [YI 0810, YI 0412, 627229]; Royal Adelaide
Hospital Research Committee; National Health and Medical Research
Council of Australia [627185, 290456, 614296]; Pacific NW Prostate
Cancer SPORE [P50 CA97186]; Veterans Affairs Research Program; Prostate
Cancer Foundation of Australia [2011/0452]
FX No potential conflicts of interest were disclosed by the authors. This
work was supported by Young Investigator Awards from the Prostate Cancer
Foundation (the Foundation 14 award; L. A. S.) and the Prostate Cancer
Foundation of Australia/Cancer Australia (L. A. S., YI 0810; M. M. C.,
YI 0412) and grants from the Prostate Cancer Foundation of
Australia/Cancer Australia (ID 627229 to L. M. B. and W. D. T.), the
Royal Adelaide Hospital Research Committee (L. M. B. and M. M. C.), the
National Health and Medical Research Council of Australia (ID 627185 to
W. D. T. and L. M. B.), the Pacific NW Prostate Cancer SPORE (ID P50
CA97186 to S. R. P.) and the Veterans Affairs Research Program (S. R.
P.). The Adelaide Prostate Cancer Research Centre is supported by an
establishment grant from the Prostate Cancer Foundation of Australia (ID
2011/0452). The Australian Prostate Cancer BioResource is supported by
the National Health and Medical Research Council of Australia (enabling
grants 290456 and 614296) and Prostate Cancer Foundation of Australia.
L. M. B. holds a senior research fellowship from the Cancer Council of
South Australia.
NR 48
TC 14
Z9 15
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY
PY 2013
VL 4
IS 5
BP 691
EP 704
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 193RU
UT WOS:000322580000006
PM 23674566
ER
PT J
AU Kang, SH
Cho, JH
Park, SH
Toothaker, R
Cho, SA
AF Kang, Sang-Hwan
Cho, Jin Hyun
Park, Sang-Hun
Toothaker, Randall
Cho, Sung-Am
TI Comparison of Osseointegration Between Laser-Etched and
Magnesium-Incorporated Oxidized Implants in the Rabbit Femur
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE histomorphometric analysis; laser-etched; magnesium-incorporated oxided
implant; removal torque
ID TREATED TITANIUM IMPLANTS; SURFACE-PROPERTIES; REMOVAL TORQUE; BONE
RESPONSE; ROUGHNESS; HYDROXYAPATITE; ALLOY
AB Purpose: To compare the osseointegration of a laser-etched (LE) implant with a magnesium-incorporated oxidized (MgO) implant, evaluating their ability to enhance the bond strength between a titanium substrate and rabbit femur. Materials and Methods: Two type of dental implants, LE (test, commercially pure [CP] titanium grade 4) and MgO (control, CP titanium grade 4) (length, 8 mm; diameter, 3.3 mm), were evaluated for the surface characteristics using a field emission scanning electron microscope (FE-SEM), an energy dispersive spectrometer (EDS), and an optical three-dimensional profiling system. After that, two types of dental implants were implanted at the right and left distal femoral metaphysis of 10 adult rabbits weighing approximately 3.0 kg. After 6 weeks, histomorphometric analysis, removal torque tests, and surface analysis of the torque-tested implants were performed. Results: After surgery, the LE group showed thick bonelike materials within the pores observed using FE-SEM (magnifications x500 and x900). The mean removal torque was 40.72 +/- 13.3 Ncm for the test (LE) implant and 22.26 +/- 6.4 Ncm for the control (MgO) implant, respectively (P = .041). The mean bone-implant contact in the three best consecutive threads in the cortical region was 63.35% +/- 16.44% in the LE group and 51.63% +/- 5.09% in the MgO. Conclusions: In the beginning stage of cancellous bone healing, biomechanical properties of the LE implant could influence a more favorable bone response than that of MgO.
C1 [Toothaker, Randall] Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA.
[Toothaker, Randall] Nebraska Western Iowa Hlth Care Syst, Dent Serv NWIHCS, US Dept Vet Affairs, Dent Lab Serv, Omaha, NE USA.
EM sungamcho@gmail.com
FU Kyungpook National University Research Fund
FX This research was supported by Kyungpook National University Research
Fund, 2011. The authors reported no conflicts of interest related to
this study.
NR 21
TC 2
Z9 2
U1 0
U2 5
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882-2786
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD MAY-JUN
PY 2013
VL 28
IS 3
BP 775
EP 781
DI 10.11607/jomi.2448
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 186XE
UT WOS:000322078500022
PM 23748308
ER
PT J
AU Maroules, CD
Blaha, MJ
El-Haddad, MA
Ferencik, M
Cury, RC
AF Maroules, Christopher D.
Blaha, Michael J.
El-Haddad, Mohamed A.
Ferencik, Maros
Cury, Ricardo C.
TI Establishing a successful coronary CT angiography program in the
emergency department: Official writing of the Fellow and Resident
Leaders of the Society of Cardiovascular Computed Tomography (FiRST)
SO JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY
LA English
DT Article
DE Coronary CT angiography; Acute chest pain triage
ID ACUTE CHEST-PAIN; AMERICAN-HEART-ASSOCIATION; CARDIAC CT; RADIATION;
TRIAGE; METAANALYSIS; CARDIOLOGY; RADIOLOGY
AB Coronary CT angiography is an effective, evidence-based strategy for evaluating acute chest pain in the emergency department for patients at low-to-intermediate risk of acute coronary syndrome. Recent multicenter trials have reported that coronary CT angiography is safe, reduces time to diagnosis, facilitates discharge, and may lower overall cost compared with routine care. Herein, we provide a 10-step approach for establishing a successful coronary CT angiography program in the emergency department. The importance of strategic planning and multidisciplinary collaboration is emphasized. Patient selection and preparation guidelines for coronary CT angiography are reviewed with straightforward protocols that can be adapted and modified to clinical sites, depending on available cardiac imaging capabilities. Technical parameters and patient-specific modifications are also highlighted to maximize the likelihood of diagnostic quality examinations. Practical suggestions for quality control, process monitoring, and standardized reporting are reviewed. Finally, the role of a "triple rule-out" protocol is featured in the context of acute chest pain evaluation in the emergency department. (C) 2013 Society of Cardiovascular Computed Tomography. All rights reserved.
C1 [Maroules, Christopher D.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA.
[Blaha, Michael J.] Johns Hopkins Univ Hosp, Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD 21287 USA.
[El-Haddad, Mohamed A.] Wayne State Univ, Med Ctr, Dept Internal Med, Detroit, MI 48202 USA.
[Ferencik, Maros] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Ferencik, Maros] Harvard Univ, Sch Med, Boston, MA USA.
[Cury, Ricardo C.] Baptist Hosp Miami, Dept Radiol, Miami, FL USA.
[Cury, Ricardo C.] Baptist Cardiac & Vasc Inst, Miami, FL USA.
RP Maroules, CD (reprint author), Univ Texas SW Med Ctr Dallas, Dept Radiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM christopher.maroules@phhs.org
NR 20
TC 5
Z9 5
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-5925
J9 J CARDIOVASC COMPUT
JI J. Cardiovasc. Comput. Tomogr.
PD MAY-JUN
PY 2013
VL 7
IS 3
BP 150
EP 156
DI 10.1016/j.jcct.2013.05.001
PG 7
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 187DU
UT WOS:000322097900002
PM 23809428
ER
PT J
AU Yuen, EK
Herbert, JD
Forman, EM
Goetter, EM
Juarascio, AS
Rabin, S
Goodwin, C
Bouchard, S
AF Yuen, Erica K.
Herbert, James D.
Forman, Evan M.
Goetter, Elizabeth M.
Juarascio, Adrienne S.
Rabin, Stephanie
Goodwin, Christina
Bouchard, Stephane
TI Acceptance based behavior therapy for social anxiety disorder through
videoconferencing
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Social anxiety; Telehealth; Telemental health; Telepsychology;
Videoconferencing; Skype
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED-CONTROLLED-TRIAL; BECK
DEPRESSION INVENTORY; FACE-TO-FACE; WORKING ALLIANCE INVENTORY; NEGATIVE
EVALUATION SCALE; SHEEHAN DISABILITY SCALE; PANIC DISORDER; PSYCHOMETRIC
PROPERTIES; CONCURRENT VALIDITY
AB Most individuals with social anxiety disorder (SAD) do not receive any type of treatment Reasons include logistical barriers (e.g., geographic location, travel time), fear of stigmatization, and fear of the social interactions associated with seeking treatment. Videoconferencing technology holds great promise in the widespread delivery of evidence-based treatments to those who would otherwise not receive treatment. This pilot study assessed the feasibility, acceptability, and initial efficacy of an acceptance-based behavioral intervention using Skype videoconferencing to treat adults with generalized SAD. Twenty-four participants received 12 sessions of weekly therapy and were assessed at pre-treatment, mid-treatment, post-treatment, and 3-month follow-up. Participants and therapists rated the intervention as acceptable and feasible. Analyses revealed significant pre-treatment to follow-up improvements in social anxiety, depression, disability, quality of life, and experiential avoidance, with effect sizes comparable to or larger than previously published results of studies delivering in-person CBT for SAD. Implications and future directions are discussed. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Yuen, Erica K.] Univ Tampa, Tampa, FL 33606 USA.
[Yuen, Erica K.; Juarascio, Adrienne S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Yuen, Erica K.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Yuen, Erica K.; Herbert, James D.; Forman, Evan M.; Goetter, Elizabeth M.; Juarascio, Adrienne S.; Rabin, Stephanie; Goodwin, Christina] Drexel Univ, Philadelphia, PA 19104 USA.
[Goetter, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Goodwin, Christina] Ohio State Univ, Columbus, OH 43210 USA.
[Bouchard, Stephane] Univ Quebec Outaouais, Quebec City, PQ, Canada.
RP Herbert, JD (reprint author), Dept Psychol, 119 Stratton,3141 Chestnut St, Philadelphia, PA 19104 USA.
EM james.herbert@drexel.edu
RI Forman, Evan/I-1042-2012;
OI Rabin, Stephanie/0000-0002-8282-0867
NR 68
TC 20
Z9 20
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD MAY
PY 2013
VL 27
IS 4
BP 389
EP 397
DI 10.1016/j.janxdis.2013.03.002
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 184IJ
UT WOS:000321883000004
PM 23764124
ER
PT J
AU Weber, M
Killgore, WDS
Rosso, IM
Britton, JC
Schwab, ZJ
Weiner, MR
Simon, NM
Pollack, MH
Rauch, SL
AF Weber, Mareen
Killgore, William D. S.
Rosso, Isabelle M.
Britton, Jennifer C.
Schwab, Zachary J.
Weiner, Melissa R.
Simon, Naomi M.
Pollack, Mark H.
Rauch, Scott L.
TI Voxel-based morphometric gray matter correlates of posttraumatic stress
disorder
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Magnetic resonance imaging; Chronic post-traumatic stress disorder;
Prefrontal cortex; Hippocampus; Amygdala
ID SMALLER HIPPOCAMPAL VOLUME; STRUCTURAL BRAIN ABNORMALITIES; MEDIAL
PREFRONTAL CORTEX; ADMINISTERED PTSD SCALE; ANTERIOR CINGULATE;
BASOLATERAL AMYGDALA; ANXIETY DISORDER; HUMAN EMOTION; CHILD-ABUSE;
GREY-MATTER
AB Posttraumatic stress disorder (PTSD) is associated with functional abnormalities within a neurocircuitry that includes the hippocampus, amygdala, and medial prefrontal cortex. Evidence of structural abnormalities within these regions, and their association with PTSD severity and symptom burden is, however, sparse. The present study evaluated the relation between indices of gray matter volume and PTSD symptom severity using voxel-based morphometry. Fifteen individuals meeting DSM-IV criteria for PTSD completed the Clinician Administered PTSD Scale and underwent structural magnetic resonance imaging. Greater PTSD severity and avoidance/numbing were correlated with increased gray matter volume of the right amygdala-hippocampal complex. Greater hyper-arousal was associated with reduced gray matter volume in the left superior medial frontal gyrus. Findings are consistent with current neurocircuitry models of PTSD, which posit that the disorder is associated with structural and functional variance within this distributed network. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Weber, Mareen; Killgore, William D. S.; Rosso, Isabelle M.; Schwab, Zachary J.; Rauch, Scott L.] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA 02478 USA.
[Britton, Jennifer C.] NIMH, Bethesda, MD 20892 USA.
[Weiner, Melissa R.] Yale Univ, New Haven, CT USA.
[Simon, Naomi M.; Pollack, Mark H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Killgore, WDS (reprint author), Harvard Univ, Social Cognit & Affect Neurosci Lab, McLean Hosp, Sch Med, 115 Mill St, Belmont, MA 02478 USA.
EM mweber@mclean.harvard.edu; killgore@mclean.harvard.edu
RI Britton, Jennifer/J-4501-2013;
OI Killgore, William/0000-0002-5328-0208
FU NIMH NIH HHS [R01 MH70730-01A2, R01 MH070730]
NR 65
TC 14
Z9 16
U1 3
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD MAY
PY 2013
VL 27
IS 4
BP 413
EP 419
DI 10.1016/j.janxdis.2013.04.004
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 184IJ
UT WOS:000321883000007
PM 23746489
ER
PT J
AU Saunders, DR
Bex, PJ
Woods, RL
AF Saunders, Daniel R.
Bex, Peter J.
Woods, Russell L.
TI Crowdsourcing a Normative Natural Language Dataset: A Comparison of
Amazon Mechanical Turk and In-Lab Data Collection
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE Internet; web; crowdsourcing; free recall
ID PSYCHOLOGICAL-RESEARCH; IMPAIRMENT; INTERNET; ONLINE
AB Background: Crowdsourcing has become a valuable method for collecting medical research data. This approach, recruiting through open calls on the Web, is particularly useful for assembling large normative datasets. However, it is not known how natural language datasets collected over the Web differ from those collected under controlled laboratory conditions.
Objective: To compare the natural language responses obtained from a crowdsourced sample of participants with responses collected in a conventional laboratory setting from participants recruited according to specific age and gender criteria.
Methods: We collected natural language descriptions of 200 half-minute movie clips, from Amazon Mechanical Turk workers (crowdsourced) and 60 participants recruited from the community (lab-sourced). Crowdsourced participants responded to as many clips as they wanted and typed their responses, whereas lab-sourced participants gave spoken responses to 40 clips, and their responses were transcribed. The content of the responses was evaluated using a take-one-out procedure, which compared responses to other responses to the same clip and to other clips, with a comparison of the average number of shared words.
Results: In contrast to the 13 months of recruiting that was required to collect normative data from 60 lab-sourced participants (with specific demographic characteristics), only 34 days were needed to collect normative data from 99 crowdsourced participants (contributing a median of 22 responses). The majority of crowdsourced workers were female, and the median age was 35 years, lower than the lab-sourced median of 62 years but similar to the median age of the US population. The responses contributed by the crowdsourced participants were longer on average, that is, 33 words compared to 28 words (P<.001), and they used a less varied vocabulary. However, there was strong similarity in the words used to describe a particular clip between the two datasets, as a cross-dataset count of shared words showed (P<.001). Within both datasets, responses contained substantial relevant content, with more words in common with responses to the same clip than to other clips (P<.001). There was evidence that responses from female and older crowdsourced participants had more shared words (P=.004 and .01 respectively), whereas younger participants had higher numbers of shared words in the lab-sourced population (P=.01).
Conclusions: Crowdsourcing is an effective approach to quickly and economically collect a large reliable dataset of normative natural language responses.
C1 [Saunders, Daniel R.; Woods, Russell L.] Schepens Eye Res Inst, Boston, MA 02114 USA.
[Bex, Peter J.] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA.
RP Saunders, DR (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM daniel_saunders@meei.harvard.edu
RI Woods, Russell/O-2600-2015
OI Woods, Russell/0000-0002-7193-1211
FU National Eye Institute [R01EY019100]
FX Supported by grant R01EY019100 from the National Eye Institute. All
research received ethics approval from the Massachusetts Eye and Ear
Infirmary Human Subjects Committee. We thank Rachel Berkowitz for
preparing the video clips and Dylan Rose for collecting the lab-sourced
data.
NR 31
TC 10
Z9 10
U1 1
U2 16
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD MAY
PY 2013
VL 15
IS 5
AR UNSP e100
DI 10.2196/jmir.2620
PG 14
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 185IK
UT WOS:000321960900005
PM 23689038
ER
PT J
AU Hung, JW
Tan, TC
AF Hung, Judy W.
Tan, Timothy C.
TI Echocardiography in Mitral Valve Disease Preface
SO CARDIOLOGY CLINICS
LA English
DT Editorial Material
C1 [Hung, Judy W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
[Tan, Timothy C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab,Div Cardiol, Boston, MA 02114 USA.
RP Hung, JW (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, YAW 5E,55 Fruit St, Boston, MA 02114 USA.
EM jhung@partners.org; TCTan@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2013
VL 31
IS 2
BP IX
EP x
DI 10.1016/j.ccl.2013.05.001
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 180LQ
UT WOS:000321597100001
PM 23743080
ER
PT J
AU Dal-Bianco, JP
Levine, RA
AF Dal-Bianco, Jacob P.
Levine, Robert A.
TI Anatomy of the Mitral Valve Apparatus Role of 2D and 3D Echocardiography
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Mitral valve apparatus; Mitral valve; Mitral annulus; Papillary muscles;
Chordae tendineae; Mitral regurgitation; Echocardiography
ID SYSTOLIC ANTERIOR MOTION; OUTFLOW TRACT OBSTRUCTION; PAPILLARY-MUSCLE
DYSFUNCTION; LEFT-VENTRICULAR DYSFUNCTION; TIME 3-DIMENSIONAL
ECHOCARDIOGRAPHY; VALVULAR HEART-DISEASE; HYPERTROPHIC CARDIOMYOPATHY;
CHORDAE TENDINEAE; FUNCTIONAL-ANATOMY; ANNULAR SHAPE
AB The mitral valve apparatus is a complex 3-dimensional (3D) functional unit that is critical to unidirectional heart pump function. This review details the normal anatomy, histology, and function of the main mitral valve apparatus components: mitral annulus, mitral valve leaflets, chordae tendineae, and papillary muscles. Two-dimensional and 3D echocardiography is ideally suited to examine the mitral valve apparatus and has provided important insights into the mechanism of mitral valve disease. An overview of standardized echocardiography image acquisition and interpretation is provided. Understanding normal mitral valve apparatus function is essential to comprehend alterations in mitral valve disease and the rationale for repair strategies.
C1 [Dal-Bianco, Jacob P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Cardiol, Boston, MA 02114 USA.
[Levine, Robert A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
RP Levine, RA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,Yawkey 5E, Boston, MA 02114 USA.
EM rlevine@partners.org
FU Leducq Foundation, Paris, France [07CVD04]; National Institutes of
Health [K24 HL67434, R01 HL72265, HL109506]
FX This work is supported in part by grant 07CVD04 of the Leducq
Foundation, Paris, France, for the Leducq Transatlantic MITRAL Network,
and by National Institutes of Health grants K24 HL67434, R01 HL72265,
and HL109506.
NR 133
TC 12
Z9 12
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2013
VL 31
IS 2
BP 151
EP +
DI 10.1016/j.ccl.2013.03.001
PG 15
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 180LQ
UT WOS:000321597100002
PM 23743068
ER
PT J
AU Solis, J
Piro, V
de Prada, JAV
Loughlin, G
AF Solis, Jorge
Piro, Victoria
Vazquez de Prada, Jose Antonio
Loughlin, Gerard
TI Echocardiographic Assessment of Mitral Regurgitation General
Considerations
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Mitral valve; Mitral regurgitation mitral; Echo Doppler; 3D
echocardiography
ID ISOVELOCITY SURFACE-AREA; COLOR DOPPLER-ECHOCARDIOGRAPHY; TIME
3-DIMENSIONAL ECHOCARDIOGRAPHY; VENA CONTRACTA AREA; ORIFICE AREA; FLOW;
SEVERITY; CONVERGENCE; RECOMMENDATIONS; QUANTIFICATION
AB Echocardiography is undoubtedly one of the main tools used in assessment of mitral regurgitation (MR) because it allows characterization of valvular morphology, assessment of the severity of the regurgitation, and its secondary effects. In this article we present an overview of the echocardiographic assessment of MR.
C1 [Solis, Jorge; Loughlin, Gerard] Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Madrid 28007, Spain.
[Solis, Jorge] Complutense Med Sch, Madrid 28007, Spain.
[Piro, Victoria] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Vazquez de Prada, Jose Antonio] Hosp Univ Marques de Valdecilla, Dept Cardiol, Santander 39008, Spain.
[Vazquez de Prada, Jose Antonio] Marques de Valdecilla Res Inst IFIMAV, Santander 39008, Spain.
RP Solis, J (reprint author), Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Doctor Esquerdo 46, Madrid 28007, Spain.
EM jsolismartin@yahoo.es
NR 29
TC 0
Z9 0
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2013
VL 31
IS 2
BP 165
EP +
DI 10.1016/j.ccl.2013.04.001
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 180LQ
UT WOS:000321597100003
PM 23743069
ER
PT J
AU Solis, J
Piro, V
Loughlin, G
de Prada, JAV
AF Solis, Jorge
Piro, Victoria
Loughlin, Gerard
Vazquez de Prada, Jose Antonio
TI How to Grade Mitral Regurgitation An Integrative Approach
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Mitral valve regurgitation; Mitral regurgitation quantification; Doppler
echocardiography; 3D echocardiography
ID VENA CONTRACTA AREA; COLOR DOPPLER-ECHOCARDIOGRAPHY; ISOVELOCITY
SURFACE-AREA; QUANTITATIVE ASSESSMENT; VALVULAR REGURGITATION; ORIFICE
AREA; IN-VITRO; VALIDATION; SEVERITY; QUANTIFICATION
AB Evaluation of mitral regurgitation (MR) severity remains complex and challenging. An integrative approach to grading MR is recommended. The use of multiple Doppler methods should be used to help discriminate between grades of severity. Importantly, MR severity should always be considered in the context of clinical data. The emerging inclusion of 3-dimensional echocardiography may provide complementary data for MR quantification and better anatomic and pathophysiological detail of the mitral valve. This article summarizes recommendations for MR assessment and highlights the importance of an integrated approach, using anatomic information as well as qualitative and quantitative Doppler measures.
C1 [Solis, Jorge; Loughlin, Gerard] Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Madrid 28007, Spain.
[Solis, Jorge] Complutense Med Sch, Madrid 28007, Spain.
[Piro, Victoria] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Vazquez de Prada, Jose Antonio] Hosp Univ Marques de Valdecilla, Dept Cardiol, Santander 39008, Spain.
[Vazquez de Prada, Jose Antonio] Marques de Valdecilla Res Inst IFIMAV, Santander 39008, Spain.
RP Solis, J (reprint author), Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Doctor Esquerdo 46, Madrid 28007, Spain.
EM jsolismartin@yahoo.es
NR 17
TC 0
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2013
VL 31
IS 2
BP 169
EP +
DI 10.1016/j.ccl.2013.04.002
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 180LQ
UT WOS:000321597100004
PM 23743070
ER
PT J
AU Hung, JW
AF Hung, Judy W.
TI Ischemic (Functional) Mitral Regurgitation
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Mitral regurgitation; Myocardial infarction; Papillary muscle;
Echocardiography
ID LEFT-VENTRICULAR DYSFUNCTION; LONG-TERM SURVIVAL; MYOCARDIAL-INFARCTION;
DILATED CARDIOMYOPATHY; HEART-FAILURE; REPAIR; ANNULOPLASTY;
REVASCULARIZATION; ECHOCARDIOGRAPHY; REPLACEMENT
AB Mitral regurgitation (MR) is a frequent complication of myocardial infarction and coronary artery disease that is associated with adverse prognosis. The main mechanism of ischemic MR relates to distortion of the spatial relationships between the mitral valve and papillary muscles secondary to ventricular remodeling. The evidence that treatment of ischemic MR improves long-term survival still remains unclear, and further studies are needed to determine whether correcting ischemic MR will improve survival and/or symptoms.
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Hung, JW (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Blake 256,55 Fruit St, Boston, MA 02114 USA.
EM jhung@partners.org
NR 37
TC 3
Z9 4
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2013
VL 31
IS 2
BP 231
EP +
DI 10.1016/j.ccl.2013.04.003
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 180LQ
UT WOS:000321597100009
PM 23743075
ER
PT J
AU Andrawes, MN
Feinman, JW
AF Andrawes, Michael N.
Feinman, Jared W.
TI 3-Dimensional Echocardiography and Its Role in Preoperative Mitral Valve
Evaluation
SO CARDIOLOGY CLINICS
LA English
DT Article
DE 3D echocardiography; Mitral valve; Mitral regurgitation; Mitral
stenosis; Perioperative echocardiography
ID ISOVELOCITY SURFACE-AREA; COLOR DOPPLER-ECHOCARDIOGRAPHY; TIME 3D
ECHOCARDIOGRAPHY; VENA CONTRACTA AREA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;
EAE/ASE RECOMMENDATIONS; FLOW CONVERGENCE; CHORDAE RUPTURE;
REGURGITATION; STENOSIS
AB Echocardiography plays a key role in the preoperative evaluation of mitral valve disease. 3-dimensional echocardiography is a relatively new development that is being used more and more frequently in the evaluation of these patients. This article reviews the available literature comparing the use of this new technology to classic techniques in the assessment of mitral valve pathology. The authors also review some of the novel insights learned from 3-dimensional echocardiography and how they may be used in surgical decision making and planning.
C1 [Andrawes, Michael N.; Feinman, Jared W.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Andrawes, MN (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM mandrawes@parters.org
NR 71
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2013
VL 31
IS 2
BP 271
EP +
DI 10.1016/j.ccl.2013.03.005
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 180LQ
UT WOS:000321597100011
PM 23743077
ER
PT J
AU Okeke, EN
Keenan, HA
Weinger, K
Abrahamson, MJ
Hsu, WC
AF Okeke, Eyiuche N.
Keenan, Hillary A.
Weinger, Katie
Abrahamson, Martin J.
Hsu, William C.
TI DO ETHNIC DISPARITIES EXTEND TO SUBSPECIALTY DIABETES CARE?
SO ENDOCRINE PRACTICE
LA English
DT Article
ID COMMUNITY-HEALTH CENTERS; MEDICARE MANAGED CARE; RACIAL DISPARITIES;
GLYCEMIC CONTROL; MEXICAN-AMERICANS; SELF-MANAGEMENT; ASSOCIATION;
POPULATION; DISEASE; QUALITY
AB Objective: It is unclear if disparities described in diabetes primary care extend to subspecialty diabetes care. This retrospective observational study examined disparities in diabetes outcomes in a subspecialty practice by assessing glycemic improvement in type 2 diabetes patients during the first year of enrollment.
Methods: Electronic data were gathered on 3,945 subjects. The outcome was the proportion of white and minority (Asian, black, and Hispanic) subjects achieving a hemoglobin A1C (A1C) level of <= 7% after the first year of care. Logistic regression was used to identify factors associated with odds of achieving A1C <= 7%.
Results: Minority patients had greater diabetes duration, more social disadvantages and missed appointments, and worse control at presentation than whites. The proportion of patients reaching target A1C rose from 37 to 52% among white patients and from 28 to 40% among minority patients. Significant differences between whites and minorities in the rates of patients reaching A1C <= 7% were found only among those with higher initial A1C (iA1C) levels (32% vs. 20.9%; P = .002 in third iA1C quartile, and 28.2% vs. 17.9%; P = .0003 in fourth iA1C quartile). The interaction between race/ethnicity and the top two iA1C quartiles remained significant in the fully adjusted model.
Conclusion: Reaching an A1C level of = 7% depends strongly upon the glycemic level at initial presentation to specialty care, not race. However, minority patients with the highest baseline A1C levels do not improve to the same degree as white patients, and therefore should be targeted for more intensive diabetes care management.
C1 [Okeke, Eyiuche N.; Keenan, Hillary A.; Weinger, Katie; Abrahamson, Martin J.; Hsu, William C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Adult Diabet, Boston, MA 02115 USA.
RP Okeke, EN (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM Eyiuche.okeke@joslin.harvard.edu
FU Herbert Graetz Fund
FX This study was funded by a clinical research award from the Herbert
Graetz Fund. The results of this study were presented as a poster
presentation at the American Diabetes Association's 70th Scientific
Sessions, June 25 to 29, 2010, in Orlando, Florida.
NR 28
TC 1
Z9 1
U1 0
U2 3
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
J9 ENDOCR PRACT
JI Endocr. Pract.
PD MAY-JUN
PY 2013
VL 19
IS 3
BP 431
EP 438
DI 10.4158/EP12254.OR
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 175XM
UT WOS:000321267000012
PM 23337143
ER
PT J
AU Danescu, LG
Roe, CA
Johnson, LW
AF Danescu, Liviu G.
Roe, Cheryl A.
Johnson, Lewis W.
TI PHOTOPLETHYSMOGRAPHY: A SIMPLIFIED METHOD FOR THE OFFICE MEASUREMENT OF
ANKLE BRACHIAL INDEX IN INDIVIDUALS WITH DIABETES
SO ENDOCRINE PRACTICE
LA English
DT Article
ID PERIPHERAL ARTERIAL-DISEASE; PREDICT CARDIOVASCULAR EVENTS; PRESSURE
INDEX; ARM INDEX; MORTALITY; DOPPLER; ATHEROSCLEROSIS; SPECIFICITY;
SENSITIVITY; HEALTH
AB Objective: To compare the use of photoplethysmography (PPG) and Doppler techniques to measure the ankle brachial index (ABI) for the evaluation of peripheral arterial disease (PAD) in individuals with diabetes.
Methods: Consecutive patients with diabetes (n = 103) referred for PAD evaluation had ABI measured by PPG and Doppler techniques in our diabetes center. Medical records were reviewed, and the results of the Doppler and PPG testing were compared.
Results: Mean age was 60 years, 57% were female, and 79% had type 2 diabetes with an average duration of 17 years. PPG readings could not be obtained in 3 individuals. Of 200 limbs evaluated, 17 (8.5%) had noncompressible (NC) vessels by both techniques. In the remaining 183 limbs, the correlation coefficient comparing the two methods was 0.864. Mean ABI values were 1.11 +/- 0.14 for Doppler and 1.12 +/- 0.14 for PPG. The sensitivity of PPG compared to the Doppler technique for detection of an abnormal result was 88.2%, and the specificity was 99.4%. ABI results were classified as discordant if Doppler and PPG varied by more than 0.15, placing them in different diagnostic categories (abnormal low [<= 0.9], borderline [0.91-0.99], normal [1.0-1.4], or abnormal high [>1.4 or NC vessels]). There were only 4 (2%) discordant results.
Conclusions: We found excellent concordance between PPG and the gold standard Doppler technique for ABI measurement in individuals with diabetes. PPG requires less training and takes less time to perform, making it highly suitable for use in an office setting.
C1 [Danescu, Liviu G.; Johnson, Lewis W.] SUNY Upstate Med Univ, Div Endocrinol Diabet & Metab, Syracuse, NY 13210 USA.
[Roe, Cheryl A.] SUNY Upstate Med Univ, Ctr Res & Evaluat, Syracuse, NY 13210 USA.
RP Johnson, LW (reprint author), Joslin Diabet Ctr, 3229 East Genesee St, Syracuse, NY 13214 USA.
EM johnsole@upstate.edu
NR 28
TC 0
Z9 1
U1 0
U2 7
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
J9 ENDOCR PRACT
JI Endocr. Pract.
PD MAY-JUN
PY 2013
VL 19
IS 3
BP 439
EP 443
DI 10.4158/EP12172.OR
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 175XM
UT WOS:000321267000013
PM 23337138
ER
PT J
AU McManus, SS
Levitsky, LL
Misra, M
AF McManus, Shilpa S.
Levitsky, Lynne L.
Misra, Madhusmita
TI POLYCYSTIC OVARY SYNDROME: CLINICAL PRESENTATION IN NORMAL-WEIGHT
COMPARED WITH OVERWEIGHT ADOLESCENTS
SO ENDOCRINE PRACTICE
LA English
DT Article
ID INSULIN-RESISTANCE; TOTAL TESTOSTERONE; SYNDROME PCOS; NORMAL WOMEN;
ENDOCRINE; PREVALENCE; OBESITY; GIRLS; HYPERANDROGENEMIA; POPULATION
AB Objective: To characterize polycystic ovary syndrome (PCOS) in adolescents and determine whether a distinct clinical presentation differentiates normal-weight (NW) from overweight (OW) PCOS.
Methods: Retrospective chart review of patients seen in a tertiary care center from 1998-2008 who met the National Institutes of Health and/or Rotterdam criteria for PCOS (N = 211; NW = 43, OW = 168). We collected data on clinical features, biochemical markers, and ultrasound findings.
Results: Patient age ranged from 11.3 to 20.3 years (mean, 15.7 +/- 1.7 years), and body mass index (BMI) from 17.4 to 64.2 kg/m(2) (mean, 31.7 +/- 7.7 kg/m(2)). Seventy-one percent of patients were Caucasian, 85% had irregular menses, 69% reported hirsutism, 18% had moderate to severe acne, 91% had a high free androgen index (FAI), and 8% had abnormal thyroid-stimulating hormone (TSH) levels. The BMI-standard deviation (SD) score was 0.1 +/- 0.5 in NW and 3.4 +/- 1.8 in OW girls. NW girls were older at diagnosis (16.4 +/- 1.4 years vs. 15.5 +/- 1.7 years; P = .0006) than OW girls, less likely to have a family history of obesity (22% vs. 65%; P<.0001), and less likely to have acanthosis nigricans (11% vs. 68%; P<.0001). NW girls were more likely to have polycystic ovaries on ultrasound (88% vs. 52%; P = .01) and a lower FAI (7.3 +/- 4.5 vs. 17.4 +/- 12.9; P<.0001). The BMI-SD score was negatively associated with sex hormone binding globulin (r(s) = -0.52; P<.0001) and positively associated with FAI (r(s) = 0.42; P<.0001).
Conclusion: NW girls are more likely to be older at diagnosis and have polycystic ovaries. Other differences in presentation between groups were attributable to differences in weight. NW PCOS is likely part of a continuous spectrum of clinical PCOS rather than a distinct entity.
C1 MassGen Hosp Children, Pediat Endocrine Unit, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Misra, M (reprint author), Massachusetts Gen Hosp, Pediat Endocrine Unit, 175 Cambridge St,5th Floor, Boston, MA 02114 USA.
EM mmisra@partners.org
FU NICHD NIH HHS [K24 HD071843]
NR 30
TC 1
Z9 1
U1 3
U2 4
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
EI 1934-2403
J9 ENDOCR PRACT
JI Endocr. Pract.
PD MAY-JUN
PY 2013
VL 19
IS 3
BP 471
EP 478
DI 10.4158/EP12235.OR
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 175XM
UT WOS:000321267000018
PM 23816935
ER
PT J
AU Daniels, GH
Sluss, P
AF Daniels, Gilbert H.
Sluss, Patrick
TI PURE T3-THYROTOXICOSIS FROM A MEXICAN WEIGHT LOSS SUPPLEMENT
SO ENDOCRINE PRACTICE
LA English
DT Letter
C1 [Daniels, Gilbert H.] Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA.
[Daniels, Gilbert H.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Daniels, Gilbert H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Thyroid Unit ACC 730, Boston, MA 02114 USA.
[Sluss, Patrick] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Sluss, Patrick] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Daniels, GH (reprint author), Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA.
EM gdaniels@partners.org; psluss@partners.org
NR 2
TC 2
Z9 2
U1 0
U2 0
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
J9 ENDOCR PRACT
JI Endocr. Pract.
PD MAY-JUN
PY 2013
VL 19
IS 3
BP 559
EP 560
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 175XM
UT WOS:000321267000028
PM 23425657
ER
PT J
AU Bhargava, A
Kaur, M
AF Bhargava, Amit
Kaur, Manmeet
TI What is the diagnosis? The patient was diagnosed with subacute
thyroiditis and booked for a repeat ultrasound in 10 weeks, with a view
to biopsy the solitary nodule in the right lobe of the thyroid
SO ENDOCRINE PRACTICE
LA English
DT Editorial Material
C1 [Bhargava, Amit] Univ Connecticut, Ctr Hlth, Div Endocrinol, Farmington, CT 06030 USA.
[Kaur, Manmeet] Hosp Cent Connecticut, Joslin Diabet Ctr Affiliate, New Britain, CT USA.
RP Bhargava, A (reprint author), Univ Connecticut, Ctr Hlth, Div Endocrinol, 263 Farmington Ave, Farmington, CT 06030 USA.
EM abhargava99@yahoo.com
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
J9 ENDOCR PRACT
JI Endocr. Pract.
PD MAY-JUN
PY 2013
VL 19
IS 3
BP 562
EP 562
DI 10.4158/EP12406.VV
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 175XM
UT WOS:000321267000030
PM 23425654
ER
PT J
AU Oh, DJ
Kang, MH
Ooi, YH
Choi, KR
Sage, EH
Rhee, DJ
AF Oh, Dong-Jin
Kang, Min Hyung
Ooi, Yen Hoong
Choi, Kyu Ryong
Sage, E. Helene
Rhee, Douglas J.
TI Overexpression of SPARC in Human Trabecular Meshwork Increases
Intraocular Pressure and Alters Extracellular Matrix
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE SPARC; adenovirus; matrix metalloproteinases; tissue inhibitors of
matrix metalloproteinases; extracellular matrix; intraocular pressure;
perfused anterior segment system
ID OPEN-ANGLE GLAUCOMA; MATRICELLULAR PROTEIN SPARC; AQUEOUS-HUMOR OUTFLOW;
OCULAR HYPERTENSION; HUMAN EYES; JUXTACANALICULAR TISSUE;
GENE-EXPRESSION; ORGAN-CULTURE; ALPHA-3 CHAIN; CELLS
AB PURPOSE. Intraocular pressure (IOP) regulation is largely unknown. SPARC-null mice demonstrate a lower IOP resulting from increased outflow. SPARC is a matricellular protein often associated with fibrosis. We hypothesized that SPARC overexpression would alter IOP by affecting extracellular matrix (ECM) synthesis and/or turnover in the trabecular meshwork (TM).
METHODS. An adenoviral vector containing human SPARC was used to increase SPARC expression in human TM endothelial cells and perfused human anterior segments using multiplicities of infection (MOIs) 25 or 50. Total RNA from TM was used for quantitative PCR, while protein from cell lysates and conditioned media were used for immunoblot analyses and zymography. After completion of perfusion, the anterior segments were fixed, sectioned, and examined by light and confocal microscopy.
RESULTS. SPARC overexpression increased the IOP of perfused human anterior segments. Fibronectin and collagens IV and I protein levels were elevated in both TM cell cultures and within the juxtacanalicular (JCT) region of perfused anterior segments. Collagen VI and laminin protein levels were increased in TM cell cultures but not in perfused anterior segments. The protein levels of pro-MMP-9 decreased while the kinetic inhibitors of metalloproteinases, TIMP-1 and PAI-1 protein levels, increased at MOI 25. At MOI 50, the protein levels of pro-MMP-1, -3, and -9 also decreased while PAI-1 and TIMP-1 and -3 increased. Only MMP-9 activity was decreased on zymography. mRNA levels of the collagens, fibronectin, and laminin were not affected by SPARC overexpression.
CONCLUSIONS. SPARC overexpression increases IOP in perfused cadaveric human anterior segments resulting from a qualitative change the JCT ECM. Selective decrease of MMP-9 activity is likely part of the mechanism. SPARC is a regulatory node for IOP.
C1 [Oh, Dong-Jin; Kang, Min Hyung; Rhee, Douglas J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
[Ooi, Yen Hoong] New York Downtown Hosp, Dept Pediat, New York, NY USA.
[Choi, Kyu Ryong] Ewha Womans Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
[Choi, Kyu Ryong] Mokdong Hosp, Med Ctr, Seoul, South Korea.
[Sage, E. Helene] Benaroya Res Inst Virginia Mason, Hope Heart Program, Seattle, WA USA.
RP Rhee, DJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM DougRhee@aol.com
FU National Eye Institute [EY 019654-01, EY 014104]; Research to Prevent
Blindness; Massachusetts Lions Eye Research Foundation; American
Glaucoma Society
FX Supported by National Eye Institute Grants EY 019654-01 and EY 014104
(MEEI Vision-Core Grant), Research to Prevent Blindness, Massachusetts
Lions Eye Research Foundation, and American Glaucoma Society.
NR 61
TC 22
Z9 22
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2013
VL 54
IS 5
BP 3309
EP 3319
DI 10.1167/iovs.12-11362
PG 11
WC Ophthalmology
SC Ophthalmology
GA 173YC
UT WOS:000321118300026
PM 23599341
ER
PT J
AU Cherfan, D
Verter, EE
Melki, S
Gisel, TE
Doyle, FJ
Scarcelli, G
Yun, SH
Redmond, RW
Kochevar, IE
AF Cherfan, Daniel
Verter, E. Eri
Melki, Samir
Gisel, Thomas E.
Doyle, Francis J., Jr.
Scarcelli, Giuliano
Yun, Seok Hyun
Redmond, Robert W.
Kochevar, Irene E.
TI Collagen Cross-Linking Using Rose Bengal and Green Light to Increase
Corneal Stiffness
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE collagen cross-linking; corneal stiffness; ectatic disorder;
keratoconus; photochemistry
ID TREATMENT IN-VITRO; RIBOFLAVIN/UVA-TREATMENT; SINGLET OXYGEN; BRILLOUIN
MICROSCOPY; OPTICAL MICROSCOPY; RABBIT CORNEA; ULTRAVIOLET-A; TISSUE;
KERATOCONUS; MODEL
AB PURPOSE. Photochemical cross-linking of corneal collagen is an evolving treatment for keratoconus and other ectatic disorders. We evaluated collagen cross-linking by rose bengal plus green light (RGX) in rabbit eyes and investigated factors important for clinical application.
METHODS. Rose bengal (RB, 0.1%) was applied to deepithelialized corneas of enucleated rabbit eyes for 2 minutes. The diffusion distance of RB into the stroma was measured by fluorescence microscopy on frozen sections. RB-stained corneas were exposed to green (532-nm) light for 3.3 to 9.9 minutes (50-150 J/cm(2)). Changes in the absorption spectrum during the irradiation were recorded. Corneal stiffness was measured by uniaxial tensiometry. The spatial distribution of the stromal elastic modulus was assessed by Brillouin microscopy. Viable keratocytes were counted on H&E-stained sections 24 hours posttreatment.
RESULTS. RB penetrated approximately 100 mu m into the corneal stroma and absorbed >90% of the incident green light. RGX (150 J/cm(2)) increased stromal stiffness by 3.8-fold. The elastic modulus increased in the anterior approximately 120 mu m of stroma. RB was partially photobleached during the 2-minute irradiation, but reapplication of RB blocked light transmission by >70%. Spectral measurements suggested that RGX initiated cross-linking by an oxygen-dependent mechanism. RGX did not decrease keratocyte viability.
CONCLUSIONS. RGX significantly increases cornea stiffness in a rapid treatment (congruent to 12 minutes total time), does not cause toxicity to keratocytes and may be used to stiffen corneas thinner than 400 mu m. Thus, RGX may provide an attractive approach to inhibit progression of keratoconus and other ectatic disorders.
C1 [Cherfan, Daniel] Boston Univ, Med Sci Program, Boston, MA 02215 USA.
[Verter, E. Eri; Gisel, Thomas E.; Doyle, Francis J., Jr.; Scarcelli, Giuliano; Yun, Seok Hyun; Redmond, Robert W.; Kochevar, Irene E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Melki, Samir] Boston Eye Grp, Boston, MA USA.
RP Kochevar, IE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM kochevar@helix.mgh.harvard.edu
OI scarcelli, giuliano/0000-0002-1736-077X
FU NEI NIH HHS [R21 EY023043]
NR 43
TC 31
Z9 31
U1 0
U2 31
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2013
VL 54
IS 5
BP 3426
EP 3433
DI 10.1167/iovs.12-11509
PG 8
WC Ophthalmology
SC Ophthalmology
GA 173YC
UT WOS:000321118300040
PM 23599326
ER
PT J
AU Rogers, DJ
Ojha, S
Maurer, R
Hartnick, CJ
AF Rogers, Derek J.
Ojha, Shilpa
Maurer, Rie
Hartnick, Christopher J.
TI Use of Adjuvant Intralesional Bevacizumab for Aggressive Respiratory
Papillomatosis in Children
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID PROLIFERATIVE DIABETIC-RETINOPATHY; HUMAN-PAPILLOMAVIRUS;
CLINICAL-COURSE; CIDOFOVIR; INJECTION; AVASTIN; LASER; RISK; TERM
AB Importance: Juvenile recurrent respiratory papillomatosis (RRP) can be an aggressive disease process necessitating frequent trips to the operating room with multiple anesthetics for tumor debulking and airway preservation. Adjuvant therapy, such as that which is reported in this article, may help reduce the number of operative procedures affected children need each year and therefore may also affect their overall quality of life (QOL).
Objective: To describe our experience with intralesional bevacizumab (Avastin) treatment for children with severe RRP by comparing median number of surgical procedures per year, median duration of time between procedures, Derkay staging, and voice QOL before and after bevacizumab treatment.
Design: Prospective, consecutive case series.
Setting: Tertiary care aerodigestive center.
Participants: Ten children, aged 18 months to 18 years, with severe RRP necessitating more than 4 operative interventions in 1 year whose parents (or legal guardians) consented to intralesional bevacizumab treatment. Interventions: Intralesional bevacizumab administered at concentration of 2.5 mg/mL for 3 consecutive injections (with 532-nm pulsed KTP [potassium titanyl phosphate] laser when necessary) at intervals of 2 to 3 weeks.
Main Outcome Measures: Time between surgical procedures, number of procedures per year, Derkay staging, total Pediatric Voice-Related Quality of Life (PVRQOL) score, Emotional PVRQOL score, and Physical PVRQOL score defined by comparing the year leading up to first of 3 bevacizumab injections with the year following the third bevacizumab injection.
Results: The median duration of time between surgical procedures increased by 5.9 weeks after bevacizumab (P=.002). The median number of procedures per year decreased by 4 (P=.002). Derkay staging decreased by 6 (P=.03). The median total PVRQOL score increased by 25.5 (P=.02), the median Emotional PVRQOL score increased by 11.3 (P=.047), and the median Physical PVRQOL score increased by 14.3 (P=.047).
Conclusions and Relevance: Intralesional bevacizumab treatment may increase duration of time between surgical procedures and decrease number of procedures per year, while improving voice QOL.
C1 [Rogers, Derek J.; Hartnick, Christopher J.] Massachusetts Eye & Ear Infirm, Dept Pediat Otolaryngol, Boston, MA 02114 USA.
[Ojha, Shilpa] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Maurer, Rie] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Maurer, Rie] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Hartnick, CJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Pediat Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM Christopher_Hartnick@meei.harvard.edu
NR 35
TC 6
Z9 6
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6181
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD MAY
PY 2013
VL 139
IS 5
BP 496
EP 501
DI 10.1001/jamaoto.2013.1810
PG 6
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 170MN
UT WOS:000320855900009
PM 23681032
ER
PT J
AU Randolph, GW
AF Randolph, Gregory W.
TI Modern Thyroidectomy and the Tailored Surgical Approach
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Editorial Material
C1 [Randolph, Gregory W.] Harvard Univ, Div Gen Otolaryngol, Dept Otolaryngol, Med Sch,Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Randolph, Gregory W.] Harvard Univ, Div Thyroid Parathyroid Surg, Dept Otolaryngol, Med Sch,Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Randolph, GW (reprint author), Harvard Univ, Div Gen Otolaryngol, Dept Otolaryngol, Med Sch,Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM gregory_randolph@meei.harvard.edu
NR 1
TC 2
Z9 2
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6181
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD MAY
PY 2013
VL 139
IS 5
BP 517
EP 518
DI 10.1001/jamaoto.2013.301
PG 3
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 170MN
UT WOS:000320855900013
PM 23681036
ER
PT J
AU Jimenez, RB
Goma, C
Nyamwanda, J
Kooy, HM
Halabi, T
Napolitano, BN
McBride, SM
Taghian, AG
Lu, HM
MacDonald, SM
AF Jimenez, Rachel B.
Goma, Carles
Nyamwanda, Jacqueline
Kooy, Hanne M.
Halabi, Tarek
Napolitano, Brian N.
McBride, Sean M.
Taghian, Alphonse G.
Lu, Hsiao-Ming
MacDonald, Shannon M.
TI Intensity modulated proton therapy for postmastectomy radiation of
bilateral implant reconstructed breasts: A treatment planning study
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE IMPT; Postmastectomy; Implant; Pencil beam; Proton
ID CANCER; RADIOTHERAPY; IMMEDIATE; COMPLICATIONS; MASTECTOMY; 3D-CRT;
TRENDS
AB Background and purpose: Delivery of post-mastectomy radiation (PMRT) in women with bilateral implants represents a technical challenge, particularly when attempting to cover regional lymph nodes. Intensity modulated proton therapy (IMPT) holds the potential to improve dose delivery and spare nontarget tissues. The purpose of this study was to compare IMPT to three-dimensional (3D) conformal radiation following bilateral mastectomy and reconstruction.
Materials and methods: Ten IMPT, 3D conformal photon/electron (P/E), and 3D photon (wide tangent) plans were created for 5 patients with breast cancer, all of whom had bilateral breast implants. Using RTOG guidelines, a physician delineated contours for both target volumes and organs-at-risk. Plans were designed to achieve 95% coverage of all targets (chest wall, IMN, SCV, axilla) to a dose of 50.4 Gy or Gy (RBE) while maximally sparing organs-at-risk.
Results: IMPT plans conferred similar target volume coverage with enhanced homogeneity. Both mean heart and lung doses using IMPT were significantly decreased compared to both PIE and wide tangent planning.
Conclusions: IMPT provides improved homogeneity to the chest wall and regional lymphatics in the post-mastectomy setting with improved sparing of surrounding normal structures for woman with reconstructed breasts. IMPT may enable women with mastectomy to undergo radiation therapy without the need for delay in breast reconstruction. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 107 (2013) 213-217
C1 [Jimenez, Rachel B.; McBride, Sean M.] Harvard Radiat Oncol Program, Boston, MA USA.
[Goma, Carles; Nyamwanda, Jacqueline; Kooy, Hanne M.; Halabi, Tarek; Napolitano, Brian N.; Taghian, Alphonse G.; Lu, Hsiao-Ming; MacDonald, Shannon M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Jimenez, RB (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Harvard Radiat Oncol Program, 75 Francis St, Boston, MA 02215 USA.
EM rbjimenez@partners.org
OI Goma, Carles/0000-0003-0336-390X
NR 12
TC 12
Z9 12
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-8140
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD MAY
PY 2013
VL 107
IS 2
BP 213
EP 217
DI 10.1016/j.radonc.2013.03.028
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 183HH
UT WOS:000321804600016
PM 23647751
ER
PT J
AU Koh, HJ
Toyoda, T
Didesch, MM
Lee, MY
Sleeman, MW
Kulkarni, RN
Musi, N
Hirshman, MF
Goodyear, LJ
AF Koh, Ho-Jin
Toyoda, Taro
Didesch, Michelle M.
Lee, Min-Young
Sleeman, Mark W.
Kulkarni, Rohit N.
Musi, Nicolas
Hirshman, Michael F.
Goodyear, Laurie J.
TI Tribbles 3 mediates endoplasmic reticulum stress-induced insulin
resistance in skeletal muscle
SO NATURE COMMUNICATIONS
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; STIMULATED GLUCOSE-TRANSPORT; PANCREATIC
BETA-CELLS; ER STRESS; RECEPTOR SUBSTRATE-1; CHEMICAL CHAPERONES;
DOWN-REGULATION; TRB3; EXPRESSION; KINASE
AB Endoplasmic reticulum stress has been linked to insulin resistance in multiple tissues but the role of endoplasmic reticulum stress in skeletal muscle has not been explored. Endoplasmic reticulum stress has been reported to increase tribbles 3 expression in multiple cell lines. Here, we report that high-fat feeding in mice, and obesity and type 2 diabetes in humans significantly increases tribbles 3 and endoplasmic reticulum stress markers in skeletal muscle. Overexpression of tribbles 3 in C2C12 myotubes and mouse tibialis anterior muscles significantly impairs insulin signalling. Incubation of C2C12 cells and mouse skeletal muscle with endoplasmic reticulum stressors thapsigargin and tunicamycin increases tribbles 3 and impairs insulin signalling and glucose uptake, effects reversed in cells overexpressing RNAi for tribbles 3 and in muscles from tribbles 3 knockout mice. Furthermore, tribbles 3 knockout mice are protected from high-fat diet-induced insulin resistance in skeletal muscle. These data demonstrate that tribbles 3 mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle.
C1 [Koh, Ho-Jin; Toyoda, Taro; Didesch, Michelle M.; Lee, Min-Young; Kulkarni, Rohit N.; Hirshman, Michael F.; Goodyear, Laurie J.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
[Koh, Ho-Jin; Toyoda, Taro; Didesch, Michelle M.; Lee, Min-Young; Kulkarni, Rohit N.; Hirshman, Michael F.; Goodyear, Laurie J.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
[Sleeman, Mark W.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
[Musi, Nicolas] Audie L Murphy VA Med Ctr, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Koh, HJ (reprint author), Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
EM Ho-Jin.Koh@joslin.harvard.edu
FU NIH [5P30DK036836, P30DK040561, R01AR045670, 5R01DK067536, P30DK036836];
ADA
FX We thank M. Montminy (Salk Institute) for providing TRB3 antibody and
adenoviruses for TRB3 and RNAi for TRB3, E. A. Caniano (Joslin Diabetes
Center) for editorial contributions, and all other members of the
Goodyear lab for critical discussions. This work was supported by NIH
grants to H.-J.K. (5P30DK036836 and P30DK040561), to L.J.G.
(R01AR045670), to R.N.K. (5R01DK067536) and to the Joslin DERC
(P30DK036836). T. T. and M.-Y.L. were supported by ADA mentor-based
fellowships (to L.J.G.).
NR 53
TC 23
Z9 24
U1 3
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAY
PY 2013
VL 4
AR 1871
DI 10.1038/ncomms2851
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 166WI
UT WOS:000320589900067
PM 23695665
ER
PT J
AU Li, G
Diogo, D
Wu, D
Spoonamore, J
Dancik, V
Franke, L
Kurreeman, F
Rossin, EJ
Duclos, G
Hartland, C
Zhou, XZ
Li, KJ
Liu, J
De Jager, PL
Siminovitch, KA
Zhernakova, A
Raychaudhuri, S
Bowes, J
Eyre, S
Padyukov, L
Gregersen, PK
Worthington, J
Gupta, N
Clemons, PA
Stahl, E
Tolliday, N
Plenge, RM
AF Li, Gang
Diogo, Dorothee
Wu, Di
Spoonamore, Jim
Dancik, Vlado
Franke, Lude
Kurreeman, Fina
Rossin, Elizabeth J.
Duclos, Grant
Hartland, Cathy
Zhou, Xuezhong
Li, Kejie
Liu, Jun
De Jager, Philip L.
Siminovitch, Katherine A.
Zhernakova, Alexandra
Raychaudhuri, Soumya
Bowes, John
Eyre, Steve
Padyukov, Leonid
Gregersen, Peter K.
Worthington, Jane
Gupta, Namrata
Clemons, Paul A.
Stahl, Eli
Tolliday, Nicola
Plenge, Robert M.
CA RACI
TI Human Genetics in Rheumatoid Arthritis Guides a High-Throughput Drug
Screen of the CD40 Signaling Pathway
SO PLOS GENETICS
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; COLLAGEN-INDUCED
ARTHRITIS; ANTI-CD40 LIGAND ANTIBODY; DENSITY-LIPOPROTEIN CHOLESTEROL;
MONOCLONAL-ANTIBODY; FETAL-HEMOGLOBIN; CONTROLLED-TRIAL; DOUBLE-BLIND;
B-CELLS
AB Although genetic and non-genetic studies in mouse and human implicate the CD40 pathway in rheumatoid arthritis (RA), there are no approved drugs that inhibit CD40 signaling for clinical care in RA or any other disease. Here, we sought to understand the biological consequences of a CD40 risk variant in RA discovered by a previous genome-wide association study (GWAS) and to perform a high-throughput drug screen for modulators of CD40 signaling based on human genetic findings. First, we fine-map the CD40 risk locus in 7,222 seropositive RA patients and 15,870 controls, together with deep sequencing of CD40 coding exons in 500 RA cases and 650 controls, to identify a single SNP that explains the entire signal of association (rs4810485, P = 1.4 x 10(-9)). Second, we demonstrate that subjects homozygous for the RA risk allele have similar to 33% more CD40 on the surface of primary human CD19+ B lymphocytes than subjects homozygous for the non-risk allele (P = 10(-9)), a finding corroborated by expression quantitative trait loci (eQTL) analysis in peripheral blood mononuclear cells from 1,469 healthy control individuals. Third, we use retroviral shRNA infection to perturb the amount of CD40 on the surface of a human B lymphocyte cell line (BL2) and observe a direct correlation between amount of CD40 protein and phosphorylation of RelA (p65), a subunit of the NF-kappa B transcription factor. Finally, we develop a high-throughput NF-kappa B luciferase reporter assay in BL2 cells activated with trimerized CD40 ligand (tCD40L) and conduct an HTS of 1,982 chemical compounds and FDA-approved drugs. After a series of counter-screens and testing in primary human CD19+ B cells, we identify 2 novel chemical inhibitors not previously implicated in inflammation or CD40-mediated NF-kappa B signaling. Our study demonstrates proof-of-concept that human genetics can be used to guide the development of phenotype-based, high-throughput small-molecule screens to identify potential novel therapies in complex traits such as RA.
C1 [Li, Gang; Diogo, Dorothee; Wu, Di; Kurreeman, Fina; Duclos, Grant; Raychaudhuri, Soumya; Stahl, Eli; Plenge, Robert M.] Harvard Univ, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Sch Med, Boston, MA 02115 USA.
[Li, Gang; Diogo, Dorothee; Wu, Di; Kurreeman, Fina; Duclos, Grant; Raychaudhuri, Soumya; Stahl, Eli; Plenge, Robert M.] Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med, Boston, MA 02115 USA.
[Diogo, Dorothee; Wu, Di; Kurreeman, Fina; Rossin, Elizabeth J.; De Jager, Philip L.; Raychaudhuri, Soumya; Gupta, Namrata; Stahl, Eli; Plenge, Robert M.] Broad Inst, Chem Biol Program, Med & Populat Genet Program, Cambridge, MA USA.
[Wu, Di; Liu, Jun] Harvard Univ, Dept Stat, Boston, MA 02115 USA.
[Spoonamore, Jim; Hartland, Cathy; Tolliday, Nicola] Broad Inst, Cambridge, MA USA.
[Dancik, Vlado; Li, Kejie; Clemons, Paul A.] Broad Inst, Chem Biol Program, Cambridge, MA USA.
[Franke, Lude; Zhernakova, Alexandra] Univ Med Ctr Groningen, Dept Genet, NL-9713 AV Groningen, Netherlands.
[Franke, Lude; Zhernakova, Alexandra] Univ Groningen, Groningen, Netherlands.
[Rossin, Elizabeth J.] Harvard Univ, Biol & Biomed Sci Program, Hlth Sci & Technol Program, Sch Med, Boston, MA 02115 USA.
[Rossin, Elizabeth J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Zhou, Xuezhong] Beijing Jiaotong Univ, Sch Comp & Informat Technol, Beijing, Peoples R China.
[De Jager, Philip L.] Brigham & Womens Hosp, Program Translat NeuroPsychiat Genom, Inst Neurosci, Dept Neurol, Boston, MA 02115 USA.
[Siminovitch, Katherine A.] Univ Toronto, Dept Med, Toronto, ON, Canada.
[Siminovitch, Katherine A.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Siminovitch, Katherine A.] Toronto Gen Res Inst, Toronto, ON, Canada.
[Zhernakova, Alexandra] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands.
[Bowes, John; Eyre, Steve; Worthington, Jane] Univ Manchester, Arthrit Res UK Epidemiol Unit, Musculoskeletal Res Grp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
[Bowes, John; Eyre, Steve; Worthington, Jane] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England.
[Padyukov, Leonid] Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden.
[Padyukov, Leonid] Karolinska Univ Hosp Solna, Stockholm, Sweden.
[Gregersen, Peter K.] North Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA.
RP Li, G (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Sch Med, Boston, MA 02115 USA.
EM rplenge@partners.org
RI Siminovitch, Katherine/K-1475-2013; Worthington, Jane/M-9770-2014;
Franke, Lude/P-7036-2016;
OI Worthington, Jane/0000-0003-0544-042X; Franke, Lude/0000-0002-5159-8802;
Zhernakova, Alexandra/0000-0002-4574-0841; Eyre,
Stephen/0000-0002-1251-6974; Padyukov, Leonid/0000-0003-2950-5670
FU NIH [R01-AR057108, R01-AR056768, U01-GM092691, R01-AR059648,
U54-LM008748]; Burroughs Wellcome Fund; [RC2-GM093080]
FX RMP was supported by grants from the NIH (R01-AR057108, R01-AR056768,
U01-GM092691, R01-AR059648) and holds a Career Award for Medical
Scientists from the Burroughs Wellcome Fund. The PhenoGenetic Project of
Brigham and Women's Hospital was supported by RC2-GM093080. Immunochip
genotype data from the i2b2 dataset was funded in part from NIH grant
U54-LM008748. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 63
TC 20
Z9 21
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2013
VL 9
IS 5
AR UNSP e1003487
DI 10.1371/journal.pgen.1003487
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 159FH
UT WOS:000320030000011
PM 23696745
ER
PT J
AU Lin, FJ
Shen, L
Jang, CW
Falnes, PO
Zhang, Y
AF Lin, Fu-Jung
Shen, Li
Jang, Chuan-Wei
Falnes, Pal O.
Zhang, Yi
TI Ikbkap/Elp1 Deficiency Causes Male Infertility by Disrupting Meiotic
Progression
SO PLOS GENETICS
LA English
DT Article
ID SEX-CHROMOSOME INACTIVATION; TRANSFER-RNA; FAMILIAL DYSAUTONOMIA; MOUSE
SPERMATOCYTES; ELONGATOR COMPLEX; MOLECULAR ARCHITECTURE;
PSEUDOAUTOSOMAL REGION; MAMMALIAN MEIOSIS; MICE; TRANSCRIPTION
AB Mouse Ikbkap gene encodes IKAP-one of the core subunits of Elongator-and is thought to be involved in transcription. However, the biological function of IKAP, particularly within the context of an animal model, remains poorly characterized. We used a loss-of-function approach in mice to demonstrate that Ikbkap is essential for meiosis during spermatogenesis. Absence of Ikbkap results in defects in synapsis and meiotic recombination, both of which result in increased apoptosis and complete arrest of gametogenesis. In Ikbkap-mutant testes, a few meiotic genes are down-regulated, suggesting IKAP's role in transcriptional regulation. In addition, Ikbkap-mutant testes exhibit defects in wobble uridine tRNA modification, supporting a conserved tRNA modification function from yeast to mammals. Thus, our study not only reveals a novel function of IKAP in meiosis, but also suggests that IKAP contributes to this process partly by exerting its effect on transcription and tRNA modification.
C1 [Lin, Fu-Jung; Shen, Li; Jang, Chuan-Wei; Zhang, Yi] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Lin, Fu-Jung; Shen, Li; Zhang, Yi] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Lin, Fu-Jung; Shen, Li; Zhang, Yi] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Falnes, Pal O.] Univ Oslo, Dept Biosci, Oslo, Norway.
[Zhang, Yi] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02115 USA.
RP Lin, FJ (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
EM yzhang@genetics.med.harvard.edu
OI LIN, FU-JUNG/0000-0003-4065-0983
FU NIH [U01DK089565]; UNC Lineberger Comprehensive Cancer Center
[T32-CA009156-36]
FX This work was supported by grant U01DK089565 from NIH. F-JL was a
recipient of the Basic Research Fellowship from the UNC Lineberger
Comprehensive Cancer Center (T32-CA009156-36). YZ is an Investigator of
the Howard Hughes Medical Institute. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 64
TC 21
Z9 21
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2013
VL 9
IS 5
AR e1003516
DI 10.1371/journal.pgen.1003516
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 159FH
UT WOS:000320030000034
PM 23717213
ER
PT J
AU Dunphy, CH
Ferry, JA
AF Dunphy, Cherie H.
Ferry, Judith A.
TI Introduction to the series of reactive and abnormal lymphoid
proliferations mimicking malignant lymphoma
SO SEMINARS IN DIAGNOSTIC PATHOLOGY
LA English
DT Editorial Material
C1 [Dunphy, Cherie H.] Lab Corp America, Ctr Mol Biol & Pathol, Res Triangle Pk, NC USA.
[Dunphy, Cherie H.] Univ N Carolina, Chapel Hill, NC USA.
[Ferry, Judith A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Ferry, Judith A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Dunphy, CH (reprint author), Lab Corp America, Ctr Mol Biol & Pathol, Res Triangle Pk, NC USA.
EM cdunphy@unch.unc.edu
NR 0
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0740-2570
J9 SEMIN DIAGN PATHOL
JI Semin. Diagn. Pathol.
PD MAY
PY 2013
VL 30
IS 2
BP 101
EP 101
DI 10.1053/j.semdp.2012.08.004
PG 1
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 172AR
UT WOS:000320972800001
PM 23541275
ER
PT J
AU Sogg, S
AF Sogg, Stephanie
TI Comment on: Pilot evaluation of a substance abuse prevention group
intervention for at-risk bariatric surgery candidates
SO SURGERY FOR OBESITY AND RELATED DISEASES
LA English
DT Editorial Material
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Weight Ctr, Boston, MA 02114 USA.
RP Sogg, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Weight Ctr, Boston, MA 02114 USA.
NR 9
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1550-7289
J9 SURG OBES RELAT DIS
JI Surg. Obes. Relat. Dis.
PD MAY-JUN
PY 2013
VL 9
IS 3
BP 468
EP 469
PG 2
WC Surgery
SC Surgery
GA 162VA
UT WOS:000320292900029
PM 23477955
ER
PT J
AU Gonzalez, SD
Xu, C
Ramirez, ME
Zavala, JM
Armas, R
Contreras, SA
Contreras, J
Dassori, A
Leach, RJ
Flores, D
Jerez, A
Raventos, H
Ontiveros, A
Nicolini, H
Escamilla, M
AF Gonzalez, S. D.
Xu, C.
Ramirez, M. E.
Zavala, J. M.
Armas, R.
Contreras, S. A.
Contreras, J.
Dassori, A.
Leach, R. J.
Flores, D.
Jerez, A.
Raventos, H.
Ontiveros, A.
Nicolini, H.
Escamilla, M.
TI Family-based association of an ANK3 haplotype with bipolar disorder in
Latino populations
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Letter
ID GENOME-WIDE ASSOCIATION; VARIANTS; CACNA1C
C1 [Gonzalez, S. D.; Xu, C.; Ramirez, M. E.; Zavala, J. M.; Escamilla, M.] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Psychiat, El Paso, TX USA.
[Gonzalez, S. D.; Xu, C.; Ramirez, M. E.; Zavala, J. M.; Escamilla, M.] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Ctr Excellence Neurosci, El Paso, TX USA.
[Armas, R.] Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA USA.
[Contreras, S. A.; Dassori, A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Contreras, J.; Raventos, H.] Univ Costa Rica, Ctr Invest Biol Celular & Mol, San Jose, Costa Rica.
[Contreras, J.; Raventos, H.] Univ Costa Rica, Escuela Biol, San Jose, Costa Rica.
[Dassori, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Leach, R. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Flores, D.] Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Ctr Harbor, Torrance, CA 90509 USA.
[Jerez, A.] Ctr Int Trastornos Afectivos & Conducta Adictiva, Guatemala City, Guatemala.
[Ontiveros, A.] Inst Informac & Invest Salud Mental AC, Monterrey, Mexico.
[Nicolini, H.] SC, Grp Estudios Med & Familiares Carracci, Mexico City, DF, Mexico.
RP Gonzalez, SD (reprint author), Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Psychiat, El Paso, TX USA.
EM m.escamilla@ttuhsc.edu
OI Raventos, Henriette/0000-0001-9423-8308; Nicolini,
Humberto/0000-0003-2494-0067
NR 10
TC 3
Z9 3
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD MAY
PY 2013
VL 3
AR e265
DI 10.1038/tp.2013.40
PG 2
WC Psychiatry
SC Psychiatry
GA 174VJ
UT WOS:000321184400011
PM 23715300
ER
PT J
AU Choy, G
Novelline, RA
AF Choy, Garry
Novelline, Robert A.
TI Past, Present, and Future of Emergency Radiology
SO CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION
CANADIENNE DES RADIOLOGISTES
LA English
DT Editorial Material
DE Emergency radiology; Acute radiology; Emergency department radiology
ID MEDICAL-SERVICES USE
C1 [Choy, Garry; Novelline, Robert A.] Massachusetts Gen Hosp, Dept Radiol, Div Emergency Radiol & Teleradiol, Boston, MA 02114 USA.
RP Choy, G (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Emergency Radiol & Teleradiol, 55 Fruit St,Founders House 210, Boston, MA 02114 USA.
EM gchoy@partners.org
NR 6
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0846-5371
J9 CAN ASSOC RADIOL J
JI Can. Assoc. Radiol. J.-J. Assoc. Can. Radiol.
PD MAY
PY 2013
VL 64
IS 2
SI SI
BP 85
EP 89
DI 10.1016/j.carj.2012.10.002
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 167LM
UT WOS:000320633500003
PM 23506981
ER
PT J
AU Yonekawa, Y
Miller, JB
Turalba, AV
Eliott, D
AF Yonekawa, Yoshihiro
Miller, John B.
Turalba, Angela V.
Eliott, Dean
TI Traumatic Macular Hole From Intentional Basketball Overinflation
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; EYE INJURY REGISTRY; EPIDEMIOLOGY
AB We report a new mechanism of ocular trauma. A basketball was intentionally overinflated until it exploded, resulting in corneal edema, hyphema, iritis, vitreous hemorrhage, commotio retinae, and a macular hole. The macular hole did not close after observation and subsequent pars plana vitrectomy with posterior hyaloid removal, but a repeat vitrectomy with internal limiting membrane peeling resulted in hole closure. Basketball overinflation to the point of explosion is a potentially blinding practice of which the public and manufacturers should be made aware.
C1 [Yonekawa, Yoshihiro; Miller, John B.; Turalba, Angela V.; Eliott, Dean] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
RP Eliott, D (reprint author), Massachusetts Eye & Ear Infirm, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM dean_eliott@meei.harvard.edu
NR 11
TC 0
Z9 0
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2013
VL 44
IS 3
BP 303
EP 305
DI 10.3928/23258160-20130503-20
PG 3
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 172QV
UT WOS:000321020100019
PM 23676239
ER
PT J
AU Li, JF
Chung, HS
Niu, YJ
Bush, J
McCormack, M
Sheen, J
AF Li, Jian-Feng
Chung, Hoo Sun
Niu, Yajie
Bush, Jenifer
McCormack, Matthew
Sheen, Jen
TI Comprehensive Protein-Based Artificial MicroRNA Screens for Effective
Gene Silencing in Plants
SO PLANT CELL
LA English
DT Article
ID ARABIDOPSIS MESOPHYLL PROTOPLASTS; TRANSLATIONAL REPRESSION; WEB SERVER;
EXPRESSION; TARGETS; BIOSYNTHESIS; RECOGNITION; INHIBITION; THALIANA;
MIRNAS
AB Artificial microRNA (amiRNA) approaches offer a powerful strategy for targeted gene manipulation in any plant species. However, the current unpredictability of amiRNA efficacy has limited broad application of this promising technology. To address this, we developed epitope-tagged protein-based amiRNA (ETPamir) screens, in which target mRNAs encoding epitope-tagged proteins were constitutively or inducibly coexpressed in protoplasts with amiRNA candidates targeting single or multiple genes. This design allowed parallel quantification of target proteins and mRNAs to define amiRNA efficacy and mechanism of action, circumventing unpredictable amiRNA expression/processing and antibody unavailability. Systematic evaluation of 63 amiRNAs in 79 ETPamir screens for 16 target genes revealed a simple, effective solution for selecting optimal amiRNAs from hundreds of computational predictions, reaching similar to 100% gene silencing in plant cells and null phenotypes in transgenic plants. Optimal amiRNAs predominantly mediated highly specific translational repression at 59 coding regions with limited mRNA decay or cleavage. Our screens were easily applied to diverse plant species, including Arabidopsis thaliana, tobacco (Nicotiana benthamiana), tomato (Solanum lycopersicum), sunflower (Helianthus annuus), Catharanthus roseus, maize (Zea mays) and rice (Oryza sativa), and effectively validated predicted natural miRNA targets. These screens could improve plant research and crop engineering by making amiRNA a more predictable and manageable genetic and functional genomic technology.
C1 [Li, Jian-Feng; Chung, Hoo Sun; Niu, Yajie; Bush, Jenifer; McCormack, Matthew; Sheen, Jen] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Li, Jian-Feng; Chung, Hoo Sun; Niu, Yajie; Bush, Jenifer; McCormack, Matthew; Sheen, Jen] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
RP Li, JF (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM jli@molbio.mgh.harvard.edu
FU National Science Foundation [IOS-0843244]; National Institutes of Health
[R01 GM60493, R01 GM70567]; Massachusetts General Hospital Executive
Committee on Research Postdoctoral Fellowship for Medical Discovery
FX We thank Frederick Ausubel for critical reading of the article, Detlef
Weigel and Rebecca Schwab for the WMD platform, Jin-Gui Chen for the
T-DNA insertion rack1 null mutants, Carolyn Lee-Parsons for C. roseus
plants, Mark Curtis and Ueli Grossniklaus for the estradiol-inducible
binary vector, and the ABRC for the mekk1 and pds3 mutants. We also
thank Guillaume Tena for the original miR319a plasmid, Li Li for maize
protoplast transfection, and Qi Hall for assistance in floral dip.
J.-F.L. is supported by the Massachusetts General Hospital Executive
Committee on Research Postdoctoral Fellowship for Medical Discovery. The
research is supported by National Science Foundation Grant IOS-0843244
and the National Institutes of Health Grants R01 GM60493 and R01 GM70567
to J.S.
NR 49
TC 40
Z9 44
U1 3
U2 52
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 1040-4651
J9 PLANT CELL
JI Plant Cell
PD MAY
PY 2013
VL 25
IS 5
BP 1507
EP 1522
DI 10.1105/tpc.113.112235
PG 16
WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
GA 172WH
UT WOS:000321035800007
PM 23645631
ER
PT J
AU Abeijon, C
Campos-Neto, A
AF Abeijon, Claudia
Campos-Neto, Antonio
TI Potential Non-invasive Urine-Based Antigen (Protein) Detection Assay to
Diagnose Active Visceral Leishmaniasis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Editorial Material
C1 [Abeijon, Claudia] DetectoGen Inc, Grafton, MA USA.
[Campos-Neto, Antonio] Forsyth Inst, Cambridge, MA USA.
RP Abeijon, C (reprint author), DetectoGen Inc, Grafton, MA USA.
EM acampos@forsyth.org
FU NIAID NIH HHS [R43AI084259-01]
NR 10
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2013
VL 7
IS 5
AR e2161
DI 10.1371/journal.pntd.0002161
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 158SW
UT WOS:000319994400003
PM 23738023
ER
PT J
AU Jung, M
Chung, D
AF Jung, Minsoo
Chung, Dongjun
TI Evidence of Social Contextual Effects on Adolescent Smoking in South
Korea
SO ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE smoking; adolescent; social environment; school; multilevel analysis;
South Korea
ID CIGARETTE-SMOKING; SCHOOL DIFFERENCES; RISK-FACTORS; PREDICTORS;
MULTILEVEL; PATTERNS; STUDENTS; BELIEFS; CHINA; RATES
AB This study explores the effect of psychological and social factors on smoking behavior among male and female adolescents in South Korea. A cross-sectional analysis was carried out via multilevel logistic regression with pupils at the first level and schools at the second level. The data were collected in 2003 using a nationally representative sample of 3449 students from 100 South Korean middle schools. For both genders, adolescents were more likely to smoke if and when they had lower academic grades, had a higher disposable monetary allowance from their parents, had more friends who smoked, and if the smoking rate at their school was higher. Psychological factors, however, were not factors that significantly influenced smoking. Consequently, the principal contextual factors related to adolescent smoking are the smoking rates in schools and among peer groups. Thus, an antismoking campaign incorporating social environmental factors may be useful in reducing the rates of adolescent smoking.
C1 [Jung, Minsoo] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Jung, Minsoo] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Chung, Dongjun] Univ Wisconsin, Madison, WI 53706 USA.
RP Chung, D (reprint author), Univ Wisconsin, Dept Stat, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.
EM dongjun.chung@gmail.com
OI Jung, Minsoo/0000-0003-3317-6507; Chung, Dongjun/0000-0002-8072-5671
NR 35
TC 6
Z9 6
U1 2
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1010-5395
J9 ASIA-PAC J PUBLIC HE
JI Asia-Pac. J. Public Health
PD MAY
PY 2013
VL 25
IS 3
BP 260
EP 270
DI 10.1177/1010539512461667
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 161AH
UT WOS:000320161700006
PM 23070756
ER
PT J
AU Cohen, LS
Viguera, AC
Masnik, S
Kwiatkowski, M
Murphy, S
Lemon, E
Hernandez-Diaz, S
AF Cohen, L. S.
Viguera, A. C.
Masnik, S.
Kwiatkowski, M.
Murphy, S.
Lemon, E.
Hernandez-Diaz, S.
TI The National Pregnancy Registry for Atypical Antipsychotics: Effects of
Fetal Exposure on Risk for Congenital Malformations and Maternal/Newborn
Outcomes
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Cohen, L. S.; Viguera, A. C.; Masnik, S.; Kwiatkowski, M.; Murphy, S.; Lemon, E.] Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Boston, MA 02114 USA.
[Viguera, A. C.] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.
[Hernandez-Diaz, S.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2013
VL 97
IS 5
SI SI
BP 296
EP 296
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 171MB
UT WOS:000320932100051
ER
PT J
AU Holmes, LB
AF Holmes, L. B.
TI Pregnancy Registry Designs for Multiple Drugs for Similar Medications:
North American AED (Antiepileptic Drug) Pregnancy Registry
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Holmes, L. B.] MassGen Hosp Children, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2013
VL 97
IS 5
SI SI
BP 296
EP 296
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 171MB
UT WOS:000320932100050
ER
PT J
AU Clark, JC
Manak, J
Darbro, B
Kanan, P
Holmes, LB
Brophy, PD
AF Clark, J. C.
Manak, J.
Darbro, B.
Kanan, P.
Holmes, L. B.
Brophy, P. D.
TI The Familial Nature of Renal Agenesis
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Clark, J. C.; Manak, J.; Darbro, B.; Brophy, P. D.] Univ Iowa, Iowa City, IA USA.
[Kanan, P.; Holmes, L. B.] MassGen Hosp Children, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2013
VL 97
IS 5
SI SI
BP 309
EP 309
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 171MB
UT WOS:000320932100074
ER
PT J
AU Nasri, HN
Macklin, EM
Holmes, LH
AF Nasri, H. N.
Macklin, E. M.
Holmes, L. H.
TI Vascular Disruption Limb Defects: Correlation with Advanced Maternal
Age?
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Nasri, H. N.] Simmons Coll, Boston, MA 02115 USA.
[Macklin, E. M.] MassGen Hosp Children, Dept Biostat, Boston, MA USA.
[Holmes, L. H.] MassGen Hosp Children, Massachusetts Gen Hosp & Med Genet, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2013
VL 97
IS 5
SI SI
BP 319
EP 319
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 171MB
UT WOS:000320932100094
ER
PT J
AU Le, KY
Uslan, DZ
Baddour, LM
Sohail, MR
Prutkin, JM
Peacock, JE
Danik, SB
Vikram, HR
Miro, JM
Blank, E
Naber, CK
Carrillo, RG
Tseng, CH
Greenspon, AJ
AF Le, K. Y.
Uslan, D. Z.
Baddour, L. M.
Sohail, M. R.
Prutkin, J. M.
Peacock, J. E., Jr.
Danik, S. B.
Vikram, H. R.
Miro, J. M.
Blank, E.
Naber, C. K.
Carrillo, R. G.
Tseng, C. -H.
Greenspon, A. J.
CA MEDIC
TI PROMPT SYSTEM EXTRACTION DECREASES MORTALITY IN PATIENTS WITH
CARDIOVASCULAR IMPLANTABLE ELECTROPHYSIOLOGIC DEVICE INFECTION
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Meeting Abstract
CT 12th International Symposium on Modern Concepts in Endocarditis and
Cardiovascular Infections
CY MAY 19-21, 2013
CL Dubrovnik, CROATIA
SP MSD Pharma
C1 [Le, K. Y.] Mayo Clin, Dept Med, Div Hosp Internal Med, Rochester, MN USA.
[Uslan, D. Z.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA.
[Baddour, L. M.; Sohail, M. R.] Mayo Clin, Dept Med, Div Infect Dis, Rochester, MN USA.
[Prutkin, J. M.] Univ Washington, Med Ctr, Div Cardiol, Seattle, WA 98195 USA.
[Peacock, J. E., Jr.] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Div Infect Dis, Winston Salem, NC 27103 USA.
[Danik, S. B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, Boston, MA USA.
[Vikram, H. R.] Mayo Clin, Dept Med, Div Infect Dis, Scottsdale, AZ USA.
[Miro, J. M.] Univ Barcelona, Hosp Clin IDIBAPS, Infect Dis Serv, Barcelona, Spain.
[Naber, C. K.] Elisabeth Hosp, Klin Kardiol & Angiol, Essen, Germany.
[Carrillo, R. G.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Tseng, C. -H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA.
[Greenspon, A. J.] Thomas Jefferson Univ Hosp, Div Cardiol, Dept Med, Philadelphia, PA 19107 USA.
EM katherine.y.le@gmail.com
RI Sohail, Muhammad/K-1803-2016
OI Sohail, Muhammad/0000-0001-6355-0526
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAY
PY 2013
VL 41
SU 1
BP S33
EP S33
PG 1
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 171KR
UT WOS:000320927100111
ER
PT J
AU Antiel, RM
Reed, DA
Van Arendonk, KJ
Wightman, SC
Hall, DE
Porterfield, JR
Horvath, KD
Terhune, KP
Tarpley, JL
Farley, DR
AF Antiel, Ryan M.
Reed, Darcy A.
Van Arendonk, Kyle J.
Wightman, Sean C.
Hall, Daniel E.
Porterfield, John R.
Horvath, Karen D.
Terhune, Kyla P.
Tarpley, John L.
Farley, David R.
TI Effects of Duty Hour Restrictions on Core Competencies, Education,
Quality of Life, and Burnout Among General Surgery Interns
SO JAMA SURGERY
LA English
DT Article
ID HOURS ENHANCING SLEEP; 80-HOUR WORK WEEK; AMERICAN SURGEONS; PROGRAM
DIRECTORS; OPERATIVE EXPERIENCE; RESIDENTS; MEDICINE; SUPERVISION;
ATTRITION; HEALTH
AB Objective: To measure the implications of the new Accreditation Council for Graduate Medical Education duty hour regulations for education, well-being, and burnout.
Design: Longitudinal study.
Setting: Eleven university-based general surgery residency programs from July 2011 to May 2012.
Participants: Two hundred thirteen surgical interns.
Main Outcome Measures: Perceptions of the impact of the new duty hours on various aspects of surgical training, including the 6 Accreditation Council for Graduate Medical Education core competencies, were measured on 3-point scales. Quality of life, burnout, balance between personal and professional life, and career satisfaction were measured using validated instruments.
Results: Half of all interns felt that the duty hour changes have decreased the coordination of patient care (53%), their ability to achieve continuity with hospitalized patients (70%), and their time spent in the operating room (57%). Less than half (44%) of interns believed that the new standards have decreased resident fatigue. In longitudinal analysis, residents' beliefs had significantly changed in 2 categories: less likely to believe that practice-based learning and improvement had improved and more likely to report no change to resident fatigue (P < .01, chi(2) tests). The majority (82%) of residents reported a neutral or good overall quality of life. Compared with the normal US population, 50 interns (32%) were 0.5 SD less than the mean on the 8-item Short Form Health Survey mental quality of life score. Approximately one-third of interns demonstrated weekly symptoms of emotional exhaustion (28%) or depersonalization (28%) or reported that their personal-professional balance was either "very poor" or "not great" (32%). Although many interns (67%) reported that they daily or weekly reflect on their satisfaction from being a surgeon, 1 in 7 considered giving up their career as a surgeon on at least a weekly basis.
Conclusions: The first cohort of surgical interns to train under the new regulations report decreased continuity with patients, coordination of patient care, and time spent in the operating room. Furthermore, suboptimal quality of life, burnout, and thoughts of giving up surgery were common, even under the new paradigm of reduced work hours.
C1 [Reed, Darcy A.] Mayo Clin, Div Primary Care Internal Med, Rochester, MN 55905 USA.
[Antiel, Ryan M.; Farley, David R.] Mayo Clin, Dept Surg, Rochester, MN 55905 USA.
[Van Arendonk, Kyle J.] Johns Hopkins Univ, Dept Surg, Baltimore, MD USA.
[Wightman, Sean C.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
[Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Porterfield, John R.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL USA.
[Horvath, Karen D.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Terhune, Kyla P.; Tarpley, John L.] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA.
RP Farley, DR (reprint author), Mayo Clin, Dept Surg, 200 1st St SW, Rochester, MN 55905 USA.
EM farley.david@mayo.edu
OI Hall, Daniel/0000-0001-6382-0522
NR 42
TC 50
Z9 50
U1 0
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6254
J9 JAMA SURG
JI JAMA Surg.
PD MAY
PY 2013
VL 148
IS 5
BP 448
EP 455
DI 10.1001/jamasurg.2013.1368
PG 8
WC Surgery
SC Surgery
GA 163IU
UT WOS:000320330300013
PM 23325404
ER
PT J
AU Lenehan, G
AF Lenehan, Gail
TI Weigh Children in Kilograms Only! Response
SO JOURNAL OF EMERGENCY NURSING
LA English
DT Letter
C1 Massachusetts Gen Hosp, Emergency Nurses Assoc, CNS, Emergency Dept, Boston, MA 02114 USA.
RP Lenehan, G (reprint author), Massachusetts Gen Hosp, Emergency Nurses Assoc, CNS, Emergency Dept, Boston, MA 02114 USA.
EM gail.lenehan@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-1767
J9 J EMERG NURS
JI J. Emerg. Nurs.
PD MAY
PY 2013
VL 39
IS 3
BP E25
EP E25
DI 10.1016/j.jen.2012.07.004
PG 1
WC Emergency Medicine; Nursing
SC Emergency Medicine; Nursing
GA 162ZX
UT WOS:000320306200002
PM 23647995
ER
PT J
AU Bennett, A
Bukowski, RM
Flaherty, K
Muir, JC
Turner, CD
AF Bennett, Amanda
Bukowski, Ronald M.
Flaherty, Keith
Muir, J. Cameron
Turner, Craig D.
TI The Cost of Hope: A Candid Roundtable Discussion
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Editorial Material
AB For Amanda Bennett and her husband Terence Foley, a 7-year battle with kidney cancer resulted in a price tag of more than $600,000, most of it spent in the final 2 years of his life. Ms. Bennett's memoir, The Cost of Hope, chronicles the couple's emotional struggle and the financial irrationality she uncovered when navigating the cancer continuum. She shared her experience in her keynote address at the NCCN 18th Annual Conference, which was followed by a roundtable discussion in which panelists discussed the difficulties inherent in dealing with cancer "uncertainties," the balancing act that seeks to maintain hope in the context of a poor prognosis, and the problem of a health care system that spends too much on some aspects of care while ignoring others.
C1 [Bukowski, Ronald M.] Bukowski Consulting LLC, Pepper Pike, OH USA.
[Bukowski, Ronald M.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH USA.
[Flaherty, Keith] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Muir, J. Cameron] Capital Caring, Qual & Access, Falls Church, VA USA.
[Muir, J. Cameron] Amer Acad Hospice & Palliat Med, Glenview, IL USA.
[Turner, Craig D.] Urol Consultants PC, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5.5
SI SI
BP 633
EP 635
PG 3
WC Oncology
SC Oncology
GA 159TX
UT WOS:000320071300002
PM 23704231
ER
PT J
AU Ligibel, JA
Denlinger, CS
AF Ligibel, Jennifer A.
Denlinger, Crystal S.
TI New NCCN Guidelines (R) for Survivorship Care
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID PHYSICAL-ACTIVITY; CANCER SURVIVORS; DIAGNOSIS
AB Survivorship is a stage in the cancer journey like diagnosis and treatment, but it tends to be somewhat neglected in the quiet afterthoughts of treatment completion. Although cancer recurrence, second cancers, and late side effects of treatment are major concerns for survivors, survivors also may experience a variety of long-term physical and psychological sequelae of a cancer diagnosis and treatment. Oncology professionals may be ill-prepared to tackle these topics, and they have few guidelines for meeting these patient needs. In this article, Dr. Jennifer A. Ligibel and Dr. Crystal S. Den linger present highlights from the inaugural NCCN Clinical Practice Guidelines in Oncology on survivorship care, focusing on the subtopics of exercise, cognitive function, immunization, and sexual function. They also discuss implementing new recommendations on survivorship assessment in the clinic.
C1 [Ligibel, Jennifer A.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA.
[Denlinger, Crystal S.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA.
RP Ligibel, JA (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM jligibel@partners.org; crystal.denlinger@fccc.edu
FU AstraZeneca Pharmaceuticals LP; MedImmune Inc.; Merrimack
Pharmaceuticals
FX Dr. Ligibel has disclosed that she has no financial interests,
arrangements, or commercial interest conflicts with the manufacturers of
any products discussed in this article or their competitors. Dr. Den
linger has disclosed that she receives research support from AstraZeneca
Pharmaceuticals LP; MedImmune Inc.; and Merrimack Pharmaceuticals.
NR 11
TC 18
Z9 19
U1 0
U2 5
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5.5
SI SI
BP 640
EP 644
PG 5
WC Oncology
SC Oncology
GA 159TX
UT WOS:000320071300004
PM 23704233
ER
PT J
AU Kantoff, PW
Mohler, JL
AF Kantoff, Philip W.
Mohler, James L.
TI New Developments in the Management of Prostate Cancer
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID RADICAL PROSTATECTOMY; INCREASED SURVIVAL; CHEMOTHERAPY; ABIRATERONE
AB Rapid progress was recently made in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer. At the NCCN 18th Annual Conference, Dr. Philip W. Kantoff reviewed the data supporting the use of abiraterone acetate, enzalutamide, cabazitaxel, sipuleucel-T, and radium-223 (pending approval), and offered recommendations for their sequential use in different settings. Dr. James L. Mohler described factors that dictate who should receive treatment, when they should receive it, and how to treat in the setting of prostate-specific antigen elevation. He explained how better treatment decisions will result from individualized estimation of threat-to-life posed by prostate cancer, chance of cure by treatment, and treatment risks.
C1 [Kantoff, Philip W.] Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kantoff, Philip W.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mohler, James L.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
RP Kantoff, PW (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Suite D-1230, Boston, MA 02115 USA.
EM philip_kantoff@dfci.harvard.edu; james.mohler@roswellpark.org
FU Bavarian Nordic Immunotherapy (BN-IT); Androbiosys, Inc.
FX Dr. Kantoff has disclosed he receives research support from Bavarian
Nordic Immunotherapy (BN-IT); and and serves as a consultant for Bayer
Health Care; Dendreon Corporation; Janssen Pharmaceutica Products, LP;
and Bavarian Nordic Immunotherapy (BN-IT). Dr. Mohler has disclosed he
has a financial relationship with Androbiosys, Inc.
NR 11
TC 5
Z9 5
U1 0
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5.5
SI SI
BP 653
EP 657
PG 5
WC Oncology
SC Oncology
GA 159TX
UT WOS:000320071300007
PM 23704236
ER
PT J
AU Abramson, JS
Zelenetz, AD
AF Abramson, Jeremy S.
Zelenetz, Andrew D.
TI Recent Advances in the Treatment of Non-Hodgkin's Lymphomas
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; RITUXIMAB; PHASE-3; BURDEN; TRIAL
AB Non-Hodgkin's lymphomas (NHL) represent a diverse set of diseases, with different treatment pathways based on the stage and type of hematologic cancer. In their presentation at the NCCN 18th Annual Conference, Dr. Jeremy Abramson and Dr. Andrew D. Zelenetz discuss 3 specific B-cell NHLs: follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. They provided an overview of the treatment strategies for patients with these hematologic malignancies, and offered highlights from recent clinical trials supporting these recommendations.
C1 [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Lymphoma Program, Boston, MA 02114 USA.
[Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
RP Abramson, JS (reprint author), Massachusetts Gen Hosp, Ctr Canc, Yawkey Ctr Outpatient Care, Mailstop Yawkey 9A,32 Fruit St, Boston, MA 02114 USA.
EM jabramson@partners.org; a-zelenetz@ski.mskcc.org
FU Abbott Laboratories; Celgene Corporation; Cephalon, Inc.; Genentech,
Inc.; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.; Onyx
Pharmaceuticals, Inc.; Allos Pharm; Calistoga, Pharmacyclics; Plexxikon;
Roche; Seattle Genetics
FX Dr. Abramson has revealed that he has served as a consultant for Seattle
Genetics. Dr. Zelenetz has revealed that he receives clinical research
support from Abbott Laboratories; Celgene Corporation; Cephalon, Inc.;
Genentech, Inc.; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.; Onyx
Pharmaceuticals, Inc.; Allos Pharm; Calistoga, Pharmacyclics; Plexxikon;
Roche; and Seattle Genetics and serves on an advisory board or as a
consultant for Abbott Laboratories; Celgene Corporation; Cell
Therapeutics, Inc.; Cephalon, Inc.; Genentech, Inc.; GlaxoSmithKline;
Altos; Cancer Genetics; Gilead; Seattle Genetics; Roche Laboratories,
Inc.; and sanofi-aventis U.S.
NR 12
TC 5
Z9 5
U1 0
U2 3
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5.5
SI SI
BP 671
EP 675
PG 5
WC Oncology
SC Oncology
GA 159TX
UT WOS:000320071300011
PM 23704240
ER
PT J
AU Anderson, KC
AF Anderson, Kenneth C.
TI Therapeutic Advances in Relapsed or Refractory Multiple Myeloma
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID BORTEZOMIB; INHIBITOR
AB The past decade has been a time of rapid progress in multiple myeloma, but the future therapeutic landscape may be even more promising, as new agents are better tolerated and novel pathways are exploited. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) now include the proteasome inhibitor carfilzomib and immunomodulatory drug pomalidomide, which are more potent than previous generations of these drugs have been. These agents are extending progression free and overall survival of patients with relapsed refractory myeloma, as is maintenance therapy with lenalidomide after initial therapy of patients with newly diagnosed disease At the NCCN 18th Annual Conference, Dr. Kenneth C. Anderson from Dana-Farber Cancer Institute reviewed the data leading to the approval of these exciting agents, discussed the efficacy of current regimens, and described the future landscape and the exciting potential of new agents to further improve and extend the lives of patients with myeloma.
C1 [Anderson, Kenneth C.] Harvard Univ, Sch Med, Kraft Family Prof Med, Boston, MA USA.
[Anderson, Kenneth C.] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02215 USA.
[Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02215 USA.
[Anderson, Kenneth C.] Brigham & Womens Canc Ctr, Boston, MA USA.
RP Anderson, KC (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM kenneth_anderson@dfci.harvard.edu
NR 15
TC 11
Z9 12
U1 0
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5.5
SI SI
BP 676
EP 679
PG 4
WC Oncology
SC Oncology
GA 159TX
UT WOS:000320071300012
PM 23704241
ER
PT J
AU Choueiri, TK
AF Choueiri, Toni K.
TI Clinical Treatment Decisions for Advanced Renal Cell Cancer
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID PROGNOSTIC MODEL; PHASE-3 TRIAL; CARCINOMA; SURVIVAL; AXITINIB
AB Seven targeted agents have improved the prognosis of advanced renal cell carcinoma (RCC), but none are effective in the post-nephrectomy adjuvant setting. Among the available first-line options for advanced RCC, sunitinib remains the most commonly used first-line therapy, but several studies suggest pazopanib may be better tolerated. Increasingly, choice of therapy may be driven by toxicity profiles. Cytoreductive nephrectomy remains important, even in the era of targeted therapies in selected patients.
C1 [Choueiri, Toni K.] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA.
RP Choueiri, TK (reprint author), Dana Farber Brigham & Womens Canc Ctr, Lank Ctr Genitourinary Oncol, 450 Brookline Ave,Dana 1230, Boston, MA 02215 USA.
EM toni_choueiri@dfci.harvard.edu
NR 14
TC 8
Z9 8
U1 0
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5.5
SI SI
BP 694
EP 697
PG 4
WC Oncology
SC Oncology
GA 159TX
UT WOS:000320071300017
PM 23704246
ER
PT J
AU Haddad, RI
AF Haddad, Robert I.
TI New Developments in Thyroid Cancer
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
AB Thyroid cancer is common but rarely deadly. Unfortunately, when the disease becomes refractory to radioactive iodine (RAI), few effective treatment options remain. This situation is changing, however, with the availability of multitargeted tyrosine kinase inhibitors. Cabozantanib and vandetanib, both recently FDA-approved for advanced or metastatic disease, have more than doubled progression-free survival in medullary thyroid cancer. New agents in the pipeline may yield even better outcomes, as discussed by Dr. Robert I. Haddad at the NCCN 18th Annual Conference.
C1 [Haddad, Robert I.] Harvard Univ, Sch Med, Boston, MA USA.
[Haddad, Robert I.] Dana Farber Canc Inst, Head & Neck Oncol Program, Dis Ctr, Boston, MA 02115 USA.
[Haddad, Robert I.] Brigham & Womens Canc Ctr, Boston, MA USA.
RP Haddad, RI (reprint author), Dana Farber Brigham & Womens Canc Ctr, 44 Binney St,SW430G, Boston, MA 02115 USA.
EM robert_haddad@dfci.harvard.edu
NR 8
TC 5
Z9 5
U1 0
U2 0
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5.5
SI SI
BP 705
EP 707
PG 3
WC Oncology
SC Oncology
GA 159TX
UT WOS:000320071300020
PM 23704249
ER
PT J
AU de Souza, DAT
Parente, DB
de Araujo, ALE
Mortele, KJ
AF de Souza, Daniel Andrade Tinoco
Parente, Daniella Braz
Eiras de Araujo, Antonio Luis
Mortele, Koenraad J.
TI Modern Imaging Evaluation of the Liver Emerging MR Imaging Techniques
and Indications
SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA
LA English
DT Article
DE Liver; Hepatic MRI; Diffusion-weighted imaging; Liver fibrosis; Hepatic
steatosis; MR elastography; MR spectroscopy; Hepatocellular contrast
ID GD-EOB-DTPA; MAGNETIC-RESONANCE ELASTOGRAPHY; FOCAL NODULAR HYPERPLASIA;
DIFFUSION-WEIGHTED MRI; CONTRAST-ENHANCED MRI; HYPERVASCULAR
HEPATOCELLULAR CARCINOMAS; HEPATIC FAT FRACTION; GADOXETATE DISODIUM;
SPIN-ECHO; TRANSIENT ELASTOGRAPHY
AB Modern MR imaging evaluation of the liver allows for a comprehensive morphologic and functional assessment of the liver parenchyma, hepatic vessels, and biliary tree, thus aiding in the diagnosis of both focal and diffuse liver diseases.
C1 [de Souza, Daniel Andrade Tinoco] Harvard Univ, Sch Med, Dana Farber Canc Inst, PET CT & Nucl Med, Boston, MA 02215 USA.
[Parente, Daniella Braz] D Or Inst Res & Educ, Labs DOr Network, Fleury Grp, BR-22470010 Rio De Janeiro, Brazil.
[Eiras de Araujo, Antonio Luis] Univ Fed Rio de Janeiro, Dept Radiol, BR-21941913 Rio De Janeiro, RJ, Brazil.
[Eiras de Araujo, Antonio Luis] Fleury Grp, Labs DOr Network, BR-22281100 Rio De Janeiro, Brazil.
[Mortele, Koenraad J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Clin MRI Abdominal Imaging & Body MRI, Boston, MA 02215 USA.
RP de Souza, DAT (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, PET CT & Nucl Med, 400 Brookline Ave, Boston, MA 02215 USA.
EM daniel.radiology@gmail.com
OI Parente, Daniella/0000-0003-0031-5785
NR 149
TC 2
Z9 3
U1 1
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1064-9689
J9 MAGN RESON IMAGING C
JI Magn. Reson. Imaging Clin. N. Am.
PD MAY
PY 2013
VL 21
IS 2
BP 337
EP +
DI 10.1016/j.mric.2013.01.001
PG 28
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 161PC
UT WOS:000320204800009
PM 23642557
ER
PT J
AU Pandey, GS
Yanover, C
Howard, TE
Sauna, ZE
AF Pandey, Gouri Shankar
Yanover, Chen
Howard, Tom E.
Sauna, Zuben E.
TI Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the
Development of Inhibitory AntiFactor VIII Antibodies during the
Treatment of Hemophilia A: A Computational Assessment
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID T-CELL RESPONSES; MILD HEMOPHILIA; KINETIC STABILITY; COMPLEXES;
BINDING; FVIII; PREVENTION; MOLECULES; MUTATION; EPITOPE
AB The development of neutralizing anti-drug-antibodies to the Factor VIII protein-therapeutic is currently the most significant impediment to the effective management of hemophilia A. Common non-synonymous single nucleotide polymorphisms (ns-SNPs) in the F8 gene occur as six haplotypes in the human population (denoted H1 to H6) of which H3 and H4 have been associated with an increased risk of developing anti-drug antibodies. There is evidence that CD4+ T-cell response is essential for the development of anti-drug antibodies and such a response requires the presentation of the peptides by the MHC-class-II (MHC-II) molecules of the patient. We measured the binding and half-life of peptide-MHC-II complexes using synthetic peptides from regions of the Factor VIII protein where ns-SNPs occur and showed that these wild type peptides form stable complexes with six common MHC-II alleles, representing 46.5% of the North American population. Next, we compared the affinities computed by NetMHCIIpan, a neural network-based algorithm for MHC-II peptide binding prediction, to the experimentally measured values and concluded that these are in good agreement (area under the ROC-curve of 0.778 to 0.972 for the six MHC-II variants). Using a computational binding predictor, we were able to expand our analysis to (a) include all wild type peptides spanning each polymorphic position; and (b) consider more MHC-II variants, thus allowing for a better estimation of the risk for clinical manifestation of anti-drug antibodies in the entire population (or a specific sub-population). Analysis of these computational data confirmed that peptides which have the wild type sequence at positions where the polymorphisms associated with haplotypes H3, H4 and H5 occur bind MHC-II proteins significantly more than a negative control. Taken together, the experimental and computational results suggest that wild type peptides from polymorphic regions of FVIII constitute potential T-cell epitopes and thus could explain the increased incidence of anti-drug antibodies in hemophilia A patients with haplotypes H3 and H4.
C1 [Pandey, Gouri Shankar; Sauna, Zuben E.] US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA.
[Yanover, Chen] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA.
[Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA.
RP Pandey, GS (reprint author), US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA.
EM zuben.sauna@fda.hhs.gov
RI Yanover, Chen/A-3754-2012
OI Yanover, Chen/0000-0003-3663-4286
FU Food and Drug Administration's Modernization of Science program;
National Heart, Lung and Blood Institute, NIH [1RC2-HL101851, HL-71130,
HL-72533]; Bayer Healthcare Corporation, Bayer Haemophilia Awards
Program; Baxter Healthcare Corporation; Clinical Translational Science
Institute at the University of Southern California's Keck School of
Medicine
FX This work was supported by the Food and Drug Administration's
Modernization of Science program to ZES. Research conducted in the
laboratory of TEH is funded by grants from the National Heart, Lung and
Blood Institute, NIH (1RC2-HL101851, HL-71130 and HL-72533) as well as
from Bayer Healthcare Corporation, Bayer Haemophilia Awards Program,
Baxter Healthcare Corporation, and the Clinical Translational Science
Institute at the University of Southern California's Keck School of
Medicine. The funders had no role in study design, data collection and
analysis, decision to publish or preparation of the manuscript.
NR 30
TC 9
Z9 9
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD MAY
PY 2013
VL 9
IS 5
AR e1003066
DI 10.1371/journal.pcbi.1003066
PG 11
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 159FX
UT WOS:000320032100027
PM 23696725
ER
PT J
AU Donovan, DM
Ingalsbe, MH
Benbow, J
Daley, DC
AF Donovan, Dennis M.
Ingalsbe, Michelle H.
Benbow, James
Daley, Dennis C.
TI 12-Step Interventions and Mutual Support Programs for Substance Use
Disorders: An Overview
SO SOCIAL WORK IN PUBLIC HEALTH
LA English
DT Review
DE 12-Step; mutual support; self-help; recovery activities
ID SELF-HELP GROUPS; ALCOHOLICS-ANONYMOUS PARTICIPATION; DUALLY DIAGNOSED
PERSONS; ONE-YEAR OUTCOMES; GROUP INVOLVEMENT; FACILITATING INVOLVEMENT;
ADDICTION TREATMENT; INITIAL VALIDATION; SOCIAL NETWORKS; ABUSE
TREATMENT
AB Social workers and other behavioral health professionals are likely to encounter individuals with substance use disorders in a variety of practice settings outside of specialty treatment. 12-Step mutual support programs represent readily available, no cost community-based resources for such individuals; however, practitioners are often unfamiliar with such programs. The present article provides a brief overview of 12-Step programs, the positive substance use and psychosocial outcomes associated with active 12-Step involvement, and approaches ranging from ones that can be utilized by social workers in any practice setting to those developed for specialty treatment programs to facilitate engagement in 12-Step meetings and recovery activities. The goal is to familiarize social workers with 12-Step approaches so that they are better able to make informed referrals that match clients to mutual support groups that best meet the individual's needs and maximize the likelihood of engagement and positive outcomes.
C1 [Donovan, Dennis M.; Ingalsbe, Michelle H.] Univ Washington, Alcohol & Drug Abuse Inst, Seattle, WA 98105 USA.
[Donovan, Dennis M.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98105 USA.
[Benbow, James] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Daley, Dennis C.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Med Ctr, Pittsburgh, PA 15213 USA.
RP Donovan, DM (reprint author), Univ Washington, Alcohol & Drug Abuse Inst, 1107 NE 45th St,Suite 120, Seattle, WA 98105 USA.
EM ddonovan@u.washington.edu
FU NIDA NIH HHS [U10 DA013714, U10 DA020036]
NR 122
TC 10
Z9 10
U1 5
U2 28
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1937-1918
J9 SOC WORK PUBLIC HLTH
JI Soc. Work Public Health
PD MAY 1
PY 2013
VL 28
IS 3-4
SI SI
BP 313
EP 332
DI 10.1080/19371918.2013.774663
PG 20
WC Public, Environmental & Occupational Health; Social Work
SC Public, Environmental & Occupational Health; Social Work
GA 161GI
UT WOS:000320180100013
PM 23731422
ER
PT J
AU Brady, KT
Haynes, LF
Hartwell, KJ
Killeen, TK
AF Brady, Kathleen T.
Haynes, Louise F.
Hartwell, Karen J.
Killeen, Therese K.
TI Substance Use Disorders and Anxiety: A Treatment Challenge for Social
Workers
SO SOCIAL WORK IN PUBLIC HEALTH
LA English
DT Article
DE Anxiety; substance use disorders; comorbidity; treatment
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY;
PLACEBO-CONTROLLED TRIAL; COMORBIDITY SURVEY REPLICATION;
COCAINE-DEPENDENT INDIVIDUALS; RANDOMIZED CONTROLLED-TRIAL;
MENTAL-HEALTH PROBLEMS; DSM-IV DISORDERS; ALCOHOL DEPENDENCE; PANIC
DISORDER
AB Converging evidence from epidemiologic and treatment studies indicate that anxiety disorders and substance use disorders commonly co-occur, and the interaction is multifaceted and variable. Epidemiological studies and investigations within clinical substance abuse populations have found an association between anxiety disorders and substance use disorders. Specific anxiety disorders including generalized anxiety disorder, panic disorder, and post traumatic stress disorder have all been associated with substance use. The association with obsessive-compulsive disorder is less robust, and some research has found a negative association. The risk of nicotine dependence is significantly higher among individuals with an anxiety disorder, and conversely, smoking has been found to be associated with trait anxiety and anxiety disorders. A review of the current literature and the relationship between specific anxiety disorders and alcohol and substance use disorders is discussed in detail. This article, written for social workers in a variety of practice settings, reviews the prevalence, diagnostic, and treatment issues at the interface of substance use disorders and anxiety disorders.
C1 [Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, Charleston, SC 29425 USA.
[Brady, Kathleen T.; Hartwell, Karen J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Haynes, Louise F.] Med Univ S Carolina, Div Neurosci, Charleston, SC 29425 USA.
[Hartwell, Karen J.; Killeen, Therese K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Brady, KT (reprint author), Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, 67 President St, Charleston, SC 29425 USA.
EM bradyk@musc.ed
FU NIDA NIH HHS [U10 DA013727]
NR 94
TC 1
Z9 2
U1 8
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1937-1918
EI 1937-190X
J9 SOC WORK PUBLIC HLTH
JI Soc. Work Public Health
PD MAY 1
PY 2013
VL 28
IS 3-4
SI SI
BP 407
EP 423
DI 10.1080/19371918.2013.774675
PG 17
WC Public, Environmental & Occupational Health; Social Work
SC Public, Environmental & Occupational Health; Social Work
GA 161GI
UT WOS:000320180100019
PM 23731428
ER
PT J
AU Roy, N
Barkmeier-Kraemer, J
Eadie, T
Sivasankar, MP
Mehta, D
Paul, D
Hillman, R
AF Roy, Nelson
Barkmeier-Kraemer, Julie
Eadie, Tanya
Sivasankar, M. Preeti
Mehta, Daryush
Paul, Diane
Hillman, Robert
TI Evidence-Based Clinical Voice Assessment: A Systematic Review
SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY
LA English
DT Review
DE voice disorders; assessment; technology; diagnostics
ID AUDITORY-PERCEPTUAL EVALUATION; DYSPHONIC VOICE; PATHOLOGY; SPEECH;
DISCRIMINATION; PARAMETERS; ACCURACY; MEDICINE; PROTOCOL
AB Purpose: To determine what research evidence exists to support the use of voice measures in the clinical assessment of patients with voice disorders.
Method: The American Speech-Language-Hearing Association (ASHA) National Center for Evidence-Based Practice in Communication Disorders staff searched 29 databases for peer-reviewed English-language articles between January 1930 and April 2009 that included key words pertaining to objective and subjective voice measures, voice disorders, and diagnostic accuracy. The identified articles were systematically assessed by an ASHA-appointed committee employing a modification of the critical appraisal of diagnostic evidence rating system.
Results: One hundred articles met the search criteria. The majority of studies investigated acoustic measures (60%) and focused on how well a test method identified the presence or absence of a voice disorder (78%). Only 17 of the 100 articles were judged to contain adequate evidence for the measures studied to be formally considered for inclusion in clinical voice assessment.
Conclusion: Results provide evidence for selected acoustic, laryngeal imaging-based, auditory-perceptual, functional, and aerodynamic measures to be used as effective components in a clinical voice evaluation. However, there is clearly a pressing need for further high-quality research to produce sufficient evidence on which to recommend a comprehensive set of methods for a standard clinical voice evaluation.
C1 [Roy, Nelson] Univ Utah, Salt Lake City, UT USA.
[Barkmeier-Kraemer, Julie] Univ Calif Davis, Sacramento, CA 95817 USA.
[Eadie, Tanya] Univ Washington, Seattle, WA 98195 USA.
[Sivasankar, M. Preeti] Purdue Univ, W Lafayette, IN 47907 USA.
[Mehta, Daryush; Hillman, Robert] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Paul, Diane] Amer Speech Language Hearing Assoc, Rockville, MD USA.
[Hillman, Robert] Harvard Univ, Sch Med, Boston, MA USA.
RP Mehta, D (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM daryush.mehta@alum.mit.edu
OI Eadie, Tanya/0000-0002-7697-1298
FU Special Interest Group 3, Voice and Voice Disorders, of the American
Speech-Language-Hearing Association (ASHA)
FX This systematic review was developed by the Ad Hoc Working Group for
Clinical Voice Assessment under the auspices of Special Interest Group
3, Voice and Voice Disorders, of the American Speech-Language-Hearing
Association (ASHA). The authors thank Leigh Deussing of ASHA for her
support in developing the CADE-M form and for feedback during the review
process. We thank Lauren Pecora and Kristin Slagle for their help with
data transcription and transfer. We would also like to thank National
Center for Evidence-Based Practice in Communication Disorders' staff
members Tracy Schooling, Hillary Leech, and Rebecca Venediktov for their
invaluable assistance with the literature review.
NR 43
TC 37
Z9 39
U1 1
U2 10
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1058-0360
J9 AM J SPEECH-LANG PAT
JI Am. J. Speech-Lang. Pathol.
PD MAY 1
PY 2013
VL 22
IS 2
BP 212
EP 226
DI 10.1044/1058-0360(2012/12-0014)
PG 15
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 156LD
UT WOS:000319822600023
PM 23184134
ER
PT J
AU Mark, EJ
Oliva, E
Young, RH
AF Mark, Eugene J.
Oliva, Esther
Young, Robert H.
TI Robert E. Scully, MD In Memoriam
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Biographical-Item
C1 [Mark, Eugene J.; Oliva, Esther; Young, Robert H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Mark, EJ (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD MAY
PY 2013
VL 137
IS 5
BP 599
EP 600
DI 10.5858/arpa.2012-0724-IM
PG 2
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA 155WF
UT WOS:000319778400001
ER
PT J
AU St Denis, TG
Hamblin, MR
AF St Denis, Tyler G.
Hamblin, Michael R.
TI Synthesis, bioanalysis and biodistribution of photosensitizer conjugates
for photodynamic therapy
SO BIOANALYSIS
LA English
DT Review
ID GROWTH-FACTOR RECEPTOR; OVARIAN-CANCER CELLS; RADIOLABELED
MONOCLONAL-ANTIBODIES; IN-VIVO; IMMUNOREACTIVE FRACTION;
CARCINOMA-CELLS; SELECTIVE PHOTODESTRUCTION; CARCINOEMBRYONIC ANTIGEN;
TARGETED PHOTOLYSIS; PHOTOIMMUNOTHERAPY
AB Photodynamic therapy (PDT) was discovered in 1900 by Raab, and has since emerged as a promising tool for treating diseases characterized by unwanted cells or hyperproliferating tissue (e.g., cancer or infectious disease). PDT consists of the light excitation of a photosensitizer (PS) in the presence of O-2 to yield highly reactive oxygen species. In recent years, PDT has been improved by the synthesis of targeted bioconjugates between monoclonal antibodies and PS, and by investigating PS biodistribution and PD. Here, we provide a comprehensive review of major developments in PS-immunoconjugate-based PDT and the bioanalysis of these agents, with a specific emphasis on anticancer and antimicrobial PDT.
C1 [St Denis, Tyler G.] Columbia Univ, Dept Chem, New York, NY 10027 USA.
[St Denis, Tyler G.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard MIT Dept Hlth Sci & Technol, Cambridge, MA USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU Columbia University II Rabi Fellowship; NIH [R01A1050875]
FX Research conducted by TG St Denis is supported by the Columbia
University II Rabi Fellowship. Research in the Hamblin laboratory is
supported by NIH R01A1050875. There was no involvement of the funders in
the design or writing of the work. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
NR 69
TC 14
Z9 14
U1 0
U2 45
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1757-6180
J9 BIOANALYSIS
JI Bioanalysis
PD MAY
PY 2013
VL 5
IS 9
BP 1099
EP 1114
DI 10.4155/BIO.13.37
PG 16
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 158FR
UT WOS:000319955400016
PM 23641699
ER
PT J
AU Singh, H
Lane, AA
Correll, M
Przychodzen, B
Sykes, DB
Stone, RM
Ballen, KK
Amrein, PC
Maciejewski, J
Attar, EC
AF Singh, H.
Lane, A. A.
Correll, M.
Przychodzen, B.
Sykes, D. B.
Stone, R. M.
Ballen, K. K.
Amrein, P. C.
Maciejewski, J.
Attar, E. C.
TI Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in
pathogenesis of myeloid malignancies
SO BLOOD CANCER JOURNAL
LA English
DT Letter
ID MYELODYSPLASTIC SYNDROMES; DNMT3A MUTATIONS; LEUKEMIA GENOME; MACHINERY;
PATHWAY
C1 [Singh, H.; Ballen, K. K.; Amrein, P. C.; Attar, E. C.] Massachusetts Gen Hosp, Ctr Canc, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
[Singh, H.; Ballen, K. K.; Amrein, P. C.; Attar, E. C.] Massachusetts Gen Hosp, Ctr Canc, Ctr Leukaemia, Boston, MA 02114 USA.
[Lane, A. A.; Stone, R. M.] Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA.
[Correll, M.] Dana Farber Canc Inst, Ctr Canc Computat Biol, Boston, MA 02115 USA.
[Przychodzen, B.; Maciejewski, J.] Cleveland Clin, Dept Hematol, Cleveland, OH 44106 USA.
[Sykes, D. B.] Massachusetts Gen Hosp, Ctr Regenerat Med & Technol, Boston, MA 02114 USA.
RP Singh, H (reprint author), Massachusetts Gen Hosp, Ctr Canc, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
EM eattar@partners.org
NR 15
TC 6
Z9 6
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD MAY
PY 2013
VL 3
AR UNSP e117
DI 10.1038/bcj.2013.16
PG 3
WC Oncology
SC Oncology
GA 156FA
UT WOS:000319806000004
PM 23708642
ER
PT J
AU Brennan-Minnella, AM
Shen, Y
El-Benna, J
Swanson, RA
AF Brennan-Minnella, A. M.
Shen, Y.
El-Benna, J.
Swanson, R. A.
TI Phosphoinositide 3-kinase couples NMDA receptors to superoxide release
in excitotoxic neuronal death (vol 4, e580, 2013)
SO CELL DEATH & DISEASE
LA English
DT Correction
C1 [Brennan-Minnella, A. M.; Shen, Y.; Swanson, R. A.] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
[El-Benna, J.] Univ Paris Diderot, Fac Med, INSERM U773,CRB3, Lab Excellence Inflamex, Paris, France.
RP Brennan-Minnella, AM (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM angela.brennan@ucsf.edu
NR 1
TC 2
Z9 2
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY
PY 2013
VL 4
AR e624
DI 10.1038/cddis.2013.164
PG 1
WC Cell Biology
SC Cell Biology
GA 156LR
UT WOS:000319824100013
ER
PT J
AU Kim, AI
Han, SH
Tran, DT
Sullivan, P
Lassman, C
Raman, S
Zimmerman, P
Chin, EE
AF Kim, Andrew I.
Han, Steven-Huy
Doan-Trang Tran
Sullivan, Peggy
Lassman, Charles
Raman, Steve
Zimmerman, Peter
Chin, Eva E.
TI Abdominal imaging can misdiagnose submassive hepatic necrosis as
cirrhosis in acute liver failure
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE cirrhosis; computed tomography; fulminant hepatic failure;
transplantation; ultrasound
ID TOMOGRAPHY; SURVIVAL; DISEASE; CT
AB Patients with acute liver failure (ALF) can be listed status I for liver transplantation (LT) whereas patients with cirrhosis must follow the MELD scoring system. Liver imaging can mistakenly diagnose submassive hepatic necrosis in ALF as cirrhosis. The purpose of our study was to assess the accuracy of ultrasound (US) and computed tomography (CT) in distinguishing cirrhosis from ALF. All patients listed for ALF and transplanted during the study period were included. Controls were age- and gender-matched cirrhotic patients who underwent LT during the same period. Abdominal US or CT scans obtained on all patients were independently reviewed by three blinded abdominal radiologists. Explants from all patients were reviewed by two blinded pathologists, and histological diagnosis was correlated with radiological diagnosis. Forty-one patients with ALF and 42 patients with cirrhosis were analyzed. Univariate and multivariate analyses both revealed overall accuracy of 85% for ultrasound and 93% for CT. US and CT scans both provide high levels of accuracy in terms of discriminating ALF from cirrhosis but measures taken to determine whether a patient has ALF vs. cirrhosis needs to approach 100% accuracy. Thus, imaging studies alone should not definitively diagnosis one etiology of liver failure over the other.
C1 [Kim, Andrew I.; Doan-Trang Tran] Univ Calif Los Angeles, David Geffen Sch Med, Dept Gastroenterol, Los Angeles, CA 90095 USA.
[Kim, Andrew I.; Han, Steven-Huy] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Han, Steven-Huy] Univ Calif Los Angeles, David Geffen Sch Med, Pfleger Liver Inst, Los Angeles, CA 90095 USA.
[Sullivan, Peggy; Lassman, Charles] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.
[Raman, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
[Zimmerman, Peter; Chin, Eva E.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA 90073 USA.
[Zimmerman, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Chin, EE (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Dept Radiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM eva.chin@va.gov
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD MAY-JUN
PY 2013
VL 27
IS 3
BP E339
EP E345
DI 10.1111/ctr.12123
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 156OT
UT WOS:000319832700023
PM 23647426
ER
PT J
AU Hayes, D
Baker, PB
Astor, TL
Preston, TJ
Kirkby, S
Galantowicz, M
Hoffman, TM
AF Hayes, Don, Jr.
Baker, Peter B.
Astor, Todd L.
Preston, Thomas J.
Kirkby, Stephen
Galantowicz, Mark
Hoffman, Timothy M.
TI Aggressive Coronary Artery Vasculopathy after Combined Heart-Lung
Transplantation
SO CONGENITAL HEART DISEASE
LA English
DT Article
DE Allograft Rejection; Bronchiolitis Obliterans Syndrome; Combined Heart
and Lung Transplantation; Coronary Artery Vasculopathy
AB Combined heart-lung transplantation remains as a treatment option for patients with cardiopulmonary failure. There is speculation that lung grafts protect the heart from developing graft vasculopathy after combined heart-lung transplantation. This protective mechanism is more likely, at best, a delay in the onset of coronary artery vasculopathy. We present our experiences in two cases of an aggressive form of cardiac allograft vasculopathy after combined heart-lung transplantation that resulted in the death of both patients.
C1 [Hayes, Don, Jr.; Baker, Peter B.; Kirkby, Stephen; Galantowicz, Mark; Hoffman, Timothy M.] Nationwide Childrens Hosp, Columbus, OH USA.
[Hayes, Don, Jr.; Baker, Peter B.; Preston, Thomas J.; Kirkby, Stephen; Galantowicz, Mark; Hoffman, Timothy M.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
[Astor, Todd L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Hayes, D (reprint author), Ohio State Univ, Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.
EM hayes.705@osu.edu
RI Hoffman, Timothy/E-3253-2011;
OI Hoffman, Timothy/0000-0001-7715-8197
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-079X
J9 CONGENIT HEART DIS
JI Congenit. Heart Dis.
PD MAY-JUN
PY 2013
VL 8
IS 3
BP E88
EP E91
DI 10.1111/j.1747-0803.2012.00681.x
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 158ST
UT WOS:000319993900007
PM 22676698
ER
PT J
AU Cyganek, K
Hebda-Szydlo, A
Skupien, J
Janas, I
Walczyk, J
Lipowska, A
Borys, S
Malecki, MT
AF Cyganek, Katarzyna
Hebda-Szydlo, Alicja
Skupien, Jan
Janas, Izabela
Walczyk, Joanna
Lipowska, Anna
Borys, Sebastian
Malecki, Maciej T.
TI Postpregnancy Glycemic Control and Weight Changes in Type 1 Diabetic
Women
SO DIABETES CARE
LA English
DT Article
ID SUBCUTANEOUS INSULIN INFUSION; PREGNANCY OUTCOMES; IMPACT
AB OBJECTIVE-Pregnancy in type 1 diabetes requires excellent glycemic control. Most pregnant type 1 diabetic women achieve normoglycemia; however, there is scarce data on their postdelivery characteristics. We aimed to examine postpregnancy glycemic control and weight changes in type 1 diabetes.
RESEARCH DESIGN AND METHODS-We identified and followed (median 20 months) 254 women with singleton pregnancies receiving postdelivery medical care at a single institution.
RESULTS-Study subjects were 28.3 +/- 4.7 years of age (mean +/- SD), with a diabetes duration of 12.0 +/- 7.7 years. Mean A1C before conception was 6.9 +/- 1.4%, and preconception weight and BMI were 64.4 +/- 10.0 kg and 23.9 +/- 3.3 kg/m(2), respectively. Mean A1C decreased during pregnancy, reaching 5.7 +/- 0.8% in the third trimester. We observed a mean weight gain of 14.4 +/- 6.5 kg during pregnancy. Within 6 months after delivery, A1C increased by 0.8% (P < 0.0001) compared with the last trimester, and body weight and BMI were 4.4 kg and 2.5 kg/m(2) higher (P < 0.0001) compared with the preconception baseline. A1C further deteriorated by 0.8% until the end of follow-up. For women in the "pregnancy planning" program (n = 117), A1C > 12 months after delivery was Worse compared with before conception (7.1 vs. 6.5%, P = 0.0018), whereas in women with unplanned pregnancies, it was similar to the pregestational levels (7.3 vs.7.4%, P = 0.59). Weight and BMI in the entire study group did not return to prepregnancy levels and were 2.5 kg (P = 0.0079) and 0.9 kg/m(2) higher (P = 0.0058).
CONCLUSIONS-In this clinical observation, type 1 diabetic women showed postpregnancy deterioration in glycemic control and were unable to return to prepregnancy weight. Type 1 diabetic women seem to require special attention after delivery to meet therapeutic targets.
C1 [Cyganek, Katarzyna; Hebda-Szydlo, Alicja; Janas, Izabela; Walczyk, Joanna; Borys, Sebastian; Malecki, Maciej T.] Univ Hosp, Krakow, Poland.
[Skupien, Jan] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA.
[Lipowska, Anna] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Malecki, Maciej T.] Jagiellonian Univ, Coll Med, Dept Metab Dis, Krakow, Poland.
RP Malecki, MT (reprint author), Univ Hosp, Krakow, Poland.
EM malecki_malecki@yahoo.cm
FU Polish Ministry of Science [N N407 414436]; Jagiellonian University
Medical College
FX This work was supported by the Polish Ministry of Science (Grant N N407
414436) and by the Jagiellonian University Medical College.
NR 12
TC 5
Z9 5
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2013
VL 36
IS 5
BP 1083
EP 1087
DI 10.2337/dc12-1340
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155WW
UT WOS:000319782100004
PM 23250804
ER
PT J
AU Morrison, F
Shubina, M
Goldberg, SI
Turchin, A
AF Morrison, Fritha
Shubina, Maria
Goldberg, Saveli I.
Turchin, Alexander
TI Performance of Primary Care Physicians and Other Providers on Key
Process Measures in the Treatment of Diabetes
SO DIABETES CARE
LA English
DT Article
ID BLOOD-PRESSURE; HEALTH-CARE; TREATMENT INTENSIFICATION; BONFERRONI
PROCEDURE; ENCOUNTER FREQUENCY; COMORBIDITY INDEX; GLYCEMIC CONTROL;
QUALITY-MEASURES; MULTIPLE TESTS; CONTINUITY
AB OBJECTIVE-Studies have shown that patients without a consistent primary care provider have inferior outcomes. However, little is known about the mechanisms for these effects. This study aims to determine whether primary care physicians (PCPs) provide more frequent medication intensification, lifestyle counseling, and patient encounters than other providers in the primary care setting.
RESEARCH DESIGN AND METHODS-This retrospective cohort study included 584,587 encounters for 27,225 patients with diabetes and elevated A1C, blood pressure, and/or LDL cholesterol monitored for at least 2 years. Encounters occurred at primary care practices affiliated with two teaching hospitals in eastern Massachusetts.
RESULTS-Of the encounters documented, 83% were with PCPs, 13% were with covering physicians, and 5% were with midlevel providers. In multivariable analysis, the odds of medication intensification were 49% (P < 0.0001) and 26% (P < 0.0001) higher for PCPs than for covering physicians and midlevel providers, respectively, whereas the odds of lifestyle counseling were 91% (P < 0.0001) and 21% (P = 0.0015) higher. During visits with acute complaints, covering physicians were even less likely, by a further 52% (P < 0.0001), to intensify medications, and midlevel providers were even less likely, by a further 41% (P < 0.0001), to provide lifestyle counseling. Compared with PCPs, the hazard ratios for time to the next encounter after a visit without acute complaints were 1.11 for covering physicians and 1.19 for midlevel providers (P < 0.0001 for both).
CONCLUSIONS-PCPs provide better care through higher rates of medication intensification and lifestyle counseling. Covering physicians and midlevel providers may enable more frequent encounters when PCP resources are constrained.
C1 [Morrison, Fritha; Shubina, Maria; Turchin, Alexander] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Goldberg, Saveli I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Turchin, Alexander] Harvard Univ, Sch Med, Boston, MA USA.
[Turchin, Alexander] Partners HealthCare Syst, Qual Performance Management, Boston, MA USA.
RP Turchin, A (reprint author), Brigham & Womens Hosp, Div Endocrinol, 75 Francis St, Boston, MA 02115 USA.
EM aturchin@partners.org
FU Agency for Healthcare Research and Quality [5RI8HS017030]; National
library of Medicine [5RCILM010460]; Diabetes Action Research and
Education Foundation
FX This study was supported in part by grants from the Agency for
Healthcare Research and Quality (5RI8HS017030), the National library of
Medicine (5RCILM010460), and the Diabetes Action Research and Education
Foundation. The funding sources had no role in the design and conduct of
the study, collection, management, analysis, or interpretation of the
study or in the preparation, review, or approval of the manuscript.
NR 48
TC 6
Z9 7
U1 2
U2 12
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2013
VL 36
IS 5
BP 1147
EP 1152
DI 10.2337/dc12-1382
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155WW
UT WOS:000319782100015
PM 23230095
ER
PT J
AU Jensen, MK
Bartz, TM
Mukamal, KJ
Djousse, L
Kizer, JR
Tracy, RP
Zieman, SJ
Rimm, EB
Sscovick, DS
Shlipak, M
Ix, JH
AF Jensen, Majken K.
Bartz, Traci M.
Mukamal, Kenneth J.
Djousse, Luc
Kizer, Jorge R.
Tracy, Russell P.
Zieman, Susan J.
Rimm, Eric B.
Siscovick, David S.
Shlipak, Michael
Ix, Joachim H.
TI Fetuin-A, Type 2 Diabetes, and Risk of Cardiovascular Disease in Older
Adults The Cardiovascular Health Study
SO DIABETES CARE
LA English
DT Article
ID ALPHA(2)-HEREMANS-SCHMID GLYCOPROTEIN/FETUIN-A; RECEPTOR TYROSINE
KINASE; INSULIN-RESISTANCE; ASSOCIATION; INHIBITOR; SERUM;
CALCIFICATION; MORTALITY; DIALYSIS; MELLITUS
AB OBJECTIVE-Fetuin-A, a hepatic secretory protein that simultaneously inhibits arterial calcification and insulin action, is associated with type 2 diabetes, but its association with cardiovascular disease (CVD) is uncertain. Preliminary studies suggest that the association of fetuin-A with CVD might differ among individuals with or without type 2 diabetes.
RESEARCH DESIGN AND METHODS-This was a prospective study of 3,810 community-living individuals older than 65 years (511 with type 2 diabetes) and free of CVD in 1992 when fetuin-A levels were measured. Participants were followed-up for incident CVD through June 2008.
RESULTS-Mean age was 75 years, and 61% were women; 1,456 participants had an incident CVD event (248 among individuals with type 2 diabetes). The association of fetuin-A with CVD was modified by type 2 diabetes (P interaction = 0.02). Higher fetuin-A was associated with lower CVD risk among persons without type 2 diabetes [hazard ratio per SD 0.1 g/L higher fetuin-A, 0.93 (95% Cl, 0.88-0.99)], whereas a trend in the opposite direction was observed among individuals with type 2 diabetes, although it was not statistically significant [1.07 (0.93 1.22)]. Among individuals without type 2 diabetes, similar effect modification was observed by obesity and insulin resistance. Consistently, higher fetuin-A was associated with lower CVD risk only in the subgroups without obesity or with HOMA-IR below the median [0.91 (0.85-0.97) and 0.87 (0.79-0.95), respectively].
CONCLUSIONS-The association of fetuin-A with risk of CVD differs among elderly individuals with and without insulin resistance or type 2 diabetes.
C1 [Jensen, Majken K.; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Bartz, Traci M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Djousse, Luc] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Aging, Boston, MA USA.
[Djousse, Luc] Boston Vet Affairs Healthcare Syst, Boston, MA USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Populat Hlth, Bronx, NY 10467 USA.
[Tracy, Russell P.] Univ Vermont, Colchester Res Facil, Dept Pathol, Colchester, VT USA.
[Zieman, Susan J.] NIA, NIH, Bethesda, MD 20892 USA.
[Rimm, Eric B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA.
[Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Shlipak, Michael] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Shlipak, Michael] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Ix, Joachim H.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Prevent Med, San Diego, CA 92103 USA.
RP Jensen, MK (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM mkjensen@hsph.harvard.edu
RI Djousse, Luc/F-5033-2017
OI Djousse, Luc/0000-0002-9902-3047
FU National Heart, Lung, and Blood Institute (NHLBI) [R01 HL094555]; NHLBI
[N01 HC-85079, N01 HC-85080, N01 HC-85081, N01 HC-85082, N01 HC-85083,
N01 HC-85084, N01 HC-85085, N01HC-85086, N01-HC-35129, N01 HC-15103, N01
HC-55222, N01 HC-75150, N01 HC-54133, N01-HC85239, U01 HL080295]
FX The study was supported by a National Heart, Lung, and Blood Institute
(NHLBI) grant (R01 HL094555). The CHS was supported by contract numbers
N01 HC-85079 through N01HC-85086, N01-HC-35129, N01 HC-15103, N01
HC-55222, N01 HC-75150, N01 HC-54133, and N01-HC85239, and grant number
U01 HL080295 from the NHLBI, with additional contributions from the
National Institute of Neurologic Disorders and Stroke. This material is
the result of work supported with resources of the VA San Diego
Healthcare System.
NR 31
TC 39
Z9 41
U1 1
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2013
VL 36
IS 5
BP 1222
EP 1228
DI 10.2337/dc12-1591
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155WW
UT WOS:000319782100026
PM 23250801
ER
PT J
AU Hayashi, T
Boyko, EJ
Sato, KK
McNeely, MJ
Leonetti, DL
Kahn, SE
Fujimoto, WY
AF Hayashi, Tomoshige
Boyko, Edward J.
Sato, Kyoko Kogawa
McNeely, Marguerite J.
Leonetti, Donna L.
Kahn, Steven E.
Fujimoto, Wilfred Y.
TI Patterns of Insulin Concentration During the OGTT Predict the Risk of
Type 2 Diabetes in Japanese Americans
SO DIABETES CARE
LA English
DT Article
ID IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL DYSFUNCTION; FASTING GLUCOSE;
RESISTANCE; SENSITIVITY; SECRETION; CLAMP; MODEL; MEN
AB OBJECTIVE-To examine whether the patterns of insulin concentration during the oral glucose tolerance test (OGTT) predict type 2 diabetes.
RESEARCH DESIGN AND METHODS-We followed 400 nondiabetic Japanese Americans for 10-11 years. Insulin concentrations at 30, 60, and 120 min during a 2-h 75-g OGTT at baseline were used to derive the following possible patterns of insulin: pattern 1 (30-min peak, higher insulin level at 60 than at 120 min), pattern 2 (30-min peak, lower or equal level at 60 vs. 120 min), pattern 3 (60-min peak); pattern 4 (120-mm peak, lower level at 30 than at 60 min), and pattern 5 (120-min peak, equal or higher level at 30 vs. 60 mm). Insulin sensitivity was estimated by homeostasis model assessment of insulin resistance (HOMA-IR) and Matsuda index. Insulin secretion was estimated by the insulinogenic index (IGI) [Delta insulin/Delta glucose (30-0 min)] and disposition index (IGI/HOMA-IR).
RESULTS-There were 86 incident cases of type 2 diabetes. The cumulative incidence was 3.2, 9.8, 15.4, 47.8, and 37.5% for patterns 1, 2, 3, 4, and 5, respectively. Compared with pattern 1, patterns 4 and 5, characterized by a lasting late insulin response, were associated with significantly less insulin sensitivity as measured by the Matsuda index and lower early insulin response by the disposition index. The multiple-adjusted odds ratios of type 2 diabetes were 12.55 (95% Cl 4.79-32.89) for pattern 4 and 8.34(2.38-29.27) for patterns compared with patterns 1 and 2. This association was independent of insulin secretion and sensitivity.
CONCLUSIONS-The patterns of insulin concentration during an OGTT strongly predict the development of type 2 diabetes.
C1 [Hayashi, Tomoshige; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Hayashi, Tomoshige; Sato, Kyoko Kogawa] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 558, Japan.
[Boyko, Edward J.; McNeely, Marguerite J.; Fujimoto, Wilfred Y.] Univ Washington, Dept Med, Seattle, WA USA.
[Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
[Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
RP Boyko, EJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
EM eboyko@u.washington.edu
RI Hayashi, Tomoshige/N-8508-2015;
OI Kahn, Steven/0000-0001-7307-9002
FU National Institutes of Health [DK-31170, HL-49293, DK-02654]; Japanese
Ministry of Education, Science, Sports, and Culture [23390177]; King
County Japanese-American community
FX This work was supported by National Institutes of Health grants
DK-31170, HL-49293, and DK-02654; facilities and services were provided
by the Diabetes and Endocrinology Research Center (DK-17047), Clinical
Nutrition Research Unit (DK-35816), and the General Clinical Research
Center (RR-00037) at the University of Washington. T.H. was supported in
part by a research grant from the Japanese Ministry of Education,
Science, Sports, and Culture (23390177). VA Puget Sound Health Care
System provided support for the participation of E.J.B. and S.E.K.; The
authors gratefully acknowledge the skilled assistance of staff members,
especially Jane B. Shofer of the Center for Studies in Demography and
Ecology, University of Washington. The authors are grateful to the King
County Japanese-American community for their support and cooperation.
NR 20
TC 10
Z9 10
U1 0
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2013
VL 36
IS 5
BP 1229
EP 1235
DI 10.2337/dc12-0246
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155WW
UT WOS:000319782100027
PM 23275353
ER
PT J
AU Franks, PW
Pearson, E
Florez, JC
AF Franks, Paul W.
Pearson, Ewan
Florez, Jose C.
TI Gene-Environment and Gene-Treatment Interactions in Type 2 Diabetes
SO DIABETES CARE
LA English
DT Review
ID BODY-MASS INDEX; IMPAIRED GLUCOSE-TOLERANCE; GENOME-WIDE ASSOCIATION;
LIFE-STYLE INTERVENTION; DIETARY-FAT INTAKE; PREVENTION PROGRAM;
PHYSICAL-ACTIVITY; INSULIN-RESISTANCE; FASTING GLUCOSE; GLYCEMIC TRAITS
C1 [Franks, Paul W.] Lund Univ, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden.
[Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Pearson, Ewan] Univ Dundee, Med Res Inst, Div Cardiovasc & Diabet Med, Dundee, Scotland.
[Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Diabet Res Ctr, Diabet Unit, Dept Med, Boston, MA 02114 USA.
[Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Florez, Jose C.] Broad Inst Harvard & Massachusetts Inst Technol, Program Med & Populat Genet, Cambridge, MA USA.
RP Franks, PW (reprint author), Lund Univ, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden.
EM paul.franks@med.lu.se
FU Excellence in Diabetes Research in Sweden (EXODIAB); Lund University;
Umea University; Region Skane Health Authority; Swedish Diabetes
Association; Swedish Heart-Lung Foundation; Swedish Research Council;
European Union; Novo Nordisk; National Institutes of Health (National
Institute of Child Health and Human Development); National Institute of
Diabetes and Digestive and Kidney Diseases [R01 DK-072041, R01
DK-088214.A1]
FX P.W.F. is funded by Excellence in Diabetes Research in Sweden (EXODIAB),
Lund University, Umea University, Region Skane Health Authority, the
Swedish Diabetes Association, the Swedish Heart-Lung Foundation, the
Swedish Research Council, the European Union, Novo Nordisk, and the
National Institutes of Health (National Institute of Child Health and
Human Development). J.C.F. is supported by National Institute of
Diabetes and Digestive and Kidney Diseases Grants R01 DK-072041 and R01
DK-088214.A1.
NR 68
TC 37
Z9 38
U1 0
U2 9
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2013
VL 36
IS 5
BP 1413
EP 1421
DI 10.2337/dc12-2211
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 155WW
UT WOS:000319782100053
PM 23613601
ER
PT J
AU Abramson, JS
AF Abramson, Jeremy S.
TI High-dose chemotherapy and autologous stem cell transplantation for
secondary central nervous system lymphoma: many are called, but few are
chosen
SO HAEMATOLOGICA
LA English
DT Editorial Material
ID NON-HODGKIN-LYMPHOMA; PRIMARY CNS LYMPHOMA; ELDERLY-PATIENTS; RECURRENT
CNS; RISK-FACTORS; FOLLOW-UP; RITUXIMAB; TRIAL; RELAPSE; LENALIDOMIDE
C1 [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA.
[Abramson, Jeremy S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Abramson, JS (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA.
EM jabramson@partners.org
NR 21
TC 1
Z9 1
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD MAY
PY 2013
VL 98
IS 5
BP 662
EP 664
DI 10.3324/haematol.2013.084285
PG 3
WC Hematology
SC Hematology
GA 157LX
UT WOS:000319898700007
PM 23633540
ER
PT J
AU Clapp, JD
Grubaugh, AL
Allen, JG
Mahoney, J
Oldham, JM
Fowler, JC
Ellis, T
Elhai, JD
Frueh, BC
AF Clapp, Joshua D.
Grubaugh, Anouk L.
Allen, Jon G.
Mahoney, Jane
Oldham, John M.
Fowler, J. Christopher
Ellis, Tom
Elhai, Jon D.
Frueh, B. Christopher
TI Modeling Trajectory of Depressive Symptoms Among Psychiatric Inpatients:
A Latent Growth Curve Approach
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID LENGTH-OF-STAY; INVENTORY-II; DECREASING LENGTH; HOSPITAL STAY;
UNITED-STATES; CARE; PSYCHOTHERAPY; OUTCOMES; ANTIDEPRESSANTS; DISORDERS
AB Objective: Changes in the parameters of inpatient psychiatric care have inspired a sizable literature exploring correlates of prolonged intervention as well as symptom change over varying lengths of hospitalization. However, existing data offer limited insight regarding the nature of symptom change over time. Objectives of this longitudinal research were to (1) model the trajectory of depressive symptoms within an inpatient psychiatric sample, (2) identify characteristics associated with unique patterns of change, and (3) evaluate the magnitude of expected gains using objective clinical benchmarks.
Method: Participants included 1,084 psychiatric inpatients treated between April 2008 and December 2010. Latent growth curve modeling was used to determine the trajectory of Beck Depression Inventory II depressive symptoms in response to treatment. Age, gender, trauma history, prior hospitalization, and DSM-IV diagnoses were examined as potential moderators of recovery.
Results: Results indicate a nonlinear model of recovery, with symptom reductions greatest following admission and slowing gradually over time. Female gender, probable trauma exposure, prior psychiatric hospitalization, and primary depressive diagnosis were associated with more severe trajectories. Diagnosis of alcohol/substance use, by contrast, was associated with more moderate trajectories. Objective benchmarks occurred relatively consistently across patient groups, with clinically significant change occurring between 2-4 weeks after admission.
Conclusions: The nonlinear trajectory of recovery observed in these data provides insight regarding the dynamics of inpatient recovery. Across all patient groups, symptom reduction was most dramatic in the initial week of hospitalization. However, notable improvement continued for several weeks after admission. Results suggest that timelines for adequate inpatient care are largely contingent on program-specific goals.
C1 [Clapp, Joshua D.; Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Grubaugh, Anouk L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Clapp, Joshua D.] Univ Wyoming, Dept Psychol, Laramie, WY 82071 USA.
[Allen, Jon G.; Mahoney, Jane; Oldham, John M.; Fowler, J. Christopher; Ellis, Tom] Menninger Clin, Houston, TX USA.
[Allen, Jon G.; Mahoney, Jane; Oldham, John M.; Fowler, J. Christopher; Ellis, Tom] Baylor Coll Med, Houston, TX 77030 USA.
[Ellis, Tom] Univ Toledo, Dept Psychol, Toledo, OH 43606 USA.
[Ellis, Tom] Univ Toledo, Dept Psychiat, Toledo, OH 43606 USA.
[Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA.
RP Clapp, JD (reprint author), Univ Wyoming, Dept Psychol, 1000 E Univ Ave, Laramie, WY 82071 USA.
EM jclapp@uwyo.edu
OI Ellis, Thomas/0000-0002-4496-5280
FU Menninger Foundation; McNair Medical Institute; National Institute of
Mental Health (NIMH); NIMH [T32 MH18869]
FX This research was supported in part by funding from the Menninger
Foundation, the McNair Medical Institute, and the National Institute of
Mental Health (NIMH). Dr Frueh is a McNair Scholar. Dr Clapp was a
NIMH-sponsored intern at the Medical University of South Carolina (T32
MH18869) during the development of this project.
NR 55
TC 12
Z9 12
U1 1
U2 10
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAY
PY 2013
VL 74
IS 5
BP 492
EP 499
DI 10.4088/JCP.12m07842
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 157IW
UT WOS:000319890800005
PM 23759452
ER
PT J
AU Bouchard, DR
Porneala, B
Janssen, I
Langlois, MF
Baillargeon, JP
Fox, CS
Meigs, JB
D'Agostino, RB
Pencina, M
Hivert, MF
AF Bouchard, Danielle R.
Porneala, Bianca
Janssen, Ian
Langlois, Marie-France
Baillargeon, Jean-Patrice
Fox, Caroline S.
Meigs, James B.
D'Agostino, Ralph B., Sr.
Pencina, Michael
Hivert, Marie-France
TI Risk of type 2 diabetes and cumulative excess weight exposure in the
Framingham Offspring Study
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Adults; Aging; BMI; Diagnosis; Epidemiology
ID OBESE WOMEN; PACK-YEAR; MELLITUS; DURATION; BMI; HYPERTENSION;
ASSOCIATION; PREVENTION; PREVALENCE; PATTERNS
AB Aim: Mid-life obesity is associated with T2D risk. However, less is known about the cumulative effect of obesity during adulthood.
Methods: Framingham Offspring Study participants who had an examination at 35 +/- 2 years and were initially free of T2D were included in this study (N=1026). A cumulative excess weight (CEW) score (year*kg/m(2)) was calculated until T2D diagnostic or the end of follow-up.
Results: Eighty-four individuals (8.2%) developed T2D over 20 +/- 6 years. Mean CEW scores were 118.+/- 114.6 year*kg/m(2) in individuals who developed T2D and 30.2 +/- 91.4 year*kg/m(2) in those who did not develop T2D (P<0.01). T2D risk was doubled for each standard deviation increase in the CEW score (OR=1.99 [1.64-2.40]; P<0.001). However, CEW score was only significantly associated with T2D incidence for participants with a baseline BMI<25 kg/m(2) (OR=2.13 [136-336]; P<0.001).
Conclusions: Accumulating weight between the mid-thirties to the mid-fifties increases the risk of developing T2D. However, BMI in mid-thirties remains a stronger predictor of T2D risk. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Bouchard, Danielle R.] Univ Manitoba, Fac Kinesiol & Recreat Management, Winnipeg, MB, Canada.
[Bouchard, Danielle R.] Hlth Leisure & Human Performance Res Inst, Winnipeg, MB, Canada.
[Porneala, Bianca] Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA.
[Janssen, Ian] Queens Univ, Dept Community Hlth Epidemiol, Kingston, ON, Canada.
[Janssen, Ian] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada.
[Langlois, Marie-France; Baillargeon, Jean-Patrice; Hivert, Marie-France] Univ Sherbrooke, Dept Med, Div Endocrinol, Sherbrooke, PQ J1K 2R1, Canada.
[Langlois, Marie-France; Baillargeon, Jean-Patrice; Hivert, Marie-France] CHU Sherbrooke, Etienne LeBel Clin Res Ctr, Sherbrooke, PQ J1H 5N4, Canada.
[Fox, Caroline S.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Fox, Caroline S.] Brigham Womens Hosp, Dept Endocrinol, Boston, MA USA.
[Meigs, James B.; Hivert, Marie-France] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA.
[D'Agostino, Ralph B., Sr.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Pencina, Michael] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
RP Hivert, MF (reprint author), Dept Med, Div Endocrinol, Sherbrooke, PQ J1H 5N4, Canada.
EM Marie-France.Hivert@USherbrooke.ca
RI Janssen, Ian/B-7700-2009
FU TheNational Heart, Lung, and Blood Institute (NHLBI); Fonds de Recherche
du Quebec-Sante (FRQ-S); Canadian Diabetes Association (CDA); FRQ-S;
NIDDK [K24 DK080140]
FX TheNational Heart, Lung, and Blood Institute (NHLBI) supported the
Framingham study. The NHLBI had no role in the design and conduct of the
study; the collection, analysis, and interpretation of the data; or the
preparation of the manuscript.; MFH is supported by a Scholar Award
(junior 1 level) from the Fonds de Recherche du Quebec-Sante (FRQ-S) and
was awarded a Canadian Diabetes Association (CDA) Clinician Scientist
award. MFL is the recipient of an FRQ-S National Researcher Award. JPB
is the recipient of an FRQ-S Senior Award. JBM is supported by NIDDK K24
DK080140.
NR 32
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAY-JUN
PY 2013
VL 27
IS 3
BP 214
EP 218
DI 10.1016/j.jdiacomp.2012.11.009
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 158YR
UT WOS:000320011600004
PM 23312789
ER
PT J
AU Brown, RT
Kiely, DK
Bharel, M
Mitchell, SL
AF Brown, Rebecca T.
Kiely, Dan K.
Bharel, Monica
Mitchell, Susan L.
TI Factors Associated with Geriatric Syndromes in Older Homeless Adults
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Homeless people; aged; middle aged; geriatric syndromes
ID MINI-MENTAL-STATE; TRAUMATIC BRAIN-INJURY; SERVICES TASK-FORCE;
RISK-FACTORS; SAN-FRANCISCO; HEALTH-STATUS; PRIMARY-CARE; ALCOHOL-USE;
POPULATION; FALLS
AB Although older homeless adults have high rates of geriatric syndromes, risk factors for these syndromes are not known. We used multivariable regression models to estimate the association of subject characteristics with the total number of geriatric syndromes in 250 homeless adults aged 50 years and older. Geriatric syndromes included falls, cognitive impairment, frailty, major depression, sensory impairment, and urinary incontinence. A higher total number of geriatric syndromes was associated with having less than a high school education, medical comorbidities (diabetes and arthritis), alcohol and drug use problems, and difficulty performing one or more activities of daily living. Clinicians who care for older homeless patients with these characteristics should consider screening them for geriatric syndromes. Moreover, this study identifies potentially modifiable risk factors associated with the total number of geriatric syndromes in older homeless adults. This knowledge may provide targets for clinical interventions to improve the health of older homeless patients.
C1 [Brown, Rebecca T.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Brown, Rebecca T.] San Francisco VA Med Ctr, San Francisco, CA 94122 USA.
[Kiely, Dan K.; Mitchell, Susan L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA.
[Bharel, Monica] Boston Healthcare Homeless Program, Boston, MA USA.
[Bharel, Monica] Boston Med Ctr, Dept Med, Boston, MA USA.
[Bharel, Monica] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Mitchell, Susan L.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA.
RP Brown, RT (reprint author), San Francisco VA Med Ctr, 4150 Clement St,181G, San Francisco, CA 94122 USA.
EM rebecca.brown@ucsf.edu
FU NIA NIH HHS [T32 AG023480, K24 AG033640, T32 AG000212]
NR 54
TC 6
Z9 6
U1 0
U2 8
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2013
VL 24
IS 2
BP 456
EP 468
PG 13
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 153VU
UT WOS:000319631400005
PM 23728022
ER
PT J
AU Doran, KM
Ragins, KT
Gross, CP
Zerger, S
AF Doran, Kelly M.
Ragins, Kyle T.
Gross, Cary P.
Zerger, Suzanne
TI Medical Respite Programs for Homeless Patients: A Systematic Review
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Review
DE Respite care; aftercare; subacute care; homeless people;
hospitalization; patient discharge
ID SHELTER-BASED CONVALESCENCE; CASE-MANAGEMENT PROGRAM; LENGTH-OF-STAY;
ADULTS; CARE; INTERVENTIONS; QUALITY; COSTS
AB Medical respite programs provide care to homeless patients who are too sick to be on the streets or in a traditional shelter, but not sick enough to warrant inpatient hospitalization. They are designed to improve the health of homeless patients while also decreasing costly hospital use. Although there is increasing interest in implementing respite programs, there has been no prior systematic review of their effectiveness. We conducted a comprehensive search for studies of medical respite program outcomes in multiple biomedical and sociological databases, and the grey literature. Thirteen articles met inclusion criteria. The articles were heterogeneous in methods, study quality, inclusion of a comparison group, and outcomes examined. Available evidence showed that medical respite programs reduced future hospital admissions, inpatient days, and hospital readmissions. They also resulted in improved housing outcomes. Results for emergency department use and costs were mixed but promising. Future research utilizing adequate comparison groups is needed.
C1 [Doran, Kelly M.; Gross, Cary P.] Yale Univ, Sch Med YU SOM, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
[Doran, Kelly M.] US Dept Vet Affairs, New Haven, CT 06520 USA.
[Zerger, Suzanne] Ctr Social Innovat, Needham, MA USA.
RP Doran, KM (reprint author), Yale Univ, Sch Med YU SOM, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
EM kelly.doran@yale.edu
NR 27
TC 11
Z9 11
U1 0
U2 10
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2013
VL 24
IS 2
BP 499
EP 524
PG 26
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 153VU
UT WOS:000319631400008
PM 23728025
ER
PT J
AU Renfrew, MR
Taing, E
Cohen, MJ
Betancourt, JR
Pasinski, R
Green, AR
AF Renfrew, Megan R.
Taing, Elizabeth
Cohen, Marya J.
Betancourt, Joseph R.
Pasinski, Roger
Green, Alexander R.
TI Barriers to Care for Cambodian Patients with Diabetes: Results from a
Qualitative Study
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Health care disparities; diabetes mellitus; type 2/diagnosis; culture;
cultural competence; health literacy; qualitative research; focus
groups; Cambodia ethnology; United States
ID SOUTHEAST-ASIAN REFUGEES; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH;
ETHNIC DISPARITIES; UNITED-STATES; CLINICAL CARE; WEIGHT CHANGE;
RISK-FACTOR; PREVALENCE; OUTCOMES
AB Racial and ethnic disparities in diabetes care have been well documented. While root causes have been explored for some minority groups, less is known about smaller immigrant populations such as Cambodians. In this study, we sought to explore the potential barriers to care for Cambodian patients with diabetes. We conducted five focus groups with three study groups: health care providers, bilingual Khmer frontline staff, and Cambodian patients with diabetes. Focus groups findings revealed that certain cultural beliefs, low health literacy, and language barriers strongly affect Cambodian patients' understanding of diabetes and self-management, as well as clinicians' ability to care effectively for Cambodian patients with diabetes. Our study supports previous literature and also adds several new insights not previously described. We recommend education for health care providers on patient-centered, cross-cultural care with an emphasis on the needs of Cambodians as well as culturally appropriate diabetes education for patients.
C1 [Renfrew, Megan R.; Taing, Elizabeth] Massachusetts Gen Hosp, Dispar Solut Ctr, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Cohen, Marya J.] Massachusetts Gen Hosp, John D Stoeckle Ctr Primary Care Innovat, Boston, MA 02114 USA.
[Cohen, Marya J.; Betancourt, Joseph R.; Pasinski, Roger; Green, Alexander R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Betancourt, Joseph R.; Green, Alexander R.] Massachusetts Gen Hosp, Dispar Solut Ctr, Boston, MA 02114 USA.
[Betancourt, Joseph R.; Green, Alexander R.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Pasinski, Roger] Massachusetts Gen Hosp, Revere HealthCare Ctr, Boston, MA 02114 USA.
EM mrrenfrew@partners.org
NR 98
TC 2
Z9 2
U1 3
U2 16
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2013
VL 24
IS 2
BP 633
EP 655
PG 23
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 153VU
UT WOS:000319631400016
PM 23728033
ER
PT J
AU Taplin, ME
AF Taplin, Mary-Ellen
TI Secondary Hormone Therapy for Castration-Resistant Prostate Cancer
SO ONCOLOGY-NEW YORK
LA English
DT Editorial Material
ID INCREASED SURVIVAL; ANDROGEN RECEPTOR; ABIRATERONE; CHEMOTHERAPY
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
RP Taplin, ME (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 44 Binney St, Boston, MA 02115 USA.
NR 14
TC 1
Z9 1
U1 0
U2 1
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
J9 ONCOLOGY-NY
JI Oncology-NY
PD MAY
PY 2013
VL 27
IS 5
BP 371
EP +
PG 3
WC Oncology
SC Oncology
GA 153RV
UT WOS:000319621100003
PM 25184257
ER
PT J
AU Ott, PA
Hodi, FS
AF Ott, Patrick A.
Hodi, F. Stephen
TI Treatment for Advanced Melanoma: New Drugs, New Opportunities, New
Challenges
SO ONCOLOGY-NEW YORK
LA English
DT Editorial Material
ID METASTATIC MELANOMA; BRAF; VEMURAFENIB; INHIBITION; COMBINATION;
IPILIMUMAB; ANTIBODY; CANCER; SAFETY
C1 [Ott, Patrick A.; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ott, Patrick A.; Hodi, F. Stephen] Harvard Univ, Sch Med, Boston, MA USA.
RP Ott, PA (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 12
TC 1
Z9 1
U1 0
U2 0
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
J9 ONCOLOGY-NY
JI Oncology-NY
PD MAY
PY 2013
VL 27
IS 5
BP 381
EP +
PG 3
WC Oncology
SC Oncology
GA 153RV
UT WOS:000319621100005
PM 25184259
ER
PT J
AU Kaaya, S
Eustache, E
Lapidos-Salaiz, I
Musisi, S
Psaros, C
Wissow, L
AF Kaaya, Sylvia
Eustache, Eddy
Lapidos-Salaiz, Ilana
Musisi, Seggane
Psaros, Christina
Wissow, Lawrence
TI Grand Challenges: Improving HIV Treatment Outcomes by Integrating
Interventions for Co-Morbid Mental Illness
SO PLOS MEDICINE
LA English
DT Editorial Material
ID TO-CHILD TRANSMISSION; QUALITY-OF-LIFE; PRIMARY-CARE; ANTIRETROVIRAL
TREATMENT; COLLABORATIVE CARE; INFECTED CHILDREN; ALCOHOL-USE; HEALTH;
SERVICES; DISORDERS
C1 [Kaaya, Sylvia] Muhimbili Univ Hlth & Allied Sci, Sch Med, Dar Es Salaam, Tanzania.
[Eustache, Eddy] Zanmi Lasante Partners Hlth, Cent Plateau, Haiti.
[Lapidos-Salaiz, Ilana] US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA.
[Musisi, Seggane] Makerere Univ, Sch Med, Kampala, Uganda.
[Psaros, Christina] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Wissow, Lawrence] Johns Hopkins Univ, Ctr Mental Hlth Pediat Primary Care, Baltimore, MD USA.
RP Kaaya, S (reprint author), Muhimbili Univ Hlth & Allied Sci, Sch Med, Dar Es Salaam, Tanzania.
EM skaaya@gmail.com
FU NIMH NIH HHS [K23 MH096651, P20 MH086048]
NR 42
TC 26
Z9 26
U1 4
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD MAY
PY 2013
VL 10
IS 5
AR e1001447
DI 10.1371/journal.pmed.1001447
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154JK
UT WOS:000319670900022
PM 23700389
ER
PT J
AU Tsai, AC
AF Tsai, Alexander C.
TI Intimate Partner Violence and Population Mental Health: Why Poverty and
Gender Inequities Matter
SO PLOS MEDICINE
LA English
DT Editorial Material
ID RANDOMIZED-CONTROLLED-TRIAL; SUB-SAHARAN AFRICA; COMMUNITY-LEVEL;
PREVENTION; WOMEN; INTERVENTION; METAANALYSIS; CARE; DEPRESSION;
OUTCOMES
C1 [Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Tsai, Alexander C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Tsai, AC (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
EM actsai@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU NIMH NIH HHS [K23 MH-096620, K23 MH096620]
NR 45
TC 10
Z9 10
U1 3
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD MAY
PY 2013
VL 10
IS 5
AR e1001440
DI 10.1371/journal.pmed.1001440
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154JK
UT WOS:000319670900015
PM 23667344
ER
PT J
AU Yeh, JM
Hur, C
Schrag, D
Kuntz, KM
Ezzati, M
Stout, N
Ward, Z
Goldie, SJ
AF Yeh, Jennifer M.
Hur, Chin
Schrag, Deb
Kuntz, Karen M.
Ezzati, Majid
Stout, Natasha
Ward, Zachary
Goldie, Sue J.
TI Contribution of H-pylori and Smoking Trends to US Incidence of
Intestinal-Type Noncardia Gastric Adenocarcinoma: A Microsimulation
Model
SO PLOS MEDICINE
LA English
DT Article
ID LUNG-CANCER MORTALITY; UNITED-STATES; CIGARETTE-SMOKING; STOMACH-CANCER;
RISK-FACTORS; PRIMARY PREVENTION; TOBACCO SMOKING; SECULAR TRENDS;
EPIDEMIOLOGY; ADULTS
AB Background: Although gastric cancer has declined dramatically in the US, the disease remains the second leading cause of cancer mortality worldwide. A better understanding of reasons for the decline can provide important insights into effective preventive strategies. We sought to estimate the contribution of risk factor trends on past and future intestinal-type noncardia gastric adenocarcinoma (NCGA) incidence.
Methods and Findings: We developed a population-based microsimulation model of intestinal-type NCGA and calibrated it to US epidemiologic data on precancerous lesions and cancer. The model explicitly incorporated the impact of Helicobacter pylori and smoking on disease natural history, for which birth cohort-specific trends were derived from the National Health and Nutrition Examination Survey (NHANES) and National Health Interview Survey (NHIS). Between 1978 and 2008, the model estimated that intestinal-type NCGA incidence declined 60% from 11.0 to 4.4 per 100,000 men, <3% discrepancy from national statistics. H. pylori and smoking trends combined accounted for 47% (range = 30%-58%) of the observed decline. With no tobacco control, incidence would have declined only 56%, suggesting that lower smoking initiation and higher cessation rates observed after the 1960s accelerated the relative decline in cancer incidence by 7% (range = 0%-21%). With continued risk factor trends, incidence is projected to decline an additional 47% between 2008 and 2040, the majority of which will be attributable to H. pylori and smoking (81%; range = 61%-100%). Limitations include assuming all other risk factors influenced gastric carcinogenesis as one factor and restricting the analysis to men.
Conclusions: Trends in modifiable risk factors explain a significant proportion of the decline of intestinal-type NCGA incidence in the US, and are projected to continue. Although past tobacco control efforts have hastened the decline, full benefits will take decades to be realized, and further discouragement of smoking and reduction of H. pylori should be priorities for gastric cancer control efforts.
C1 [Yeh, Jennifer M.; Ward, Zachary; Goldie, Sue J.] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
[Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Schrag, Deb] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kuntz, Karen M.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
[Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, London, England.
[Stout, Natasha] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA.
Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
RP Yeh, JM (reprint author), Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, 665 Huntington Ave, Boston, MA 02115 USA.
EM jyeh@hsph.harvard.edu
OI Ward, Zachary/0000-0002-4007-2207; Hur, Chin/0000-0002-2819-7576
FU National Institutes of Health's National Cancer Institute [K07-CA143044]
FX JMY was funded by the National Institutes of Health's National Cancer
Institute (K07-CA143044). The funder had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 55
TC 13
Z9 13
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD MAY
PY 2013
VL 10
IS 5
AR e1001451
DI 10.1371/journal.pmed.1001451
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154JK
UT WOS:000319670900026
PM 23700390
ER
PT J
AU Stineman, MG
Zhang, GY
Kurichi, JE
Zhang, Z
Streim, JE
Pan, Q
Xie, DW
AF Stineman, Margaret G.
Zhang, Guangyu
Kurichi, Jibby E.
Zhang, Zi
Streim, Joel E.
Pan, Qiang
Xie, Dawei
TI Prognosis for Functional Deterioration and Functional Improvement in
Late Life Among Community-Dwelling Persons
SO PM&R
LA English
DT Article
ID OLDER-PEOPLE; LIMITATION PATHWAYS; ELDERLY-PEOPLE; HEALTH; DISABILITY;
REHABILITATION; INDEPENDENCE; TRANSITIONS; VALIDATION; MORTALITY
AB Objective: To examine how health-related, socioeconomic, and environmental factors combine to influence the onset of activity of daily living (ADL) limitations or prognosis for death or further functional deterioration or improvement among elderly people.
Design: A national representative sample with 2-year follow-up.
Setting: Community-dwelling people.
Participants: Included were 9447 persons (>= 70 years of age) in the United States from the Second Longitudinal Study of Aging who were interviewed in 1994, 1995, or 1996.
Methods: Self- or proxy-reported health conditions, ADLs expressed as 5 stages describing severity and pattern of limitations, and other baseline characteristics were obtained. A multinomial logistic regression model was used to predict stage transitions. Because of incomplete follow-up (17.7% of baseline sample), primary analyses were determined by multiple imputation to address potential bias associated with loss to follow-up.
Main Outcome Measurement: ADL stage transitions in 2 years (death, deteriorated, stable, and improved ADL function).
Results: In the imputed-case analysis, the percentages for those who died, deteriorated, were stable, and improved were 12.6%, 32.7%, 48.4%, and 6.2%, respectively. Persons at a mild stage of ADL limitation were most likely to deteriorate further. Persons at advanced stages were most likely to die. Married people and high school graduates had a lower likelihood of deterioration. The risk of mortality and functional deterioration increased with age. Certain conditions, such as diabetes, were associated both with mortality and functional deterioration; other conditions, such as cancer, were associated with mortality only, and arthritis was associated only with functional deterioration.
Conclusions: Although overlap occurs, different clinical traits are associated with mortality, functional deterioration, and functional improvement. ADL stages might aid physical medicine and rehabilitation clinicians and researchers in developing and monitoring disability management strategies targeted to maintaining and enhancing self-care among community-dwelling older people.
C1 [Stineman, Margaret G.; Kurichi, Jibby E.; Zhang, Zi; Pan, Qiang; Xie, Dawei] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Stineman, Margaret G.] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
[Zhang, Guangyu] Univ Maryland, Dept Epidemiol & Biostat, College Pk, MD 20742 USA.
[Streim, Joel E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Streim, Joel E.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network VISN 4, Philadelphia, PA USA.
RP Stineman, MG (reprint author), 423 Guardian Dr,904 Blockley Hall, Philadelphia, PA 19104 USA.
EM mstinema@exchange.upenn.edu
FU nonprofit/government agencies, NIA [R01 AG032420-01A1]
FX grant support for research from nonprofit/government agencies, NIA,
grant (#R01 AG032420-01A1)
NR 46
TC 11
Z9 11
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAY
PY 2013
VL 5
IS 5
BP 360
EP 371
DI 10.1016/j.pmrj.2013.02.008
PG 12
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 156SO
UT WOS:000319844400002
PM 23454447
ER
PT J
AU Liang, CL
Han, S
AF Liang, Chiawen Lucy
Han, Steve
TI Neuromuscular Junction Disorders
SO PM&R
LA English
DT Article
ID EATON-MYASTHENIC-SYNDROME; REPETITIVE NERVE-STIMULATION; GRAVIS;
ELECTROMYOGRAPHY; EPIDEMIOLOGY; DIAGNOSIS; MUSCLES
AB Disorders of the neuromuscular junction, such as myasthenia gravis and Lambert-Eaton myasthenic syndrome, constitute an important and treatable class of diseases. Both disorders are typically caused by an immunologically mediated attack on discrete components of the neuromuscular junction, compromise the efficacy of neurotransmitter transmission, and produce clinically distinct syndromes of fatigable muscle weakness. Although the history, clinical examination, and routine antibody testing can be diagnostic in many cases, specialized neurophysiological tests, such as repetitive nerve stimulation and single-fiber electromyography, are essential tools in the diagnostic evaluation of patients with more complicated or atypical conditions. In this review, we introduce primary disorders of the neuromuscular junction, and discuss the salient clinical and laboratory workup appropriate for recognizing these disorders, and the typical findings seen on electrodiagnostic testing with repetitive nerve stimulation and single-fiber electromyography.
C1 [Liang, Chiawen Lucy] CNS Multispecialty Clin, Wellesley, MA 02481 USA.
[Han, Steve] Massachusetts Gen Hosp, Dept Neurol, Neuromuscular Div, Boston, MA 02114 USA.
RP Liang, CL (reprint author), CNS Multispecialty Clin, 65 Walnut St,Suite 150, Wellesley, MA 02481 USA.
EM lucypmr@gmail.com
FU American Academy of Neurology/ALS Association Career Development Award;
Harvard Catalyst KL2 MeRIT award
FX Disclosures outside this publication: grants, American Academy of
Neurology/ALS Association Career Development Award; Harvard Catalyst KL2
MeRIT award
NR 29
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAY
PY 2013
VL 5
IS 5
SU S
BP S81
EP S88
DI 10.1016/j.pmrj.2013.03.016
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 156SQ
UT WOS:000319844600012
PM 23524069
ER
PT J
AU Di Leone, BAL
Vogt, D
Gradus, JL
Street, AE
Giasson, HL
Resick, PA
AF Di Leone, Brooke A. L.
Vogt, Dawne
Gradus, Jaimie L.
Street, Amy E.
Giasson, Hannah L.
Resick, Patricia A.
TI Predictors of Mental Health Care Use Among Male and Female Veterans
Deployed in Support of the Wars in Afghanistan and Iraq
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE veteran; mental health; gender; military; service use
ID POSTTRAUMATIC STRESS SYMPTOMATOLOGY; WOMEN VETERANS; ADMINISTRATION
CARE; MILITARY SERVICE; SAMPLE; RISK; QUESTIONNAIRE; STRENGTHS;
BARRIERS; SEEKING
AB What factors predict whether Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans who need mental health care receive that care? The present research examined factors associated with a need for care, sociodemographic characteristics, deployment experiences, and perceptions of care as gender-specific predictors of overall mental health care use and Veterans Affairs (VA) mental health care use for male and female OEF/OIF veterans (N = 1,040). Only veterans with a probable need for mental health care, as determined by scores on self-report measures of mental health symptomatology, were included in the sample. Overall, predictors of service use were similar for women and men. A notable exception was the finding that lower income predicted use of both overall and VA mental health care for women, but not men. In addition, sexual harassment was a unique predictor of VA service use for women, whereas non-White race was predictive of VA service use for men only. Knowledge regarding the factors that are associated with use of mental health care (broadly and at VA) is critical to ensuring that veterans who need mental health care receive it.
C1 [Di Leone, Brooke A. L.; Vogt, Dawne; Gradus, Jaimie L.; Street, Amy E.; Giasson, Hannah L.; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Di Leone, Brooke A. L.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Vogt, Dawne; Gradus, Jaimie L.; Street, Amy E.; Resick, Patricia A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA.
[Gradus, Jaimie L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
RP Di Leone, BAL (reprint author), VA Boston HCS, Ctr Org Leadership & Management Res 152M, 150 South Huntington Ave, Boston, MA 02130 USA.
EM brooke.dileone@va.gov
OI Gradus, Jaimie/0000-0003-1459-5327
NR 35
TC 13
Z9 13
U1 0
U2 5
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2013
VL 10
IS 2
SI SI
BP 145
EP 151
DI 10.1037/a0032088
PG 7
WC Psychology, Clinical
SC Psychology
GA 156DW
UT WOS:000319802300002
PM 23730960
ER
PT J
AU Ben Barnes, J
Nickerson, A
Adler, AB
Litz, BT
AF Ben Barnes, J.
Nickerson, Angela
Adler, Amy B.
Litz, Brett T.
TI Perceived Military Organizational Support and Peacekeeper Distress: A
Longitudinal Investigation
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE stress; posttraumatic stress; perceived organizational support;
peacekeeping; structural equation modeling
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; SOCIAL SUPPORT;
DEPRESSION; SYMPTOMS; PTSD; IRAQ; SYMPTOMATOLOGY; RESILIENCE; TRAUMA
AB Many professions vital to the safety of society require workers to face high magnitude and potentially traumatizing events. Because this routine exposure can cause high levels of stress in workers, it is important to investigate factors that contribute to both risk of posttraumatic stress disorder (PTSD), and healthy responses to stress. Although some research has found social support to mitigate the effects of posttraumatic stress symptoms, scant research has investigated organizational support. The aim of the present study is to investigate the temporal relationship between stress symptoms and perceived organizational support in a sample of 1,039 service members deployed to the peacekeeping mission to Kosovo. Participants completed self-report measures of stress symptoms and perceived organizational support at 4 study time points. Bivariate latent difference score structural equation modeling was utilized to examine the temporal relationship among stress and perceived organizational support. In general, across the 4 time points, latent PCL scores evidenced a salient and negative relationship to subsequent POS latent difference scores. However, no significant relationship was found between latent POS variables and subsequent PCL latent difference scores. Findings suggest that prior stress symptoms are influencing service member's perceptions of the supportiveness of their organization such that increased prior stress is associated with worsening perceptions of support. These results illustrate that targeting stress directly may potentiate the positive influence of organizational support and that institutional support programs should be adapted to better account for the negative biases increased distress may encourage.
C1 [Ben Barnes, J.; Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA.
[Nickerson, Angela] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.
[Adler, Amy B.] Walter Reed Army Inst Res, US Army Med Res Unit Europe, Heidelberg, Germany.
[Litz, Brett T.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA.
RP Litz, BT (reprint author), VA Boston Healthcare Syst, Vet Epidemiol Res & Informat Ctr, 150 South Huntington Ave 116-B4, Boston, MA 02130 USA.
EM brett.litz@va.gov
NR 50
TC 0
Z9 0
U1 2
U2 20
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2013
VL 10
IS 2
SI SI
BP 177
EP 185
DI 10.1037/a0032607
PG 9
WC Psychology, Clinical
SC Psychology
GA 156DW
UT WOS:000319802300006
ER
PT J
AU Lehavot, K
Der-Martirosian, C
Simpson, TL
Sadler, AG
Washington, DL
AF Lehavot, Keren
Der-Martirosian, Claudia
Simpson, Tracy L.
Sadler, Anne G.
Washington, Donna L.
TI Barriers to Care for Women Veterans With Posttraumatic Stress Disorder
and Depressive Symptoms
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE women veterans; posttraumatic stress disorder; depression; barriers to
care; health care
ID HEALTH ADMINISTRATION PATIENTS; FEMALE VETERANS; RANDOMIZED-TRIAL;
MEDICAL ILLNESS; SERVICE USE; VA; AFFAIRS; IRAQ; AFGHANISTAN; PTSD
AB As the number of women veterans continues to rise, an issue of concern is whether those with mental health symptoms experience disproportionate barriers to care. The purpose of this study was to examine unmet medical needs and barriers to health care among women veterans who screened positive for lifetime posttraumatic stress disorder (PTSD), current depressive symptoms, both or neither. Using the National Survey of Women Veterans dataset (N = 3,593), we compared women veterans corresponding to these 4 groups on whether they had unmet medical needs in the past year, reasons for unmet needs, and barriers to using VA care for those not currently doing so. The majority of women veterans who screened positive for both PTSD and depressive symptoms had unmet medical care needs in the prior 12 months (59%), compared to 30% of women with PTSD symptoms only, 18% of those with depressive symptoms only, and 16% of women with neither set of symptoms. Among those reporting unmet medical needs (n = 840), those with both PTSD and depressive symptoms were more likely than the other groups to identify affordability as a reason for going without or delaying care. Among women veterans not using VA health care (n = 1,677), women with both PTSD and depressive symptoms were more likely to report not knowing if they were eligible for VA benefits and were less likely to have health insurance to cover care outside of the VA. These data highlight specific areas of vulnerability of women veterans with comorbid PTSD and depressive symptoms and identify areas of concern as VA and other health facilities work to ensure equitable access to care.
C1 [Lehavot, Keren; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Der-Martirosian, Claudia; Washington, Donna L.] Ctr Excellence Study Healthcare Provider Behav, VA Greater Los Angeles Hlth Serv Res & Dev, Sepulveda, CA USA.
[Simpson, Tracy L.] Univ Washington, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98195 USA.
[Sadler, Anne G.] Univ Iowa, Carver Coll Med, Iowa City VA Med Ctr, Iowa City, IA 52242 USA.
[Sadler, Anne G.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA.
[Washington, Donna L.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
RP Lehavot, K (reprint author), 1660 S Columbian Way S-116-POC, Seattle, WA 98108 USA.
EM klehavot@uw.edu
NR 46
TC 6
Z9 6
U1 2
U2 12
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2013
VL 10
IS 2
SI SI
BP 203
EP 212
DI 10.1037/a0031596
PG 10
WC Psychology, Clinical
SC Psychology
GA 156DW
UT WOS:000319802300009
PM 23730964
ER
PT J
AU Simpson, TL
Balsam, KF
Cochran, BN
Lehavot, K
Gold, SD
AF Simpson, Tracy L.
Balsam, Kimberly F.
Cochran, Bryan N.
Lehavot, Keren
Gold, Sari D.
TI Veterans Administration Health Care Utilization Among Sexual Minority
Veterans
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE veterans; health care utilization; lesbian; gay; bisexual
ID HATE-CRIME VICTIMIZATION; BEHAVIORAL-MODEL; BISEXUAL ADULTS;
STRESS-DISORDER; PTSD CHECKLIST; SERVICES USE; ACCESS; GAY; WOMEN;
PREVALENCE
AB According to recent census reports, nearly a million veterans have a same-sex partner, yet little is known about them or their use of Veterans Health Care Administration (VHA) services. Gay, lesbian, and bisexual (GLB) veterans recruited from the community (N = 356) completed an on-line survey to assess their rates of VHA utilization and whether they experience specific barriers to accessing VHA services. Andersen's model of health care utilization was adapted to provide an analytic and conceptual framework. Overall, 45.5% reported lifetime VHA utilization and 28.7% reported past-year VHA utilization. Lifetime VHA health care utilization was predicted by positive service connection, positive screen for both posttraumatic stress disorder (PTSD) and depression, and history of at least one interpersonal trauma during military service related to respondent's GLB status. Past-year VHA health care utilization was predicted by female gender, positive service connection, positive screen for both PTSD and depression, lower physical functioning, a history of military interpersonal trauma related to GLB status, and no history of stressful experiences initiated by the military to investigate or punish GLB status. Rates of VHA utilization by GLB veterans in this sample are comparable to those reported by VHA Central Office for all veterans. Of those who utilized VHA services, 33% reported open communication about their sexual orientation with VHA providers. Twenty-five percent of all participants reported avoiding at least one VHA service because of concerns about stigma. Stigma and lack of communication between GLB veterans and their providers about sexual orientation are areas of concern for VHA.
C1 [Simpson, Tracy L.; Lehavot, Keren; Gold, Sari D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Simpson, Tracy L.; Lehavot, Keren; Gold, Sari D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Balsam, Kimberly F.] Univ Washington, Dept Social Work, Seattle, WA 98195 USA.
[Cochran, Bryan N.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA.
RP Simpson, TL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM tracy.simpson@va.gov
NR 45
TC 16
Z9 16
U1 3
U2 23
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2013
VL 10
IS 2
SI SI
BP 223
EP 232
DI 10.1037/a0031281
PG 10
WC Psychology, Clinical
SC Psychology
GA 156DW
UT WOS:000319802300011
PM 23730965
ER
PT J
AU Macdonald, A
Greene, CJ
Torres, JG
Frueh, BC
Morland, LA
AF Macdonald, Alexandra
Greene, Carolyn J.
Torres, Jennifer G.
Frueh, B. Christopher
Morland, Leslie A.
TI Concordance Between Clinician-Assessed and Self-Reported Symptoms of
Posttraumatic Stress Disorder Across Three Ethnoracial Groups
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE posttraumatic stress disorder; diagnostic assessment; cultural; ethnic
minorities
ID ADMINISTERED PTSD SCALE; ASIAN-AMERICAN; MENTAL-HEALTH; ANXIETY
DISORDERS; COLLEGE-STUDENTS; NONINFERIORITY; VETERANS
AB Posttraumatic stress disorder (PTSD) is a significant health problem that affects people from all ethnoracial groups. In the United States, investigators have found that minority groups, particularly Asian Americans, are more likely to withdraw from treatment and to display poor health treatment outcomes compared with Caucasians. Despite the extant research regarding ethnicity and treatment, limited research exists focusing on the relationship between ethnicity and the assessment of mental health symptoms. Previous literature has found that Asian Americans may underreport mental health symptoms. Relatively less empirical work has been conducted with indigenous populations, especially those of the Pacific Islands, such as Native Hawaiians, Samoans, and Tahitians. Questions remain as to whether the method of assessment may influence symptom reporting. For example, researchers have not studied whether or not clinician-assessed ratings of mental health symptoms differ from self-report measures. The current study examined the concordance between clinician-assessed and self-reported ratings of PTSD severity in male veterans with PTSD who identified themselves as Asian American, Native Hawaiian/Pacific Islander, or Caucasian. Results suggest moderate concordance between clinician-administered and self-report PTSD assessments. Findings from this study can be used to develop more accurate methods of capturing PTSD symptoms among Asian Americans, Native Hawaiians/Pacific Islanders, and other minority groups.
C1 [Macdonald, Alexandra] VA Boston Hlth Care Syst, Boston, MA USA.
[Macdonald, Alexandra] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Greene, Carolyn J.] Dept Vet Affairs Palo Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, Palo Alto, CA USA.
[Greene, Carolyn J.] Dept Vet Affairs Pacific Isl Hlth Care Syst, Natl Ctr PTSD, Pacific Isl Div, Honolulu, HI USA.
[Torres, Jennifer G.] VA Boston Hlth Care Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA.
[Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA.
[Morland, Leslie A.] Dept Vet Affairs Pacific Isl Hlth Care Syst, Natl Ctr PTSD, Pacific Isl Div, Honolulu, HI USA.
RP Macdonald, A (reprint author), VA Boston Hlth Care Syst, 150 South Huntington Ave, Jamaica Plain, MA 02130 USA.
EM alexandra.macdonald@va.gov
NR 42
TC 6
Z9 6
U1 2
U2 7
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD MAY
PY 2013
VL 5
IS 3
BP 201
EP 208
DI 10.1037/a0031879
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 149GU
UT WOS:000319307800001
ER
PT J
AU Charney, ME
Keane, TM
AF Charney, Meredith E.
Keane, Terence M.
TI The Psychological, Psychosocial, and Physical Health Status of
HIV-Positive Refugees: A Comparative Analysis
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE HIV; refugees; trauma
ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; ANTIRETROVIRAL
MEDICATION; MENTAL-HEALTH; COMORBIDITY; PREDICTORS; CHECKLIST;
ADHERENCE; EVENTS; PTSD
AB Refugees living with HIV are a relatively new group being resettled in the United States. In an effort to more fully understand the current status of refugees living with HIV, 84 HIV-positive adults including 26 refugees, 25 Puerto Rican individuals, and 33 individuals born in the U.S. were interviewed. We assessed psychological, psychosocial, and physical health domains across these groups to collect comparative information on the status of HIV-positive refugees. Results revealed that HIV-positive refugee individuals experienced greater problems in functioning than the other groups with the most significant differences observed in psychosocial functioning. These results underscore the importance of approaching refugee mental health from a multidisciplinary framework and have implications for the development of interventions for resettled HIV-positive refugees.
C1 [Charney, Meredith E.; Keane, Terence M.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Charney, Meredith E.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
RP Charney, ME (reprint author), Massachusetts Gen Hosp, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM mecharney@partners.org
NR 33
TC 0
Z9 0
U1 0
U2 1
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD MAY
PY 2013
VL 5
IS 3
BP 209
EP 216
DI 10.1037/a0027506
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 149GU
UT WOS:000319307800003
ER
PT J
AU Khan, S
Cohen, D
AF Khan, Sheraz
Cohen, David
TI Note: Magnetic noise from the inner wall of a magnetically shielded room
SO REVIEW OF SCIENTIFIC INSTRUMENTS
LA English
DT Article
ID MAGNETOENCEPHALOGRAPHY; BRAIN
AB We measured the thermal magnetic noise generated by the inner high-permeability wall of a magnetically shielded room. This room houses a magnetoencephalogram (MEG), which contains 102 "small" identical magnetometers. For the measurement, we created two large magnetometers by summing the outputs of 46 magnetometers equally on the helmet's left and right side, to look at the summed noise of the right and left vertical walls. From these summed outputs, we calculated the rms noise amplitude due to all six walls at the MEG location to be similar to 0.5 f T/root Hz at 100 Hz, only slowly rising with lower frequency. This is well below the system noise of each small MEG magnetometer, hence is negligible for the MEG. (C) 2013 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 Unported License.
C1 [Khan, Sheraz] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA.
[Khan, Sheraz; Cohen, David] Harvard Univ, MIT, Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Cohen, David] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02129 USA.
[Cohen, David] MIT, Francis Bitter Magnet Lab, Cambridge, MA 02139 USA.
RP Cohen, D (reprint author), Harvard Univ, MIT, Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
EM davcohen@mit.edu
OI Khan, Sheraz/0000-0002-6792-3577
NR 10
TC 2
Z9 2
U1 0
U2 7
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
MELVILLE, NY 11747-4501 USA
SN 0034-6748
J9 REV SCI INSTRUM
JI Rev. Sci. Instrum.
PD MAY
PY 2013
VL 84
IS 5
AR 056101
DI 10.1063/1.4802845
PG 3
WC Instruments & Instrumentation; Physics, Applied
SC Instruments & Instrumentation; Physics
GA 158UO
UT WOS:000319999300075
PM 23742599
ER
PT J
AU Lee, J
Quintana, FA
Muller, P
Trippa, L
AF Lee, Jaeyong
Quintana, Fernando A.
Mueller, Peter
Trippa, Lorenzo
TI Defining Predictive Probability Functions for Species Sampling Models
SO STATISTICAL SCIENCE
LA English
DT Article
DE Species sampling prior; exchangeable partition probability functions;
prediction probability functions
ID NORMALIZED RANDOM MEASURES; BAYESIAN DENSITY-ESTIMATION; PRIORS;
MIXTURES; REPRESENTATION; DISTRIBUTIONS; CONSISTENCY; PARTITIONS
AB We review the class of species sampling models (SSM). In particular, we investigate the relation between the exchangeable partition probability function (EPPF) and the predictive probability function (PPF). It is straightforward to define a PPF from an EPPF, but the converse is not necessarily true. In this paper we introduce the notion of putative PPFs and show novel conditions for a putative PPF to define an EPPF. We show that all possible PPFs in a certain class have to define (unnormalized) probabilities for cluster membership that are linear in cluster size. We give a new necessary and sufficient condition for arbitrary putative PPFs to define an EPPF. Finally, we show posterior inference for a large class of SSMs with a PPF that is not linear in cluster size and discuss a numerical method to derive its PPF. Key words and phrases: Species sampling prior, exchangeable partition
C1 [Lee, Jaeyong] Seoul Natl Univ, Dept Stat, Seoul 151747, South Korea.
[Quintana, Fernando A.] Pontificia Univ Catolica Chile, Dept Estadist, Santiago 22, Chile.
[Mueller, Peter] Univ Texas Austin, Dept Math, Austin, TX 78712 USA.
[Trippa, Lorenzo] Harvard Univ, Dept Biostat, Boston, MA 02115 USA.
[Trippa, Lorenzo] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
RP Lee, J (reprint author), Seoul Natl Univ, Dept Stat, Seoul 151747, South Korea.
EM leejyc@gmail.com; quintana@mat.puc.cl; pmueller@math.utexas.edu;
ltrippa@jimmy.harvard.edu
FU National Research Foundation of Korea (NRF); Korea government (MEST)
[2011-0030811]; FONDECYT [1100010]; NIH/NCI [CA075981]
FX Jaeyong Lee was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea government (MEST) (No. 2011-0030811).
Fernando Quintana was supported by Grant FONDECYT 1100010. Peter Muller
was partially funded by Grant NIH/NCI CA075981.
NR 38
TC 6
Z9 6
U1 3
U2 8
PU INST MATHEMATICAL STATISTICS
PI CLEVELAND
PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA
SN 0883-4237
J9 STAT SCI
JI Stat. Sci.
PD MAY
PY 2013
VL 28
IS 2
BP 209
EP 222
DI 10.1214/12-STS407
PG 14
WC Statistics & Probability
SC Mathematics
GA 157JL
UT WOS:000319892300004
PM 24368874
ER
PT J
AU Puram, SV
Hasserjian, RP
Faquin, WC
Lin, HW
Rocco, JW
AF Puram, Sidharth V.
Hasserjian, Robert P.
Faquin, William C.
Lin, Harrison W.
Rocco, James W.
TI Castleman disease presenting in the neck: Report of a case and review of
the literature
SO AMERICAN JOURNAL OF OTOLARYNGOLOGY
LA English
DT Review
ID LYMPH-NODE HYPERPLASIA; HIV-INFECTION
AB Castleman disease is a rare lymphoproliferative disorder with two primary subtypes that vary in presentation and course. Unicentric Castleman disease (UCD) presents as a solitary mass, most commonly in the mediastinum, and rarely in the head and neck. In contrast to multicentric Castleman disease (MCD), which features peripheral lymphadenopathy and numerous systemic symptoms, UCD is not typically associated with generalized symptoms. Here, we present an unusual case of UCD presenting as a slowly expanding, isolated neck mass in a 29-year-old woman. This case demonstrates the distinguishing clinical, radiologic, and histologic findings unique to UCD, which is often misdiagnosed as lymphoma or other malignant process. These findings stand in contrast to those observed in MCD patients, and hence, offer insight into the practical aspects of diagnosis and management of Castleman disease in the head and neck. Published by Elsevier Inc.
C1 [Puram, Sidharth V.; Faquin, William C.; Lin, Harrison W.; Rocco, James W.] Massachusetts Eye & Ear Infirm, Div Head & Neck Surg, Dept Otolaryngol, Boston, MA 02114 USA.
[Hasserjian, Robert P.; Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Rocco, James W.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Rocco, James W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Puram, SV (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM spuram@partners.org
NR 19
TC 5
Z9 5
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0196-0709
J9 AM J OTOLARYNG
JI Am. J. Otolaryngol.
PD MAY-JUN
PY 2013
VL 34
IS 3
BP 239
EP 244
DI 10.1016/j.amjoto.2012.11.007
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 141TJ
UT WOS:000318749100011
PM 23375540
ER
PT J
AU Wyatt, GE
Gomez, CA
Hamilton, AB
Valencia-Garcia, D
Gant, LM
Graham, CE
AF Wyatt, Gail E.
Gomez, Cynthia A.
Hamilton, Alison B.
Valencia-Garcia, Dellanira
Gant, Larry M.
Graham, Charles E.
TI The Intersection of Gender and Ethnicity in HIV Risk, Interventions, and
Prevention New Frontiers for Psychology
SO AMERICAN PSYCHOLOGIST
LA English
DT Article
DE HIV; gender; ethnicity; sociocultural; intersectionality
ID AFRICAN-AMERICANS; POSITIVE WOMEN; UNITED-STATES; PUBLIC-HEALTH;
IMMUNODEFICIENCY SYNDROME; SAN-FRANCISCO; SEXUAL-ABUSE; SELF-ESTEEM;
BLACK-MEN; AIDS
AB This article articulates a contextualized understanding of gender and ethnicity as interacting social determinants of HIV risk and acquisition, with special focus on African Americans and Hispanics/Latinos-2 ethnic groups currently at most risk for HIV/AIDS acquisition in the United States. First, sex and gender are defined. Second, a conceptual model of gender, ethnicity, and HIV risk and resilience is presented. Third, a historical backdrop of gender and ethnic disparities is provided, with attention to key moments in history when notions of the intersections between gender, ethnicity, and HIV have taken important shifts. Finally, new frontiers in psychology are presented, with recommendations as to how psychology as a discipline can better incorporate considerations of gender and ethnicity as not only HIV risk factors but also as potential avenues of resilience in ethnic families and communities. Throughout the article, we promulgate the notion of a syndemic intersectional approach, which provides a critical framework for understanding and building the conditions that create and sustain overall community health by locating gendered lived experiences and expectations within the layered conceptual model ranging from the biological self to broader societal structures that define and constrain personal decisions, behaviors, actions, resources, and consequences. For ethnic individuals and populations, health disparities, stress and depression, substance abuse, and violence and trauma are of considerable concern, especially with regard to HIV risk, infection, and treatment. The conceptual model poses new frontiers for psychology in HIV policy, research, interventions, and training.
C1 [Wyatt, Gail E.; Hamilton, Alison B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Gomez, Cynthia A.; Valencia-Garcia, Dellanira] San Francisco State Univ, Hlth Equ Inst, San Francisco, CA USA.
[Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gant, Larry M.; Graham, Charles E.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA.
RP Wyatt, GE (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,38-232 NPI,Box 175919, Los Angeles, CA 90024 USA.
EM gwyatt@mednet.ucla.edu
NR 108
TC 12
Z9 13
U1 7
U2 27
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
J9 AM PSYCHOL
JI Am. Psychol.
PD MAY-JUN
PY 2013
VL 68
IS 4
SI SI
BP 247
EP 260
DI 10.1037/a0032744
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA 146FS
UT WOS:000319075900005
PM 23688092
ER
PT J
AU Willers, H
Azzoli, CG
Santivasi, WL
Xia, F
AF Willers, Henning
Azzoli, Christopher G.
Santivasi, Wil L.
Xia, Fen
TI Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy
in Lung Cancer
SO CANCER JOURNAL
LA English
DT Review
DE Lung cancer; cytotoxic therapies; DNA repair pathways
ID GROWTH-FACTOR RECEPTOR; HOMOLOGOUS RECOMBINATION REPAIR; CISPLATIN-BASED
CHEMOTHERAPY; SQUAMOUS-CELL CARCINOMA; DNA-REPAIR; TUMOR VOLUME;
PHASE-III; POLY(ADP-RIBOSE) POLYMERASE; ADJUVANT CHEMOTHERAPY;
CONCURRENT CHEMORADIATION
AB In recent years, there have been multiple breakthroughs in our understanding of lung cancer biology. Despite significant advances in molecular targeted therapies, DNA-damaging cytotoxic therapies will remain the mainstay of lung cancer management for the near future. Similar to the concept of personalized targeted therapies, there is mounting evidence that perturbations in DNA repair pathways are common in lung cancers, altering the resistance of the affected tumors to many chemotherapeutics as well as radiation. Defects in DNA repair may be due to a multitude of mechanisms including gene mutations, epigenetic events, and alterations in signal transduction pathways such as epidermal growth factor receptor and phosphoinositide 3-kinase/AKT. Functional biomarkers that assess the subcellular localization of central repair proteins in response to DNA damage may prove useful for individualization of cytotoxic therapies including poly(adenosine diphosphate-ribose) polymerase inhibitors. A better mechanistic understanding of cellular sensitivity and resistance to DNA damaging agents should facilitate the development of novel, individualized treatment approaches. Absolute resistance to radiation therapy, however, does not exist. To some extent, radiation therapy will always have to remain unselective and indiscriminant to eradicate persistent, drug-resistant tumor stem cell pools.
C1 [Willers, Henning] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol,Med Sch, Boston, MA 02114 USA.
[Azzoli, Christopher G.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol,Dept Med,Med Sch, Boston, MA 02114 USA.
[Santivasi, Wil L.; Xia, Fen] Ohio State Univ, Coll Med, Dept Radiat Oncol, Columbus, OH 43210 USA.
RP Xia, F (reprint author), Ohio State Univ, Coll Med, Dept Radiat Oncol, Columbus, OH 43210 USA.
EM Fen.Xia@osumc.edu
RI Xia, Fen/G-3708-2013; Mendez, Pedro /J-8955-2016
OI Mendez, Pedro /0000-0001-6713-7907
FU Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer [NCI P50
CA090578]; Proton Therapy Research and Treatment Center [C06 CA059267]
FX H. W. is currently receiving partial support from the
Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer, NCI P50
CA090578, and the Federal Share of program income earned by
Massachusetts General Hospital on C06 CA059267, Proton Therapy Research
and Treatment Center. F. X. is currently receiving R01 NIH NCI CA163838.
The remaining authors have disclosed that they have no significant
relationships with, or financial interest in, any commercial companies
pertaining to this article.
NR 101
TC 26
Z9 29
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1528-9117
J9 CANCER J
JI Cancer J.
PD MAY-JUN
PY 2013
VL 19
IS 3
BP 200
EP 207
DI 10.1097/PPO.0b013e318292e4e3
PG 8
WC Oncology
SC Oncology
GA 152UV
UT WOS:000319557700004
PM 23708066
ER
PT J
AU Cottini, F
Lautenschlaeger, T
AF Cottini, Francesca
Lautenschlaeger, Tim
TI Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in
Locally Advanced Lung Cancer
SO CANCER JOURNAL
LA English
DT Review
DE Biomarker; lung cancer; EGFR; KRAS; ALK; ERCC1; RPM1; review
ID GROWTH-FACTOR-RECEPTOR; EML4-ALK FUSION GENE; PREVIOUSLY TREATED
PATIENTS; VINORELBINE PLUS CISPLATIN; RANDOMIZED PHASE-II; ADJUVANT
CHEMOTHERAPY; TYROSINE KINASE; DNA-REPAIR; PROGNOSTIC-SIGNIFICANCE;
ACQUIRED-RESISTANCE
AB Lung cancer accounts for the majority of cancer-related deaths worldwide. We sought out to summarize the current state of molecular predictors for response and toxicity in locally advanced lung cancer. Several changes have been introduced in recent years in the standard-of-care treatment of advanced non-small cell lung cancer based on the identification of specific molecular alterations that determine response probability to certain therapies. Eligibility for these treatments is assessed by a biomarker test, evaluating if the molecular alteration is present or not in a patient's tumor. In particular, tissue testing for epidermal growth factor receptor and anaplastic lymphoma kinase alterations is currently recommended for certain patients with advanced non-small cell lung cancer, whereas excision repair cross-complementation group 1 and ribonucleotide reductase 1 as markers for outcome after platinum and gemcitabine therapy are promising but are currently not recommended outside a clinical trial. However, their application to the therapy of locally advanced disease is still mostly investigational. Moreover, additional candidate markers for response and toxicity for locally advanced lung cancer are under further investigation.
C1 [Cottini, Francesca] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lautenschlaeger, Tim] Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 USA.
RP Lautenschlaeger, T (reprint author), Ohio State Univ, Dept Radiat Oncol, 410 W 12th Ave, Columbus, OH 43210 USA.
EM TL@osumc.edu
NR 86
TC 1
Z9 1
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-9117
EI 1540-336X
J9 CANCER J
JI Cancer J.
PD MAY-JUN
PY 2013
VL 19
IS 3
BP 263
EP 271
DI 10.1097/PPO.0b013e318297216a
PG 9
WC Oncology
SC Oncology
GA 152UV
UT WOS:000319557700011
PM 23708073
ER
PT J
AU Pretorius, E
Lipinski, B
AF Pretorius, Etheresia
Lipinski, Boguslaw
TI Thromboembolic ischemic stroke changes red blood cell morphology
SO CARDIOVASCULAR PATHOLOGY
LA English
DT Article
DE Red blood cells; Thromboembolic ischemic stroke
AB Background or Introduction: Stroke is one of the most debilitating diseases causing morbidity and mortality worldwide. During ischemic stroke, erythrocytes undergo oxidative and proteolytic changes resulting not only in inflammation but also in changes in cellular rheology. During the event, fibrin fibers, which are typically a fine net, clot abnormally to form a clot of dense matted deposits (DMDs). This atypical coagulum causes blood cells to be trapped in the mesh.
Methods: Here we study red blood cell (RBC) ultrastructure in thromboembolic ischemic stroke using high resolution scanning electron microscopy.
Results: We show that RBCs in patients change shape, with membrane extensions that form close interactions with the DMDs.
Conclusions: We suggest that the RBC membrane changes and resulting DMD interactions play a pivotal role in the persistent presence of thrombi. This ultrastructural observation might open a renewed debate regarding possible additional structural and biochemical roles of RBCs in the circulatory system. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Pretorius, Etheresia] Univ Pretoria, Fac Hlth Sci, Dept Physiol, ZA-0007 Arcadia, South Africa.
[Lipinski, Boguslaw] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Pretorius, E (reprint author), Univ Pretoria, Fac Hlth Sci, Dept Physiol, Private Bag x323, ZA-0007 Arcadia, South Africa.
EM resia.pretorius@up.ac.za
OI Pretorius, Etheresia/0000-0002-9108-2384
FU Medical Research Council of South Africa
FX The Medical Research Council of South Africa funded the research of E.
Pretorius.
NR 5
TC 11
Z9 11
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-8807
J9 CARDIOVASC PATHOL
JI Cardiovasc. Pathol.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 241
EP 242
DI 10.1016/j.carpath.2012.11.005
PG 2
WC Cardiac & Cardiovascular Systems; Pathology
SC Cardiovascular System & Cardiology; Pathology
GA 153YV
UT WOS:000319639600009
PM 23312065
ER
PT J
AU Ekundayo, OJ
Saver, JL
Fonarow, GC
Schwamm, LH
Xian, Y
Zhao, X
Hernandez, AF
Peterson, ED
Cheng, EM
AF Ekundayo, Olaniyi James
Saver, Jeffrey L.
Fonarow, Gregg C.
Schwamm, Lee H.
Xian, Ying
Zhao, Xin
Hernandez, Adrian F.
Peterson, Eric D.
Cheng, Eric M.
TI Patterns of Emergency Medical Services Use and Its Association With
Timely Stroke Treatment Findings From Get With the Guidelines-Stroke
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE emergency medical services; Get With the Guidelines-Stroke; stroke
ID TRANSIENT ISCHEMIC ATTACK; TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE
DASH; NORTH-CAROLINA; POPULATION; KNOWLEDGE; DELAY; INTERVENTION;
STATEMENT; COMMUNITY
AB Background-Prior studies found that only about half of stroke patients arrived at hospitals via emergency medical services (EMSs), yet since then, there have been efforts to increase public awareness that time is brain. Using contemporary Get With the Guidelines-Stroke data, we assessed nationwide EMS use by stroke patients.
Methods and Results-We analyzed data from 204 591 patients with ischemic and hemorrhagic stroke admitted to 1563 Get With the Guidelines-Stroke participating hospitals with data on National Institute of Health Stroke Score and insurance status. Hospital arrival by EMSs was observed in 63.7% of patients. Older patients, those with Medicaid and Medicare insurance, and those with severe stroke were more likely to activate EMSs. In contrast, minority race and ethnicity and living in rural communities were associated with decreased odds of EMS use. EMS transport was independently associated with earlier arrival (onset-to-door time, <= 3 hours; adjusted odds ratio, 2.00; 95% confidence interval, 1.93-2.08), prompter evaluation (more patients with door-to-imaging time, <= 25 minutes; odds ratio, 1.89; 95% confidence interval, 1.78-2.00), more rapid treatment (more patients with door-to-needle time, <= 60 minutes; odds ratio, 1.44; 95% confidence interval, 1.28-1.63), and more eligible patients to be treated with tissue-type plasminogen activator if onset is <= 2 hours (67% versus 44%; odds ratio, 1.47; 95% confidence interval, 1.33-1.64).
Conclusions-Although EMS use is independently associated with more rapid evaluation and treatment of stroke, more than one third of stroke patients fail to use EMSs. Interventions aimed at increasing EMS activation should target populations at risk, particularly younger patients and those of minority race and ethnicity.
C1 [Ekundayo, Olaniyi James] Meharry Med Coll, Dept Family & Community Med, Nashville, TN 37208 USA.
[Saver, Jeffrey L.] Univ Calif Los Angeles, UCLA Stroke Ctr, Los Angeles, CA USA.
[Ekundayo, Olaniyi James; Saver, Jeffrey L.; Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Xian, Ying; Zhao, Xin; Hernandez, Adrian F.; Peterson, Eric D.] Duke Univ, Duke Clin Res Inst, Durham, NC USA.
[Cheng, Eric M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Ekundayo, OJ (reprint author), Meharry Med Coll, Dept Family & Community Med, 1005 Dr DB. Todd Jr Blvd,Old Hosp Bldg,Ste C216, Nashville, TN 37208 USA.
EM jekundayo@mmc.edu
RI Hernandez, Adrian F./A-7818-2016
OI Saver, Jeffrey/0000-0001-9141-2251; Schwamm, Lee/0000-0003-0592-9145;
Hernandez, Adrian F./0000-0003-3387-9616
FU American Heart Association (AHA); National Institutes of Health/National
Institute of Neurological Disorders and Stroke [K23NS058571]; National
Institutes of Health; Agency for Healthcare Research and Quality; AHA
[0675060N]
FX Drs Ekundayo, Fonarow, Saver, Xian, Hernandez, Peterson, and Cheng are
supported by an award from the American Heart Association (AHA)
Pharmaceutical Roundtable and David and Stevie Spina. Dr Cheng is
supported by a career development award from National Institutes of
Health/National Institute of Neurological Disorders and Stroke
(K23NS058571). Dr Fonarow serves as a member of the AHA GWTG Steering
Committee; receives research support from the National Institutes of
Health (significant) and Agency for Healthcare Research and Quality
(significant); and serves as a consultant to Novartis (significant). Dr
Saver serves as a member of the GWTG Science Subcommittee; serves as a
scientific consultant regarding trial design and conduct to CoAxia,
Concentric Medical, Talacris, Ferrer, Photothera, Brainsgate, Sygnis,
and Ev3; received lecture honoraria from Ferrer; and is an employee of
the University of California, which holds a patent on retriever devices
for stroke. Drs Zhao and Hernandez are members of the Duke Clinical
Research Institute, which serves as the AHA GWTG data coordinating
center. Dr Hernandez is a recipient of an AHA Pharmaceutical Roundtable
grant (0675060N); has received a research grant from Johnson & Johnson;
and has received honorarium from AstraZeneca and Amgen. Dr Peterson has
received research grants from Lilly, Johnson & Johnson, Bristol-Myers
Squibb, Sanofi-Aventis, and Merck-Schering Plough partnership. Dr
Peterson serves as principle investigator of the Data Analytic Center
for AHA GWTG. Dr Schwamm serves as chair of the AHA GWTG Steering
Committee; serves as a consultant to the Research Triangle Institute and
the Massachusetts Department of Public Health; and serves on the
Steering Committee for Lundbeck's Desmoteplase in Acute Ischemic Stroke
(DIAS4) clinical trial.
NR 34
TC 26
Z9 26
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2013
VL 6
IS 3
BP 262
EP 269
DI 10.1161/CIRCOUTCOMES.113.000089
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 150LS
UT WOS:000319392600006
PM 23633218
ER
PT J
AU Qian, F
Fonarow, GC
Smith, EE
Xian, Y
Pan, WQ
Hannan, EL
Shaw, BA
Glance, LG
Peterson, ED
Eapen, ZJ
Hernandez, AF
Schwamm, LH
Bhatt, DL
AF Qian, Feng
Fonarow, Gregg C.
Smith, Eric E.
Xian, Ying
Pan, Wenqin
Hannan, Edward L.
Shaw, Benjamin A.
Glance, Laurent G.
Peterson, Eric D.
Eapen, Zubin J.
Hernandez, Adrian F.
Schwamm, Lee H.
Bhatt, Deepak L.
TI Racial and Ethnic Differences in Outcomes in Older Patients With Acute
Ischemic Stroke
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE disparities; outcome; race and ethnicity; stroke
ID AMERICAN-HEART-ASSOCIATION; NORTHERN MANHATTAN STROKE; QUALITY-OF-CARE;
GUIDELINES-STROKE; HEALTH-CARE; PLASMINOGEN-ACTIVATOR; MORTALITY;
DISPARITIES; POPULATION; BLACKS
AB Background-Little is known as to whether long-term outcomes of acute ischemic stroke (AIS) vary by race/ethnicity. Using the American Heart Association Get With The Guidelines-Stroke registry linked with Medicare claims data set, we examined whether 30-day and 1-year outcomes differed by race/ethnicity among older patients with AIS.
Methods and Results-We analyzed 200 900 patients with AIS >65 years of age (170 694 non-Hispanic whites, 85.0%; 20 514 non-Hispanic blacks, 10.2%; 6632 Hispanics, 3.3%; 3060 non-Hispanic Asian Americans, 1.5%) from 926 US centers participating in the Get With The Guidelines-Stroke program from April 2003 through December 2008. Compared with whites, other racial and ethnic groups were on average younger and had a higher median score on the National Institutes of Health Stroke Scale. Whites had higher 30-day unadjusted mortality than other groups (white versus black versus Hispanic versus Asian=15.0% versus 9.9% versus 11.9% versus 11.1%, respectively). Whites also had higher 1-year unadjusted mortality (31.7% versus 28.6% versus 28.1% versus 23.9%, respectively) but lower 1-year unadjusted all-cause rehospitalization (54.7% versus 62.5% versus 60.0% versus 48.6%, respectively). After risk adjustment, Asian American patients with AIS had lower 30-day and 1-year mortality than white, black, and Hispanic patients. Relative to whites, black and Hispanic patients had higher adjusted 1-year all-cause rehospitalization (black: adjusted odds ratio, 1.28 [95% confidence interval, 1.21-1.37]; Hispanic: adjusted odds ratio, 1.22 [95% confidence interval, 1.11-1.35]), whereas Asian patients had lower odds (adjusted odds ratio, 0.83 [95% confidence interval, 0.74-0.94]).
Conclusions-Among older Medicare beneficiaries with AIS, there were significant differences in long-term outcomes by race/ethnicity, even after adjustment for stroke severity, other prognostic variables, and hospital characteristics.
C1 [Qian, Feng; Hannan, Edward L.; Shaw, Benjamin A.] SUNY Albany, Rensselaer, NY 12144 USA.
[Fonarow, Gregg C.] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Xian, Ying; Pan, Wenqin; Peterson, Eric D.; Eapen, Zubin J.; Hernandez, Adrian F.] Duke Univ, Durham, NC USA.
[Glance, Laurent G.] Univ Rochester, Rochester, NY USA.
[Schwamm, Lee H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Qian, F (reprint author), SUNY Albany, Sch Publ Hlth, Dept Hlth Policy Management & Behav, GEC Room 169,1 Univ Pl, Rensselaer, NY 12144 USA.
EM fqian@albany.edu
RI Smith, Eric/C-5443-2012; Hernandez, Adrian F./A-7818-2016
OI Smith, Eric/0000-0003-3956-1668; Schwamm, Lee/0000-0003-0592-9145;
Hernandez, Adrian F./0000-0003-3387-9616
NR 46
TC 22
Z9 22
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2013
VL 6
IS 3
BP 284
EP 292
DI 10.1161/CIRCOUTCOMES.113.000211
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 150LS
UT WOS:000319392600009
PM 23680966
ER
PT J
AU Ko, DT
Wijeysundera, HC
Jackevicius, CA
Yousef, A
Wang, J
Tu, JV
AF Ko, Dennis T.
Wijeysundera, Harindra C.
Jackevicius, Cynthia A.
Yousef, Altayyeb
Wang, Julie
Tu, Jack V.
TI Diabetes Mellitus and Cardiovascular Events in Older Patients With
Myocardial Infarction Prescribed Intensive-Dose and Moderate-Dose
Statins
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE acute coronary syndrome; intensive-dose statins; new-onset diabetes
mellitus
ID ACUTE CORONARY SYNDROMES; MORTALITY PREDICTION RULES; HEART-DISEASE
MORTALITY; LIPID-LOWERING THERAPY; ELDERLY-PATIENTS; ADMINISTRATIVE
DATA; METAANALYSIS; ONTARIO; RISK; ASSOCIATION
AB Background-Practice guidelines recommend intensive-dose statins for patients with acute coronary syndrome, but recent data about the risk of new-onset diabetes mellitus have raised concerns about its use. Our main objective was to evaluate the association between intensive statin therapy and new-onset diabetes mellitus in patients with myocardial infarction and to evaluate the association of intensive statin therapy with long-term adverse clinical outcomes.
Methods and Results-A propensity score-matched cohort was created consisting of 17 080 patients with myocardial infarction aged >65 years old, hospitalized in Ontario, Canada, from 2004 to 2010. Clinical outcomes were compared in patients prescribed intensive-dose versus moderate-dose statins at hospital discharge. At 5 years, 13.6% of patients receiving intensive-dose statins and 13.0% of patients receiving moderate-dose statins had new-onset diabetes, which was not significantly different (P=0.19). By contrast, the 5-year rate of death or acute coronary syndrome was significantly lower at 44.8% in the intensive-dose statin group compared with 46.5% in the moderate-dose group (P=0.044). The reduction in combined clinical outcome was driven mainly by a significantly lower rate of acute coronary syndrome (P=0.039) associated with intensive-dose statins. No significant difference in mortality rates (34.8% in both groups) was observed between the treatment groups during the study period (P=0.89).
Conclusions-In older patients with myocardial infarction, we found intensive-dose statin therapy to be effective in reducing repeat hospitalization for acute coronary syndrome. The rate of new-onset diabetes mellitus at long term was not significantly different between intensive-dose and moderate-dose statins.
C1 [Ko, Dennis T.; Wijeysundera, Harindra C.; Jackevicius, Cynthia A.; Yousef, Altayyeb; Wang, Julie; Tu, Jack V.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Ko, Dennis T.; Wijeysundera, Harindra C.; Tu, Jack V.] Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Toronto, ON M4N 3M5, Canada.
[Ko, Dennis T.; Wijeysundera, Harindra C.; Jackevicius, Cynthia A.; Tu, Jack V.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA USA.
[Jackevicius, Cynthia A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Ko, DT (reprint author), Inst Clin Evaluat Sci G1 06, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM dennis.ko@ices.on.ca
OI Ko, Dennis/0000-0001-6840-8051
FU Institute for Clinical Evaluative Sciences; Ontario Ministry of Health
and Long-Term Care; Canadian Institutes of Health Research [102487];
Canada Research Chair in Health Services Research; Heart and Stroke
Foundation of Ontario
FX This study was supported by the Institute for Clinical Evaluative
Sciences, which is funded by an annual grant from the Ontario Ministry
of Health and Long-Term Care. The opinions, results and conclusions
reported in this article are those of the authors and are independent
from the funding sources. No endorsement by the Institute for Clinical
Evaluative Sciences or the Ontario Ministry of Health and Long-term Care
is intended or should be inferred.; The analysis of this study was
supported by a Canadian Institutes of Health Research operating grant
MOP (102487). Dr Ko is supported by a Canadian Institutes of Health
Research New Investigator Award. Dr Tu is supported by a Canada Research
Chair in Health Services Research and a Career Investigator Award from
the Heart and Stroke Foundation of Ontario.
NR 32
TC 20
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2013
VL 6
IS 3
BP 315
EP 322
DI 10.1161/CIRCOUTCOMES.111.000015
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 150LS
UT WOS:000319392600013
PM 23674307
ER
PT J
AU Sternfeld, B
LaCroix, A
Caan, BJ
Dunn, AL
Newton, KM
Reed, SD
Guthrie, KA
Booth-LaForce, C
Sherman, KJ
Cohen, L
Freeman, MP
Carpenter, JS
Hunt, JR
Roberts, M
Ensrud, KE
AF Sternfeld, Barbara
LaCroix, Andrea
Caan, Bette J.
Dunn, Andrea L.
Newton, Katherine M.
Reed, Susan D.
Guthrie, Katherine A.
Booth-LaForce, Cathryn
Sherman, Karen J.
Cohen, Lee
Freeman, Marlene P.
Carpenter, Janet S.
Hunt, Julie R.
Roberts, Melanie
Ensrud, Kristine E.
TI Design and methods of a multi-site, multi-behavioral treatment trial for
menopausal symptoms: The MsFLASH experience
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Vasomotor symptoms; Randomized controlled trial; Yoga; Exercise; Omega-3
fatty acids; Factorial design
ID RANDOMIZED CONTROLLED-TRIAL; HEART-RATE-VARIABILITY; POSTMENOPAUSAL
WOMEN; PHYSICAL-ACTIVITY; UNITED-STATES; HOT FLUSHES; HEALTH; YOGA;
OMEGA-3-FATTY-ACIDS; TRANSITION
AB Background: Behavioral strategies are recommended for menopausal symptoms, but little evidence exists regarding efficacy.
Purpose: Describe design and methodology of a randomized controlled 3 by 2 factorial trial of yoga, exercise and omega-3 fatty acids.
Methods: Women from three geographic areas with a weekly average of >= 14 hot flashes/night sweats, who met exclusion/inclusion criteria, were randomized to 12 weeks of: 1) yoga classes and daily home practice; 2) supervised, facility-based aerobic exercise training; or 3) usual activity. Women in each arm were further randomized to either omega-3 supplement or placebo. Standardized training, on-going monitoring, and site visits were adopted to ensure consistency across sites and fidelity to the intervention. Participant adherence to the intervention protocol was monitored continuously, and retention was actively encouraged by staff. Information on adverse events was systematically collected.
Results: Of 7377 women who responded to mass mailings, 355 (4.8%) were randomized; mean age was 54.7 (sd = 3.7), 26.2% were African American, 81.7% were post-menopausal, and mean baseline frequency of daily hot flashes/night sweats was 7.6 (sd = 3.8). Adherence of >= 80% was 59% for yoga, 77% for exercise training, and 80% for study pills. Final week 12 data were collected from 95.2%
Conclusions: Conducting a multi-site, multi-behavioral randomized trial for menopausal symptoms is challenging but feasible. Benefits included cost-effective study design, centralized recruitment, and methodologic standardization. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Sternfeld, Barbara; Caan, Bette J.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
[LaCroix, Andrea; Guthrie, Katherine A.; Hunt, Julie R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Dunn, Andrea L.] Klein Buendel Inc, Denver, CO USA.
[Newton, Katherine M.; Sherman, Karen J.] Grp Hlth Res Inst, Seattle, WA USA.
[Reed, Susan D.] Univ Washington, Sch Med, Seattle, WA USA.
[Booth-LaForce, Cathryn] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
[Cohen, Lee; Freeman, Marlene P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Carpenter, Janet S.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA.
[Roberts, Melanie] Natl Inst Fitness & Sport, Indianapolis, IN USA.
[Ensrud, Kristine E.] Univ Minnesota, Dept Med, VA Med Ctr, Dept Med & Epidemiol, Minneapolis, MN 55455 USA.
RP Sternfeld, B (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM Barbara.sternfeld@kp.org
FU National Institute of Aging (NIA); Eunice Kennedy Shriver National
Institute of Child Health and Development (NICHD); National Center for
Complementary and Alternative Medicine (NCCAM); Office of Research and
Women's Health (ORWH); NIA At the Indiana University site [U01 AG032656,
U01AG032659, U01AG032669, U01AG032682, U01AG032699, U01AG032700];
Indiana Clinical and Translational Sciences Institute; National
Institutes of Health, National Center for Research Resources [UL1
RR025761]; Clinical and Translational Sciences Award
FX This study was supported by a cooperative agreement issued by the
National Institute of Aging (NIA), in collaboration with the Eunice
Kennedy Shriver National Institute of Child Health and Development
(NICHD), the National Center for Complementary and Alternative Medicine
(NCCAM) and the Office of Research and Women's Health (ORWH), and grants
U01 AG032656, U01AG032659, U01AG032669, U01AG032682, U01AG032699,
U01AG032700 from the NIA At the Indiana University site, the project was
funded in part with support from the Indiana Clinical and Translational
Sciences Institute, funded in part by grant UL1 RR025761 from the
National Institutes of Health, National Center for Research Resources,
Clinical and Translational Sciences Award.
NR 31
TC 14
Z9 14
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAY
PY 2013
VL 35
IS 1
BP 25
EP 34
DI 10.1016/j.cct.2013.02.009
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 153YD
UT WOS:000319637800004
PM 23462342
ER
PT J
AU Berge, EM
Bowles, DW
Flaig, TW
Lam, ET
Jimeno, A
AF Berge, E. M.
Bowles, D. W.
Flaig, T. W.
Lam, E. T.
Jimeno, A.
TI TIVOZANIB: PRACTICAL IMPLICATIONS FOR RENAL CELL CARCINOMA AND OTHER
SOLID TUMORS
SO DRUGS OF TODAY
LA English
DT Article
DE Tivozanib; VEGFR-1 (FLT-1) inhibitors; VEGFR-2 (FLK-1/KDR) inhibitors;
VEGFR-3 (FLT-4) inhibitors; TIVO
ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-III TRIAL;
ANTITUMOR-ACTIVITY; DOUBLE-BLIND; LUNG-CANCER; RETROSPECTIVE ANALYSIS;
SELECTIVE INHIBITOR; AXITINIB AG-013736; 1ST-LINE TREATMENT
AB Tivozanib is a recently developed, small-molecule tyrosine kinase inhibitor with specific affinity for the vascular endothelial growth factor receptor (VEGFR) family of kinases. Given known relevance of VHL (Von Hippel-Lindau disease tumor suppressor) deregulation in the clear cell variant of renal cell carcinoma, renal cell carcinoma remains an area of interest and subject of recent registration trials with this approach. TIVO-1, a phase III study evaluating tivozanib versus sorafenib in the first-line setting, met its primary endpoint of progression-free survival (11.9 months for tivozanib vs. 9.1 months for sorafenib), with a manageable toxicity profile, leading to formal consideration of regulatory approval in this setting. This review focuses on the preclinical development, pharmacokinetics and early clinical activity of tivozanib in renal cell carcinoma and other solid tumors.
C1 [Berge, E. M.; Bowles, D. W.; Flaig, T. W.; Lam, E. T.; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA.
[Bowles, D. W.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Jimeno, A (reprint author), Univ Colorado, Sch Med, Div Med Oncol, 12801 East 17th Ave,MS 8117, Aurora, CO 80045 USA.
EM antonio.jimeno@ucdenver.edu
FU Novartis; GlaxoSmithKline; Pfizer; Bayer/Onyx; Genentech; Bristol-Myers
Squibb; Argos; Exelixis
FX T. Flaig sits on the advisory board of GTx, and has acted as a
consultant for sanofi-aventis. he has received clinical trial funding
from Novartis, GlaxoSmithKline, Pfizer, Bayer/Onyx and Genentech. E. Lam
has received research funding from Bristol-Myers Squibb, Argos,
Genentech and Exelixis. The other authors state no conflicts of
interest.
NR 78
TC 5
Z9 5
U1 0
U2 4
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD MAY
PY 2013
VL 49
IS 5
BP 303
EP 315
DI 10.1358/dot.2013.49.5.1960218
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 155PC
UT WOS:000319759400002
PM 23724410
ER
PT J
AU Jennesson, M
van Eeghen, AM
Caruso, PA
Paolini, JL
Thiele, EA
AF Jennesson, Melanie
van Eeghen, Agnies M.
Caruso, Paul A.
Paolini, Jan L.
Thiele, Elizabeth A.
TI Clobazam therapy of refractory epilepsy in tuberous sclerosis complex
SO EPILEPSY RESEARCH
LA English
DT Article
DE Epilepsy; Drug therapy; Anticonvulsants; Clobazam
ID ADD-ON THERAPY; CHILDREN; EFFICACY; LAMOTRIGINE; EXPERIENCE
AB Clobazam (CLB) was recently approved by the FDA, but has not been evaluated in tuberous sclerosis complex (TSC). We retrospectively reviewed a cohort of patients with TSC and refractory epilepsy who started CLB over a 5-year period. Clinical characteristics and number of tubers on MRI were assessed. Duration of therapy, therapeutic response and adverse events were recorded. CLB was prescribed in 29 adults and children of whom 72% were cognitively impaired, with a median age at seizure onset of 5 months. Mean duration of CLB therapy was 17.3 months with a 12 and 24-month estimated retention rate of 82% and 68%, respectively. Twenty patients (69%) reported a good response (>50% seizure reduction) at the end of the titration, and six patients (21%) remained good responders after 12 months of CLB therapy. Adverse events occurred in 13 patients, predominantly somnolence and behavioral disorders. One quarter of the responders reported improvement in behavior. No predictive factor for a good response could be identified. CLB appears to be a well-tolerated and valuable option for treatment of refractory epilepsy in TSC. (C) 2012 Published by Elsevier B.V.
C1 [Jennesson, Melanie; van Eeghen, Agnies M.; Paolini, Jan L.; Thiele, Elizabeth A.] Massachusetts Gen Hosp, Pediat Epilepsy Program, Dept Neurol, Boston, MA 02114 USA.
[Caruso, Paul A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Thiele, EA (reprint author), Massachusetts Gen Hosp, Pediat Epilepsy Program, 175 Cambridge St,Suite 340, Boston, MA 02114 USA.
EM ethiele@partners.org
FU Carol and James Herscot Center for Tuberous Sclerosis Complex;
"association des Amis de l'American Memorial Hospital de Reims" (France)
FX This study was supported by the Carol and James Herscot Center for
Tuberous Sclerosis Complex.; Dr. Jennesson receives financial assistance
from the "association des Amis de l'American Memorial Hospital de Reims"
(France).
NR 28
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
J9 EPILEPSY RES
JI Epilepsy Res.
PD MAY
PY 2013
VL 104
IS 3
BP 269
EP 274
DI 10.1016/j.eplepsyres.2012.10.010
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 150DC
UT WOS:000319369400011
PM 23219029
ER
PT J
AU Braunwald, E
AF Braunwald, Eugene
TI Chronic heart failure: a look through the rear view mirror
SO EUROPEAN HEART JOURNAL
LA English
DT Editorial Material
ID NATRIURETIC PEPTIDE; MORTALITY; MORBIDITY; DEATH
C1 Harvard Univ, Sch Med, TIMI Study Grp, Div Cardiovasc Med,Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Braunwald, E (reprint author), Harvard Univ, Sch Med, TIMI Study Grp, Div Cardiovasc Med,Brigham & Womens Hosp, Boston, MA 02115 USA.
EM ebraunwald@partners.org
NR 7
TC 6
Z9 6
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD MAY
PY 2013
VL 34
IS 19
BP 1391
EP 1392
DI 10.1093/eurheartj/ehs363
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 151MN
UT WOS:000319464700005
PM 23103661
ER
PT J
AU Murphy, SA
AF Murphy, Sabina A.
TI When 'digoxin use' is not the same as 'digoxin use': lessons from the
AFFIRM trial
SO EUROPEAN HEART JOURNAL
LA English
DT Editorial Material
ID PROPENSITY SCORE
C1 Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
RP Murphy, SA (reprint author), Brigham & Womens Hosp, TIMI Study Grp, 350 Longwood Ave,1st Off Floor, Boston, MA 02115 USA.
EM smurphy15@partners.org
NR 9
TC 10
Z9 10
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD MAY
PY 2013
VL 34
IS 20
BP 1465
EP 1467
DI 10.1093/eurheartj/eht087
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 151MQ
UT WOS:000319465000005
PM 23592709
ER
PT J
AU Rice, TR
Sher, L
AF Rice, T. R.
Sher, L.
TI Killing in combat and suicide risk
SO EUROPEAN PSYCHIATRY
LA English
DT Letter
DE Suicide; Epidemiology; Suicide risk assessment; Veterans; Military
combat; Aggression
ID MENTAL-HEALTH SYMPTOMS; WAR VETERANS; IMPACT
C1 [Rice, T. R.; Sher, L.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Sher, L.] James P Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Rice, TR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.
EM Timothy.Rice@mssm.edu
NR 9
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0924-9338
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD MAY
PY 2013
VL 28
IS 4
BP 261
EP 261
DI 10.1016/j.eurpsy.2012.10.001
PG 1
WC Psychiatry
SC Psychiatry
GA 152RL
UT WOS:000319548700010
PM 23182848
ER
PT J
AU Cano, T
Morales-Quezada, JL
Bikson, M
Fregni, F
AF Cano, Thais
Morales-Quezada, Jorge Leon
Bikson, Marom
Fregni, Felipe
TI Methods to focalize noninvasive electrical brain stimulation: principles
and future clinical development for the treatment of pain
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Editorial Material
DE brain mapping; clinical practice; electrical stimulation; electrical
stimulation therapy; neuronal plasticity; pain; transcranial direct
current stimulation; transcranial magnetic stimulation
ID MOTOR CORTEX; HD-TDCS; ELECTROTHERAPY; MODULATION
C1 [Cano, Thais; Morales-Quezada, Jorge Leon; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil,Lab Neuromodulat, Boston, MA 02115 USA.
[Cano, Thais; Morales-Quezada, Jorge Leon; Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Bikson, Marom] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA.
RP Fregni, F (reprint author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil,Lab Neuromodulat, Boston, MA 02115 USA.
EM fregni.felipe@mgh.harvard.edu
NR 23
TC 6
Z9 6
U1 1
U2 7
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7175
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD MAY
PY 2013
VL 13
IS 5
BP 465
EP 467
DI 10.1586/ERN.13.41
PG 3
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 150EK
UT WOS:000319372800002
PM 23621302
ER
PT J
AU Manchikanti, L
Boswell, MV
Hirsch, JA
AF Manchikanti, Laxmaiah
Boswell, Mark V.
Hirsch, Joshua A.
TI Lessons learned in the abuse of pain-relief medication: a focus on
healthcare costs
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
DE abuse; adverse consequences; chronic pain; diversion; healthcare costs;
lessons learned; misuse; opioid use; opioids
ID CHRONIC NONCANCER PAIN; LOW-BACK-PAIN; PRESCRIPTION OPIOID ABUSE;
PHYSICIANS ASIPP GUIDELINES; MASS-SPECTROMETRY LC/MS/MS; CHRONIC
NONMALIGNANT PAIN; ILLICIT DRUG-USE; UNITED-STATES; OVERDOSE DEATHS;
PRESCRIBING PATTERNS
AB The increasing prevalence of chronic pain with its major societal impact and the escalating use of opioids in managing it, along with their misuse, abuse, associated fatalities and costs, are epidemics in modern medicine. Over the past two decades, multiple lessons have been learned addressing various issues of abuse. Multiple measures have already been incorporated and more are expected to be incorporated in the future, which in turn may curtail the abuse of drugs and reduce healthcare costs, but these measures may also jeopardize access to appropriate pain treatment. This manuscript describes the lessons learned from the misuse, abuse and diversion of opioids, escalating healthcare costs and the means to control this epidemic.
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY 42003 USA.
[Manchikanti, Laxmaiah; Boswell, Mark V.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40202 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA.
RP Manchikanti, L (reprint author), Pain Management Ctr Paducah, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
NR 126
TC 18
Z9 18
U1 2
U2 17
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7175
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD MAY
PY 2013
VL 13
IS 5
BP 527
EP 544
DI 10.1586/ERN.13.33
PG 18
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 150EK
UT WOS:000319372800014
PM 23621310
ER
PT J
AU Bhatia, RS
Milford, CE
Picard, MH
Weiner, RB
AF Bhatia, R. Sacha
Milford, Creagh E.
Picard, Michael H.
Weiner, Rory B.
TI An Educational Intervention Reduces the Rate of Inappropriate
Echocardiograms on an Inpatient Medical Service
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE appropriate use criteria; feedback; resident education; transthoracic
echocardiography
ID APPROPRIATE USE CRITERIA; CARDIOLOGY FOUNDATION/AMERICAN SOCIETY;
TRANSTHORACIC ECHOCARDIOGRAPHY; REMINDER MESSAGES; RANDOMIZED-TRIAL;
PRIMARY-CARE; IMPROVEMENT; REFERRALS; FEEDBACK; QUALITY
AB OBJECTIVES This study sought to prospectively study the impact of an appropriate use criteria (AUC)-based educational intervention on transthoracic echocardiography (TIE) ordering among house staff on the inpatient general internal medicine service at an academic medical center.
BACKGROUND AUC for TIE were developed in response to concerns about inappropriate use of TIE. To date, educational interventions based on the AUC to reduce inappropriate use of TIT have not been prospectively studied.
METHODS A prospective, time series analysis of an educational intervention was conducted and then compared with TIE ordering on the same medical service during a control period. The intervention consisted of: 1) a lecture to house staff on the 2011 AUC for TIE; 2) a pocket card that applied the AUC to common clinical scenarios; and 3) biweekly e-mail feedback regarding ordering behavior. TIE ordering was tracked over the intervention period on a daily basis and feedback reports were e-mailed at 2-week intervals. The primary outcome was the proportion of inappropriate and appropriate TIE ordered during the intervention period.
RESULTS Of all TTEs ordered in the control and study periods, 99% and 98%, respectively, were classifiable using the 2011 AUC. During the study period, there was a 26% reduction in the number of TTE ordered per day compared with the number ordered during the control period (2.9 vs. 3.9 TIE, p < 0.001). During the study period, the proportion of inappropriate TIE was significantly lower (5% vs. 13%, p < 0.001) and the proportion of appropriate TIE was significantly higher (93% vs. 84%, p < 0.001).
CONCLUSIONS A simple educational intervention produced a significant reduction in the proportion of inappropriate TIE and increased the proportion of appropriate TIT ordered on an inpatient academic medical service. This study provides a practical approach for using the AUC to reduce the number of inappropriate TIE. Further study in other practice environments is warranted. (J Am Coll Cardiol Img 2013;6:545-55) (C) 2013 by the American College of Cardiology Foundation
C1 [Bhatia, R. Sacha; Milford, Creagh E.; Picard, Michael H.; Weiner, Rory B.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Weiner, RB (reprint author), Massachusetts Gen Hosp, Div Cardiol, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA.
EM rweiner@partners.org
OI Picard, Michael/0000-0002-9264-3243
FU Massachusetts General Physicians Organization Clinical Innovation Award
FX This study was funded by the Massachusetts General Physicians
Organization Clinical Innovation Award. The authors have reported that
they have no relationships relevant to the contents of this paper to
disclose.
NR 25
TC 43
Z9 43
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD MAY
PY 2013
VL 6
IS 5
BP 545
EP 555
DI 10.1016/j.jcmg.2013.01.010
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 154CH
UT WOS:000319648600002
PM 23582360
ER
PT J
AU Taiwo, B
Hunt, PW
Gandhi, RT
Ellingson, A
McKenna, M
Jacobson, JM
Gripshover, B
Bosch, RJ
AF Taiwo, Babafemi
Hunt, Peter W.
Gandhi, Rajesh T.
Ellingson, Andrew
McKenna, Matthew
Jacobson, Jeffrey M.
Gripshover, Barbara
Bosch, Ronald J.
TI CD8+T-Cell Activation in HIV-1-Infected Patients Experiencing Transient
Low-level Viremia During Antiretroviral Therapy
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 19th Conference on Retroviruses and Opportunistic Infections (CROI)
CY MAR 05-08, 2012
CL Seattle, WA
DE low level; viremia; blip; immune; activation; CD8(+)
ID HIV-INFECTED PATIENTS; INTERMITTENT VIREMIA; IMMUNE ACTIVATION; VIRAL
SUPPRESSION; DRUG-RESISTANCE; BLIPS; RECONSTITUTION; INDIVIDUALS;
REPLICATION; RESERVOIR
AB Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4(+) T-cell reconstitution. Using CD38/HLA-DR expression on CD8(+) T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8(+) T-cell activation and that higher CD8(+) T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.
C1 [Taiwo, Babafemi] Northwestern Univ, Div Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA.
[Hunt, Peter W.] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA.
[Gandhi, Rajesh T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Gandhi, Rajesh T.] Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp, Ragon Inst, Charlestown, MA USA.
[Ellingson, Andrew; McKenna, Matthew; Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Jacobson, Jeffrey M.] Drexel Univ, Coll Med, Div Infect Dis & HIV MED, Philadelphia, PA 19104 USA.
[Gripshover, Barbara] Case Western Reserve Univ, Div Infect Dis & HIV MED, Cleveland, OH USA.
RP Taiwo, B (reprint author), Northwestern Univ, Div Infect Dis, 645 N Michigan Ave,Suite 900, Chicago, IL 60611 USA.
EM b-taiwo@northwestern.edu
FU NIAID NIH HHS [U01 AI068636, UM1 AI069496, U01AI068636, UM1 AI069471,
U01 AI068634, UM1 AI069412, U01AI68634]
NR 25
TC 13
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2013
VL 63
IS 1
BP 101
EP 104
DI 10.1097/QAI.0b013e3182895af4
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 146SW
UT WOS:000319112200023
PM 23392463
ER
PT J
AU Schmults, CD
Karia, PS
Carter, JB
Han, JL
Qureshi, AA
AF Schmults, Chrysalyne D.
Karia, Pritesh S.
Carter, Joi B.
Han, Jiali
Qureshi, Abrar A.
TI Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell
Carcinoma A 10-Year, Single-Institution Cohort Study
SO JAMA DERMATOLOGY
LA English
DT Article
ID ADJUVANT RADIOTHERAPY; SPECIMENS FORMALIN; SKIN EXCISION; RISK;
METASTASES; SHRINKAGE; SURGERY; CANCER; NECK; HEAD
AB Importance: Although most cases of cutaneous squamous cell carcinoma (CSCC) are easily cured with surgery or ablation, a subset of these tumors recur, metastasize, and cause death. We conducted the largest study of CSCC outcomes since 1968.
Objective: To identify risk factors independently associated with poor outcomes in primary CSCC.
Design: A 10-year retrospective cohort study.
Setting: An academic hospital in Boston.
Participants: Nine hundred eighty-five patients with 1832 tumors.
Main Outcomes and Measures: Subhazard ratios for local recurrence, nodal metastasis, disease-specific death, and all-cause death adjusted for presence of known prognostic risk factors.
Results: The median follow-up was 50 (range, 2-142) months. Local recurrence occurred in 45 patients (4.6%) during the study period; 36 (3.7%) developed nodal metastases; and 21 (2.1%) died of CSCC. In multivariate competing risk analyses, independent predictors for nodal metastasis and disease-specific death were a tumor diameter of at least 2 cm (subhazard ratios, 7.0 [95% CI, 2.2-21.6] and 15.9 [4.8-52.3], respectively), poor differentiation (6.1 [2.5-14.9] and 6.7 [2.7-16.5], respectively), invasion beyond fat (9.3 [2.8-31.1] and 13.0 [4.3-40.0], respectively), and ear or temple location (3.8 [1.1-13.4] and 5.9 [1.3-26.7], respectively). Perineural invasion was also associated with disease-specific death (subhazard ratio, 3.6 [95% CI, 1.1-12.0]), as was anogenital location, but few cases were anogenital. Overall death was associated with poor differentiation (subhazard ratio, 1.3 [95% CI, 1.1-1.6]) and invasion beyond fat (1.7 [1.1-2.8]).
Conclusions and Relevance: Cutaneous squamous cell carcinoma carries a low but significant risk of metastasis and death. In this study, patients with CSCC had a 3.7% risk of metastasis and 2.1% risk of diseasespecific death. Tumor diameter of at least 2 cm, invasion beyond fat, poor differentiation, perineural invasion, and ear, temple, or anogenital location were risk factors associated with poor outcomes. Accurate risk estimation of outcomes from population-based data and clinical trials proving the utility of disease-staging modalities and adjuvant therapy is needed.
C1 [Schmults, Chrysalyne D.; Karia, Pritesh S.; Han, Jiali; Qureshi, Abrar A.] Harvard Univ, Brigham & Womens Hosp, Dept Dermatol, Sch Med, Boston, MA 02115 USA.
[Carter, Joi B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Schmults, CD (reprint author), Brigham & Womens Hosp, Dept Dermatol, 1153 Ctr St,Ste 4349, Jamaica Plain, MA 02130 USA.
EM cschmults@partners.org
NR 26
TC 52
Z9 52
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAY
PY 2013
VL 149
IS 5
BP 541
EP 547
PG 7
WC Dermatology
SC Dermatology
GA 154JV
UT WOS:000319672100005
PM 23677079
ER
PT J
AU Hamilton, JR
Parvataneni, R
Stuart, SE
Chren, MM
AF Hamilton, Jeffrey R.
Parvataneni, Rupa
Stuart, Sarah E.
Chren, Mary-Margaret
TI Rerecurrence 5 Years After Treatment of Recurrent Cutaneous Basal Cell
and Squamous Cell Carcinoma
SO JAMA DERMATOLOGY
LA English
DT Letter
ID MOHS MICROGRAPHIC SURGERY
C1 [Hamilton, Jeffrey R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
[Parvataneni, Rupa; Stuart, Sarah E.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, Mt Zion Canc Res Bldg,2340 Sutter St,Room N412,Ma, San Francisco, CA 94143 USA.
EM chrenm@derm.ucsf.edu
FU NIAMS NIH HHS [K24 AR052667, R01 AR054983]
NR 5
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAY
PY 2013
VL 149
IS 5
BP 616
EP 618
PG 4
WC Dermatology
SC Dermatology
GA 154JV
UT WOS:000319672100026
PM 23677098
ER
PT J
AU Shive, M
Bhatt, M
Cantino, A
Kvedar, J
Jethwani, K
AF Shive, Melissa
Bhatt, Mehul
Cantino, Andrew
Kvedar, Joseph
Jethwani, Kamal
TI Perspectives on Acne: What Twitter Can Teach Health Care Providers
SO JAMA DERMATOLOGY
LA English
DT Letter
C1 [Shive, Melissa] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA.
[Shive, Melissa] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Bhatt, Mehul] Harvard Univ, Sch Business, Boston, MA 02163 USA.
[Cantino, Andrew] Iterat Labs LLC, San Francisco, CA USA.
[Kvedar, Joseph; Jethwani, Kamal] Dept Dermatol, Boston, MA USA.
[Bhatt, Mehul] Harvard Univ, Sch Med, Boston, MA USA.
[Kvedar, Joseph; Jethwani, Kamal] Partners Healthcare, Ctr Connected Hlth, Boston, MA USA.
[Kvedar, Joseph; Jethwani, Kamal] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
RP Jethwani, K (reprint author), Ctr Connected Hlth, 25 New Chardon St, Boston, MA 02114 USA.
EM kjethwani@partners.org
NR 5
TC 9
Z9 10
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAY
PY 2013
VL 149
IS 5
BP 621
EP 622
PG 2
WC Dermatology
SC Dermatology
GA 154JV
UT WOS:000319672100028
PM 23677100
ER
PT J
AU Liou, AP
AF Liou, A. P.
TI DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: G protein-coupled receptors
in nutrient chemosensation and gastrointestinal hormone secretion
SO JOURNAL OF ANIMAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 12th International Symposium on Digestive Physiology of Pigs
CY MAY 29-JUN 01, 2012
CL Keystone, CO
DE carbohydrate sensing; enteroendocrine; intestinal chemosensation; lipid
sensing; protein sensing; taste receptors
ID CALCIUM-SENSING RECEPTOR; GLUCAGON-LIKE PEPTIDE-1; CHAIN FATTY-ACIDS;
EXTRACELLULAR CA2+-SENSING RECEPTOR; ENTEROENDOCRINE STC-1 CELLS; RAT
SMALL-INTESTINE; STIMULATE CHOLECYSTOKININ SECRETION; BITTER TASTE
RECEPTORS; MOUSE SMALL-INTESTINE; SWEET TASTE
AB The gastrointestinal tract is a highly effective and efficient organ system that digests and absorbs nutrients, contributes to the regulation of glucose homeostasis, and signals postprandial satiety. A network of enteroendocrine cells orchestrates these events through the release of neuropeptide hormones secreted in response to the specific nutrient components within the intraluminal milieu. Nutrient chemosensing by these cells is mediated by cell membrane proteins that have been localized to hormone-producing cells. However, functional studies of the nutrient detection abilities of the endocrine cell population have been limited due to its rare and singly distributed cell type. Recent technological advances have enabled investigations with primary endocrine cells that promise to enhance our current understanding of enteroendocrine cell biology. This review focuses on a particular subset of chemosensing receptors, the G protein-coupled receptors (GPCR), that have been identified as putative nutrient sensors of the major macronutrients, lipids, proteins, and carbohydrates by enteroendocrine cells. The contributions of these receptors in directly activating and stimulating hormone secretion in several subsets of enteroendocrine cells will be discussed, based on evidence gathered by functional studies in animal models, in vitro studies in endocrine cell lines, and newly described findings in primary endocrine cells. Key insights in chemosensory detection and hormone secretion from enteroendocrine cells may help further the studies in larger animal models and guide the formulation of feed or supplements to influence the gastrointestinal signals regulating optimal food intake, absorptive capacity, and growth.
C1 [Liou, A. P.] Massachusetts Gen Hosp, Obes Metab & Nutr Inst, Boston, MA 02114 USA.
[Liou, A. P.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
RP Liou, AP (reprint author), Massachusetts Gen Hosp, Obes Metab & Nutr Inst, Boston, MA 02114 USA.
EM aliou@partners.org
FU Lucta S. A. (Barcelona, Spain); American Society of Animal Science;
Journal of Animal Science
FX Based on a presentation at the preconference symposium titled "Gut
Chemosensing: Integrating nutrition, gut function and metabolism in
pigs" preceding the 12th International Symposium on Digestive Physiology
of Pigs in Keystone, Colorado, May 29 to June 1, 2012, with publication
sponsored by Lucta S. A. (Barcelona, Spain), the American Society of
Animal Science, and the Journal of Animal Science.
NR 107
TC 9
Z9 10
U1 2
U2 25
PU AMER SOC ANIMAL SCIENCE
PI CHAMPAIGN
PA PO BOX 7410, CHAMPAIGN, IL 61826-7410 USA
SN 0021-8812
EI 1525-3163
J9 J ANIM SCI
JI J. Anim. Sci.
PD MAY
PY 2013
VL 91
IS 5
BP 1946
EP 1956
DI 10.2527/jas.2012-5910
PG 11
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 154TA
UT WOS:000319697600003
PM 23230119
ER
PT J
AU Kaji, I
Akiba, Y
Kaunitz, JD
AF Kaji, I.
Akiba, Y.
Kaunitz, J. D.
TI DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Involvement of gut
chemosensing in the regulation of mucosal barrier function and defense
mechanisms
SO JOURNAL OF ANIMAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 12th International Symposium on Digestive Physiology of Pigs
CY MAY 29-JUN 01, 2012
CL Keystone, CO
DE anion secretion; bicarbonate; duodenum; enteroendocrine cells;
glucagon-like peptides; serotonin
ID DUODENAL ENTEROENDOCRINE CELLS; INTESTINAL EPITHELIUM; BICARBONATE
SECRETION; ENDOCRINE-CELLS; RAT DUODENUM; PEPTIDASE-IV; BLOOD-FLOW;
RECEPTOR; GUSTDUCIN; RELEASE
AB Meal ingestion is followed by release of numerous hormones from enteroendocrine cells interspersed among the epithelial cells lining the intestine. Recently, the de-orphanization of G protein-coupled receptor (GPCR)-type nutrient receptors, expressed on the apical membranes of enteroendocrine cells, has suggested a plausible mechanism whereby luminal nutrients trigger the release of gut hormones. Activation of nutrient receptors triggers intracellular signaling mechanisms that promote exocytosis of hormone-containing granules into the submucosal space. Hormones released by foregut enteroendocrine cells include the glucagon-like peptides (GLP) affecting glycemic control (GLP-1) and releasing proproliferative, hypertrophy-inducing growth factors (GLP-2). The foregut mucosa, being exposed to pulses of concentrated HCl, is protected by a system of defense mechanisms, which includes epithelial bicarbonate and mucus secretion and augmentation of mucosal blood flow. We have reported that luminal co-perfusion of AA with nucleotides in anesthetized rats releases GLP-2 into the portal vein, associated with increased bicarbonate and mucus secretion and mucosal blood flow. The GLP-2 increases bicarbonate secretion via release of vasoactive intestinal peptide (VIP) from myenteric nerves. Luminal bile acids also release gut hormones due to activation of the bile-acid receptor known as G Protein-Coupled Receptor (GPR) 131, G Protein Bile Acid Receptor (GPBAR) 1, or Takeda G Protein-Coupled Receptor (TGR) 5, also expressed on enteroendocrine cells. The GLP are metabolized by dipeptidyl peptidase IV (DPPIV), an enzyme of particular interest to pharmaceutical, because its inhibition increases plasma concentrations of GLP-1 to treat diabetes. We have also reported that DPPIV inhibition enhances the secretory effects of nutrient-evoked GLP-2. Understanding the release mechanism and the metabolic pathways of gut hormones is of potential utility to the formulation of feedstuff additives that, by increasing nutrient absorption due to increased mucosal mass, can increase yields.
C1 [Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Affairs Healthcare Syst, WLAVA Med Ctr, Los Angeles, CA 90095 USA.
[Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, Brentwood Biomed Res, Los Angeles, CA 90095 USA.
[Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Kaji, I.; Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Kaji, I.] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.
RP Kaunitz, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Affairs Healthcare Syst, WLAVA Med Ctr, Los Angeles, CA 90095 USA.
EM jake@ucla.edu
FU Lucta S.A. (Barcelona, Spain); American Society of Animal Science;
Journal of Animal Science; Japan Society for the Promotion of Science;
Ajinomoto, Japan; Department of Veterans Affairs; NIH-NIDDK [R01
DK54221]
FX Based on a presentation at the preconference symposium titled "Gut
Chemosensing: Integrating nutrition, gut function and metabolism in
pigs" preceding the 12th International Symposium on Digestive Physiology
of Pigs in Keystone, Colorado, May 29-June 1, 2012, with publication
sponsored by Lucta S.A. (Barcelona, Spain), the American Society of
Animal Science, and the Journal of Animal Science.; We thank Bea Palileo
for her assistance with manuscript preparation. Supported by funding
from a Grant-in-Aid for Japan Society for the Promotion of Science
Fellow (I. Kaji), a research grant from Ajinomoto, Japan (Y. Akiba),
Department of Veterans Affairs Merit Review Award (J.D. Kaunitz), and
NIH-NIDDK R01 DK54221 (J.D. Kaunitz).
NR 32
TC 5
Z9 6
U1 1
U2 18
PU AMER SOC ANIMAL SCIENCE
PI CHAMPAIGN
PA PO BOX 7410, CHAMPAIGN, IL 61826-7410 USA
SN 0021-8812
EI 1525-3163
J9 J ANIM SCI
JI J. Anim. Sci.
PD MAY
PY 2013
VL 91
IS 5
BP 1957
EP 1962
DI 10.2527/jas.2012-5941
PG 6
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 154TA
UT WOS:000319697600004
PM 23345558
ER
PT J
AU Sharifi, M
Marshall, G
Marshall, R
Bottino, C
Goldman, R
Sequist, T
Taveras, EM
AF Sharifi, Mona
Marshall, Gareth
Marshall, Richard
Bottino, Clement
Goldman, Roberta
Sequist, Thomas
Taveras, Elsie M.
TI Accelerating Progress in Reducing Childhood Obesity Disparities:
Exploring Best Practices of Positive Outliers
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Editorial Material
DE Obesity; disparities; children; positive outliers
ID WEIGHT-LOSS MAINTENANCE; HEART-DISEASE RISK; PEER-SUPPORT;
RANDOMIZED-TRIAL; COST-EFFECTIVENESS; AFRICAN-AMERICANS; CONTROL
REGISTRY; US CHILDREN; DEVIANCE; INTERVENTION
AB Childhood obesity rates may have plateaued in some U.S. population subgroups, yet overall rates remain high and racial/ethnic and socioeconomic disparities appear to be widening. Successful strategies and best practices to inform obesity interventions and accelerate progress in reducing disparities in childhood obesity can be found among people who can be categorized as positive outliers, i.e., individuals who have succeeded, where many others have not, in changing their health behaviors, reducing their body mass index, and developing resilience in the context of adverse built and social environments. In this commentary, we discuss the central premise of a positive outlier approach and how successful strategies learned from positive outliers can be generalized and promoted to accelerate progress in childhood obesity.
C1 [Sharifi, Mona; Marshall, Gareth] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA USA.
[Sharifi, Mona; Marshall, Gareth] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Sharifi, Mona; Bottino, Clement] Boston Childrens Hosp, Dept Med, Div Gen Pediat, Boston, MA USA.
[Marshall, Richard; Sequist, Thomas] Harvard Vanguard Med Associates, Dept Pediat, Boston, MA USA.
[Goldman, Roberta] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Sequist, Thomas] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Taveras, Elsie M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Taveras, EM (reprint author), 100 Cambridge St, Boston, MA 02114 USA.
EM etavaras@partners.org
NR 40
TC 4
Z9 4
U1 0
U2 6
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2013
VL 24
IS 2
SU S
BP 193
EP 199
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 151VB
UT WOS:000319487300018
PM 23727974
ER
PT J
AU Maciejewski, PK
Prigerson, HG
AF Maciejewski, Paul K.
Prigerson, Holly G.
TI Emotional Numbness Modifies the Effect of End-of-Life Discussions on
End-of-Life Care
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Cancer; terminal illness; end-of-life care; communication; numbness;
psychological reactions; grief; dissociation
ID ILL PATIENTS; NEAR-DEATH; DISSOCIATION; COMMUNICATION; QUESTIONNAIRE;
ASSOCIATIONS; PROGNOSIS; SYMPTOMS; DISTRESS; OUTCOMES
AB Context. Overall, end-of-life (EOL) discussions are unrelated to psychological distress and associated with lower rates of aggressive care near death. Nevertheless, patients who report that they feel emotionally numb about their illness might encounter difficulties cognitively processing an EOL discussion.
Objectives. We hypothesized that emotional numbness would modify the effect of EOL discussions on the receipt of less aggressive EOL care.
Methods. Data were derived from structured interviews with 290 participants in the federally-funded Coping with Cancer Study, a multisite, prospective cohort study of patients with advanced cancer followed-up till their death. Patients' reports of EOL discussions with their physician and emotional numbness were assessed at a median of 4.6 months before their death. Information about aggressive EOL care (i.e., ventilation, resuscitation in the last week of life, death in the intensive care unit) was obtained from postmortem caregiver interviews and medical charts. Main and interactive effects of EOL discussions and emotional numbness on aggressive EOL care, adjusting for potential confounds, were evaluated using multiple logistic regression.
Results. The likelihood of aggressive EOL care associated with having EOL discussions increased by a factor of nine (adjusted odds ratio = 9.02, 95% CI 1.37, 59.6, P = 0.022) for every unit increase in a patient's emotional numbness score.
Conclusion. Emotional numbness diminishes a patient's capacity to benefit from EOL discussions. The EOL decision making may be more effective if clinical communications with emotionally numb patients are avoided. (C) 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Maciejewski, Paul K.; Prigerson, Holly G.] Harvard Univ, Brigham & Womens Hosp, Dept Psychiat, Sch Med, Boston, MA 02115 USA.
[Maciejewski, Paul K.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA.
[Maciejewski, Paul K.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA.
RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, 1134 Dana Bldg,450 Brookline Ave, Boston, MA 02115 USA.
EM holly_prigerson@dfci.harvard.edu
FU National Institute of Mental Health [MH63892]; National Cancer Institute
[CA 106370, CA 156732]
FX This research was supported in part by the following grants to Dr. H. G.
Prigerson: MH63892 from the National Institute of Mental Health, and CA
106370 and CA 156732 from the National Cancer Institute. Neither author
has relationships with any entities having financial interest in this
topic.
NR 19
TC 10
Z9 10
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD MAY
PY 2013
VL 45
IS 5
BP 841
EP 847
DI 10.1016/j.jpainsymman.2012.04.003
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 145YU
UT WOS:000319056800010
PM 22926093
ER
PT J
AU Johansen, KL
AF Johansen, Kirsten L.
TI Obesity and Body Composition for Transplant Wait-List
Candidacy-Challenging or Maintaining the BMI Limits?
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID MASS INDEX; RENAL-TRANSPLANTATION; WEIGHT; ASSOCIATIONS; RECIPIENTS;
MORTALITY; OUTCOMES; IMPACT; GRAFT
AB Most kidney transplantation programs have a maximum body mass index (BMI) above which they will not place a patient on the active waiting list. However, obesity is common among patients with end-stage renal disease (ESRD), and weight loss is difficult, resulting in many patients being denied the opportunity to be considered for a transplant. BMI limits are in place because of data that outcomes are worse among obese transplant recipients than among those with lower BMI. However, the data to suggest that patient and graft survival are affected by obesity are not consistent, and obese patients with ESRD have better survival after kidney transplantation compared with remaining on dialysis. Therefore, it is important to carefully examine the question of BMI limits to ensure that we are achieving the right balance and making the best use of donated kidneys. (C) 2013 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
RP Johansen, KL (reprint author), Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM kirsten.johansen@ucsf.edu
FU National Institutes of Health [N01-DK-7-0005]
FX This work was supported in part by National Institutes of Health
contract N01-DK-7-0005. The interpretation and reporting of the data
presented here are the responsibility of the authors and in no way
should be seen as an official policy or interpretation of the U.S.
government.
NR 14
TC 5
Z9 5
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAY
PY 2013
VL 23
IS 3
BP 207
EP 209
DI 10.1053/j.jrn.2013.02.005
PG 3
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA 147XF
UT WOS:000319203500014
PM 23611548
ER
PT J
AU Kopans, DB
AF Kopans, Daniel B.
TI Point: The New England Journal of Medicine Article Suggesting
Overdiagnosis From Mammography Screening Is Scientifically Incorrect and
Should Be Withdrawn
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID BREAST-CANCER INCIDENCE; MORTALITY; AGE
C1 Harvard Univ, Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Breast Imaging Div,Dept Radiol,Sch Med, Boston, MA 02114 USA.
RP Kopans, DB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Breast Imaging Div,Dept Radiol,Sch Med, 15 Parkman St,ACC Suite 240, Boston, MA 02114 USA.
EM dkopans@partners.org
NR 10
TC 16
Z9 16
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2013
VL 10
IS 5
BP 317
EP 319
DI 10.1016/j.jacr.2013.01.024
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 146NR
UT WOS:000319098300007
PM 23542028
ER
PT J
AU Kopans, DB
AF Kopans, Daniel B.
TI Counterpoint: The New England Journal of Medicine Article Suggesting
Overdiagnosis From Mammography Screening Is Scientifically Correct and
Should Not Be Withdrawn Response
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID SUPPORT
C1 Harvard Univ, Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Breast Imaging Div,Dept Radiol,Sch Med, Boston, MA 02114 USA.
RP Kopans, DB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Breast Imaging Div,Dept Radiol,Sch Med, 15 Parkman St,ACC Suite 240, Boston, MA 02114 USA.
EM dkopans@partners.org
NR 4
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2013
VL 10
IS 5
BP 324
EP 324
DI 10.1016/j.jacr.2013.01.015
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 146NR
UT WOS:000319098300010
ER
PT J
AU Woodard, PK
White, RD
Abbara, S
Araoz, PA
Cury, RC
Dorbala, S
Earls, JP
Hoffmann, U
Hsu, JY
Jacobs, JE
Javidan-Nejad, C
Krishnamurthy, R
Mammen, L
Martin, ET
Ryan, T
Shah, AB
Steiner, RM
Vogel-Claussen, J
White, CS
AF Woodard, Pamela K.
White, Richard D.
Abbara, Suhny
Araoz, Philip A.
Cury, Ricardo C.
Dorbala, Sharmila
Earls, James P.
Hoffmann, Udo
Hsu, Joe Y.
Jacobs, Jill E.
Javidan-Nejad, Cylen
Krishnamurthy, Rajesh
Mammen, Leena
Martin, Edward T.
Ryan, Thomas
Shah, Amar B.
Steiner, Robert M.
Vogel-Claussen, Jens
White, Charles S.
TI ACR Appropriateness Criteria Chronic Chest Pain-Low to Intermediate
Probability of Coronary Artery Disease
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Appropriateness criteria; chronic chest pain; low probability of
coronary artery disease; intermediate probability of coronary artery
disease
ID CHRONIC STABLE ANGINA; CARDIOVASCULAR MAGNETIC-RESONANCE;
COMPUTED-TOMOGRAPHY ANGIOGRAPHY; ASSOCIATION TASK-FORCE;
EMERGENCY-DEPARTMENT; AMERICAN-COLLEGE; PROGNOSTIC VALUE; CT
ANGIOGRAPHY; PRACTICE GUIDELINES; SYNDROME-X
AB Chronic chest pain can arise from a variety of etiologies. However, of those potential causes, the most life-threatening include cardiac disease. Chronic cardiac chest pain may be caused either by ischemia or atherosclerotic coronary artery disease or by other cardiac-related etiologies, such as pericardial disease. To consider in patients, especially those who are at low risk for coronary artery disease, are etiologies of chronic noncardiac chest pain. Noncardiac chest pain is most commonly related to gastroesophageal reflux disease or other esophageal diseases. Alternatively, it may be related to costochondritis, arthritic or degenerative diseases, old trauma, primary or metastatic tumors, or pleural disease. Rarely, noncardiac chest pain may be referred pain from organ systems below the diaphragm, such as the gallbladder.
The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
C1 [Woodard, Pamela K.] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA.
[White, Richard D.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
[Abbara, Suhny; Hoffmann, Udo] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Araoz, Philip A.] Mayo Clin, Rochester, MN USA.
[Cury, Ricardo C.] Baptist Hosp Miami, Kendall, FL USA.
[Dorbala, Sharmila] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Dorbala, Sharmila] Soc Nucl Med & Mol Imaging, Reston, VA USA.
[Earls, James P.] Fairfax Radiol Consultants, Fairfax, VA USA.
[Hoffmann, Udo] Harvard Univ, Sch Med, Boston, MA USA.
[Hsu, Joe Y.] Kaiser Permanente, Los Angeles, CA USA.
[Jacobs, Jill E.] NYU Med Ctr, New York, NY 10016 USA.
[Javidan-Nejad, Cylen] Washington Univ, Sch Med, St Louis, MO USA.
[Krishnamurthy, Rajesh] Texas Childrens Hosp, Houston, TX 77030 USA.
[Mammen, Leena] Adv Radiol Serv, Grand Rapids, MI USA.
[Martin, Edward T.] Oklahoma Heart Inst, Tulsa, OK USA.
[Martin, Edward T.; Ryan, Thomas] Amer Coll Cardiol, Washington, DC USA.
[Ryan, Thomas] Ohio State Univ, Heart & Vasc Ctr, Columbus, OH 43210 USA.
[Shah, Amar B.] Westchester Med Ctr, Valhalla, NY USA.
[Steiner, Robert M.] Temple Univ Hlth Syst, Philadelphia, PA USA.
[Vogel-Claussen, Jens] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[White, Charles S.] Univ Maryland Hosp, Baltimore, MD 21201 USA.
RP Woodard, PK (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA.
EM woodardp@mir.wustl.edu
OI White, Richard D./0000-0002-1133-7819
FU Astellas Pharma US Inc; GE Healthcare (Milwaukee, Wisconsin); National
Institutes of Health (Bethesda, Maryland)
FX Dr Araoz performs core laboratory analysis for Medtronic, Inc
(Minneapolis, Minnesota). Dr Cury is a consultant for Astellas Pharma US
Inc (Northbrook, Illinois) and has received research grants from
Astellas Pharma US Inc and GE Healthcare (Milwaukee, Wisconsin). Dr
Dorbala has received a research grant from Astellas Pharma US Inc and is
funded by a K23 grant from the National Institutes of Health (Bethesda,
Maryland).
NR 38
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2013
VL 10
IS 5
BP 329
EP 334
DI 10.1016/j.jacr.2013.01.018
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 146NR
UT WOS:000319098300013
PM 23542027
ER
PT J
AU Gunn, AJ
Sahani, DV
Bennett, SE
Choy, G
AF Gunn, Andrew J.
Sahani, Dushyant V.
Bennett, Susan E.
Choy, Garry
TI Re: "Recent Measures to Improve Radiology Reporting: Perspectives From
Primary Care Physicians" Response
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Letter
C1 [Gunn, Andrew J.; Sahani, Dushyant V.; Bennett, Susan E.; Choy, Garry] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gunn, Andrew J.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Sahani, Dushyant V.; Bennett, Susan E.; Choy, Garry] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Gunn, AJ (reprint author), Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2013
VL 10
IS 5
BP 387
EP 388
DI 10.1016/j.jacr.2013.03.008
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 146NR
UT WOS:000319098300029
PM 23642883
ER
PT J
AU Segata, N
Boernigen, D
Tickle, TL
Morgan, XC
Garrett, WS
Huttenhower, C
AF Segata, Nicola
Boernigen, Daniela
Tickle, Timothy L.
Morgan, Xochitl C.
Garrett, Wendy S.
Huttenhower, Curtis
TI Computational meta'omics for microbial community studies
SO MOLECULAR SYSTEMS BIOLOGY
LA English
DT Review
DE meta'omics; microbial communities; microbiome computational models
ID RIBOSOMAL-RNA GENE; COMPARATIVE-ANALYSIS SYSTEM; DISTAL GUT MICROBIOTA;
DE-NOVO ASSEMBLER; SINGLE-CELL; METAGENOMIC SEQUENCES; UNCULTURED
MICROORGANISMS; TAXONOMIC CLASSIFICATION; METABOLIC PATHWAYS; GENOMIC
FRAGMENTS
AB Complex microbial communities are an integral part of the Earth's ecosystem and of our bodies in health and disease. In the last two decades, culture-independent approaches have provided new insights into their structure and function, with the exponentially decreasing cost of high-throughput sequencing resulting in broadly available tools for microbial surveys. However, the field remains far from reaching a technological plateau, as both computational techniques and nucleotide sequencing platforms for microbial genomic and transcriptional content continue to improve. Current microbiome analyses are thus starting to adopt multiple and complementary meta'omic approaches, leading to unprecedented opportunities to comprehensively and accurately characterize microbial communities and their interactions with their environments and hosts. This diversity of available assays, analysis methods, and public data is in turn beginning to enable microbiome-based predictive and modeling tools. We thus review here the technological and computational meta'omics approaches that are already available, those that are under active development, their success in biological discovery, and several outstanding challenges.
C1 [Segata, Nicola; Boernigen, Daniela; Tickle, Timothy L.; Morgan, Xochitl C.; Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Boernigen, Daniela; Tickle, Timothy L.; Morgan, Xochitl C.; Garrett, Wendy S.; Huttenhower, Curtis] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Garrett, Wendy S.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Garrett, Wendy S.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Garrett, Wendy S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Huttenhower, C (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA.
EM chuttenh@hsph.harvard.edu
OI Morgan, Xochitl/0000-0002-6264-6961; Huttenhower,
Curtis/0000-0002-1110-0096; Segata, Nicola/0000-0002-1583-5794
FU NIH [1R01CA154426, 1R01HG005969]; Danone Research [PLF-5972-GD];
Juvenile Diabetes Research Foundation [17-2011-529]; NSF [DBI-1053486];
ARO [W911NF-11-1-0473]
FX We thank Felix Jouwai Wong for assistance with figures, the members of
the Huttenhower and Garrett labs for their input and thoughtful
discussions, and Mihai Pop for his in-depth investigation of metagenome
assembly in the human microbiome. This work was supported by NIH
1R01CA154426 and Danone Research PLF-5972-GD to WSG, the Juvenile
Diabetes Research Foundation 17-2011-529 (Ramnik Xavier), NIH
1R01HG005969, NSF CAREER DBI-1053486, and ARO W911NF-11-1-0473 to CH.
NR 175
TC 90
Z9 93
U1 8
U2 179
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-4292
J9 MOL SYST BIOL
JI Mol. Syst. Biol.
PD MAY
PY 2013
VL 9
AR 666
DI 10.1038/msb.2013.22
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 156QE
UT WOS:000319836700003
PM 23670539
ER
PT J
AU Wolk, DA
Mancuso, L
Kliot, D
Arnold, SE
Dickerson, BC
AF Wolk, David A.
Mancuso, Lauren
Kliot, Daria
Arnold, Steven E.
Dickerson, Bradford C.
TI Familiarity-based memory as an early cognitive marker of preclinical and
prodromal AD
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Memory; Recollection; Familiarity; Alzheimer's disease; Medial temporal
lobe; Preclinical Alzheimer's disease; Mild cognitive impairment
ID MEDIAL TEMPORAL-LOBE; ALZHEIMERS ASSOCIATION WORKGROUPS;
POSITRON-EMISSION-TOMOGRAPHY; SURFACE-BASED ANALYSIS; HUMAN
CEREBRAL-CORTEX; RECOGNITION MEMORY; NEUROFIBRILLARY TANGLES; CORTICAL
SURFACE; AMYLOID BURDEN; OLDER-ADULTS
AB There is great interest in the development of cognitive markers that differentiate "normal" age-associated cognitive change from that of Alzheimer's disease (AD) in its prodromal (i.e., mild cognitive impairment; MCI) or even preclinical stages. Dual process models posit that recognition memory is supported by the dissociable processes of recollection and familiarity. Familiarity-based memory has generally been considered to be spared during normal aging, but it remains controversial whether this type of memory is impaired in early AD. Here, we describe findings of estimates of recollection and familiarity in young adults (YA), cognitively normal older adults (CN), and patients with amnestic-MCI (a-MCI). These measures in the CN and a-MCI patients were then related to a structural imaging biomarker of AD that has previously been demonstrated to be sensitive to preclinical and prodromal AD, the Cortical Signature of AD (ADsig). Consistent with much work in the literature, recollection, but not familiarity, was impaired in CN versus YA. Replicating our prior findings, a-MCI patients displayed impairment in both familiarity and recollection. Finally, the familiarity measure was correlated with the ADsig biomarker across the CN and a-MCI group, as well as within the CN adults alone. No other standard psychometric measure was as highly associated with the ADsig, suggesting that familiarity may be a sensitive biomarker of AD-specific brain changes in preclinical and prodromal AD and that it may offer a qualitatively distinct measure of early AD memory impairment relative to normal age-associated change. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Wolk, David A.; Mancuso, Lauren; Kliot, Daria; Arnold, Steven E.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Wolk, David A.; Mancuso, Lauren; Kliot, Daria; Arnold, Steven E.] Univ Penn, Penn Memory Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Arnold, Steven E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Frontotemporal Dementia Unit, Boston, MA 02114 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Dickerson, Bradford C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Wolk, DA (reprint author), Penn Memory Ctr, 3615 Chestnut St,212, Philadelphia, PA USA.
EM david.wolk@uphs.upenn.edu
FU NIH [K23-AG028018, P30AG010124, R01AG29411, R21AG29840, P50-AG005134];
Alzheimer's Association [NIRG-12-242765]
FX This work was supported by grants from NIH, including K23-AG028018,
P30AG010124, R01AG29411, R21AG29840, P50-AG005134, and the Alzheimer's
Association (NIRG-12-242765).
NR 83
TC 19
Z9 21
U1 0
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD MAY
PY 2013
VL 51
IS 6
BP 1094
EP 1102
DI 10.1016/j.neuropsychologia.2013.02.014
PG 9
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 152MK
UT WOS:000319535600008
PM 23474075
ER
PT J
AU Vuoksimaa, E
Panizzon, MS
Chen, CH
Eyler, LT
Fennema-Notestine, C
Fiecas, MJA
Fischl, B
Franz, CE
Grant, MD
Jak, AJ
Lyons, MJ
Neale, MC
Thompson, WK
Tsuang, MT
Xian, H
Dale, AM
Kremen, WS
AF Vuoksimaa, Eero
Panizzon, Matthew S.
Chen, Chi-Hua
Eyler, Lisa T.
Fennema-Notestine, Christine
Fiecas, Mark Joseph A.
Fischl, Bruce
Franz, Carol E.
Grant, Michael D.
Jak, Amy J.
Lyons, Michael J.
Neale, Michael C.
Thompson, Wesley K.
Tsuang, Ming T.
Xian, Hong
Dale, Anders M.
Kremen, William S.
TI Cognitive reserve moderates the association between hippocampal volume
and episodic memory in middle age
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Cognitive reserve; General cognitive ability; Episodic memory;
Hippocampus; Verbal learning
ID ALZHEIMERS-DISEASE; EDUCATION; PERFORMANCE; IMPAIRMENT; BRAIN; DECLINE;
AD; ENVIRONMENT; HYPOTHESIS; PATHOLOGY
AB Cognitive reserve is hypothesized to help people withstand greater brain pathology without manifesting clinical symptoms, and may be regarded as a preventive factor of dementia. It is unclear whether the effect of cognitive reserve is evident only among the older adults or after conversion to dementia, or if it can also be seen earlier in life before the prominent effects of cognitive aging become apparent. While finding a main effect of cognitive reserve on cognitive outcome may be consistent with the reserve hypothesis, in our view, it is unnecessary to invoke the idea of reserve if only a main effect is present. Rather, it is the interaction between a measure of reserve and a brain measure on cognitive outcome that is key for confirming that the effects of brain pathology affect people differently according to their cognitive reserve. We studied whether general cognitive ability at an average age of 20 years, as a direct measure of cognitive reserve, moderates the association between hippocampal volume and episodic memory performance in 494 middle-aged men ages 51 to 60. Whereas there was no statistically significant direct relationship between hippocampal volume and episodic memory performance in middle age, we found a statistically significant interaction such that there was a positive association between hippocampal volume and episodic memory only among people with lower general cognitive ability at age 20, i.e., lower levels of cognitive reserve. Our results provide support for the hypothesis that cognitive reserve moderates the relationship between brain structure and cognition in middle age, well before the onset of dementia. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Vuoksimaa, Eero; Panizzon, Matthew S.; Chen, Chi-Hua; Eyler, Lisa T.; Fennema-Notestine, Christine; Fiecas, Mark Joseph A.; Franz, Carol E.; Jak, Amy J.; Thompson, Wesley K.; Tsuang, Ming T.; Dale, Anders M.; Kremen, William S.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Vuoksimaa, Eero; Panizzon, Matthew S.; Chen, Chi-Hua; Fiecas, Mark Joseph A.; Franz, Carol E.; Tsuang, Ming T.; Kremen, William S.] Univ Calif San Diego, Ctr Behav Genom, Twin Res Lab, La Jolla, CA 92093 USA.
[Vuoksimaa, Eero] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
[Chen, Chi-Hua; Fiecas, Mark Joseph A.; Dale, Anders M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Eyler, Lisa T.] VA San Diego Healthcare Syst, Mental Illness Res Educ & Clin Ctr, San Diego, CA USA.
[Fennema-Notestine, Christine] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.
[Fischl, Bruce] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Fischl, Bruce] Harvard Univ, Sch Med, Boston, MA USA.
[Fischl, Bruce] MIT, Comp Sci & AI Lab, Cambridge, MA 02139 USA.
[Grant, Michael D.; Lyons, Michael J.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Neale, Michael C.] Virginia Commonwealth Univ, Sch Med, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
[Tsuang, Ming T.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
[Tsuang, Ming T.] Harvard Univ, Sch Med, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA.
[Tsuang, Ming T.] Sch Publ Hlth, Boston, MA USA.
[Xian, Hong] St Louis Vet Affairs Med Ctr, Res Serv, St Louis, MO USA.
[Xian, Hong] St Louis Univ, Sch Publ Hlth, Dept Biostat, St Louis, MO 63103 USA.
[Jak, Amy J.; Kremen, William S.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, La Jolla, CA USA.
RP Vuoksimaa, E (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr MC0738, La Jolla, CA 92093 USA.
EM eero.vuoksimaa@helsinki.fi
OI Fennema-Notestine, Christine/0000-0002-6527-6361; Lyons,
Michael/0000-0001-6516-9219
FU National Institute on Aging [R01 AG022982, R01 AG018386, R01 AG022381,
R01 AG018384]; National Institute of Drug Abuse [DA029475]; National
Institute of Neurological Disorders and Stroke [NS056883]; National
Center for Research Resources [P41-RR14075, BIRN002, U24 RR021382];
National Institute for Biomedical Imaging and Bioengineering [EB006758];
National Center for Alternative Medicine [RC1 AT005728-01]; National
Institute for Neurological Disorders and Stroke [NS052585-01,
1R21NS072652-01, 1R01NS070963]; Ellison Medical Foundation; Academy of
Finland; Sigrid Juselius Foundation
FX This work was supported by grants from the National Institute on Aging
[R01 AG022982, R01 AG018386, and R01 AG022381, R01 AG018384]; National
Institute of Drug Abuse [DA029475]; National Institute of Neurological
Disorders and Stroke [NS056883], National Center for Research Resources
[P41-RR14075, BIRN002, U24 RR021382]; National Institute for Biomedical
Imaging and Bioengineering [EB006758]; National Center for Alternative
Medicine [RC1 AT005728-01]; National Institute for Neurological
Disorders and Stroke [NS052585-01, 1R21NS072652-01, 1R01NS070963]; the
Ellison Medical Foundation; Academy of Finland; and a Sigrid Juselius
Foundation Fellowship (E.V.). The content of this paper is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIA or the NIH.
NR 46
TC 5
Z9 5
U1 3
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
EI 1873-3514
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD MAY
PY 2013
VL 51
IS 6
BP 1124
EP 1131
DI 10.1016/j.neuropsychologia.2013.02.022
PG 8
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 152MK
UT WOS:000319535600012
PM 23499725
ER
PT J
AU Knaul, FM
Chabner, BA
AF Knaul, Felicia M.
Chabner, Bruce A.
TI Announcing a New Section: Global Health and Cancer
SO ONCOLOGIST
LA English
DT Editorial Material
C1 [Knaul, Felicia M.] Harvard Global Equ Initiat, Boston, MA 02115 USA.
[Chabner, Bruce A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Knaul, Felicia M.] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA.
[Chabner, Bruce A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Knaul, FM (reprint author), Harvard Global Equ Initiat, 651 Huntington Ave,FXB Bldg, Boston, MA 02115 USA.
EM felicia_knaul@harvard.edu
NR 6
TC 0
Z9 0
U1 0
U2 2
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD MAY
PY 2013
VL 18
IS 5
BP 485
EP 486
DI 10.1634/theoncologist.2013-0158
PG 2
WC Oncology
SC Oncology
GA 152UA
UT WOS:000319555600001
ER
PT J
AU Yao, JC
Lagunes, DR
Kulke, MH
AF Yao, James C.
Lagunes, Diane Reidy
Kulke, Matthew H.
TI Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial
Challenges and Lessons Learned
SO ONCOLOGIST
LA English
DT Article
DE Everolimus; Neuroendocrine tumors; Octreotide; Sunitinib; Trial design
ID PHASE-II TRIALS; PROGRESSION-FREE SURVIVAL; MALIGNANT
CARCINOID-SYNDROME; ENETS CONSENSUS GUIDELINES; PROGNOSTIC-FACTORS;
ANTICANCER AGENTS; DRUG-DEVELOPMENT; CHROMOGRANIN-A; SOLID TUMORS;
MANAGEMENT
AB In the past 3 years, we have witnessed the completion of four randomized phase Ill studies in neuroendocrine tumors and the approval of two new drugs, everolimus and sunitinib, for the treatment of patients with well-differentiated pancreatic neuroendocrine tumors. These studies demonstrate a shift from case series and single-arm studies toward prospective, randomized controlled clinical trials and evidence-based therapy in the neuroendocrine tumor field. However, the clinical development of these agents also highlights the potential challenges awaiting other new drugs in this area. Herein, we discuss the strengths and weaknesses of the most recent phase II and phase III neuroendocrine tumor studies and discuss how limitations inherent in current trial design can lead to potential pitfalls. We also discuss how trial design can be improved, with the hope of increasing the number of drugs successfully developed to treat patients with neuroendocrine tumors.
C1 [Yao, James C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Lagunes, Diane Reidy] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Yao, JC (reprint author), Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM jyao@mdanderson.org
FU Novartis Pharmaceuticals Corporation
FX The everolimus phase II and III studies discussed in this review were
funded by Novartis Pharmaceuticals Corporation. The studies were
designed by the academic investigators and representatives of the
sponsor. Data were collected with the use of the sponsor's data
management systems and were analyzed by the sponsor's statistical team.
All authors contributed to the interpretation of data and to subsequent
writing, reviewing, and amending of the manuscript. All authors vouch
for the accuracy and completeness of the reported data.
NR 60
TC 17
Z9 17
U1 0
U2 4
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD MAY
PY 2013
VL 18
IS 5
BP 525
EP 532
DI 10.1634/theoncologist.2012-0434
PG 8
WC Oncology
SC Oncology
GA 152UA
UT WOS:000319555600008
PM 23615698
ER
PT J
AU Faris, JE
Blaszkowsky, LS
McDermott, S
Guimaraes, AR
Szymonifka, J
Huynh, MA
Ferrone, CR
Wargo, JA
Allen, JN
Dias, LE
Kwak, EL
Lillemoe, KD
Thayer, SP
Murphy, JE
Zhu, AX
Sahani, DV
Wo, JY
Clark, JW
Fernandez-del Castillo, C
Ryan, DP
Hong, TS
AF Faris, Jason E.
Blaszkowsky, Lawrence S.
McDermott, Shaunagh
Guimaraes, Alexander R.
Szymonifka, Jackie
Huynh, Mai Anh
Ferrone, Cristina R.
Wargo, Jennifer A.
Allen, Jill N.
Dias, Lauren E.
Kwak, Eunice L.
Lillemoe, Keith D.
Thayer, Sarah P.
Murphy, Janet E.
Zhu, Andrew X.
Sahani, Dushyant V.
Wo, Jennifer Y.
Clark, Jeffrey W.
Fernandez-del Castillo, Carlos
Ryan, David P.
Hong, Theodore S.
TI FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts
General Hospital Cancer Center Experience
SO ONCOLOGIST
LA English
DT Article
DE FOLFIRINOX; Locally advanced pancreatic cancer; Neoadjuvant; RO
resection; Chemoradiation
ID PHASE-III; CHEMORADIATION; GEMCITABINE; CHEMORADIOTHERAPY; CHEMOTHERAPY;
ADENOCARCINOMA; CARCINOMA; TRIAL
AB The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic cancer (LAPC). Patients with LAPC treated with FOLFIRINOX were identified via the Massachusetts General Hospital Cancer Center pharmacy data base. Demographic information, clinical characteristics, and safety/tolerability data were compiled. Formal radiographic review was performed to determine overall response rates (ORRs). Twenty-two patients with LAPC began treatment with FOLFIRINOX between July 2010 and February 2012. The ORR was 27.3%, and the median progression-free survival was 11.7 months. Five of 22 patients were able to undergo SO resections following neoadjuvant FOLFIRINOX and chemoradiation. Three of the five patients have experienced distant recurrence within 5 months. Thirty-two percent of patients required at least one emergency department visit or hospitalization while being treated with FOLFIRINOX. FOLFIRINOX possesses substantial activity in patients with LAPC. The use of FOLFIRINOX was associated with conversion to resectability in >20% of patients. However, the recurrences following SO resection in three of five patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC..
C1 [Faris, Jason E.; Blaszkowsky, Lawrence S.; Allen, Jill N.; Kwak, Eunice L.; Murphy, Janet E.; Zhu, Andrew X.; Clark, Jeffrey W.; Ryan, David P.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
[Huynh, Mai Anh; Wo, Jennifer Y.; Hong, Theodore S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[McDermott, Shaunagh; Guimaraes, Alexander R.; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Szymonifka, Jackie; Fernandez-del Castillo, Carlos] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Ferrone, Cristina R.; Lillemoe, Keith D.; Thayer, Sarah P.] Massachusetts Gen Hosp, Dept Gen & Gastrointestinal Surg, Boston, MA 02114 USA.
[Wargo, Jennifer A.] Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA.
[Dias, Lauren E.] North Shore Canc Ctr, Dept Hematol Oncol, Danvers, MA USA.
RP Faris, JE (reprint author), Massachusetts Gen Hosp, Ctr Canc, Yawkey 7E,55 Fruit St, Boston, MA 02114 USA.
EM jfaris@partners.org
FU NCI NIH HHS [P01 CA117969, P50 CA127003]; NIBIB NIH HHS [K08 EB012859]
NR 17
TC 69
Z9 69
U1 0
U2 4
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD MAY
PY 2013
VL 18
IS 5
BP 543
EP 548
DI 10.1634/theoncologist.2012-0435
PG 6
WC Oncology
SC Oncology
GA 152UA
UT WOS:000319555600010
PM 23657686
ER
PT J
AU Misiukiewicz, KJ
Camille, N
Tishler, R
Haddad, R
Limaye, S
Posner, M
AF Misiukiewicz, Krzysztof J.
Camille, Nadia
Tishler, Roy
Haddad, Robert
Limaye, Sewanti
Posner, Marshall
TI Organ Preservation for Adenoid Cystic Carcinoma of the Larynx
SO ONCOLOGIST
LA English
DT Article
DE Adenoid cystic carcinoma; Cancer; Case series; Chemoradiotherapy;
Larynx; Organ-sparing; Organ preservation; Local regional control
ID LOCALLY ADVANCED HEAD; NECK-CANCER; RADIOTHERAPY; CHEMORADIOTHERAPY;
CHEMOTHERAPY; PACLITAXEL; EXPERIENCE; RADIATION; CARBOPLATIN; SURGERY
AB Objectives. Two cases of adenoid cystic carcinoma (ACC) of the larynx were treated with chemoradiotherapy (CRT) for organ preservation. We reviewed case series and current literature to contrast the potential role of primary CRT as an organ-sparing modality with standard laryngectomy and radiotherapy in patients with laryngeal ACC.
Methods. Two treatment-naive patients with laryngeal ACC treated at Dana-Farber Cancer Institute between 2002 and 2007 were identified. Both patients were offered standard laryngectomy followed by adjuvant radiotherapy or organ-sparing treatment modality.
Results. Both patients were males, aged 57 and 73. The patients completed a course of combined chemoradiotherapy with weekly carboplatin and paclitaxel and 7-8 weeks of radiotherapy to a total dose of 6,600 and 7,000 cGy over 50 and 57 days, respectively. There were no treatment breaks or delays because of toxicity. The major toxicities reported by both patients, as anticipated, were Grade 3 mucositis, desquamative dermatitis, and severe dysphagia, all of which resolved. Both patients are alive with local regional control and functional larynx; one at 112+ months with pulmonary metastases at 54 months, and the other disease free at 60+ months.
Conclusions. Definitive chemoradiation with weekly carboplatin and paclitaxel may be a potential alternative to the current standard of surgery and radiation for patients with locally advanced laryngeal ACC who request an organ-sparing approach. In this group of patients, salvage laryngectomy may be reserved for those who are locally recurrent or chemoradiotherapy resistant. Although CRT provided long-term local regional control in our two patients, there are evident limitations in obtaining evidence for a determination of treatment of rare diseases. This report provides support for following an organ preservation plan in selected patients.
C1 [Misiukiewicz, Krzysztof J.; Camille, Nadia; Posner, Marshall] Mt Sinai Sch Med, Dept Med Hematol & Med Oncol, New York, NY 10029 USA.
[Tishler, Roy; Limaye, Sewanti] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Haddad, Robert] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Misiukiewicz, KJ (reprint author), Mt Sinai Sch Med, Dept Med Hematol & Med Oncol, 19E 98th St, New York, NY 10029 USA.
EM Krzysztof.Misiukiewicz@mssm.edu
NR 28
TC 5
Z9 6
U1 0
U2 3
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD MAY
PY 2013
VL 18
IS 5
BP 579
EP 583
DI 10.1634/theoncologist.2012-0349
PG 5
WC Oncology
SC Oncology
GA 152UA
UT WOS:000319555600014
PM 23615699
ER
PT J
AU Bhasin, MK
Dusek, JA
Chang, BH
Joseph, MG
Denninger, JW
Fricchione, GL
Benson, H
Libermann, TA
AF Bhasin, Manoj K.
Dusek, Jeffery A.
Chang, Bei-Hung
Joseph, Marie G.
Denninger, John W.
Fricchione, Gregory L.
Benson, Herbert
Libermann, Towia A.
TI Relaxation Response Induces Temporal Transcriptome Changes in Energy
Metabolism, Insulin Secretion and Inflammatory Pathways
SO PLOS ONE
LA English
DT Article
ID PROTEIN REFERENCE DATABASE; SET ENRICHMENT ANALYSIS; NF-KAPPA-B;
NITRIC-OXIDE; OXIDATIVE-STRESS; PSYCHOLOGICAL STRESS; RISK-FACTORS;
GENOME-WIDE; EXPRESSION; MEDITATION
AB The relaxation response (RR) is the counterpart of the stress response. Millennia-old practices evoking the RR include meditation, yoga and repetitive prayer. Although RR elicitation is an effective therapeutic intervention that counteracts the adverse clinical effects of stress in disorders including hypertension, anxiety, insomnia and aging, the underlying molecular mechanisms that explain these clinical benefits remain undetermined. To assess rapid time-dependent (temporal) genomic changes during one session of RR practice among healthy practitioners with years of RR practice and also in novices before and after 8 weeks of RR training, we measured the transcriptome in peripheral blood prior to, immediately after, and 15 minutes after listening to an RR-eliciting or a health education CD. Both short-term and long-term practitioners evoked significant temporal gene expression changes with greater significance in the latter as compared to novices. RR practice enhanced expression of genes associated with energy metabolism, mitochondrial function, insulin secretion and telomere maintenance, and reduced expression of genes linked to inflammatory response and stress-related pathways. Interactive network analyses of RR-affected pathways identified mitochondrial ATP synthase and insulin (INS) as top upregulated critical molecules (focus hubs) and NF-kappa B pathway genes as top downregulated focus hubs. Our results for the first time indicate that RR elicitation, particularly after long-term practice, may evoke its downstream health benefits by improving mitochondrial energy production and utilization and thus promoting mitochondrial resiliency through upregulation of ATPase and insulin function. Mitochondrial resiliency might also be promoted by RR-induced downregulation of NF-kappa B-associated upstream and downstream targets that mitigates stress.
C1 [Bhasin, Manoj K.; Denninger, John W.; Fricchione, Gregory L.; Benson, Herbert; Libermann, Towia A.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.
[Denninger, John W.; Fricchione, Gregory L.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Benson, Herbert] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
[Bhasin, Manoj K.; Libermann, Towia A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA.
[Bhasin, Manoj K.; Joseph, Marie G.; Libermann, Towia A.] Beth Israel Deaconess Med Ctr, BIDMC Genom & Prote Ctr, Boston, MA 02215 USA.
[Dusek, Jeffery A.] Abbott NW Hosp, Inst Hlth & Healing, Minneapolis, MN 55407 USA.
[Chang, Bei-Hung] VA Boston Healthcare Syst, Boston, MA USA.
[Chang, Bei-Hung] Boston Univ, Dept Hlth Policy & Management, Sch Publ Hlth, Boston, MA USA.
RP Libermann, TA (reprint author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.
EM tliberma@bidmc.harvard.edu
OI Libermann, Towia/0000-0002-4006-8179; Dusek, Jeffery/0000-0001-9581-0564
FU Centers for Disease Control and Prevention (CDC) [H75/CCH123424, R01
DP000339]; National Center for Complementary and Alternative Medicine
(NCCAM) [RO1 AT006464-01]; NCRR, National Institutes of Health (The
Harvard-Thorndike GCRC) [M01 RR01032]
FX The study was funded by grants H75/CCH123424 and R01 DP000339 from the
Centers for Disease Control and Prevention (CDC) (HB), RO1 AT006464-01
from the National Center for Complementary and Alternative Medicine
(NCCAM) (HB) and grant M01 RR01032 from the NCRR, National Institutes of
Health (The Harvard-Thorndike GCRC). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 69
TC 49
Z9 49
U1 4
U2 46
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2013
VL 8
IS 5
AR e62817
DI 10.1371/journal.pone.0062817
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 147KY
UT WOS:000319167000076
PM 23650531
ER
PT J
AU Shah, M
Lee, G
Lefebvre, DR
Kronberg, B
Loomis, S
Brauner, SC
Turalba, A
Rhee, DJ
Freitag, SK
Pasquale, LR
AF Shah, Mamta
Lee, Grace
Lefebvre, Daniel R.
Kronberg, Benjamin
Loomis, Stephanie
Brauner, Stacey C.
Turalba, Angela
Rhee, Douglas J.
Freitag, Suzanne K.
Pasquale, Louis R.
TI A Cross-Sectional Survey of the Association between Bilateral Topical
Prostaglandin Analogue Use and Ocular Adnexal Features
SO PLOS ONE
LA English
DT Article
ID SMOOTH-MUSCLE-CELLS; ORBITAL FAT; MATRIX METALLOPROTEINASES; BIMATOPROST
THERAPY; LID SULCUS; LATANOPROST; INVOLVEMENT; TRAVOPROST
AB We studied the relation between prostaglandin analogue use and ocular adnexal features. We used a prospective, cross-sectional study involving 157 current, 15 past, and 171 never users of prostaglandin analogues. Patients 50 years of age or older and without conditions affecting ocular adnexal anatomy underwent glaucoma medication use history, external digital photography and systematic external adnexal exam. Two masked readers assessed the digital photos for upper lid dermatochalasis and lower lid steatoblepharon using a validated grading scheme. Another masked clinical examiner also assessed upper lid ptosis, levator muscle function, and inferior scleral show. We performed ordinal logistic regression analysis accounting for multiple covariates to assess the relation between prostaglandin analogue use and adnexal features. Multivariable analyses indicated there was a 230-fold increased risk of incremental involution of dermatochalasis (odds ratio (OR) = 2.30; 95% confidence interval (CI) 1.43-3.69; p = 5.44E-04) and a 249-fold increased risk of incremental loss of lower lid steatoblepharon (OR = 2.49; 95% CI, 1.54-4.03; p = 1.98E-04) associated with current prostaglandin analogue use (bimatoprost 0.03%, travoprost 0.005%, or latanoprost 0.004%) versus prostaglandin analogue never or past users. Upper lid ptosis (OR = 4.04; 95% CI, 2.43-6.72; p = 7.37E-08), levator dysfunction (OR = 7.51; 95% CI, 3.39-16.65; p = 6.74E-07) and lower lid retraction (OR = 2.60; 95% CI, 1.58-4.28; p = 1.72E-04) were highly associated with current prostaglandin analogue use versus prostaglandin analogue never or past users. The associations between prostaglandin analogue use and deepening of the upper lid sulci and between prostaglandin analogue use and loss of inferior periorbital fat are confirmed in this multivariable analysis. The associations between prostaglandin analogue use and levator muscle dysfunction and between prostaglandin analogue use and upper lid ptosis represent significant side effects that could impact visual function in glaucoma patients.
C1 [Shah, Mamta] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
[Lee, Grace; Lefebvre, Daniel R.; Kronberg, Benjamin; Loomis, Stephanie; Brauner, Stacey C.; Turalba, Angela; Rhee, Douglas J.; Freitag, Suzanne K.; Pasquale, Louis R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Shah, M (reprint author), Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
EM mshah@bu.edu
FU Research to Prevent Blindness (RPB) Medical Student Fellowship; Harvard
Glaucoma Center of Excellence and a Distinguished Ophthalmology Scholar
award
FX The study is supported by the Research to Prevent Blindness (RPB)
Medical Student Fellowship 2011-2012. The Harvard Glaucoma Center of
Excellence and a Distinguished Ophthalmology Scholar award support Dr.
LRP. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 26
TC 14
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2013
VL 8
IS 5
AR e61638
DI 10.1371/journal.pone.0061638
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 147KY
UT WOS:000319167000019
PM 23650502
ER
PT J
AU Huang, LL
Wan, JB
Wang, B
He, CW
Ma, H
Li, TW
Kang, JX
AF Huang, Li-Li
Wan, Jian-Bo
Wang, Bin
He, Cheng-Wei
Ma, Huan
Li, Tian-Wang
Kang, Jing X.
TI Suppression of acute ethanol-induced hepatic steatosis by
docosahexaenoic acid is associated with downregulation of stearoyl-CoA
desaturase 1 and inflammatory cytokines
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE Alcoholic liver disease; Hepatic steatosis; Docosahexaenoic acid;
Stearoyl-CoA desaturase 1; Inflammatory cytokines
ID ALCOHOLIC-LIVER-DISEASE; POLYUNSATURATED FATTY-ACIDS; ELEMENT-BINDING
PROTEIN-1; FISH-OIL; OXIDATIVE-STRESS; GENE-EXPRESSION; MICE; INJURY;
RATS; DEFICIENCY
AB Excessive alcohol consumption can lead to hepatic steatosis. Omega-3 (n-3) polyunsaturated fatty acids (PUFA) have been shown to be effective in reducing hepatic accumulation of triglycerides (TG) by downregulation of TG biosynthesis in the liver. The aim of this study was to examine whether supplementation with the n-3 PUFA, docosahexaenoic acid (DHA), can effectively reduce acute alcohol-induced hepatic steatosis. Acute alcohol-induced hepatic steatosis was generated in 9-week-old male mice (C57BL/6J) by oral gavage of ethanol (4.7 g/kg BW) diluted in water (60%, v/v), with or without DHA (250 mg/kg BW), every 12 h for 3 administrations. Compared to the control (ethanol-alone) group, animals supplemented with DHA were protected against ethanol-induced TG accumulation in the liver. Accordingly, hepatic stearoyl-CoA desaturase-1 (SCD-1) expression, serum alanine aminotransferase (ALT) activity, and the levels of inflammatory cytokines (such as IL-6 and TNF-alpha) in the liver were significantly reduced, whereas the expression of heme oxygenase-1 (HO-1), an enzyme that can improve cell survival in liver tissue, was markedly increased in DHA-supplemented mice compared to the control animals. There were no differences in serum TG level and hepatic production of reactive oxygen species (ROS) between the two groups. Our findings demonstrate that DHA supplementation protects against acute ethanol-induced hepatic steatosis, which may be associated with reduced expression of SCD-1 and inflammatory cytokines. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Huang, Li-Li; Wan, Jian-Bo; Wang, Bin; He, Cheng-Wei; Ma, Huan; Li, Tian-Wang; Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA.
[Huang, Li-Li; Wan, Jian-Bo; Wang, Bin; He, Cheng-Wei; Ma, Huan; Li, Tian-Wang; Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA.
[Huang, Li-Li] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Obstet & Gynecol, Guangzhou 510275, Guangdong, Peoples R China.
[Wan, Jian-Bo; He, Cheng-Wei] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Peoples R China.
RP Kang, JX (reprint author), Massachusetts Gen Hosp, Room 4001,149 13th St, Charlestown, MA 02129 USA.
EM jxkang@partners.org
RI Wan, Jian-Bo/D-8368-2014
OI Wan, Jian-Bo/0000-0002-6750-2617
FU E-fund Education Foundation, Guangzhou, China
FX This study is partially supported by the E-fund Education Foundation,
Guangzhou, China.
NR 44
TC 21
Z9 22
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD MAY
PY 2013
VL 88
IS 5
BP 347
EP 353
DI 10.1016/j.plefa.2013.02.002
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
GA 152RU
UT WOS:000319549600003
PM 23474173
ER
PT J
AU Zhang, JJ
Zhang, LJ
Ye, XX
Chen, LY
Zhang, LT
Gao, YH
Kang, JX
Cai, C
AF Zhang, Junjie
Zhang, Lijian
Ye, Xiaoxia
Chen, Liyu
Zhang, Liangtao
Gao, Yihua
Kang, Jing X.
Cai, Chun
TI Characteristics of fatty acid distribution is associated with colorectal
cancer prognosis
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE Fatty acid; Colorectal cancer; Gas chromatography; Mass spectrometry
ID ALPHA-LINOLENIC ACID; BREAST-CANCER; PROSTATE-CANCER; PLASMA
PHOSPHOLIPIDS; ADIPOSE-TISSUE; CELL-GROWTH; OLEIC-ACID; RISK;
ERYTHROCYTE; PROLIFERATION
AB To investigate tissue fatty acid distribution in relation to the incidence of colorectal cancer prognosis, adjacent normal tissue and cancerous tissue from 35 samples of clinically incident colorectal cancer were obtained. Fatty acids were measured in the colorectal mucosa phospholipid fraction by gas chromatography mass spectrometry. Palmitoleic acid and oleic acid were significantly lower in colorectal cancerous tissue, ranging from 20% to 50% less than the adjacent normal tissue. The omega-6 (n-6) fatty acid family members (20:2, 20:3, 20:4 and 22:4) were higher by 1-3 fold in cancerous colorectal tissue. Contrary with the high level of n-6 fatty acids, about a 37% to 87% reduction in EPA and DHA was observed in colorectal cancerous tissue. A higher level of linoleic acid and arachidonic acid was detected in the C cancer stage than in the B cancer stage (p < 0.05), but a lower level of oleic acid and docosahexenoic acid was detected in the C cancer stage (p < 0.05). The fatty acid distribution of colorectal tissue is strongly linked to the incidence of colorectal cancer. This study also provides scientific basis for identifying novel biomarkers for the diagnosis and treatment of cancer. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Zhang, Junjie; Zhang, Lijian; Ye, Xiaoxia; Chen, Liyu; Zhang, Liangtao; Gao, Yihua; Cai, Chun] Guangdong Med Coll, Zhanjiang 524023, Guangdong, Peoples R China.
[Kang, Jing X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
RP Zhang, LJ (reprint author), Guangdong Med Coll, 2 Eastern Wenming Rd, Zhanjiang 524023, Guangdong, Peoples R China.
EM gdmczlj@sina.com
FU National Natural Science Foundation of China
FX This work was supported by a grant from The National Natural Science
Foundation of China.
NR 45
TC 9
Z9 9
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
EI 1532-2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD MAY
PY 2013
VL 88
IS 5
BP 355
EP 360
DI 10.1016/j.plefa.2013.02.005
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
Metabolism
GA 152RU
UT WOS:000319549600004
PM 23465412
ER
PT J
AU Yuppa, DP
Nichols, S
AF Yuppa, David Peter
Nichols, Scott
TI Amiodarone-Induced Delirium in Advanced Cancer: A Case Report
SO PSYCHOSOMATICS
LA English
DT Article
C1 [Yuppa, David Peter; Nichols, Scott] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10021 USA.
RP Yuppa, DP (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave,SW411, Boston, MA 02215 USA.
EM davidyuppa@gmail.com
NR 9
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
J9 PSYCHOSOMATICS
JI Psychosomatics
PD MAY-JUN
PY 2013
VL 54
IS 3
BP 294
EP 296
PG 3
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 151WQ
UT WOS:000319491500014
PM 23218061
ER
PT J
AU Van Tyne, D
Martin, MJ
Gilmore, MS
AF Van Tyne, Daria
Martin, Melissa J.
Gilmore, Michael S.
TI Structure, Function, and Biology of the Enterococcus faecalis Cytolysin
SO TOXINS
LA English
DT Review
DE cytolysin; lantibiotic; bacteriocin
ID HOST BACILLUS-SUBTILIS; STREPTOCOCCUS-FAECALIS; LIPID-II; HEMOLYSIN
BACTERIOCIN; ANTIMICROBIAL RESISTANCE; PATHOGENICITY ISLAND; LANTIBIOTIC
NISIN; PROKARYOTIC CELLS; VIRULENCE FACTORS; IN-VITRO
AB Enterococcus faecalis is a Gram-positive commensal member of the gut microbiota of a wide range of organisms. With the advent of antibiotic therapy, it has emerged as a multidrug resistant, hospital-acquired pathogen. Highly virulent strains of E. faecalis express a pore-forming exotoxin, called cytolysin, which lyses both bacterial and eukaryotic cells in response to quorum signals. Originally described in the 1930s, the cytolysin is a member of a large class of lanthionine-containing bacteriocins produced by Gram-positive bacteria. While the cytolysin shares some core features with other lantibiotics, it possesses unique characteristics as well. The current understanding of cytolysin biosynthesis, structure/function relationships, and contribution to the biology of E. faecalis are reviewed, and opportunities for using emerging technologies to advance this understanding are discussed.
C1 [Gilmore, Michael S.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Microbiol & Immunobiol, Boston, MA 02114 USA.
RP Gilmore, MS (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM michael_gilmore@meei.harvard.edu
FU NIH/NIAID [AI083214]; NIH [AI072360, EY08289]
FX Portions of this work were supported by the NIH/NIAID supported
Harvard-wide Program on Antibiotic Resistance (AI083214), and by NIH
research grants to examine different aspects of the pathogenesis of
enterococci (AI072360, EY08289). The authors also thank current and
former members of the Gilmore Laboratory for input and feedback during
the preparation of this manuscript.
NR 99
TC 25
Z9 25
U1 0
U2 36
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6651
J9 TOXINS
JI Toxins
PD MAY
PY 2013
VL 5
IS 5
BP 895
EP 911
DI 10.3390/toxins5050895
PG 17
WC Toxicology
SC Toxicology
GA 151CO
UT WOS:000319438400003
PM 23628786
ER
PT J
AU Bovenberg, MSS
Degeling, MH
Tannous, BA
AF Bovenberg, M. Sarah S.
Degeling, M. Hannah
Tannous, Bakhos A.
TI Advances in stem cell therapy against gliomas
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
DE neural stem cells; mesenchymal stem cells; hematopoietic stem cells;
cell therapy; glioma; clinical trials; gene therapy; prodrug; oncolytic
virus
ID MESENCHYMAL STROMAL CELLS; HEMATOPOIETIC PROGENITOR CELLS; HUMAN
BRAIN-TUMORS; GENE-THERAPY; BONE-MARROW; MALIGNANT GLIOMA;
BREAST-CANCER; GLIOBLASTOMA-MULTIFORME; ONCOLYTIC ADENOVIRUS; NEURAL
PRECURSORS
AB Malignant gliomas are one of the most lethal cancers, and despite extensive research very little progress has been made in improving prognosis. Multimodality treatment combining surgery, radiation, and chemotherapy is the current gold standard, but effective treatment remains difficult due to the invasive nature and high recurrence of gliomas. Stem cell-based therapy using neural, mesenchymal, or hematopoietic stem cells may be an alternative approach because it is tumor selective and allows targeted therapy that spares healthy brain tissue. Stem cells can be used to establish a long-term antitumor response by stimulating the immune system and delivering prodrug, metabolizing genes, or oncolytic viruses. In this review, we discuss current trends and the latest developments in stem cell therapy against malignant gliomas from both the experimental laboratory and the clinic.
C1 [Bovenberg, M. Sarah S.; Degeling, M. Hannah; Tannous, Bakhos A.] Massachusetts Gen Hosp, Dept Neurol, Neurosci Ctr, Expt Therapeut & Mol Imaging Lab, Boston, MA 02129 USA.
[Bovenberg, M. Sarah S.; Degeling, M. Hannah; Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
[Bovenberg, M. Sarah S.; Degeling, M. Hannah] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands.
RP Tannous, BA (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neurosci Ctr, Expt Therapeut & Mol Imaging Lab, Boston, MA 02129 USA.
EM btannous@hms.harvard.edu
FU National Institutes of Health; National Institute of Neurological
Disorders and Stroke [1R01NS064983]; National Cancer Institute
[1R01CA166077]; Fulbright scholarship; Saal van Zwanenberg Foundation;
VSB fonds; Dr Hendrik Muller Vaderlandschfonds; Dutch Cancer Foundation
(KWF Kankerbestrijding); Hersenstichting brain fund; Jo Keur (Leiden
hospital)
FX B.A.T. is supported by grants from the National Institutes of Health,
the National Institute of Neurological Disorders and Stroke
(1R01NS064983) and the National Cancer Institute (1R01CA166077). M.H.D.
is supported by a Fulbright scholarship, the Saal van Zwanenberg
Foundation, VSB fonds, Dr Hendrik Muller Vaderlandschfonds, the Dutch
Cancer Foundation (KWF Kankerbestrijding), the Hersenstichting brain
fund, as well as the Jo Keur (Leiden hospital). M.S.B. is supported by a
Fulbright scholarship, the Huygens Scholarship Program, VSB fonds and
the Saal van Zwanenberg Foundation. The authors would like to thank Mr
Romain Amante for assistance in drawing Figure 2.
NR 91
TC 12
Z9 14
U1 3
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD MAY
PY 2013
VL 19
IS 5
BP 281
EP 291
DI 10.1016/j.molmed.2013.03.001
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 155AH
UT WOS:000319717300003
PM 23537753
ER
PT J
AU Mattsson, N
Andreasson, U
Persson, S
Carrillo, MC
Collins, S
Chalbot, S
Cutler, N
Dufour-Rainfray, D
Fagan, AM
Heegaard, NHH
Hsiung, GYR
Hyman, B
Iqbal, K
Lachno, DR
Lleo, A
Lewczuk, P
Molinuevo, JL
Parchi, P
Regeniter, A
Rissman, R
Rosenmann, H
Sancesario, G
Schroder, J
Shaw, LM
Teunissen, CE
Trojanowski, JQ
Vanderstichele, H
Vandijck, M
Verbeek, MM
Zetterberg, H
Blennow, K
Kaser, SA
AF Mattsson, Niklas
Andreasson, Ulf
Persson, Staffan
Carrillo, Maria C.
Collins, Steven
Chalbot, Sonia
Cutler, Neal
Dufour-Rainfray, Diane
Fagan, Anne M.
Heegaard, Niels H. H.
Hsiung, Ging-Yuek Robin
Hyman, Bradley
Iqbal, Khalid
Lachno, D. Richard
Lleo, Alberto
Lewczuk, Piotr
Molinuevo, Jose L.
Parchi, Piero
Regeniter, Axel
Rissman, Robert
Rosenmann, Hanna
Sancesario, Giuseppe
Schroeder, Johannes
Shaw, Leslie M.
Teunissen, Charlotte E.
Trojanowski, John Q.
Vanderstichele, Hugo
Vandijck, Manu
Verbeek, Marcel M.
Zetterberg, Henrik
Blennow, Kaj
Kaeser, Stephan A.
CA Alzheimers Assoc QC Program
TI CSF biomarker variability in the Alzheimer's Association quality control
program
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Cerebrospinal fluid; Biomarkers; External
assurance; Quality control; Proficiency testing
ID CEREBROSPINAL-FLUID BIOMARKERS; NEUROCHEMICAL DEMENTIA DIAGNOSTICS; MILD
COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; DISEASE; TAU; RECOMMENDATIONS;
WORKGROUPS; GUIDELINES
AB Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta 1-42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient management. However, there are large variations in biomarker measurements among and within laboratories.
Methods: Data from the first nine rounds of the Alzheimer's Association quality control program was used to define the extent and sources of analytical variability. In each round, three CSF samples prepared at the Clinical Neurochemistry Laboratory (Molndal, Sweden) were analyzed by single-analyte enzyme-linked immunosorbent assay (ELISA), a multiplexing xMAP assay, or an immunoassay with electrochemoluminescence detection.
Results: A total of 84 laboratories participated. Coefficients of variation (CVs) between laboratories were around 20% to 30%; within-run CVs, less than 5% to 10%; and longitudinal within-laboratory CVs, 5% to 19%. Interestingly, longitudinal within-laboratory CV differed between biomarkers at individual laboratories, suggesting that a component of it was assay dependent. Variability between kit lots and between laboratories both had a major influence on amyloid beta 1-42 measurements, but for total tau and phosphorylated tau, between-kit lot effects were much less than between-laboratory effects. Despite the measurement variability, the between-laboratory consistency in classification of samples (using prehoc-derived cutoffs for AD) was high (>90% in 15 of 18 samples for ELISA and in 12 of 18 samples for xMAP).
Conclusions: The overall variability remains too high to allow assignment of universal biomarker cutoff values for a specific intended use. Each laboratory must ensure longitudinal stability in its measurements and use internally qualified cutoff levels. Further standardization of laboratory procedures and improvement of kit performance will likely increase the usefulness of CSF AD biomarkers for researchers and clinicians. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Mattsson, Niklas; Andreasson, Ulf; Persson, Staffan; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad,Inst Neurosci & Physiol, Clin Neurochem Lab,Dept Psychiat & Neurochem, Molndal, Sweden.
[Mattsson, Niklas] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94143 USA.
[Carrillo, Maria C.] Alzheinzers Assoc, Chicago, IL USA.
[Collins, Steven] Univ Melbourne, Dept Pathol, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia.
[Chalbot, Sonia; Iqbal, Khalid] New York State Inst Basic Res, Staten Isl, NY USA.
[Cutler, Neal] Worldwide Clin Trials, Beverly Hills, CA USA.
[Dufour-Rainfray, Diane] CHRU Tours, Nucl Med Lab, Tours, France.
[Dufour-Rainfray, Diane] Univ Tours, Val Loire Univ, PRES Ctr, Tours, France.
[Dufour-Rainfray, Diane] Univ Tours, Val Loire Univ, PRES Ctr, UMR INSERM Imagerie & Cerveau U930, Tours, France.
[Fagan, Anne M.] Washington Univ, St Louis, MO USA.
[Heegaard, Niels H. H.] Statens Serum Inst, Dept Clin Biochem Immunol & Genet, DK-2300 Copenhagen, Denmark.
[Hsiung, Ging-Yuek Robin] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Hyman, Bradley] MassGen Inst Neurodegenerat Dis, Charlestown, MA USA.
[Lachno, D. Richard] Eli Lilly & Co, Windlesham, Surrey, England.
[Lleo, Alberto] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
[Lewczuk, Piotr] Univ Klinikum Erlangen, Erlangen, Germany.
[Molinuevo, Jose L.] ICN Hosp Clin & Univ, Neurol Serv, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain.
[Molinuevo, Jose L.] Pasqual Maragall Fdn, Barcelona, Spain.
[Parchi, Piero] Univ Bologna, Inst Neurol Sci, Bologna, Italy.
[Parchi, Piero] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
[Regeniter, Axel] Univ Basel Hosp, CH-4031 Basel, Switzerland.
[Rissman, Robert] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
[Rosenmann, Hanna] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel.
[Sancesario, Giuseppe] Univ Roma Tor Vergata, Gen Hosp, Rome, Italy.
[Schroeder, Johannes] Univ Klinikum Heidelberg, Sekt Gerontopsychiat, Heidelberg, Germany.
[Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Philadelphia, PA 19104 USA.
[Teunissen, Charlotte E.] Vrije Univ Amsterdam Med Ctr, Dept Clin Chem, Amsterdam, Netherlands.
[Vanderstichele, Hugo] ADx NeuroSci, Ghent, Belgium.
[Vandijck, Manu] Innogenet Nv, Ghent, Belgium.
[Verbeek, Marcel M.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain, Dept Neurol, NL-6525 ED Nijmegen, Netherlands.
[Verbeek, Marcel M.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain, Dept Lab Med, NL-6525 ED Nijmegen, Netherlands.
[Zetterberg, Henrik] UCL, Inst Neurol, London, England.
[Kaeser, Stephan A.] Univ Tubingen, Tubingen, Germany.
RP Mattsson, N (reprint author), Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad,Inst Neurosci & Physiol, Clin Neurochem Lab,Dept Psychiat & Neurochem, Molndal, Sweden.
EM niklas.mattsson@neuro.gu.se
RI Otto, Markus/F-4304-2015; Verbeek, Marcel/D-1971-2010; Vecsei,
Laszlo/B-2066-2010; Parchi, Piero/L-9833-2015; Chiasserini,
Davide/K-7074-2016;
OI Otto, Markus/0000-0003-4273-4267; Molinuevo, Jose
Luis/0000-0003-0485-6001; Kummer, Markus/0000-0002-0993-2918; Vecsei,
Laszlo/0000-0001-8037-3672; Parchi, Piero/0000-0002-9444-9524;
Chiasserini, Davide/0000-0002-1169-3258; Collins,
Steven/0000-0002-5245-6611
FU NIA NIH HHS [P01 AG026276, P50 AG005131, P50 AG005134, P50 AG005681]
NR 28
TC 116
Z9 118
U1 4
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2013
VL 9
IS 3
BP 251
EP 261
DI 10.1016/j.jalz.2013.01.010
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147QZ
UT WOS:000319183400001
PM 23622690
ER
PT J
AU Royall, DR
Palmer, RF
AF Royall, Donald R.
Palmer, Raymond F.
TI Alzheimer's disease pathology does not mediate the association between
depressive symptoms and subsequent cognitive decline
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Aging; Alzheimer's disease; Depression; Longitudinal; Neuropathology
ID OLDER PERSONS; MISSING DATA; RISK-FACTOR; DEMENTIA; IMPAIRMENT;
CRITERIA; PLAQUES; TANGLES; WORK; AD
AB Background: Depressive symptoms in nondemented individuals appear to hasten the progression from mild cognitive impairment to clinical Alzheimer's disease (AD) and double the risk of incident AD. However, the mechanism(s) by which depression might affect this risk has not been well established. The purpose of this analysis was to test the hypothesis that AD pathology mediates depression's apparent effect on the risk of dementia conversion using longitudinally collected psychometric testing and autopsy data from the Honolulu-Asia Aging Study.
Methods: Latent factor variables representing AD, cortical Lewy body (CLB), and ischemic neuropathology were tested as potential mediators of the association between the Center for Epidemiological Studies depression scale (CES-D) score and the 10-year prospective rate of cognitive decline, adjusted for baseline cognition, age, education, total number of medications, and brain weight at autopsy.
Results: CES-D scores, neurofibrillary tangle counts, CLB counts, and ischemic lesions each made significant independent contributions to cognitive decline. However, CES-D scores were not significantly associated with any pathological variable; thus the pathological variables were not mediators of the effect of CES-D scores on cognitive decline.
Conclusions: Subsyndromal depressive symptoms are significantly associated with subsequent cognitive decline. Although the effect is relatively modest, it is stronger than that of amyloid-related neuropathologies and independent of that of neurofibrillary tangles, cortical Lewy bodies, and ischemic lesions. Our results argue against the role of AD-related neuropathology as a mediator of depression's effect on cognitive decline, but cannot rule out a significant mediation effect in a subset of cases, perhaps with more severe baseline depressive symptoms. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Royall, Donald R.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Royall, Donald R.] Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Audie L Murphy Div, South Texas Vet Hlth Syst, San Antonio, TX 78284 USA.
RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
EM royall@uthscsa.edu
FU National Institute of Neurological Disorders and Stroke (National
Institutes of Health, USA) [NSO48123-01]; Julia and Van Buren Parr
professorship in Aging and Geriatric Psychiatry; NINDS [NS048123-01,
N01-AG-4-2149]; National Institute on Aging [U01 AG0 19349]
FX HAAS data were provided by Lon R. White, the HAAS Principal
Investigator, but the HAAS staff were not further involved in the
analysis or interpretation of the data. This work was funded by National
Institute of Neurological Disorders and Stroke (National Institutes of
Health, USA), grant number NSO48123-01. HAAS neuropathological data were
entirely generated by a team of 4 expert neuropathologists under the
leadership of Dr. William Markesbery (deceased), with the oversight of
Lon R. White, the HAAS Principal Investigator. Other members of the team
were Dr. John Hardman (deceased), Dr. James Nelson (retired), and Dr.
Daron Davis (who left the study for a clinical practice in 2001). D.R.R.
and R.F.P. were funded by the Julia and Van Buren Parr professorship in
Aging and Geriatric Psychiatry. The authors accept full responsibility
for all analyses, results, and interpretations.; This work has been
supported by NINDS R21 Grant NS048123-01, contract N01-AG-4-2149, and
grant U01 AG0 19349 from the National Institute on Aging.
NR 33
TC 15
Z9 15
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2013
VL 9
IS 3
BP 318
EP 325
DI 10.1016/j.jalz.2011.11.009
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147QZ
UT WOS:000319183400009
PM 23154050
ER
PT J
AU Rountree, SD
Atri, A
Lopez, OL
Doody, RS
AF Rountree, Susan D.
Atri, Alireza
Lopez, Oscar L.
Doody, Rachelle S.
TI Effectiveness of antidementia drugs in delaying Alzheimer's disease
progression
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Clinical trials; Therapeutics
ID PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND;
MEMANTINE TREATMENT; OPEN-LABEL; CHOLINESTERASE INHIBITION; GLOBAL
FUNCTION; DONEPEZIL; MODERATE; EFFICACY
AB Background: Randomized controlled trials (RCTs) provide safety and efficacy data for regulatory approval of antidementia drugs, but offer limited data regarding real-world effectiveness. Long-term observational controlled studies (LTOCs) extend our understanding by providing longitudinal data across multiple stages of Alzheimer's disease (AD).
Methods: Comparisons of strengths, limitations, evidence level, and results for monotherapy (cholinesterase inhibitors) and combination therapy (cholinesterase inhibitors + memantine) in RCTs versus LTOCs were made.
Results: Similar to RCTs, LTOCs have shown that both monotherapy and combination therapy are associated with slower cognitive and functional decline. Combination therapy is associated with better cognitive outcomes and greater delays in time to nursing home admission versus monotherapy or no treatment. Persistent antidementia drug treatment is associated with slower decline in cognition, daily function, and global severity, even in patients with advanced disease.
Conclusions: LTOCs provide complementary evidence regarding effectiveness of antidementia therapy over many years, a time course relevant to AD management. These findings also provide compelling arguments in favor of using LTOCs to estimate effectiveness, risk benefit, and costs of AD treatments. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Rountree, Susan D.; Doody, Rachelle S.] Baylor Coll Med, Dept Neurol, Alzheimers Dis & Memory Disorders Ctr, Houston, TX 77030 USA.
[Atri, Alireza] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Atri, Alireza] Neurol Memory Disorders Unit, Boston, MA USA.
[Atri, Alireza] ENRM VA Med Ctr, GRECC, Bedford, MA USA.
[Lopez, Oscar L.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
RP Rountree, SD (reprint author), Baylor Coll Med, Dept Neurol, Alzheimers Dis & Memory Disorders Ctr, Houston, TX 77030 USA.
EM rountree@bcm.edu
OI Atri, Alireza/0000-0003-4405-6973
FU Forest Laboratories, Inc. (PL); Forest Research Institute; National
Institute on Aging
FX This article summarizes a roundtable discussion, funded by Forest
Laboratories, Inc. (PL), that was held in conjunction with the
International Conference on Alzheimer's Disease on July 12, 2010.
Prescott Medical Communications Group (Chicago, IL) provided the authors
with assistance in preparing slides for the roundtable event and
manuscript timelines and formatting; however, neither FLI nor Prescott
Medical Communications Group provided input into the manuscript content.
The authors were compensated by FLI for participation in the roundtable
discussion, but no compensation was provided in conjunction with this
manuscript.; Conflicts of interest pertaining to Forest Laboratories,
Inc., the sponsor of the roundtable held in conjunction with the
International Conference on Alzheimer's Disease, 2010. S.D.R.,
Investigator-Initiated Grant Funding: Forest Research Institute;
Honorarium: Forest Research Institute, for attending this roundtable.
A.A., Continuing Medical Education (CME), Education Media and Lecture
Honoraria: Forest, Prescott Medical Communications, Harvard Medical
School CME, Massachusetts General Hospital Academy of Medical Educators
and Reed Medical Education, Merz, Lundbeck, Turner White Communications;
Consultant: Forest Research Institute; Investigator-Initiated Grant
Funding: Forest Research Institute, National Institute on Aging. O.L.L.,
Consultant: Lundbeck, Pfizer. R.S.D. Honorarium: Forest Research
Institute, for attending this roundtable.
NR 54
TC 23
Z9 23
U1 1
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2013
VL 9
IS 3
BP 338
EP 345
DI 10.1016/j.jalz.2012.01.002
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147QZ
UT WOS:000319183400012
PM 23102979
ER
PT J
AU Grill, JD
Karlawish, J
Elashoff, D
Vickrey, BG
AF Grill, Joshua D.
Karlawish, Jason
Elashoff, David
Vickrey, Barbara G.
TI Risk disclosure and preclinical Alzheimer's disease clinical trial
enrollment
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Preclinical; Prevention; Predementia; Recruitment;
Risk; Clinical trial
ID GENETIC RISK; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL
INSTITUTE; RECOMMENDATIONS; CHALLENGES
AB To identify the facilitators and barriers to preclinical Alzheimer's disease (AD) clinical trial recruitment, 50 cognitively normal participants were interviewed after being randomized to one of two hypothetical AD risk scenarios: (1) the general age-related risk for AD, or (2) being at 50% increased risk for AD. Participants provided uncued barriers and facilitators to the hypothetical decision of whether they would enroll. Thirteen themes of facilitators and five themes of barriers were identified. The most common barrier was fear related to taking study drug. Those randomized to being at increased risk for AD more frequently cited lowering personal risk as a facilitator (P = .01) and less frequently cited time as a barrier to enrollment (P = .02). These results suggest potential challenges to preclinical AD clinical trial recruitment and that disclosing risk information may enhance enrollment. (C) 2013 The Alzheimer's Association. All rights reserved.
C1 [Grill, Joshua D.; Elashoff, David] Univ Calif Los Angeles, Mary Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA.
[Grill, Joshua D.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Karlawish, Jason] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Penn Memory Ctr, Philadelphia, PA 19104 USA.
[Karlawish, Jason] Univ Penn, Penn Ctr Bioeth, Philadelphia, PA 19104 USA.
[Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Grill, JD (reprint author), Univ Calif Los Angeles, Mary Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA.
EM jgrill@mednet.ucla.edu
FU NIA [AG016570]; Sidell Kagan Foundation; Marian S. Ware Alzheimer
Program
FX This work was supported by NIA AG016570 and the Sidell Kagan Foundation.
Dr. J.K. is supported by the Marian S. Ware Alzheimer Program. The
authors are grateful to the volunteer participants who made this work
possible and to Dr. Po H. Lu who participated in the cutting-and-sorting
analyses.
NR 14
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2013
VL 9
IS 3
BP 356
EP 359
DI 10.1016/j.jalz.2012.03.001
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147QZ
UT WOS:000319183400014
PM 23141383
ER
PT J
AU Sherman, AV
Gubitz, AK
Al-Chalabi, A
Bedlack, R
Berry, J
Conwit, R
Harris, BT
Horton, DK
Kaufmann, P
Leitner, ML
Miller, R
Shefner, J
Vonsattel, JP
Mitsumoto, H
AF Sherman, Alexander V.
Gubitz, Amelie K.
Al-Chalabi, Ammar
Bedlack, Richard
Berry, James
Conwit, Robin
Harris, Brent T.
Horton, D. Kevin
Kaufmann, Petra
Leitner, Melanie L.
Miller, Robert
Shefner, Jeremy
Vonsattel, Jean Paul
Mitsumoto, Hiroshi
TI Infrastructure resources for clinical research in amyotrophic lateral
sclerosis
SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
LA English
DT Article
DE Amyotrophic lateral sclerosis (ALS); motor neuron disease (MND);
clinical research infrastructure; North America; Europe
ID NEURON DISEASE; STEM-CELLS; ALS; EPIDEMIOLOGY
AB Clinical trial networks, shared clinical databases, and human biospecimen repositories are examples of infrastructure resources aimed at enhancing and expediting clinical and/or patient oriented research to uncover the etiology and pathogenesis of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurodegenerative disease that leads to the paralysis of voluntary muscles. The current status of such infrastructure resources, as well as opportunities and impediments, were discussed at the second Tarrytown ALS meeting held in September 2011. The discussion focused on resources developed and maintained by ALS clinics and centers in North America and Europe, various clinical trial networks, U. S. government federal agencies including the National Institutes of Health (NIH), the Agency for Toxic Substances and Disease Registry (ATSDR) and the Centers for Disease Control and Prevention (CDC), and several voluntary disease organizations that support ALS research activities. Key recommendations included 1) the establishment of shared databases among individual ALS clinics to enhance the coordination of resources and data analyses; 2) the expansion of quality-controlled human biospecimen banks; and 3) the adoption of uniform data standards, such as the recently developed Common Data Elements (CDEs) for ALS clinical research. The value of clinical trial networks such as the Northeast ALS (NEALS) Consortium and the Western ALS (WALS) Consortium was recognized, and strategies to further enhance and complement these networks and their research resources were discussed.
C1 [Sherman, Alexander V.] Massachusetts Gen Hosp, NCRI, Boston, MA 02114 USA.
[Gubitz, Amelie K.; Conwit, Robin; Kaufmann, Petra] NINDS, NIH, Bethesda, MD 20892 USA.
[Al-Chalabi, Ammar] Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London WC2R 2LS, England.
[Bedlack, Richard] Duke Inst Brain Sci, Sch Med, Div Neurol, Durham, NC USA.
[Berry, James] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Harris, Brent T.] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA.
[Horton, D. Kevin] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA.
[Leitner, Melanie L.] Prize4Life, Cambridge, MA USA.
[Miller, Robert] Calif Pacific Med Ctr, Forbes Norris MDA ALS Res Ctr, San Francisco, CA USA.
[Shefner, Jeremy] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.
[Vonsattel, Jean Paul] Columbia Univ, New York Presbyterian Hosp, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA.
[Mitsumoto, Hiroshi] Columbia Univ, Dept Neurol, Med Ctr, Eleanor & Lou Gehrig MDA ALS Res Ctr, New York, NY USA.
RP Sherman, AV (reprint author), Massachusetts Gen Hosp, 13th St,Bldg 149, Charlestown, MA 02129 USA.
EM avsherman@partners.org
RI Al-Chalabi, Ammar/E-5361-2010
OI Al-Chalabi, Ammar/0000-0002-4924-7712
NR 22
TC 7
Z9 7
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 2167-8421
EI 2167-9223
J9 AMYOTROPH LAT SCL FR
JI Amyotroph. Lateral Scher. Frontotemp. Degenerat.
PD MAY
PY 2013
VL 14
SU 1
BP 53
EP 61
DI 10.3109/21678421.2013.779058
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 145KH
UT WOS:000319014100006
PM 23678880
ER
PT J
AU Chad, DA
Bidichandani, S
Bruijn, L
Capra, JD
Dickie, B
Ferguson, J
Figlewicz, D
Forsythe, M
Kaufmann, P
Kirshner, A
Monti, W
AF Chad, David A.
Bidichandani, Sanjay
Bruijn, Lucie
Capra, J. Donald
Dickie, Brian
Ferguson, John
Figlewicz, Denise
Forsythe, Melissa
Kaufmann, Petra
Kirshner, Annette
Monti, William
TI Funding agencies and disease organizations: Resources and
recommendations to facilitate ALS clinical research
SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
LA English
DT Article
DE ALS; funding agencies; patient voluntary organizations
AB Ten groups presented their perspectives on facilitating clinical research in ALS including four federal agencies, four disease organizations, one foundation and one advocacy group. The federal agencies (National Institute of Neurological Disorders and Stroke, National Institute of Environmental Health Sciences, Office of Rare Diseases Research, Department of Defense) encourage fostering a team approach between pre-clinical and clinical research investigators, coordinating with patient groups in the early phases of clinical studies, enhancing private and public partnerships, and investigating the interplay between genetic susceptibility and environmental exposure. The disease organizations (Muscular Dystrophy Association, ALS Association, ALS Society of Canada, and the Motor Neurone Disease Association UK) support fellowship training programs to develop ALS clinician scientists, and encourage work on the epidemiology of ALS, on genetic and epigenetic mechanisms that are relevant to ALS pathogenesis, on developing ALS registries and biobanks, and building bridges of collaboration among study groups. The Foundation supports innovative projects, including stem-cell research, and Patient Advocacy is committed to supporting excellence in ALS research and patient care, and believes strongly in enhancing communication between patients and members of the research community.
C1 [Chad, David A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Dickie, Brian] Motor Neuron Dis Assoc, Northampton, England.
[Ferguson, John] NIH, Off Rare Dis Res, Bethesda, MD 20892 USA.
[Figlewicz, Denise] ALS Soc Canada, Bethesda, MD USA.
[Forsythe, Melissa] USA, Med Res & Mat Command, Congressionally Directed Med Res Programs Off, Bethesda, MD USA.
[Kaufmann, Petra] NINDS, NIH, Bethesda, MD 20892 USA.
[Kirshner, Annette] NIEHS, NIH, Bethesda, MD USA.
[Monti, William] ALS Advocacy, New York, NY USA.
RP Chad, DA (reprint author), Neuromuscular Diagnost Ctr, 165 Cambridge St,Suite 820,CPZ 8, Boston, MA 02114 USA.
EM dchad@partners.org
NR 0
TC 1
Z9 1
U1 0
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 2167-8421
J9 AMYOTROPH LAT SCL FR
JI Amyotroph. Lateral Scher. Frontotemp. Degenerat.
PD MAY
PY 2013
VL 14
SU 1
BP 62
EP 66
DI 10.3109/21678421.2013.778588
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 145KH
UT WOS:000319014100007
PM 23678881
ER
PT J
AU Chad, DA
Rowland, LP
Armon, C
Bedlack, R
Durham, H
Factor-Litvak, P
Heiman-Patterson, T
Heitzman, D
Lacomis, D
Ludolph, A
Maragakis, N
Miller, R
Pattee, G
Shoesmith, C
Sorenson, E
Turner, MR
AF Chad, David A.
Rowland, Lewis P.
Armon, Carmel
Bedlack, Richard
Durham, Heather
Factor-Litvak, Pam
Heiman-Patterson, Terry
Heitzman, Daragh
Lacomis, David
Ludolph, Albert
Maragakis, Nicholas
Miller, Robert
Pattee, Gary
Shoesmith, Christen
Sorenson, Eric
Turner, Martin R.
TI Peer recommendations on how to improve clinical research, and Conference
wrap-up
SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
LA English
DT Article
DE ALS; clinical research; peer recommendations
ID HEXANUCLEOTIDE REPEAT; ALS; C9ORF72; FTD
AB To promote clinical and patient oriented research, as part of the Second International ALS Conference in Tarrytown, NY, USA, seven pairs of clinicians and scientists were asked to lead discussions with meeting attendees on six major topics (one of which was discussed by two groups); each one the focus of a 90-min Breakout Session. Approximately 25 meeting attendees participated in each session. The Breakout Sessions considered six major themes: 1) Approaches to encourage clinicians to engage in more clinical research to discover the pathogenesis and cause of ALS; 2) Exploring avenues to build more effective partnerships between basic scientists and ALS physicians; 3) Increasing patient interest and commitment to participating in non-trial clinical research; 4) Brainstorming about factors that are most critical to the discovery of the pathogenesis and cause of ALS; 5) Finding ways to incorporate clinical research projects into clinical trials; and 6) Developing state-of-the-art epidemiological studies to solve the mystery of ALS. In this paper, we present the reports from each of the Breakout Sessions; and we provide a wrap-up of the entire conference.
C1 [Chad, David A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Rowland, Lewis P.] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA.
[Armon, Carmel] Baystate Med Ctr, Div Neurol, Springfield, MA USA.
[Bedlack, Richard] Duke Univ, Med Ctr, Duke ALS Clin, Durham, NC USA.
[Durham, Heather] McGill Univ, Dept Neurol, Montreal, PQ H3A 2T5, Canada.
[Factor-Litvak, Pam] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
[Heiman-Patterson, Terry] Drexel Univ, Dept Neurol, Coll Med, Philadelphia, PA 19104 USA.
[Heitzman, Daragh] Texas Neurol, Dallas, TX USA.
[Lacomis, David] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Ludolph, Albert] Univ Ulm, Dept Neurol, D-89069 Ulm, Germany.
[Maragakis, Nicholas] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA.
[Miller, Robert] Calif Pacific Med Ctr, Forbes Norris MDA ALS Res Ctr, San Francisco, CA USA.
[Pattee, Gary] Univ Nebraska Med Ctr, Dept Neurol, Omaha, NE USA.
[Shoesmith, Christen] London Hlth Sci Ctr, Dept Neurol, London, ON, Canada.
[Sorenson, Eric] Mayo Clin, Dept Neurol, Rochester, MN USA.
[Turner, Martin R.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England.
RP Chad, DA (reprint author), Neuromuscular Diagnost Ctr, 165 Cambridge St,Suite 820,CPZ 8, Boston, MA 02114 USA.
EM dchad@partners.org
OI Turner, Martin/0000-0003-0267-3180
FU Medical Research Council [G0701923]; NIEHS NIH HHS [R01 ES016348]
NR 7
TC 1
Z9 1
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 2167-8421
J9 AMYOTROPH LAT SCL FR
JI Amyotroph. Lateral Scher. Frontotemp. Degenerat.
PD MAY
PY 2013
VL 14
SU 1
BP 67
EP 73
DI 10.3109/21678421.2013.778605
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 145KH
UT WOS:000319014100008
PM 23678882
ER
PT J
AU Vincenzi, B
Borba, CPC
Gray, DA
Copeland, PM
Wang, XY
Fan, XD
Aragam, GG
Henderson, DC
AF Vincenzi, Brenda
Borba, Christina P. C.
Gray, Deborah A.
Copeland, Paul M.
Wang, Xingyue
Fan, Xiaoduo
Aragam, Gowri G.
Henderson, David C.
TI An exploratory study examining lipid-lowering medications in reducing
fasting serum lipids in schizophrenia patients treated with atypical
antipsychotics
SO ANNALS OF CLINICAL PSYCHIATRY
LA English
DT Article
DE schizophrenia; fibrate treatment; statin treatment; metabolic disorders;
atypical antipsychotics
ID CORONARY-HEART-DISEASE; LIPOPROTEIN SUBPARTICLE PROFILES; SIMVASTATIN
PLUS FENOFIBRATE; MIXED DYSLIPIDEMIA; CARDIOVASCULAR-DISEASE;
DIABETES-MELLITUS; HDL CHOLESTEROL; WEIGHT-GAIN; METABOLIC SYNDROME;
RISK-FACTOR
AB BACKGROUND: We present a retrospective study examining response to treatment with fibrates or statins in schizophrenia patients.
METHODS: We identified the patient population using the Research Patient Data Registry. Demographic data, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and non-HDL cholesterol (non-HDL-C) levels were obtained before initiation of treatment with lipid-lowering medication (LLM) and after LLM treatment was initiated (N = 183).
RESULTS: Treatment with LLMs resulted in a statistically significant decrease in total cholesterol, triglycerides, LDL-C, and non-HDL-C. An independent-samples t test comparing the statin treatment-alone group with the fibrate treatment-alone group showed a significant reduction in triglyceride levels from baseline to 1-year follow-up in the fibrate treatment-alone group.
CONCLUSIONS: The results of this study indicate that schizophrenia patients respond to LLMs in a manner consistent with the general population. Future studies would benefit from a larger sample, as well as comparisons between more specific treatment groups, such as those defined by type of statin or fibrate, to observe differential effects on specific markers of dyslipidemia in this population.
C1 [Vincenzi, Brenda; Gray, Deborah A.; Wang, Xingyue; Aragam, Gowri G.] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA.
[Borba, Christina P. C.; Fan, Xiaoduo; Henderson, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Schizophrenia Program, Boston, MA USA.
[Copeland, Paul M.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
RP Vincenzi, B (reprint author), Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA.
EM bvincenzi@partners.org
FU Novartis; Otsuka
FX Dr. Vincenzi, Dr. Borba, Ms. Gray, Ms. Wang, and Ms. Aragam report no
financial relationship with any company whose products are mentioned in
this article or with manufacturers of competing products. Dr. Copeland
is a consultant to sanofi-aventis. Dr. Fan is a consultant to Eli Lilly
and Company. Dr. Henderson receives grant or research support from
Novartis and Otsuka and is a consultant to Alkermes.
NR 54
TC 7
Z9 7
U1 2
U2 4
PU QUADRANT HEALTHCOM INC
PI PARSIPPANY
PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA
SN 1040-1237
EI 1547-3325
J9 ANN CLIN PSYCHIATRY
JI Ann. Clin. Psychiatry
PD MAY
PY 2013
VL 25
IS 2
BP 141
EP 148
PG 8
WC Psychiatry
SC Psychiatry
GA 149HL
UT WOS:000319309500009
PM 23638445
ER
PT J
AU Vielma, SA
Klein, RL
Levingston, CA
Young, MRI
AF Vielma, Silvana A.
Klein, Richard L.
Levingston, Corinne A.
Young, M. Rita I.
TI Premalignant Lesions Skew Spleen Cell Responses to Immune Modulation by
Adipocytes
SO ANTICANCER RESEARCH
LA English
DT Article
DE Adipocytes; cytokines; immune regulation; inflammation; premalignant
lesion cells
ID REGULATORY T-CELLS; CANCER-RISK; INSULIN-RESISTANCE; BREAST-CANCER;
OBESITY; CYTOKINES; LEPTIN; INFLAMMATION; ADIPOKINES; DIFFERENTIATION
AB Obesity can promote a chronic inflammatory state and is associated with an increased risk for cancer. Since adipocytes can produce mediators that can regulate conventional immune cells, this study sought to determine if the presence of premalignant oral lesions would skew how immune cells respond to adipocyte-derived mediators to create an environment that may be more favorable for their progression toward cancer. While media conditioned by adipocytes stimulated normal spleen cell production of the T helper (Th) type-1 cytokines interleukin (IL)-2, interferon-gamma (IFN-gamma), IL-12 and granulocyte-monocyte colony-stimulating factor (GM CSF), media from premalignant lesion cells either blocked or had no added affect on the adipocyte-stimulated Th1 cytokine production. In contrast, media conditioned by premalignant lesion cells exacerbated adipocyte-stimulated spleen cell production of the Th2 cytokines IL-10 and IL-13, although it did not further enhance the adipocyte-stimulated spleen cell production of IL-4 and TGF-beta. The premalignant lesion environment also heightened the adipocyte-stimulated spleen cell production of the inflammatory mediators IL 1 alpha, IL-1 beta, IL-6 and IL-9, although it did not further increase the adipocyte-stimulated production of tumor necrosis factor-alpha (TNF-alpha). IL 17 production was unaffected by the adipocyte-derived mediators, but was synergistically triggered by adding media from premalignant lesion cells. These stimulatory effects on spleen cell production of Th2 and inflammatory mediators were not induced in the absence of media conditioned by adipocytes. In contrast, media conditioned by adipocytes did not stimulate production of predominantly monocyte-derived chemokine C-X-C motif ligand (CXCL)9, chemokine C-C motif ligand (CCL)3 or CCL4, although it stimulated production of CCL2 and the predominantly T cell-derived chemokine CCL5, which was the only chemokine whose production was further increased by media from premalignant lesions. These results suggest that the responsiveness of spleen cells to adipocyte-derived mediators is influenced by mediators from premalignant lesion cells to favor conventional immune cell production of a Th2 and inflammatory cytokines.
C1 [Vielma, Silvana A.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
[Young, M. Rita I.] Med Univ S Carolina, Dept Med, Dept Hematol Oncol, Charleston, SC 29425 USA.
[Vielma, Silvana A.] Univ Los Andes, Dept Clin Microbiol & Parasitol, Merida, Venezuela.
[Klein, Richard L.; Levingston, Corinne A.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM Rita.Young@va.gov
FU Biomedical Laboratory of the Department of Veterans Affairs; Department
of Veterans Affairs; National Institute of Health [I01-CX000100, R01
CA128837, R01 DE018268]
FX This work was supported by the Biomedical Laboratory and Clinical
Sciences Programs of the Department of Veterans Affairs. and by grants
from the National Institute of Health awarded to M. Rita I. Young
(I01-CX000100, R01 CA128837 and R01 DE018268).
NR 45
TC 2
Z9 2
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD MAY
PY 2013
VL 33
IS 5
BP 1809
EP 1818
PG 10
WC Oncology
SC Oncology
GA 148GR
UT WOS:000319233100004
PM 23645725
ER
PT J
AU Martinez-Pastor, B
Cosentino, C
Mostoslavsky, R
AF Martinez-Pastor, Barbara
Cosentino, Claudia
Mostoslavsky, Raul
TI A Tale of Metabolites: The Cross-Talk between Chromatin and Energy
Metabolism
SO CANCER DISCOVERY
LA English
DT Editorial Material
ID HISTONE ACETYLATION
AB Mitochondrial metabolism influences histone and DNA modifications by retrograde signaling and activation of transcriptional programs. Considering the high number of putative sites for acetylation and methylation in chromatin, we propose in this perspective article that epigenetic modifications might impinge on cellular metabolism by affecting the pool of acetyl-CoA and S-adenosylmethionine. Cancer Discov; 3(5); 497-501. (C) 2013 AACR.
C1 [Martinez-Pastor, Barbara; Cosentino, Claudia; Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
RP Mostoslavsky, R (reprint author), Massachusetts Gen Hosp, 185 Cambridge St,Simches Bldg CPZN 4208, Boston, MA 02114 USA.
EM rmostoslavsky@mgh.harvard.edu
FU NCI NIH HHS [R01 CA175727]; NIDDK NIH HHS [DK088190-01A1, R01 DK088190];
NIGMS NIH HHS [GM093072-01, R01 GM093072]
NR 15
TC 22
Z9 22
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD MAY
PY 2013
VL 3
IS 5
BP 497
EP 501
DI 10.1158/2159-8290.CD-13-0059
PG 5
WC Oncology
SC Oncology
GA 147ZI
UT WOS:000319210600021
PM 23658298
ER
PT J
AU Sanda, T
Tyner, JW
Gutierrez, A
Ngo, VN
Glover, J
Chang, BH
Yost, A
Ma, WX
Fleischman, AG
Zhou, WJ
Yang, YD
Kleppe, M
Ahn, Y
Tatarek, J
Kelliher, MA
Neuberg, DS
Levine, RL
Moriggl, R
Muller, M
Gray, NS
Jamieson, CHM
Weng, AP
Staudt, LM
Druker, BJ
Look, AT
AF Sanda, Takaomi
Tyner, Jeffrey W.
Gutierrez, Alejandro
Ngo, Vu N.
Glover, Jason
Chang, Bill H.
Yost, Arla
Ma, Wenxue
Fleischman, Angela G.
Zhou, Wenjun
Yang, Yandan
Kleppe, Maria
Ahn, Yebin
Tatarek, Jessica
Kelliher, Michelle A.
Neuberg, Donna S.
Levine, Ross L.
Moriggl, Richard
Mueller, Mathias
Gray, Nathanael S.
Jamieson, Catriona H. M.
Weng, Andrew P.
Staudt, Louis M.
Druker, Brian J.
Look, A. Thomas
TI TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic
Leukemia
SO CANCER DISCOVERY
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; ACTIVATING MUTATIONS; KINASE INHIBITOR;
LUNG-CANCER; INTERLEUKIN-10; BCL-2; RECEPTOR; LYMPHOMA; TARGETS; JAK1
AB Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the Janus-activated kinase (JAK) tyrosine kinase family, TYK2, and its downstream effector STAT1, in T-cell acute lymphoblastic leukemia (T-ALL). Gene knockdown experiments consistently showed TYK2 dependence in both T-ALL primary specimens and cell lines, and a small-molecule inhibitor of JAK activity induced T-ALL cell death. Activation of this TYK2-STAT1 pathway in T-ALL cell lines occurs by gain-of-function TYK2 mutations or activation of interleukin (IL)-10 receptor signaling, and this pathway mediates T-ALL cell survival through upregulation of the antiapoptotic protein BCL2. These findings indicate that in many T-ALL cases, the leukemic cells are dependent upon the TYK2-STAT1-BCL2 pathway for continued survival, supporting the development of molecular therapies targeting TYK2 and other components of this pathway.
SIGNIFICANCE: In recent years, "pathway dependence" has been revealed in specific types of human cancer, which can be important because they pinpoint proteins that are particularly vulnerable to antitumor-targeted inhibition (so-called Achilles' heel proteins). Here, we use RNAi technology to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression. Cancer Discov; 3(5); 564-77. (C) 2013 AACR.
C1 [Sanda, Takaomi; Gutierrez, Alejandro; Ahn, Yebin; Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Zhou, Wenjun; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Gutierrez, Alejandro; Look, A. Thomas] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Tatarek, Jessica; Kelliher, Michelle A.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA USA.
[Tyner, Jeffrey W.; Fleischman, Angela G.; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Glover, Jason; Chang, Bill H.] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Hematol & Oncol, Portland, OR 97239 USA.
[Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA.
[Ngo, Vu N.] City Hope Natl Med Ctr, Beckman Res Inst, Div Hematopoiet Stem Cell & Leukemia Res, Duarte, CA 91010 USA.
[Ma, Wenxue] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Ma, Wenxue; Jamieson, Catriona H. M.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Yost, Arla; Weng, Andrew P.] BC Canc Agcy, Terry Fox Lab, Dept Pathol, Vancouver, BC, Canada.
[Yang, Yandan; Staudt, Louis M.] NCI, Metab Branch, Bethesda, MD 20892 USA.
[Kleppe, Maria; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
[Moriggl, Richard] Univ Vet Med Vienna, Ludwig Boltzmann Inst Canc Res, Vienna, Austria.
[Mueller, Mathias] Univ Vet Med Vienna, Inst Anim Breeding & Genet, Vienna, Austria.
RP Look, AT (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Mayer Bldg,Rm 630,450 Brookline Ave, Boston, MA 02215 USA.
EM drukerb@ohsu.edu; thomas_look@dfci.harvard.edu
RI Kleppe, Maria/C-6341-2014; Weng, Andrew/I-5015-2014;
OI Fleischman, Angela/0000-0002-3701-6079; Chang, Bill/0000-0003-3783-1820;
Moriggl, Richard/0000-0003-0918-9463; Kleppe, Maria/0000-0002-4372-6704;
Gutierrez, Alejandro/0000-0002-0249-9007; Tyner,
Jeffrey/0000-0002-2133-0960
FU William Lawrence and Blanche Hughes Fund; Leukemia & Lymphoma Society;
Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research; National Cancer Institute [4R00CA151457-03];
Oregon Clinical and Translational Research Institute (OCTRI) from the
National Center for Research Resources (NRCC), a component of the NIH
[UL1 RR024140]; NIH Roadmap for Medical Research; NIH [NCI 1K99CA157951,
NCI 1K08CA133103]; Children's Leukemia Research Association; Japan
Society for the Promotion of Science; Oregon Child Health Research
Center; Austrian Science Fund FWF [SFB F28]; NCI [5P01CA109901, NCI
5P01CA68484]; Alex's Lemonade Stand Foundation Bridge grant; European
Molecular Biology Organization (EMBO) long-term fellowship; CIHR/Terry
Fox Foundation; California Institute for Regenerative Medicine (CIRM)
[TR21789, RN2-00910-1, DR1-01430]; Leichtag Family Foundation; Ratner
Family Foundation; [5P30CA069533]
FX This work was supported in part by the William Lawrence and Blanche
Hughes Fund, the Leukemia & Lymphoma Society, and the Intramural
Research Program of the NIH, National Cancer Institute, Center for
Cancer Research. J.W. Tyner is supported by grants from the National
Cancer Institute (4R00CA151457-03) and the Oregon Clinical and
Translational Research Institute (OCTRI), grant number UL1 RR024140 from
the National Center for Research Resources (NRCC), a component of the
NIH, and the NIH Roadmap for Medical Research. T. Sanda is supported by
NIH grant NCI 1K99CA157951, Children's Leukemia Research Association,
and the Japan Society for the Promotion of Science. A. Gutierrez is
supported by NIH grant NCI 1K08CA133103 and is a scholar of the American
Society of Hematology-Amos Medical Faculty Development Program. B.H.
Chang is supported by the Oregon Child Health Research Center and is a
St. Baldrick's Scholar. R. Moriggl and M. Muller are supported by grant
SFB F28 of the Austrian Science Fund FWF. A.T. Look and D.S. Neuberg are
supported by NCI grants 5P01CA109901 and NCI 5P01CA68484, and A.T. Look
is supported by an Alex's Lemonade Stand Foundation Bridge grant. B.J.
Druker is an investigator of the Howard Hughes Medical Institute and
principal investigator of the OHSU cancer center support grant
5P30CA069533. M. Kleppe is supported by the European Molecular Biology
Organization (EMBO) long-term fellowship. R.L. Levine is a Scholar of
the Leukemia and Lymphoma Society. A. Yost and A.P. Weng are supported
by a CIHR/Terry Fox Foundation program project grant. W. Ma and C.H.M.
Jamieson are supported by the California Institute for Regenerative
Medicine (CIRM) grants (TR21789; RN2-00910-1; DR1-01430) as well as the
Leichtag Family Foundation and the Ratner Family Foundation.
NR 47
TC 42
Z9 42
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD MAY
PY 2013
VL 3
IS 5
BP 564
EP 577
DI 10.1158/2159-8290.CD-12-0504
PG 14
WC Oncology
SC Oncology
GA 147ZI
UT WOS:000319210600027
PM 23471820
ER
PT J
AU Maki, T
Hayakawa, K
Pham, LDD
Xing, CH
Lo, EH
Arai, K
AF Maki, Takakuni
Hayakawa, Kazuhide
Pham, Loc-Duyen D.
Xing, Changhong
Lo, Eng H.
Arai, Ken
TI Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS
Diseases
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Article
DE Neurovascular unit; stroke; central nervous system injury;
neuroprotection; remodeling; astrocyte; cerebral endothelial cell;
microglia
ID BLOOD-BRAIN-BARRIER; AMYOTROPHIC-LATERAL-SCLEROSIS; ENDOTHELIAL
GROWTH-FACTOR; OLIGODENDROCYTE PRECURSOR CELLS; AMYLOID-BETA CLEARANCE;
ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; IN-VIVO;
MATRIX METALLOPROTEINASES
AB In the past decade, evidence has emerged that there is a variety of bidirectional cell-cell and/or cell-extracellular matrix interactions within the neurovascular unit (NVU), which is composed of neuronal, glial, and vascular cells along with extracellular matrix. Many central nervous system diseases, which lead to NVU dysfunction, have common features such as glial activation/transformation and vascular/blood-brain-barrier alteration. These phenomena show dual opposite roles, harmful at acute phase and beneficial at chronic phase. This diverse heterogeneity may induce biphasic clinical courses, i.e. degenerative and regenerative processes in the context of dynamically coordinated cell-cell/cell-matrix interactions in the NVU. A deeper understanding of the seemingly contradictory actions in cellular levels is essential for NVU protection or regeneration to suppress the deleterious inflammatory reactions and promote adaptive remodeling after central nervous system injury. This mini-review will present an overview of recent progress in the biphasic roles of the NVU and discuss the clinical relevance of NVU responses associated with central nervous system diseases, such as stroke and other chronic neurodegenerative diseases.
C1 Massachusetts Gen Hosp, Dept Radiol & Neurol, Neuroprotect Res Lab, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Arai, K (reprint author), Neuroprotect Res Lab, MGH East 149-2401, Charlestown, MA 02129 USA.
EM karai@partners.org
FU Research Abroad from the Japan Society for the Promotion of Science;
Deane Foundation; American Heart Association; National Institutes of
Health
FX This work was supported in part by Research Abroad from the Japan
Society for the Promotion of Science (T.M.), the Deane Foundation (E.H.L
and K.A.), American Heart Association (E.H.L and K.A.), and National
Institutes of Health (E.H.L and K.A.). The authors thank Drs. Ji Hae Seo
and Nobukazu Miyamoto for many helpful discussions.
NR 175
TC 28
Z9 29
U1 1
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1871-5273
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PD MAY
PY 2013
VL 12
IS 3
BP 302
EP 315
PG 14
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 145CE
UT WOS:000318990800004
PM 23469847
ER
PT J
AU Leak, RK
Zhang, LL
Stetler, RA
Weng, ZF
Li, PY
Atkins, GB
Gao, YQ
Chen, J
AF Leak, Rehana K.
Zhang, Lili
Stetler, R. Anne
Weng, Zhongfang
Li, Peiying
Atkins, G. Brandon
Gao, Yanqin
Chen, Jun
TI HSP27 Protects the Blood-Brain Barrier Against Ischemia-Induced Loss of
Integrity
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Article
DE Endothelial cell; heat shock protein; HSP25; HSPB1; microvessel; stroke;
tight junction; vascular
ID HEAT-SHOCK-PROTEIN; FOCAL CEREBRAL-ISCHEMIA; MONOCYTE CHEMOATTRACTANT
PROTEIN-1; INTRACEREBRAL HEMORRHAGE; CYTOCHROME-C; CELL-DEATH;
ISCHEMIA/REPERFUSION INJURY; MOLECULAR CHAPERONES; NEURONAL INJURY;
PRECURSOR CELLS
AB Loss of integrity of the blood-brain barrier (BBB) in stroke victims initiates a devastating cascade of events including extravasation of blood-borne molecules, water, and inflammatory cells deep into brain parenchyma. Thus, it is important to identify mechanisms by which BBB integrity can be maintained in the face of ischemic injury in experimental stroke. We previously demonstrated that the phylogenetically conserved small heat shock protein 27 (HSP27) protects against transient middle cerebral artery occlusion (tMCAO). Here we show that HSP27 transgenic overexpression also maintains the integrity of the BBB in mice subjected to tMCAO. Extravasation of endogenous IgG antibodies and exogenous FITC-albumin into the brain following tMCAO was reduced in transgenic mice, as was total brain water content. HSP27 overexpression abolished the appearance of TUNEL-positive profiles in microvessel walls. Transgenics also exhibited less loss of microvessel proteins following tMCAO. Notably, primary endothelial cell cultures were rescued from oxygen-glucose deprivation (OGD) by lentiviral HSP27 overexpression according to four viability assays, supporting a direct effect on this cell type. Finally, HSP27 overexpression reduced the appearance of neutrophils in the brain and inhibited the secretion of five cytokines. These findings reveal a novel role for HSP27 in attenuating ischemia/reperfusion injury - the maintenance of BBB integrity. Endogenous upregulation of HSP27 after ischemia in wild-type animals may exert similar protective functions and warrants further investigation. Exogenous enhancement of HSP27 by rational drug design may lead to future therapies against a host of injuries, including but not limited to a harmful breach in brain vasculature.
C1 [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
[Zhang, Lili; Stetler, R. Anne; Weng, Zhongfang; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
[Zhang, Lili; Stetler, R. Anne; Weng, Zhongfang; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.
[Zhang, Lili; Stetler, R. Anne; Weng, Zhongfang; Li, Peiying; Chen, Jun] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, Pittsburgh, PA 15213 USA.
[Atkins, G. Brandon] Case Western Reserve Univ, Case Cardiovasc Res Inst, Dept Med, Sch Med, Cleveland, OH 44106 USA.
[Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, S507 Biomed Sci Tower, Pittsburgh, PA 15213 USA.
EM yqgao@shmu.edu.cn; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016;
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU Mylan School of Pharmacy at Duquesne University; VA Merit Review grant;
National Institutes of Neurological Disorders and Stroke [NS043802,
NS045048, NS036736, NS056118]; Chinese Natural Science Foundation
[30670642, 30870794, 81020108021]; VA Research Career Scientist Award;
RK Mellon Endowed Chair from UPMC
FX RKL and LZ contributed equally to this work. RKL, LZ, RAS,
ZW, and PL performed the experiments and analyzed the data. RKL wrote
the manuscript. JC and YG designed the experiments, analyzed the data,
and helped write the manuscript. GBA contributed new research reagents.
The authors acknowledge the administrative assistance of Pat Strickler,
Deb Wilson, Mary Caruso, and Jackie Farrer. RKL was supported by a
startup from the Mylan School of Pharmacy at Duquesne University. JC was
supported by VA Merit Review grant and National Institutes of
Neurological Disorders and Stroke grants NS043802, NS045048, NS036736,
and NS056118. YG was supported by Chinese Natural Science Foundation
grants 30670642, 30870794, and 81020108021. JC is a recipient of the VA
Research Career Scientist Award and the RK Mellon Endowed Chair from
UPMC.
NR 61
TC 6
Z9 7
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1871-5273
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PD MAY
PY 2013
VL 12
IS 3
BP 325
EP 337
PG 13
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 145CE
UT WOS:000318990800006
PM 23469858
ER
PT J
AU Richards, D
Larkin, M
Milaszewski, K
Javier, E
Casey, T
Grey, M
AF Richards, Denise
Larkin, Mary
Milaszewski, Kerry
Javier, Elaine
Casey, Terri
Grey, Margaret
TI Learning Needs of Youth With Type 2 Diabetes
SO DIABETES EDUCATOR
LA English
DT Article
ID SELF-MANAGEMENT EDUCATION; CHILDREN
AB Purpose
The purpose of this study was to examine reports of diabetes learning needs by youth with type 2 diabetes and their family support person (FSP) and to examine correlations of these perceptions with demographic variables.
Methods
Data were analyzed from the Participant Needs Assessment (PNA), a routinely self-administered questionnaire designed to assess learning needs, in 191 youth (mean age = 14.0 +/- 1.9 years, duration 8.78 +/- 6.30 months; 36% black, non-Hispanic; 40% Hispanic; 20% white) enrolled in the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study. Youth and their FSPs completed the PNA at scheduled study visits, rating their learning needs on a 5-point scale, with higher scores indicating higher needs. Paired t tests and ANOVA were used.
Results
There were no differences in reported learning needs by gender, although scores on the Teen Issues scale approached significance, with girls reporting higher needs than boys. Youth and FSPs were similar on their reports of needs on 3 scales (Ordinary Day, Nutrition, and Living With Diabetes), but youth reported higher needs than FSPs on Focus and Teen Issues. Controlling for duration of diabetes, these differences between youth and FSPs persisted. In general, learning needs for both youth and FSPs decreased over time.
Conclusions
Youth with type 2 diabetes and their FSPs have high levels of ongoing learning needs despite completion of a standard diabetes education program. Continued assessment of learning needs, follow-up education, and behavioral approaches are warranted for these high-risk youth.
C1 [Richards, Denise; Larkin, Mary; Javier, Elaine] Mass Gen Hosp, Boston, MA 02114 USA.
[Milaszewski, Kerry] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Casey, Terri] Univ Case Med Ctr, Cleveland, OH USA.
[Grey, Margaret] Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
RP Richards, D (reprint author), Mass Gen Hosp, 50 Staniford St,Suite 340, Boston, MA 02114 USA.
EM drichards1@partners.org
NR 10
TC 0
Z9 0
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-7217
J9 DIABETES EDUCATOR
JI Diabetes Educ.
PD MAY-JUN
PY 2013
VL 39
IS 3
BP 314
EP 319
DI 10.1177/0145721713485305
PG 6
WC Endocrinology & Metabolism; Public, Environmental & Occupational Health
SC Endocrinology & Metabolism; Public, Environmental & Occupational Health
GA 148DR
UT WOS:000319223600003
PM 23589327
ER
PT J
AU Brown-Guion, SY
Youngerman, SM
Hernandez-Tejada, MA
Dismuke, CE
Egede, LE
AF Brown-Guion, Stephanie Y.
Youngerman, Stephanie M.
Hernandez-Tejada, Melba A.
Dismuke, Clara E.
Egede, Leonard E.
TI Racial/Ethnic, Regional, and Rural/Urban Differences in Receipt of
Diabetes Education
SO DIABETES EDUCATOR
LA English
DT Article
ID CARE; INTERVENTION; METAANALYSIS; PERCEPTIONS; ADULTS
AB Purpose
The objective of this study is to examine the differences in receipt of diabetes education according to risk factors that are associated with the disease, including race/ethnicity, region, and rural/urban location.
Methods
National data from the 2007 Medical Expenditure Panel Survey (MEPS) were analyzed to examine likelihood of receipt of diabetes education in terms of race, urban/rural location, and region.
Results
Of 1747 adults with type 2 diabetes, 65.6% were white, 15% black, and 19.4% other. In addition, 49.3% were male, 50.6% female; 46.9% were under age 64; 39.8% had more than high school; 34.1% were from low-income households, 35.1% middle income, and 30.8% high income; 39.5% lived in the South while other regions were equally represented; 80.6% lived in rural areas; 63.7% did not receive any type 2 diabetes education. Patients in the South were least likely to receive education (67.5% did not). Logistic regression demonstrated that being black (odds ratio [OR] = 1.38, 95% confidence interval [CI], 1.03-1.84) and living in an urban area (OR = 1.40, 95% CI, 1.00-1.97) were associated with a higher likelihood of receiving diabetes education. By contrast, being 65 or older was associated with lower probability of receiving education (OR = 0.59, 95% CI, 0.40-0.87), as was lack of insurance (OR = 0.54, 95% CI, 0.33-0.88)
Conclusions
Being black independently increased likelihood of receiving diabetes education, but living in rural areas, being uninsured, and living in the South reduced chances one would receive this helpful information. Therefore, further research should examine benefits of leveraging technology such as telemedicine to improve delivery of diabetes education to those living in rural areas.
C1 [Brown-Guion, Stephanie Y.; Hernandez-Tejada, Melba A.; Dismuke, Clara E.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
[Youngerman, Stephanie M.; Dismuke, Clara E.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
NR 27
TC 3
Z9 3
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-7217
J9 DIABETES EDUCATOR
JI Diabetes Educ.
PD MAY-JUN
PY 2013
VL 39
IS 3
BP 327
EP 334
DI 10.1177/0145721713480002
PG 8
WC Endocrinology & Metabolism; Public, Environmental & Occupational Health
SC Endocrinology & Metabolism; Public, Environmental & Occupational Health
GA 148DR
UT WOS:000319223600005
PM 23482514
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI How to Catch a Suspicious Bleeding Site in Flagrante
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Gastrointestinal bleeding; Gastrointestinal endoscopy; Geometric
probability; Medical decision analysis; Outcome research; Probability
theory
AB In search for a source of gastrointestinal bleeding, endoscopy frequently reveals mucosal lesions of questionable dignity.
To investigate the probability of ascertaining conclusive evidence for gastrointestinal bleeding from a suspicious mucosal lesion through a single or multiple consecutive endoscopies.
A mathematical model is developed to estimate the probability of successful diagnosis of a bleeding gastrointestinal lesion associated with single or multiple endoscopies.
The probability of a successful confirmation through endoscopy depends on the length of time that signs of recent bleed persist at the site of the mucosal lesion and on the number of repeat endoscopies that one is willing to invest in confirmation. Assuming persistence of endoscopic evidence for 6-12 hours after the initial bleeding, a single endoscopy is associated with a 22 %-38 % chance of observing a suspicious site with clear evidence of bleeding. Using potentially up to 2 additional repeat endoscopies can raise such chances to 52 %-76 %.
The rates of success may provide useful guidance in scheduling endoscopies for the work-up of gastrointestinal bleeding and decision making about the utility of repeat endoscopy in instances of suspicious but inconclusive mucosal lesions.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 6
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAY
PY 2013
VL 58
IS 5
BP 1194
EP 1197
DI 10.1007/s10620-012-2488-6
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 149VU
UT WOS:000319350300009
PM 23179160
ER
PT J
AU Surti, B
Spiegel, B
Ippoliti, A
Vasiliauskas, EA
Simpson, P
Shih, DQ
Targan, SR
McGovern, DPB
Melmed, GY
AF Surti, Bijal
Spiegel, Brennan
Ippoliti, Andrew
Vasiliauskas, Eric A.
Simpson, Peter
Shih, David Q.
Targan, Stephan R.
McGovern, Dermot P. B.
Melmed, Gil Y.
TI Assessing Health Status in Inflammatory Bowel Disease Using a Novel
Single-Item Numeric Rating Scale
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; Health
related quality of life; Patient reported outcome
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CROHNS-DISEASE;
RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; PHYSICIANS PERSPECTIVES;
ULCERATIVE-COLITIS; ACTIVITY INDEX; PATIENT; PERCEPTIONS
AB Current instruments used to measure disease activity and health-related quality of life in patients with Crohn's disease (CD) and ulcerative colitis (UC) are often cumbersome, time-consuming, and expensive; although used in clinical trials, they are not convenient for clinical practice. A numeric rating scale (NRS) is a quick, inexpensive, and convenient patient-reported outcome that can capture the patient's overall perception of health.
The aim of this study was to assess the validity, reliability, and responsiveness of an NRS and evaluate its use in clinical practice in patients with CD and UC.
We prospectively evaluated patient-reported NRS scores and measured correlations between NRS and a range of severity measures, including physician-reported NRS, Crohn's disease activity index (CDAI), Harvey-Bradshaw index (HBI), inflammatory bowel disease questionnaire (IBDQ), and C-reactive protein (CRP) in patients with CD. Subsequently, we evaluated the correlation between the NRS and standard measures of health status (HBI or simple colitis clinical activity index [SCCAI]) and laboratory tests (sedimentation rate [ESR], CRP, and fecal calprotectin) in patients with CD and UC.
The patient-reported NRS showed excellent correlation with CDAI (R (2) = 0.59, p < 0.0001), IBDQ (R (2) = 0.66, p < 0.0001), and HBI (R (2) = 0.32, p < 0.0001) in patients with CD. The NRS showed poor, but statistically significant correlation with SCCAI (R (2) = 0.25, p < 0.0001) in patients with UC. The NRS did not correlate with CRP, ESR, or calprotectin. The NRS was reliable and responsive to change.
The NRS is a valid, reliable, and responsive measure that may be useful to evaluate patients with CD and possibly UC.
C1 [Surti, Bijal; Ippoliti, Andrew; Vasiliauskas, Eric A.; Simpson, Peter; Shih, David Q.; Targan, Stephan R.; McGovern, Dermot P. B.; Melmed, Gil Y.] Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, Los Angeles, CA 90048 USA.
[Surti, Bijal; Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA.
[Spiegel, Brennan] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Outcomes Res, Digest Dis Res Ctr, Los Angeles, CA USA.
RP Melmed, GY (reprint author), Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, 8635 W 3rd St 960 Wv, Los Angeles, CA 90048 USA.
EM Gil.Melmed@cshs.org
FU Centocor, Inc.; USPHS [PO1DK046763, DK062413]; Cedars-Sinai F. Widjaja
Foundation Inflammatory Bowel and Immunobiology Research Institute;
Helmsley Foundation; European Union; Crohn's and Colitis Foundation of
America; Feintech Family Chair in IBD; Joshua L. and Lisa Z. Greer Chair
in IBD Genetics
FX This study was funded in part by an unrestricted Investigator-Initiated
grant from Centocor, Inc. The authors gratefully acknowledge Dr Fasiha
Kanwal and Dr Ron Hays (UCLA) for methodologic input and Dr Patricio
Ibanez (Cedars-Sinai) for assistance with patient recruitment. IBD
Research at Cedars-Sinai that contributed to this study is supported by
USPHS grant PO1DK046763, DK062413 and the Cedars-Sinai F. Widjaja
Foundation Inflammatory Bowel and Immunobiology Research Institute
Research Funds. Project investigators are support by The Helmsley
Foundation, The European Union and the Crohn's and Colitis Foundation of
America (D.P.B.M.), The Feintech Family Chair in IBD (S.R.T.), The
Joshua L. and Lisa Z. Greer Chair in IBD Genetics (D.P.B.M.).
NR 51
TC 5
Z9 5
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAY
PY 2013
VL 58
IS 5
BP 1313
EP 1321
DI 10.1007/s10620-012-2500-1
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 149VU
UT WOS:000319350300025
PM 23250673
ER
PT J
AU Hochedlinger, K
AF Hochedlinger, Konrad
TI Understanding cellular reprogramming and pluripotency
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Conference of the British-Society-for-Gene-and-Cell-Therapy (BSGCT)
CY APR 17-19, 2013
CL Univ London, Royal Holloway, Egham, ENGLAND
SP British Soc Gene & Cell Therapy (BSGCT)
HO Univ London, Royal Holloway
C1 [Hochedlinger, Konrad] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD MAY
PY 2013
VL 24
IS 5
BP A9
EP A9
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 146TN
UT WOS:000319114700025
ER
PT J
AU Ahn, KY
Hur, H
Kim, DH
Min, J
Jeong, DH
Chu, SH
Lee, JW
Ligibel, JA
Meyerhardt, JA
Jones, LW
Jeon, JY
Kim, NK
AF Ahn, Ki-Yong
Hur, Hyuk
Kim, Dong-Hyun
Min, Jihee
Jeong, Duck Hyoun
Chu, Sang Hui
Lee, Ji Won
Ligibel, Jennifer A.
Meyerhardt, Jeffrey A.
Jones, Lee W.
Jeon, Justin Y.
Kim, Nam Kyu
TI The effects of inpatient exercise therapy on the length of hospital stay
in stages I-III colon cancer patients: randomized controlled trial
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Article
DE Exercise; Paralytic ileus; Colectomy; Recovery
ID CLINICAL-TRIAL; MULTIMODAL OPTIMIZATION; ENHANCED RECOVERY; SURGICAL
CARE; SURGERY; MANAGEMENT; RESECTION; REHABILITATION; METAANALYSIS;
PROTOCOL
AB This study aimed to examine the effects of a postsurgical, inpatient exercise program on postoperative recovery in operable colon cancer patients
We conducted the randomized controlled trial with two arms: postoperative exercise vs. usual care. Patients with stages I-III colon cancer who underwent colectomy between January and December 2011 from the Colorectal Cancer Clinic, were recruited for the study. Subjects in the intervention group participated in the postoperative inpatient exercise program consisted of twice daily exercise, including stretching, core, balance, and low-intensity resistance exercises. The usual care group was not prescribed a structured exercise program. The primary endpoint was the length of hospital stay. Secondary endpoints were time to flatus, time to first liquid diet, anthropometric measurements, and physical function measurements.
A total of 31 (86.1 %) patients completed the trial, with adherence to exercise interventions at 84.5 %. The mean length of hospital stay was 7.82 +/- 1.07 days in the exercise group compared with 9.86 +/- 2.66 days in usual care (mean difference, 2.03 days; 95 % confidence interval (CI), -3.47 to -0.60 days; p = 0.005) in per-protocol analysis. The mean time to flatus was 52.18 +/- 21.55 h in the exercise group compared with 71.86 +/- 29.2 h in the usual care group (mean difference, 19.69 h; 95 % CI, -38.33 to -1.04 h; p = 0.036).
Low-to-moderate-intensity postsurgical exercise reduces length of hospital stay and improves bowel motility after colectomy procedure in patients with stages I-III colon cancer.
C1 [Ahn, Ki-Yong; Kim, Dong-Hyun; Min, Jihee; Jeon, Justin Y.] Yonsei Univ, Dept Sport & Leisure Studies, Seoul 120749, South Korea.
[Hur, Hyuk; Kim, Dong-Hyun; Kim, Nam Kyu] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea.
[Chu, Sang Hui] Yonsei Univ, Coll Nursing, Nursing policy Res Inst, Dept Clin Nursing Sci,Biobehav Res Ctr, Seoul 120749, South Korea.
[Lee, Ji Won] Yonsei Univ, Coll Med, Dept Family Med, Seoul, South Korea.
[Ligibel, Jennifer A.; Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Jones, Lee W.] Duke Canc Inst, Durham, NC USA.
RP Jeon, JY (reprint author), Yonsei Univ, Dept Sport & Leisure Studies, 134 Seodaemun Gu, Seoul 120749, South Korea.
EM jjeon@yonsei.ac.kr; namkyuk@yuhs.ac
OI Kim, Nam-Kyu/0000-0003-0639-5632
FU national research foundation of Korea (NRF), Ministry of Education
[2011-0004892]
FX The current study was supported by the national research foundation of
Korea (NRF), Ministry of Education (No. 2011-0004892).
NR 15
TC 4
Z9 4
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-1958
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD MAY
PY 2013
VL 28
IS 5
BP 643
EP 651
DI 10.1007/s00384-013-1665-1
PG 9
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 142HY
UT WOS:000318789200006
PM 23417645
ER
PT J
AU Solin, LJ
Gray, R
Baehner, FL
Butler, SM
Hughes, LL
Yoshizawa, C
Cherbavaz, DB
Shak, S
Page, DL
Sledge, GW
Davidson, NE
Ingle, JN
Perez, EA
Wood, WC
Sparano, JA
Badve, S
AF Solin, Lawrence J.
Gray, Robert
Baehner, Frederick L.
Butler, Steven M.
Hughes, Lorie L.
Yoshizawa, Carl
Cherbavaz, Diana B.
Shak, Steven
Page, David L.
Sledge, George W., Jr.
Davidson, Nancy E.
Ingle, James N.
Perez, Edith A.
Wood, William C.
Sparano, Joseph A.
Badve, Sunil
TI A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal
Carcinoma In Situ of the Breast
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID SURGICAL ADJUVANT BREAST; GENE-EXPRESSION; EUROPEAN ORGANIZATION;
CONSERVING THERAPY; CANCER; TAMOXIFEN; PROJECT; RADIOTHERAPY; RADIATION;
PROTOCOL
AB Background For women with ductal carcinoma in situ (DCIS) of the breast, the risk of developing an ipsilateral breast event (IBE; defined as local recurrence of DCIS or invasive carcinoma) after surgical excision without radiation is not well defined by clinical and pathologic characteristics.
Methods The Oncotype DX breast cancer assay was performed for patients with DCIS treated with surgical excision without radiation in the Eastern Cooperative Oncology Group (ECOG) E5194 study. The association of the prospectively defined DCIS Score (calculated from seven cancer-related genes and five reference genes) with the risk of developing an IBE was analyzed using Cox regression. All statistical tests were two-sided.
Results There were 327 patients with adequate tissue for analysis. The continuous DCIS Score was statistically significantly associated with the risk of developing an IBE (hazard ratio [HR] = 2.31, 95% confidence interval [CI] = 1.15 to 4.49; P = .02) when adjusted for tamoxifen use (prespecified primary analysis) and with invasive IBE (unadjusted HR = 3.68, 95% CI = 1.34 to 9.62; P = .01). For the prespecified DCIS risk groups of low, intermediate, and high, the 10-year risks of developing an IBE were 10.6%, 26.7%, and 25.9%, respectively, and for an invasive IBE, 3.7%, 12.3%, and 19.2%, respectively (both log rank P = .006). In multivariable analyses, factors associated with IBE risk were DCIS Score, tumor size, and menopausal status (all P = .02).
Conclusions The DCIS Score quantifies IBE risk and invasive IBE risk, complements traditional clinical and pathologic factors, and provides a new clinical tool to improve selecting individualized treatment for women with DCIS who meet the ECOG E5194 criteria.
C1 [Solin, Lawrence J.] Albert Einstein Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19141 USA.
[Gray, Robert] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gray, Robert] Eastern Cooperat Oncol Grp Coordinating Ctr, Boston, MA USA.
[Baehner, Frederick L.; Butler, Steven M.; Yoshizawa, Carl; Cherbavaz, Diana B.; Shak, Steven] Genom Hlth Inc, Redwood City, CA USA.
[Baehner, Frederick L.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.
[Hughes, Lorie L.] City Hope Natl Med Ctr, Cartersville, GA USA.
[Page, David L.] Vanderbilt Univ, Dept Pathol, Nashville, TN USA.
[Sledge, George W., Jr.] Indiana Univ, Dept Med Oncol, Indianapolis, IN 46204 USA.
[Badve, Sunil] Indiana Univ, Dept Pathol, Indianapolis, IN 46204 USA.
[Davidson, Nancy E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Ingle, James N.] Mayo Clin, Rochester, MN USA.
[Perez, Edith A.] Mayo Clin, Jacksonville, FL 32224 USA.
[Wood, William C.] Emory Univ, Dept Surg, Atlanta, GA 30322 USA.
[Sparano, Joseph A.] Albert Einstein Coll Med, Dept Med Oncol, Montefiore Med Ctr, New York, NY USA.
RP Solin, LJ (reprint author), Albert Einstein Med Ctr, Dept Radiat Oncol, 5501 Old York Rd, Philadelphia, PA 19141 USA.
EM solin@einstein.edu
FU Public Health Service Grants [CA23318, CA66636, CA21115, CA13650,
CA49883, CA49957, CA39229, CA25224, CA14958]; National Cancer Institute;
National Institutes of Health; Department of Health and Human Services;
Genomic Health, Inc.; Breast Cancer Research Foundation
FX This work was supported in part by Public Health Service Grants CA23318,
CA66636, CA21115, CA13650, CA49883, CA49957, CA39229, CA25224, and
CA14958, and by the National Cancer Institute, the National Institutes
of Health, and the Department of Health and Human Services. Other
supporting grants include Genomic Health, Inc. and The Breast Cancer
Research Foundation.
NR 44
TC 149
Z9 151
U1 2
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 10
BP 701
EP 710
DI 10.1093/jnci/djt067
PG 10
WC Oncology
SC Oncology
GA 149JS
UT WOS:000319315700009
PM 23641039
ER
PT J
AU Hoffman, RM
Koyama, T
Fan, KH
Albertsen, PC
Barry, MJ
Goodman, M
Hamilton, AS
Potosky, AL
Stanford, JL
Stroup, AM
Penson, DF
AF Hoffman, Richard M.
Koyama, Tatsuki
Fan, Kang-Hsien
Albertsen, Peter C.
Barry, Michael J.
Goodman, Michael
Hamilton, Ann S.
Potosky, Arnold L.
Stanford, Janet L.
Stroup, Antoinette M.
Penson, David F.
TI Mortality After Radical Prostatectomy or External Beam Radiotherapy for
Localized Prostate Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID ANDROGEN SUPPRESSION; RADIATION-THERAPY; SURVIVAL; MEN; OUTCOMES; TERM
AB Background No randomized trials have compared survival outcomes for men with localized prostate cancer (PC) being treated with radical prostatectomy (RP) or external beam radiotherapy (EBRT). The goal of the study, therefore, was to estimate the association of RP (compared with EBRT) with overall and PC mortality.
Methods We analyzed an observational cohort from the population-based Prostate Cancer Outcomes Study, which included men aged 55 to 74 years diagnosed with localized PC between October 1994 and October 1995 who underwent either RP (n = 1164) or EBRT (n = 491) within 1 year of diagnosis. Patients were followed until death or study end (December 31, 2010). Overall and disease-specific mortality were assessed with multivariable survival analysis, with propensity scores to adjust for potential treatment selection confounders (demographics, comorbidities, and tumor characteristics). All statistical tests were two-sided.
Results After 15 years of follow-up, there were 568 deaths, including 104 from PC. RP was associated with statistically significant advantages for overall (hazard ratio [HR] = 0.60, 95% confidence interval [CI] = 0.53 to 0.70, P < .0001.) and disease-specific mortality (HR = 0.35, 95% CI = 0.26 to 0.49, P < .0001.). Mortality benefits for RP were also observed within treatment propensity quintiles, when subjects were pair-matched on propensity scores, and in subgroup analyses based on age, tumor characteristics, and comorbidity.
Conclusions Population-based observational data on men diagnosed with localized PC in the mid-1990s suggest a mortality benefit associated with RP vs EBRT. Possible explanations include residual selection bias or a true survival advantage. Results might be less applicable for men facing treatment decisions today.
C1 [Hoffman, Richard M.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA.
[Hoffman, Richard M.] New Mexico VA Healthcare Syst, Med Serv, Albuquerque, NM USA.
[Albertsen, Peter C.] Univ Connecticut, Sch Med, Dept Surg, Div Urol, Farmington, CT USA.
[Barry, Michael J.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Goodman, Michael] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Hamilton, Ann S.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Potosky, Arnold L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Stanford, Janet L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Stroup, Antoinette M.] Univ Utah, Salt Lake City, UT USA.
[Koyama, Tatsuki; Fan, Kang-Hsien] Vanderbilt Univ, Dept Biostat, Nashville, TN 37203 USA.
[Koyama, Tatsuki; Fan, Kang-Hsien] Vanderbilt Univ, Ctr Quantitat Sci, Nashville, TN 37203 USA.
[Penson, David F.] Vanderbilt Univ, Dept Urol Surg, Nashville, TN 37203 USA.
[Penson, David F.] Vanderbilt Univ, Ctr Surg Qual & Outcomes Res, Nashville, TN 37203 USA.
[Penson, David F.] VA Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA.
RP Penson, DF (reprint author), Vanderbilt Univ, Med Ctr, 2525W End Ave,Ste 600, Nashville, TN 37203 USA.
EM david.penson@vanderbilt.edu
FU National Cancer Institute, National Institutes of Health, Bethesda, MD
[R01-CA114524]; [N01-PC-67007]; [N01-PC-67009]; [N01-PC-67010];
[N01-PC-67006]; [N01-PC-67005]; [N01-PC-67000]
FX This study was supported by the National Cancer Institute, National
Institutes of Health, Bethesda, MD, through grant R01-CA114524 and the
following contracts from the each of the participating institutions:
N01-PC-67007, N01-PC-67009, N01-PC-67010, N01-PC-67006, N01-PC-67005,
and N01-PC-67000.
NR 33
TC 32
Z9 33
U1 2
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 10
BP 711
EP 718
DI 10.1093/jnci/djt059
PG 8
WC Oncology
SC Oncology
GA 149JS
UT WOS:000319315700010
PM 23615689
ER
PT J
AU Joh, HK
Giovannucci, EL
Bertrand, KA
Lim, S
Cho, E
AF Joh, Hee-Kyung
Giovannucci, Edward L.
Bertrand, Kimberly A.
Lim, Soo
Cho, Eunyoung
TI Predicted Plasma 25-Hydroxyvitamin D and Risk of Renal Cell Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID VITAMIN-D-RECEPTOR; TOTAL-ENERGY-INTAKE; PROSPECTIVE COHORT;
ULTRAVIOLET-B; UNITED-STATES; CARCINOMA; MORTALITY; EPIDEMIOLOGY;
METAANALYSIS; EXPRESSION
AB Background Although the kidney is a primary organ for vitamin D metabolism, the association between vitamin D and renal cell cancer (RCC) remains unclear.
Methods We prospectively evaluated the association between predicted plasma 25-hydroxyvitamin D [25(OH)D] and RCC risk among 72 051 women and 46 380 men in the period from 1986 to 2008. Predicted plasma 25(OH)D scores were computed using validated regression models that included major determinants of vitamin D status (race, ultraviolet B flux, physical activity, body mass index, estimated vitamin D intake, alcohol consumption, and postmenopausal hormone use in women). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. All statistical tests were two-sided.
Results During 22 years of follow-up, we documented 201 cases of incident RCC in women and 207 cases in men. The multivariable hazard ratios between extreme quintiles of predicted 25(OH)D score were 0.50 (95% CI = 0.32 to 0.80) in women, 0.59 (95% CI = 0.37 to 0.94) in men, and 0.54 (95% CI = 0.39 to 0.75; P-trend < .001) in the pooled cohorts. An increment of 10 ng/mL in predicted 25(OH)D score was associated with a 44% lower incidence of RCC (pooled HR = 0.56, 95% CI = 0.42 to 0.74). We found no statistically significant association between vitamin D intake estimated from food-frequency questionnaires and RCC incidence.
Conclusion Higher predicted plasma 25(OH)D levels were associated with a statistically significantly lower risk of RCC in men and women. Our findings need to be confirmed by other prospective studies using valid markers of long-term vitamin D status.
C1 [Joh, Hee-Kyung] Seoul Natl Univ, Coll Med, Dept Med, Seoul, South Korea.
[Joh, Hee-Kyung] Seoul Natl Univ, Dept Family Med, Hlth Serv Ctr, Seoul, South Korea.
[Giovannucci, Edward L.; Bertrand, Kimberly A.; Cho, Eunyoung] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Bertrand, Kimberly A.; Cho, Eunyoung] Harvard Univ, Sch Med, Boston, MA USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Bertrand, Kimberly A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Lim, Soo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA.
[Lim, Soo] Seoul Natl Univ, Coll Med, Songnam, South Korea.
[Lim, Soo] Seoul Natl Univ, Bundang Hosp, Songnam, South Korea.
RP Cho, E (reprint author), Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM eunyoung.cho@channing.harvard.edu
FU National Institutes of Health [CA87969, CA55075]; Dana-Farber/Harvard
Cancer Center Kidney Cancer Specialized Programs of Research Excellence
(SPORE) [NIH P50CA101942]; Nutritional Epidemiology of Cancer Training
Grant [R25 CA098566]
FX This study was supported by research grant CA87969 and CA55075 from the
National Institutes of Health, and Dana-Farber/Harvard Cancer Center
Kidney Cancer Specialized Programs of Research Excellence (SPORE; NIH
P50CA101942). KAB was supported by the Nutritional Epidemiology of
Cancer Training Grant (R25 CA098566).
NR 40
TC 15
Z9 15
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 10
BP 726
EP 732
DI 10.1093/jnci/djt082
PG 7
WC Oncology
SC Oncology
GA 149JS
UT WOS:000319315700012
PM 23568327
ER
PT J
AU Thompson, BR
Douglass, JA
Ellis, MJ
Kelly, VJ
O'Hehir, RE
King, GG
Verbanck, S
AF Thompson, Bruce R.
Douglass, Jo A.
Ellis, Matthew J.
Kelly, Vanessa J.
O'Hehir, Robyn E.
King, Gregory G.
Verbanck, Sylvia
TI Peripheral lung function in patients with stable and unstable asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Severe asthma; acinar airways; peripheral gas mixing
ID INERT-GAS WASHOUT; VENTILATION HETEROGENEITY; COMPUTED-TOMOGRAPHY;
RESPIRATORY SOCIETY; AIRWAY INVOLVEMENT; NITROGEN WASHOUT;
FUNCTION-TESTS; DISTAL LUNG; INFLAMMATION; ADULTS
AB Background: Exacerbations of asthma are thought to be caused by airflow obstruction resulting from airway inflammation, bronchospasm, and mucus plugging. Histologic evidence suggests the small airways, including acinar air spaces, are involved; however, this has not been corroborated in vivo by measurements of peripheral small-airway function.
Objective: We sought to determine whether asthma severity is linked to small-airway function, particularly in patients with acute severe asthma.
Methods: Eighteen subjects admitted for an asthma exacerbation underwent lung function testing, including measures of acinar ventilation heterogeneity (S-acin) and conductive ventilation heterogeneity (S-cond) using the multiple-breath nitrogen washout. Treatment requirement was defined according to Global Initiative for Asthma scores. Data were compared with those obtained in 19 patients with stable asthma.
Results: For the asthma exacerbation group, the median FEV1 was 59% of predicted value (95% CI, 45% to 75% of predicted value), the median S-cond value was 185% of predicted value (95% CI, 119% to 245% of predicted value), and the median S-acin value was 225% of predicted value (95% CI, 143% to 392% of predicted value). FEV1 (percent predicted) was correlated with S-acin (percent predicted) values (Spearman rho = -0.67, P =.006) but not with S-cond (percent predicted) values (P >.1). The Global Initiative for Asthma score was significantly related to S-acin (percent predicted) (Spearman rho = 0.59, P = .016) but not to S-cond (percent predicted) values (P >.1). The unstable group was characterized by considerably lower forced vital capacity (P <. 001) and higher S-cond (P =.001) values than the unstable group. In a subgroup of 11 unstable patients who could be reviewed after 4 weeks, FEV1, forced vital capacity, S-acin, and S-cond values showed marked improvements.
Conclusion: Our findings suggest that unstable asthma is characterized by a combined abnormality in the acinar and conductive lung zones, both of which are partly reversible. Functional abnormality in the acinar lung zone in particular showed a direct correlation with airflow obstruction and treatment requirement in patients with acute severe asthma.
C1 [Thompson, Bruce R.; Ellis, Matthew J.; O'Hehir, Robyn E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic 3004, Australia.
[Thompson, Bruce R.; Ellis, Matthew J.; O'Hehir, Robyn E.] Monash Univ, Melbourne, Vic 3004, Australia.
[Thompson, Bruce R.; Ellis, Matthew J.; O'Hehir, Robyn E.; King, Gregory G.] Cooperat Res Ctr Asthma & Airways, Sydney, NSW, Australia.
[Douglass, Jo A.] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Parkville, Vic 3050, Australia.
[Douglass, Jo A.] Univ Melbourne, Parkville, Vic 3052, Australia.
[Kelly, Vanessa J.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Kelly, Vanessa J.] Harvard Univ, Sch Med, Boston, MA USA.
[King, Gregory G.] Woolcock Inst Med Res, Sydney, NSW, Australia.
[Verbanck, Sylvia] Vrije Univ Brussel, Acad Hosp, Div Resp, Brussels, Belgium.
RP Thompson, BR (reprint author), Alfred Hosp, Dept Allergy Immunol & Resp Med, Lung Funct Lab, Commercial Rd, Melbourne, Vic 3004, Australia.
EM b.thompson@alfred.org.au
RI O'Hehir, Robyn/H-3627-2011;
OI O'Hehir, Robyn/0000-0002-3489-7595; Thompson, Bruce/0000-0002-5885-0652
FU Cooperative Research Centre for Asthma and Airways; National Health and
Medical Research Council, Australia; National Health and Medical
Research Council; AstraZeneca; GlaxoSmithKline,; Novartis; Pharmaxis;
Pharmaxis, and the Asthma Foundation
FX Support for this study was provided by the Cooperative Research Centre
for Asthma and Airways and the National Health and Medical Research
Council, Australia.; Disclosure of potential conflict of interest: B. R.
Thompson, M. J. Ellis, V. J. Kelly, R. E. O'Hchir, and S. Verbanck have
received grants from the National Health and Medical Research Council
and the Cooperative Research Centre for Asthma and Airways. J. A.
Douglass has received grants from the National Health and Medical
Research Council and the Cooperative Research Centre for Asthma and
Airways; is on an advisory board for Novartis; has received payment for
lectures from AstraZeneca, GlaxoSmithKline, and Novartis; and has
received royalties from Health Press Limited. G. G. King has received
grants from the National Health and Medical Research Council,
GlaxoSmithKline, Boehringer Ingelheim, Pharmaxis, and the Asthma
Foundation; has received travel support from GlaxoSmithKline, Novartis,
AstraZeneca, Boehringer Ingelheim, and Pfizer; has received subject
payments for clinical trials from Pharmaxis; and is part of a
consultancy agreement between GlaxoSmithKline, Novartis, AstraZeneca,
Boehringer Ingelheim, Pfizer, and the Woolcock Institute of Medical
Research, and his research group receives an unrestricted allocation as
part of the monies received from the consultancy agreements.
NR 37
TC 30
Z9 30
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD MAY
PY 2013
VL 131
IS 5
BP 1322
EP 1328
DI 10.1016/j.jaci.2013.01.054
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 144AU
UT WOS:000318912200007
PM 23561802
ER
PT J
AU Mehling, M
Brinkmann, V
Burgener, AV
Gubser, P
Luster, AD
Kappos, L
Hess, C
AF Mehling, Matthias
Brinkmann, Volker
Burgener, Anne-Valerie
Gubser, Patrick
Luster, Andrew D.
Kappos, Ludwig
Hess, Christoph
TI Homing frequency of human T cells inferred from peripheral blood
depletion kinetics after sphingosine-1-phosphate receptor blockade
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID MULTIPLE-SCLEROSIS; LYMPH-NODES; SUBSETS; LYMPHOCYTES; FTY720; MEMORY
C1 [Mehling, Matthias; Burgener, Anne-Valerie; Gubser, Patrick; Hess, Christoph] Univ Basel Hosp, Dept Biomed, Immunobiol Lab, CH-4031 Basel, Switzerland.
[Mehling, Matthias; Burgener, Anne-Valerie; Gubser, Patrick; Hess, Christoph] Univ Basel Hosp, Med Outpatient Dept, CH-4031 Basel, Switzerland.
[Mehling, Matthias; Kappos, Ludwig] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland.
[Mehling, Matthias; Kappos, Ludwig] Univ Basel Hosp, Dept Biomed, Clin Neuroimmunol Lab, CH-4031 Basel, Switzerland.
[Brinkmann, Volker] Novartis Inst BioMed Res, Dept Autoimmun Transplantat & Inflammat, Basel, Switzerland.
[Luster, Andrew D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA.
RP Mehling, M (reprint author), Univ Basel Hosp, Dept Biomed, Immunobiol Lab, CH-4031 Basel, Switzerland.
EM chess@uhbs.ch
NR 12
TC 3
Z9 3
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD MAY
PY 2013
VL 131
IS 5
BP 1440
EP +
DI 10.1016/j.jaci.2012.12.1520
PG 11
WC Allergy; Immunology
SC Allergy; Immunology
GA 144AU
UT WOS:000318912200031
PM 23434284
ER
PT J
AU Vaduganathan, M
Gheorghiade, M
AF Vaduganathan, Muthiah
Gheorghiade, Mihai
TI Return of Digoxin and Recovery of Renal Function
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Editorial Material
ID DECOMPENSATED HEART-FAILURE; EVEREST TRIAL; DYSFUNCTION; OUTCOMES
C1 [Vaduganathan, Muthiah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 645 North Michigan Ave,Suite 1006, Chicago, IL 60611 USA.
EM m-gheorghiade@northwestern.edu
NR 18
TC 3
Z9 3
U1 0
U2 1
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD MAY
PY 2013
VL 19
IS 5
BP 303
EP 305
DI 10.1016/j.cardfail.2013.03.006
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 148LQ
UT WOS:000319246500002
PM 23663811
ER
PT J
AU Milfred-Laforest, SK
Chow, SL
Didomenico, RJ
Dracup, K
Ensor, CR
Gattis-Stough, W
Heywood, JT
Lindenfeld, J
Page, RL
Patterson, JH
Vardeny, O
Massie, BM
AF Milfred-Laforest, Sherry K.
Chow, Sheryl L.
Didomenico, Robert J.
Dracup, Kathleen
Ensor, Christopher R.
Gattis-Stough, Wendy
Heywood, J. Thomas
Lindenfeld, Joann
Page, Robert L.
Patterson, J. Herbert
Vardeny, Orly
Massie, Barry M.
TI Clinical Pharmacy Services in Heart Failure: An Opinion Paper From the
Heart Failure Society of America and American College of Clinical
Pharmacy Cardiology Practice and Research Network
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Heart failure; clinical pharmacist; multidisciplinary team; heart
transplant
ID UNITED-STATES HOSPITALS; ADVERSE DRUG-REACTIONS; INPATIENT MEDICATION
RECONCILIATION; VENTRICULAR ASSIST DEVICE; PRESCRIBER ORDER ENTRY;
INTENSIVE-CARE-UNIT; PHARMACEUTICAL CARE; CARDIOVASCULAR-DISEASE;
TRANSPLANT RECIPIENT; MANAGEMENT PROGRAM
AB Background: Heart failure (BF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple comorbidities. This situation is a "perfect storm" of factors that predispose patients to medication errors.
Methods and Results: The goals of this paper are to outline potential roles for clinical pharmacists in a multidisciplinary BF team, to document outcomes associated with interventions by clinical pharmacists, to recommend minimum training for clinical pharmacists engaged in HF care, and to suggest financial strategies to support clinical pharmacy services within a multidisciplinary team. As patients transition from inpatient to outpatient settings and between multiple caregivers, pharmacists can positively affect medication reconciliation and education, assure consistency in management that results in improvements in patient satisfaction and medication adherence, and reduce medication errors. For mechanical circulatory support and heart transplant teams, the Centers for Medicare and Medicaid Services considers the participation of a transplant pharmacology expert (e.g., clinical pharmacist) to be a requirement for accreditation, given the highly specialized and complex drug regimens used. Although reports of outcomes from pharmacist interventions have been mixed owing to differences in study design, benefits such as increased use of evidence-based therapies, decreases in HF hospitalizations and emergency department visits, and decreases in all-cause readmissions have been demonstrated. Clinical pharmacists participating in HF or heart transplant teams should have completed specialized postdoctoral training in the form of residencies and/or fellowships in cardiovascular and/or transplant pharmacotherapy, and board certification is recommended. Financial mechanisms to support pharmacist participation in the HF teams are variable.
Conclusions: Positive outcomes associated with clinical pharmacist activities support the value of making this resource available to HF teams.
C1 [Milfred-Laforest, Sherry K.] Louis Stokes Cleveland VA Med Ctr, Dept Pharm, Cleveland, OH USA.
[Chow, Sheryl L.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA.
[Didomenico, Robert J.] Univ Illinois, Coll Pharm, Chicago, IL USA.
[Dracup, Kathleen] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Ensor, Christopher R.] Univ Pittsburgh, Coll Pharm, Pittsburgh, PA USA.
[Gattis-Stough, Wendy] Campbell Univ, Coll Pharm & Hlth Sci, Dept Clin Res, Buies Creek, NC 27506 USA.
[Heywood, J. Thomas] Scripps Clin, Dept Med, La Jolla, CA 92037 USA.
[Lindenfeld, Joann] Univ Colorado Denver, Dept Med, Div Cardiol, Heart Transplantat Program, Aurora, CO USA.
[Page, Robert L.] Univ Colorado Denver, Sch Pharm, Aurora, CO USA.
[Page, Robert L.] Univ Colorado Denver, Sch Med, Aurora, CO USA.
[Patterson, J. Herbert] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA.
[Vardeny, Orly] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA.
[Vardeny, Orly] Univ Wisconsin, Sch Med, Madison, WI USA.
[Massie, Barry M.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chow, SL (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA.
EM schow@westernu.edu; barry.massie@va.gov
RI Stough, Wendy/R-4287-2016;
OI Stough, Wendy/0000-0001-8290-1205; DiDomenico,
Robert/0000-0002-9374-8012
FU Medtronic; Gambro; St. Jude; Zensun; Otsuka; Novartis; Amgen
FX J. Thomas Heywood has received speaking honoraria from Actelion,
Medtronic, St Jude, and Thoratec; is a consultant for Actelion,
Medtronic, and Thoratec; and has received research grants from Medtronic
and Gambro and fellowship support from St. Jude. JoAnn Lindenfeld is a
consultant for St Jude, Boston Scientific, and Abbott and has received a
research grant from Zensun. J. Herbert Patterson has received speaking
honoraria from Otsuka, is a consultant for Otsuka and Novartis, and has
received research grants from Otsuka, Novartis, and Amgen. All of the
other authors report no potential conflict of interest.
NR 136
TC 8
Z9 9
U1 2
U2 15
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD MAY
PY 2013
VL 19
IS 5
BP 354
EP 369
DI 10.1016/j.cardfail.2013.02.002
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 148LQ
UT WOS:000319246500009
PM 23663818
ER
PT J
AU Bahraini, N
Brenner, LA
AF Bahraini, Nazanin
Brenner, Lisa A.
TI Screening for TBI and Persistent Symptoms Provides Opportunities for
Prevention and Intervention
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Editorial Material
ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MALE VIETNAM
VETERANS; WAR-ZONE STRESSORS; FEMALE; SOLDIERS
C1 [Bahraini, Nazanin; Brenner, Lisa A.] VA VISN Mental Illness Res Educ & Clin Ctr MIRECC, Denver, CO USA.
[Bahraini, Nazanin; Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Psychiat, Aurora, CO USA.
[Bahraini, Nazanin] Univ Colorado, Denver Sch Med, Dept Neurol, Aurora, CO USA.
[Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA.
RP Brenner, LA (reprint author), Denver VA Med Ctr, VISN MIRECC 19, 1055 Clermont St, Denver, CO 80220 USA.
EM lisa.brenner@va.gov
NR 22
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-9701
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD MAY-JUN
PY 2013
VL 28
IS 3
BP 223
EP 226
DI 10.1097/HTR.0b013e318291dab7
PG 4
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 149PS
UT WOS:000319334000010
PM 23661075
ER
PT J
AU Collier, TL
Liang, SH
Vasdev, N
AF Collier, Thomas Lee
Liang, Steven H.
Vasdev, Neil
TI Interfacing of a NanoTek microfluidic system with an H-Cube
continuous-flow hydrogenation reactor and a GE FXN synthesizer
SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
LA English
DT Meeting Abstract
C1 [Collier, Thomas Lee] Advion Inc, Ithaca, NY USA.
[Collier, Thomas Lee; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Collier, Thomas Lee; Liang, Steven H.; Vasdev, Neil] Harvard Univ, Sch Med, Boston, MA USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0362-4803
J9 J LABELLED COMPD RAD
JI J. Label. Compd. Radiopharm.
PD MAY
PY 2013
VL 56
SU 1
MA P386
BP S473
EP S473
PG 1
WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry,
Analytical
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 140ZD
UT WOS:000318694100474
ER
PT J
AU Liang, SH
Collier, TL
Rotstein, B
Lewis, R
Steck, M
Vasdev, N
AF Liang, Steven H.
Collier, T. Lee
Rotstein, Benjamin
Lewis, Rebecca
Steck, Mia
Vasdev, Neil
TI Deprotection and reduction of F-18-labeled compounds by rapid flow
hydrogenation
SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
LA English
DT Meeting Abstract
C1 [Liang, Steven H.; Collier, T. Lee; Rotstein, Benjamin; Lewis, Rebecca; Steck, Mia; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA.
[Liang, Steven H.; Collier, T. Lee; Rotstein, Benjamin; Lewis, Rebecca; Steck, Mia; Vasdev, Neil] Harvard Univ, Sch Med, Boston, MA USA.
[Collier, T. Lee] Advion Inc, Ithaca, NY USA.
[Lewis, Rebecca] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0362-4803
J9 J LABELLED COMPD RAD
JI J. Label. Compd. Radiopharm.
PD MAY
PY 2013
VL 56
SU 1
MA P084
BP S171
EP S171
PG 1
WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry,
Analytical
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 140ZD
UT WOS:000318694100172
ER
PT J
AU Reiner, T
Keliher, EJ
Emmetiere, F
Lewis, JS
Weissleder, R
AF Reiner, Thomas
Keliher, Edmund J.
Emmetiere, Fabien
Lewis, Jason S.
Weissleder, Ralph
TI Tetrazines/trans-cyclooctenes and their application as chemically
orthogonal reaction partners in radiochemical synthesis
SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
LA English
DT Meeting Abstract
C1 [Reiner, Thomas; Emmetiere, Fabien; Lewis, Jason S.; Weissleder, Ralph] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA.
[Keliher, Edmund J.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0362-4803
J9 J LABELLED COMPD RAD
JI J. Label. Compd. Radiopharm.
PD MAY
PY 2013
VL 56
SU 1
MA O-047
BP S47
EP S47
PG 1
WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry,
Analytical
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 140ZD
UT WOS:000318694100048
ER
PT J
AU Otis, JD
Sanderson, K
Hardway, C
Pincus, M
Tun, C
Soumekh, S
AF Otis, John D.
Sanderson, Kristen
Hardway, Christina
Pincus, Michael
Tun, Carlos
Soumekh, Sharona
TI A Randomized Controlled Pilot Study of a Cognitive-Behavioral Therapy
Approach for Painful Diabetic Peripheral Neuropathy
SO JOURNAL OF PAIN
LA English
DT Article
DE Cognitive-behavioral therapy; neuropathic pain; chronic pain; diabetes;
treatment
ID LOW-BACK-PAIN; QUALITY-OF-LIFE; UPDATED GUIDELINES; CONTROLLED-TRIAL;
METAANALYSIS; DEPRESSION; IMPACT; INVENTORY; HEADACHE; MODELS
AB The purpose of the present pilot study was to assess the efficacy of cognitive-behavioral therapy (CBT) for painful diabetic peripheral neuropathy. This was a randomized, treatment as usual (TAU), controlled, nonblinded intervention pilot study with a 4-month follow-up conducted in a VA medical center. It was hypothesized that participants who received CBT, as compared to those who received TAU, would report significant decreases on self-report measures of pain severity, interference, and depressive symptoms from pretreatment to 4-month follow-up. Participants meeting inclusion criteria were randomly assigned to 1 of the study conditions. Of the 20 eligible participants, 12 were randomized to CBT and 8 were randomized to TAU. Participants randomized to CBT showed significant decreases on measures of pain severity (B = -.54) and pain interference (B = -.77) from pretreatment to 4-month follow-up. There were no significant changes in the TAU participants' scores on measures of pain severity (B = .00) or pain interference (B = -.09). Neither CBT nor TAU participants showed significant changes in their levels of depressive symptoms from pretreatment to 4-month follow-up. CBT may be an effective treatment approach for reducing pain severity and interference associated with painful diabetic peripheral neuropathy.
Perspective: The results of this study suggest that engaging patients in CBT for painful diabetic peripheral neuropathy may provide them the skills to become more active and experience less pain. Published by Elsevier Inc. on behalf of the American Pain Society
C1 [Otis, John D.; Tun, Carlos; Soumekh, Sharona] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Otis, John D.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Sanderson, Kristen] Univ Florida, Gainesville, FL USA.
[Hardway, Christina] Merrimack Coll, N Andover, MA 01845 USA.
[Pincus, Michael] UMass Mem Med Ctr, Worcester, MA USA.
[Soumekh, Sharona] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Otis, JD (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA.
EM johnotis@bu.edu
OI Otis, John/0000-0002-5441-7421
FU Veterans of Foreign Wars (VFW)
FX This work was supported by a grant from the Veterans of Foreign Wars
(VFW) to the diabetes research program at VA Boston Healthcare System,
Boston, MA.
NR 31
TC 8
Z9 8
U1 0
U2 7
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD MAY
PY 2013
VL 14
IS 5
BP 475
EP 482
DI 10.1016/j.jpain.2012.12.013
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 145QT
UT WOS:000319032600006
PM 23452825
ER
PT J
AU Agar, M
Ko, DN
Sheehan, C
Chapman, M
Currow, DC
AF Agar, Meera
Ko, Danielle N.
Sheehan, Caitlin
Chapman, Michael
Currow, David C.
TI Informed Consent in Palliative Care Clinical Trials: Challenging but
Possible
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID PULMONARY-ARTERY CATHETERS; END-OF-LIFE; PROXY CONSENT; EMERGENCY
RESEARCH; CAPACITY; VALIDITY; PHASE
AB Obtaining informed consent is a key protection that should be afforded universally to people using health services and the basis around which any participation in clinical trials is built.
Randomized controlled effectiveness studies are necessary to answer key questions in hospice and palliative care, in order to help systematically improve the quality of care. In order to be properly generalizable, such trials need to have broad inclusion criteria to reflect the population most likely to be affected by the condition. The inclusion of patients who are seriously ill, and therefore potentially vulnerable, requires careful exploration of ethical and legal principles that underpin informed consent.
Specific challenges in obtaining informed consent for randomised clinical trials (RCTs) in clinically unstable populations such as hospice and palliative care include higher rates of people with impaired cognitive capacity as well as interventional studies in clinical situations which may present as a sudden change in condition. None of these challenges is unique to hospice and palliative care research, but the combination and frequency with which they are encountered require systematic and considered solutions.
This article outlines five different ethically valid consent approaches and discusses their applicability to hospice and palliative care research trials. These include: consent by the patient (at the time of enrolment, in advance of the study, or delayed until after the study has commenced); a proxy (or legally authorised representative); or a consent waiver. Increased use of the less traditional modes of informed consent may lead to greater participation rates in hospice and palliative care trials, thereby improving the evidence base more rapidly in part by better reflecting the population served and hence improving generalizability.
C1 [Agar, Meera; Sheehan, Caitlin; Currow, David C.] Flinders Univ S Australia, Discipline Palliat & Support Serv, Bedford Pk, SA 5042, Australia.
[Agar, Meera] Braeside Hosp, Dept Palliat Care, Hammond Care, Prairiewood, NSW, Australia.
[Agar, Meera] Univ New S Wales, South West Sydney Clin Sch, Liverpool, NSW, Australia.
[Ko, Danielle N.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Sheehan, Caitlin] Cunningham Ctr Palliat Care, Darlinghurst, NSW, Australia.
[Sheehan, Caitlin] Sacred Heart Ctr, Darlinghurst, NSW, Australia.
[Chapman, Michael] Sunshine Hosp, Western Hlth, Dept Geriatr Med, St Albans, Vic, Australia.
RP Currow, DC (reprint author), Flinders Univ S Australia, Discipline Palliat & Support Serv, Daws Rd, Daw Pk, SA 5041, Australia.
EM david.currow@flinders.edu.au
OI Currow, David/0000-0003-1988-1250
NR 47
TC 7
Z9 7
U1 0
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD MAY
PY 2013
VL 16
IS 5
BP 485
EP 491
DI 10.1089/jpm.2012.0422
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 145GV
UT WOS:000319004100007
PM 23631612
ER
PT J
AU Martinez-Gamboa, L
Lesemann, K
Kuckelkorn, U
Scheffler, S
Ghannam, K
Hahne, M
Gaber-Elsner, T
Egerer, K
Naumann, L
Buttgereit, F
Dorner, T
Kloetzel, PM
Burniester, GR
Faustman, DL
Feist, E
AF Martinez-Gamboa, Lorena
Lesemann, Karsten
Kuckelkorn, Ulrike
Scheffler, Sonja
Ghannam, Khetam
Hahne, Martin
Gaber-Elsner, Timo
Egerer, Karl
Naumann, Lydia
Buttgereit, Frank
Doerner, Thomas
Kloetzel, Peter M.
Burniester, Gerd R.
Faustman, Denise L.
Feist, Eugen
TI Gene Expression of Catalytic Proteasome Subunits and Resistance Toward
Proteasome Inhibition of B Lymphocytes from Patients with Primary
Sjogren Syndrome
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE PROTEASOME SYSTEM; PROTEASOME INHIBITION; SJOGREN SYNDROME; B
LYMPHOCYTES
ID NF-KAPPA-B; MULTIPLE-MYELOMA CELLS; NECROSIS-FACTOR-ALPHA;
INTERFERON-GAMMA; 20S PROTEASOME; SALIVARY-GLANDS; T-CELLS;
PROINFLAMMATORY CYTOKINES; DEFECTIVE APOPTOSIS; AUTOIMMUNE-DISEASES
AB Objective. Dysregulation of proteasome subunit beta 1i expression has been shown in total blood mononuclear cells (PBMC) from patients with primary Sjogren syndrome (pSS), a B cell-driven systemic autoimmune disorder.
Methods. Proteasome activation was investigated in sorted blood cells from patients with pSS and controls by measuring transcript levels of constitutive (beta 1/beta 2/beta 5) and corresponding immunoproteasome catalytic subunits (beta 1i/beta 2i/beta 5i) using real-time PCR. At protein level, beta 1i protein expression was analyzed by immunoblotting. Functional effects of proteasome inhibition on proteolytic activity and induction of apoptosis were also evaluated in cellular subsets.
Results. The proteasome was found to be activated in pSS, with upregulation of gene expression of catalytic proteasome subunits. Western blot analysis revealed decreased beta 1i protein expression in pSS B lymphocytes, with decreased protein despite increased messenger RNA (mRNA) levels. After proteasome inhibition in vitro, proteolytic activity was less reduced and resistance to apoptosis was increased in B lymphocytes compared to other cells.
Conclusion. In pSS, catalytic subunits of the proteasome are upregulated at the mRNA level, while dysregulation of subunit beta 1i is attributed to B lymphocytes. B cell resistance after proteasome inhibition differs from the classical concept of increased susceptibility toward inhibition in activated cells, supporting the novel notion that susceptibility depends on cellular intrinsic factors and on proteasome activation.
C1 [Martinez-Gamboa, Lorena; Lesemann, Karsten; Scheffler, Sonja; Ghannam, Khetam; Hahne, Martin; Gaber-Elsner, Timo] Charite, Dept Rheumatol & Clin Immunol, Rheumatol Res Lab, D-13353 Berlin, Germany.
[Kuckelkorn, Ulrike; Kloetzel, Peter M.] Charite, Dept Biochem, D-13353 Berlin, Germany.
German Rheumatol Res Ctr DRFZ, Berlin, Germany.
Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany.
Dept Rheurnatol & Clin Immunol, Berlin, Germany.
[Faustman, Denise L.; Feist, Eugen] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Immunobiol Lab, Charlestown, MA USA.
RP Martinez-Gamboa, L (reprint author), Charite Forschungslab Rheumatol, AG Feist, Campus Mitte,Virchowweg 10,Nordflugel,5 Stock,Cha, D-10117 Berlin, Germany.
EM lorena.martinez_g@charite.de
FU German Ministry for Economy and Technology (BMWi) [ZIM KF2088101MD8];
DFG [FE470/3-1]; SFB650 (TP17 Targeting of memory plasma cells secreting
pathogenic antibodies); Sjogren's Syndrome Foundation
FX Supported by the German Ministry for Economy and Technology (BMWi, ZIM
KF2088101MD8), the DFG (FE470/3-1), the SFB650 (TP17 Targeting of memory
plasma cells secreting pathogenic antibodies), and the Sjogren's
Syndrome Foundation.
NR 69
TC 5
Z9 5
U1 2
U2 5
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAY
PY 2013
VL 40
IS 5
BP 663
EP 673
DI 10.3899/jrheum.120680
PG 11
WC Rheumatology
SC Rheumatology
GA 147MO
UT WOS:000319171900020
PM 23504381
ER
PT J
AU Dello Russo, N
AF Dello Russo, Nicholas
TI COST OF EDUCATION
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
ID ORAL-HEALTH; MIDLEVEL PROVIDERS
C1 Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Div Dent, Boston, MA 02114 USA.
RP Dello Russo, N (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Div Dent, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 0
U2 1
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD MAY
PY 2013
VL 144
IS 5
BP 464
EP +
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 147RM
UT WOS:000319184700004
PM 23633689
ER
PT J
AU Seldin, EB
AF Seldin, Edward B.
TI MIDLEVEL PROVIDERS
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Seldin, EB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD MAY
PY 2013
VL 144
IS 5
BP 464
EP 464
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 147RM
UT WOS:000319184700003
PM 23633688
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI CBCT FINDINGS
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
ID INCIDENTAL FINDINGS; PREDICT; RISK
C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA USA.
[Friedlander, Arthur H.] VA Greater Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.
RP Friedlander, AH (reprint author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD MAY
PY 2013
VL 144
IS 5
BP 466
EP +
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 147RM
UT WOS:000319184700005
PM 23633690
ER
PT J
AU De Freitas, J
Falls, BA
Haque, OS
Bursztajn, HJ
AF De Freitas, Julian
Falls, Brian A.
Haque, Omar S.
Bursztajn, Harold J.
TI Vulnerabilities to misinformation in online pharmaceutical marketing
SO JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
LA English
DT Review
ID HEALTH INFORMATION; CONSUMERS SEARCH; FOCUS GROUPS; INTERNET; SEEKING
AB Given the large percentage of Internet users who search for health information online, pharmaceutical companies have invested significantly in online marketing of their products. Although online pharmaceutical marketing can potentially benefit both physicians and patients, it can also harm these groups by misleading them. Indeed, some pharmaceutical companies have been guilty of undue influence, which has threatened public health and trust. We conducted a review of the available literature on online pharmaceutical marketing, undue influence and the psychology of decision-making, in order to identify factors that contribute to Internet users' vulnerability to online pharmaceutical misinformation. We find five converging factors: Internet dependence, excessive trust in the veracity of online information, unawareness of pharmaceutical company influence, social isolation and detail fixation. As the Internet continues to change, it is important that regulators keep in mind not only misinformation that surrounds new web technologies and their contents, but also the factors that make Internet users vulnerable to misinformation in the first place. Psychological components are a critical, although often neglected, risk factor for Internet users becoming misinformed upon exposure to online pharmaceutical marketing. Awareness of these psychological factors may help Internet users attentively and safely navigate an evolving web terrain.
C1 [De Freitas, Julian] Yale Univ, Dept Psychol, New Haven, CT 06520 USA.
[Falls, Brian A.] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Boston, MA 02169 USA.
[Haque, Omar S.] Harvard Univ, Sch Med, Program Psychiat & Law, Boston, MA 02138 USA.
[Bursztajn, Harold J.] Harvard Univ, Sch Med, Dept Psychiat, Program Psychiat & Law,BIDMC Psychiat, Cambridge, MA 02138 USA.
RP Bursztajn, HJ (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Program Psychiat & Law,BIDMC Psychiat, Cambridge, MA 02138 USA.
EM harold_bursztajn@hms.harvard.edu
NR 30
TC 6
Z9 6
U1 1
U2 13
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0141-0768
J9 J ROY SOC MED
JI J. R. Soc. Med.
PD MAY
PY 2013
VL 106
IS 5
BP 184
EP 189
DI 10.1177/0141076813476679
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148JA
UT WOS:000319239400012
PM 23761527
ER
PT J
AU Kasotakis, G
Sideris, A
Yang, YC
de Moya, M
Alam, H
King, DR
Tompkins, R
Velmahos, G
AF Kasotakis, George
Sideris, Antonis
Yang, Yuchiao
de Moya, Marc
Alam, Hasan
King, David R.
Tompkins, Ronald
Velmahos, George
CA Inflammation Host Response Injury
TI Aggressive early crystalloid resuscitation adversely affects outcomes in
adult blunt trauma patients: An analysis of the Glue Grant database
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Crystalloid; resuscitation; outcomes; blunt trauma; Glue Grant
ID MULTIPLE ORGAN FAILURE; RESPIRATORY-DISTRESS-SYNDROME; LACTATED RINGERS
SOLUTION; FRESH-FROZEN PLASMA; MAJOR ABDOMINAL-SURGERY; TISSUE
OXYGEN-TENSION; FLUID RESUSCITATION; HEMORRHAGIC-SHOCK; MASSIVE
TRANSFUSION; BLOOD-TRANSFUSION
AB BACKGROUND: Evidence suggests that aggressive crystalloid resuscitation is associated with significant morbidity in various clinical settings. We wanted to assess whether aggressive early crystalloid resuscitation adversely affects outcomes in adult blunt trauma patients.
METHODS: Datawere derived from the Glue Grant database. Our primary outcome measurewas all-cause in-hospital mortality. Secondary outcomes included days on mechanical ventilation; intensive care unit (ICU) and hospital length of stay (LOS); inflammatory (acute lung injury and adult respiratory distress syndrome, or multiple-organ failure) and resuscitation-related morbidity (abdominal and extremity compartment syndromes or acute renal failure) and nosocomial infections (ventilator-associated pneumonia, bloodstream, urinary tract, and surgical site infections).
RESULTS: In our sample of 1,754 patients, in-hospital mortality was not affected, but ventilator days (p < 0.001) as well as ICU (p = 0.009) and hospital (p = 0.002) LOS correlated strongly with the amount of crystalloids infused in the first 24 hours after injury. Amount of crystalloid resuscitation was also associated with the development of adult respiratory distress syndrome (p < 0.001), multiple-organ failure (p < 0.001), bloodstream (p = 0.001) and surgical site infections (p < 0.001), as well as abdominal (p < 0.001) and extremity compartment syndromes (p = 0.028) in a dose-dependent fashion, when age, Glasgow Coma Scale (GCS), severity of injury and acute physiologic derangement, comorbidities, as well as colloid and blood product transfusions were controlled for.
CONCLUSION: Crystalloid resuscitation is associated with a substantial increase in morbidity, as well as ICU and hospital LOS in adult blunt trauma patients. (Copyright (c) 2013 by Lippincott Williams Wilkins)
C1 [Kasotakis, George; Sideris, Antonis; Yang, Yuchiao; de Moya, Marc; Alam, Hasan; King, David R.; Tompkins, Ronald; Velmahos, George; Inflammation Host Response Injury] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Crit Care, Boston, MA 02114 USA.
RP Kasotakis, G (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM gkasotakis@mail.harvard.edu
FU NIGMS NIH HHS [R24 GM102656, U54 GM062119]
NR 48
TC 37
Z9 38
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD MAY
PY 2013
VL 74
IS 5
BP 1215
EP 1221
PG 7
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 149JZ
UT WOS:000319316600007
PM 23609270
ER
PT J
AU Sillesen, M
Johansson, PI
Rasmussen, LS
Jin, G
Jepsen, CH
Imam, AM
Hwabejire, J
Lu, J
Duggan, M
Velmahos, G
deMoya, M
Alam, HB
AF Sillesen, Martin
Johansson, Par I.
Rasmussen, Lars S.
Jin, Guang
Jepsen, Cecilie H.
Imam, Ayehsa M.
Hwabejire, John
Lu, Jennifer
Duggan, Michael
Velmahos, George
deMoya, Marc
Alam, Hasan B.
TI Platelet activation and dysfunction in a large-animal model of traumatic
brain injury and hemorrhage
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Platelets; hemorrhage; traumatic brain injury; inflammation; swine
ID INTRACRANIAL HEMORRHAGE; COAGULOPATHY; TISSUE; CD40; PROGRESSION; SHOCK
AB BACKGROUND: Traumatic brain injury (TBI) and hemorrhage are the leading causes of trauma-related mortality. Both TBI and hemorrhage are associated with coagulation disturbances, including platelet dysfunction. We hypothesized that platelet dysfunction could be detected early after injury, and that this dysfunction would be associated with early activation, as measured by circulating levels of platelet activation markers.
METHODS: A total of 33 swine were allocated to TBI and hypotension (n = 27, TBI and volume-controlled 40% blood loss) or controls (n = 6, anesthesia and instrumentation only). Animals in the TBI/Hemorrhage group were left hypotensive, defined as mean arterial pressure of 35 mm Hg, for 2 hours. Blood samples were drawn at baseline and 3 minutes and 15 minutes following injury as well as following 2 hours of shock. Samples were analyzed for platelet aggregation using impedance aggregometry with agonists collagen, arachidonic acid, and adenosine diphosphate (ADP) and thromboelastography (TEG) and circulating levels of platelet activation markers transforming growth factor-A (TGF-A), CD40 ligand, and sP-selectin.
RESULTS: Platelet ADP aggregation was significantly lower in the TBI/Hemorrhage group when compared with the control group 15 minutes following injury (62.4 vs. 80.4 U, p = 0.03) as well as following 2 hours of hypotension (59.9 vs. 73.5 U, p < 0.01). The latter was associated with lower TEG measured clot strength (TEG-MA, 74.1 vs. 79.4 mm, p = 0.05). No difference in collagen or arachidonic acid aggregation was observed. TGF-A levels were significantly higher in the TBI/Hemorrhage group following 2 hours of hypotension (1,764 vs. 1,252 pg/mL, p = 0.01). No differences in CD40 ligand or sP-selectin levels were observed.
CONCLUSION: In this combined model of TBI and hemorrhage, a significantly lower ADP-induced platelet aggregation was detected 15 minutes following injury that was further aggravated during the 2-hour shock period. This dysfunction was associated with an increase in platelet activation marker TGF-A. (C) 2013 by Lippincott Williams & Wilkins
C1 [Sillesen, Martin; Rasmussen, Lars S.] Copenhagen Univ Hosp, Rigshosp, Dept Anesthesia, Ctr Head & Orthoped, Copenhagen, Denmark.
[Johansson, Par I.; Jepsen, Cecilie H.] Copenhagen Univ Hosp, Rigshosp, Capital Reg Blood Bank, Copenhagen, Denmark.
[Sillesen, Martin; Jepsen, Cecilie H.; Imam, Ayehsa M.; Hwabejire, John; Lu, Jennifer; Duggan, Michael; Velmahos, George; deMoya, Marc; Alam, Hasan B.] Harvard Univ, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Johansson, Par I.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX USA.
[Jin, Guang; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
RP Alam, HB (reprint author), Univ Michigan Hosp, Taubman Ctr 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM alamh@med.umich.edu
RI Johansson, Par/P-9283-2015;
OI Johansson, Par/0000-0001-9778-5964; Rasmussen, Lars/0000-0002-7480-3004
FU US Army Medical Research and Materiel Command [GRANTT00521959];
Copenhagen University Hospital, Rigshospitalet (Denmark); Laerdal
Foundation (Norway); Aase and Ejnar Danielsen Foundation (Denmark); Olof
Norlander Foundation (Sweden); Maersk Foundation (Denmark); Tryg
Foundation (Denmark); Lundbeck Foundation (Denmark)
FX The study was funded by a grant from the US Army Medical Research and
Materiel Command (GRANTT00521959) to H.B.A., grants from Copenhagen
University Hospital, Rigshospitalet (Denmark), The Laerdal Foundation
(Norway), The Aase and Ejnar Danielsen Foundation (Denmark), The Olof
Norlander Foundation (Sweden), and The Maersk Foundation (Denmark) to
M.S. L.S.R. has received funding from the Tryg Foundation (Denmark).
P.I.J. received funding from the Lundbeck Foundation (Denmark). The
Multiplate machine was on unconditional loan from US Distributor
Diapharma Group Inc. (West Chester, OH) for the duration of the study,
while the TEG-5000 machine was on unconditional loan from Haemonetics
Corp. (Braintree, MA). These companies did not participate in study
planning, execution, data analysis, or manuscript preparation.
NR 23
TC 23
Z9 23
U1 1
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD MAY
PY 2013
VL 74
IS 5
BP 1252
EP 1259
DI 10.1097/TA.0b013e31828c7a6b
PG 8
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 149JZ
UT WOS:000319316600017
PM 23609275
ER
PT J
AU Ursiny, M
Eisner, BH
AF Ursiny, Michal
Eisner, Brian H.
TI Cost-Effectiveness of Anti-Retropulsion Devices for Ureteroscopic
Lithotripsy
SO JOURNAL OF UROLOGY
LA English
DT Article
DE ureter; ureteral calculi; ureteroscopy; lithotripsy; disposable
equipment
ID PROXIMAL URETERAL STONES; HOLMIUM-YAG LASER; IN-VITRO; PNEUMATIC
LITHOTRIPSY; CLINICAL-TRIAL; PREVENTION; MIGRATION; CONE; FRAGMENTATION;
GENERATION
AB Purpose: We evaluated the cost-effectiveness of anti-retropulsion devices used during ureteroscopic lithotripsy.
Materials and Methods: A decision analysis model was constructed to compare the cost-effectiveness of ureteroscopic lithotripsy with vs without an anti-retropulsion device. The risk of stone retropulsion was determined from published data in the English language literature. Expected value calculations were used to determine whether the additional cost of a device would be cost-effective to prevent secondary procedures used to treat retropulsed stones. Device cost was determined using the average cost of all commercially available devices.
Results: It became cost-effective to use an anti-retropulsion device at or above a 6.3% retropulsion rate. The weighted probability of retropulsion with vs without an anti-retropulsion device was 98.1% vs 83.7%. The estimated costs of secondary procedures needed to treat retropulsed stones were $5,290 for shock wave lithotripsy and $6,390 for ureteroscopy. Average device cost was $278. Thus, the average additional cost of ureteroscopic lithotripsy with vs without an anti-migration device would be $384 vs $952.
Conclusions: It is cost-effective to use an anti-retropulsion device at a retropulsion rate of greater than 6.3%.
C1 [Ursiny, Michal; Eisner, Brian H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Kidney Stone Ctr, Boston, MA USA.
RP Eisner, BH (reprint author), Massachusetts Gen Hosp, Dept Neurol, GRB 1102,55 Fruit St, Boston, MA 02114 USA.
EM beisner@partners.org
FU Endourological Society
FX Supported by an Endourological Society grant (MU).
NR 19
TC 6
Z9 6
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD MAY
PY 2013
VL 189
IS 5
BP 1762
EP 1766
DI 10.1016/j.juro.2012.11.085
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 148QZ
UT WOS:000319262900045
PM 23159589
ER
PT J
AU Lech, M
Gunthner, R
Lorenz, G
Ryu, M
Grobmayr, R
Susanti, H
Kobayashi, KS
Flavell, RA
Anders, HJ
AF Lech, Maciej
Guenthner, Roman
Lorenz, Georg
Ryu, Mi
Groebmayr, Regina
Susanti, Heni
Kobayashi, Koichi S.
Flavell, Richard A.
Anders, Hans-Joachim
TI IRAK-M IN RENAL FIBROSIS UPON UNILATERAL URETERAL OBSTRUCTION
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Meeting Abstract
CT 50th European-Renal-Association -
European-Dialysis-and-Transplant-Association Congress
CY MAY 18-21, 2013
CL Istanbul, TURKEY
SP European Renal Assoc (ERA), European Dialysis & Transplant Assoc (EDTA)
C1 [Lech, Maciej; Guenthner, Roman; Lorenz, Georg; Ryu, Mi; Groebmayr, Regina; Susanti, Heni; Anders, Hans-Joachim] Klinikum Univ Munchen, Nephrol Zentrum, Med Klin & Poliklin 4, Munich, Germany.
[Kobayashi, Koichi S.; Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, Sect Immunobiol, New Haven, CT 06510 USA.
[Kobayashi, Koichi S.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAY
PY 2013
VL 28
SU 1
BP 190
EP 190
PG 1
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 151ZF
UT WOS:000319498201078
ER
PT J
AU de Borst, MH
Hajhosseiny, R
Tamez, H
Wenger, J
Thadhani, R
Goldsmith, DJ
AF de Borst, Martin H.
Hajhosseiny, Reza
Tamez, Hector
Wenger, Julia
Thadhani, Ravi
Goldsmith, David J.
TI META-ANALYSIS OF THE IMPACT OF VITAMIN D RECEPTOR ACTIVATORS FOR
REDUCTION OF PROTEINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A
SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Meeting Abstract
CT 50th European-Renal-Association -
European-Dialysis-and-Transplant-Association Congress
CY MAY 18-21, 2013
CL Istanbul, TURKEY
SP European Renal Assoc (ERA), European Dialysis & Transplant Assoc (EDTA)
C1 [de Borst, Martin H.] Univ Med Ctr Groningen, Dept Med, Div Nephrol, NL-9713 AV Groningen, Netherlands.
[de Borst, Martin H.] Univ Groningen, Groningen, Netherlands.
[Tamez, Hector; Wenger, Julia; Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Hajhosseiny, Reza; Goldsmith, David J.] Guys Campus Kings Hlth Partners AHSC, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAY
PY 2013
VL 28
SU 1
BP 366
EP 366
PG 1
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 151ZF
UT WOS:000319498202114
ER
PT J
AU Manchikanti, L
Falco, FJE
Benyamin, R
Helm, S
Singh, V
Hirsch, JA
AF Manchikanti, Laxmaiah
Falco, Frank J. E.
Benyamin, Ramsin
Helm, Standiford, II
Singh, Vijay
Hirsch, Joshua A.
TI Value-Based Interventional Pain Management: A Review of Medicare
National and Local Coverage Determination Policies
SO PAIN PHYSICIAN
LA English
DT Review
DE Interventional pain management; interventional techniques; national
coverage determinations (NCDs); local coverage determinations (LCDs);
contractor medical director (CMD); Centers for Medicare and Medicaid
Services (CMS); Department of Health and Human Services (HHS);
guidelines; evidence-based medicine; evidence development with coverage
ID LOW-BACK-PAIN; SPINAL-CORD STIMULATION; INTERLAMINAR EPIDURAL
INJECTIONS; EVIDENCE-BASED MEDICINE; MEDIAL BRANCH BLOCKS;
PERIPHERAL-NERVE STIMULATION; ACTIVE-CONTROL TRIAL; 2-YEAR FOLLOW-UP;
CLINICAL-PRACTICE GUIDELINES; LUMBAR SURGERY SYNDROME
AB Major policies, regulations, and practice patterns related to interventional pain management are dependent on Medicare policies which include national coverage policies - national coverage determinations (NCDs), and local coverage policies -local coverage determinations (LCDs).
The NCDs are Medicare coverage policies issued by the Centers for Medicare and Medicaid Services (CMS). The process used by the CMS in deciding what is and what is not medically necessary is lengthy, involving a review of evidence-based literature on the subject, expert opinion, and public comments. In contrast, LCDs are rules and Medicare coverage that are issued by regional contractors and fiscal intermediaries when an NCD has not addressed the policy at issue. The evidence utilized in preparing LCDs includes the highest level of evidence which is based on published authoritative evidence derived from definitive randomized clinical trials or other definitive studies, and general acceptance by the medical community (standard of practice), as supported by sound medical evidence. In addition, the intervention must be safe and effective and appropriate including duration and frequency that is considered appropriate for the item or service in terms of whether it is furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function.
In addition, the safe and effective provision includes that service must be furnished in a setting appropriate to the patient's medical needs and condition, ordered and furnished by qualified personnel, the service must meet, but does not exceed, the patient's medical need, and be at least as beneficial as an existing and available medically appropriate alternative. The LCDs are prepared with literature review, state medical societies, and carrier advisory committees (CACs) of which interventional pain management is a member. The LCDs may be appealed by beneficiaries. The NCDs are prepared by the CMS following a request for a national coverage decision after an appropriate national coverage request along with a draft decision memorandum, and public comments. After the request, the staff review, external technology assessment, Medicare Evidence Development and Coverage Advisory Committee (MedCAC) assessment, public comments, a draft decision memorandum may be posted which will be followed by a final decision and implementation instructions. This decision may be appealed to the department appeals board, but may be difficult to reverse.
This manuscript describes NCDs and LCDs and the process of development, their development, issues related to the development, and finally their relation to interventional pain management.
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
[Falco, Frank J. E.] Mid Atlantic Spine & Pain Phys, Newark, DE USA.
[Falco, Frank J. E.] Temple Univ Hosp & Med Sch, Pain Med Fellowship Program, Philadelphia, PA 19140 USA.
[Benyamin, Ramsin] Millennium Pain Ctr, Bloomington, IL USA.
[Benyamin, Ramsin] Univ Illinois, Coll Med, Urbana, IL USA.
[Helm, Standiford, II] Helm Ctr Pain Management, Laguna Hills, CA USA.
[Singh, Vijay] Spine Pain Diagnost Associates, Niagara, WI USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Endovasc Neurosurg & Neuroendovasc Program, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
FU Cephalon/Teva; AstraZeneca; Purdue Pharma, LP
FX Dr. Helm is a clinical investigator with Epimed and receives research
support from Cephalon/Teva, AstraZeneca, and Purdue Pharma, LP. He has
attended an advisory group meeting for Activas.
NR 273
TC 22
Z9 22
U1 2
U2 7
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD MAY-JUN
PY 2013
VL 16
IS 3
BP E145
EP E180
PG 36
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA 149SN
UT WOS:000319341600003
PM 23703416
ER
PT J
AU Manchikanti, L
Falco, FJE
Pampati, V
Cash, KA
Benyamin, RM
Hirsch, JA
AF Manchikanti, Laxmaiah
Falco, Frank J. E.
Pampati, Vidyasagar
Cash, Kimberly A.
Benyamin, Ramsin M.
Hirsch, Joshua A.
TI Cost Utility Analysis of Caudal Epidural Injections in the Treatment of
Lumbar Disc Herniation, Axial or Discogenic Low Back Pain, Central
Spinal Stenosis, and Post Lumbar Surgery Syndrome
SO PAIN PHYSICIAN
LA English
DT Review
DE Caudal epidural injections; chronic low back pain; lumbar disc
herniation; lumbar discogenic pain; lumbar spinal stenosis; lumbar post
surgery syndrome; cost utility analysis; cost effectiveness analysis;
quality-adjusted life years
ID RANDOMIZED CONTROLLED-TRIAL; ACTIVE-CONTROL TRIAL; 2-YEAR FOLLOW-UP;
FACET JOINT INTERVENTIONS; DOUBLE-BLIND TRIAL; PHYSICIANS ASIPP
GUIDELINES; MANAGING CHRONIC PAIN; AFFORDABLE CARE ACT; NONOPERATIVE
TREATMENT; SYSTEMATIC EVALUATION
AB Background: In this era of escalating health care costs and the questionable effectiveness of multiple interventions, cost effectiveness or cost utility analysis has become the cornerstone of evidence-based medicine, and has an influence coverage decisions. Even though multiple cost effectiveness analysis studies have been performed over the years, extensive literature is lacking for interventional techniques. Cost utility analysis studies of epidural injections for managing chronic low back pain demonstrated highly variable results including a lack of cost utility in randomized trials and contrasting results in observational studies. There has not been any cost utility analysis studies of epidural injections in large randomized trials performed in interventional pain management settings.
Objectives: To assess the cost utility of caudal epidural injections in managing chronic low back pain secondary to lumbar disc herniation, axial or discogenic low back pain, lumbar central spinal stenosis, and lumbar post surgery syndrome.
Study Design: This analysis is based on 4 previously published randomized trials.
Setting: A private, specialty referral interventional pain management center in the United States.
Methods: Four randomized trials were conducted assessing the clinical effectiveness of caudal epidural injections with or without steroids for lumbar disc herniation, lumbar discogenic or axial low back pain, lumbar central spinal stenosis, and post surgery syndrome. A cost utility analysis was performed with direct payment data for a total of 480 patients over a period of 2 years from these 4 trials. Outcome included various measures with significant improvement defined as at least a 50% improvement in pain reduction and disability status.
Results: The results of 4 randomized controlled trials of low back pain with 480 patients with a 2 year follow-up with the actual reimbursement data showed cost utility for one year of quality-adjusted life year (QALY) of $2,206 for disc herniation, $2,136 for axial or discogenic pain without disc herniation, $2,155 for central spinal stenosis, and $2,191 for post surgery syndrome. All patients showed significant improvement clinically and showed positive results in the cost utility analysis with an average cost per one year QALY of $2,172.50 for all patients and $1,966.03 for patients judged to be successful. The results of this assessment show a better cost utility or lower cost of managing chronic, intractable low back pain with caudal epidural injections at a QALY that is similar or lower in price than medical therapy only, physical therapy, manipulation, and surgery in most cases.
Limitations: The limitations of this cost utility analysis include that it is a single center evaluation, even though 480 patients were included in the analysis. Further, only the costs of interventional procedures and physician visits were included. The benefits of returning to work were not assessed.
Conclusion: This cost utility analysis of caudal epidural injections in the treatment of disc herniation, axial or discogenic low back pain, central spinal stenosis, and post surgery syndrome in the lumbar spine shows the clinical effectiveness and cost utility of these injections at less than $2,200 per one year of QALY.
C1 [Manchikanti, Laxmaiah; Pampati, Vidyasagar; Cash, Kimberly A.] Pain Management Ctr Paducah, Paducah, KY USA.
[Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
[Falco, Frank J. E.] Mid Atlantic Spine & Pain Phys, Newark, DE USA.
[Falco, Frank J. E.] Temple Univ Hosp & Med Sch, Pain Med Fellowship Program, Philadelphia, PA 19140 USA.
[Benyamin, Ramsin M.] Millennium Pain Ctr, Bloomington, IL USA.
[Benyamin, Ramsin M.] Univ Illinois, Coll Med, Urbana, IL USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Endovasc Neurosurg & Neuroendovasc Program, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
NR 103
TC 41
Z9 42
U1 7
U2 18
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD MAY-JUN
PY 2013
VL 16
IS 3
BP E129
EP E143
PG 15
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA 149SN
UT WOS:000319341600002
PM 23703415
ER
PT J
AU Avery, LL
Scheinfeld, MH
AF Avery, Laura L.
Scheinfeld, Meir H.
TI Imaging of Penile and Scrotal Emergencies
SO RADIOGRAPHICS
LA English
DT Article
ID SEGMENTAL TESTICULAR INFARCTION; RADIOLOGIC-PATHOLOGICAL CORRELATION;
COLOR DOPPLER ULTRASOUND; BELL-CLAPPER DEFORMITY; HIGH-FLOW PRIAPISM;
FOURNIERS GANGRENE; DIAGNOSIS; TRAUMA; MANAGEMENT; TORSION
AB Penile and scrotal emergencies are uncommon, but when they do occur, urgent or emergent diagnosis and treatment are necessary. Emergent conditions of the male genitalia are primarily infectious, traumatic, or vascular. Infectious conditions, such as epididymitis and epididymo-orchitis, are well evaluated at ultrasonography (US), and their key findings include heterogeneity and hyperemia. Pyocele and abscess may also be seen at US. Fournier gangrene is best evaluated at computed tomography, which depicts subcutaneous gas. Vascular conditions, such as testicular torsion, infarction, penile Mondor disease, and priapism, are well evaluated at duplex Doppler US. The key imaging finding of testicular torsion and infarction is a lack of blood flow in the testicle or a portion of the testicle. Penile Mondor disease is characterized by a lack of flow to and noncompressibility of the superficial dorsal vein of the penis. Clinical examination and history are usually adequate for diagnosis of priapism, but Doppler US may help confirm the diagnosis. Traumatic injuries of the penis and scrotum are initially imaged with US, which depicts whether the penile corpora and testicular seminiferous tubules are contained by the tunicae albuginea; herniation of contents and discontinuity of the tunica albuginea indicate rupture. In some cases, magnetic resonance imaging may be performed because of its ability to directly depict discontinuity of the tunica albuginea. Radiologists must closely collaborate with emergency physicians, surgeons, and urologists to quickly and efficiently diagnose or rule out emergent conditions of the male genitalia to facilitate prompt and appropriate treatment.
C1 [Avery, Laura L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Emergency Radiol, Boston, MA 02114 USA.
[Scheinfeld, Meir H.] Albert Einstein Coll Med, Montefiore Med Ctr, Div Emergency Radiol, Bronx, NY 10467 USA.
RP Avery, LL (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Emergency Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM Lavery@partners.org
OI Scheinfeld, Meir H/0000-0001-8880-4318
NR 85
TC 13
Z9 15
U1 0
U2 6
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAY-JUN
PY 2013
VL 33
IS 3
BP 721
EP 740
DI 10.1148/rg.333125158
PG 20
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 146SR
UT WOS:000319111700011
PM 23674771
ER
PT J
AU Cai, W
Kim, SH
Lee, JG
Yoshida, H
AF Cai, Wenli
Kim, Se Hyung
Lee, June-Goo
Yoshida, Hiroyuki
TI Informatics in Radiology Dual-Energy Electronic Cleansing for
Fecal-Tagging CT Colonography(1)
SO RADIOGRAPHICS
LA English
DT Article
ID VIRTUAL COLONOSCOPY; COMPUTED-TOMOGRAPHY; CATHARTIC PREPARATION;
RECONSTRUCTION; SEGMENTATION; FEASIBILITY; EXPERIENCE; FILTRATION;
NEOPLASIA; ACCURACY
AB Electronic cleansing (EC) is an emerging technique for the removal of tagged fecal materials at fecal-tagging computed tomographic (CT) colonography. However, existing EC methods may generate various types of artifacts that severely impair the quality of the cleansed CT colonographic images. Dual-energy fecal-tagging CT colonography is regarded as a nextgeneration imaging modality. EC that makes use of dual-energy fecal-tagging CT colonographic images promises to be effective in reducing cleansing artifacts by means of applying the material decomposition capability of dual-energy CT. The dual-energy index (DEI), which is calculated from the relative change in the attenuation values of a material at two different photon energies, is a reliable and effective indicator for differentiating tagged fecal materials from various types of tissues on fecal-tagging CT colonographic images. A DEI-based dual-energy EC scheme uses the DEI to help differentiate the colonic lumen-including the luminal air, tagged fecal materials, and air-tagging mixture-from the colonic soft-tissue structures, and then segments the entire colonic lumen for cleansing of the tagged fecal materials. As a result, dual-energy EC can help identify partialvolume effects in the air-tagging mixture and inhomogeneous tagging in residual fecal materials, the major causes of EC artifacts. This technique has the potential to significantly improve the quality of EC and promises to provide images of a cleansed colon that are free of the artifacts commonly observed with conventional single-energy EC methods.
C1 [Cai, Wenli; Lee, June-Goo; Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Cai, Wenli; Lee, June-Goo; Yoshida, Hiroyuki] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Kim, Se Hyung] Seoul Natl Univ Hosp, Dept Radiol, Coll Med, Seoul 110744, South Korea.
RP Cai, W (reprint author), Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St,400C, Boston, MA 02114 USA.
EM Cai.Wenli@mgh.harvard.edu
FU NIH/NCI; National Cancer Institute [R01CA131718, R01CA095279]; American
Cancer Society
FX H.Y.: Related financial activities: grants from NIH/NCI. Other financial
activities: royalties from the University of Chicago, patent holder with
Hologic and MEDIAN Technologies. W.C.: Related financial activities:
grant from the American Cancer Society. Other financial activities:
none.; The work was supported by the National Cancer Institute [grant
numbers R01CA131718, R01CA095279].
NR 54
TC 9
Z9 9
U1 0
U2 3
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAY-JUN
PY 2013
VL 33
IS 3
BP 891
EP 912
DI 10.1148/rg.333125039
PG 22
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 146SR
UT WOS:000319111700021
PM 23479680
ER
PT J
AU Ullrich, PM
Lincoln, RK
Tackett, MJ
Miskevics, S
Smith, BM
Weaver, FM
AF Ullrich, Philip M.
Lincoln, Randi K.
Tackett, M. Jan
Miskevics, Scott
Smith, Bridget M.
Weaver, Frances M.
TI Pain, Depression, and Health Care Utilization Over Time After Spinal
Cord Injury
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE spinal cord injury; pain; depression; health care
ID PHYSICAL-DISABILITIES; COGNITIVE DISTORTION; VETERANS; ANXIETY; PEOPLE;
MANAGEMENT; SYMPTOMS; RISK; BIAS; USA
AB Objective: The aim of this research was to examine comorbid pain and depression after spinal cord injury (SCI) in terms of: frequency, longitudinal course, and associations with medical conditions and use of SCI specialty care. Method: Three consecutive standardized annual psychological evaluations were reviewed for 286 persons with SCI receiving care at an SCI specialty care center. Chart abstraction included medical and demographic information, a depression scale, and a pain scale. Administrative databases were used to collect SCI specialty care utilization data. Participants were categorized as having elevated pain, elevated depression, both elevated pain and depression, or neither elevated, using cut-off scores on the pain and depression scales. ANOVA and repeated measures ANOVA were used to compare study groups. Results: Approximately 20% of the sample showed both elevated pain and depression at Year 1. Persons with elevated pain and depression showed higher scores on those measures than did persons with either pain or depression alone. Pain scores tended to be stable over time. Depression scores tended to improve over 3 years, but persons with elevated pain and depression showed less improvement on depression scores than did persons with depression alone. Persons with pain and depression tended to utilize more SCI specialty care. Conclusions: Pain and depression are often comorbid after SCI. This comorbidity is associated with higher pain and depression severity, more persistent pain and depression over time, and more use of SCI specialty care. Comorbid pain and depression should be anticipated among persons with SCI and addressed in care plans.
C1 [Ullrich, Philip M.; Lincoln, Randi K.; Tackett, M. Jan] VA Puget Sound Healthcare Syst, Spinal Cord Injury & Disorders Serv, Dept Vet Affairs, Seattle, WA USA.
[Ullrich, Philip M.; Lincoln, Randi K.; Tackett, M. Jan] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Miskevics, Scott] Spinal Cord Injury Qual Enhancement Res Initiat, Dept Vet Affairs, Hines, IL USA.
[Miskevics, Scott] Edward Hines Jr Dept Vet Affairs Hosp, Ctr Management Complex Chron Care, Hines, IL USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Dept Vet Affairs, Chicago, IL 60611 USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Spinal Cord Injury Qual Enhancement Res Initiat, Chicago, IL 60611 USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Ctr Management Complex Chron Care, Edward Hines Jr Dept Vet Affairs Hosp, Chicago, IL 60611 USA.
[Smith, Bridget M.; Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Program Hlth Serv Res, Chicago, IL 60611 USA.
RP Ullrich, PM (reprint author), 128 NAT,1660 S Columbian Way, Seattle, WA 98108 USA.
EM philip.ullrich@va.gov
NR 55
TC 9
Z9 9
U1 1
U2 15
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD MAY
PY 2013
VL 58
IS 2
BP 158
EP 165
DI 10.1037/a0032047
PG 8
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA 150DH
UT WOS:000319369900005
PM 23713727
ER
PT J
AU Weisbord, SD
AF Weisbord, Steven D.
TI Sexual Dysfunction and Quality of Life in Patients on Maintenance
Dialysis
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID MALE HEMODIALYSIS-PATIENTS; ERECTILE DYSFUNCTION; SILDENAFIL TREATMENT;
DEPRESSION; WOMEN; ASSOCIATION; VARDENAFIL; MANAGEMENT; PAIN
C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, 7E Room 120,111F-U, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
NR 18
TC 4
Z9 4
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAY-JUN
PY 2013
VL 26
IS 3
BP 278
EP 280
DI 10.1111/sdi.12068
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 146DL
UT WOS:000319069300009
PM 23458106
ER
PT J
AU Fung, CH
Martin, JL
Igodan, U
Jouldjian, S
Alessi, C
AF Fung, Constance H.
Martin, Jennifer L.
Igodan, Uyi
Jouldjian, Stella
Alessi, Cathy
TI The association between difficulty using positive airway pressure
equipment and adherence to therapy: a pilot study
SO SLEEP AND BREATHING
LA English
DT Article
DE Sleep-disordered breathing; Therapy; Patient compliance; Patient outcome
assessment
ID OBSTRUCTIVE SLEEP-APNEA; PRIMARY-CARE PATIENTS; CPAP ADHERENCE; HEALTH;
OUTCOMES; ADULTS
AB Little is known about the ease of use of positive airway pressure (PAP) equipment and whether PAP equipment usability is associated with adherence. This pilot project aims to determine whether perceived difficulty with the mechanics of using PAP equipment is associated with nonadherence.
Within a larger study of insomnia treatments, we screened (via telephone interview) 148 adults for sleep apnea/prior PAP use and asked them to describe the degree of difficulty putting on their PAP mask, adjusting their mask straps, turning dials/pushing PAP machine buttons, disconnecting tubing, and removing the machine's water chamber (five items; five-point Likert-like scale) and to report their PAP use (0 versus a parts per thousand yen1 days in the past week).
Mean age of participants was 66.7 years (SD 7.0). Thirty respondents (20.3 %) reported at least "some difficulty" with at least one aspect of PAP equipment usability, and 15 respondents (10.1 %) reported at least "quite a lot of difficulty" with one or more aspects of PAP equipment usability. Of the participants, 43.9 % reported not using PAP equipment at all during the past week. Participants (73.3 %) with substantial PAP equipment difficulty (at least quite a lot of difficulty) versus 40.6 % without substantial difficulty reported zero nights of PAP use in the past week (chi-square 5.86, p = .015).
Difficulty using PAP equipment is associated with PAP nonadherence. Studies are needed to confirm these findings and to identify determinants of poor usability. If findings are confirmed, strategies could be developed to improve PAP usability, which may improve adherence.
C1 [Fung, Constance H.; Martin, Jennifer L.; Igodan, Uyi; Jouldjian, Stella; Alessi, Cathy] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC 11E, North Hills, CA 91343 USA.
[Fung, Constance H.; Martin, Jennifer L.; Alessi, Cathy] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Fung, CH (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC 11E, 16111 Plummer St, North Hills, CA 91343 USA.
EM constance.h.fung@gmail.com
FU Department of Veterans Affairs Advanced Geriatrics Fellowship Program,
Veterans Administration Health Services Research and Development [Alessi
IIR 08-295]; American Federation for Aging Research; John A. Hartford
Foundation; Centers of Excellence National Program; Veterans
Administration Greater Los Angeles Geriatric Research, Education and
Clinical Center
FX This study was supported by the Department of Veterans Affairs Advanced
Geriatrics Fellowship Program, Veterans Administration Health Services
Research and Development (Alessi IIR 08-295); American Federation for
Aging Research, The John A. Hartford Foundation, the Centers of
Excellence National Program; and Veterans Administration Greater Los
Angeles Geriatric Research, Education and Clinical Center. The authors
thank our project manager, Karen Josephson, the study coordinators,
Terry Vandenberg and Sergio Martinez, and our research staff who
assisted with the telephone interviews, Ana Grigorian, Jessica Bautista,
and Rebecca Saia. All work was completed at VA Greater Los Angeles
Healthcare System.
NR 32
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1520-9512
J9 SLEEP BREATH
JI Sleep Breath.
PD MAY
PY 2013
VL 17
IS 2
BP 853
EP 859
DI 10.1007/s11325-012-0779-y
PG 7
WC Clinical Neurology; Respiratory System
SC Neurosciences & Neurology; Respiratory System
GA 146FR
UT WOS:000319075800062
PM 23149875
ER
PT J
AU Shimatsu, Y
Yamada, K
Horii, W
Hirakata, A
Sakamoto, Y
Waki, S
Sano, J
Saitoh, T
Sahara, H
Shimizu, A
Yazawa, H
Sachs, DH
Nunoya, T
AF Shimatsu, Yoshiki
Yamada, Kazuhiko
Horii, Wataru
Hirakata, Atsushi
Sakamoto, Yuji
Waki, Shiori
Sano, Junichi
Saitoh, Toshiki
Sahara, Hisashi
Shimizu, Akira
Yazawa, Hajime
Sachs, David H.
Nunoya, Tetsuo
TI Production of cloned NIBS (Nippon Institute for Biological Science) and
alpha-1, 3-galactosyltransferase knockout MGH miniature pigs by somatic
cell nuclear transfer using the NIBS breed as surrogates
SO XENOTRANSPLANTATION
LA English
DT Article
DE -1; 3-galactosyltransferase knockout; embryo transfer; GalT-KO MGH
miniature; miniature pigs; Nippon Institute for Biological Science
miniature pigs; somatic cell nuclear transfer
ID ALPHA-1,3-GALACTOSYLTRANSFERASE GENE; EMBRYOS; CLONING; ADULT; DONORS;
CALVES; XENOTRANSPLANTATION; REJECTION; SWINE
AB Background Nuclear transfer (NT) technologies offer a means for producing the genetically modified pigs necessary to develop swine models for mechanistic studies of disease processes as well as to serve as organ donors for xenotransplantation. Most previous studies have used commercial pigs as surrogates. Method and Results In this study, we established a cloning technique for miniature pigs by somatic cell nuclear transfer (SCNT) using Nippon Institute for Biological Science (NIBS) miniature pigs as surrogates. Moreover, utilizing this technique, we have successfully produced an -1, 3-galactosyltransferase knockout (GalT-KO) miniature swine. Fibroblasts procured from a NIBS miniature pig fetus were injected into 1312 enucleated oocytes. The cloned embryos were transferred to 11 surrogates of which five successfully delivered 13 cloned offspring; the production efficiency was 1.0% (13/1312). In a second experiment, lung fibroblasts obtained from neonatal GalT-KO MGH miniature swine were used as donor cells and 1953 cloned embryos were transferred to 12 surrogates. Six cloned offspring were born from five surrogates, a production efficiency of 0.3% (6/1953). Conclusions These results demonstrate successful establishment of a miniature pig cloning technique by SCNT using NIBS miniature pigs as surrogates. To our knowledge, this is the first demonstration of successful production of GalT-KO miniature swine using miniature swine surrogates. This technique could help to ensure a stable supply of the cloned pigs through the use of miniature pig surrogates and could expand production in countries with limited space or in facilities with special regulations such as specific pathogen-free or good laboratory practice.
C1 [Shimatsu, Yoshiki; Horii, Wataru; Sakamoto, Yuji; Sano, Junichi; Saitoh, Toshiki] Nippon Inst Biol Sci, Dept Res & Dev, Hokuto, Yamanashi 4080041, Japan.
[Yamada, Kazuhiko; Hirakata, Atsushi; Waki, Shiori; Sahara, Hisashi] Kagoshima Univ, Ctr Adv Biomed Sci & Swine Res, Div Organ Replacement & Xenotransplantat Surg, Kagoshima 8908520, Japan.
[Yamada, Kazuhiko; Shimizu, Akira; Sachs, David H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02129 USA.
[Yazawa, Hajime; Nunoya, Tetsuo] Nippon Inst Biol Sci, Tokyo, Japan.
RP Yamada, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Organ Transplantat Tolerance & Xenotransplantat L, Sch Med,MGH East,Transplantat Biol Res Ctr, Bldg 149-9014,13th St, Boston, MA 02129 USA.
EM shimatsu@nibs.or.jp; kaz.yamada@tbrc.mgh.harvard.edu
FU Ministry of Education, Science, Sports, Culture and Technology of Japan;
NIH/NIAID
FX We thank Dr. Byeong-Chun Lee (College of Veterinary Medicine, Seoul
National University) for technical advice and Mr. Scott Arn for breeding
and maintenance of the MGH GalT-KO miniature swine heard. We also thank
Dr. Robert Hawley, Dr. Isabel Hanekamp and Dr. Masayuki Tasaki for their
critical review of this manuscript. This work was supported by
Grant-in-Aid for Scientific Research (A) from the Ministry of Education,
Science, Sports, Culture and Technology of Japan (KY) and
2P01AI45897-11A1 from NIH/NIAID (DHS and KY).
NR 40
TC 8
Z9 11
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0908-665X
J9 XENOTRANSPLANTATION
JI Xenotransplantation
PD MAY-JUN
PY 2013
VL 20
IS 3
BP 157
EP 164
DI 10.1111/xen.12031
PG 8
WC Medicine, Research & Experimental; Transplantation
SC Research & Experimental Medicine; Transplantation
GA 150QO
UT WOS:000319406100004
PM 23581451
ER
PT J
AU Waldo, SW
Armstrong, EJ
Kulkarni, A
Hoffmayer, K
Kinlay, S
Hsue, P
Ganz, P
McCabe, JM
AF Waldo, Stephen W.
Armstrong, Ehrin J.
Kulkarni, Ameya
Hoffmayer, Kurt
Kinlay, Scott
Hsue, Priscilla
Ganz, Peter
McCabe, James M.
TI Comparison of Clinical Characteristics and Outcomes of Cardiac Arrest
Survivors Having Versus Not Having Coronary Angiography
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; LONG-TERM PROGNOSIS; TO-BALLOON TIME;
INTERVENTION; RESUSCITATION; ANGIOPLASTY; ASSOCIATION; MORTALITY;
REGISTRY; IMPACT
AB Prompt percutaneous coronary intervention is associated with improved survival in patients presenting with cardiac arrest. Few studies; however, have focused on patients with cardiac arrest not selected for coronary angiography. The aim of the present study was to evaluate the clinical characteristics and outcomes of patients with cardiac arrest denied emergent angiography. Patients with cardiac arrest were identified within a registry that included all catheterization laboratory activations from 2008 to 2012. Logistic regression and proportional-hazards models were created to assess the clinical characteristics and mortality associated with denying emergent angiography. Among 664 patients referred for catheterization, 110 (17%) had cardiac arrest, and 26 of these patients did not undergo emergent angiography. Most subjects (69%) were turned down for angiography for clinical reasons and a minority for perceived futility (27%). After multivariate adjustment, pulseless electrical activity as the initial arrest rhythm (adjusted odds ratio [AOR] 13.27, 95% confidence interval [CI] 1.76 to 100.12), <1.0 mm of ST-segment elevation (AOR 10.26,95% CI 1.68 to 62.73), female gender (AOR 4.45, 95% CI 1.04 to 19.08), and advancing age (AOR 1.10 per year, 95% CI 1.04 to 1.16) were associated with increased odds of with-holding angiography. The mortality rate was markedly higher for patients who were denied emergent angiography (hazard ratio 3.64, 95% CI 2.05 to 6.49), even after adjustment for medical acuity (hazard ratio 2.29, 95% CI 1.19 to 4.41). In conclusion, Older subjects, women, and patients without ST-segment elevation were more commonly denied emergent angiography after cardiac arrest. Patients denied emergent angiography had increased mortality that persisted after adjustment for illness severity. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Waldo, Stephen W.; Hoffmayer, Kurt; Hsue, Priscilla; Ganz, Peter] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.
[Armstrong, Ehrin J.] Univ Calif Davis, Dept Med, Div Cardiovasc Med, Davis, CA 95616 USA.
[Kulkarni, Ameya] Massachusetts Gen Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02114 USA.
[Kinlay, Scott; McCabe, James M.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA.
RP Waldo, SW (reprint author), Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.
EM stephen.waldo@ucsf.edu
NR 26
TC 14
Z9 14
U1 1
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD MAY 1
PY 2013
VL 111
IS 9
BP 1253
EP 1258
DI 10.1016/j.amjcard.2013.01.267
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 142WI
UT WOS:000318827900003
PM 23391104
ER
PT J
AU Ziogas, DC
Gras-Miralles, B
Mustafa, S
Geiger, BM
Najarian, RM
Nagel, JM
Flier, SN
Popov, Y
Tseng, YH
Kokkotou, E
AF Ziogas, Dimitrios C.
Gras-Miralles, Beatriz
Mustafa, Sarah
Geiger, Brenda M.
Najarian, Robert M.
Nagel, Jutta M.
Flier, Sarah N.
Popov, Yury
Tseng, Yu-Hua
Kokkotou, Efi
TI Anti-melanin-concentrating hormone treatment attenuates chronic
experimental colitis and fibrosis
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article
DE melanin-concentrating hormone; inflammatory bowel disease; Crohn's
disease; ulcerative colitis; experimental colitis; chronic dextran
sodium sulfate colitis; intestinal fibrosis; myofibroblasts
ID INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INTESTINAL INFLAMMATION;
GROWTH-FACTORS; IGF-I; EXPRESSION; CELLS; MYOFIBROBLASTS; MICE;
PROLIFERATION
AB Fibrosis represents a major complication of several chronic diseases, including inflammatory bowel disease (IBD). Treatment of IBD remains a clinical challenge despite several recent therapeutic advances. Melanin-concentrating hormone (MCH) is a hypothalamic neuropeptide shown to regulate appetite and energy balance. However, accumulating evidence suggests that MCH has additional biological effects, including modulation of inflammation. In the present study, we examined the efficacy of an MCH-blocking antibody in treating established, dextran sodium sulfate-induced experimental colitis. Histological and molecular analysis of mouse tissues revealed that mice receiving anti-MCH had accelerated mucosal restitution and lower colonic expression of several proinflammatory cytokines, as well as fibrogenic genes, including COL1A1. In parallel, they spared collagen deposits seen in the untreated mice, suggesting attenuated fibrosis. These findings raised the possibility of perhaps direct effects of MCH on myofibroblasts. Indeed, in biopsies from patients with IBD, we demonstrate expression of the MCH receptor MCHR1 in alpha-smooth muscle actin(+) subepithelial cells. CCD-18Co cells, a primary human colonic myofibroblast cell line, were also positive for MCHR1. In these cells, MCH acted as a profibrotic modulator by potentiating the effects of IGF-1 and TGF-beta on proliferation and collagen production. Thus, by virtue of combined anti-inflammatory and anti-fibrotic effects, blocking MCH might represent a compelling approach for treating IBD.
C1 [Ziogas, Dimitrios C.; Gras-Miralles, Beatriz; Mustafa, Sarah; Geiger, Brenda M.; Najarian, Robert M.; Nagel, Jutta M.; Flier, Sarah N.; Popov, Yury; Kokkotou, Efi] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Tseng, Yu-Hua] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Kokkotou, E (reprint author), Beth Israel Deaconess Med Ctr, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.
EM ekokkoto@bidmc.harvard.edu
OI Gras-Miralles, Beatriz/0000-0002-5943-7755; Popov, Yury
V./0000-0001-7973-942X
FU National Institutes of Health [R01-DK080058]; Broad Medical Research
Program of The Broad Foundation [IBD-0165]; Harvard Clinical Nutrition
Research Center [P30-DK040561]; American Gastroenterological Association
Foundation
FX This work was supported by research grant R01-DK080058 from the National
Institutes of Health, IBD-0165 from the Broad Medical Research Program
of The Broad Foundation, P30-DK040561 from the Harvard Clinical
Nutrition Research Center, and an American Gastroenterological
Association Foundation Grant to E. Kokkotou.
NR 49
TC 3
Z9 3
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD MAY
PY 2013
VL 304
IS 10
BP G876
EP G884
DI 10.1152/ajpgi.00305.2012
PG 9
WC Gastroenterology & Hepatology; Physiology
SC Gastroenterology & Hepatology; Physiology
GA 144VD
UT WOS:000318968100004
PM 23538494
ER
PT J
AU Kim, JI
Kim, J
Jang, HS
Noh, MR
Lipschutz, JH
Park, KM
AF Kim, Jee In
Kim, Jinu
Jang, Hee-Seong
Noh, Mi Ra
Lipschutz, Joshua H.
Park, Kwon Moo
TI Reduction of oxidative stress during recovery accelerates normalization
of primary cilia length that is altered after ischemic injury in murine
kidneys
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE primary cilia; reactive oxygen species; ERK; ischemia; ROS
ID INDUCED FUNCTIONAL INJURY; MAPK KINASE ACTIVATION; RENAL CILIA; URETERAL
OBSTRUCTION; MOUSE; MICE; REPERFUSION; PROGRESSION; PREVENTION; FLAGELLA
AB The primary cilium is a microtubule-based nonmotile organelle that extends from the surface of cells, including renal tubular cells. Here, we investigated the alteration of primary cilium length during epithelial cell injury and repair, following ischemia/reperfusion (I/R) insult, and the role of reactive oxygen species in this alteration. Thirty minutes of bilateral renal ischemia induced severe renal tubular cell damage and an increase of plasma creatinine (PCr) concentration. Between 8 and 16 days following the ischemia, the increased PCr returned to normal range, although without complete histological restoration. Compared with the primary cilium length in normal kidney tubule cells, the length was shortened 4 h and 1 day following ischemia, increased over normal 8 days after ischemia, and then returned to near normal 16 days following ischemia. In the urine of I/R-subjected mice, acetylated tubulin was detected. The cilium length of proliferating cells was shorter than that in nonproliferating cells. Mature cells had shorter cilia than differentiating cells. Treatment with Mn(III) tetrakis(1-methyl-4-pyridyl) porphyrin (MnTMPyP), an antioxidant, during the recovery of damaged kidneys accelerated normalization of cilia length concomitant with a decrease of oxidative stress and morphological recovery in the kidney. In the Madin-Darby canine kidney (MDCK) cells, H2O2 treatment caused released ciliary fragment into medium, and MnTMPyP inhibited the deciliation. The ERK inhibitor U0126 inhibited elongation of cilia in normal and MDCK cells recovering from H2O2 stress. Taken together, our results suggest that primary cilia length reflects cell proliferation and the length of primary cilium is regulated, at least, in part, by reactive oxygen species through ERK.
C1 [Kim, Jee In; Kim, Jinu; Jang, Hee-Seong; Noh, Mi Ra; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu, South Korea.
[Kim, Jee In; Jang, Hee-Seong; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Cardiovasc Res Inst, Taegu, South Korea.
[Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Park, KM (reprint author), Kyungpook Natl Univ, Sch Med, Dept Anat, 101 Dongindong 2Ga, Junggu 700422, Daegu, South Korea.
EM kmpark@knu.ac.kr
OI Jang, Hee-Seong/0000-0002-9620-351X
FU Kyungpook National University Research Fund; National Research
Foundation; Korean Government [NRF-2011-220-E00001]; Korean Health
Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
[A111366]
FX This research was supported by the Kyungpook National University
Research Fund 2012, a National Research Foundation Grant funded by the
Korean Government (NRF-2011-220-E00001 to K. M. Park), and the Korean
Health Technology R&D Project, Ministry of Health & Welfare, Republic of
Korea (A111366 to K. M. Park).
NR 35
TC 6
Z9 6
U1 0
U2 1
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD MAY
PY 2013
VL 304
IS 10
BP F1283
EP F1294
DI 10.1152/ajprenal.00427.2012
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 144UM
UT WOS:000318966100007
PM 23515720
ER
PT J
AU Tapias, LF
Muniappan, A
Wright, CD
Gaissert, HA
Wain, JC
Morse, CR
Donahue, DM
Mathisen, DJ
Lanuti, M
AF Tapias, Luis F.
Muniappan, Ashok
Wright, Cameron D.
Gaissert, Henning A.
Wain, John C.
Morse, Christopher R.
Donahue, Dean M.
Mathisen, Douglas J.
Lanuti, Michael
TI Short and Long-Term Outcomes After Esophagectomy for Cancer in Elderly
Patients
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT Late-Breaking Clinical Trial Abstract Session on Congenital Heart
Surgery at the 48th Annual Meeting of the Society-of-Thoracic-Surgeons /
Surgical Motion Picture Session
CY JAN 28-FEB 01, 2012
CL Fort Lauderdale, FL
SP Soc Thorac Surg
ID AGE; ESOPHAGUS; CARCINOMA; SURGERY; OCTOGENARIANS; MORTALITY; CARDIA
AB Background. As worldwide life expectancy rises, the number of candidates for surgical treatment of esophageal cancer over 70 years will increase. This study aims to examine outcomes after esophagectomy in elderly patients.
Methods. This study is a retrospective review of 474 patients undergoing esophagectomy for cancer during 2002 to 2011. A total of 334 (70.5%) patients were less than 70 years old (group A), 124 (26.2%) 70 to 79 years (group B), and 16 (3.4%) 80 years or greater (group C). We analyzed the effect of age on outcome variables including overall and disease specific survival.
Results. Major morbidity was observed to occur in 115 (35.6%) patients of group A, 58 (47.9%) of group B, and 10 (62.5%) of group C (p = 0.010). Mortality, both 30-day and 90-day was observed in 2 (0.6%) and 7 (2.2%) of group A, 4 (3.2%) and 7 (6.1%) of group B, and 1 (6.3%) and 2 (14.3%) of group C, respectively (p = 0.032 and p = 0.013). Anastomotic leak was observed in 16 (4.8%) patients of group A, 6 (4.8%) of group B, and 0 (0%) of group C (p = 0.685). Anastomotic stricture (defined by the need for 2 dilations) was observed in 76 (22.8%) of groupA, 13 (10.5%) of group B, and 1 (6.3%) of group C (p = 0.005). Five-year overall and disease specific survival was 64.8% and 72.4% for group A, 41.7% and 53.4% for group B, 49.2% and 49.2% for group C patients (p = 0.0006), respectively.
Conclusions. Esophagectomy should be carefully considered in patients 70 to 79 years old and can be justified with low mortality. Outcomes in octogenarians are worse suggesting esophagectomy be considered on a case by case basis. Stricture rate is inversely associated to age. (C) 2013 by The Society of Thoracic Surgeons
C1 [Tapias, Luis F.; Muniappan, Ashok; Wright, Cameron D.; Gaissert, Henning A.; Wain, John C.; Morse, Christopher R.; Donahue, Dean M.; Mathisen, Douglas J.; Lanuti, Michael] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA.
RP Lanuti, M (reprint author), 55 Fruit St,Blake 1570, Boston, MA 02114 USA.
EM mlanuti@partners.org
FU NCATS NIH HHS [UL1 TR000170, 8UL1TR000170 05,]
NR 18
TC 17
Z9 20
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2013
VL 95
IS 5
BP 1741
EP 1748
DI 10.1016/j.athoracsur.2013.01.084
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 144VO
UT WOS:000318969500058
PM 23500043
ER
PT J
AU Manoach, DS
Wamsley, EJ
Shinn, AK
Tucker, MA
Ono, KE
McKinley, SK
Ely, AV
Goff, DC
Stickgold, R
AF Manoach, Dara S.
Wamsley, Erin J.
Shinn, Ann K.
Tucker, Matthew A.
Ono, Kim E.
McKinley, Sophia K.
Ely, Alice V.
Goff, Donald C.
Stickgold, Robert
TI Can we Improve Cognitive Function in Schizophrenia by Treating Abnormal
Sleep?
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE sleep spindles; schizophrenia; memory; eszopiclone; cognition
C1 [Manoach, Dara S.; Ono, Kim E.; Goff, Donald C.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Manoach, Dara S.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Wamsley, Erin J.; Tucker, Matthew A.; McKinley, Sophia K.; Ely, Alice V.; Stickgold, Robert] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
[Shinn, Ann K.] McLean Hosp, Psychot Disorders Div, Belmont, MA 02178 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 66
BP 21S
EP 22S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800067
ER
PT J
AU Spencer, K
AF Spencer, Kevin
TI When Gamma Goes Up: Increased Gamma and Psychosis
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; gamma oscillation; NMDA receptor hypofunction
C1 [Spencer, Kevin] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 91
BP 29S
EP 30S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800092
ER
PT J
AU Rabinak, CA
Angstadt, M
Sripada, CS
Milad, MR
Liberzon, I
Phan, KL
AF Rabinak, Christine A.
Angstadt, Mike
Sripada, Chandra S.
Milad, Mohammed R.
Liberzon, Israel
Phan, K. Luan
TI Cannabinoid Facilitation of Extinction Recall via Increased Recruitment
of Prefrontal-Hippocampal Circuitry in Healthy Humans
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE cannabinoid; fear extinction; cognitive enhancer; prefrontal cortex;
fMRI
C1 [Rabinak, Christine A.; Angstadt, Mike; Sripada, Chandra S.; Liberzon, Israel; Phan, K. Luan] Univ Michigan, Ann Arbor, MI 48109 USA.
[Milad, Mohammed R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Milad, Mohammed R.] Harvard Univ, Sch Med, Boston, MA USA.
[Phan, K. Luan] Univ Illinois, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 105
BP 34S
EP 34S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800106
ER
PT J
AU Fanous, A
Ripke, S
Amdur, R
Bigdeli, T
Holmans, P
Corvin, A
Corvin, A
Kendler, K
AF Fanous, Ayman
Ripke, Stephan
Amdur, Richard
Bigdeli, Tim
Holmans, Peter
Corvin, Aiden
Corvin, Aiden
Kendler, Kenneth
CA Schizophrenia Psychiat Genomics Co
TI Genome-wide Association Study of Symptomatic Dimensions of Schizophrenia
in the Psychiatric Genomics Consortium
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; psychosis; symptom; genetic; gwas
C1 [Fanous, Ayman; Amdur, Richard] Georgetown Univ, Washington, DC USA.
[Ripke, Stephan] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Bigdeli, Tim; Kendler, Kenneth] Virginia Commonwealth Univ, Richmond, VA USA.
[Holmans, Peter] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF10 3AX, S Glam, Wales.
[Corvin, Aiden; Corvin, Aiden] Trinity Coll Dublin, Dublin, Ireland.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 114
BP 37S
EP 37S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800115
ER
PT J
AU Coombs, G
Loggia, ML
Buckner, RL
Greve, DN
Holt, DJ
AF Coombs, Garth
Loggia, Marco L.
Buckner, Randy L.
Greve, Douglas N.
Holt, Daphne J.
TI Amygdala Perfusion is Predicted by its Functional Connectivity with the
Ventromedial Prefrontal Cortex and Negative Affect
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Amygdala; Functional connectivity; Arterial spin labeling; Negative
affect; Resting state
C1 [Coombs, Garth; Loggia, Marco L.; Buckner, Randy L.; Greve, Douglas N.; Holt, Daphne J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Coombs, Garth; Loggia, Marco L.; Buckner, Randy L.; Greve, Douglas N.; Holt, Daphne J.] Harvard Univ, Sch Med, Boston, MA USA.
[Coombs, Garth; Buckner, Randy L.] Harvard Univ, Cambridge, MA 02138 USA.
[Coombs, Garth; Loggia, Marco L.; Buckner, Randy L.; Greve, Douglas N.; Holt, Daphne J.] MGH HST MIT Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA.
[Buckner, Randy L.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Buckner, Randy L.] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 154
BP 50S
EP 50S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800155
ER
PT J
AU Hayes, JP
Miller, D
Lafleche, G
Salat, D
Verfaellie, M
AF Hayes, Jasmeet P.
Miller, Danielle
Lafleche, Ginette
Salat, David
Verfaellie, Mieke
TI Shared and Distinct White Matter Signatures Associated with PTSD and
Mild TBI
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE PTSD; TBI; diffusion tensor imaging; white matter; blast induced
neurotrauma
C1 [Hayes, Jasmeet P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Hayes, Jasmeet P.; Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Miller, Danielle; Lafleche, Ginette] Boston Univ, Sch Med, Memory Disorders Res Ctr, Boston, MA 02118 USA.
[Salat, David] VA Boston Healthcare Syst, Neuroimaging Res Ctr Vet, Boston, MA USA.
[Salat, David] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 163
BP 53S
EP 53S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800164
ER
PT J
AU Lasko, NB
Elman, I
Gurvits, TV
Tschibelu, E
Spring, JD
Pitman, RK
AF Lasko, Natasha B.
Elman, Igor
Gurvits, Tamara V.
Tschibelu, Evelyne
Spring, Justin D.
Pitman, Roger K.
TI Neurological Soft Signs in Individuals with Pathological Gambling
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Pathological Gambling; Neurological Soft Signs; Copy Figure Test;
constructional apraxia; visual agnosia
C1 [Lasko, Natasha B.] Massachisetts Gen Hosp, Charlestown, MA USA.
[Elman, Igor] Providence VA Med Ctr, Providence, RI USA.
[Elman, Igor; Tschibelu, Evelyne] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Somerville, MA USA.
[Gurvits, Tamara V.; Spring, Justin D.; Pitman, Roger K.] Massachisetts Gen Hospita, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 178
BP 58S
EP 58S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800179
ER
PT J
AU Pitman, RK
Marin, MF
Vitek, ME
Orr, SP
Goldberg, J
AF Pitman, Roger K.
Marin, Marie-France
Vitek, Mary Ellen
Orr, Scott P.
Goldberg, Jack
TI Post-Traumatic Stress Disorder Symptoms and Their Relationship to Trauma
Exposure
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Post-Traumatic Stress Disorder; Nightmares; Twin Study; Symptom
Specificity; Mississippi Scale for Combat-Related PTSD
C1 [Pitman, Roger K.; Marin, Marie-France; Orr, Scott P.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Pitman, Roger K.; Orr, Scott P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Vitek, Mary Ellen; Goldberg, Jack] Seattle Epidemiol Res & Informat Ctr, Vietnam Era Twin Registry, Dept Vet Affairs, Dept Epidemiol, Seattle, WA USA.
[Vitek, Mary Ellen; Goldberg, Jack] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 192
BP 62S
EP 62S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800193
ER
PT J
AU Rosenbaum, BL
Bui, E
Holt, DJ
Orr, SP
Pitman, RK
Milad, MR
AF Rosenbaum, Blake L.
Bui, Eric
Holt, Daphne J.
Orr, Scott P.
Pitman, Roger K.
Milad, Mohammed R.
TI Do Sociodemographic Factors Really Predict Variance in Conditioned Fear?
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Fear conditioning; Fear Extinction; Sociodemographic Factors; Skin
Conductance
C1 [Rosenbaum, Blake L.; Bui, Eric; Holt, Daphne J.; Orr, Scott P.; Pitman, Roger K.; Milad, Mohammed R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Rosenbaum, Blake L.; Bui, Eric; Holt, Daphne J.; Orr, Scott P.; Pitman, Roger K.; Milad, Mohammed R.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
RI Bui, Eric/J-8347-2015
OI Bui, Eric/0000-0002-1413-6473
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 193
BP 62S
EP 63S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800194
ER
PT J
AU Jensen, KP
Kranzler, HR
Stein, MB
Gelernter, J
AF Jensen, Kevin P.
Kranzler, Henry R.
Stein, Murray B.
Gelernter, Joel
TI The Effects of a Predicted MAP2K5 Microrna Target Site SNP on Risk for
Anxiety and Depressive Disorders
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE anxiety; depression; genetics; microRNA; GWAS
C1 [Jensen, Kevin P.; Gelernter, Joel] Yale Univ Sch Med, Dept Psychiat, West Haven, CT USA.
[Jensen, Kevin P.; Gelernter, Joel] VA CT Hlth Care Ctr, West Haven, CT USA.
[Kranzler, Henry R.] Univ Penn Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA.
[Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA.
[Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Gelernter, Joel] Yale Univ Sch Med, Dept Genet, West Haven, CT USA.
[Gelernter, Joel] Yale Univ Sch Med, Dept Neurobiol, West Haven, CT USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 208
BP 67S
EP 67S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800209
ER
PT J
AU Evans, KC
McLaren, DG
Song, TY
Patel, A
Dougherty, DD
AF Evans, Karleyton C.
McLaren, Donald G.
Song, Tian-Yue
Patel, Achint
Dougherty, Darin D.
TI Hypercapnia Evokes Exaggerated Amygdalar Cerebral Blood Flow in Panic
Disorder: An Arterial Spin Labeled FMRI Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Panic; fMRI; amygdala; CBF; ASL
C1 [Evans, Karleyton C.; McLaren, Donald G.; Song, Tian-Yue; Patel, Achint; Dougherty, Darin D.] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 224
BP 73S
EP 73S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800224
ER
PT J
AU Marin, MF
Staples, LK
VanElzakker, MB
Pace-Schott, EF
Lasko, NB
Pitman, RK
Shin, LM
Milad, MR
AF Marin, Marie-France
Staples, Lindsay K.
VanElzakker, Michael B.
Pace-Schott, Edward F.
Lasko, Natasha B.
Pitman, Roger K.
Shin, Lisa M.
Milad, Mohammed R.
TI Medial Prefrontal Cortex Resting Glucose Metabolism Predicts Fear
Learning and Extinction in Post-Traumatic Stress Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE post-traumatic stress disorder; fear extinction; dorsal anterior
cingulate cortex; ventromedial prefrontal cortex; skin conductance
C1 [Marin, Marie-France; Staples, Lindsay K.; VanElzakker, Michael B.; Pace-Schott, Edward F.; Lasko, Natasha B.; Pitman, Roger K.; Shin, Lisa M.; Milad, Mohammed R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Staples, Lindsay K.; VanElzakker, Michael B.; Shin, Lisa M.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA.
[Pace-Schott, Edward F.; Lasko, Natasha B.; Pitman, Roger K.; Milad, Mohammed R.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 225
BP 73S
EP 73S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800225
ER
PT J
AU Mueller-Pfeiffer, C
Zeffiro, T
O'Gorman, R
Michels, L
Baumann, P
Spring, JD
Wood, NE
Rufer, M
Pitman, RK
Orr, SP
AF Mueller-Pfeiffer, Christoph
Zeffiro, Thomas
O'Gorman, Ruth
Michels, Lars
Baumann, Peter
Spring, Justin D.
Wood, Nellie E.
Rufer, Michael
Pitman, Roger K.
Orr, Scott P.
TI Cortical Modulation of Autonomic Responses to Salient Auditory Stimuli
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Functional magnetic resonance imaging; Unconditioned response; Autonomic
nervous system; Saliency
C1 [Mueller-Pfeiffer, Christoph; Spring, Justin D.; Wood, Nellie E.; Pitman, Roger K.; Orr, Scott P.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Mueller-Pfeiffer, Christoph; Pitman, Roger K.; Orr, Scott P.] Harvard Univ, Sch Med, Boston, MA USA.
[Mueller-Pfeiffer, Christoph; Baumann, Peter; Rufer, Michael] Univ Zurich Hosp, Dept Psychiat & Psychotherapy, CH-8091 Zurich, Switzerland.
[Mueller-Pfeiffer, Christoph] Ctr Educ & Res COEUR, Psychiat Serv Cty St Gallen North, Wil, Switzerland.
[Zeffiro, Thomas] Massachusetts Gen Hosp, Neural Syst Grp, Boston, MA 02114 USA.
[O'Gorman, Ruth; Michels, Lars] Univ Childrens Hosp Zurich, Ctr MR Res, Zurich, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 226
BP 73S
EP 73S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800226
ER
PT J
AU Rosso, IM
Britton, JC
Stewart, SE
Papamiditriou, G
Killgore, WDS
Makris, N
Wilhelm, S
Jenike, MA
Rauch, SL
AF Rosso, Isabelle M.
Britton, Jennifer C.
Stewart, S. Evelyn
Papamiditriou, George
Killgore, William D. S.
Makris, Nikos
Wilhelm, Sabine
Jenike, Michael A.
Rauch, Scott L.
TI Brain White Matter Integrity and Association with Age at Onset in
Pediatric Obsessive-Compulsive Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE obsessive-compulsive disorder; childhood; diffusion tensor imaging;
corpus callosum; thalamus
C1 [Rosso, Isabelle M.; Killgore, William D. S.; Jenike, Michael A.; Rauch, Scott L.] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA USA.
[Britton, Jennifer C.] Univ Miami, Miami, FL USA.
[Stewart, S. Evelyn] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Papamiditriou, George; Makris, Nikos; Wilhelm, Sabine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Britton, Jennifer/J-4501-2013; Stewart, Evelyn/K-6961-2014
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 232
BP 75S
EP 75S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800232
ER
PT J
AU Webb, CA
Killgore, WDS
Britton, JC
Schwab, ZJ
Price, LM
Weiner, MR
Gold, AL
Rosso, IM
Simon, NM
Pollack, MH
Rauch, SL
AF Webb, Christian A.
Killgore, William D. S.
Britton, Jennifer C.
Schwab, Zachary J.
Price, Lauren M.
Weiner, Melissa R.
Gold, Andrea L.
Rosso, Isabelle M.
Simon, Naomi M.
Pollack, Mark H.
Rauch, Scott L.
TI Comparing Categorical versus Dimensional Predictors of Functional
Response Across Three Anxiety Disorders
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Amygdala; Insula; PTSD; Social anxiety; Specific phobia
C1 [Webb, Christian A.; Killgore, William D. S.; Schwab, Zachary J.; Rosso, Isabelle M.; Rauch, Scott L.] McLean Hosp, Ctr Depress Anxiety & Stress Res, Belmont, MA 02178 USA.
[Britton, Jennifer C.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA.
[Price, Lauren M.] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
[Weiner, Melissa R.; Gold, Andrea L.] Yale Univ, Dept Psychol, New Haven, CT 06520 USA.
[Simon, Naomi M.] Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, Boston, MA 02114 USA.
[Pollack, Mark H.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
RI Britton, Jennifer/J-4501-2013
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 230
BP 75S
EP 75S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800230
ER
PT J
AU Weber, M
Killgore, WDS
Rosso, IM
Britton, JC
Simon, NM
Pollack, MH
Rauch, SL
AF Weber, Mareen
Killgore, William D. S.
Rosso, Isabelle M.
Britton, Jennifer C.
Simon, Naomi M.
Pollack, Mark H.
Rauch, Scott L.
TI Gray Matter Correlates of Posttraumatic Stress Disorder - A Voxel-Based
Morphometry Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE PTSD; Amygdala; Hippocampus; Morphometry
C1 [Weber, Mareen; Killgore, William D. S.; Rosso, Isabelle M.; Rauch, Scott L.] McLean Hosp, Ctr Depress Anxiety & Stress Res, Belmont, MA 02178 USA.
[Britton, Jennifer C.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA.
[Simon, Naomi M.] Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, Boston, MA 02114 USA.
[Pollack, Mark H.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
RI Britton, Jennifer/J-4501-2013
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 231
BP 75S
EP 75S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800231
ER
PT J
AU Spring, JD
Wood, NE
Marin, MF
Lasko, NB
Mueller-Pfeiffer, C
Pitman, RK
Orr, SP
AF Spring, Justin D.
Wood, Nellie E.
Marin, Marie-France
Lasko, Natasha B.
Mueller-Pfeiffer, Christoph
Pitman, Roger K.
Orr, Scott P.
TI Pre-Reactivation Propranolol Fails to Reduce Skin Conductance Reactivity
to Fear-Conditioned Stimuli
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE post-traumatic stress disorder; memory reconsolidation; fear
conditioning; anxiety; propranolol
C1 [Spring, Justin D.; Wood, Nellie E.; Marin, Marie-France; Lasko, Natasha B.; Mueller-Pfeiffer, Christoph; Pitman, Roger K.; Orr, Scott P.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Lasko, Natasha B.; Mueller-Pfeiffer, Christoph; Pitman, Roger K.; Orr, Scott P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Mueller-Pfeiffer, Christoph] Univ Zurich Hosp, Dept Psychiat & Psychotherapy, CH-8091 Zurich, Switzerland.
[Mueller-Pfeiffer, Christoph] Ctr Educ & Res COEUR, Psychiat Serv Cty St Gallen North, Wil, Switzerland.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 308
BP 99S
EP 100S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800307
ER
PT J
AU Wood, NE
Spring, JD
Marin, MF
Lasko, NB
Orr, SP
Pitman, RK
AF Wood, Nellie E.
Spring, Justin D.
Marin, Marie-France
Lasko, Natasha B.
Orr, Scott P.
Pitman, Roger K.
TI Effect of Pre-Reactivation Mifepristone and D-Cycloserine on Subsequent
Physiological Responding During Traumatic Imagery in PTSD
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE post-traumatic stress disorder; memory reconsolidation; mifepristone;
d-cycloserine; psychophysiology
C1 [Wood, Nellie E.; Spring, Justin D.; Marin, Marie-France; Lasko, Natasha B.; Orr, Scott P.; Pitman, Roger K.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Lasko, Natasha B.; Orr, Scott P.; Pitman, Roger K.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 320
BP 103S
EP 103S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800319
ER
PT J
AU Shvil, E
Sullivan, GM
Schafer, S
Campeas, M
Joyner, E
Wager, T
Markowitz, J
Milad, MR
Neria, Y
AF Shvil, Erel
Sullivan, Gregory M.
Schafer, Scott
Campeas, Miriam
Joyner, Emily
Wager, Tor
Markowitz, John
Milad, Mohammed R.
Neria, Yuval
TI Sex Differences in Fear Perception and Processing in PTSD - An FMRI
Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE fMRI; Skin conductance response; Posttraumatic stress disorder; Fear
processing; Gender
C1 [Shvil, Erel; Sullivan, Gregory M.; Markowitz, John; Neria, Yuval] Columbia Univ, New York, NY USA.
[Shvil, Erel; Sullivan, Gregory M.; Campeas, Miriam; Joyner, Emily; Markowitz, John; Neria, Yuval] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Schafer, Scott; Wager, Tor] Univ Colorado, Boulder, CO 80309 USA.
[Milad, Mohammed R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 336
BP 108S
EP 108S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800335
ER
PT J
AU Spencer, KM
AF Spencer, Kevin M.
TI Electrophysiological Measures of Stimulus-Specific Plasticity in
Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; plasticity; event-related potentials; gamma oscillations
C1 [Spencer, Kevin M.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 365
BP 118S
EP 118S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800361
ER
PT J
AU Woodward, SH
Kuo, JR
Kaloupek, DG
AF Woodward, Steven H.
Kuo, Janice R.
Kaloupek, Danny G.
TI Amygdala Volume in Combat-Exposed Veterans with and without PTSD
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE PTSD; amygdala
C1 [Woodward, Steven H.] Palo Alto VA Healthcare Syst, Palo Alto, CA USA.
[Kuo, Janice R.] Ryerson Univ, Toronto, ON, Canada.
[Kaloupek, Danny G.] VA New England Hlth Care Syst, Natl Ctr PTSD, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 389
BP 125S
EP 125S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800385
ER
PT J
AU Aranovich, G
McClure, SM
Shanbhag, H
Roach, BJ
Mathalon, DH
AF Aranovich, Gabriel
McClure, Samuel M.
Shanbhag, Harshad
Roach, Brian J.
Mathalon, Daniel H.
TI Neural Correlates of Delay Discounting for Monetary Rewards in Chronic
Cigarette Smokers
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Discounting; Medial Prefrontal Cortex; DLPFC; Ventral Striatum;
Addiction
C1 [Aranovich, Gabriel; Shanbhag, Harshad; Roach, Brian J.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
[Aranovich, Gabriel; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[McClure, Samuel M.] Stanford Univ, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 404
BP 130S
EP 130S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800400
ER
PT J
AU Lee, PH
AF Lee, Phil H.
TI Genome-Wide Analyses of Brain-Imaging Phenotypes Reveal Enriched
Association of Neuronal and Psychiatric Genes
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE imaging genetics; functional connectiviity; genome wide association
study; pathway analysis; network analysis
C1 [Lee, Phil H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 439
BP 141S
EP 141S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800435
ER
PT J
AU Roffman, JL
Silverstein, NJ
Holmes, AJ
Lee, PH
Hollinshead, MO
Smoller, JW
Buckner, RL
AF Roffman, Joshua L.
Silverstein, Noah J.
Holmes, Avram J.
Lee, Phil H.
Hollinshead, Marisa O.
Smoller, Jordan W.
Buckner, Randy L.
TI Genetic Variation Across the Folate Metabolic Pathway Influences
Cortical Thickness in Healthy Individuals
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Cortical thickness; Folate; Schizophrenia; Neurodevelopment
C1 [Roffman, Joshua L.; Silverstein, Noah J.; Holmes, Avram J.; Lee, Phil H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA.
[Hollinshead, Marisa O.; Buckner, Randy L.] Harvard Univ, Massachusetts Gen Hosp, Charlestown, MA USA.
[Smoller, Jordan W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 440
BP 141S
EP 142S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800436
ER
PT J
AU Chou, TN
Deckersbach, T
Coombs, G
Corse, AK
Arulpragasam, A
Marioutina, M
Dougherty, DD
AF Chou, Tina
Deckersbach, Thilo
Coombs, Garth
Corse, Andrew K.
Arulpragasam, Amanda
Marioutina, Mariya
Dougherty, Darin D.
TI The Neural Effective Connectivity of the Aftereffects of Emotion
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE fMRI; PPI; emotion; corticolimbic network; default network
C1 [Chou, Tina; Coombs, Garth] Harvard Univ, Cambridge, MA 02138 USA.
[Chou, Tina; Deckersbach, Thilo; Coombs, Garth; Corse, Andrew K.; Arulpragasam, Amanda; Marioutina, Mariya; Dougherty, Darin D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 509
BP 161S
EP 162S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800497
ER
PT J
AU Hazlett, EA
Fernandez, N
Sasso, S
Mascitelli, KA
New, AS
Goodman, M
AF Hazlett, Erin A.
Fernandez, Nicolas
Sasso, Scott
Mascitelli, Kathryn A.
New, Antonia S.
Goodman, Marianne
TI Larger Startle-Eyeblink Amplitude During Unpleasant Pictures = Greater
Severity of Suicidal Behavior: A Promising Endophenotype For RDOC
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE affective startle eyeblink; suicide; emotion regulation;
psychophysiology; suicidal behavior
C1 [Hazlett, Erin A.; New, Antonia S.; Goodman, Marianne] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Hazlett, Erin A.; Fernandez, Nicolas; Sasso, Scott; Mascitelli, Kathryn A.; New, Antonia S.; Goodman, Marianne] James J Peters VAMC, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 512
BP 162S
EP 162S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800500
ER
PT J
AU Ramanathan, D
Mathalon, DH
Ford, J
Brown, GG
Stern, H
Mueller, B
Greve, DN
McCarthy, G
Voyvodic, J
Berger, A
Glover, G
Diaz, M
Yetter, E
Ozyurt, B
Jorgensen, KW
Wible, CG
Van Erp, TGM
Turner, J
Thompson, WK
Shanbhag, H
Potkin, SG
AF Ramanathan, Dhakshin
Mathalon, Daniel H.
Ford, Judith
Brown, Gregory G.
Stern, Hal
Mueller, Bryon
Greve, Douglas N.
McCarthy, Gregory
Voyvodic, James
Berger, Aysenil
Glover, Gary
Diaz, Michele
Yetter, Elizabeth
Ozyurt, Burak
Jorgensen, Kasper W.
Wible, Cynthia G.
Van Erp, Theo G. M.
Turner, Jessica
Thompson, Wesley K.
Shanbhag, Harshad
Potkin, Steven G.
TI Role of Ventral Prefrontal Cortex in Reorientation to Vs. Regulation of
Emotional Distractors During Concurrent Cognitive Task
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE emotion; regulation; distraction; prefrontal; VLPFC
C1 [Ramanathan, Dhakshin; Mathalon, Daniel H.; Ford, Judith; Jorgensen, Kasper W.; Shanbhag, Harshad] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Ramanathan, Dhakshin; Mathalon, Daniel H.; Ford, Judith; Jorgensen, Kasper W.; Shanbhag, Harshad] San Francisco VA Med Ctr, San Francisco, CA USA.
[Brown, Gregory G.; Yetter, Elizabeth] VA San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA.
[Brown, Gregory G.; Yetter, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA.
[Stern, Hal] Univ Calif Irvine, Dept Stat, Irvine, CA USA.
[Mueller, Bryon] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
[Greve, Douglas N.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[McCarthy, Gregory] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
[Voyvodic, James; Diaz, Michele; Potkin, Steven G.] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC USA.
[Berger, Aysenil] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA.
[Glover, Gary] Stanford Univ, Stanford, CA 94305 USA.
[Ozyurt, Burak; Thompson, Wesley K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Wible, Cynthia G.] Harvard Univ, Sch Med, Dept Psychiat, Brockton, MA 02401 USA.
[Wible, Cynthia G.] Brockton VAMC, Brockton, MA USA.
[Van Erp, Theo G. M.] Univ Calif Irvine, Dept Psychiat, Irvine, CA 92717 USA.
[Turner, Jessica] Mind Res Network, Albuquerque, NM USA.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 521
BP 165S
EP 165S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800509
ER
PT J
AU Dunn, EC
AF Dunn, Erin C.
TI Genetic Variants Modify the Association Between Developmental Timing of
Child Maltreatment and Symptoms of Depression In Young Adulthood:
Results from the National Longitudinal Study on Adolescent Health
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE depression; gene-environment interaction; timing of child maltreatment;
sensitive period
C1 [Dunn, Erin C.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 544
BP 173S
EP 173S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800532
ER
PT J
AU Camprodon, JA
Dougherty, D
Duffy, AM
Peters, AT
Peckham, AD
Rodman, AM
Rauch, S
Deckersbach, T
AF Camprodon, Joan A.
Dougherty, D.
Duffy, A. M.
Peters, A. T.
Peckham, A. D.
Rodman, A. M.
Rauch, S.
Deckersbach, T.
TI Neural Correlates of Executive Dysfunction in Bipolar Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE bipolar disorder; cognition; frontol lobe function; neuroimaging; fMRI
C1 [Camprodon, Joan A.; Dougherty, D.; Duffy, A. M.; Peters, A. T.; Peckham, A. D.; Rodman, A. M.; Rauch, S.; Deckersbach, T.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Camprodon, Joan A.; Dougherty, D.; Rauch, S.; Deckersbach, T.] Harvard Univ, Sch Med, Boston, MA USA.
[Rauch, S.] McLean Hosp, Belmont, MA 02178 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 619
BP 196S
EP 197S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800607
ER
PT J
AU Perez-Rodriguez, MM
New, AS
Yuan, QP
Zhou, ZF
Hodgkinson, C
Goodman, M
Koenigsberg, HW
Goldstein, KE
Goldman, D
Siever, LJ
Hazlett, EA
AF Perez-Rodriguez, M. Mercedes
New, Antonia S.
Yuan, Qiaoping
Zhou, Zhifeng
Hodgkinson, Colin
Goodman, Manrianne
Koenigsberg, Harold W.
Goldstein, Kim E.
Goldman, David
Siever, Larry J.
Hazlett, Erin A.
TI Impaired Extinction of Amygdala Response to Unpleasant Pictures in
Borderline Personality Disorder Associated with BDNF genotype
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE BDNF; habituation; emotional processing; amygdala; borderline
personality disorder
C1 [Perez-Rodriguez, M. Mercedes; New, Antonia S.; Goodman, Manrianne; Koenigsberg, Harold W.; Goldstein, Kim E.; Siever, Larry J.; Hazlett, Erin A.] Mt Sinai Sch Med, New York, NY USA.
[Perez-Rodriguez, M. Mercedes; New, Antonia S.; Goodman, Manrianne; Siever, Larry J.; Hazlett, Erin A.] James J Peters VAMC, Mirecc, Bronx, NY USA.
[Yuan, Qiaoping; Zhou, Zhifeng; Hodgkinson, Colin; Goldman, David] NIAAA, Rockville, MD 20852 USA.
[Koenigsberg, Harold W.] James J Peters VAMC, Mhcc, Bronx, NY USA.
RI Perez Rodriguez, Maria/B-9410-2013
OI Perez Rodriguez, Maria/0000-0001-5137-1993
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 629
BP 200S
EP 200S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800617
ER
PT J
AU Greenberg, MS
Wood, NE
Spring, JD
Nagurney, JT
Zafonte, RD
Gurvits, TV
Pitman, RK
AF Greenberg, Mark S.
Wood, Nellie E.
Spring, Justin D.
Nagurney, John T.
Zafonte, Ross D.
Gurvits, Tamara V.
Pitman, Roger K.
TI Neurological Soft Signs in Mild Traumatic Brain Injury (MTBI)
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE mild traumatic brain injury; concussion; recovery of function;
post-concussive syndrome
C1 [Greenberg, Mark S.; Gurvits, Tamara V.; Pitman, Roger K.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Greenberg, Mark S.; Wood, Nellie E.; Spring, Justin D.; Pitman, Roger K.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Greenberg, Mark S.; Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA USA.
[Nagurney, John T.] Massachusetts Gen Hosp, Emergency Serv, Boston, MA 02114 USA.
[Nagurney, John T.; Zafonte, Ross D.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 653
BP 208S
EP 208S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671800641
ER
PT J
AU Marder, SR
AF Marder, Stephen R.
TI Glutamate-Related Treatment Strategies in Schizophrenia Patients
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Glutamate; Neurocognition; Negative Symptoms
C1 [Marder, Stephen R.] Univ Calif Los Angeles, VA Greater LA Hlth Care Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 706
BP 225S
EP 226S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801016
ER
PT J
AU Orr, SP
AF Orr, Scott P.
TI Psychophysiological Markers for PTSD
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE PTSD; Psychophysiology; Diagnosis
C1 [Orr, Scott P.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Orr, Scott P.] Harvard Univ, Sch Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 731
BP 234S
EP 234S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801041
ER
PT J
AU Rasmusson, AM
AF Rasmusson, Ann M.
TI Integration of Neuroendocrinological Markers for PTSD with Relevance to
PTSD Risk, Recovery, and Treatment
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE PTSD; Neuroendocrinology; Neuroactive Steroids; Biomarkers; Fear
Conditioning
C1 [Rasmusson, Ann M.] VA Boston Healthcare Syst, Boston, MA USA.
[Rasmusson, Ann M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 733
BP 234S
EP 234S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801043
ER
PT J
AU Deckersbach, T
Corse, AK
Chou, T
Arulpragasam, A
Kaur, N
Rauch, SL
Nierenberg, AA
Dougherty, DD
AF Deckersbach, Thilo
Corse, Andrew K.
Chou, Tina
Arulpragasam, Amanda
Kaur, Navneet
Rauch, Scott L.
Nierenberg, Andrew A.
Dougherty, Darin D.
TI Attention and Positive Affect in Bipolar Disorder: An FMRI Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE attention; positive affect; cognition; bipolar disorder; emotion
regulation
C1 [Deckersbach, Thilo; Corse, Andrew K.; Chou, Tina; Arulpragasam, Amanda; Kaur, Navneet; Rauch, Scott L.; Nierenberg, Andrew A.; Dougherty, Darin D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Chou, Tina] Harvard Univ, Cambridge, MA 02138 USA.
[Rauch, Scott L.] McLean Hosp, Belmont, MA 02178 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 838
BP 268S
EP 268S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801148
ER
PT J
AU Lau, E
Weber, K
Delaney-Busch, N
Ustine, C
Fanucci, K
Hamalainen, M
Kuperberg, GR
AF Lau, Ellen
Weber, Kirsten
Delaney-Busch, Nate
Ustine, Candida
Fanucci, Kristina
Hamalainen, Matti
Kuperberg, Gina R.
TI Spatiotemporal Imaging of Language Reveals Dissociations Between
Prediction Generation and Belief Updating in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; language; prediction error; fMRI; MEG/ERP
C1 [Lau, Ellen; Weber, Kirsten; Delaney-Busch, Nate; Ustine, Candida; Fanucci, Kristina; Kuperberg, Gina R.] Tufts Univ, Dept Psychol, Boston, MA 02111 USA.
[Lau, Ellen; Weber, Kirsten; Delaney-Busch, Nate; Ustine, Candida; Fanucci, Kristina; Hamalainen, Matti; Kuperberg, Gina R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Lau, Ellen; Weber, Kirsten; Delaney-Busch, Nate; Ustine, Candida; Fanucci, Kristina; Hamalainen, Matti; Kuperberg, Gina R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Lau, Ellen; Kuperberg, Gina R.] Univ Maryland, Dept Linguist, College Pk, MD 20742 USA.
RI Hamalainen, Matti/C-8507-2013
NR 0
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 843
BP 269S
EP 270S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801153
ER
PT J
AU Hall, MH
Levy, DL
Salisbury, DF
Cohen, BM
Lohan, M
Ongur, D
Smoller, JW
AF Hall, Mei-Hua
Levy, Deborah L.
Salisbury, Dean F.
Cohen, Bruce M.
Lohan, Mary
Oenguer, Dost
Smoller, Jordan W.
TI Comparing Auditory Event Related Potential Deficits in Schizophrenia and
Bipolar Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; bipolar disorder; event related potentials; cognitive
dysfunction
C1 [Hall, Mei-Hua; Lohan, Mary; Oenguer, Dost] Harvard Univ, McLean Hosp, Sch Med, Psychot Disorders Div, Belmont, MA USA.
[Levy, Deborah L.] Harvard Univ, McLean Hosp, Sch Med, Psychol Res Lab, Belmont, MA USA.
[Salisbury, Dean F.] Univ Pittsburgh, Sch Med, Clin Neurophysiol Res Lab, Pittsburgh, PA USA.
[Cohen, Bruce M.] Harvard Univ, McLean Hosp, Sch Med, Shervert Frazier Res Inst, Belmont, MA USA.
[Smoller, Jordan W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 844
BP 270S
EP 270S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801154
ER
PT J
AU Hay, RA
Roach, BJ
Attygalle, SS
Cadenhead, K
Carrion, R
Bachman, P
Johannesen, J
Duncan, E
Belger, A
Niznikiewicz, M
McCarley, RW
Light, G
Pillay, N
Addington, J
Cannon, T
Cornblatt, B
McGlashan, T
Perkins, D
Seidman, L
Tsuang, M
Walker, E
Woods, S
Donkers, F
Mathalon, DH
AF Hay, Rachel A.
Roach, Brian J.
Attygalle, Suneth S.
Cadenhead, Kristin
Carrion, Ricardo
Bachman, Peter
Johannesen, Jason
Duncan, Erica
Belger, Aysenil
Niznikiewicz, Margaret
McCarley, Robert W.
Light, Gregory
Pillay, Neelan
Addington, Jean
Cannon, Tyrone
Cornblatt, Barbara
McGlashan, Thomas
Perkins, Diana
Seidman, Larry
Tsuang, Ming
Walker, Elaine
Woods, Scott
Donkers, Franc
Mathalon, Daniel H.
CA NAPLS Consortium
TI Mismatch Negativity Abnormalities Are Associated with Poorer Functioning
in Youth at Clinical High Risk for Psychosis: Evidence from the NAPLS
Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Mismatch negativity; Schizophrenia; Social Function; Prodrome; High Risk
C1 [Hay, Rachel A.; Roach, Brian J.; Attygalle, Suneth S.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Hay, Rachel A.; Roach, Brian J.; Attygalle, Suneth S.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cadenhead, Kristin; Light, Gregory; Tsuang, Ming] Univ Calif San Diego, San Diego, CA 92103 USA.
[Carrion, Ricardo; Cornblatt, Barbara] Zucker Hillside Hosp, New York, NY USA.
[Bachman, Peter] Univ Calif Los Angeles, Los Angeles, CA USA.
[Johannesen, Jason; Cannon, Tyrone; McGlashan, Thomas; Woods, Scott] Yale Univ, New Haven, CT USA.
[Duncan, Erica; Walker, Elaine] Emory Univ, Atlanta, GA 30322 USA.
[Duncan, Erica] Atlanta VAMC, Atlanta, GA USA.
[Belger, Aysenil; Perkins, Diana; Donkers, Franc] Univ N Carolina, Chapel Hill, NC USA.
[Niznikiewicz, Margaret; McCarley, Robert W.; Seidman, Larry] Harvard Univ, Boston, MA 02115 USA.
[Pillay, Neelan; Addington, Jean] Univ Calgary, Calgary, AB, Canada.
RI Donkers, Franc/H-2391-2013
OI Donkers, Franc/0000-0002-8252-0426
NR 0
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 850
BP 272S
EP 272S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801160
ER
PT J
AU Brandel, M
Ford, JM
Turner, JA
Van Erp, TG
Voyvodic, J
Preda, A
Belger, A
Bustillo, J
O'Leary, D
Mueller, B
Lim, KO
McEwen, SC
Calhoun, VD
Diaz, M
Glover, G
Greve, D
Wible, C
Vaidya, J
Potkin, SG
Mathalon, DH
AF Brandel, Michael
Ford, Judith M.
Turner, Jessica A.
Van Erp, Theodorus G.
Voyvodic, James
Preda, Adrian
Belger, Aysenil
Bustillo, Juan
O'Leary, Daniel
Mueller, Bryon
Lim, Kelvin O.
McEwen, Sarah C.
Calhoun, Vince D.
Diaz, Michelle
Glover, Gary
Greve, Douglas
Wible, Cindy
Vaidya, Jatin
Potkin, Steven G.
Mathalon, Daniel H.
CA FBIRN
TI Reduced Amplitude of Low Frequency Bold Fluctuations in Resting State
FMRI is AssociatedwWith Attention Deficits in Schizophrenia: Evidence
from the FBIRN Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Resting State fMRI; Schizophrenia; Attention; Amplitude of Low Frequency
Fluctuations; Default Mode
C1 [Brandel, Michael; Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Brandel, Michael; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Turner, Jessica A.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA.
[Van Erp, Theodorus G.; Preda, Adrian; Potkin, Steven G.] Univ Calif Irvine, Irvine, CA USA.
[Voyvodic, James; Diaz, Michelle] Duke Univ, Raleigh, NC USA.
[Belger, Aysenil] Univ N Carolina, Chapel Hill, NC USA.
[Bustillo, Juan; Calhoun, Vince D.] Univ New Mexico, Albuquerque, NM 87131 USA.
[O'Leary, Daniel; Vaidya, Jatin] Univ Iowa, Iowa City, IA USA.
[Mueller, Bryon; Lim, Kelvin O.] Univ Minnesota, Minneapolis, MN USA.
[McEwen, Sarah C.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Glover, Gary] Stanford Univ, Stanford, CA 94305 USA.
[Greve, Douglas] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wible, Cindy] Harvard Univ, Boston, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 856
BP 274S
EP 274S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801166
ER
PT J
AU Vinogradov, S
AF Vinogradov, Sophia
TI Heterogeneity in Cognitive Improvement After Intensive Cognitive
Training in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; cognition; cortical plasticity; cognitive training
C1 [Vinogradov, Sophia] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 857
BP 274S
EP 274S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801167
ER
PT J
AU del Re, EC
Niznikiewicz, M
Hosokawa, T
McCarley, RW
Spencer, KM
AF del Re, Elisabetta C.
Niznikiewicz, Margaret
Hosokawa, Taiga
McCarley, Robert W.
Spencer, Kevin M.
TI Habituation of Novelty and Target Stimulus-Evoked ERPS in First Episode
Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
C1 [del Re, Elisabetta C.] VA Boston Healthcare Syst, Psychiat, Brookline, MA USA.
[del Re, Elisabetta C.; Niznikiewicz, Margaret; Hosokawa, Taiga; McCarley, Robert W.; Spencer, Kevin M.] Harvard Univ, Boston, MA 02115 USA.
[Niznikiewicz, Margaret; Hosokawa, Taiga; McCarley, Robert W.; Spencer, Kevin M.] VA Boston Healthcare Syst, Psychiat, Brockton, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 864
BP 276S
EP 276S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801174
ER
PT J
AU Perez-Rodriguez, MM
Shen, PH
Bevilacqua, L
Yuang, QP
Zhou, ZF
Hodgkinson, C
Ripoll, L
Goodman, M
Koenigsberg, H
Goldman, D
Siever, LJ
New, AS
AF Perez-Rodriguez, M. Mercedes
Shen, Pei-Hong
Bevilacqua, Laura
Yuang, Qiaoping
Zhou, Zhifeng
Hodgkinson, Colin
Ripoll, Luis
Goodman, Marianne
Koenigsberg, Harold
Goldman, David
Siever, Larry J.
New, Antonia S.
TI Oxytocin Gene Variants Modulate Core Dimensions of Borderline
Personality Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Oxytocin; Single Nucleotide Polymorphism; Empathy; Impulsivity;
Aggression
C1 [Perez-Rodriguez, M. Mercedes; Ripoll, Luis; Goodman, Marianne; Koenigsberg, Harold; Siever, Larry J.; New, Antonia S.] James J Peters VAMC, Mt Sinai Sch Med, New York, NY USA.
[Perez-Rodriguez, M. Mercedes; Ripoll, Luis; Goodman, Marianne; Koenigsberg, Harold; Siever, Larry J.; New, Antonia S.] James J Peters VAMC, MIRECC, New York, NY USA.
[Shen, Pei-Hong; Bevilacqua, Laura; Yuang, Qiaoping; Zhou, Zhifeng; Hodgkinson, Colin; Goldman, David] NIAAA, Lab Neurogenet, NIH, Rockville, MD 20852 USA.
RI Perez Rodriguez, Maria/B-9410-2013
OI Perez Rodriguez, Maria/0000-0001-5137-1993
NR 0
TC 0
Z9 0
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 891
BP 285S
EP 285S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801201
ER
PT J
AU Yao, JK
Dougherty, GG
Reddy, RD
Montrose, DM
Matson, WR
Kaddurah-Daouk, R
Keshavan, M
AF Yao, Jeffrey K.
Dougherty, George G.
Reddy, Ravinder D.
Montrose, Debra M.
Matson, Wayne R.
Kaddurah-Daouk, Rima
Keshavan, Matcheri
TI Interactions between Purine Metabolites and Monoamine Neurotransmitters
in First-Episode Psychosis
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Schizophrenia; First-episode psychosis; Purine catabolism; Monoamine
neurotransmitters
C1 [Yao, Jeffrey K.; Dougherty, George G.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
[Yao, Jeffrey K.; Dougherty, George G.; Reddy, Ravinder D.; Montrose, Debra M.; Keshavan, Matcheri] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Matson, Wayne R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA.
[Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA.
[Keshavan, Matcheri] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
[Keshavan, Matcheri] Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 913
BP 291S
EP 291S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801221
ER
PT J
AU Palzes, V
AF Palzes, Vanessa
TI Predictions Break Down Between Motor Plans and Their Consequences in
Schizophrneia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Schizophrenia; ERP; Corollary discharge; Prediction error
C1 [Palzes, Vanessa] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 931
BP 297S
EP 297S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801239
ER
PT J
AU Forsyth, JK
McEwen, S
Gee, DG
Addington, J
Bearden, CE
Cadenhead, KS
Cornblatt, BA
Mathalon, DH
McGlashan, TH
Perkins, DO
Seidman, LJ
Tsuang, MT
Walker, EF
Woods, SW
Cannon, TD
AF Forsyth, Jennifer K.
McEwen, Sarah
Gee, Dylan G.
Addington, Jean
Bearden, Carrie E.
Cadenhead, Kristin S.
Cornblatt, Barbara A.
Mathalon, Daniel H.
McGlashan, Thomas H.
Perkins, Diana O.
Seidman, Larry J.
Tsuang, Ming T.
Walker, Elaine F.
Woods, Scott W.
Cannon, Tyrone D.
TI Abnormalities of Neural Activation During Working Memory Predict
Conversion to Psychosis in Clinical High-Risk Youth: A Preliminary
Analysis from the North American Prodrome Longitudinal Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE schizophrenia; fMRI; prodromal; working memory; clinical high-risk
C1 [Forsyth, Jennifer K.; McEwen, Sarah; Gee, Dylan G.; Bearden, Carrie E.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Addington, Jean] Univ Calgary, Calgary, AB, Canada.
[Cadenhead, Kristin S.; Tsuang, Ming T.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Cornblatt, Barbara A.] Zucker Hillside Hosp, Long Isl City, NY USA.
[Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[McGlashan, Thomas H.; Woods, Scott W.; Cannon, Tyrone D.] Yale Univ, New Haven, CT USA.
[Perkins, Diana O.] Univ N Carolina, Chapel Hill, NC USA.
[Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Walker, Elaine F.] Emory Univ, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 938
BP 300S
EP 300S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801246
ER
EF